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A B S T R A C T
Background
Evidence on the health effects of total polyunsaturated fatty acids (PUFA) is equivocal. Fish oils are rich in omega-3 PUFA and plant
oils in omega-6 PUFA. Evidence suggests that increasing PUFA-rich foods, supplements or supplemented foods can reduce serum
cholesterol, but may increase body weight, so overall cardiovascular effects are unclear.
Objectives
To assess effects of increasing total PUFA intake on cardiovascular disease and all-cause mortality, lipids and adiposity in adults.
Search methods
We searchedCENTRAL,MEDLINE and Embase to April 2017 and clinicaltrials.gov and theWorldHealthOrganization International
Clinical Trials Registry Platform to September 2016, without language restrictions. We checked trials included in relevant systematic
reviews.
Selection criteria
We included randomised controlled trials (RCTs) comparing higher with lower PUFA intakes in adults with or without cardiovascular
disease that assessed effects over 12 months or longer. We included full texts, abstracts, trials registry entries and unpublished data.
Outcomes were all-cause mortality, cardiovascular disease mortality and events, risk factors (blood lipids, adiposity, blood pressure),
and adverse events. We excluded trials where we could not separate effects of PUFA intake from other dietary, lifestyle or medication
interventions.
Data collection and analysis
Two review authors independently screened titles and abstracts, assessed trials for inclusion, extracted data, and assessed risk of bias.
We wrote to authors of included trials for further data. Meta-analyses used random-effects analysis, sensitivity analyses included fixed-
effects and limiting to low summary risk of bias. We assessed GRADE quality of evidence.
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Main results
We included 49 RCTs randomising 24,272 participants, with duration of one to eight years. Eleven included trials were at low summary
risk of bias, 33 recruited participants without cardiovascular disease. Baseline PUFA intake was unclear in most trials, but 3.9% to 8%
of total energy intake where reported. Most trials gave supplemental capsules, but eight gave dietary advice, eight gave supplemental
foods such as nuts or margarine, and three used a combination of methods to increase PUFA.
Increasing PUFA intake probably has little or no effect on all-causemortality (risk 7.8%vs 7.6%, risk ratio (RR) 0.98, 95% confidence
interval (CI) 0.89 to 1.07, 19,290 participants in 24 trials), but probably slightly reduces risk of coronary heart disease events from
14.2% to 12.3% (RR 0.87, 95% CI 0.72 to 1.06, 15 trials, 10,076 participants) and cardiovascular disease events from 14.6% to
13.0% (RR 0.89, 95% CI 0.79 to 1.01, 17,799 participants in 21 trials), all moderate-quality evidence. Increasing PUFAmay slightly
reduce risk of coronary heart disease death (6.6% to 6.1%, RR 0.91, 95% CI 0.78 to 1.06, 9 trials, 8810 participants) andstroke
(1.2% to 1.1%, RR 0.91, 95% CI 0.58 to 1.44, 11 trials, 14,742 participants, though confidence intervals include important harms),
but has little or no effect on cardiovascular mortality (RR 1.02, 95% CI 0.82 to 1.26, 16 trials, 15,107 participants) all low-quality
evidence. Effects of increasing PUFA on major adverse cardiac and cerebrovascular events and atrial fibrillation are unclear as
evidence is of very low quality.
Increasing PUFA intake slightly reduces total cholesterol (mean difference (MD) -0.12mmol/L, 95%CI -0.23 to -0.02, 26 trials, 8072
participants) and probably slightly decreases triglycerides (MD -0.12 mmol/L, 95% CI -0.20 to -0.04, 20 trials, 3905 participants),
but has little or no effect on high-density lipoprotein (HDL) (MD -0.01 mmol/L, 95% CI -0.02 to 0.01, 18 trials, 4674 participants)
or low-density lipoprotein (LDL) (MD -0.01 mmol/L, 95% CI -0.09 to 0.06, 15 trials, 3362 participants). Increasing PUFA probably
causes slight weight gain (MD 0.76 kg, 95% CI 0.34 to 1.19, 12 trials, 7100 participants).
Effects of increasing PUFA on serious adverse events such as pulmonary embolism and bleeding are unclear as the evidence is of very
low quality.
Authors’ conclusions
This is the most extensive systematic review of RCTs conducted to date to assess effects of increasing PUFA on cardiovascular disease,
mortality, lipids or adiposity. Increasing PUFA intake probably slightly reduces risk of coronary heart disease and cardiovascular disease
events, may slightly reduce risk of coronary heart disease mortality and stroke (though not ruling out harms), but has little or no effect
on all-cause or cardiovascular disease mortality. The mechanism may be via lipid reduction, but increasing PUFA probably slightly
increases weight.
P L A I N L A N G U A G E S U M M A R Y
Polyunsaturated fatty acids for prevention and treatment of diseases of the heart and circulation
Review question
We reviewed randomised trials (participants have an equal chance to be assigned to either treatment) examining effects of increasing
intake of polyunsaturated fatty acids (PUFA) on deaths and diseases of the heart and circulation (cardiovascular diseases), including
heart attacks and stroke.
Background
We eat PUFA in our usual food, but quantities of PUFA eaten vary. There is some evidence that increasing the amount of PUFA we
eat can reduce our blood cholesterol and make us less likely to develop cardiovascular disease, particularly if PUFAs are eaten instead of
saturated fats (fats from animal sources such as meat and cheese). But eating more PUFA may increase our body weight, and omega-
6 fats (one component of PUFA) may worsen cardiovascular risk by increasing inflammation. Evidence on the benefits or harms of
increasing PUFA intake on diseases of the heart and circulation, or on other health outcomes, is inconclusive.
Trial characteristics
Evidence in this Cochrane Review is current to 27 April 2017. We included 49 trials randomising 24,272 participants, for one to eight
years. These trials assessed effects of eating more, compared to less PUFA, on diseases of the heart and circulation, and deaths. Twelve
trials were very trustworthy (had low risk of bias overall). Participants were men and women, some with existing illnesses and some
not. Trials took place in North America, Asia, Europe and Australia, and sixteen were funded only by national or charitable agencies.
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Key results
Increasing PUFA probably makes little or no difference (neither benefit nor harm) to our risk of death (moderate-quality evidence),
and may make little or no difference to our risk of dying from cardiovascular disease (low-quality evidence). However, increasing PUFA
probably slightly reduces our risk of heart disease events and of combined heart and stroke events (moderate-quality evidence). Fifty
three people would need to eat more PUFA to prevent one person experiencing a heart disease event, and 63 people to prevent one
person experiencing a heart or stroke event. Increasing PUFA may very slightly reduce risk of death due to heart disease, as well as
stroke, but harm is possible (low-quality evidence). PUFA probably slightly reduces fats circulating in the blood (cholesterol, high-
quality evidence and triglycerides, moderate-quality evidence). Increasing PUFA probably slightly increases body weight (moderate-
quality evidence). The evidence mainly comes from trials of men living in high-income countries.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Higher PUFA compared to lower PUFA for CVD
Patient or population: people with or without exist ing CVD, men and women
Setting: includes f ree-living part icipants and those living in inst itut ions. Includes part icipants f rom all cont inents but most events occurred in trials carried out in Europe or
North America.
Intervention: higher PUFA intake
Comparison: lower PUFA intake
Eligible trials compared higher with lower total PUFA intakes. The intervent ion had to be dietary supplementat ion, or a provided diet, or advice on diet. The advice, foodstuf f s
or supplements had to aim to increase or decrease total PUFA intake, or a dietary component high in total PUFA intake such as vegetable oil, or, if no clear aim was stated
(but implied, such as aim ing to provide a ’heart health’, ’reduced fat ’ or ’Mediterranean’ diet) then the intervent ion had to achieve an increase or decrease of at least 10%of the
baseline total PUFA level
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stroke (f rom 1.2% to 1.
1% in the study popula-
t ion, NNT= 1000), low-
quality evidence. How-
ever, the 95% conf i-
dence intervals include
important harms as
well as benef it
21 per 1000 15 per 1000
(10 to 24)
CVD at baseline (secondary prevent ion)






months to 96 months






Ef fects of increasing
PUFA on MACCEs are
unclear as the evidence
is of very low quality206 per 1000 142 per 1000
(105 to 192)
CVD at baseline (secondary prevent ion)
332 per 1000 329 per 1000
(289 to 372)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).























































































































GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aAll- cause mortality
1. Risk of bias: ef fect size did not alter when restricted to trials at low summary risk of bias, low risk of bias f rom
allocat ion, attent ion or compliance. Not downgraded.
2. Inconsistency: consistent ef fects, I2 stat ist ic less than 50%. Not downgraded.
3. Indirectness: most data came f rom trials of men, but some were f rom trials of women or men and women combined.
Most events occurred in older part icipants, but events also occurred in younger and middle-aged part icipants. Included trials
were f rom all cont inents but most events occurred in trials carried out in Europe or North America. Not downgraded.
4. Imprecision: over 1400 events occurred in trials including over 19,000 part icipants over at least 12 months. However,
95%CI included important benef its. Downgraded once.
5. Publication bias: f unnel plot did not suggest small study bias, we are aware of few events that could not be added to the
meta-analysis. Not downgraded.
bCoronary heart disease events
1. Risk of bias: sensit ivity analyses restrict ing trials to low risk of bias for attent ion and compliance give sim ilar results to
the main analysis, as do restrict ing to trials without industry funding or pre-2010 and trials on trials registries, and larger trials
all conf irmed a small benef icial ef fect on coronary heart disease (CHD) events. However, lim it ing to trials at low risk of bias
f rom allocat ion concealment and to trials of low summary risk of bias suggest increased CHD risk with more PUFA, making
us less certain of the ef fect of increasing PUFA on this outcome. It was further noted by the WHO NUGAG Subgroup on Diet
and Health that although lim it ing to trials at low risk of bias f rom allocat ion concealment and to trials of low summary risk of
bias suggest increased CHD risk with more PUFA, results of the most heavily weighted trial are consistent with results of the
main analysis, while the next largest trial dif f ers f rom the main result ; therefore, conf idence in the results of these analyses is
low and the outcome was not downgraded. Not downgraded, but part of the downgrading for imprecision was for risk of bias.
2. Inconsistency: consistent ef fects, I2 stat ist ic less than 50%. Not downgraded.
3. Indirectness: most events occurred in men, and in high-income countries. Not downgraded.
4. Imprecision: the 95% conf idence intervals did not exclude harm f rom increased PUFA. Downgraded once (with risk of
bias).
5. Publication bias: f unnel plot did not suggest small study bias, we are aware of few events that could not be added to the
meta-analysis. Not downgraded.
cStroke
1. Risk of bias: some sensit ivity analyses suggested benef it of increased PUFA, some suggested harm or lit t le ef fect. It























































































































were consistent with the main results, and the outcome was therefore not downgraded. Not downgraded, but part of the
downgrading for imprecision was for risk of bias.
2. Inconsistency: consistent ef fects, I2 stat ist ic less than 50%. Not downgraded.
3. Indirectness: most events occurred in men, and in high-income countries. Not downgraded.
4. Imprecision: with only 166 part icipants experiencing a stroke imprecision was high, the 95% conf idence intervals did not
exclude important harm f rom increased PUFA. Downgraded twice (with risk of bias).
5. Publication bias: f unnel plot did not suggest small study bias, we are aware of few events that could not be added to the
meta-analysis. Not downgraded.
dMajor adverse cardiac and cerebrovascular events (MACCEs)
1. Risk of bias: neither of the included trials were at low risk f rom allocat ion concealment, or at low summary risk of bias.
Downgraded once.
2. Inconsistency: I2 stat ist ic = 79%. Downgraded once.
3. Indirectness: all part icipants of the included trials were men, and trials were conducted in Europe and North America.
Not downgraded.
4. Imprecision: 817 people experienced MACCEs, although harm was not excluded by the 95%CI. Downgraded once.























































































































B A C K G R O U N D
Description of the condition
The World Health Organization (WHO) reports cardiovascular
diseases as the primary cause of death in the world (WHO 2016).
In 2012 they estimated that 17.5 million people died from car-
diovascular diseases, three-quarters of whom were in low- to mid-
dle-income countries. Cardiovascular diseases are disorders of the
heart and blood vessels and include a range of conditions. Some
are diseases of blood vessels supplying the heart (coronary heart
disease), brain (cerebrovascular disease), or arms or legs (periph-
eral arterial disease). Others are due to infection (rheumatic heart
disease, where damage to the heart muscle and valves is due to
rheumatic fever), are present at birth (congenital heart disease), or
are due to blood clots (deep vein thrombosis and pulmonary em-
bolism) (WHO 2016). This review is concerned with the forms
of cardiovascular disease that are potentially modifiable by dietary
means, particularly coronary heart disease and cerebrovascular dis-
ease.
Description of the intervention
Polyunsaturated fatty acids (PUFAs) are fats that include at least
two double carbon-to-carbon bonds (unsaturated carbon bonds)
in their long hydrocarbon chain. Thismakes the fats pack less well,
so they tend to be liquid at room temperature, rather than solid
like many saturated fats. PUFAs can be omega-3 (where the first
double bond is three carbons away from the methyl-carbon end
of the molecule), omega-6 or omega-9 (although most omega-9
fats do not have at least two double bonds, so are not included).
Fish and plant oils are often rich in PUFAs, with fish being rich
in omega-3 and plant oils rich in omega-6. Two PUFAs, alpha-
linolenic acid (omega-3) and linoleic acid (omega-6), are essential
nutrients in humans.
Dietary fats have been implicated in cardiovascular health since
Keys published his groundbreaking study linking plasma choles-
terol and dietary saturated fat (Keys 1950), and Oliver reported
higher levels of low density lipoprotein (LDL) in those surviving
myocardial infarction compared to controls without myocardial
infarction (Oliver 1953). In 1965 Hegsted published an equation
that quantified the relationship between dietary fat and serum to-
tal cholesterol, suggesting that increasing saturated fats increased
serum cholesterol, while increasing PUFA reduced serum choles-
terol (Hegsted 1965). More recently there has been debate about
what type of PUFA may be protective, with interest in omega-
3 PUFAs following randomised controlled trials (RCTs) with di-
etary fish and fish oil supplementation interventions in the 1980s
and 1990s (Burr 1989; GISSI-P 1999), although subsequent tri-
als have been equivocal (Abdelhamid 2018; Hooper 2006). Simi-
larly, while there are good theoretical grounds for suggesting that
omega-6 fats may be protective against cardiovascular diseases,
the RCT evidence is limited (Hooper 2018). However, there is
evidence that replacing saturated fats with PUFAs does protect
against cardiovascular disease, and that PUFAs appear to be more
protective than reducing saturated fats and replacing them with
carbohydrates (Hooper 2015a). On the other hand, reducing di-
etary fat (including PUFAs) appears to result in lower weight in
adults, suggesting that lower PUFA intake would tend to protect
against cardiovascular disease (Hooper 2015b).
How the intervention might work
PUFAs are generally thought to work by producing a reduction
in serum total cholesterol and LDL, which slows the progress of
atherosclerosis (a complex syndrome in which plaque builds up
inside the arteries over time, reducing blood flow and leading to
an increased risk of blood clots), and so delays or prevents the
onset of cardiovascular and cerebrovascular disease. This theory is
reinforced by evidence that replacing saturated fats with polyun-
saturated fats is associated with greater reductions in cardiovas-
cular events and with greater reduction of serum total choles-
terol (Hooper 2015a). Additional modes of action have been pro-
posed for omega-3 PUFAs (particularly EPA (eicosapentaenoic
acid) and DHA (docosahexaenoic acid) both fish-based omega-3
polyunsaturated fatty acids. These modes of action include: low-
ering of blood pressure; reducing thrombotic tendency; anti-in-
flammatory and antiarrhythmic effects; improving vascular en-
dothelial function; increasing plaque stability (through increased
plaque calcification); and improving insulin sensitivity (Calder
2012; Ohwada 2016). Omega-6 PUFAs may reflect the gen-
eral lipid-lowering effects of PUFAs, but there has been concern
that high levels of omega-6 intake can increase production of
2-series prostaglandins and 4-series leukotrienes compared with
the 3-series prostaglandins and 5-series leukotrienes associated
with omega-3 intake. As the 2-series prostaglandins and 4-series
leukotrienes exert a more potent pro-inflammatory effect, omega-
6 could increase the risk of cardiovascular disease by promoting
inflammation (Russo 2009).
Why it is important to do this review
The evidence on the health effects of total PUFA intake, which
is the combination of omega-3 and omega-6 fats, is equivocal. As
cardiovascular diseases are important determinants of health, that
particularly burden the poorest people (WHO 2016), we need
to understand the role of PUFAs to provide the best advice for
individuals and populations about how to eat to reduce the risk of
ill health. This assessment of health effects of total PUFA intake
is needed alongside updated assessment of the effects of omega-3
and omega-6 fats (Hooper 2018; Abdelhamid 2018).
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The World Health Organization (WHO) is currently updating
its guidance on polyunsaturated fatty acid intake in adults and
children. This new review was commissioned byWHONutrition
Guidance Expert Advisory Group (NUGAG) Subgroup on Diet
and Health in order to inform and contribute to the development
of updated WHO recommendations. The results of this review
including GRADE assessments were discussed and reviewed by
the WHO NUGAG Subgroup on Diet and Health as part of
their guideline development process. This is a new review and
forms a set with Abdelhamid 2018 (assessing effects of omega-3
fats), Hooper 2018 (assessing effects of omega-6 fats), reviews of
diabetes and glucose tolerance (Brown 2017), inflammatory bowel
disease (IBD) (Thorpe 2017), cognition (Jimoh 2017), depression
(Hanson 2017a), bone and muscle health (Abdelhamid 2017),
and cancers (Hanson 2017b).
O B J E C T I V E S
To assess effects of increasing total PUFA intake on cardiovascular
disease and all-cause mortality, lipids and adiposity in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) that compared
higher with lower polyunsaturated fatty acid intakes and assessed
effects over at least 12 months (12 months’ continuous involve-
ment). We included trials reported as full text, those published as
abstracts only, as trials registry entries and unpublished data. We
did not include cross-over trials (unless we could use data from the
first part of the cross-over only), as this design is inappropriate for
outcomes such as cardiovascular disease events or mortality, but
included cluster-randomised trials, as long as there were at least
six clusters (to facilitate equivalence of the arms at baseline).
Types of participants
We included trials of adults (18 years of age and above). Included
participants could be adults who were well, or with increased risk
of cancer, those undergoing - or who had undergone - coronary
artery bypass grafting or angioplasty, and those with current or pre-
vious cardiovascular disease, diabetes mellitus, rheumatoid arthri-
tis, depression, cognitive impairment, or multiple sclerosis. We
were interested in both primary and secondary prevention, so in-
cluded people with or without a history of cardiovascular disease.
We excluded participants who were pregnant or acutely ill, and
defined acute illness as including people with diagnosed current
cancer, undergoing heart or renal transplantation, with HIV or
AIDS, on haemodialysis, with immunoglobulin A (IgA) glomeru-
lonephritis, or any other renal problem except diabetic nephropa-
thy. Our reasoning was to exclude people with conditions that
may affect the relationship between polyunsaturated fatty acids
and cardiovascular disease events.
Where trials included some adults and some people under 18 years
of age, then we included the trial if at least 90% of participants
were aged 18 years or over at baseline, or where outcomes for adults
could be separated from those for younger people.
Types of interventions
Eligible trials compared higher with lower total polyunsaturated
fatty acid (PUFA) intakes. The intervention had to be dietary sup-
plementation, or a provided diet, or advice on diet. The advice,
foodstuffs or supplements had to aim to increase or decrease total
PUFA intake, or a dietary component high in total PUFA intake
such as vegetable oil, or, if no clear aim was stated (but implied,
such as aiming to provide a ’heart health’, ’reduced fat’ or ’Mediter-
ranean’ diet), then the intervention had to achieve an increase or
decrease of at least 10% of the baseline total PUFA level.
Supplementation had to be in oil or capsule form, or as foodstuffs
provided, to be consumed bymouth (we excluded enteral and par-
enteral feeds, and enemas). Trials were included if they compared
the effect of this intervention with usual diet, no advice, no sup-
plementation or placebo (as appropriate) or with a lower PUFA
intake.
We did not include trials if they included multiple risk factor in-
tervention on lifestyle factors such as weight reduction, smoking
or physical activity goals, or differential dietary interventions not
involving dietary fats (such as advice to eat more fruit and vegeta-
bles, increase fibre, or take a vitamin supplement), except where
that other intervention was a direct replacement for polyunsat-
urated fatty acids or the effect of the fat intervention could be
separated out from the other interventions. Where a single inter-
vention that increased PUFA intake (such as increasing walnuts,
sunflower oil or a margarine) included additional nutrients (they
all do) we included it, regardless of what nutrients were displaced.
We interpreted this consistently across the review.
We made decisions on inclusion using the following decision tree:
1. Include if the trial aimed to increase total PUFA regardless
of dose (or aimed to increase a combination of omega-3 and
omega-6). If not then assess point 2.
2. Include if the trial provided within-trial intervention and
control group total PUFA intake data, and the difference was
10% or more of the control group total PUFA intake OR the
difference was 10% or more of baseline total PUFA intake or an
assumed baseline intake of 6% of energy (6% E) from total
PUFA. The assumed baseline intake of 6% E from total PUFA
was an average from the trials for which there were data, so we
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included trials that provided 0.6% E or above (or ≥ 1.33 g/d)
more or less total PUFA to the intervention arm compared to
control. If not then assess point 3.
3. Include if the trial provided within-trial intervention and
control group total PUFA intake aims, and the difference was
10% or more of the control group total PUFA intake OR the
difference was 10% or more of baseline total PUFA intake or an
assumed baseline intake of 6% E from total PUFA. Where intake
information came from trial aims we looked for corroboration
that there was a higher total PUFA intake in one arm than the
other, using information on control group supplements or
advice, body fat markers of total PUFA or serum total
cholesterol. Where a suggested higher intake of PUFA in one arm
by trial aims was contradicted by biomarker or total cholesterol
data (assuming lower total cholesterol with higher PUFA) we
excluded. We included trials that provided an additional total
PUFA of 0.6% E or more, or 1.33 g/d or more to the
intervention arm compared to control (taking into account
PUFA content of placebo and excluding if placebo content was
unclear). If no inclusion from point 3 then we excluded the trial.
We documented our reasoning over inclusion decisions in
Characteristics of included studies (see ’Inclusion basis’) and rea-
sons for exclusion in Characteristics of excluded studies. We
also ran sensitivity analyses on risk of bias from compliance (see
Sensitivity analysis).




2. coronary heart disease events: number of participants
experiencing at least one myocardial infarction (fatal or non-
fatal) or angina;
3. stroke (number of participants experiencing an ischaemic
and/or haemorrhagic stroke); and
4. major adverse cardiac and cerebrovascular events
(MACCEs, used where we could assess the numbers of
participants experiencing fatal or non-fatal myocardial
infarction, unstable angina or stroke).
Secondary outcomes
Secondary outcomes were all systematically reviewed. If any trial
fulfilled the other inclusion criteria and reported a secondary out-
come (even if no primary outcomes were reported) we included
it. Secondary outcomes included:
1. cardiovascular mortality (deaths due to cardiovascular
causes including myocardial infarction and stroke)
2. cardiovascular events (all available data on number of
participants experiencing any of fatal and non-fatal myocardial
infarction, angina and/or stroke);
3. coronary heart disease mortality;
4. myocardial infarction;
5. sudden cardiac death;
6. atrial fibrillation (arrhythmias including atrial fibrillation,
ventricular fibrillation and ventricular tachycardia);
7. angina;
8. heart failure;
9. Peripheral arterial disease (PAD);
10. revascularisation (participants experiencing angioplasty or
coronary artery bypass grafting);
11. measures of adiposity (including body weight, body mass
index (BMI), waist circumference, percentage body fat);
12. serum lipids (including total cholesterol, fasting
triglycerides, high-density lipoprotein (HDL) and low density
lipoprotein (LDL)).
Tertiary outcomes
Tertiary outcomes (not formally systematically reviewed) in-
cluded:
1. blood pressure (systolic and diastolic);
2. quality-of-life measures (such as feelings of health and time
off work);
3. economic costs;
4. serious adverse events (all serious adverse events presented
were collated but cancers, inflammatory bowel disease,
neurocognitive outcomes such as dementia, diabetes, functional
outcomes and depression are not reported here);
5. dropouts.
We included trials where data on any primary or secondary out-
come were available in published reports or based on contact with
trial authors. We collated data on tertiary outcomes where they
were present in included trials. Data on cancers (Hanson 2017b),
inflammatory bowel disease (Thorpe 2017), neurocognitive out-
comes including dementia (Jimoh 2017), diabetes (Brown 2017),
bone and muscle outcomes (Abdelhamid 2017) and depression
(Hanson 2017a) are reported fully and systematically in associated
reviews within this series, rather than a subset being presented
within this review.
Where it was clear that no participants experienced a particular
primary or secondary outcome (and the study had not collected
data on other primary or secondary outcomes) we excluded the
trial. For example, on exploration, a number of trial authors con-
firmed that no participants had died or experienced heart attacks in
their trials; in the absence of other primary or secondary outcomes
being recorded we excluded these from this review and noted them
in the exclusion list. Their inclusion into the review would have
swollen the size of the review without adding any useful data.
Key outcomes
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When the WHO NUGAG Subgroup on Diet and Health re-
quested this review they named the following as key outcomes to
inform their planned dietary guidance:
1. all-cause mortality;
2. cardiovascular disease mortality;
3. cardiovascular disease events
4. coronary heart disease mortality
5. coronary heart disease events
6. stroke
7. atrial fibrillation (arrhythmia)
8. serum lipids including total cholesterol, fasting
triglycerides, HDL and LDL; and
9. measures of adiposity (body weight and BMI)
We were not able make all of these primary outcomes. However,
because WHO NUGAG Subgroup on Diet and Health will use
these outcomes to underpin guidance, we carried out sensitivity
analyses, subgroup analyses and GRADE assessment of quality of
evidence for them, even when they were not primary outcomes.
All of these outcomes were formally systematically reviewed.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases on 27 April 2017
to identify reports of relevant randomised controlled trials:
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 4) in the Cochrane Library;
• Epub Ahead of Print, In-Process & Other Non-Indexed
Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 27
April 2017);
• Embase Classic and Embase (Ovid, 1947 to 27 April 2017).
We adapted the search strategy for MEDLINE (Ovid) from the
search strategy in Hooper 2018 and also used it to locate trials to
updateHooper 2018. This complex strategywas adapted for use in
the other databases (Appendix 1). We applied the Cochrane sensi-
tivity and precision-maximising RCT filter toMEDLINE (Ovid),
and for Embase, we applied terms recommended in the Cochrane
Handbook for Systematic Reviews of Interventions (Lefebvre 2011).
As we were also running searches for, updating and extending,
another existing Cochrane Review of the effects of omega-3 fats on
health outcomes (Abdelhamid 2018), and there was a great deal
of overlap between the searches, the omega-3 searches were also
run to May 2017, using the same RCT filters (Appendix 2). The
results of these searches were de-duplicated with the results from
the searches for this review and all the titles and abstracts assessed
as a single set. We created a dataset of RCTs that compared higher
versus lower omega-6 fats, omega-3 fats or total PUFA in adults
with a duration of at least 6 months. We used this dataset as the
wider trial pool from which to select included trials for all the
systematic reviews in this series (Abdelhamid 2016; Abdelhamid
2017; Abdelhamid 2018; Brown 2017; Hanson 2017a; Hanson
2017b; Jimoh 2017; Hooper 2018; Thorpe 2017).
We searched two clinical trials registers, ClinicalTrials.gov (
www.ClinicalTrials.gov) and theWHO International Clinical Tri-
als Registry Platform (ICTRP, www.who.int/ictrp/en/) during
September 2016 for registry entries for relevant completed and
ongoing trials.
Searching other resources
We checked included trials of relevant systematic reviews, and
wrote to authors of included studies for additional trials and trial
data (including unpublished outcome data).
We attempted to obtain full-text translations or evaluations of all
relevant non-English articles. Where these were not available we
translated papers ourselves using our existing language skills and
language translation software.
Data collection and analysis
Selection of studies
Two review authors independently screened titles and abstracts
identified by the searches and coded them as ’retrieve’ (eligible
or potentially eligible/unclear) or ’do not retrieve’. All review au-
thors carried out screening. All articles coded for retrieval by ei-
ther reviewer were collected in full text. We retrieved full-text
study reports/publications and two review authors independently
screened the full text, assessed studies for inclusion, and identi-
fied and recorded reasons for exclusion of ineligible trials (LH and
AA). We resolved any disagreement through discussion. Where a
trial met our inclusion criteria with the exception that they did
not report any relevant outcome, we wrote to the trial author to
ask whether any relevant outcomes occurred. We excluded trials
when no relevant primary or secondary outcome events had oc-
curred and the trial had not collected any data on our primary or
secondary continuous outcomes.
We identified and collated multiple reports of the same trial (as
each trial, rather than each report, was the unit of interest in the
review). We recorded the selection process in sufficient detail to
complete a PRISMA flow diagram and Characteristics of excluded
studies table (Moher 2009).
Data extraction and management
We developed a draft data collection form for collating study char-
acteristics and outcome data, then all review authors piloted the
form on a single included trial to standardise data extraction and
improve the data extraction form. All review authors took part in
data extraction. Two review authors each extracted the following
characteristics from included trials, independently in duplicate:
1. bibliographic details;
11Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2. trial registration database and number;
3. methods: trial design, total trial duration, details of any ’run
in’ period, number of study centres and location, trial setting,
withdrawals, and trial dates;
4. participants: number randomised in each arm, number
analysed in each arm, mean age, age range, gender, health status,
cardiovascular disease risk and a brief description of participants.
We categorised baseline cardiovascular risk as primary prevention
(participants not included on the basis of having existing
cardiovascular disease) and secondary prevention (participants
included on the basis of existing cardiovascular disease, such as
angina or a previous stroke or myocardial infarction);
5. interventions: intervention (including composition and
dose of PUFA intake advised or supplement used), comparison,
concomitant medications, and excluded medications;
6. outcomes: primary, secondary and tertiary outcomes
specified in trial registry, data on outcomes reported in
publications and by contact with authors, time points reported.
We assessed dichotomous outcomes at the latest point of
available follow-up within the trial, while we assessed continuous
outcomes at the latest point available in the trial (and after at
least 12 months);
7. process data: intake data (mean and standard deviation
(SD) of total PUFA, omega-3, omega-6, total fat, saturated fat,
monounsaturated fat (MUFA), carbohydrate, protein, energy,
alcohol and trans fat intake), biomarker data (erythrocyte, serum
or adipose tissue fatty acid status data) and serum total
cholesterol in intervention and control groups at latest point
available during RCT;
8. study funding and notable conflicts of interest of trial
authors.
We resolved disagreements between data extractions by consensus
or by involving a third person (LH or AA). One review author
(AA or LH) transferred data into the Review Manager 5 (RevMan
5) file (RevMan 2014). We double-checked that data had been
entered correctly from the agreed data extraction by comparing
the data presented in the systematic review with data extraction
(AA, JB, TJB or LH).
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
trial, alongside data extraction, using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011a). All review authors carried out data extraction and assess-
ment of risk of bias. We resolved disagreements by discussion or
by involving another author (LH or AA). We assessed the risk of
bias according to the following domains:
1. random sequence generation (selection bias);
2. allocation concealment (selection bias);
3. blinding of participants and personnel (performance bias);
4. blinding of outcome assessment (detection bias);
5. incomplete outcome data (attrition bias);
6. selective outcome reporting (reporting bias);
7. attention bias (another aspect of performance bias, where
the intervention or control groups receive more time and/or
attention from trial or health personnel during the trial); and
8. compliance (to be assessed as at low risk of bias regarding
compliance, the higher PUFA arm had to demonstrate an
increase in PUFA over control in a body biomarker (total PUFA
had to be assessed by at least linoleic acid plus one or more
further components of PUFA), or greater reduction in total
cholesterol in the higher PUFA arm. Where lipid biomarker and
total cholesterol contradicted each other we chose unclear.
9. other risk of bias
These are the domains of the Cochrane ’Risk of bias’ tool, with the
exceptions of attention bias and compliance, which were specific
to our review and added after discussion with theWHONUGAG
Subgroup on Diet and Health. We followed recommendations in
Higgins 2011a, recording funding data in the Characteristics of
included studies but not using them as a separate issue for assessing
risk of bias.
We graded each potential source of bias as high, low or unclear
risk and provided trial details, a quote from the trial report, or
both, together with a justification for our judgment in the ’Risk
of bias’ tables. We assessed summary risk of bias for each trial.
Where information on risk of bias related to unpublished data or
correspondence with a trial author, we noted it in the ’Risk of
bias’ tables. Further details of how we interpreted the risk of bias
elements across trials are found in Table 1.
Summary risk of bias
Schultz 1995 found that poorly concealed allocation was associ-
ated with a 40% greater effect size and so randomisation and allo-
cation concealment are core issues for all trials. Lack of blinding is
associated with bias, though smaller levels of bias than lack of allo-
cation concealment (Savovic 2012), especially in trials with objec-
tively measured outcomes (Wood 2008). Most of our outcomes
were objectively measured. Although we originally planned to as-
sess summary risk of bias in the same way across all trials in this
CochraneReview, the omega-3CochraneReview and the omega-6
Cochrane Review (Abdelhamid 2016; Abdelhamid 2018; Hooper
2018) we adopted a different approach after discussing the differ-
ent nature of supplement trials compared to dietary advice or food
provision trials with the NUGAG Subgroup on Diet and Health.
We considered a supplement or capsule-type trial to be at low
summary risk of bias, where we judged randomisation, allocation
concealment, blinding of participants and personnel, and blinding
of outcome assessors adequate. We considered all other trials at
moderate or high risk of bias (a single category).
We considered a dietary-advice or all-food-provided-type trial to
be at low summary risk of bias, where we judged randomisation,
allocation concealment, and blinding of outcome assessors ade-
quate. We considered all other trials at moderate or high risk of
bias (a single category).
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Assessment of bias in conducting the systematic
review
We conducted this Cochrane Review according to the published
Cochrane protocol and reported any deviations from it in the
’Differences between protocol and review’ section of the systematic
review.
Measures of treatment effect
We analysed dichotomous data as risk ratios (RRs) with 95% con-
fidence intervals (CIs) and continuous data as mean difference
(MD) with 95%CIs.We presented continuous data with a consis-
tent direction of effect (as a smaller reading is generally positive),
with the exception of HDL, where an increase is positive.
We used change data (change from baseline to latest point in trial
in each arm) for continuous data where available with appropriate
variance data. When change data were not available we used abso-
lute data from the latest point in each trial arm, unless baseline data
were too different between arms. (We considered baseline data too
different to use when the change in both arms, from baseline to
end data, was smaller than the baseline difference between arms).
Where continuous data were too different to use this we noted it
in the outcome section of Characteristics of included studies but
we did not add data to meta-analyses.
We intended narrative description of skewed data reported as me-
dians (without variance data or with interquartile ranges). We
added these data to forest plots so that there could be visual com-
parison of findings (though we did not include these data in
meta-analyses). We intended to use standardised mean differences
(SMD) to combine data where included trials had used different
scales to measure the same factor (such as quality of life). We did
not find any such data, so did not use SMD. We converted data
on different scales to the same scale, such as mg/dL and mmol/L
for lipids.
Unit of analysis issues
Trials with multiple intervention groups
Where trials included more than two arms we assessed all arms for
inclusion.Where there weremore than one intervention arm and a
single control armwe combineddichotomous and continuous data
for the intervention arms and compared them to the single control
arm. This meant there were no problems with trial participants
appearing more than once in any forest plot.
Cluster-RCTs
Where cluster-RCTs were included we planned to account for unit
of analysis issues by data extracting a direct estimate of the required
effect measure (for example, a RR with its CI) from an analysis
that accounted for the cluster design properly (for example, an
analysis based on a ‘multilevel model’, a ‘variance components
analysis’ or that used ‘generalised estimating equations (GEEs)’).
Where these data were available we planned to use them in meta-
analysis using the generic inverse-variance method (Deeks 2011).
Where no such correct analysis of the cluster-randomised data
were available, we planned to use approximate analyses using intra-
cluster correlation co-efficient (ICC) analysis as outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011b, section 16.3.4). We did not identify any such cluster-
randomised trials, so we did not need this methodology.
Dealing with missing data
We contacted (or attempted to contact) the authors of all poten-
tially included RCTs to better assess inclusion. We contacted au-
thors of all included trials that had randomised at least 100 partic-
ipants (and some smaller trials) to request available data on all of
the trial outcomes relevant to our set of reviews and key informa-
tion on risk of bias. Due to limited resources, we focused on con-
tacting authors of larger trials, who we thought were most likely to
provide substantial quantities of useful data. We sent an email and
a posted letter to the corresponding author at the latest address
we were able to obtain (tracking latest publications in Medline).
Where data on at least one review outcome were available (and at
least one person had experienced a relevant outcome), we included
the RCT, and asked the authors to provide any additional data
about trial methodology or risk of bias.
Where papers reported continuous results as change from baseline
we used these data, otherwise we used data at the latest point
available. We did not impute change data.
Assessment of heterogeneity
We used the I2 statistic (Higgins 2003) to measure heterogeneity
among the trials in each analysis. Where we identified substantial
heterogeneity (assumed when I2 was greater than 50%, as 30% to
60% represents moderate heterogeneity and we were allowing for
the varied dietary interventions included as well as potential dose
effects) we reported it and explored possible causes by prespecified
subgroup analysis.
Assessment of reporting biases
Where we were able to pool at least 10 trials, we created and
examined a funnel plot to explore possible reporting biases for the
primary outcomes (Sterne 2011).
We noted where we were aware of missing data. This occurred
where trial methods noted that an outcome had been measured
but those data had not been presented or had been presented
but not by trial arm, where continuous data were unbalanced at
baseline, or presented as medians or as means but without variance
information.
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Data synthesis
We undertook meta-analyses only where we considered it to be
meaningful, that is, where the treatments, participants and the un-
derlying clinical question were similar enough for pooling tomake
sense.We carried out statistical analysis using RevMan 5 (RevMan
2014). We used a random-effects model, as dietary interventions
are complex and somewhat heterogeneous by their nature (more
so than most medical treatments), but we compared the results of
random-effects and fixed-effect meta-analysis in sensitivity analy-
ses. As the random-effects model assigns more weight to smaller
trials, it is more conservative and may lead to imprecise estimates
of effect. We also carried out sensitivity analyses to assess the ef-
fects of methodological rigour (see Sensitivity analysis).
’Summary of findings’ table
We created a ’Summary of findings’ table for the primary out-
comes:
1. all-cause mortality;
2. coronary heart disease events;
3. stroke; and
4. MACCEs.
As WHO NUGAG Subgroup on Diet and Health required a
specific set of key outcomes for their guidance, we created a second
’Summary of findings’ table for the key outcomes not represented
in the main ’Summary of findings’ table:
1. cardiovascular mortality;
2. cardiovascular events;
3. coronary heart disease mortality;
4. atrial fibrillation;
5. measures of adiposity - body weight;
6. measures of adiposity - BMI; and
7. serum lipids (including total cholesterol, fasting
triglycerides, HDL and LDL).
We used the five GRADE considerations (trial limitations, con-
sistency of effect, imprecision, indirectness and publication bias)
to assess the quality of a body of evidence as it related to the tri-
als that contributed data to the meta-analyses for the prespecified
outcomes. We used methods and recommendations described in
Section 8.5 (Higgins 2011a) and Chapter 12 (Schünemann 2011)
of the Cochrane Handbook for Systematic Reviews of Interventions,
and used GRADEpro GDT software (GRADEpro GDT 2015).
We justified all decisions to downgrade the quality of trials using
footnotes and made comments to aid reader’s understanding of
the review where necessary.
Subgroup analysis and investigation of heterogeneity
We explored the effects of PUFA intake on primary outcomes and
key outcomes by performing exploratory subgroup analyses on:
1. total PUFA dose (and dose response: total PUFA dose < 1%
E, 1% E to < 2% E; 2% E to < 5% E and ≥ 5% E where dose is
the difference in total PUFA intake between intervention and
control arms);
2. trial duration: trials with medium follow-up (12 to 23
months), medium to long follow-up (24 to 47 months), and
long follow-up (48 months or more);
3. baseline risk of cardiovascular disease (primary prevention,
or secondary prevention);
4. baseline total PUFA intake (< 6% E from total PUFA, 6%
E to < 11% E, and ≥ 11% E from total PUFA);
5. replacement of saturated fat, MUFA, carbohydrate and
protein with total PUFA;
6. participants’ sex (> 70% of the control group were men, >
70% of the control group were women, and mixed men and
women);
7. participants’ age (mean age in control group < 50 years, 50
to < 65 years and ≥ 65 years);
8. statin use (at least 50% of control group on statins versus
fewer than 50% on statins); and
9. intervention type (dietary advice, supplements (capsules),
supplemental foods and all foods provided, or any combination)
We also planned to subgroup by change in the omega-3/omega-
6 fat ratio (assessing whether the intervention primarily increased
omega-3 fats (putting up the ratio) or omega-6 fats (lowering
the ratio)). However, in almost no trials did we have information
allowing us to calculate the omega-3/omega-6 fat ratio, so we did
not carry out this subgrouping.
The 6%E and 11% E cut-offs for total PUFA were prespecified by
WHO NUGAG Subgroup on Diet and Health, as their existing
recommendations for PUFA intake were 6% E to 11% E in adults
(WHO/FAO 2008).
We have not discussed differential effects of omega-3 and omega-
6 PUFAs in this review, as separate reviews address the effects of
omega-3 and omega-6 fats on cardiovascular disease in more detail
(Hooper 2018; Abdelhamid 2018).
We used the formal test for subgroup interactions in RevMan 5
(RevMan 2014). These subgroupings were requested by WHO
NUGAG Subgroup on Diet and Health to better help them un-
derstand the data. The danger of having so many subgroup anal-
yses is that they may be over-interpreted, increasing the risk of a
type one error.
Meta-regression
We planned meta-regression to further explore effects of total
PUFA dose (looking for evidence of dose response), baseline to-
tal PUFA intake and duration on dichotomous primary and sec-
ondary outcomes with at least seven included trials and for which
subgrouping was undertaken. However baseline total PUFA in-
take was only clear in a handful of trials, so we did not run meta-
regression by baseline PUFA intake. Random-effects meta-regres-
sion (Berkley 1995) was performed using the STATA command
metareg (Sharp 1998): log(e) relative risk versus [dose or primary/
secondary prevention or type of intervention or risk of bias or du-
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ration], weighted by the standard error of the log(e) relative risk.
Where there were no events in one arm we added 0.1 to the num-
bers for both groups (so a trial with 10 people experiencing stroke
in one arm but none in the other arm would be entered as 10.1
and 0.1).
Sensitivity analysis
We planned to carry out the following sensitivity analyses on all
primary outcomes, and key outcomes:
1. only including trials with a low risk of bias for allocation
concealment;
2. only including trials with a low risk of attention bias;
3. only including trials with a low risk of bias from
compliance;
4. only including trials at low summary risk of bias;
5. only including all trials up to 2010, plus trials post-2010
that were registered in a trials register (Roberts 2015, regardless
of the date of registration);
6. only including trials with no industry funding reported
(trials with funding or support from partial bodies such as
government boards to support specific foods or where funding
was not mentioned were also excluded);
7. only including trials with less than 10% difference in intake
of trans fats between trial arms during the intervention;
8. only including trials that randomised at least 100
participants;
9. only including trials that randomised at least 250
participants;
10. using fixed-effect meta-analysis.
Unfortunately almost no data on trans fats were available, so we
did not carry out sensitivity analysis around trans fats.
Reaching conclusions
We based our conclusions only on findings from the quantitative
or narrative synthesis of included trials for this review. Outcome
data were interpreted as follows:
1. Is there an effect? (Options were ‘increased risk’, ‘decreased
risk’, or ‘little or no effect’). Our main outcome measures were
RR and MD so we decided on existence of an effect using RR.
RR >8% (RR <0.92 or >1.08) for the highest quality evidence
suggested increased or decreased risk (otherwise little or no
effect). The presence or not of an effect was decided on the RR
for the main analysis and sensitivity analyses.
2. Quality of evidence was assessed using GRADE assessment
(GRADE Working Group 2004) for key outcomes. We used the
five GRADE considerations (risk of bias, consistency of effect,
imprecision, indirectness and publication bias) to assess the
quality of the body of evidence as it related to the trials that
contributed data to the meta-analyses for the prespecified
outcomes. We used methods and recommendations described in
Section 8.5 and Chapter 12 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), plus
GRADEpro GDT software (GRADEpro GDT 2015). We
justified all decisions to downgrade the quality of trials using
footnotes and made comments to aid reader’s understanding of
the review.
3. Where there was a suggested effect the size of effect was
assessed using the MD, NNT or ARR.
We avoided making recommendations for practice and our im-
plications for research suggest priorities for future research and
outline the remaining uncertainties in the area.
R E S U L T S
Description of studies
Results of the search
The electronic searches for the full set of reviews (populating the
dataset of all trials that assessed effects of higher versus lower
omega-6, omega-3 or PUFA over at least 6 months) generated
37,810 titles and abstracts, which we de-duplicated to 19,772 hits.
We assessed these along with 53 studies previously included from
Hooper 2018 and Abdelhamid 2018, to reassess for inclusion;
986 potentially relevant trials registry entries; and 35 new refer-
ences gained from systematic review reference lists. In total, we
assessed 20,846 titles and abstracts in duplicate to decide whether
to retrieve full texts. We ultimately assessed 2155 full-text reports,
of which 226 were systematic reviews. Two review authors inde-
pendently assessed the remaining 1929 papers for inclusion and
grouped them into studies. Of these, we included 208 RCTs in a
wider set of trials that underpinned the full set of reviews (this re-
view and several others including Abdelhamid 2018; Abdelhamid
2017;Hooper 2018; Brown2017;Hanson 2017a;Hanson 2017b;
Jimoh 2017; Thorpe 2017). This wider set of trials included RCTs
of omega-3, omega-6 or total polyunsaturated fatty acids (PUFA)
interventions with a duration of at least six months (Figure 1) and
comprised 730 reports.
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Figure 1. Study flow diagram
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Of these 208 RCTs:
• 22 RCTs (26 documents) assessed effects of PUFA over at
least one year but were ongoing (without published outcome
data);
• 137 RCTs (361 documents) did not assess effects of a high
enough dose of PUFA or had a duration of less than one year, so
we excluded them; and
• 49 RCTs (183 documents) were eligible for inclusion in this
review.
Of these 49 RCTs, 48 were included in meta-analyses.
Details of the flow of trials are in Figure 1.
The 22 potential ongoing trials are described in the table of
Characteristics of ongoing studies. These trials are very difficult
to assess for inclusion in terms of total PUFA dose until further
details are published. We will formally assess these trials for inclu-
sion when we update this review.
Included studies
The details of the methods, participants, intervention, compar-
ison group, and outcome measures for each of the included tri-
als are shown in the Characteristics of included studies table.
Forty-nine trials, including 24,272 randomised participants, met
the inclusion criteria. Trials ranged in size from 36 randomised
participants (Rossing 1996) to 4997 randomised participants
(PREDIMED 2013), with 15 trials randomising at least 250
participants (AlphaOmega - ALA; Bates 1989; DART fat 1989;
EPIC-1 2008; EPIC-2 2008; EPOCH 2011; FAAT - Leaf 2005;
MRC 1968; NDHS Open 1st 1968; ORL 2013; PREDIMED
2013; Sydney Diet-Heart 1978; Veterans Admin 1969; WAHA -
Ros 2016; WINS 2006).
Twenty-two trials recruited mostly men (at least 70% men in
the control group, Ahn 2016; AlphaOmega - ALA; DART fat
1989; DIPP-Tokudome 2015; Doi 2014; Dullaart 1992; FAAT
- Leaf 2005; GLAMT 1993; HARP- Sacks 1995; Kumar 2012;
Ley 2004; Mendis 2001; MRC 1968; NDHS Faribault 1968;
NDHS Open 1st 1968; Nodari 2011 HF; Nye 1990; ORL 2013;
Raitt 2005; Sydney Diet-Heart 1978; Veterans Admin 1969;
Vijayakumar 2014), six trials recruited mostly women (at least
70% women in the control group, Bassey 2000-Post; Bassey
2000-Pre; Dodin 2005; Proudman 2015; Simon 1997; WINS
2006), 16 recruited similar numbers of men and women while five
trials did not state the sex or participants (Bates 1977; EPOCH
2011; HERO-Tapsell 2009; McIllmurray 1987; Rose 1965).
Almost half of the trials (24 trials) recruited participants with a
mean age between 50 and 65 years, but 12 trials recruited younger
participants (mean age < 50 years, Bassey 2000-Pre; Bates 1978;
Bates 1989; Dullaart 1992; EPIC-1 2008; EPIC-2 2008; NDHS
Faribault 1968; NDHSOpen 1st 1968; Puri 2005; Rossing 1996;
Simon 1997; SydneyDiet-Heart 1978), eight trials recruited older
participants (mean age 65 years or more, AlphaOmega - ALA;
Doi 2014; FAAT - Leaf 2005; Kumar 2013; Nodari 2011 AF;
PREDIMED 2013; Veterans Admin 1969; WAHA - Ros 2016),
and five trials did not give a mean age or range that could be
classified (Ahn 2016; Bates 1977; EPOCH 2011; Houtsmuller
1979; Mendis 2001).
Twenty trials were conducted in Europe (AlphaOmega - ALA;
Bassey 2000-Post; Bassey 2000-Pre; Bates 1977; Bates 1978; Bates
1989; Brox 2001; DART fat 1989;Dullaart 1992; GLAMT1993;
Houtsmuller 1979;MARINA - Sanders 2011;McIllmurray 1987;
MRC 1968; Nodari 2011 AF; Nodari 2011 HF; PREDIMED
2013; Rose 1965; Rossing 1996;WELCOME 2015), 10 inNorth
America (Black 1994; Dodin 2005; FAAT - Leaf 2005; HARP-
Sacks 1995; NDHS Faribault 1968; NDHSOpen 1st 1968; Raitt
2005; Simon 1997; Veterans Admin 1969;WINS 2006), seven in
Asia (Ahn 2016;DIPP-Tokudome 2015;Doi 2014;Mendis 2001;
Mita 2007; ORL 2013; Vijayakumar 2014), eight in Australia or
NewZealand (EPOCH2011;HERO-Tapsell 2009; Kumar 2012;
Kumar 2013; Ley 2004; Nye 1990; Proudman 2015; Sydney
Diet-Heart 1978), while four trials were conducted across several
continents (EPIC-1 2008; EPIC-2 2008; Puri 2005;WAHA - Ros
2016).
The trials varied in the types of participants recruited and their level
of cardiovascular risk. Most trials recruited participants without
a personal history of cardiovascular disease (primary prevention),
but 16 recruited participants with existing cardiovascular disease
of some sort (secondary prevention of cardiovascular disease, Ahn
2016; AlphaOmega - ALA; DART fat 1989; Doi 2014; FAAT -
Leaf 2005; HARP- Sacks 1995; Kumar 2012; Kumar 2013; MRC
1968; Nodari 2011 AF; Nodari 2011 HF; Nye 1990; Raitt 2005;
Rose 1965; Sydney Diet-Heart 1978; Vijayakumar 2014).
Total PUFA dose (the difference in total PUFA between interven-
tion and control arms) was between 0.6% E and less than 1% E
for 13 trials (Doi 2014; EPOCH2011; FAAT - Leaf 2005; Kumar
2012; Kumar 2013; Ley 2004; MARINA - Sanders 2011; Mita
2007; Nodari 2011 AF; Nodari 2011 HF; ORL 2013; Puri 2005;
Raitt 2005), 1% E to less than 2% E total PUFA in 17 trials (Ahn
2016; AlphaOmega - ALA; Bassey 2000-Post; Bassey 2000-Pre;
Bates 1977; Bates 1978; Bates 1989; Brox 2001; DIPP-Tokudome
2015; Dodin 2005; EPIC-1 2008; EPIC-2 2008; Nye 1990;
PREDIMED 2013; Proudman 2015; WELCOME 2015; WINS
2006), 2% E to less than 5% E in eight trials (Black 1994; DART
fat 1989; Dullaart 1992; GLAMT 1993; HARP- Sacks 1995;
McIllmurray 1987; Mendis 2001; Rossing 1996), and at least 5%
E from total PUFA in 11 trials (HERO-Tapsell 2009;Houtsmuller
1979; MRC 1968; NDHS Faribault 1968; NDHS Open 1st
1968; Rose 1965; Simon 1997; SydneyDiet-Heart 1978; Veterans
Admin 1969; Vijayakumar 2014; WAHA - Ros 2016).
Increases in total PUFA were delivered to participants in various
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ways. Most trials gave supplemental capsules or foods taken as
supplements (supplemental oil drunk with meals in Rose 1965,
seal or cod liver oil drunk in Brox 2001 and flax seed incor-
porated into foods in Dodin 2005), while eight trials gave di-
etary advice resulting in increased PUFA (Black 1994; DART fat
1989; Dullaart 1992; Houtsmuller 1979; Ley 2004; Simon 1997;
Sydney Diet-Heart 1978; WINS 2006), eight trials gave supple-
mental foods such as margarines or nuts (AlphaOmega - ALA;
HERO-Tapsell 2009; NDHS Faribault 1968; NDHS Open 1st
1968; PREDIMED 2013; Veterans Admin 1969; Vijayakumar
2014; WAHA - Ros 2016), and three trials used a combination of
methods (DIPP-Tokudome 2015; Mendis 2001; MRC 1968).
Baseline total PUFA intake was unclear in most trials, but where
information was provided it ranged from 3.9% E (NDHS Open
1st 1968) to 8% E (Black 1994) in control groups. Seven trials
had baseline total PUFA intake less than 6% E (Dodin 2005;
HERO-Tapsell 2009; Ley 2004; NDHS Faribault 1968; NDHS
Open 1st 1968; Veterans Admin 1969; WINS 2006), while nine
had baselines of at least 6% E PUFA (Black 1994; DART fat
1989;DIPP-Tokudome 2015;Dullaart 1992;MARINA - Sanders
2011; PREDIMED 2013; Simon 1997; SydneyDiet-Heart 1978;
WAHA - Ros 2016). PUFA replaced saturated fat at least par-
tially in nine trials (DART fat 1989; Dullaart 1992; HARP- Sacks
1995;MRC1968;NDHSFaribault 1968;NDHSOpen1st 1968;
Sydney Diet-Heart 1978; Veterans Admin 1969; Vijayakumar
2014), replaced monounsaturated fats in 21 trials (AlphaOmega -
ALA; Bates 1977; Bates 1978; Bates 1989; EPOCH 2011; FAAT
- Leaf 2005; HARP- Sacks 1995; MARINA - Sanders 2011;
NDHS Faribault 1968; NDHS Open 1st 1968; Nodari 2011
AF; Nodari 2011 HF; Nye 1990; PREDIMED 2013; Proudman
2015; Raitt 2005; Rose 1965; Rossing 1996; Sydney Diet-Heart
1978; Veterans Admin 1969;WELCOME 2015), replaced carbo-
hydrate in 11 trials (Black 1994; DIPP-Tokudome 2015; Dodin
2005; Houtsmuller 1979; Ley 2004; MARINA - Sanders 2011;
Mendis 2001; Rose 1965; Simon 1997; WAHA - Ros 2016;
WINS 2006), and replaced protein at least partially in four trials
(HERO-Tapsell 2009; Ley2004;MRC1968;WAHA-Ros 2016).
In some trials PUFA replaced several dietary components, in oth-
ers there was one main replacement, but replacements were un-
clear for 14 trials (Ahn 2016; Bassey 2000-Post; Bassey 2000-Pre;
Brox 2001; Doi 2014;GLAMT1993; Kumar 2012; Kumar 2013;
EPIC-1 2008; EPIC-2 2008;McIllmurray 1987;Mita 2007;ORL
2013; Puri 2005).
In most trials fewer than 50% of participants in the control group
were taking statins (assumed in trials published before 1994 when
the 4S Trial 1994 was published showing overall benefits from
statins in higher-risk populations and statin use began to rise,
and in populations not at particular cardiovascular disease risk),
but in seven trials at least 50% of participants were taking statins
(Ahn 2016; AlphaOmega - ALA; Doi 2014;HERO-Tapsell 2009;
Kumar 2013; Vijayakumar 2014; WELCOME 2015), and three
trials were unclear (FAAT - Leaf 2005; Ley 2004; WAHA - Ros
2016).
The duration of the intervention was one to less than two years
in most trials, but was two to less than four years in 16 trials
(AlphaOmega - ALA; Bates 1977; Bates 1978; Bates 1989; Black
1994; DART fat 1989; DIPP-Tokudome 2015; Dullaart 1992;
HARP- Sacks 1995; McIllmurray 1987; Mita 2007; Raitt 2005;
Rose 1965; Simon 1997; Vijayakumar 2014;WAHA - Ros 2016),
and four years or more in duration in six trials (Houtsmuller
1979; MRC 1968; PREDIMED 2013; Sydney Diet-Heart 1978;
Veterans Admin 1969; WINS 2006).
Included trials were published over half a century between the
1960s (Rose 1965; MRC 1968; NDHS Faribault 1968; NDHS
Open 1st 1968; Veterans Admin 1969) and the 2010s (Ahn 2016;
AlphaOmega - ALA; DIPP-Tokudome 2015; Doi 2014; EPOCH
2011; Kumar 2012; Kumar 2013; MARINA - Sanders 2011;
Nodari 2011 AF; Nodari 2011 HF; ORL 2013; PREDIMED
2013; Proudman 2015; Vijayakumar 2014; WAHA - Ros 2016;
WELCOME 2015), with some trials published in each decade.
Funding sources were reported and appeared to be purely from
national or charitable agencies in 17 trials (Ahn 2016; Black 1994;
Brox 2001; DIPP-Tokudome 2015; Dullaart 1992; FAAT - Leaf
2005; Houtsmuller 1979; Ley 2004; MARINA - Sanders 2011;
Mendis 2001; MRC 1968; NDHS Faribault 1968; NDHS Open
1st 1968;Nodari 2011AF; SydneyDiet-Heart 1978;Vijayakumar
2014; WINS 2006). Seven trials appeared to be directly funded
by industrial sources (Bassey 2000-Post; Bassey 2000-Pre; EPIC-1
2008; EPIC-2 2008; GLAMT 1993; ORL 2013; Puri 2005), two
funded by bodies set up to promote specific foods (HERO-Tapsell
2009; WAHA - Ros 2016), 16 trials funded by some governmen-
tal or charity sources with additional funding or support from
commercial sources (AlphaOmega - ALA; Bates 1977; Bates 1978;
Bates 1989; DART fat 1989; EPOCH 2011; HARP- Sacks 1995;
Kumar 2012; Nye 1990; PREDIMED 2013; Proudman 2015;
Raitt 2005; Rossing 1996; Simon 1997; Veterans Admin 1969;
WELCOME 2015), two trials that included authors on industry
honoraria (Doi 2014;Nodari 2011HF), andfive trialswhere fund-
ing was not reported (Dodin 2005; Kumar 2013; McIllmurray
1987; Mita 2007; Rose 1965).
Most included trials had a single intervention arm and a single
control arm, but some trials were more complex.
1. Bates 1977 had four arms, two intervention arms each had
their own control arm, so were dealt with as separate trials. Both
were included, as deaths appear to have occurred, but it is no
longer clear how many or which arms they occurred in.
2. Bates 1978 also had two intervention arms each with their
own control arm, but comparison C versus D did not have any
relevant outcome data so we excluded it. We only included A
versus B.
3. Brox 2001 had two intervention arms and one control arm.
For all outcomes, we combined the two intervention groups and
compared to the single control group.
4. DART fat 1989 was a factorial trial, but we have included
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only one of the three factorial interventions in this review, so all
participants have been included only once.
5. MARINA - Sanders 2011 had three intervention arms of
different doses and one control arm. Only one intervention arm
was included in this review (D2) and compared to the control
arm.
6. NDHS Faribault 1968 and NDHS Open 1st 1968 each
had three intervention arms and a single control. We combined
data for the three arms and compared them to the single control
arm in each trial.
7. Nye 1990 had three arms, but one was irrelevant to this
review so not included.
8. ORL 2013 had three arms, but we only included two arms
(higher vs lower dose omega-3)
9. PREDIMED 2013 had three arms, a Mediterranean diet
with nuts, a Mediterranean diet with olive oil and a low-fat arm.
For this review we compared the Mediterranean diet with nuts
(high PUFA) with the Mediterranean diet with olive oil (low
PUFA) as these two arms were very similar but with different
PUFA intakes. For many outcomes data were reported in
publications by trial centre (or combination of trial centres), so
we checked for overlap of participants then reported the
outcome centre by centre where we were sure that no
participants were included more than once.
Excluded studies
We have presented details and reasons for exclusion of the trials
thatmost closelymissed the inclusion criteria in theCharacteristics
of excluded studies table.
Risk of bias in included studies
Our assessment of risk of bias of included trials is summarised in
Figure 2 and detailed by trial in Figure 3.We assessed eleven of the
49 included trials as being at low summary risk of bias; eight trials
as being at low risk of bias from randomisation, allocation con-
cealment, performance and detection biases (AlphaOmega - ALA;
EPOCH2011;MARINA - Sanders 2011;NDHSFaribault 1968;
NDHSOpen 1st 1968; Proudman 2015; Puri 2005;WELCOME
2015), and three trials, which were dietary advice or provision
trials, as being at low risk of bias from randomisation, allocation
concealment and detection bias (Ley 2004; Sydney Diet-Heart
1978; WINS 2006). We assessed the remaining 37 trials as being
at moderate or high risk of bias.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial
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Allocation
Randomisation was adequate in 36 of the 49 trials, not well de-
scribed in 12 trials and at high risk in one trial (PREDIMED
2013). Allocation concealment was appropriate in 22 included
trials, unclear in 26, and at high risk of bias in one (PREDIMED
2013). Twenty-two trials were at low risk of selection bias, with
low risk of bias from both randomisation and allocation conceal-
ment (see Figure 3).
Blinding
Blinding of participants and personnel appeared at low risk of
bias for 17 trials, unclear for 13 and at high risk of bias for the
remaining 19 trials. Blinding of outcome assessors was at low risk
of bias in 26 trials, unclear in 18 and at high risk of bias in five
trials. Eleven trials were well blinded, at low risk of bias from both
blinding of participants, personnel and outcome assessors.
Incomplete outcome data
Twenty-nine trials appeared to be at low risk of attrition bias, 11
were at high risk and the remainder unclear.
Selective reporting
We found five trials that had a trials registry entry or protocol
published before data collection was completed, and reported all
outcomes suggested in the entry or protocol. Thirty-three were
unclear, generally because no trials registry entry or protocol was
identified, or because they were published after the end of data
collection. We found 11 trials were at high risk of selective report-
ing, as at least one outcome suggested in the trials registry entry
or protocol was not reported in full.
We attempted to access additional outcome data as well asmethod-
ological data from most included trials. We established contact
with most trial authors, and received data on outcomes that had
not been fully published from many (noted in Characteristics of
included studies for relevant trials), although some trial authors
were unable to provide additional information or repeated phrases
from their published papers. We tried to contact, but did not re-
ceive any reply from, authors of 10 trials (Ahn 2016; Doi 2014;
GLAMT 1993; Houtsmuller 1979; Kumar 2012; Kumar 2013;
Mendis 2001; Nodari 2011 AF; ORL 2013; Raitt 2005). We did
not attempt to contact authors of some of the oldest trials, as the
trials were conducted in the 1960s and their authors were unlikely
to be accessible (NDHS Faribault 1968; NDHS Open 1st 1968;
Rose 1965; Veterans Admin 1969), although we hadmade contact
with the retired statistician of another older trial when including
that trial in an earlier systematic review (MRC 1968). We did not
attempt to contact authors of five trials (Bassey 2000-Post; Bassey
2000-Pre; HERO-Tapsell 2009; Mita 2007; Nye 1990).
Other potential sources of bias
We assessed attention bias, where intervention participants ap-
peared to receive more time or attention from health professionals
than those in the control group. Thirty-six trials appeared to be at
low risk of attention bias, eight were at high risk, and the remain-
ing five were unclear.
We assessed compliance, to ensure that PUFA truly appeared to
have been higher in one arm than the other, by looking for evi-
dence of changes or differences in a body biomarker (total PUFA
had to be assessed by at least linoleic acid (LA) plus one or more
further components of PUFA), or greater reduction in total choles-
terol in the higher PUFA arm. Where lipid biomarker and total
cholesterol contradicted each other we chose unclear. We found
that 17 trials demonstrated appropriate compliance, 10 suggested
poor compliance while 22 trials were unclear.
Four trials were found to be at high risk from other potential bias.
Ahn 2016 was unclear about whether the control arm received a
placebo or not, and some SDs appeared to be incorrectly reported.
When we looked for additional data on Houtsmuller 1979 we
found that concerns had been raised over potential research fraud
of the first author in later trials (assessing effects of diet on cancer).
While no concerns were found about the included research we
felt that this did potentially reflect a risk of fraud in the included
trial. In Kumar 2013, 21 of the 39 participants randomised to the
intervention were inexplicably crossed over to the control condi-
tion at six months, so that 12-month outcomes were only reported
for 17 of the 39 randomised participants. The main publication
of PREDIMED 2013 was retracted and republished in 2018 due
to randomisation and allocation concealment problems not men-
tioned in the initial publication that resulted in a distribution of
baseline variables inconsistentwith randomisation (Carlisle 2017).
We found McIllmurray 1987 and Mendis 2001 to be at unclear
risk of other bias, as neither described their control group inter-
ventions. The remaining trials were considered to be at low risk of
other potential bias.
Effects of interventions
See: Summary of findings for the main comparison Higher
polyunsaturated fatty acid (PUFA) compared to lower PUFA for
cardiovascular disease - primary outcomes; Summary of findings
2 Higher polyunsaturated fatty acid (PUFA) compared to lower
PUFA for cardiovascular disease - additional key outcomes
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Primary outcomes
For ’Summary of findings’ table on primary outcomes see
Summary of findings for the main comparison.
All-cause mortality
PUFA intake probably has little or no effect on all-cause mortality
(moderate-quality evidence).
Twenty-four trials including 19,290 participants reported at least
one death and could be added to the meta-analysis. There was no
clear effect of more PUFA compared to less PUFA intake on all-
cause mortality (RR 0.98, 95% CI 0.89 to 1.07, I2 = 0%, 1443
deaths; Analysis 1.1). This lack of effect did not differ in fixed-
effect analysis (RR 0.98, 95% CI 0.89 to 1.07; Analysis 1.3), or
sensitivity analysis restricting to trials at low risk of bias for allo-
cation concealment (RR 1.03, 95% CI 0.87 to 1.22), low risk of
attention bias (RR 0.96, 95% CI 0.87 to 1.07), compliance bias
(RR 1.01, 95% CI 0.89 to 1.14), low summary risk of bias (RR
1.04, 95% CI 0.87 to 1.26), trials registry or pre-2010 publica-
tion (RR 0.99, 95% CI 0.90 to 1.08), trials without any industry
funding (RR 1.09, 95% CI 0.84 to 1.42), that randomised at least
100 participants (RR 0.98, 95% CI 0.89 to 1.08) or at least 250
participants (RR 1.00, 95% CI 0.91 to 1.10; Analysis 1.2). The
funnel plot did not suggest any publication bias, though we are
aware of two trials with deaths that we were not able to add to the
analyses (Bates 1977; Simon 1997).
Subgrouping did not suggest differential effects by total PUFA
dose (Analysis 1.4), duration (Analysis 1.5), primary or secondary
prevention (Analysis 1.6), baseline PUFA intake (Analysis 1.7),
dietary component displaced by the increase in PUFA (Analysis
1.8), participant sex (Analysis 1.9), participant age (Analysis 1.10),
statin use (Analysis 1.11), or type of intervention (Analysis 1.12).
There was no suggestion of important effects in any of the four
trials each taking more than 10% of the weight in meta-analy-
sis (AlphaOmega - ALA; DART fat 1989; PREDIMED 2013;
Veterans Admin 1969).
Meta-regression did not suggest any relationships between total
PUFA dose (P = 0.94) or trial duration (P = 0.81) and all-cause
mortality. We did not run meta-regression of baseline PUFA dose
and all-cause mortality as few trials provided this information.
We downgraded the GRADE evidence level for imprecision as the
95%CI included important benefits (moderate-quality evidence),
Summary of findings for the main comparison.
Coronary heart disease events
PUFA intake probably reduces risk of coronary heart disease events
slightly (NNT 53, moderate-quality evidence).
Fifteen trials including 10,076 participants were included and
1351 participants reported at least one coronary heart disease
event. Meta-analysis suggested that higher PUFA intake resulted
in 13% fewer participants having coronary heart disease events
(RR 0.87, 95% CI 0.72 to 1.06, I2 = 45%; Analysis 1.13). None
of the four trials that carried at least 10% of the weight of the
meta-analyses suggested statistically significant effects in their own
right (AlphaOmega - ALA; DART fat 1989;MRC 1968; Veterans
Admin 1969). The funnel plot did not suggest any serious publi-
cation bias (not shown).
Sensitivity analyses using fixed-effects analysis suggested a 10%
reduction in risk of coronary heart disease with increased PUFA
(RR 0.90, 95% CI 0.82 to 0.99; Analysis 1.15), but other sensi-
tivity analyses suggested varying results both sides of no effect (RR
1.00). These included restricting to trials at low risk of bias for
allocation concealment (RR 1.14, 95% CI 0.73 to 1.78), low risk
of attention bias (RR 0.86, 95%CI 0.72 to 1.02), compliance bias
(RR 0.87, 95% CI 0.65 to 1.17), low summary risk of bias (RR
1.18, 95% CI 0.76 to 1.81), trials registry or pre-2010 publica-
tion (RR 0.87, 95% CI 0.72 to 1.06), trials without any industry
funding (RR 0.72, 95% CI 0.31 to 1.63), that randomised at least
100 participants (RR 0.87, 95% CI 0.70 to 1.08) or at least 250
participants (RR 0.94, 95% CI 0.82 to 1.09; Analysis 1.14).
Subgrouping by PUFA dose and trial duration did not suggest
important differences between subgroups, or dose or duration ef-
fects. There were only six events in trials with doses of less than
1% E (Analysis 1.16) and 21 events in trials of less than two years
(Analysis 1.17). Meta-regression did not suggest any relationship
between PUFA dose (P = 0.69) or trial duration (P = 0.51) and
coronary heart disease events.
Subgrouping did not suggest differential effects by primary or sec-
ondary prevention (P = 0.12; Analysis 1.18), baseline PUFA in-
take (Analysis 1.19), replacement of saturated fat or MUFA with
PUFA (Analysis 1.20), age (Analysis 1.22), statin use or interven-
tion type (Analysis 1.23; Analysis 1.24). Most coronary heart dis-
ease events occurred in trials of men, there is insufficient infor-
mation to understand effects in other subgroups, though rather
surprisingly there was a significant difference between subgroups
of men and women combined and trials of mostly men or mostly
women (Analysis 1.21).
We downgraded the GRADE evidence level for imprecision and
risk of bias combined (as despite over 10,000 participants the 95%
confidence intervals included harm from increasing PUFA as well
as benefit). PUFA intake probably reduces risk of coronary heart
disease events, from 14.2% to 12.3% in the study populations,
NNT 53 (moderate-quality evidence), Summary of findings for
the main comparison.
Stroke
PUFA intake may very slightly reduce risk of stroke (NNT 1000,
low-quality evidence). However, the 95% confidence intervals in-
clude important harms as well as benefit.
Eleven trials including 14,742 participants of whom 166 expe-
rienced at least one fatal or non-fatal stroke. Meta-analysis sug-
gested some reduction in risk of stroke with increased PUFA, but
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confidence intervals were wide (RR 0.91, 95% CI 0.58 to 1.44, I2
= 24%; Analysis 1.25). The funnel plot did not suggest any small
study bias (not shown).
This suggestion of benefit from PUFA was also seen in the fixed-
effect sensitivity analysis (RR 0.82, 95% CI 0.61 to 1.11, Analysis
1.27). While sensitivity analyses retaining only trials at low risk
of bias from allocation concealment, attention and low summary
risk of bias all suggested reduced stroke risk with increased PUFA,
as did those on trials registers or pre-2010, and trials of at least 100
participants, this was not the case for sensitivity analyses of trials
at low risk of bias from compliance (RR 1.36, 95% CI 0.45 to
4.11, I2 = 56%), trials without industry funding or of at least 250
participants (RR 0.98, 95% CI 0.60 to 1.60, I2 = 33%), Analysis
1.26.
Subgrouping did not suggest greater effects with higher doses of
PUFA (Analysis 1.28), or longer duration (Analysis 1.29), without
significant differences between subgroups.Meta-regressiondidnot
suggest relationships between PUFA dose and stroke (P = 0.69),
but there was limited non-statistically significant suggestion of
greater benefit in longer trials (P = 0.11).
There were no significant differences between subgroups by pri-
mary or secondary prevention (P = 0.20; Analysis 1.30), base-
line PUFA dose (Analysis 1.31), sex (Analysis 1.33), statin use
(Analysis 1.35), fatal or non-fatal stroke (Analysis 1.37), replace-
ment (Analysis 1.32), or intervention type (Analysis 1.36). There
were differences when subgrouping was by age (Analysis 1.34),
but greater protection at older age was balanced by harm in mid-
life - a confusing picture. Where data on ischaemic or haemor-
rhagic stroke could be separated out, both subgroups suggested
harm from increased PUFA, while data on combined ischaemic
and haemorrhagic events suggested benefit from increased PUFA,
again a non-intuitive pattern (Analysis 1.38).
We downgraded the GRADE quality assessment twice for impre-
cision (even though over 14,000 participants were included only
166 people experienced stroke so we were underpowered to as-
sess effects). PUFA intake may reduce risk of stroke, from 1.2%
to 1.1% in the study populations, NNT 1000 (low-quality evi-
dence), but harms are not ruled out, Summary of findings for the
main comparison.
Major adverse cardiac and cardiovascular events (MACCEs)
Effects of PUFA on risk of MACCEs are unclear as data are of
very low quality.
Two trials recruited 1879 participants, and 817 people experi-
enced at least one MACCE. The trials suggested a 16% decrease
in MACCE risk with increased PUFA, but were highly heteroge-
neous (RR 0.84, 95% CI 0.59 to 1.20, I2 = 79%; Analysis 1.39).
With only two included trials assessment of small study bias was
not possible, and fixed-effect analysis also suggested some benefit
of PUFA (RR 0.92, 95% CI 0.82 to 1.04, I2 = 79%; Analysis
1.41). Most sensitivity analyses preserved the suggested reduction
of risk of MACCEs with increased PUFA but no trials were at
low summary risk of bias and none were at low risk of bias from
allocation concealment (Analysis 1.40).
With only two trials, subgrouping was generally uninformative (
Analysis 1.42; Analysis 1.43; Analysis 1.44; Analysis 1.45; Analysis
1.46; Analysis 1.47; Analysis 1.48; Analysis 1.49; Analysis 1.50).
Whenever the two trials were in separate subgroups there was a
statistically significant difference between subgroups. We did not
attempt meta-regression.
We downgradedGRADE assessment for risk of bias, inconsistency
and imprecision. Effects of PUFA on risk ofMACCEs was unclear
as data are of very low quality, Summary of findings for the main
comparison.
Secondary outcomes
We formally systematically reviews secondary outcomes, in that
we included all relevant trials that collected data on any of these
outcomes. Summary of findings 2 displays GRADE assessments
for the key outcomes not included in this review’s primary out-
comes.
Cardiovascular mortality
Increasing PUFA intake may have little or no effect on cardiovas-
cular mortality (low-quality evidence).
Sixteen trials randomising 15,107 participants of whom 729 died
of cardiovascular causes were included. Meta-analysis suggested
little effect of PUFA intake on cardiovascular disease deaths (RR
1.02, 95% CI 0.82 to 1.26, I2 = 31%; Analysis 2.1). Sensitivity
analyses suggested small non-significant benefits (limiting to trials
at low risk of bias for attention) or non-significant harms (limiting
to trials at low risk of bias for allocation concealment, compliance,
summary risk of bias, trials registry entry or pre-2010, no industry
funding, and larger trials; Analysis 2.2), and fixed-effect analysis
suggested no effect (RR 1.01, 95% CI 0.88 to 1.16; Analysis 2.3).
The funnel plot suggested that one or two smaller trials with RRs
greater than 1.00 might be missing - replacing these would tend
to raise the RR, suggesting slight harm.
Subgrouping by PUFA dose suggested no statistically significant
subgroup differences (Analysis 2.4). Meta-regression did not sug-
gest any relationship with dose (P = 0.54). Subgrouping by du-
ration showed no important differences between subgroups (P =
0.72; Analysis 2.5). Meta-regression on duration was not statisti-
cally significant (P = 0.11).
Subgrouping by primary or secondary prevention, replacement,
sex, statin use, and intervention type did not explain any of the
heterogeneity and subgroups did not differ significantly (Analysis
2.6; Analysis 2.8; Analysis 2.9; Analysis 2.11; Analysis 2.12). Sub-
grouping by baseline PUFA intake included six trials and suggested
benefit of increasing PUFA intake in groups with baseline total
PUFA intake less than 6% E (RR 0.71, 95% CI 0.52 to 0.97, I2 =
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0%, 141 cardiovascular disease deaths), but harm in groups with
higher baseline PUFA intake (RR 1.32, 95% CI 1.07 to 1.62, I2
= 0%, 326 cardiovascular disease deaths), removing heterogeneity
and suggesting a statistically significant test for subgroup differ-
ences (P = 0.003; Analysis 2.7). Subgrouping by participant age
also reduced heterogeneity and suggested significant subgroup dif-
ferences (P = 0.02; Analysis 2.10), suggesting harm from addi-
tional PUFA in adults aged under 50 years, more modest harm
in those aged 50 to 65 years, and benefit in those aged at least 65
years. These data could suggest greater utility of increasing total
PUFA when baseline intake is low, and in older adults, but given
the small number of trials caution is appropriate.
We downgraded the GRADE assessment twice for imprecision
(as important benefits and harms were included in the 95% con-
fidence intervals). Increasing PUFA intake may have little or no
effect on cardiovascular mortality (low-quality evidence).
Cardiovascular events
Increasing PUFA intake probably reduces risk of cardiovascular
events a little (NNT 59, moderate-quality evidence).
Twenty trials randomising 17,799 participants reported at least
one cardiovascular event in 2442 participants. Meta-analysis sug-
gested that increasing total PUFA intake reduced the risk of car-
diovascular disease events by 11%, with little heterogeneity (RR
0.89, 95% CI 0.79 to 1.01, I2 = 30%; Analysis 2.13), as did fixed-
effect analysis (RR 0.92, 95% CI 0.86 to 0.98; Analysis 2.15).
Sensitivity analyses limiting to trials with low risk of bias from
attention bias, trials registry entry or pre-2010, trials with at least
100 or at least 250 participants all retained suggestion of bene-
fit from increased PUFA, while sensitivity analyses for allocation
concealment, compliance, and industry funding suggested no im-
portant effects, and limiting to studies with low summary risk of
bias suggested increased risk (Analysis 2.14). The funnel plot did
not suggest small study bias (not shown).
Subgrouping by PUFA dose and trial duration did not show sta-
tistically significant differences between subgroups (P = 0.17 and
0.18 respectively; Analysis 2.16; Analysis 2.17). Meta-regression
did not suggest relationships between cardiovascular disease events
and PUFA dose (P = 0.78) or trial duration (P = 0.70).
Subgrouping by primary or secondary prevention, baseline PUFA
dose, replacement, sex, statin use, and intervention type did not
reduce heterogeneity and did not suggest significant differences
between subgroups (Analysis 2.18; Analysis 2.19; Analysis 2.20;
Analysis 2.21; Analysis 2.23; Analysis 2.24). Subgrouping by par-
ticipant age suggested harm in younger participants (RR 1.66,
95% CI 1.05 to 2.61, I2 = 0%), but benefit in middle-aged and
older participants (RR 0.86, 95% CI 0.78 to 0.96, I2 = 0%), with
statistically significant differences between subgroups (P = 0.03;
Analysis 2.22).
We downgraded the GRADE assessment for risk of bias (as sen-
sitivity analyses suggested benefit, no effect and some harm from
increased PUFA). Increasing PUFA intake probably reduces risk
of cardiovascular events from 14.6% to 13.0% in study popula-
tions, NNT 63 (moderate-quality evidence).
Coronary heart disease mortality
Increasing PUFA intake may reduce risk of coronary heart disease
death by a small amount (NNT 200, low-quality evidence).
Nine trials randomised 8810 participants of whom 556 died of
coronary heart disease. Meta-analysis suggested that increasing
PUFA intake reduced risk of coronary heart disease death, without
heterogeneity (RR 0.91, 95% CI 0.78 to 1.06, I2 = 0%; Analysis
2.25). Results from the fixed-effect analysis were very similar (RR
0.90, 95%CI 0.77 to 1.05, I2 = 0%; Analysis 2.27). Although nine
trials provided data, of the 556 deaths, 340 occurred in DART fat
1989, which carried 65% of the weight of the meta-analysis, and
138 occurred in AlphaOmega - ALA, which carried 23% of the
weight. Results of all the sensitivity analyses were similar, all sug-
gesting modest protection from increased PUFA (Analysis 2.26),
although no subgroups were statistically significant. The funnel
plot suggested that some small trials with RR over 1.0 may be
missing, and if these trials were added back in they would tend to
raise the RR towards 1.0 (Figure 4).
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Figure 4. Funnel plot of comparison 2. Higher PUFA vs lower PUFA - dichotomous secondary outcomes,
outcome: 2.25 CORONARY HEART DISEASE (CHD) MORTALITY
Subgrouping by dose and duration did not suggest subgroup dif-
ferences (P = 0.92 and 0.90 respectively), though there was a
counter-intuitive suggestion that lower doses and shorter durations
produced greater benefits (Analysis 2.28; Analysis 2.29). Meta-re-
gression did not suggest strong relationships between PUFA dose
(P = 0.62) or trial duration (P = 0.71) and risk of coronary heart
disease death.
Subgrouping by primary or secondary cardiovascular disease pre-
vention, baseline PUFA dose, replacement, sex, age, statin use, or
intervention type did not suggest important differences between
subgroups (Analysis 2.30; Analysis 2.31; Analysis 2.32; Analysis
2.33; Analysis 2.34; Analysis 2.35; Analysis 2.36).
We downgraded the GRADE assessment for imprecision and pub-
lication bias. Increasing PUFA intake may reduce risk of coronary
heart disease death a little from 6.6% to 6.1% in the study popu-
lations, NNT 200 (low-quality evidence).
Myocardial infarction
Increasing PUFA may reduce risk of myocardial infarction.
Fifteen trials randomising 15,609 participants recorded 880 my-
ocardial infarctions.Meta-analysis suggested that increasing PUFA
reduced the risk of myocardial infarction by 12% without hetero-
geneity (RR 0.88, 95% CI 0.78 to 0.99, I2 = 0%; Analysis 2.37).
We did not plan to carry out sensitivity analyses, subgroup analy-
ses or meta-regression for this outcome.
Sudden cardiac death
The effect of increasing PUFA on sudden cardiac death is unclear.
Five trials recruited 1731 participants of whom 69 experienced
sudden cardiac death. Meta-analysis suggested some benefit from
increasingPUFA (RR0.80, 95%CI0.50 to 1.29, I2 =0%;Analysis
2.38), but the effect was not statistically significant, and did not
exclude important harms. There were insufficient trials to assess
the funnel plot. We did not plan to carry out sensitivity analyses,
subgroup analyses or meta-regression for this outcome.
Atrial fibrillation
The effect of increasingPUFA intake on atrial fibrillation is unclear
as the evidence is of very low quality.
Eleven trials recruited 11,692 participants of whom 811 experi-
enced new or recurrent atrial fibrillation. Meta-analysis suggested
that increasing PUFA reduced the risk of atrial fibrillation by 13%
25Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
with substantial heterogeneity (RR 0.87, 95% CI 0.72 to 1.06, I
2 = 57%, Analysis 2.39). Fixed-effect analysis suggested marginal
statistical significance (RR 0.87, 95% CI 0.72 to 1.06, I2 = 57%;
Analysis 2.39). Sensitivity analyses generally suggested a non-sig-
nificant protective effect of the trials at lower risk of bias, but trials
without industry funding and those at low risk from allocation
concealment suggested a statistically significant reduction(Analysis
2.40). No trials were at low risk of bias from compliance problems.
Subgrouping by new or recurrent atrial fibrillation suggested no
important differences between subgroups (P = 0.31; Analysis
2.39). Subgrouping by PUFA dose did not suggest important dif-
ferences between subgroups (Analysis 2.42), but subgrouping by
duration suggested greater protection in shorter trials (P = 0.001;
Analysis 2.43). Meta-regression suggested that there was no rela-
tionship between PUFA dose and atrial fibrillation (P = 0.91), but
there was a marginally significant relationship between duration
and risk of atrial fibrillation (with benefit in shorter trials and harm
in longer trials, P = 0.056).
Subgrouping suggested no important effects by replacement, sex,
age, intervention type or statin use (no subgroup differences;
Analysis 2.46; Analysis 2.47; Analysis 2.48; Analysis 2.49; Analysis
2.50). Subgrouping suggested that PUFA was harmful in primary
prevention (RR1.33, 95%CI0.99 to 1.79, I2 =0%) andbeneficial
in secondary prevention of cardiovascular disease (RR 0.80, 95%
CI 0.67 to 0.96, I2 = 58%), with significant subgroup differences
(P = 0.004; Analysis 2.44). Only one trial had a known baseline
PUFA intake so subgrouping was unhelpful (Analysis 2.45).
We downgraded the GRADE assessment for risk of bias, inconsis-
tency and imprecision. The effect of increasing PUFA intake on
atrial fibrillation is unclear as the evidence is of very low quality.
Angina
The effect of increasing PUFA intake on angina is unclear.
Seven trials including 2070 participants reported 100 participants
experiencing new or worsening angina. Meta-analysis suggested
that increasing PUFA reduced risk of angina (RR 0.64, 95% CI
0.35 to 1.16, I2 = 46%; Analysis 2.51). There were insufficient
trials to assess the funnel plot and we did not plan to carry out
sensitivity analyses, subgroup analyses or meta-regression for this
outcome. One included trial had adequate allocation concealment
and none were at low summary risk of bias.
Heart failure
The effect of increasing PUFA intake on heart failure is unclear.
Seven trials including 25,257 participants reported 137 partici-
pants experiencing new or worsening heart failure. Meta-analysis
suggested that increasing PUFA reduced risk of heart failure but re-
sults were heterogeneous and important harms were not excluded
(RR 0.74, 95% CI 0.40 to 1.36, I2 = 54%; Analysis 2.52). There
were insufficient trials to assess the funnel plot and we did not
plan to carry out sensitivity analyses, subgroup analyses or meta-
regression for this outcome. Two included trials had adequate al-
location concealment and one was at low summary risk of bias.
Peripheral arterial disease
Increasing PUFA intake may increase the risk of peripheral arterial
disease.
Four trials including 8937 participants reported 97 participants
experiencing new or worsening peripheral arterial disease. Meta-
analysis suggested that increasing PUFA increased risk of periph-
eral arterial disease but important benefits were not excluded (RR
1.20, 95% CI 0.81 to 1.77, I2 = 0%; Analysis 2.53). There were
insufficient trials to assess the funnel plot and we did not plan to
carry out sensitivity analyses, subgroup analyses or meta-regres-
sion for this outcome. Two included trials had adequate allocation
concealment and two were at low summary risk of bias.
Revascularisation
The effect of increasing PUFA intake on revascularisation is un-
clear.
Six trials including 1182 participants reported 46 participants un-
dergoing revascularisation.Meta-analysis suggested that increasing
PUFA reduced risk of revascularisation but important harms were
not excluded (RR 0.70, 95% CI 0.40 to 1.24, I2 = 0%; Analysis
2.54). There were insufficient trials to assess the funnel plot and
we did not plan to carry out sensitivity analyses, subgroup analyses
or meta-regression for this outcome. One included trial had ade-
quate allocation concealment and one was at low summary risk of
bias.
Adiposity - body weight
Higher PUFA intake probably results in greater weight gain (mod-
erate-quality evidence).
Twelve trials presenting 15 comparisons, of which 13 could be
included in meta-analyses, included 7100 participants with data
on body weight. Meta-analyses suggested that weight increased
with increased PUFA intake, although trials were heterogeneous
(MD 0.76 kg, 95% CI 0.34 to 1.19, I2 = 59%; Analysis 3.1). The
funnel plot suggested that some trials with smallerweight increases
or reductions in the increased PUFA group may be missing. If
replaced, these trials would tend to reduce the weight increase in
the higher PUFA participants. Two trials (both also suggesting
increasedweight in the higher PUFA arm) did not provide variance
data so could not be included in the meta-analysis, though they
are shown in the forest plot (Analysis 3.1). A further five trials
collected data on weight but did not provide those data in a way
that could be included inmeta-analysis (MARINA - Sanders 2011;
NDHS Faribault 1968; NDHS Open 1st 1968; Simon 1997;
Vijayakumar 2014).
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The effect was larger when we used fixed-effect analysis (MD 1.08
kg, 95% CI 0.96 to 1.21; Analysis 3.3). Sensitivity analyses all
suggested increased body weight with increased PUFA intake (al-
though not statistically significantly when we limited to trials at
low risk of compliance bias, Analysis 3.2).
Subgrouping by PUFA dose, duration, primary or secondary pre-
vention, replacement, sex, age and statin use did not differ sig-
nificantly by subgroups (Analysis 3.4; Analysis 3.5; Analysis 3.6;
Analysis 3.8; Analysis 3.9; Analysis 3.10; Analysis 3.11). There
were important differences between subgroups when grouping by
baseline PUFA dose, with greater weight increases for those with
lower baseline PUFA intake (Analysis 3.7). Subgrouping by inter-
vention type suggested differences between subgroups (P = 0.01;
Analysis 3.12), suggesting greater weight increases with increased
PUFA intake by dietary advice (MD 2.37 kg, 95% CI 1.19 to
3.55, I2 = 0%) than in trials of supplemental foods or diet pro-
vided (MD 0.71 kg, 95% CI 0.18 to 1.25, I2 = 73%), or in sup-
plemental trials (MD 0.37 kg, 95% CI -0.18 to 0.91, I2 = 0%).
We downgraded the GRADE assessment of evidence for publica-
tion bias, leading to a moderate quality of evidence. Higher PUFA
intake probably results in greater weight gain.
Adiposity - BMI
Higher PUFA intake may lead to higher BMI (low-quality evi-
dence).
Eight trials reported 11 comparisons including 4798 participants
with BMI reported.Meta-analysis suggested that increasing PUFA
intake results in greater BMI, but effects were heterogeneous (MD
0.17 kg/m2, 95% CI -0.08 to 0.42, I2 = 80%, Analysis 3.13).
Fixed-effect analysis was statistically significant (MD 0.27 kg/m2,
95%CI0.20 to 0.35, I2 =80%;Analysis 3.15). The funnel plot did
not suggest any small study bias, and we are aware of two trials that
assessed BMI but did not provide data that could be used in meta-
analysis (Simon 1997; Vijayakumar 2014). Sensitivity analyses all
confirmed slightly increased BMI with increased PUFA intake
(Analysis 3.14).
Subgrouping by PUFA dose, duration, primary or secondary pre-
vention, baseline PUFA intake, replacement, sex, age, statin use
and intervention type did not suggest important differences be-
tween subgroups (Analysis 3.16; Analysis 3.17; Analysis 3.18;
Analysis 3.19; Analysis 3.20; Analysis 3.21; Analysis 3.22; Analysis
3.23; Analysis 3.24), and did not reduce heterogeneity.
We downgraded the GRADE assessment for inconsistency and
imprecision, leading to low-quality evidence. Higher PUFA intake
may lead to higher BMI.
Adiposity - other measures
Several trials reported waist circumference (1298 participants in
two trials; Analysis 3.25), percentage body fat (309 participants in
two trials; Analysis 3.26) and body fat in kg (214 participants in a
single trial; Analysis 3.27). Meta-analyses on waist circumference
andpercentage body fat both suggested greaterweight gain in those
on higher PUFA intake, while the single trial with data on body fat
in kg suggestednodifference in body fat regardless of PUFA intake.
We are aware of several trials that assessed adiposity but did not
provide data in a format that could be included in meta-analysis.
HERO-Tapsell 2009 and Simon 1997 assessed percentage of body
fat, and WAHA - Ros 2016 assessed waist circumference (shown
in the meta-analysis but without variance data).
Lipids - serum total cholesterol
Higher PUFA intake leads to lower total cholesterol (high-quality
evidence).
Twenty six trials, incorporating data from 8072 participants (and
28 trial arms), provideddata on serum total cholesterol.Meta-anal-
ysis suggested that increasing PUFA intake reduced total choles-
terol, although datawere heterogeneous (MD-0.12mmol/L, 95%
CI -0.23 to -0.02, I2 = 79%; Analysis 3.28). The funnel plot was
difficult to interpret, but we were aware of one trial (MRC 1968)
that provided total cholesterol data without variance information,
so could not be included in meta-analysis. This trial also suggested
reduced total cholesterol in the higher PUFA arm (Analysis 3.28).
Total cholesterol data from five trials (Dullaart 1992; EPOCH
2011; ORL 2013; Veterans Admin 1969; WINS 2006) could not
be included in meta-analysis, so are missing.
Sensitivity analyses, including fixed-effect analysis, all suggested
greater total cholesterol reduction with higher PUFA intake, al-
though some were not statistically significant (Analysis 3.29;
Analysis 3.30).
Subgrouping by PUFA dose and duration did not suggest impor-
tant differences between subgroups (Analysis 3.31; Analysis 3.32).
We did not plan to runmeta-regressions for continuous outcomes.
Subgrouping by primary or secondary prevention, baseline PUFA
intake, replacement, age, sex, statin use and intervention type did
not suggest important differences between subgroups (Analysis
3.33; Analysis 3.34; Analysis 3.35; Analysis 3.36; Analysis 3.37;
Analysis 3.38; Analysis 3.39).
We did not downgrade the GRADE assessment of evidence.
Higher PUFA intake leads to lower total cholesterol (high-quality
evidence).
Lipids - serum fasting triglyceride
Higher PUFA intake probably leads to lower triglyceride levels
(moderate-quality evidence).
Twenty trials incorporating data from 3905 participants (and 22
trial arms) provided data on serum triglycerides. Meta-analysis
suggested that increasing PUFA intake reduced triglycerides, al-
though data were heterogeneous (MD -0.12 mmol/L, 95% CI -
0.20 to -0.04, I2 = 50%; Analysis 3.40). The funnel plot did not
suggest small study bias, but we are aware of a further eight trials
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that did not report triglycerides in away that could be incorporated
into meta-analysis (Ahn 2016; EPOCH 2011; NDHS Faribault
1968; NDHS Open 1st 1968; ORL 2013; Rossing 1996; WAHA
- Ros 2016; WINS 2006).
Sensitivity analyses, including fixed-effect analysis, all suggested
greater triglyceride reduction with higher PUFA intake, although
some were not statistically significant (Analysis 3.41; Analysis
3.42).
Subgroup analyses did not suggest differential effects by dose, du-
ration, baseline PUFA intake, replacement, statin use, interven-
tion type, primary or secondary prevention, sex, or age (Analysis
3.43; Analysis 3.44; Analysis 3.45; Analysis 3.46; Analysis 3.47;
Analysis 3.48; Analysis 3.49; Analysis 3.50).
We downgraded the GRADE evidence once for inconsistency.
Higher PUFA intake probably leads to lower triglyceride levels
(moderate-quality evidence).
Lipids - high density lipoprotein (HDL)
Higher PUFA intake probably has no important effects on HDL
(moderate-quality evidence).
Eighteen trials incorporating data from 4674 participants (and 20
trial arms) provided data on HDL. Meta-analysis suggested that
increasing PUFA intake had little or no effect on HDL, without
heterogeneity (MD -0.01 mmol/L, 95% CI -0.02 to 0.01, I2 =
0%; Analysis 3.52). The funnel plot suggested that some trials
with lower HDL in the higher PUFA arms may be missing, and
adding any such trials into the meta-analysis would tend to lead
to lower HDL with higher PUFA. We are aware of five trials that
measured HDL but did not report the data in a way that could
be incorporated into meta-analysis (EPOCH 2011; ORL 2013;
Rossing 1996; WAHA - Ros 2016; WINS 2006).
Sensitivity analyses, including fixed-effect analysis, all confirmed
lack of an important effect (Analysis 3.53; Analysis 3.54).
Subgrouping did not suggest differential effects of PUFA dose,
duration, primary or secondary prevention, baseline PUFA intake,
replacement, sex, age, statin use or intervention type (Analysis
3.55; Analysis 3.56; Analysis 3.57; Analysis 3.58; Analysis 3.59;
Analysis 3.60; Analysis 3.61; Analysis 3.62; Analysis 3.63).
We downgraded the GRADE assessment for publication bias.
Higher PUFA intake probably has no important effects on HDL
(moderate-quality evidence).
Lipids - low density lipoprotein (LDL)
Higher PUFA intake probably has no important effects on LDL
(moderate-quality evidence).
Fifteen trials incorporating data from 3362 participants (and 17
trial arms) provided data on LDL. Meta-analysis suggested that
increasing PUFA intake had little or no effect on LDL, without
major heterogeneity (MD -0.01 mmol/L, 95% CI -0.09 to 0.06, I
2 = 44%; Analysis 3.64). The funnel plot suggested that some trials
with lower LDL associated with higher PUFA may be missing,
adding such trials in would tend to suggest that increasing PUFA
reduces LDL. We are aware of three trials that measured LDL but
did not report it in a way that could be included in meta-analysis
(Dullaart 1992; EPOCH 2011; ORL 2013).
Sensitivity analyses, including fixed-effect analysis, all confirmed
this lack of effect (Analysis 3.65; Analysis 3.66).
Subgrouping did not suggest differential effects of PUFA dose,
duration, primary or secondary prevention, baseline PUFA intake,
replacement, sex, age, statin use or intervention type (Analysis
3.68; Analysis 3.69; Analysis 3.70; Analysis 3.71; Analysis 3.72;
Analysis 3.73; Analysis 3.74; Analysis 3.75).
We downgraded the GRADE assessment for publication bias.
Higher PUFA intake probably has no important effects on LDL
(moderate-quality evidence).
Tertiary outcomes
We did not formally systematically review tertiary outcomes.
Where the included trials reported these outcomes, we collated
and analysed them.
Blood pressure, systolic and diastolic
Nine trials reported systolic bloodpressure from7356participants,
and eight trials reported diastolic blood pressure from 7327 par-
ticipants. There was no suggestion of an effect of increased PUFA
on systolic (MD -0.47 mmHg, 95% CI -2.20 to 1.26, I2 = 47%;
Analysis 4.1) or diastolic blood pressure (MD 0.24 mmHg, 95%
CI -0.55 to 1.02, I2 = 31%; Analysis 4.2). There were insufficient
trials to assess the funnel plots, but we are aware of four trials that
assessed blood pressure and did not report it fully (EPOCH 2011;
MRC 1968; NDHS Open 1st 1968; Rossing 1996), though the
data fromMRC 1968 are displayed in the forest plot. We did not
plan to carry out sensitivity analyses, subgroup analyses or meta-
regressions for these outcomes. Six of the trials in each analysis
had low risk of bias from allocation concealment, and six were
at low summary risk of bias. Lack of reporting of this commonly
collected outcomemay suggest publication bias, and the four trials
with missing data would tend to confirm this.
Quality of life
One trial (Dodin 2005) assessed the effect of their flaxseed in-
tervention on quality of life, using the MENQOL scale. MEN-
QOL assesses the impact of four domains (vasomotor, psychoso-
cial, physical and sexual) of menopausal symptoms over the pre-
vious month with scores ranging from 0 (no impact, high qual-
ity of life) to 32 (very poor quality of life in all domains). They
found that over 12 months the MENQOL score fell slightly in
both groups (intervention group -0.23, SD 0.62, N = 85, control
group -0.14, SD 0.58, N = 94). This suggested little effect of the
intervention on quality of life related to menopausal symptoms.
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We found no further data on quality of life in the included trials,
though dropouts may provide some information on how willing
to continue the interventions participants were.
Economic costs
We did not find any data on economic costs in the included trials.
Serious adverse events
Adverse events reported in one or two trials each included the
following, with no clear effects for any outcomes (Analysis 4.3).
1. Pulmonary embolism (RR 2.15, 95% CI 0.48 to 9.57, I2 =
0%, 2 trials, 2087 participants, 7 events)
2. Mutliple sclerosis worsened or acute attack (RR 1.11, 95%
CI 0.95 to 1.30, I2 = 0%, 2 trials, 268 participants, 142 events)
3. Bleeding (RR 0.80, 95% CI 0.34 to 1.85, I2 = 0%, 2 trials,
748 participants, 21 events)
4. Gastrointestinal hospitalisation (RR 1.75, 95% CI 0.53 to
5.79, 1 trial, 200 participants, 11 events)
5. Retinopathy diagnosis (RR 1.02, 95% CI 0.56 to 1.86, 1
trial, 2424 participants, 42 events)
Effects of increased PUFA intake on dementia and neurocogni-
tive outcomes (Jimoh 2017), type 2 diabetes and measures of glu-
cose metabolism (Brown 2017), inflammatory bowel disease and
inflammatory markers (Thorpe 2017), cancers (Hanson 2017b),
depression and anxiety (Hanson 2017a) and functional outcomes
(Abdelhamid 2017) are systematically reviewed elsewhere, so we
have not reported results of effects seen in trials included in this
review, as they are a potentially misleading subset. The systematic
reviews on these health outcomes are not yet published, so we
have provided references to their protocols so that the systematic
reviews can be located.
Effects of increasing PUFA on pulmonary embolism and bleeding
are unclear as the evidence is of very low quality.
Dropouts
Twenty-seven trials reported 1675 dropouts, suggesting that being
in the higher or lower PUFA arm did not make much difference
to the likelihood of dropping out (RR 0.99, 95% CI 0.87 to 1.13,
I2 = 41%; Analysis 4.4). This may suggest that increasing PUFA
is an acceptable intervention.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Higher PUFA compared to lower PUFA - dichotomous secondary outcomes for prevention of cardiovascular disease
Patient or population: people with or without exist ing cardiovascular disease, men and women
Setting: includes f ree-living part icipants and those living in inst itut ions. Includes part icipants f rom all cont inents but most events and assessments occurred in trials carried
out in Europe or North America.
Intervention: higher PUFA intake
Comparison: lower PUFA intake
Eligible trials compared higher with lower total PUFA intakes. The intervent ion had to be dietary supplementat ion, or a provided diet, or advice on diet. The advice, foodstuf f s
or supplements had to aim to increase or decrease total PUFA intake, or a dietary component high in total PUFA intake such as vegetable oil, or, if no clear aim was stated
(but implied, such as aim ing to provide a ’heart health’, ’reduced fat ’ or ’Mediterranean’ diet) then the intervent ion had to achieve an increase or decrease of at least 10%of the
baseline total PUFA level
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the evidence is of very
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Adiposity - BMI, kg/m2
f ollow-up: range 12
months to 60 months
Mean BMI was 26.9 kg/
m2
MD 0.17 higher









terol (TC, mmol/ L)
Follow-up: range 12
months to 96 months
Mean serum TC was 5.
46 mmol/ L
MD 0.12 lower







leads to lower TC.
Serum fasting triglyc-
eride (TG, mmol/ L)
Follow-up: range 12
months to 72 months
Mean serum TG was 1.
57 mmol/ L
MD 0.12 lower
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Mean serum HDL 1.31
mmol/ L
MD 0.01 lower
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months to 60 months
Mean serum LDL 2.86
mmol/ L
MD 0.01 lower







probably has lit t le or no
ef fect on LDL.
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
BMI: Body Mass Index; CI: conf idence interval; CVD: cardiovascular disease; MD: mean dif ference; OR: odds rat io; PUFA: polyunsaturated fatty acids; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.

























































































































1. Risk of bias: lim it ing trials to those at low summary risk of bias, low risk f rom allocat ion concealment, f rom attent ion
bias, f rom compliance, by trial f unding and trial size suggests small benef its and harms f rom increasing PUFA intake. Tends
to conf irm lack of important ef fect. Not downgraded.
2. Inconsistency: I2 stat ist ic less than 50%, not downgraded.
3. Indirectness: most events occurred in men, and in trials carried out in high-income nations. Not downgraded.
4. Imprecision: 95% conf idence intervals range f rom important benef it to important harm. Downgraded twice.
5. Publication bias: some suggest ion that one or two small t rials may be missing. If added in they would tend to increase
the RR. Not a large ef fect, not downgraded.
bCardiovascular events
1. Risk of bias: sensit ivity analyses suggested reduced risk of CVD events with more PUFA, lack of ef fect, and some harm.
Downgraded once.
2. Inconsistency: I2 stat ist ic less than 50%, not downgraded.
3. Indirectness: most events occurred in men, and in trials carried out in high-income nations. Not downgraded.
4. Imprecision: over 17,000 part icipants randomised, of whom more than 2400 experienced CVD events. 95% conf idence
intervals excluded important harms. Not downgraded.
5. Publication bias: no suggest ion of m issing trials in the funnel plot. Not downgraded.
cCoronary heart disease mortality (CHD)
1. Risk of bias: all sensit ivity analyses concurred that increased PUFA reduced risk of CHD deaths. Not downgraded.
2. Inconsistency: I2 stat ist ic less than 50%, not downgraded.
3. Indirectness: most events occurred in men, and in trials carried out in high-income nations. Not downgraded.
4. Imprecision: over 8800 part icipants randomised and over 500 CHD deaths. However, the 95% conf idence intervals didn’t
exclude important harm. Downgraded once.
5. Publication bias: some suggest ion of publicat ion bias. If present replacing missing trials would tend to raise the risk
rat io towards 1.0 (no ef fect). Downgraded once.
dAtrial fibrillation and arrhythmias
1. Risk of bias: no included trials were at low risk of compliance problems, all other sensit ivity analyses suggested
reduced risk of AF with increased PUFA. However there was no dose response, a suggest ion of benef it in short trials, and
harm in longer trials supported by meta-regression. Downgraded once.
2. Inconsistency: I2 stat ist ic greater than 50%. Downgraded once.
3. Indirectness: most events occurred in men, and in trials carried out in high-income nations. Not downgraded.
4. Imprecision: 95% conf idence intervals exclude serious harm, but included the null. Downgraded once.
5. Publication bias: no suggest ion of m issing trials in the funnel plot. Not downgraded.
eAdiposity - body weight
1. Risk of bias: sensit ivity analyses assessing ef fects of dif f erent biases all suggested greater weight gain in those taking
higher total PUFA. Not downgraded.
2. Inconsistency: I2 stat ist ic greater than 50% but part ially explained by type of intervent ion and durat ion of intervent ion.
Not downgraded.























































































































4. Imprecision: 95% conf idence intervals only included increased weight with increased PUFA intake. Not downgraded.
5. Publication bias: the funnel plot suggests that some trials with less weight gain in the higher PUFA arm may be missing.
Two trials with weight data could not be included in meta-analysis, but they also suggested greater weight gain in the higher
PUFA arm. Other missing trials, if due to publicat ion bias, are likely to have not been published because they suggested
increased weight in the higher PUFA arm, so are likely to support the main analysis. Downgraded once.
fAdiposity - Body Mass Index (BMI)
1. Risk of bias: sensit ivity analyses assessing ef fects of dif f erent biases all suggested greater weight gain in those taking
higher total PUFA. Not downgraded.
2. Inconsistency: I2 stat ist ic greater than 50%, and not explained by subgrouping. Downgraded once.
3. Indirectness: weight was assessed in both men and women, but all t rials were conducted in high-income countries. Not
downgraded.
4. Imprecision: 95% conf idence intervals did not include important benef its, but did include the null. Downgraded once.
5. Publication bias: no suggest ion of m issing data. Not downgraded.
gSerum total cholesterol (TC)
1. Risk of bias: sensit ivity analyses all suggested greater lipid reduct ion with higher PUFA intake. Not downgraded.
2. Inconsistency: I2 stat ist ic greater than 50%, and while no single factor explains this there were greater TC reduct ions
with low stat in use, higher PUFA dose, lower baseline PUFA, and replacement of saturated fats and monounsaturated fats.
Not downgraded.
3. Indirectness: data provided by men and women, and comes f rom high-income and low- to middle-income countries. Not
downgraded.
4. Imprecision: data came f rom thousands of part icipants and 95% conf idence intervals did not include harm. Not
downgraded.
5. Publication bias: f unnel plot not interpretable, known missing data are consistent with data used in meta-analysis. Not
downgraded.
hSerum triglycerides (TG)
1. Risk of bias: sensit ivity analyses all suggested greater lipid reduct ion with higher PUFA intake. Not downgraded.
2. Inconsistency: I2 stat ist ic = 50%, without any clear explanat ion f rom subgrouping. Downgraded once.
3. Indirectness: data provided by men and women, and comes f rom high-income and industrialising countries. Not
downgraded.
4. Imprecision: data came f rom thousands of part icipants and 95% conf idence intervals did not include harm. Not
downgraded.
5. Publication bias: no suggest ion of m issing data. Not downgraded.
iSerum HDL
1. Risk of bias: consistent lack of ef fect of PUFA in all sensit ivity analyses. Not downgraded.
2. Inconsistency: I2 stat ist ic less than 50%. Not downgraded.
3. Indirectness: data provided by men and women, and comes f rom high-income and industrialising countries. Not
downgraded.
4. Imprecision: data came f rom thousands of part icipants and conf idence interval excludes important ef fects. Not
downgraded.























































































































1. Risk of bias: consistent lack of ef fect of PUFA in all sensit ivity analyses. Not downgraded.
2. Inconsistency: I2 stat ist ic less than 50%. Not downgraded.
3. Indirectness: data provided by men and women, and comes f rom high-income and industrialising countries. Not
downgraded.
4. Imprecision: data came f rom thousands of part icipants and conf idence interval excludes important ef fects. Not
downgraded.

























































































































D I S C U S S I O N
Summary of main results
This Cochrane Review included 49 RCTs randomising 24,272
participants, for one to eight years. We identified 22 potential
ongoing trials. Total PUFA dose (the difference in total PUFA
between intervention and control arms) was 0.6% E to less than
1% E for 13 trials, 1% E to less than 2% E in 17 trials, 2% E to
less than 5% E in eight trials, and 5% E or more from total PUFA
in 11 trials. We assessed 11 of the 49 included trials as being at
low summary risk of bias.
Increasing PUFA intake probably has little or no effect on all-cause
mortality (risk changes from 7.8% to 7.6%, RR 0.98, 95% CI
0.89 to 1.07, I2 = 0%, 1443 deaths, 24 trials, moderate-quality
evidence, downgraded for imprecision). Increasing PUFA proba-
bly reduces the risk of coronary heart disease events (from 14.2%
to 12.3%, RR 0.87, 95% CI 0.72 to 1.06, I2 = 45%, 1351 peo-
ple with coronary heart disease events, 15 trials, moderate quality
evidence, downgraded for imprecision and risk of bias combined)
and stroke (from 1.2% to 1.1%, RR 0.91, 95% CI 0.58 to 1.44, I
2 = 24%, 166 strokes, 11 trials, however the confindence intervals
included important harm, low-quality evidence downgraded once
for imprecision and once for risk of bias and imprecision com-
bined). Effects on MACCEs (RR 0.84, 95% CI 0.59 to 1.20, I
2 = 79%, 817 events, 2 trials) are unclear as evidence is of very
low quality (downgraded for risk of bias, imprecision and incon-
sistency).
For secondary outcomes we found that increasing PUFA intake
probably reduces risk of cardiovascular disease events (from14.6%
to 13.0%, RR 0.89, 95% CI 0.79 to 1.01, I2 = 30%, 2442 events,
21 trials,moderate-quality evidence). IncreasingPUFA intakemay
slightly reduce risk of coronary heart disease death from 6.6% to
6.1% (RR 0.91, 95% CI 0.78 to 1.06, I2 = 0%, 556 coronary
heart disease deaths, 9 trials) and myocardial infarction (RR 0.88,
95% CI 0.78 to 0.99, I2 = 0%, 880 myocardial infarctions, 15
trials) but may increase the risk of peripheral arterial disease (RR
1.20, 95% CI 0.81 to 1.77, I2 = 0%, 97 events, 4 trials) and have
little or no effect on cardiovascular mortality (4.8% to 4.9%, RR
1.02, 95% CI 0.82 to 1.26, I2 = 31%, 729 cardiovascular disease
deaths, 16 trials), all low-quality evidence. The effect of increasing
PUFA on sudden cardiac death, angina, atrial fibrillation, heart
failure and revascularisation is unclear as the evidence is of very
low quality.
High-quality evidence suggests that increasing PUFA intake
slightly reduces total serum cholesterol over at least one year (MD
-0.12 mmol/L, 95% CI -0.23 to -0.02, I2 = 79%, 8072 partic-
ipants, 26 trials). Increasing PUFA intake probably causes some
weight gain (MD 0.76 kg, 95% CI 0.34 to 1.19, I2 = 59%, 7100
participants, 12 trials), decreases triglycerides (MD -0.12 mmol/
L, 95% CI -0.20 to -0.04, I2 = 50%, 3905 participants, 20 trials)
and has little effect on HDL (MD -0.01 mmol/L, 95% CI -0.02
to 0.01, I2 = 0%, 4674 participants, 18 trials) or LDL (MD -0.01
mmol/L, 95% CI -0.09 to 0.06, I2 = 44%, 3362 participants, 15
trials) (all moderate-quality evidence).
There was limited information on blood pressure, quality of life,
economic outcomes or adverse health effects. Effects of increasing
PUFA on pulmonary embolism and bleeding are unclear as the
evidence is of very low quality. Effects of PUFA intake on other
serious adverse health effects (cancers, inflammatory bowel dis-
ease, depression or anxiety, neurocognitive outcomes, functional
outcomes and diabetes) are systematically reviewed and reported
elsewhere.
We looked for dose and duration effects using subgrouping and
meta-regression, finding none except a duration effect in atrial fib-
rillation, with protective effects in shorter trials (up to two years),
little or no effect in trials of two to less than four years, and harm
in longer trials (Analysis 2.43). We found no evidence of no linear
dose effects, though assessment of PUFA doses actually delivered
by trials were difficult to ascertain, often due tomissing control in-
formation. Baseline PUFA intake (or PUFA intake in the control
group as a proxy) were poorly reported, reducing our ability to see
subgroup differences - there was a suggestion of greater benefit of
PUFA with lower baseline PUFA intake for cardiovascular disease
mortality, but not for other cardiovascular outcomes.
There were no clear patterns of differential effects across outcomes
by primary or secondary prevention, replacement, sex, age, statin
use or intervention type. Subgrouping did not suggest differences
between effects in primary or secondary prevention, except for
atrial fibrillation, where increasing PUFA in primary prevention
was harmful and increasing PUFA in secondary prevention was
beneficial (Analysis 2.44). There were no differential effects by
replacement, sex or statin use. For cardiovascular disease mortal-
ity there was a suggestion of harm from increasing PUFA intake
in younger adults, smaller levels of harm in middle-aged adults
and benefit in those aged at least 65 years (Analysis 2.10). This
pattern was repeated for cardiovascular disease events, except that
some benefit was seen in the middle-aged group (Analysis 2.22),
although this pattern was not seen for other outcomes. Dietary
advice appeared to lead to greater increases in body weight and
BMI (Analysis 3.12; Analysis 3.24), while dietary advice and sup-
plements to increase PUFA appeared to reduce triglyceride to a
greater extent than supplemental foods or diet provided (Analysis
3.51).
Overall completeness and applicability of
evidence
Included trials randomised 24,272 participants over periods of at
least a year. Participants were men and women aged from their 20s
into their 80s but most trials recruited participants with a mean
age of 50 to 65 years. Most coronary heart disease events occurred
in these ’middle-aged’ trials, but most deaths occurred in trials of
older adults. Twenty-two trials included 70% or more men, and
many of these were exclusively in men, six included 70% or more
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women, and sixteen included a balanced proportion of men and
women. Despite this, most coronary heart disease events (1289
of 1351) and deaths (1134 of 1443) occurred in trials mainly of
men, so while women are included it is not clear whether any
effects are generalisable to them. Similarly, while younger adults
are included, most events occurred in older adults, which partly
explains the lack of appearance of some trials of younger adults in
many of the analyses on health events. We included these trials as
they reported data on lipids or adiposity, or both, and sometimes
one or two health events.
Two included trials were from countries with developing
economies (Mendis 2001 from Sri Lanka and Vijayakumar 2014
from India) but while both provided lipid data, the only events
were two deaths in Vijayakumar 2014. This means that the bulk
of the information in this review is from countries with devel-
oped economies. Some trials were from areas with non-west-
ern dietary practices, including South Korea (Ahn 2016), Japan
(DIPP-Tokudome 2015; Doi 2014; Mita 2007; ORL 2013), Sri
Lanka (Mendis 2001), and India (Vijayakumar 2014), however
often the dietary intakes of these populations at baseline and dur-
ing the trial were not well described.
Our data spring from trials conducted from the 1960s (MRC
1968; NDHS Faribault 1968; NDHSOpen 1st 1968; Rose 1965;
Veterans Admin 1969) to the present, and during this sixty year
period cardiovascular disease incidence has altered. For example,
in 2010 one in four deaths worldwide was from ischaemic heart
disease or stroke, up from one in five in 1990 (Lozano 2012). But
this worldwide increase hides more complex trends, with different
rates and trends in different parts of the world. Death rates from
CHD inmen aged 35 to 74were 839/100,000 inUkraine in 2000,
but ~200/100,000 in the USA and UK, and only 54/100,000 in
Japan. Rates in women were lower but followed the same trends
by country (WHO 2004). In the UK as in most high-income
countries age-standardised death rates from coronary heart disease
in adults of all ages fell by 72% between 1979 and 2013, and
stroke mortality fell by 71% over the same period (Bhatnagar
2016). Globally age-adjusted annual incidence of stroke in men
and women of all ages has increased slightly from 1990 to 2010,
but this masks falls in high-income countries and rises in low
and middle-income countries (Feigin 2014; Carandang 2006).
While we assess effects using risk ratios in this review so that we
can see relative effects regardless of baseline incidence, baseline
incidence affects absolute effects including numbers needed to
treat. Our results suggest that we need to increase total PUFA
intake in ~53 people to prevent one person experiencing a CHD
event, in ~63 people to prevent a CVD event, and even more
for CHD death and stroke. But in populations at greater risk
NNTs will be lower (fewer people needing to increase their PUFA
to prevent one person experiencing an event), and in lower risk
populations NNTs will be higher. The greatest import of dietary
increases in total PUFA intake is likely to be in low- and middle-
income countries where rates of CVD are higher (and rising).
Results relate to both primary and secondary prevention of car-
diovascular disease. However, as would be expected, most events
occurred in those with existing cardiovascular disease. For exam-
ple, 1130 of 1443 deaths (78%) were in participants with car-
diovascular disease at baseline (Analysis 1.6). Effects in the sec-
ondary prevention group (risk barely altering from 11.7% in the
lower PUFA arm to 11.5% (95% CI 10.1 to 13.1%) in the higher
PUFA arm) were similar to those without cardiovascular disease
at baseline (primary prevention, risk barely altering from 3.4% in
the lower PUFA arm to 3.3% (95% CI 2.7 to 4.1%) in the higher
PUFA arm). For cardiovascular disease events 2013 of 2435 peo-
ple (83%) experiencing cardiovascular disease events had existing
cardiovascular disease at baseline (Analysis 2.18). Risk of a cardio-
vascular disease event fell by 2.5% from 23.3% to 20.8% (95%CI
17.5% to 24.5%) in secondary prevention, and fell by 0.9% from
5.8% to 4.9% (95% CI 4.2% to 5.9%) in primary prevention
when increasing PUFA intake.
We are aware of missing trials. We were unable to access data for
AFORRD; NCT00309439; NCT00410020; Chandrakala 2010
or ACTRN12610000594022, which all appeared likely to be el-
igible. They were all registered before the end of 2010 or had
plannedfinish dates up to the endof 2015, hence appear to be com-
pleted but unpublished (see Characteristics of ongoing studies).
We are also aware of some missing data within included trials -
for example there were deaths in Bates 1977 but they were re-
ported combined with dropouts and the trial author no longer
has the data, and two deaths in Simon 1997 not reported by in-
tervention arm. Houtsmuller 1979 reported coronary heart dis-
ease events and mortality, but not all-cause deaths or cardiovascu-
lar disease events. Sixteen trials (Ahn 2016; Black 1994; Dullaart
1992; EPOCH 2011; HERO-Tapsell 2009; MARINA - Sanders
2011;MRC1968;NDHSFaribault 1968;NDHSOpen1st 1968;
ORL 2013; Rossing 1996; Simon 1997; Veterans Admin 1969;
Vijayakumar 2014; WAHA - Ros 2016; WINS 2006) reported at
least one continuous outcome without variance data or without
change data and with baseline data too different to allow us to use
end data (so we missed at least six sets of data on total cholesterol,
eight on triglyceride, seven on body weight and four sets on blood
pressure). On the other hand, we were provided the full dataset on
events for DART fat 1989, so were able to include data for almost
all of our outcomes, data for Sydney Diet-Heart 1978 were well
reported in recent re-analyses and the trial authors kindly aug-
mented these data, and outcome data in Veterans Admin 1969
were very well reported, so data are probably almost complete for
these large trials. Authors of many other trials provided some ad-
ditional data on outcomes and/or confirmed that no participants
experienced specific outcomes.
We identified 22 potential ongoing trials (Characteristics of
ongoing studies), but these trials are very difficult to assess for in-
clusion in terms of total PUFA dose, until further details are pub-
lished. We will formally assess these trials for inclusion when we
update this review. Two of these trials specifically include women,
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who are underrepresented in trials already included in this review
(NCT01784042; NCT02295059). Other ongoing trials appear
generally to be in both men and women, which will increase the
proportion of data provided by women. Two trials appear to be
planned for developing economies (India Chandrakala 2010 and
China n-3 on plasma lipid), but the majority appear to be carried
out in Europe, North America and Australia. It is not possible to
assess whether any of these trials will document trans fat intake
or status, or indeed intake or status of other key fats and nutri-
ents. There is no suggestion that any of these trials are targeting
participants with low baseline total PUFA intakes. Overall, they
may begin to address information about womenmore thoroughly,
but not deficiencies in the database of information on participants
from lower-income countries, and they are not clearly of higher
quality when it comes to assessment of dietary intakes and nutri-
tional status before and during the trials.
We all consume PUFA already (it is essential in our diets). It would
be useful to understand whether increasing PUFA in people who
eat very little has the same effect as increasing PUFA in people
already consuming large amounts. Unfortunately few trials as-
sessed overall dietary intake of participants at baseline or through
the trial. Only 16 of the 49 included trials provide information
on baseline or control-arm PUFA intake (we used control-arm
PUFA intake in lieu of baseline PUFA intake where no baseline
intake was given and the control arm were on ’usual intake’). Of
these 16 trials, participants in seven consumed less than 6% E
from PUFA and nine 6% E and above. Despite these limited data
there is a pattern across the review that effects in participants with
less than 6% E PUFA intake at baseline are positive, but effects
in those with higher baseline PUFA intake are negative or neu-
tral - though we do not see statistically significant differences be-
tween subgroups and data are very limited. The pattern is evident
for coronary heart disease events (Analysis 1.19), stroke (Analysis
1.31), MACCEs (Analysis 1.45), cardiovascular disease mortality
(Analysis 2.7), and cardiovascular disease events (Analysis 2.19),
but not in all-cause mortality where no effects are seen in any
group (Analysis 1.7) or coronary heart disease mortality (Analysis
2.31), and we lack data for atrial fibrillation. This relationship
needs to be checked in future trials, but suggests that increasing
total PUFA intake to at least 6% E may be appropriate.
Other subgrouping and meta-regression effects that would tend to
support true effects of increasing total PUFA on some cardiovas-
cular outcomes include seeing greater effects with higher PUFA
doses or with longer duration (for dichotomous outcomes). We
consistently do not see dose or duration effects within the review,
and this weakens our findings of health effects arising from in-
creasing PUFA.
Total PUFA is the sum of omega-3, omega-6 and some omega-9
fats, which may have their own specific effects on our outcomes.
We have assessed specific effects of omega-3 (Abdelhamid 2018)
and omega-6 (Hooper 2018) in separate reviews, but this review
aims to assess whether there is a group effect of PUFAs. It would
be useful to assess effects of omega-3/omega-6 ratio in this re-
view - but these data are not available. Similarly data on trans fats
would be useful, as it is possible that some trials increased trans
fats when providing PUFA (through use of partially hydrogenated
fats). There is evidence that trans fats may be harmful (de Souza
2015), and so may confound our understanding of the PUFA tri-
als. Unfortunately almost no information on trans fat intake was
found, so we could not assess this issue.
Despite systematic review evidence that omega-3 fats do not in-
fluence cardiovascular disease risk (Abdelhamid 2018) there is a
theory that the ratio of omega-3 to omega-6 fats is important for
cardiovascular health and body weight (Simopoulos 2016). We
planned to subgroup by change in the omega-3/omega-6 fat ratio,
assessing whether the intervention primarily increased omega-3
fats (putting up the ratio) or omega-6 fats (lowering the ratio).
However, only three trials (DIPP-Tokudome 2015; PREDIMED
2013; WAHA - Ros 2016) reported both omega-3 and omega-6
intakes (understanding supplemental intakes only would not be
adequate). This means that we cannot use this review to assess
health effects of altering the omega-3/omega-6 ratio.
Therewere no clear dose or duration effects in the review.Whilewe
would expect that replacing saturated fat, MUFA or carbohydrate
with PUFA would give different health effects, we do see greatest
reduction in total cholesterol with replacement of saturated fat
(Analysis 3.35), and greatest reduction of triglyceride with replace-
ment of MUFA (Analysis 3.47). However, there are no statistically
significant differences between subgroups for these outcomes or
any other health outcomes. There are no clear replacement ef-
fects. It is also surprising to see increased PUFA intake reducing
total cholesterol and triglyceride (Analysis 3.28; Analysis 3.40),
with no change in LDL (Analysis 3.64). The Friedewald equation
(Friedewald 1972) states that ’total cholesterol = LDL + HDL +
triglyceride/2.19’ (all components in mmol/L), so for the changes
of total cholesterol and triglyceride we see, wewould expect similar
falls in LDL, but this is not seen. Reasons for this are not clear, but
it is possible that changes in very low density lipoprotein (VLDL)
added to triglyceride reductions and very small changes in HDL
and LDL could add up to the overall total cholesterol reduction.
Overall, included data are applicable, but not entirely complete.
While further trials of increasing PUFA intake in women and in
developing economies are needed, they should include participants
with low PUFA intakes at baseline, as well as those with higher
intakes. Dietary advice needs to ensure that trans fat intake is kept
low as PUFA increases, and intakes of all fat fractions, including
trans fat intakes should be assessed and checked using reliable
biomarkers.
Quality of the evidence
GRADE assessment includes consideration of risk of bias, incon-
sistency, indirectness, publication bias and imprecision (Summary
of findings for the main comparison and Summary of findings 2).
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We assessed risk of bias by assessing whether effect sizes and direc-
tions altered when limited to trials at low risk of bias from allo-
cation concealment, from attention bias, from compliance, trials
at low summary risk of bias, with trials registry registration (or
pre-2010), without industry funding, and that randomised at least
100 or 250 participants. Sensitivity analyses generally supported
the primary analysis for all-cause mortality, coronary heart disease
mortality, cardiovascular disease mortality, weight and lipid out-
comes (Analysis 1.2; Analysis 2.2; Analysis 2.14; Analysis 2.26;
Analysis 3.2; Analysis 3.14; Analysis 3.29; Analysis 3.41; Analysis
3.53; Analysis 3.65), sowe did not downgrade these for risk of bias.
Either sensitivity analyses contradicted the primary analyses (for
coronary heart disease events and stroke; Analysis 1.14; Analysis
1.26) or therewere no trials at low summary risk of bias, or low risk
of compliance problems (MACCEs and atrial fibrillation; Analysis
1.40; Analysis 2.40), so we downgraded these outcomes for risk
of bias.
We judged imprecision by whether the 95% CI included the null,
and whether it included important benefits and harms. Where
both important benefits and harms were included within the con-
fidence interval we downgraded twice, where it only included the
null we downgraded once unless there was a very small overlap.
We downgraded the evidence on all primary and some secondary
outcomes for imprecision, suggesting that included trials may still
be underpowered to determine effectiveness on these outcomes.
There was no evidence of under-powering for lipid outcomes.
We judged inconsistency using the I2 statistic for each primary
and secondary outcome. We considered an I2 statistic greater than
50% to be a problem and led to us downgrading for inconsis-
tency unless we found an element that explained that inconsis-
tency (through subgrouping or meta-regression). We downgraded
the primary outcome, MACCEs for inconsistency, and also sec-
ondary outcomes, atrial fibrillation, BMI and triglyceride.
We judged indirectness according to whether data on an outcome
related to both women and men, those with and without cardio-
vascular disease at baseline, and whether low- and middle-income,
and high-income countries were represented. While indirectness
is important, we suspect that the mechanisms of action of PUFA
are similar in all these populations so we did not downgrade for
indirectness.
We judged publication bias according to whether there was any
suggestion of publication or small study bias in the funnel plot,
or where we knew that data were missing that differed from the
summary assessment. We downgraded the secondary outcomes,
coronary heart disease mortality, body weight, HDL and LDL for
publication bias.
Trial funding can be an important indicator of study bias but is
not included in ’Risk of bias’ assessment. Sixteen trials reported
funding sources, which appeared to be purely from national or
charitable agencies, seven trials appeared to be directly funded
by industrial sources, two funded by bodies set up to promote
specific foods, 16 by some governmental or charity sources with
additional funding or support from commercial sources, two trials
included authors on industry honoraria, and five trials did not
report funding.
Trial pre-registration or early publication of a trial protocol is help-
ful in understanding potential biases in data presentation (includ-
ing outcome selection bias). We ran sensitivity analyses assessing
whether trials that were pre-registered or had a published protocol
suggested different effects than trials without such documenta-
tion. We found trials registry entries for most included trials pub-
lished after 2010. Making datasets of all outcomes available via
trials registers would also help systematic reviewers to gather all
appropriate data, and minimise publication bias.
Applying the GRADE criteria suggests that we have high-qual-
ity evidence on effects of PUFA on serum total cholesterol (not
downgraded), moderate-quality evidence on all-cause mortality,
coronary heart disease events, cardiovascular disease events, body
weight, triglyceride, HDL and LDL (each downgraded once),
and low-quality evidence for stroke, cardiovascular disease mortal-
ity, coronary heart disease mortality and BMI (each downgraded
twice). All other evidence was of very low quality. Reasons for
grading, and statements of findings based on these levels of evi-
dence are found in Summary of findings for the main comparison
and Summary of findings 2.
Potential biases in the review process
We conducted a large number of sensitivity analyses and subgroup
analyses for each primary outcome, as well as some secondary
outcomes (key outcomes). The danger in these is that subgroups
may be spuriously statistically significant, but we used them to
check the stability of our primary analyses, as well as to try to
explain heterogeneity, assessing for dose effects, duration effects
and differential effects by what PUFA replaces in the diet. We have
tried not to over-interpret any of these analyses.
We only considered trials with interventions or follow-up peri-
ods of 12 months or more, making the review relevant for public
health interventions. We considered including shorter trials, but
were concerned that if we found no effect then this might be due
to including trials too short to reflect health effects of increasing or
decreasing PUFA intake. The decision on duration depended on
assumed mechanism of action of PUFA. If we assumed a choles-
terol-led atheroscleroticmechanism thenwe could justify deciding
only to include trials of at least two years’ duration. However an-
othermechanismdiscussed for omega-3 and omega-6 fats includes
inflammation - likely to work more quickly than atherosclerosis,
so allowing six months for equilibration of body tissues with the
new dietary intake, and a further six months to allow for reflection
of this new status in health outcomes, appears most appropriate
to us. We ran subgroup analyses to assess whether trial duration
made an important difference to our primary outcomes. We did
not find any suggestion of greater effects in longer trials (those
of at least four years) compared to shorter trials (one to less than
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two years, or two to less than four years) for all-cause mortality
(Analysis 1.5), coronary heart disease events (Analysis 1.17), or
stroke (Analysis 1.29).Only two trials provided data onMACCEs,
but these two trials did suggest a protective effect in the longer trial
(Analysis 1.43). Meta-regression did not suggest duration effects
for any primary outcome. Similarly there were no duration effects
in subgrouping or meta-regression for cardiovascular disease mor-
tality (Analysis 2.5), cardiovascular disease events (Analysis 2.17),
or coronary heart disease mortality (Analysis 2.29), though visual
inspection tended to suggest greater protection in the shortest tri-
als, despite them reporting few events. There was a suggestion of
a duration effect for atrial fibrillation, but the suggestion was for
greater effect in shorter trials, andno effect in longer trials (Analysis
2.43). Conversely participants taking more PUFA gained more
weight and their BMI rose more in longer trials (Analysis 3.5;
Analysis 3.17).
Our inclusion criteria could potentially cause some bias. Few trials
directly aimed to assess effects of increasing PUFA with usual or
lower PUFA intake, so included trials are a combination of trials
that aimed to increase PUFA, trials that aimed to increase omega-
3 or omega-6 fats and resulted in an increase of at least 10% of
baseline PUFA intake, and trials that aimed to reduce total fat
intake and resulted in a decrease of at least 10% of baseline PUFA
intake (while not aiming to alter dietary components other than fat
or replacements for the change in PUFA). This allowed assessment
of effects of altering PUFA intake, but we had to exclude trials
that may have been relevant but did not report aims for or effects
on total PUFA, so we may be missing other trials that would be
relevant to this review. It is also possible that we included trials that
aimed to increase or decrease total PUFA but did not achieve the
planned changes in PUFA intake. To help guard against this we
also conducted sensitivity analyses around compliance, removing
trialswherewe didnot have biomarker confirmationof a difference
in PUFA status between trial arms.
Even though we excluded clearly multifactorial trials, when we al-
ter one dietary component, other components inevitably alter too.
For example, when PUFA intake is increased we need to reduce
energy intake elsewhere, so saturated fat or carbohydrate intake
may fall to compensate. The danger is that we may see a health
effect from increasing PUFA that is actually due to a reduction in
saturated fat. However, in this review some trials that increased
PUFA reduced saturated fat, and in other trials PUFA and sat-
urated fat were both reduced in the intervention arm. Regard-
less of which arm the trial considered to be the intervention arm
we compared the arm with higher PUFA against the arm with
lower PUFA to look for consistent effects of higher PUFA intake.
Because saturated fat (and other dietary components) sometimes
moved with PUFA and sometimes moved in the opposite direc-
tion the only consistent difference between arms was in PUFA
intake. This means that health effects noted are unlikely to be spu-
rious effects of other dietary components. Combining higher ver-
sus lower PUFA intake across different types of trials may balance
out effects of other dietary (fat and non-fat) components while
providing power to assess health effects of changing PUFA.
Agreements and disagreements with other
studies or reviews
We recently published a Cochrane Review of long-term RCTs that
assessed effects of reducing saturated fats, replacing them with a
variety of other energy sources (Hooper 2015a). This review found
no effect of reducing saturated fats on all-causemortality or cardio-
vascular disease mortality, but the evidence suggested that reduc-
ing saturated fats reduced the risk of cardiovascular disease events
(RR 0.83, 95% CI 0.72 to 0.96, I2 = 65%, including 4377 events
in over 53,000 randomised participants). Subgrouping, assessing
whether the saturated fats were being replaced by PUFA, MUFA,
carbohydrate and/or protein found that there were no statistically
significant effects in these subgroups except where saturated fat
was being replaced by PUFA (RR 0.73, 95% CI 0.58 to 0.92, I2 =
69%, 884 events in over 3000 participants). Hooper 2015a con-
firmed results expected from the Friedewald equation (Friedewald
1972). The trials included in the saturated fat review and this one
are distinct due to rather different inclusion criteria (for example,
the saturated fat review only included trials of at least two years
duration, and included trials with dietary interventions decreas-
ing saturated fat plus altering other dietary variables). The impli-
cations of the reviews are similar - Hooper 2015a suggests that
reducing saturated fat and replacement by polyunsaturated fats
reduces the risk of cardiovascular disease events, while this review
also suggests that increasing PUFA may reduce the risk of cardio-
vascular disease events, as well as coronary heart disease mortality
(as well as reducing total cholesterol and triglyceride). However,
this current review also suggests that increasing PUFA intake also
leads to slight weight gain.
Two previous systematic reviews of RCTs assessed effects of PUFA
replacing saturated fat: Ramsden 2010 and Mozaffarian 2010.
Ramsden 2010 included seven trials that compared increasing
mixed omega-3 and omega-6 PUFA or omega-6 alone and re-
placing dietary saturated fat with usual dietary intake. Their data
suggested no effect on all-cause mortality (RR 0.99, 95% CI 0.89
to 1.11), but likely reductions in coronary heart disease mortality
(RR 0.91, 95% CI 0.74 to 1.10), and myocardial infarction and
cardiac death combined (RR 0.85, 95% CI 0.73 to 0.99). These
are similar results to this review (no effect on all-cause mortal-
ity, reductions in coronary heart disease mortality and myocar-
dial infarction). Ramsden 2010 included fewer trials than this re-
view, four trials that we included (MRC 1968; Rose 1965; Sydney
Diet-Heart 1978; Veterans Admin 1969), and three we excluded.
We excluded two for being multifactorial (Oslo Diet-Heart 1966;
STARS 1992) and one for having inconsistent enrolment so that
many participants were included for less than 12 months con-
tinuously (Minnesota Coronary 1989). The other systematic re-
view, Mozaffarian 2010, also included seven trials replacing sat-
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urated fat with PUFA, three that we included (DART fat 1989;
MRC 1968; Veterans Admin 1969), and four that we excluded.
One we excluded due to lack of randomisation (Finnish Mental
Hosp 1972), one for inconsistent enrolment (Minnesota Coronary
1989), and two because the intervention was multifactorial (Oslo
Diet-Heart 1966; STARS 1992).Mozaffarian 2010 found that in-
creasing PUFA by replacing saturated fat reduced coronary heart
disease events by 19% (RR 0.81, 95%CI 0.70 to 0.95), unlike this
review, where we found that the evidence was of very low quality,
so could not assess effects on this outcome.
Recent observational data of more than 30,000 adults aged over
30 years from the National Health and Nutrition Examination
Survey (NHANES) was not entirely consistent with our results.
They suggested that the tertile of adults with highest PUFA intake
were at lowest risk of all-causemortality (HR0.94, 95%CI 0.90 to
0.98 compared to the tertile with lowest intake) and cardiovascular
disease mortality (HR 0.93, 95% CI 0.89 to 0.97), when adjusted
for ethnicity, BMI, alcohol intake, smoking, education, physical
activity, fibre intake and blood pressure (Ricci 2018).
The suggestion of weight gain with increased PUFA intake reflects
data from other systematic reviews that reducing dietary fat (in-
cluding PUFAs) appears to result in lower weight in adults. As
weight gainmay increase cardiovascular risk, thismaywork against
more positive lowering of total cholesterol and triglycerides when
assessing overall effects of increasing PUFA on cardiovascular dis-
ease (Hooper 2015b).
We interpreted the total cholesterol andweight results usingQRisk
2-2017 (QRISK 2-2017). In a Pakistani non-smoking male aged
64 years without existing cardiovascular disease or diabetes, height
173 cm,weighing 81 kgwith systolic blood pressure of 145mmHg
and total cholesterol 5.46 mmol/L, HDL 1.31 (total cholesterol/
HDL 4.17) at baseline (typical values for the trials in this review)
their 10-year QRISK 2-2017 score would be 23.5%. A reduction
of total cholesterol by 0.12 mmol/L, HDL by 0.01 mmol/L and
weight rise of 0.76 kg reduces the QRISK 2-2017 score to 23.2%.
QRISK 2-2017 suggests that in 1000 people with the same risk
factors, 235 are likely to have a heart attack or stroke within the
next 10 years at baseline, falling to 232 having a heart attack or
stroke following increased PUFA intake. Three people of the 1000
would be prevented from experiencing a heart attack or stroke by
the increased PUFA. This is a smaller effect than the estimated
reduction from 58 per 1000 to 49 (95% CI 42 to 59) per 1000
predicted for primary prevention of cardiovascular disease events
within this review (Summary of findings 2).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Increasing polyunsaturated fatty acid (PUFA) intake probably
makes little or no difference (neither benefit nor harm) to all-
cause mortality and probably slightly reduces the risk of coronary
heart disease events and cardiovascular disease events (all moder-
ate-quality evidence). Increased PUFA intake may slightly reduce
risk of coronary heart disease mortality and stroke (although for
stroke the confidence intervals include important harm), but may
have little or no effect on cardiovascular disease mortality (all low-
quality evidence). Increasing PUFA does reduce total cholesterol,
probably reduces triglyceride, probably has little or no effect on
high-density lipoprotein (HDL) or low-density lipoprotein (LDL)
and probably increases body weight.
This suggests that increasing PUFA intake may have beneficial ef-
fects on risk of cardiovascular disease events, coronary heart disease
mortality, coronary heart disease events and stroke. The mecha-
nism may be via reduction of total cholesterol and triglyceride.
However increasing PUFAwill probably lead to slight bodyweight
increase.
Implications for research
Further trials assessing cardiovascular effects of increasing PUFA
intake in women and people living in developing economies are
needed. Given the low power for assessing effects by baseline
PUFA, more research in populations with a low baseline intake of
less than 6% E is needed to understand whether there is greater
benefit from increasing PUFA intake in these groups. Further tri-
als should include participants with low PUFA intakes at baseline,
as well as those with higher intakes. Dietary advice needs to ensure
that trans fat intake is kept low as PUFA increases. Intake and
status of all fat fractions, including trans fat, should be assessed
and checked using reliable biomarkers.
A C K N OW L E D G E M E N T S
Thank you, to all of the authors of primary trials who kindly pro-
videduswith the best set of data available, including:DKromhout,
Wageningen University (AlphaOmega - ALA; AlphaOmega -
EPA+DHA); HS Black, Veterans Affairs Medical Center (Black
1994); J Brox, University hospital of North Norway (Brox 2001);
ML Burr, University of Wales and A Ness, University of Bris-
tol (DART fat 1989); S Tokudome, National Institue of Health
and Nutrition, Japan (DIPP-Tokudome 2015); S Dodin, Uni-
versite Laval (Dodin 2005); RPF Dullaart, University of Gronin-
gen, Netherlands (Dullaart 1992); D Schoenfeld, Harvard Med-
ical School (FAAT - Leaf 2005); London, P Metcalf, University
of Auckland, New Zeland (Ley 2004); T Sanders, King’s College,
London, UK (MARINA - Sanders 2011); T Sheldon, Univer-
sity of York, UK (MRC 1968); M James, Royal Adelaide Hos-
pital, Australia (Proudman 2015); MS Simon, Wayne State Uni-
versity, Simon 1997; C Ramsden, National Institutes of Health,
USA, D Zamora, University of North Carolina and Boonseng
Leelarthaepin, retired (SydneyDiet-Heart 1978);MVijayakumar,
41Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Amrita Institute of Medical Sciences, India (Vijayakumar 2014);
J Sabaté, Loma Linda University, California (WAHA - Ros 2016);
E Scorletti, University of Southampton, UK (WELCOME 2015).
Thanks also to the authors who replied but were not able to pro-
vide further details or confirmed no relevant outcomes, includ-
ing: D Bates, Royal Victoria Infirmary, Newcastle on Tyne, R
Dworkin, University of Rochester, UK, (Bates 1977; Bates 1978;
Bates 1989); MB McIllmurray, Cancer Care, UK (McIllmurray
1987); B Puri, Imperial College London (Puri 2005); M Raitt,
OregonHealth&ScienceUniversity, USA (Raitt 2005);DPRose,
American Health Foundation (WINS 2006).
Thank you to Juan-Pablo Casas for discussions on the protocol,
and to all Cochrane Heart staff and editors for fast and helpful
comments and support. Thank you also to the World Health Or-
ganization for commissioning and funding the review.
This review was carried out by the Polyunsaturated Fats and
Health (PUFAH) Group, and written by the authors on behalf of
the PUFAH group. The Polyunsaturated Fats and Health (PU-
FAH) group includes Asmaa Abdelhamid1, Zoya Ahmed1, Sarah
MA Ajabnoor1,6 , Fai K AlAbdulghafoor1, Lena Al-Khudairy2,
Priti Biswas3 , Julii Suzanne Brainard1 , Charlene Bridges4 , Tracey
J Brown1, Katherine HO Deane3, Daisy H Donaldson1 , Sarah
Hanson3 , Oluseyi F Jimoh1, Nicole Martin4, Katie Maas1, He-
len J Moore5, Alex T O’Brien1, Karen Rees2, Ruksana Sivakaran
1, Fujian Song1, Carolyn D Summerbell5,, Gabrielle C Thorpe
3, Xia Wang1 , Ailsa Welch1, Lauren Winstanley1 , Helen V Wor-
thington7 and Lee Hooper1
(1Norwich Medical School, University of East Anglia, 2Warwick
Medical School, University of Warwick, 3School of Health Sci-
ences,University of East Anglia, 4CochraneHeart,UniversityCol-
lege London, 5Durham University, 6Clinical Nutrition Depart-
ment, Faculty of Applied Medical Sciences, King Abdulaziz Uni-
versity, KSA, 7School of Dentistry, University of Manchester).
R E F E R E N C E S
References to studies included in this review
Ahn 2016 {published data only (unpublished sought but not used)}
Ahn J, Park SK, Park TS, Kim JH, Yun E, Kim SP, et al.
Effect of n-3 polyunsaturated fatty acids on regression of
coronary atherosclerosis in statin treated patients undergoing
percutaneous coronary intervention. Korean Circulation
Journal 2016;46(4):481–9. PUBMED: 27482256]
AlphaOmega - ALA {published and unpublished data}
Brouwer IA, Geleijnse JM, Klaasen VM, Smit LA, Giltay
EJ, De Goede J, et al. Effect of alpha linolenic acid
supplementation on serum prostate specific antigen (PSA):
results from the Alpha Omega Trial. PloS One 2013;8(12):
e81519.
Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ,
Klungel OH, Kromhout D. Effects of n-3 fatty acids on
major cardiovascular events in statin users and non-users
with a history of myocardial infarction. European Heart
Journal 2012;33(13):1582–8.
Geleijnse J, Giltay E, Kromhout D. Effects of n-3 fatty acids
on cognitive decline: a randomized double-blind, placebo-
controlled trial in stable myocardial infarction patients.
Alzheimer’s & Dementia 2011;1:S512.
Geleijnse JM, Giltay EJ, Kromhout D. Effects of n-3 fatty
acids on cognitive decline: a randomized, double-blind,
placebo-controlled trial in stable myocardial infarction
patients. Alzheimer’s & Dementia 2012;8(4):278–87.
Geleijnse JM, Giltay EJ, Schouten EG, De Goede J,
Oude Griep LM, Teitsma-Jansen AM, et al. Effect of
low doses of n-3 fatty acids on cardiovascular diseases in
4,837 post-myocardial infarction patients: design and
baseline characteristics of the Alpha Omega Trial. American
Heart Journal 2010;159(4):539–46. DOI: 10/1016/
j.ahj.2009.12.033
Giltay EJ, Geleijnse JM, Heijboer AC, De Goede J, Oude
Griep LM, Blankenstein MA, et al. No effects of n-3 fatty
acid supplementation on serum total testosterone levels in
older men: the Alpha Omega Trial. International Journal of
Andrology 2012;35(5):680–7.
Giltay EJ, Geleijnse JM, Kromhout D. Effects of n-3 fatty
acids on depressive symptoms and dispositional optimism
after myocardial infarction. American Journal of Clinical
Nutrition 2011;94(6):1442–50.
Hoogeveen E, Gemen E, Geleijnse M, Kusters R, Kromhout
D, Giltay E. Effects of n-3 fatty acids on decline of kidney
function after myocardial infarction: Alpha Omega Trial.
Nephrology, Dialysis, Transplantation 2012;27:ii64.
Hoogeveen EK, Geleijnse JM, Kromhout D, Giltay EJ.
No effect of n-3 fatty acids on high-sensitivity C-reactive
protein after myocardial infarction: the Alpha Omega Trial.
European Journal of Preventive Cardiology 2014;21(11):
1429–36.
Hoogeveen EK, Geleijnse JM, Kromhout D, Stijnen T,
Gemen EF, Kusters R, et al. Effect of omega-3 fatty acids
on kidney function after myocardial infarction: the Alpha
Omega Trial. Clinical Journal of The American Society of
Nephrology: CJASN 2014;9(10):1676–83.
Kromhout D, Geleijnse JM, De Goede J, Oude Griep LM,
Mulder BJ, De Boer MJ, et al. N-3 fatty acids, ventricular
arrhythmia-related events, and fatal myocardial infarction in
postmyocardial infarction patients with diabetes. Diabetes
Care 2011;34(12):2515–20.
∗ Kromhout D, Giltay EJ, Geleijnse JM. N-3 fatty acids
and cardiovascular events after myocardial infarction. New
England Journal of Medicine 2010;363(18):2015–26.
NCT00127452. Alpha Omega Trial: study of omega-3
42Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
fatty acids and coronary mortality. clinicaltrials.gov/ct2/
show/NCT00127452 (first posted 5 August 2005).
Bassey 2000-Post {published data only}
Bassey EJ, Littlewood JJ, Rothwell MC, Pye DW. Lack of
effect of supplementation with essential fatty acids on bone
mineral density in healthy pre- and postmenopausal women:
two randomized controlled trials of Efacal v. calcium alone.
British Journal of Nutrition 2000;83(6):629–35. PUBMED:
10911771]
Bassey 2000-Pre {published data only}
Bassey EJ, Littlewood JJ, Rothwell MC, Pye DW. Lack of
effect of supplementation with essential fatty acids on bone
mineral density in healthy pre- and postmenopausal women:
two randomized controlled trials of Efacal v. calcium alone.
British Journal of Nutrition 2000;83(6):629–35. PUBMED:
10911771]
Bates 1977 {published data only (unpublished sought but not used)}
∗ Bates D, Fawcett PR, Shaw DA, Weightman D. Trial
of polyunsaturated fatty acids in non-relapsing multiple
sclerosis. British Medical Journal 1977;2(6092):932–3.
Dworkin RH, Bates D, Millar JH, Paty DW. Linoleic acid
and multiple sclerosis: a reanalysis of three double-blind
trials. Neurology 1984;34(11):1441–5.
Bates 1978 {published data only (unpublished sought but not used)}
∗ Bates D, Fawcett PR, Shaw DA, Weightman D.
Polyunsaturated fatty acids in treatment of acute remitting
multiple sclerosis. British Medical Journal 1978;2(6149):
1390–1.
Dworkin RH, Bates D, Millar JH, Paty DW. Linoleic acid
and multiple sclerosis: a reanalysis of three double-blind
trials. Neurology 1984;34(11):1441–5.
Bates 1989 {published data only (unpublished sought but not used)}
Bates D, Cartlidge NE, French JM, JacksonMJ, Nightingale
S, Shaw DA, et al. A double-blind controlled trial of long
chain n-3 polyunsaturated fatty acids in the treatment of
multiple sclerosis. Journal of Neurology, Neurosurgery &
Psychiatry 1989;52(1):18–22.
Black 1994 {published and unpublished data}
∗ Black HS, Herd JA, Goldberg LH, Wolf-JE J, Thornby JI,
Rosen T, et al. Effect of a low-fat diet on the incidence of
actinic keratosis. New England Journal of Medicine 1994;
330(18):1272–5.
Black HS, Thornby JI, Wolf-JE J, Goldberg LH, Herd JA,
Rosen T, et al. Evidence that a low-fat diet reduces the
occurrence of non-melanoma skin cancer. International
Journal of Cancer 1995;62(2):165–9.
Jaax S, Scott LW, Wolf-JE J, Thornby JI, Black HS. General
guidelines for a low-fat diet effective in the management
and prevention of nonmelanoma skin cancer. Nutrition and
Cancer 1997;27(2):150–6.
Brox 2001 {published and unpublished data}
Brox J, Olaussen K, Osterud B, Elvevoll EO, Bjornstad
E, Brattebog G, et al. A long-term seal- and cod-liver-oil
supplementation in hypercholesterolemic subjects. Lipids
2001;36(1):7–13.
DART fat 1989 {published and unpublished data}
Burr ML, Fehily AM. Fish and the heart. Lancet 1989;ii:
1450–2.
∗ Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM,
Sweetnam PM, et al. Effects of changes in fat, fish, and
fibre intakes on death and myocardial reinfarction: diet and
reinfarction trial (DART). Lancet 1989;2(8666):757–61.
Burr ML, Fehily AM, Rogers S, Welsby E, King S, Sandham
S. Diet and reinfarction trial (DART): design, recruitment,
and compliance. European Heart Journal 1989;10(6):
558–67.
Burr ML, Holliday RM, Fehily AM, Whitehead PJ.
Haematological prognostic indices after myocardial
infarction: evidence from the diet and reinfarction trial
(DART). European Heart Journal 1992;13(2):166–70.
Burr ML, Sweetham PM, Fehily AM. Diet and reinfarction
[letter]. European Heart Journal 1994;15(8):1152–3.
Fehily AM, Vaughan-Williams E, Shiels K, Williams AH,
Horner M, Bingham G, et al. The effect of dietary advice
on nutrient intakes: evidence from the diet and reinfarction
trial (DART). Journal of Human Nutrition & Dietetics 1989;
2(4):225–5.
DIPP-Tokudome 2015 {published and unpublished data}
∗ Tokudome S, Kuriki K, Yokoyama Y, Sasaki M, Joh T,
Kamiya T, et al. Dietary n-3/long-chain n-3 polyunsaturated
fatty acids for prevention of sporadic colorectal tumors: a
randomized controlled trial in polypectomized participants.
Prostaglandins, Leukotrienes, and Essential Fatty Acids 2015;
94:1–11. PUBMED: 25451556]
Tokudome S, Yokoyama Y, Kamiya T, Seno K, Okuyama
H, Kuriki K, et al. Rationale and study design of dietary
intervention in patients polypectomized for tumors of the
colorectum. Japanese Journal of Clinical Oncology 2002;32
(12):550–3. PUBMED: 12578906]
UMIN000000461. Dietary intervention in patients
polypectomized for tumors of the colorectum.
upload.umin.ac.jp/cgi-open-bin/ctr e/ctr view.cgi?recptno=
R000000534 (date of disclosure 3 August 2006).
Dodin 2005 {published and unpublished data}
Dodin S, Cunnane SC, Masse B, Lemay A, Jacques H,
Asselin G, et al. Flaxseed on cardiovascular disease markers
in healthy menopausal women: a randomized, double-
blind, placebo-controlled trial. Nutrition (Burbank, Los
Angeles County, Calif.) 2008;24(1):23–30. PUBMED:
17981439]
∗ Dodin S, Lemay A, Jacques H, Legare F, Forest JC, Masse
B. The effects of flaxseed dietary supplement on lipid
profile, bone mineral density, and symptoms in menopausal
women: a randomized, double-blind, wheat germ placebo-
controlled clinical trial. Journal of Clinical Endocrinology and
Metabolism 2005;90(3):1390–7. PUBMED: 15613422]
Doi 2014 {published data only (unpublished sought but not used)}
Doi M, Nosaka K, Miyoshi T, Iwamoto M, Kajiya M,
Okawa K, et al. Clinical outcomes of early initiation of
pure eicosapentaenoic acid supplement after percutaneous
coronary intervention in patients with acute coronary
43Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
syndrome. European Heart Journal 2014;35(Abstract
Supplement):1156.
∗ Doi M, Nosaka K, Miyoshi T, Iwamoto M, Kajiya M,
Okawa K, et al. Early eicosapentaenoic acid treatment
after percutaneous coronary intervention reduces acute
inflammatory responses and ventricular arrhythmias in
patients with acute myocardial infarction: a randomized,
controlled study. International Journal of Cardiology 2014;
176(3):577–82. PUBMED: 25305703]
Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa
K, Tsukuda S, et al. Early initiation of eicosapentaenoic
acid and statin treatment is associated with better clinical
outcomes than statin alone in patients with acute coronary
syndromes: 1-year outcomes of a randomized controlled
study. International Journal of Cardiology 2017;228:173–9.
DOI: 10.1016/j.ijcard.2016.11.105
Nosaka K, Miyoshi T, Okawa K, Tsukuda S, Sogo M,
Nishibe T, et al. Early initiation of eicosapentaenoic
acid and statin treatment is associated with better clinical
outcomes than statin alone in patients with acute coronary
syndromes: 1-year outcomes of a randomized controlled
study. Journal of the American College of Cardiology 2016;
67:573.
UMIN000016723. Clinical effect of early loading
of eicosepentaenoic acid after percutaneous coronary
intervention in patients with acute coronary syndrome: a
prospective, open-labeled, randomized controlled clinical
trial. upload.umin.ac.jp/cgi-open-bin/ctr e/ctr view.cgi?
recptno=R000019385 (date of disclosure 1 April 2015).
Dullaart 1992 {published and unpublished data}
Dullaart RP, Beusekamp BJ, Meijer S, Hoogenberg K, Van
Doormaal JJ, Sluiter WJ. Long-term effects of linoleic-acid-
enriched diet on albuminuria and lipid levels in type 1
(insulin-dependent) diabetic patients with elevated urinary
albumin excretion. Diabetologia 1992;35(2):165–72.
PUBMED: 1547922]
EPIC-1 2008 {published and unpublished data}
∗ Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S,
D’Haens G, Bradette M, et al. Omega-3 free fatty acids
for the maintenance of remission in Crohn disease: the
EPIC Randomized Controlled Trials. JAMA 2008;299(14):
1690–7.
NCT00613197. EPANOVA in Crohn’s disease, study 1
(EPIC-1). clinicaltrials.gov/ct2/show/NCT00613197 (first
posted 12 February 2008).
EPIC-2 2008 {published and unpublished data}
∗ Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S,
D’Haens G, Bradette M, et al. Omega-3 free fatty acids
for the maintenance of remission in Crohn disease: the
EPIC Randomized Controlled Trials. JAMA 2008;229(14):
1690–7.
NCT00074542. An efficacy and safety study of omega-
3 free fatty acids (Epanova) for the maintenance of
symptomatic remission in subjects with Crohn’s disease.
clinicaltrials.gov/ct2/show/NCT00074542 (first posted 16
December 2003).
EPOCH 2011 {published and unpublished data}
ACTRN12607000278437. Older people, omega-3,
and cognitive health [An 18 month study investigating
the effects of long chain omega–3 polyunsaturated fatty
acids supplementation on cognition and wellbeing in
older people]. www.anzctr.org.au/Trial/Registration/
TrialReview.aspx?ACTRN=12607000278437 (date
registered 24 May 2007).
Danthiir V, Burns NR, Nettelbeck T, Wilson C, Wittert G.
The older people, omega-3, and cognitive health (EPOCH)
trial design and methodology: a randomised, double-
blind, controlled trial investigating the effect of long-chain
omega-3 fatty acids on cognitive ageing and wellbeing in
cognitively healthy older adults. Nutrition Journal 2011;10:
117. PUBMED: 22011460]
∗ Danthiir V, Hosking D, Burns NR, Wilson C, Nettelbeck
T, Calvaresi E, et al. Cognitive performance in older
adults is inversely associated with fish consumption but not
erythrocyte membrane n-3 fatty acids. Journal of Nutrition
2014;144(3):311–20. PUBMED: 24353345]
FAAT - Leaf 2005 {published and unpublished data}
∗ Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J,
Kang JX, et al. Prevention of fatal arrhythmias in high-risk
subjects by fish oil n-3 fatty acid intake. Circulation 2005;
112(18):2762–8.
NCT00004559. Fatty Acid Antiarrhythmia Trial (FAAT).
clinicaltrials.gov/ct2/show/NCT00004559 (first posted 10
February 2000).
GLAMT1993 {published data only (unpublished sought but not used)}
Keen H, Payan J, Allawi J, Walker J, Jamal GA, Weir AI, et
al. Treatment of diabetic neuropathy with gamma-linolenic
acid. Diabetes Care 1993;16(1):8–15.
HARP- Sacks 1995 {published and unpublished data}
NCT00000461. Harvard Atherosclerosis Reversibility
Project (HARP). clinicaltrials.gov/ct2/show/NCT00000461
(first posted 28 October 1999).
Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson
CM, Sacks FM. Effect of combination therapy with lipid-
reducing drugs in patients with coronary heart disease
and “normal” cholesterol levels. A randomized, placebo-
controlled trial. Annals of Internal Medicine 1996;125(7):
529–40. PUBMED: 8815751]
Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone
PH. Effect on coronary atherosclerosis of decrease in plasma
cholesterol concentrations in normocholesterolaemic
patients. Lancet 1994;344(8931):1182–6. PUBMED:
7934538]
∗ Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner
B, Pasternak RC. Controlled trial of fish oil for regression
of human coronary atherosclerosis. Journal of the American
College of Cardiology 1995;25(7):1492–8.
HERO-Tapsell 2009 {published and unpublished data}
ACTRN12607000600448. Healthy eating to reduce
overweight in people with type 2 diabetes [The
role of walnuts in satiety and energy balance in
overweight individuals with type 2 diabetes mellitus].
44Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=
82353 (date registered 21 November 2007).
Tan SY. Dietary Manipulation and Weight Management
[thesis]. Wollongong (Australia): School of Health Sciences,
University of Wollongong, 2010.
∗ Tapsell LC, Batterham MJ, Teuss G, Tan SY, Dalton S,
Quick CJ, et al. Long-term effects of increased dietary
polyunsaturated fat from walnuts on metabolic parameters
in type II diabetes. European Journal of Clinical Nutrition
2009;63(8):1008–15. PUBMED: 19352378]
Houtsmuller 1979 {published data only (unpublished sought but not
used)}
Houtsmuller AJ, Van Hal-Ferwerda J, Zahn KJ, Henkes HE.
Favourable influences of linoleic acid on the progression
of diabetic micro- and macroangiopathy. Nutrition and
Metabolism 1980;24(Suppl 1):105–18.
Houtsmuller AJ, Van Hal-Ferwerda J, Zahn KJ, Henkes
HE. Influence of different diets on the progression of
diabetic retinopathy. Progress in Food Nutritition and Science
1980;4(5):41–6.
∗ Houtsmuller AJ, Zahn KJ, Henkes HE. Unsaturated
fats and progression of diabetic retinopathy. Documenta
Ophthalmologia 1979;48(2):363–71.
Kumar 2012 {published data only (unpublished sought but not used)}
∗ Kumar S, Sutherland F, Morton JB, Lee G, Morgan J,
Wong J, et al. Long-term omega-3 polyunsaturated fatty
acid supplementation reduces the recurrence of persistent
atrial fibrillation after electrical cardioversion. Heart Rhythm
2012;9(4):483–91. DOI: 10.1016/j.hrthm.2011.11.034
NCT00232219. Use of fish oils to reduce recurrence of atrial
fibrillation following DC cardioversion. clinicaltrials.gov/
ct2/show/NCT00232219 (first posted 4 October 2005).
Kumar 2013 {published data only}
∗ Kumar S, Sutherland F, Stevenson I, Lee JM,
Garg ML, Sparks PB. Effects of long-term omega-3
polyunsaturated fatty acid supplementation on paroxysmal
atrial tachyarrhythmia burden in patients with implanted
pacemakers: results from a prospective randomised study.
International Journal of Cardiology 2013;168(4):3812–7.
PUBMED: 23890856]
NCT00232245. Use of fish oils to reduce the frequency
and duration of episodes of atrial fibrillation in patients
with paroxysmal atrial fibrillation. clinicaltrials.gov/ct2/
show/NCT00232245 (first posted 4 October 2005).
Ley 2004 {published and unpublished data}
∗ Ley SJ,Metcalf PA, Scragg RKR, Swinburn BA. Long-term
effects of a reduced fat diet intervention on cardiovascular
disease risk factors in individuals with glucose intolerance.
Diabetes Research and Clinical Practice 2004;63:103–12.
Swinburn BA, Metcalf PA, Ley SJ. Long-term (5-year)
effects of a reduced-fat diet intervention in individuals with
glucose intolerance. Diabetes Care 2001;24(4):619–24.
Swinburn BA, Woollard GA, Chang EC, Wilson MR.
Effects of reduced-fat diets consumed ad libitum on intake
of nutrients particularly antioxidant vitamins. Journal of the
American Dietetic Association 1999;99(11):1400–5.
MARINA - Sanders 2011 {published and unpublished data}
Al-Hilal M, Alsaleh A, Maniou Z, Lewis FJ, Hall WL,
Sanders TA, et al. Genetic variation at the FADS1-FADS2
gene locus influences delta-5 desaturase activity and LC-
PUFA proportions after fish oil supplement. Journal of
Lipid Research 2013;54(2):542–51. PUBMED: 23160180]
AlSaleh A, Maniou Z, Lewis FJ, Hall WL, Sanders TA,
O’Dell SD. Interaction between a CSK gene variant and
fish oil intake influences blood pressure in healthy adults.
Journal of Nutrition 2014;144(3):267–72. PUBMED:
24401815]
Alsaleh A, Crepostnaia D, Maniou Z, Lewis FJ, Hall WL,
Sanders TA, et al. Adiponectin gene variant interacts with
fish oil supplementation to influence serum adiponectin
in older individuals. Journal of Nutrition 2013;143(7):
1021–7. PUBMED: 23658423]
Hall WL, Hay G, Maniou Z, Seed PT, Chowienczyk
PJ, Sanders TA. Effect of low doses of long chain n-
3 polyunsaturated fatty acids on sleep-time heart rate
variability: a randomized, controlled trial. International
Journal of Cardiology 2013;168:4439–42.
ISRCTN66664610. Vascular effects of eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA): the MARINA
study. www.isrctn.com/ISRCTN66664610 (date assigned
17 December 2008).
Pinto AM, Hall WL, Sanders TAB. Effect of low doses
of long chain n-3 PUFA intake on daytime heart rate
variability: results from the MARINA study. European
Journal of Preventive Cardiology 2015;1:S146.
Proudman S, Spargo L, Hall C, McWilliams L, Lee A,
Maureen R, et al. Fish oil in rheumatoid arthritis: a
randomised, double blind trial comparing high dose with
low dose. Internal Medicine Journal 2012;42:2–3.
∗ Sanders TA, Hall WL, Maniou Z, Lewis F, Seed PT,
Chowienczyk PJ. Effect of low doses of long-chain n-3
PUFAs on endothelial function and arterial stiffness: a
randomized controlled trial. American Journal of Clinical
Nutrition 2011;94(4):973–80. PUBMED: 21865334]
Sanders TAB, Chowienczyk PJ, Hall W, Lewis F, Seed P,
Maniou Z, et al. The influences of increasing intakes of
EPA and DHA on vascular function and risk factors for
cardiovascular disease. Food Standards Agency Project
N02041. Final Report 2011.
McIllmurray 1987 {published data only (unpublished sought but not
used)}
McIllmurray MB, Turkie W. Controlled trial of gamma
linolenic acid in Duke’s C colorectal cancer. BMJ (Clinical
Research Ed.) 1987;294(6582):1260 (Erratum in: BMJ
1987;295(6596):475).
Mendis 2001 {published data only (unpublished sought but not used)}
Mendis S, Samarajeewa U, Thattil RO. Coconut fat and
serum lipoproteins: effects of partial replacement with
unsaturated fats. British Journal of Nutrition 2001;85(5):
583–9.
Mita 2007 {published data only}
Mita T, Watada H, Ogihara T, Nomiyama T, Ogawa
O, Kinoshita J, et al. Eicosapentaenoic acid reduces the
45Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
progression of carotid intima-media thickness in patients
with type 2 diabetes. Atherosclerosis 2007;191(1):162–7.
MRC 1968 {published and unpublished data}
Ederer F, Leren P, Turpeinen O, Frantz ID Jr. Cancer
among men on cholesterol lowering diets: experience of five
clinical trials. Lancet 1971;2:203–6.
Heady JA. Are PUFA harmful?. British Medical Journal
1974;1(898):115–6.
∗ MRC. Controlled trial of soya-bean oil in myocardial
infarction; report of a medical research committee to the
Medical Research Council. Lancet 1968;2(570):693–9.
NDHS Faribault 1968 {published data only}
The National Diet-Heart Study. Nutrition Reviews 1968;
Vol. 26, issue 5:133–6.
∗ The National Diet-Heart Study final report. Circulation
1968; Vol. 37, issue II:1–428.
Baker BM, Frantz ID Jr, Keys A, Kinsell LW, Page IH,
Stamler J, et al. The National Diet-Heart Study: an initial
report. JAMA 1963;185:105–6.
Brown HB. The National Diet Heart Study - implications
for dietitians and nutritionists. Journal of the American
Dietetic Association 1968;52:279–87.
Ederer F, Leren P, Turpeinen O, Frantz ID Jr. Cancer
among men on cholesterol-lowering diets: experience from
five clinical trials. Lancet 1971;298(7717):203–6.
Page IH, Brown HB. Some observations on the National
Diet-Heart Study. Circulation 1968;37:313–5.
NDHS Open 1st 1968 {published data only}
The National Diet-Heart Study. Nutrition Reviews 1968;
Vol. 26, issue 5:133–6.
∗ The National Diet-Heart Study final report. Circulation
1968; Vol. 37, issue II:1–428.
Baker BM, Frantz ID Jr, Keys A, Kinsell LW, Page IH,
Stamler J, et al. The National Diet-Heart Study: an initial
report. JAMA 1963;185:105–6.
Brown HB. The National Diet Heart Study - implications
for dietitians and nutritionists. Journal of the American
Dietetic Association 1968;52:279–87.
Ederer F, Leren P, Turpeinen O, Frantz ID Jr. Cancer
among men on cholesterol-lowering diets: experience from
five clinical trials. Lancet 1971;298(7717):203–6.
Page IH, Brown HB. Some observations on the National
Diet-Heart Study. Circulation 1968;37:313–5.
Nodari 2011 AF {published data only (unpublished sought but not
used)}
NCT01198275. N-3 polyunsaturated fatty acids (PUFAs)
in the prevention of atrial fibrillation. clinicaltrials.gov/ct2/
show/NCT01198275 (first posted 21 July 2011).
∗ Nodari S, Triggiani M, Campia U, Manerba A, Milesi G,
Cesana BM, et al. N-3 polyunsaturated fatty acids in the
prevention of atrial fibrillation recurrences after electrical
cardioversion: a prospective, randomized study. Circulation
2011;124(10):1100–6. PUBMED: 21844082]
Nodari 2011 HF {published and unpublished data}
NCT01223703. PUFAs and left ventricular function in
heart failure (CS-PUFA-02). clinicaltrials.gov/ct2/show/
NCT01223703 (first posted 19 October 2010).
NCT01223703. PUFAs and left ventricular function in
heart failure (CS-PUFA-02). clinicaltrials.gov/ct2/show/
results/NCT01223703 (first posted 19 October 2010).
Nodari S, Triggiani M, Berlinghieri N, Milesi G, Foresti A,
Gheorghiade M, et al. Effects of n-3 polyunsaturated fatty
acids on left ventricular function and functional capacity in
heart failure patients. European Heart Journal 2010;31:850.
∗ Nodari S, Triggiani M, Campia U, Manerba A, Milesi
G, Cesana BM, et al. Effects of n-3 polyunsaturated fatty
acids on left ventricular function and functional capacity
in patients with dilated cardiomyopathy. Journal of the
American College of Cardiology 2011;57(7):870–9.
Nodari S, Triggiani M, Campia U, Zhao L, Manerba A,
Milesi G, et al. Plasma levels of n-3 polyunsaturated fatty
acids and risk of hospitalization in patients with non-
ischemic cardiomyopathy. Circulation 2012;126(21 SUPPL
1):17431.
Nye 1990 {published data only}
Ilsey CDJ, Nye ER, Sutherland W, Ram J, Ablett MB.
Randomised placebo controlled trial of MAXEPA and
aspirin/persantin after successful coronary angioplasty.
Australian & New Zealand Journal of Medicine 1987;17:559.
∗ Nye ER, Ablett MB, Robertson MC, Ilsley CD,
Sutherland WH. Effect of eicosapentaenoic acid on
restenosis rate, clinical course and blood lipids in patients
after percutaneous transluminal coronary angioplasty.
Australian and New Zealand Journal of Medicine 1990;20
(4):549–52.
ORL 2013 {published data only (unpublished sought but not used)}
NCT01350999. Long-term efficacy and safety study
of TAK-085 in participants with hypertriglyceridemia.
clinicaltrials.gov/ct2/show/NCT01350999 (first posted 10
May 2011).
∗ Tatsuno I, Saito Y, Kudou K, Ootake J. Long-term
safety and efficacy of TAK-085 in Japanese subjects with
hypertriglyceridemia undergoing lifestyle modification:
the omega-3 fatty acids randomized long-term (ORL)
study. Journal of Clinical Lipidology 2013;7(6):615–25.
PUBMED: 24314359]
PREDIMED 2013 {published data only (unpublished sought but not
used)}
PREDIMED study - Mediteranian diet in the primary
prevention of cardiovascular disease: research protocol,
version 1. www.predimed.es/uploads/8/0/5/1/8051451/
1estr protocol olf.pdf (accessed prior to 11 April 2018).
Alvarez-Perez J, Sanchez-Villegas A, Diaz-Benitez EM,
Ruano-Rodriguez C, Corella D, Martinez-Gonzalez MA,
et al. Influence of a Mediterranean dietary pattern on
body fat distribution: results of the PREDIMED-Canarias
intervention randomized trial. Journal of the American
College of Nutrition 2016;35(6):1–13.
Babio N, Toledo E, Estruch R, Ros E, Martinez-Gonzalez
MA, Castaner O, et al. Mediterranean diets and metabolic
syndrome status in the PREDIMED randomized trial.
CMAJ Canadian Medical Association Journal 2014;186(17):
46Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
E649–57.
Barcelo F, Perona JS, Prades J, Funari SS, Gomez-Gracia
E, Conde M, et al. Mediterranean-style diet effect on the
structural properties of the erythrocyte cell membrane
of hypertensive patients: the Prevencion con Dieta
Mediterranea Study. Hypertension 2009;54(5):1143–50.
Bullo M, Amigo-Correig P, Marquez-Sandoval F, Babio N,
Martinez-Gonzalez MA, Estruch R, et al. Mediterranean
diet and high dietary acid load associated with mixed nuts:
effect on bone metabolism in elderly subjects. Journal of the
American Geriatrics Society 2009;57(10):1789–98.
Casas R, Sacanella E, Urpi-Sarda M, Chiva-Blanch G,
Ros E, Martinez-Gonzalez MA, et al. The effects of
the Mediterranean diet on biomarkers of vascular wall
inflammation and plaque vulnerability in subjects with high
risk for cardiovascular disease. A randomized trial. PloS One
2014;9(6):e100084.
Casas RM, Urpi-Sarda M, Chiva-Blanch G, Valderas-
Martinez P, Arranz S, Roth I, et al. Inhibition of circulating
immune cells related to atherogenesis intervention after 1, 3
and 5 years with Mediterranean diet. Annals of Nutrition
and Metabolism 2013;62:43–4.
Cohen J, Rimm EB, Martinez-Gonzalez MA, Salas-Salvado
J, Covas MI, Corella D, et al. The association between
obesity status and long-term adherence to Mediterranean
diet in the PREDIMED trial. Circulation 2013;127(12
Meeting Abstracts):AP098.
Damasceno NR, Sala-Vila A, Cofan M, Perez-Heras AM,
Fito M, Ruiz-Gutierrez V, et al. Mediterranean diet
supplemented with nuts reduces waist circumference and
shifts lipoprotein subfractions to a less atherogenic pattern
in subjects at high cardiovascular risk. Atherosclerosis 2013;
230(2):347–53.
Domenech M, Estruch R, Ros E, Coca A. Effect of the
Mediterranean diet on blood pressure: the ambulatory
blood pressure substudy (Predimed-ABPM). Journal of
Hypertension 2010;28:e373.
Domenech M, Roman P, Lapetra J, Garcia de la Corte FJ,
Sala-Vila A, de la Torre R, et al. Mediterranean diet reduces
24-hour ambulatory blood pressure, blood glucose, and
lipids: one-year randomized, clinical trial. Hypertension
2014;64(1):69–76.
∗ Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella
D, Aros F, et al. Primary prevention of cardiovascular
disease with a Mediterranean diet. New England Journal
of Medicine 2013;368(14):1279-90 (Erratum in: New
England Journal of Medicine 2014;370(9):886). DOI:
10.1056/NEJMoa1200303
Estruch R, Ros E, Salas-Salvadó J, Covas M, Corella D, Arós
F, et al. Retraction and republication: Primary prevention
of cardiovascular disease with a Mediterranean diet. N Engl
J Med 2013; 368:1279-90. NEJM 2018;378:25. DOI:
10.1056/NEJMc1805501
Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D,
Arós F, et al. Primary prevention of cardiovascular disease
with a Mediterranean diet supplemented with extra-virgin
olive oil or nuts [this is a republication of primary paper
Estruch 2013]. New England Journal of Medicine 2018;378:
e34. DOI: 10.1056/NEJMoa1800389
ISRCTN35739639. Effects of Mediterranean diet
on the primary prevention of cardiovascular disease.
www.isrctn.com/ISRCTN35739639 (date assigned 5
October 2005).
Martínez-González MÁ, Corella D, Salas-Salvadó J, Ros
E, Covas MI, Fiol M, et al. Cohort profile: design and
methods of the PREDIMED study. International Journal
of Epidemiology 2012;41(2):377–85. DOI: 10.1093/ije/
dyq250
Papadaki A, Martínez-González MÁ, Alonso-Gómez A,
Rekondo J, Salas-Salvadó J, Corella D, et al. Mediterranean
diet and risk of heart failure: results from the PREDIMED
randomized controlled trial. European Journal of Heart
Failure 2017;19(9):1179–85. DOI: 10.1002/ejhf.750
Razquin C, Martinez JA, Martinez-Gonzalez MA, Mitjavila
MT, Estruch R, Marti A. A 3 years follow-up of a
Mediterranean diet rich in virgin olive oil is associated with
high plasma antioxidant capacity and reduced body weight
gain. European Journal of Clinical Nutrition 2009;63(12):
1387–93.
Ruiz-Canela M, Estruch R, Corella D, Salas-Salvado J,
Martinez-Gonzalez MA. Association of Mediterranean diet
with peripheral artery disease: the PREDIMED randomized
trial. JAMA 2014;311(4):415–7.
Sala-Vila A, Romero-Mamani ES, Gilabert R, Nunez I,
de la Torre R, Corella D, et al. Changes in ultrasound-
assessed carotid intima-media thickness and plaque with a
Mediterranean diet: a substudy of the PREDIMED trial.
Arteriosclerosis, Thrombosis & Vascular Biology 2014;34(2):
439–45.
Salas-Salvado J, Bullo M, Babio N, Martinez-Gonzalez
MA, Ibarrola-Jurado N, Basora J, et al. Reduction in the
incidence of type 2 diabetes with the Mediterranean diet:
results of the PREDIMED-Reus nutrition intervention
randomized trial. Diabetes Care 2011;34(1):14–9.
Salas-Salvado J, Bullo M, Estruch R, Ros E, Covas MI,
Ibarrola-Jurado N, et al. Prevention of diabetes with
Mediterranean diets: a subgroup analysis of a randomized
trial. Annals of Internal Medicine 2014;160(1):1–10.
Salas-Salvado J, Fernandez-Ballart J, Ros E, Martinez-
Gonzalez MA, Fito M, Estruch R, et al. Effect of a
Mediterranean diet supplemented with nuts on metabolic
syndrome status: one-year results of the PREDIMED
randomized trial. Archives of Internal Medicine 2008;168
(22):2449–58.
Sanchez-Villegas A, Martinez-Gonzalez MA, Estruch R,
Salas-Salvado J, Corella D, Covas MI, et al. Mediterranean
dietary pattern and depression: the PREDIMED
randomized trial. BMC Medicine 2013;11:208.
Sola R, Fito M, Estruch R, Salas-Salvado J, Corella D, de
la Torre R, et al. Effect of a traditional Mediterranean diet
on apolipoproteins B, A-I, and their ratio: a randomized,
controlled trial. Atherosclerosis 2011;218(1):174–80.
Toledo E, Hu FB, Estruch R, Buil-Cosiales P, Corella D,
Salas-Salvado J, et al. Effect of the Mediterranean diet on
47Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
blood pressure in the PREDIMED trial: results from a
randomized controlled trial. BMC Medicine 2013;11:207.
Toledo E, Salas-Salvado J, Donat-Vargas C, Buil-Cosiales
P, Estruch R, Ros E, et al. Mediterranean diet and invasive
breast cancer risk among women at high cardiovascular
risk in the PREDIMED Trial: a randomized clinical trial.
JAMA Internal Medicine 2015;175(11):1752–60.
Valls-Pedret C, Sala-Vila A, Serra-Mir M, Corella D, de la
Torre R, Martinez-Gonzalez MA, et al. Mediterranean diet
and age-related cognitive decline: a randomized clinical
trial. JAMA Internal Medicine 2015;175(7):1094–103.
Proudman 2015 {published and unpublished data}
ACTRN12613000579796. Fish oil in recent onset
rheumatoid arthritis: High versus low dose fish oil
on a background of dose-responsive combination
disease-modifying anti-rheumatic drugs [Fish oil in
anti–inflammatory doses in recent onset rheumatoid
arthritis: a randomized, double–blind controlled trial
within algorithm–based drug use with DMARD use as the
primary outcome]. www.anzctr.org.au/Trial/Registration/
TrialReview.aspx?id=364265 (date registered 23 May 2013).
Proudman S, Spargo L, Hall C, McWilliams L, Lee A,
Maureen R, et al. Fish oil in rheumatoid arthritis: a
randomised, double blind trial comparing high dose with
low dose. Internal Medicine Journal 2012;42(Suppl 1):2–3.
∗ Proudman SM, Cleland LG, Metcalf RG, Sullivan TR,
Spargo LD, James MJ. Plasma n-3 fatty acids and clinical
outcomes in recent-onset rheumatoid arthritis. British
Journal of Nutrition 2015;114(6):885–90. PUBMED:
26283657]
Proudman SM, James MJ, Spargo LD, Metcalf RG,
Sullivan TR, Rischmueller M, et al. Fish oil in recent
onset rheumatoid arthritis: a randomised, double-blind
controlled trial within algorithm-based drug use. Annals
of the Rheumatic Diseases 2015;74(1):89–95. PUBMED:
24081439]
Puri 2005 {published and unpublished data}
ISRCTN79170611. A multicentre, multinational,
double blind, randomised, parallel group, placebo-
controlled study of ethyl-eicosapentaenoate (EPA) in
patients with Huntington’s disease (HD). doi.org/10.1186/
ISRCTN79170611 (date assigned 3 February 2003).
∗ Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt
A, Greenamyre JT, et al. Ethyl-EPA in Huntington disease:
a double-blind, randomized, placebo-controlled trial.
Neurology 2005;65(2):286–92.
Raitt 2005 {published data only (unpublished sought but not used)}
NCT00004558. Antiarrhythmic effects of n-3 fatty acids.
clinicaltrials.gov/ct2/show/NCT00004558 (first posted 10
February 2000).
∗ Raitt MH, Connor WE, Morris C, Kron J, Halperin
B, Chugh SS, et al. Fish oil supplementation and risk
of ventricular tachycardia and ventricular fibrillation in
patients with implantable defibrillators: a randomized
controlled trial. JAMA 2005;293(23):2884–91.
Rose 1965 {published data only}
Rose GA, Thomson WB, Williams RT. Corn oil in
treatment of ischaemic heart diseases. British Medical
Journal 1965;1(5449):1531–3. PUBMED: 14288105]
Rossing 1996 {published and unpublished data}
Myrup B, Rossing P, Jensen T, Parving HH, Holmer G,
Gram J, et al. Lack of effect of fish oil supplementation
on coagulation and transcapillary escape rate of albumin
in insulin-dependent diabetic patients with diabetic
nephropathy. Scandinavian Journal of Clinical & Laboratory
Investigation 2001;61(5):349–56.
∗ Rossing P, Hansen BV, Nielsen FS, Myrup B, Holmer G,
Parving HH. Fish oil in diabetic nephropathy. Diabetes
Care 1996;19(11):1214–9.
Simon 1997 {published and unpublished data}
Djuric Z, Heilbrun LK, Reading BA, Boomer A, Valeriote
FA, Martino S. Effects of a low fat diet on levels of oxidative
damage to DNA in human peripheral nucleated blood cells.
Journal of the National Cancer Institute 1991;83(11):766–9.
Djuric Z, Martino S, Heilbrun LK, Hart RW. Dietary
modulation of oxidative DNA damage. Advances In
Experimental Medicine and Biology 1994;354:71–83.
Kasim SE, Martino S, Kim P-N, Khilnani S, Boomer A,
Depper J, et al. Dietary and anthropometric determinants
of plasma lipoproteins during a long-term low-fat diet in
healthy women. American Journal of Clinical Nutrition
1993;57:146–53.
∗ Simon MS, Heilbrun LK, Boomer A, Kresge C, Depper
J, Kim PN, et al. A randomised trial of a low-fat dietary
intervention in women at high risk for breast cancer.
Nutrition and Cancer 1997;27(2):136–42.
Sydney Diet-Heart 1978 {published and unpublished data}
Blacket RB, Leelarthaepin B, McGilchrist C, Palmer AJ,
Woodhill JM. The synergistic effect of weight loss and
changes in dietary lipids on the serum cholesterol of
obese men with hypercholesterolaemia: implications for
prevention of coronary heart disease. Australian and New
Zealand Journal of Medicine 1979;9:521–9.
Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-
Hong SF, Faurot KR, Suchindran CM, et al. Use of dietary
linoleic acid for secondary prevention of coronary heart
disease and death: evaluation of recovered data from the
Sydney Diet Heart Study and updated meta-analysis. BMJ
2013;346:e8707 (Erratum in: BMJ 2013;346:f903).
∗ Woodhill JM, Palmer AJ, Leelarthaepin B, McGilchrist
C, Blacket RB. Low fat, low cholesterol diet in secondary
prevention of coronary heart disease. Advances in
Experimental Medicine and Biology 1978;109:317–30.
Veterans Admin 1969 {published data only}
Dayton S, Hashimoto S, DixonW, PearceML. Composition
of lipids in human serum and adipose tissue during
prolonged feeding of a diet high in unsaturated fat. Journal
of Lipid Research 1966;7:103–11.
Dayton S, Hashimoto S, Pearce ML. Adipose tissue linoleic
acid as a criterion of adherence to a modified diet. Journal
of Lipid Research 1967;8:508–10.
Dayton S, Hashimoto S, Pearce ML. Influence of a diet
48Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
high in unsaturated fat upon composition of arterial tissue
and atheromata in man. Circulation 1965;32:911–24.
Dayton S, Hashimoto S, Rosenblum D, Pearce M. Vitamin
E status of humans during prolonged feeding of unsaturated
fats. Journal of Laboratory and Clinical Medicine 1965;65
(5):739–47.
Dayton S, Pearce ML. Diet and atherosclerosis. Lancet
1970;1(644):473–4.
Dayton S, Pearce ML. Diet and cardiovascular diseases.
Lancet 1969;1(584):51–2.
Dayton S, Pearce ML. Diet high in unsaturated fat: a
controlled clinical trial. Minnesota Medicine 1969;1969:
1237–42.
Dayton S, Pearce ML. Prevention of coronary heart disease
and other complications of atherosclerosis by modified diet.
American Journal of Medicine 1969;46:751–62.
Dayton S, Pearce ML. Trial of unsaturated-fat diet. Lancet
1968;2(581):1296–7.
Dayton S, Pearce ML, Goldman H, Harnish A, Plotkin
D, Shickman M, et al. Controlled trial of a diet high
in unsaturated fat for prevention of atherosclerotic
complications. Lancet 1968;2(577):1060–2.
∗ Dayton S, Pearce ML, Hashimoto S, DixonWJ, Tomayasu
U. A controlled clinical trial of a diet high in unsaturated fat
in preventing complications of atherosclerosis. Circulation
1969;15(1, Suppl 2):II–1-63.
Dayton S, Pearce ML, Hashimoto S, Fakler LJ, Hiscock
E, Dixon WJ. A controlled clinical trial of a diet high in
unsaturated fat. New England Journal of Medicine 1962;
266:1017–23.
Ederer F, Leren P, Turpeinen O, Frantz ID Jr. Cancer
among men on cholesterol-lowering diets: experience from
five clinical trials. Lancet 1971;298(7717):203–6.
Hiscock E, Dayton S, Pearce ML, Hashimoto S. A palatable
diet high in unsaturated fat. Journal of the American Dietetic
Association 1962;40:427–31.
Pearce ML, Dayton S. Incidence of cancer in men on a diet
high in polyunsaturated fat. Lancet 1971;1(697):464–7.
Sturdevant RA, Pearce ML, Dayton S. Increased prevalence
of cholelithiasis in men ingesting a serum-cholesterol-
lowering diet. New England Journal of Medicine 1973;288
(1):24–7.
Tompkins MJ, Dayton S, Pearce ML. Effect of long-term
feeding of various fats on whole blood clotting times in
men. Journal of Laboratory and Clinical Medicine 1964;64
(5):763–72.
Vijayakumar 2014 {published and unpublished data}
Nandakumar S, Vijayakumar M, Krishnan S. Coconut oil
vs sunflower oil in atherosclerosis: challenges in dietary
intervention. Indian Heart Journal 2014;66:S11.
∗ Vijayakumar M, Krishnaan S, Sundram KR, Vasudevan
DM, Nandakumar S. What oil in patients with established
coronary artery disease: outcomes of two year dietary
intervention with coconut oil & sunflower oil. Indian Heart
Journal 2014;66:S12.
Vijayakumar M, Vasudevan DM, Sundaram KR, Krishnan
S, Vaidyanathan K, Nandakumar S, et al. A randomized
study of coconut oil versus sunflower oil on cardiovascular
risk factors in patients with stable coronary heart disease.
Indian Heart Journal 2016;68:498–506. DOI: 10.1016/
j.ihj.2015.10.384
WAHA - Ros 2016 {published and unpublished data}
Bitok E, Jaceldo-Siegl K, Rajaram S, Serra-Mir M, Roth
I, Feitas-Simoes T, et al. Favourable nutrient intake and
displacement with long-term walnut supplementation
among elderly: results of a randomised trial. British
Journal of Nutrition 2017;118(3):201–9. DOI: 10.1017/
S0007114517001957
Bitok E, Rajaram S, Ros E, Kazzi N, Huey L, Jaceldo K, et
al. Does a daily walnut supplement given for a year result in
body weight gain?. FASEB Journal 2016;30(1):1157.
Huey L, Bitok E, Kazzi N, Sirirat R, Haddad Tabrizi S, Ros
E, et al. Dietary compliance of walnut or no walnut intake
in a 1-year randomized intervention trial among free-living
elderly in the Walnuts and Healthy Aging Study (WAHA).
FASEB Journal 2016; Vol. 30:1157.10.
NCT01634841. Walnuts and Healthy Aging (WAHA).
clinicaltrials.gov/ct2/show/NCT01634841 (first posted 6
July 2012).
Rajaram S, Valls-Pedret C, Cofan M, Sabate J, Serra-Mir
M, Perez-Heras AM, et al. The Walnuts and Healthy Aging
Study (WAHA): protocol for a nutritional intervention trial
with walnuts on brain aging. Frontiers in Aging Neuroscience
2016;8:333. PUBMED: 28119602]
∗ Ros E, Rajaram S, Sala-Vila A, Serra-Mir M, Valls-
Pedret C, Cofan M, et al. Effect of a 1-year walnut
supplementation on blood lipids among older individuals:
findings from the walnuts and healthy aging (WAHA)
study. FASEB Journal 2016;30(1 Suppl):293–4.
WELCOME 2015 {published and unpublished data}
Bhatia L, Scorletti E, Curzen N, Clough GF, Calder PC,
Byrne CD. Improvement in non-alcoholic fatty liver disease
severity is associated with a reduction in carotid intima-
media thickness progression. Atherosclerosis 2016;246:
13–20. PUBMED: 26748347]
Byrne CD, Targher G. Ectopic fat, insulin resistance,
and nonalcoholic fatty liver disease: implications for
cardiovascular disease. Arteriosclerosis, Thrombosis, and
Vascular Biology 2014;34(6):1155–61. PUBMED:
24743428]
Byrne CD, Targher G. Time to replace assessment of
liver histology with MR-based imaging tests to assess
efficacy of interventions for nonalcoholic fatty liver disease.
Gastroenterology 2016; Vol. 150, issue 1:7–10. PUBMED:
26602219]
Clough GF, McCormick KG, Scorletti E, Bhatia L,
Calder PC, Griffin MJ, et al. Higher body fat percentage
is associated with enhanced temperature perception in
NAFLD: results from the randomised Wessex Evaluation
of fatty Liver and Cardiovascular markers in NAFLD with
OMacor thErapy trial (WELCOME) trial. Diabetologia
2016;59(7):1422–9. PUBMED: 27106721]
∗ McCormick KG, Scorletti E, Bhatia L, Calder PC,
Griffin MJ, Clough GF, et al. Impact of high dose n-
49Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3 polyunsaturated fatty acid treatment on measures of
microvascular function and vibration perception in non-
alcoholic fatty liver disease: results from the randomised
WELCOME trial. Diabetologia 2015;58(8):1916–25.
PUBMED: 26021488]
NCT00760513. Treatment of non alcoholic fatty liver
disease with n-3 fatty acids. clinicaltrials.gov/ct2/show/
NCT00760513 (first posted 26 September 2008).
Scorletti E, Bhatia L, McCormick KG, Clough GF,
Nash K, Calder PC, et al. Design and rationale of the
WELCOME trial: a randomised, placebo controlled
study to test the efficacy of purified long chainomega-
3 fatty acid treatment in non-alcoholic fatty liver disease.
Contemporary Clinical Trials 2014;37(2):301-11 (Erratum
in: Contemporary Clinical Trials 2014 May;38(1):156).
PUBMED: 24556343]
Scorletti E, West AL, Bhatia L, Hoile SP, McCormick KG,
Burdge GC, et al. Treating liver fat and serum triglyceride
levels in NAFLD, effects of PNPLA3 and TM6SF2
genotypes: results from the WELCOME trial. Journal of
Hepatology 2015;63(6):1476–83. PUBMED: 26272871]
Targher G, Byrne CD. Clinical review: nonalcoholic
fatty liver disease: a novel cardiometabolic risk factor
for type 2 diabetes and its complications. Journal of
Clinical Endocrinology and Metabolism 2013;98(2):483–95.
PUBMED: 23293330]
WINS 2006 {published and unpublished data}
Chlebowski RT, Blackburn GL, Buzzard IM, Rose DP,
Martino S, Khandekar JD, et al. Adherence to a dietary
fat intake reduction program in postmenopausal women
receiving therapy for early breast cancer. The Women’s
Intervention Nutrition Study. Journal of Clinical Oncology
1993;11(11):2072–80.
∗ Chlebowski RT, Blackburn GL, Thomson CA, Nixon
DW, Shapiro A, Hoy MK, et al. Dietary fat reduction and
breast cancer outcome: interim efficacy results from the
women’s intervention nutrition study. JNCI Journal of the
National Cancer Institute 2006;98(24):1767–76.
Chlebowski RT, Rose DP, Buzzard IM, Blackburn GL, York
M, Insull W, et al. Dietary fat reduction in adjuvant breast
cancer therapy: current rationale and feasibility issues.
Adjuvant. The Cancer Journal 1990;6:357–63.
Hoy MK, Winters BL, Chlebowski RT, Papoutsakis C,
Shapiro A, Lubin MP, et al. Implementing a low-fat eating
plan in the Women’s Intervention Nutrition Study. Journal
of the American Dietetic Association 2009;109(4):688–96.
Rose DP, Chlebowski RT, Connolly JM, Jones LA, Wynder
EL. Effects of tamoxifen adjuvant therapy and a low-fat
diet on serum binding proteins and estradiol bioavailability
in postmenopausal breast cancer patients. Cancer Research
1992;52:5386–90.
Rose DP, Connolly JM, Chlebowski RT, Buzzard IM,
Wynder EL. The effects of a low-fat dietary intervention
and tamoxifen adjuvant therapy on the serum estrogen
and sex hormone-binding globulin concentrations of
postmenopausal breast cancer patients. Breast Cancer
Research & Treatment 1993;27(3):253–62.
Wynder EL, Cohen LA, Winters BL. The challenges of
assessing fat intake in cancer research investigations. Journal
of the American Dietetic Association 1997;97(7 Suppl):S5–8.
References to studies excluded from this review
ADCS-Quinn 2010 {published data only}
Quinn JF, Raman R, Thomas RG, Yurko-Mauro K,
Nelson EB, Van Dyck C, et al. Docosahexaenoic acid
supplementation and cognitive decline in Alzheimer disease:
a randomized trial. JAMA 2010;304(17):1903–11.
AFFORD 2014 {published data only}
∗ Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza
A, et al. Fish oil for the reduction of atrial fibrillation
recurrence, inflammation, and oxidative stress. Journal of
the American College of Cardiology 2014;64(14):1441–8.
Nigam A, Talajic M, Roy D, Nattel S, Lambert J, Nozza A,
et al. Multicentre trial of fish oil for the reduction of atrial
fibrillation recurrence, inflammation and oxidative stress:
the Atrial Fibrillation Fish Oil Research Study. Canadian
Journal of Cardiology 2013;1:S383.
AlphaOmega - EPA+DHA {published and unpublished data}
Brouwer IA, Geleijnse JM, Klaasen VM, Smit LA, Giltay
EJ, De Goede J, et al. Effect of alpha linolenic acid
supplementation on serum prostate specific antigen (PSA):
results from the alpha omega trial. PLoS One 2013;8(12):
e81519.
Eussen SR, Geleijnse JM, Giltay EJ, Rompelberg CJ,
Klungel OH, Kromhout D. Effects of n-3 fatty acids on
major cardiovascular events in statin users and non-users
with a history of myocardial infarction. European Heart
Journal 2012;33(13):1582–8.
Geleijnse J, Giltay E, Kromhout D. Effects of n-3 fatty acids
on cognitive decline: a randomized double-blind, placebo-
controlled trial in stable myocardial infarction patients.
Alzheimer’s & Dementia 2011;1:S512.
Geleijnse JM, Giltay EJ, Kromhout D. Effects of n-3 fatty
acids on cognitive decline: a randomized, double-blind,
placebo-controlled trial in stable myocardial infarction
patients. Alzheimer’s & Dementia 2012;8(4):278–87.
Geleijnse JM, Giltay EJ, Schouten EG, De Goede J,
Oude Griep LM, Teitsma-Jansen AM, et al. Effect of
low doses of n-3 fatty acids on cardiovascular diseases in
4,837 post-myocardial infarction patients: design and
baseline characteristics of the Alpha Omega Trial. American
Heart Journal 2010;159(4):539–46. DOI: 10/1016/
j.ahj.2009.12.033
Giltay EJ, Geleijnse JM, Heijboer AC, De Goede J, Oude
Griep LM, Blankenstein MA, et al. No effects of n-3 fatty
acid supplementation on serum total testosterone levels in
older men: the Alpha Omega Trial. International Journal of
Andrology 2012;35(5):680–7.
Giltay EJ, Geleijnse JM, Kromhout D. Effects of n-3 fatty
acids on depressive symptoms and dispositional optimism
50Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
after myocardial infarction. American Journal of Clinical
Nutrition 2011;94(6):1442–50.
Hoogeveen E, Gemen E, Geleijnse M, Kusters R, Kromhout
D, Giltay E. Effects of n-3 fatty acids on decline of kidney
function after myocardial infarction: Alpha Omega trial.
Nephrology Dialysis Transplantation 2012;27:ii64.
Hoogeveen EK, Geleijnse JM, Kromhout D, Giltay EJ.
No effect of n-3 fatty acids on high-sensitivity C-reactive
protein after myocardial infarction: the Alpha Omega trial.
European Journal of Preventive Cardiology 2014;21(11):
1429–36.
Hoogeveen EK, Geleijnse JM, Kromhout D, Stijnen T,
Gemen EF, Kusters R, et al. Effect of omega-3 fatty acids
on kidney function after myocardial infarction: the Alpha
Omega trial. Clinical Journal of The American Society of
Nephrology: CJASN 2014;9(10):1676–83.
Kromhout D, Geleijnse JM, De Goede J, Oude Griep LM,
Mulder BJ, De Boer MJ, et al. N-3 fatty acids, ventricular
arrhythmia-related events, and fatal myocardial infarction in
postmyocardial infarction patients with diabetes. Diabetes
Care 2011;34(12):2515–20.
∗ Kromhout D, Giltay EJ, Geleijnse JM. N-3 fatty acids
and cardiovascular events after myocardial infarction. New
England Journal of Medicine 2010;363(18):2015–26.
AREDS2 2014 {published and unpublished data}
∗ Bonds DE, Harrington M, Worrall BB, Bertoni AG,
Eaton CB, Hsia J, et al. Effect of long-chain omega-3 fatty
acids and lutein + zeaxanthin supplements on cardiovascular
outcomes: results of the Age-Related Eye Disease Study
2 (AREDS2) randomized clinical trial. JAMA Internal
Medicine 2014;174(5):763–71.
Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally
A, McBee W, et al. The Age-Related Eye Disease Study
2 (AREDS2): study design and baseline characteristics
(AREDS2 report number 1). Ophthalmology 2012;119(11):
2282–9.
Chew EY, Clemons TE. In reply: making sense of
the evidence from the age-related eye disease study 2
randomized clinical trial. JAMA Ophthalmology 2014;132
(8):1031–2.
Chew EY, Clemons TE, Agron E, Launer LJ, Grodstein F,
Bernstein PS, et al. Effect of omega-3 fatty acids, lutein/
zeaxanthin, or other nutrient supplementation on cognitive
function: the AREDS2 randomized clinical trial. JAMA
2015;314(8):791–801.
Chew EY, Clemons TE, SanGiovanni JP, Danis RP, Ferris
FL III, Elman MJ, et al. Secondary analyses of the effects
of lutein/zeaxanthin on age-related macular degeneration
progression: AREDS2 report No. 3. JAMA Ophthalmology
2014;132(2):142–9.
Chew EY, SanGiovanni JP, Ferris FL, Wong WT, Agron E,
Clemons TE, et al. Lutein/zeaxanthin for the treatment of
age-related cataract: AREDS2 randomized trial report no.
4. JAMA Ophthalmology 2013;131(7):843–50.
Huynh N, Nicholson BP, Agron E, Clemons TE, Bressler
SB, Rosenfeld PJ, et al. Visual acuity after cataract surgery
in patients with age-related macular degeneration: age-
related eye disease study 2 report number 5. Ophthalmology
2014;121(6):1229–36.
ASCEND {unpublished data only}
Bowman L, Aung T, Haynes R, Armitage J. ASCEND:
design and baseline characteristics of a large randomised
trial in diabetes. Diabetes 2012;61:A556–7.
Azadbakht 2007 {published and unpublished data}
Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi F. Better
dietary adherence and weight maintenance achieved by a
long-term moderate fat diet. British Journal of Nutrition
2007;97:399–404.
Baldassarre 2006 {published data only}
Baldassarre D, Amato M, Eligini S, Barbieri SS, Mussoni
L, Frigerio B, et al. Effect of n-3 fatty acids on carotid
atherosclerosis and haemostasis in patients with combined
hyperlipoproteinemia: a double-blind pilot study in primary
prevention. Annals of Medicine 2006;38(5):367–75. DOI:
10.1080/07853890600852880
Berson 2004 {published data only}
∗ Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco
C, Moser A, Brockhurst RJ, et al. Clinical trial of
docosahexaenoic acid in patients with retinitis pigmentosa
receiving vitamin A treatment. Archives of Ophthalmology
2004;122(9):1297–305.
Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco
C, Moser A, Brockhurst RJ, et al. Further evaluation of
docosahexaenoic acid in patients with retinitis pigmentosa
receiving vitamin A treatment: subgroup analyses. Archives
of Ophthalmology 2004;122(9):1306–14.
Caldwell 2011 {published data only}
Argo CK, Patrie JT, Lackner C, Henry TD, de Lange EE,
Weltman AL, et al. Effects of n-3 fish oil on metabolic
and histological parameters in NASH: a double-blind,
randomized, placebo-controlled trial. Journal of Hepatology
2015;62(1):190–7. PUBMED: 25195547]
∗ Caldwell SH, Argo CK, Henry TD, Lackner C,
Pramoonjago P, Weltman AL, et al. Dissociated histological
and metabolic effects of omega-e (3000 mg/d) versus placebo
with both exercise and diet in a double-blind randomized
controlled trial of NASH. Journal of Hepatology 2011; Vol.
54:S8.
DART 2 - Burr 2003 {published and unpublished data}
∗ Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM,
Breay P, Ashton T, et al. Lack of benefit of dietary advice
to men with angina: results of a controlled trial. European
Journal of Clinical Nutrition 2003;57(2):193–200.
Ness AR, Ashfield-Watt PAL, Whiting JM, Smith GD,
Hughes J, Burr ML. The long-term effect of dietary advice
on the diet of men with angina: the diet and angina
randomized trial. Journal of Human Nutrition and Dietetics
2004;17:1–3.
Ness AR, Gallacher JE, Bennett PD, Gunnell DJ, Rogers
PJ, Kessler D, et al. Advice to eat fish and mood: a
randomised controlled trial in men with angina. Nutritional
Neuroscience 2003;6(1):63–5.
51Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
DART fish Burr 1989 {published and unpublished data}
Burr ML, Fehily AM. Fatty fish and heart disease: a
randomized controlled trial. World Review of Nutrition and
Dietetics 1991;66:306–12.
Burr ML, Fehily AM. Fish and the heart [letter]. Lancet
1989;ii:1451–2.
∗ Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM,
Sweetnam PM, et al. Effects of changes in fat, fish, and
fibre intakes on death and myocardial reinfarction: diet and
reinfarction trial (DART). Lancet 1989;2(8666):757–61.
Burr ML, Fehily AM, Rogers S, Welsby E, King S, Sandham
S. Diet and reinfarction trial (DART): design, recruitment,
and compliance. European Heart Journal 1989;10(6):
558–67.
Burr ML, Holliday RM, Fehily AM, Whitehead PJ.
Haematological prognostic indices after myocardial
infarction: evidence from the diet and reinfarction trial
(DART). European Heart Journal 1992;13(2):166–70.
Burr ML, Sweetham PM, Fehily AM. Diet and reinfarction
[letter]. European Heart Journal 1994;15(8):1152–3.
Fehily AM, Vaughan-Williams E, Shiels K, Williams
AH, Horner M, Bingham G, et al. Factors influencing
compliance with dietary advice: the Diet and Reinfarction
Trial (DART). Journal of Human Nutrition and Dietetics
1991;4:33–42.
Fehily AM, Vaughan-Williams E, Shiels K, Williams AH,
Horner M, Bingham G, et al. The effect of dietary advice
on nutrient intakes: evidence from the diet and reinfarction
trial (DART). Journal of Human Nutrition & Dietetics 1989;
2:4235.
Ness AR, Hughes J, Elwood PC, Whitley E, Smith GD,
Burr ML. The long-term effect of dietary advice in men with
coronary disease: follow-up of the Diet and Reinfarction
Trial (DART). European Journal of Clinical Nutrition 2002;
56(6):512–8.
Ness AR, Whitley E, Burr ML, Elwood PC, Smith GD,
Ebrahim S. The long-term effect of advice to eat more fish
on blood pressure in men with coronary disease: results
from the diet and reinfarction trial. Journal of Human
Hypertension 1999;13(11):729–33.
Derosa 2016 {published and unpublished data}
Derosa G, Cicero AF, D’Angelo A, Borghi C, Maffioli P.
Effects of n-3 PUFAs on fasting plasma glucose and insulin
resistance in patients with impaired fasting glucose or
impaired glucose tolerance. BioFactors (Oxford, England)
2016;42(3):316–22. PUBMED: 27040503]
Deslypere 1992 {published and unpublished data}
Blok WL, Deslypere JP, Demacker PN, Van der Ven-
Jongekrijg J, Hectors MP, Van der Meer JW, et al. Pro-
and anti-inflammatory cytokines in healthy volunteers fed
various doses of fish oil for 1 year. European Journal of
Clinical Investigation 1997;27(12):1003–8. PUBMED:
9466128]
∗ Deslypere JP. Influence of supplementation with n-3 fatty
acids on different coronary risk factors in men: a placebo
controlled study. Verhandelingen - Koninklijke Vlaamse
Academie voor Geneeskunde van Belgie 1992;54(3):189–216.
PUBMED: 1413984]
Katan MB, Deslypere JP, Van Birgelen AP, Penders M,
Zegwaard M. Kinetics of the incorporation of dietary fatty
acids into serum cholesteryl esters, erythrocyte membranes,
and adipose tissue: an 18-month controlled study. Journal
of Lipid Research 1997;38(10):2012–22. PUBMED:
9374124]
DISAF - Harrison 2005 {published and unpublished data}
Harrison RA, Elton P. From pies to pilchards: dietary
assistants increase consumption of oil rich fish. Journal of
Epidemiology and Community Health 2000;Suppl:6.
Harrison RA, Elton PJ. Can an oil-rich fish diet improve
treatment outcomes following cardioversion for atrial
fibrillation? A randomised controlled trial. Study design
and compliance [poster]. International Society for the
Study of Fatty Acids and Lipids (ISSFAL); 2003; Montreal,
Canada. 2003.
∗ Harrison RA, Elton PJ. Is there a role for long-chain
omega3 or oil-rich fish in the treatment of atrial fibrillation?
. Medical Hypotheses 2005;64(1):59–63. PUBMED:
15533612]
Harrison RA, Purnell P, Elton PJ. Using community-based
dietary assistants to increase the intake of oil-rich fish among
older people. European Journal of Public Health 2003;13
(Suppl 1):105.
DO Health {published data only}
NCT01745263. DO-HEALTH / vitamin D3 - omega3
- home exercise - healthy ageing and longevity trial.
clinicaltrials.gov/ct2/show/NCT01745263 (first posted 10
December 2012).
DO IT 2006 {published and unpublished data}
Berstad P, Seljeflot I, Veierod MB, Hjerkinn EM, Arnesen
H, Pedersen JI, et al. Supplementation with fish oil affects
the association between very long-chain n-3 polyunsaturated
fatty acids in serum non-esterified fatty acids and soluble
vascular cell adhesion molecule-1. Clinical Science 2003;
105(1):13–20.
Ellingsen I, Hjerkinn EM, Seljeflot I, Arnesen H, Tonstad
S, Ellingsen I, et al. Consumption of fruit and berries is
inversely associated with carotid atherosclerosis in elderly
men. British Journal of Nutrition 2008;99(3):674-81
(Erratum in: British Journal of Nutrition 2008;99(3):697).
Ellingsen I, Seljeflot I, Arnesen H, Tonstad S, et al. Vitamin
C consumption is associated with less progression in
carotid intima media thickness in elderly men: a 3-year
intervention study. Nutrition Metabolism & Cardiovascular
Diseases 2009;19(1):8–14.
Furenes EB, Seljeflot I, Solheim S, Hjerkinn EM, Arnesen
H, Furenes EB, et al. Long-term influence of diet and/
or omega-3 fatty acids on matrix metalloproteinase-9 and
pregnancy-associated plasma protein A in men at high risk
of coronary heart disease. Scandinavian Journal of Clinical
& Laboratory Investigation 2008;68(3):177–84.
∗ Hjerkinn EM, Abdelnoor M, Breivik L, Bergengen L,
Ellingsen I, Seljeflot I, et al. Effect of diet or very long
chain omega-3 fatty acids on progression of atherosclerosis,
52Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
evaluated by carotid plaques, intima-media thickness
and by pulse wave propagation in elderly men with
hypercholesterolaemia. European Journal of Cardiovascular
Prevention & Rehabilitation 2006;13(3):325–33.
Hjerkinn EM, Seljeflot I, Ellingsen I, Berstad P, Hjermann
I, Sandvik L, et al. Influence of long-term intervention with
dietary counselling, long-chain n-3 fatty acid supplements,
or both on circulating markers of endothelial activation in
men with long-standing hyperlipidemia. American Journal
of Clinical Nutrition 2005;81(3):583–9.
Lindman AS, Pedersen JI, Hjerkinn EM, Arnesen H,
Veierod MB, Ellingsen I, et al. The effects of long-term diet
and omega-3 fatty acid supplementation on coagulation
factor VII and serum phospholipids with special emphasis
on the R353Q polymorphism of the FVII gene. Thrombosis
& Haemostasis 2004;91(6):1097–104.
Troseid M, Arnesen H, Hjerkinn EM, Seljeflot I. Serum
levels of interleukin-18 are reduced by diet and n-3 fatty
acid intervention in elderly high-risk men. Metabolism:
Clinical & Experimental 2009;58(11):1543–9.
Troseid M, Seljeflot I, Hjerkinn EM, Arnesen H.
Interleukin-18 is a strong predictor of cardiovascular events
in elderly men with the metabolic syndrome: synergistic
effect of inflammation and hyperglycemia. Diabetes Care
2009;32(3):486–92.
DO IT - Einvik 2010 {published and unpublished data}
Berstad P, Seljeflot I, Veierod MB, Hjerkinn EM, Arnesen
H, Pedersen JI. Supplementation with fish oil affects the
association between very long-chain n-3 polyunsaturated
fatty acids in serum non-esterified fatty acids and soluble
vascular cell adhesion molecule-1. Clinical Science 2003;
105(1):13–20.
Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Ellingsen I,
Seljeflot I. Effect of diet and omega-3 fatty acid intervention
on asymmetric dimethylarginine. Nutrition & Metabolism
2006;3:4.
Eid HMA, Arnesen H, Hjerkinn EM, Lyberg T, Ellingsen I,
Seljeflot I. Effect of diet and omega-3 fatty acid intervention
on asymmetric dimethylarginine. Nutrition and Metabolism
2006;3:1–10.
Einvik G, Ekeberg O, Lavik JG, Ellingsen I, Klemsdal
TO, Hjerkinn EM. The influence of long-term awareness
of hyperlipidemia and of 3 years of dietary counseling
on depression, anxiety, and quality of life. Journal of
Psychosomatic Research 2010;68(6):567–72.
∗ Einvik G, Klemsdal TO, Sandvik L, Hjerkinn EM. A
randomized clinical trial on n-3 polyunsaturated fatty acids
supplementation and all-cause mortality in elderly men at
high cardiovascular risk. European Journal of Cardiovascular
Prevention & Rehabilitation 2010;17(5):588–92.
Ellingsen I, Hjerkinn EM, Arnesen H, Seljeflot I, Hjermann
I, Tonstad S. Follow-up of diet and cardiovascular risk
factors 20 years after cessation of intervention in the Oslo
Diet and Antismoking study. European Journal of Clinical
Nutrition 2006;60(3):378–85.
Furenes EB, Seljeflot I, Solheim S, Hjerkinn EM, Arnesen
H, Furenes EB. Long-term influence of diet and/or
omega-3 fatty acids on matrix metalloproteinase-9 and
pregnancy-associated plasma protein A in men at high risk
of coronary heart disease. Scandinavian Journal of Clinical
and Laboratory Investigation 2008;68(3):177–84.
Hjerkinn EM, Abdelnoor M, Breivik L, Bergengen L,
Ellingsen I, Seljeflot I, et al. Effect of diet or very long
chain omega-3 fatty acids on progression of atherosclerosis,
evaluated by carotid plaques, intima-media thickness
and by pulse wave propagation in elderly men with
hypercholesterolaemia. European Journal of Cardiovascular
Prevention & Rehabilitation 2006;13(3):325–33.
Hjerkinn EM, Seljeflot I, Ellingsen I, Berstad P, Hjermann
I, Sandvik L, et al. Influence of long-term intervention with
dietary counseling, long-chain n-3 fatty acid supplements,
or both on circulating markers of endothelial activation in
men with long-standing hyperlipidemia. American Journal
of Clinical Nutrition 2005;81(3):583–9.
Lindman AS, Pedersen JI, Hjerkinn EM, Arnesen H,
Veierod MB, Ellingsen I, et al. The effects of long-term diet
and omega-3 fatty acid supplementation on coagulation
factor VII and serum phospholipids with special emphasis
on the R353Q polymorphism of the FVII gene. Thrombosis
& Haemostasis 2004;91(6):1097–104.
Troseid M, Arnesen H, Hjerkinn EM, Seljeflot I. Serum
levels of interleukin-18 are reduced by diet and n-3 fatty
acid intervention in elderly high-risk men. Metabolism:
Clinical and Experimental 2009;58(11):1543–9.
Troseid M, Seljeflot I, Weiss TW, Klemsdal TO, Hjerkinn
EM, Arnesen H. Arterial stiffness is independently
associated with interleukin-18 and components of the
metabolic syndrome. Atherosclerosis 2010;209(2):337–9.
EPE-A study 2014 {published and unpublished data}
Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW,
Chojkier M. No significant effects of ethyl-eicosapentanoic
acid on histologic features of nonalcoholic steatohepatitis in
a phase 2 trial. Gastroenterology 2014;147(2):377–84.e1.
PUBMED: 24818764]
Erdogan 2007 {published data only}
∗ Erdogan A, Bayer M, Kollath D, Greiss H, Voss R,
Neumann T, et al. Omega AF study: polyunsaturated fatty
acids (PUFA) for prevention of atrial fibrillation relapse
after successful external cardioversion. Heart Rhythm 2007;
4(5):S185–6.
Heidt MC, Vician M, Stracke SKH, Stadlbauer T, Grebe
MT, Boening A, et al. Beneficial effects of intravenously
administered n-3 fatty acids for the prevention of atrial
fibrillation after coronary artery bypass surgery: a
prospective randomized study. Thoracic and Cardiovascular
Surgeon 2009;57:276–80. DOI: 10.1055/s-0029-1185301
Mariani J, Doval HC, Nul D, Varini S, Grancelli H,
Ferrante D, et al. N-3 polyunsaturated fatty acids to
prevent atrial fibrillation: updated systematic review and
meta-analysis of randomized controlled trials. Journal of the
American Heart Association 2013;2(1):e005033.
Finnish Mental Hosp 1972 {published data only}
∗ Miettinen M, Turpeinen O, Karvonen MJ, Elosuo
R, Paavilainen E. Effect of cholesterol-lowering diet on
53Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
mortality from coronary heart-disease and other causes: a
twelve-year clinical trial in men and women. Lancet 1972;2
(782):835–8.
Miettinen M, Turpeinen O, Karvonen MJ, Pekkarinen M,
Paavilainen E, Elosuo R. Dietary prevention of coronary
heart disease in women: the Finnish mental hospital study.
International Journal of Epidemiology 1983;12(1):17–25.
Turpeinen O, Miettinen M, Karvonen M, Roine P,
Pekkarinen M, Lehtosuo EJ, et al. Dietary prevention
of coronary heart disease: long-term experiment. I.
Observations on male subjects. American Journal of Clinical
Nutrition 1968;21(4):255–76.
FLAX-PAD 2013 {published data only}
Caligiuri SP, Aukema HM, Ravandi A, Guzman R, Dibrov
E, Pierce GN. Flaxseed consumption reduces blood pressure
in patients with hypertension by altering circulating
oxylipins via an alpha-linolenic acid-induced inhibition of
soluble epoxide hydrolase. Hypertension 2014;64(1):53–9.
PUBMED: 24777981]
Caligiuri SP, Rodriguez-Leyva D, Aukema HM, Ravandi A,
Weighell W, Guzman R, et al. Dietary flaxseed reduces
central aortic blood pressure without cardiac involvement
but through changes in plasma oxylipins. Hypertension
2016;68(4):1031–8. PUBMED: 27528063]
∗ Edel A, Rodriguez-Leyva D, Weighell W, La Vallee R,
Aliani M, Guzman R, et al. Flaxseed lignan metabolites
elicit antihypertensive effects in pad patients in the flax-pad
trial. Annals of Nutrition and Metabolism 2013;63:1339.
Edel AL, Rodriguez-Leyva D, Maddaford TG, Caligiuri
SP, Austria JA, Weighell W, et al. Dietary flaxseed
independently lowers circulating cholesterol and lowers
it beyond the effects of cholesterol-lowering medications
alone in patients with peripheral artery disease. Journal of
Nutrition 2015;145(4):749–57. PUBMED: 25694068]
Leyva DR, Zahradka P, Ramjiawan B, Guzman R, Aliani
M, Pierce GN. The effect of dietary flaxseed on improving
symptoms of cardiovascular disease in patients with
peripheral artery disease: rationale and design of the FLAX-
PAD randomized controlled trial. Contemporary Clinical
Trials 2011;32(5):724–30. PUBMED: 21616170]
Pierce GN, Edel AL, LaVallee R, Caligiuri S, Aukema H,
Ravandi A, et al. The use of dietary flaxseed to promote
cardiovascular health. Acta Physiologica 2014;211:15.
Pierce GN, Rodriguez-Leyva D, Edel A, Guzman R, Aliani
M. The clinical use of flaxseed as a powerful nutritional
intervention to treat cardiovascular disease. Cardiology
(Switzerland) 2013;126:201.
Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R,
Dibrov E, Pinneker R, et al. Potent antihypertensive action
of dietary flaxseed in hypertensive patients. Hypertension
2013;62(6):1081–9. PUBMED: 24126178]
FORWARD 2013 {published and unpublished data}
∗ Macchia A, Grancelli H, Varini S, Nul D, Laffaye N,
Mariani J, et al. Omega-3 fatty acids for the prevention
of recurrent symptomatic atrial fibrillation: results of
the FORWARD (randomized trial to assess efficacy of
PUFA for the maintenance of sinus rhythm in persistent
atrial fibrillation) trial. Journal of the American College of
Cardiology 2013;61(4):463–8. PUBMED: 23265344]
Macchia A, Varini S, Grancelli H, Nul D, Laffaye N,
Ferrante D, et al. The rationale and design of the
FORomegaARD trial: a randomized, double-blind,
placebo-controlled, independent study to test the efficacy
of n-3 PUFA for the maintenance of normal sinus rhythm
in patients with previous atrial fibrillation. American Heart
Journal 2009;157(3):423–7. PUBMED: 19249410]
FOSTAR 2016 {published and unpublished data}
Chen JS, Hill CL, Lester S, Ruediger CD, Battersby R,
Jones G, et al. Supplementation with omega-3 fish oil
has no effect on bone mineral density in adults with
knee osteoarthritis: a 2-year randomized controlled
trial. Osteoporosis International 2016;27(5):1897–905.
PUBMED: 26694596]
Hill C, Lester SE, Jones G. Response to ’Low-dose
versus high-dose fish oil for pain reduction and function
improvement in patients with knee osteoarthritis’ by Chen
et al. Annals of the Rheumatic Diseases 2016; Vol. 75, issue
1:e8. PUBMED: 26662278]
∗ Hill CL, March LM, Aitken D, Lester SE, Battersby R,
Hynes K, et al. Fish oil in knee osteoarthritis: a randomised
clinical trial of low dose versus high dose. Annals of
the Rheumatic Diseases 2016;75(1):23–9. PUBMED:
26353789]
Franzen 1993 {published and unpublished data}
Franzen D. Unknown. Catheterization and Cardiovascular
Diagnosis 1993;28:301–10.
∗ Franzen D, Geisel J, Hopp HW, Oette K, Hilger HH.
Long-term effects of low dosage fish oil on serum lipids and
lipoproteins [Langzeiteffekte von niedrigdosiertem fischol
auf serumlipide und lipoproteine]. Medizinische Klinik
1993;88(3):134–8.
Gill 2012 {published data only}
Gill EA, Chen MA, Paramsothy P, Fish B, Isquith D,
Thirumalai A, et al. Abstract 12697: Omega-3 fatty acids
effects on carotid IMT in metabolic syndrome. Circulation
2014;130:A1269.
∗ Gill EA, Chen MA, Thirumalai A, Fish B, Paramsothy
P. Omega-3 fatty acids improve dyslipidemia but not
inflammatory markers in metabolic syndrome. Journal of
Clinical Lipidology 2012;6:278–9.
GISSI-HF 2008 {published data only}
Aleksova A, Masson S, Maggioni AP, Lucci D, Fabbri G,
Beretta L, et al. N-3 polyunsaturated fatty acids and atrial
fibrillation in patients with chronic heart failure: the GISSI-
HF trial. European Journal of Heart Failure 2013;15(11):
1289–95.
Canepa M, Temporelli PL, Rossi A, Gonzini L, Nicolosi
GL, Staszewsky L, et al. Prevalence and prognostic impact
of chronic obstructive pulmonary disease in patients with
chronic heart failure. Data from the GISSI-Heart Failure
trial. European Journal of Heart Failure 2016;18:442–3.
Cowie MR, Cure S, Bianic F, McGuire A, Goodall G,
Tavazzi L. Cost-effectiveness of highly purified omega-3
polyunsaturated fatty acid ethyl esters in the treatment of
54Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
chronic heart failure: results of Markov modelling in a
UK setting. European Journal of Heart Failure 2011;13(6):
681–9. DOI: 10.1093/eurjhf/hfr023
Finzi A, Barlera S, Serra DM, Rossi MG, Ruggeri A,
Mezzani A, et al. Antiarrhythmic effects of n-3 PUFA in
patients with heart failure and an implantable cardioverter
defibrillator in the GISSI-HF trial. European Heart Journal
2009;30:279.
Finzi AA, Latini R, Barlera S, Rossi MG, Ruggeri A,
Mezzani A, et al. Effects of n-3 polyunsaturated fatty
acids on malignant ventricular arrhythmias in patients
with chronic heart failure and implantable cardioverter-
defibrillators: a substudy of the Gruppo Italiano per lo
Studio della Sopravvivenza nell’Insufficienza Cardiaca
(GISSI-HF) trial. American Heart Journal 2011;161(2):
338–43. DOI: 10.1016/j.ahj.2010.10.032
Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini
M, et al. Effects of n-3 polyunsaturated fatty acids and of
rosuvastatin on left ventricular function in chronic heart
failure: a substudy of GISSI-HF trial. European Journal of
Heart Failure 2010;12(12):1345–53.
La Rovere MT, Barlera S, Staszewsky L, Mezzani A, Midi
P, Marchioli R, et al. Effect of n-3PUFA on heart rate
variability. Data from the GISSI-HF holter substudy.
Circulation 2011;124(21 SUPPL 1):14829.
La Rovere MT, Pinna GD, Maestri R, Barlera S,
Bernardinangeli M, Veniani M, et al. Autonomic markers
and cardiovascular and arrhythmic events in heart failure
patients: still a place in prognostication? Data from the
GISSI-HF trial. European Journal of Heart Failure 2012;14
(12):1410–9.
La Rovere MT, Staszewsky L, Barlera S, Maestri R,
Mezzani A, Midi P, et al. N-3PUFA and holter-derived
autonomic variables in patients with heart failure: data
from the Gruppo Italiano per lo Studio della Sopravvivenza
nell’Insufficienza Cardiaca (GISSI-HF) Holter substudy.
Heart Rhythm 2013;10(2):226–32.
Latini R, Masson S, Tacconi M, Bernasconi R, Dragani L,
Milani V, et al. Circulating levels of n-3 polyunsaturated
fatty acids in patients with chronic heart failure. Data from
the GISSI-HF trial. European Heart Journal 2011;32:919.
Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi
MG, Latini R, et al. Effects of rosuvastatin on atrial
fibrillation occurrence: ancillary results of the GISSI-HF
trial. Eupropean Heart Journal 2009;30(19):232736.
Marchioli R, Aldegheri MP, Borghese L, Franzosi MG,
Latini R, Marfisi RM, et al. Time course analysis of the
effect of n-3 PUFA on fatal and non fatal arrhythmias
in heart failure: secondary results of the GISSI-HF trial.
European Heart Journal 2009;30:165.
Marchioli R, Cucchi G, Gualco A, Franzosi MG, Levantesi
G, Maggioni AP, et al. Time course analysis of the effect of
n-3 PUFA on fatal and non fatal heart failure: Secondary
results of the GISSI-HF trial. European Heart Journal 2009;
30:432.
Marchioli R, Franzosi MG, Latini R, Maggioni AP, Marfisi
RM, Minneci C, et al. Prognostic ability of a Mediterranean
dietary score in heart failure: preliminary analysis of the
GISSI-Heart failure trial. European Heart Journal 2009;30:
1026.
Marchioli R, Franzosi MG, Latini R, Maggioni AP, Marfisi
RM, Nicolosi GL, et al. Effect of n-3 PUFA in heart failure
patients with different dietary habits: preliminary results of
the GISSI-heart failure trial. European Heart Journal 2009;
30:426.
Marchioli R, Franzosi MG, Levantesi G, Marfisi RM,
Maggioni AP, Nicolosi GL, et al. Effect of n-3 PUFA
according to fish intake: preliminary results of GISSI-Heart
Failure. European Heart Journal 2009;30:707.
Marchioli R, Levantesi G, Silletta MG, Barlera S,
Bernardinangeli M, Carbonieri E, et al. Effect of n-3
polyunsaturated fatty acids and rosuvastatin in patients with
heart failure: results of the GISSI-HF trial. Expert Review of
Cardiovascular Therapy 2009;7(7):735–48.
Masson S, Latini R, Milani V, Moretti L, Rossi MG,
Carbonieri E, et al. Prevalence and prognostic value of
elevated urinary albumin excretion in patients with chronic
heart failure: data from the GISSI-Heart Failure trial.
Circulation: Heart Failure 2010;3(1):65–72.
Masson S, Marchioli R, Mozaffarian D, Bernasconi R,
Milani V, Dragani L, et al. Plasma n-3 polyunsaturated fatty
acids in chronic heart failure in the GISSI-Heart Failure
trial: relation with fish intake, circulating biomarkers, and
mortality. American Heart Journal 2013;165(2):208–15.
Røysland R, Masson S, Omland T, Milani V, Bjerre M,
Flyvbjerg A, et al. Prognostic value of osteoprotegerin
in chronic heart failure: the GISSI-HF trial. American
Heart Journal 2010;160(2):286–93. DOI: 10.1016/
j.ahj.2010.05.015
∗ Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi
MG, Latini R, et al. Effect of n-3 polyunsaturated fatty
acids in patients with chronic heart failure (the GISSI-
HF trial): a randomised, double-blind, placebo-controlled
trial. Lancet 2008;372(9645):1223–30. DOI: 10.1016/
S01406736(08)61239-8
Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni
AP, Marchioli R, et al. Rationale and design of the GISSI
heart failure trial: a large trial to assess the effects of n-3
polyunsaturated fatty acids and rosuvastatin in symptomatic
congestive heart failure. European Journal of Heart Failure
2004;6(5):635–41. DOI: 10.1016/j.ejheart.2004.03.001
GISSI-P 1999 {published data only}
Franzosi MG, Brunetti M, Marchioli R, Marfisi RM,
Tognoni G, Valagussa F, et al. Cost-effectiveness analysis
of n-3 polyunsaturated fatty acids (PUFA) after myocardial
infarction: results from Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto (GISSI)-Prevenzione trial.
Pharmacoeconomics 2001;19(4):411–20.
∗ GISSI-Prevenzione Investigators. Dietary supplementation
with n-3 polyunsaturated fatty acids and vitamin E after
myocardial infarction: results of the GISSI-Prevenzione
trial. Lancet 1999;354:447–55.
Marchioli R. Treatment with n-3 polyunsaturated fatty
acids after myocardial infarction: results of GISSI-
55Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Prevenzione trial. European Heart Journal Supplements
2001;3(Supplement D):D85–D97.
Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio
DDMR, Franzosi MG, et al. Early protection against
sudden death by n-3 polyunsaturated fatty acids after
myocardial infarction: time course analysis of the results
of the Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation
2002;105:1897–903.
Marchioli R, Di Pasquale A. The biochemical,
pharmacological and epidemiological reference picture of
the GISSI-Prevention. Giornale Italiano di Cardiologia
1993;23(9):933–64.
Marchioli R, Valagussa F. The results of the GISSI-
Prevenzione trial in the general framework of secondary
prevention. European Heart Journal 2000;21(12):949–52.
JELIS 2007 {published and unpublished data}
Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical
trials update from the American Heart Association:
REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II,
SURVIVE, and PROACTIVE. The European Journal
of Heart Failure 2006;8(1):105–10. DOI: 10.1016/
j.ejheart.2005.12.003
Ishikawa Y, Yokoyama M, Saito Y, Matsuzaki M, Origasa
H, Oikawa S, et al. Preventive effects of eicosapentaenoic
acid on coronary artery disease in patients with peripheral
artery disease. Circulation Journal 2010;74(7):1451–7.
DOI: 10.1253/circj.CJ-09-0520
Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa
Y, Oikawa S, et al. Incremental effects of eicosapentaenoic
acid on cardiovascular events in statin-treated patients with
coronary artery disease. Secondary prevention analysis from
JELIS. Circulation Journal 2009;73(7):1283–90.
Oikawa S, Yokoyama M, Origasa H, Matsuzaki M,
Matsuzawa Y, Saito Y, et al. Suppressive effect of EPA on the
incidence of coronary events in hypercholesterolemia with
impaired glucose metabolism: sub-analysis of the Japan EPA
Lipid Intervention Study (JELIS). Atherosclerosis 2009;206
(2):535–9. DOI: 10.1016/j.atherosclerosis.2009.03.029
Origasa H, Yokoyama M, Matsuzaki M, Saito Y, Matsuzawa
Y, JELIS Investigators. Clinical importance of adherence
to treatment with eicosapentaenoic acid by patients with
hypercholesterolemia. Circulation Journal 2010;74(3):
510–7. DOI: 10.1253/circj.CJ-09-0746
Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa
Y, Ishikawa Y, et al. Effects of EPA on coronary artery
disease in hypercholesterolemic patients with multiple
risk factors: sub-analysis of primary prevention cases
from the Japan EPA Lipid Intervention Study (JELIS).
Atherosclerosis 2008;200(1):135–40. DOI: 10.1016/
j.atherosclerosis.2008.06.003
Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki
M, Saito Y, et al. Reduction in the recurrence of stroke by
eicosapentaenoic acid for hypercholesterolemic patients:
subanalysis of the JELIS trial. Stroke 2008;39(8):2052–8.
DOI: 10.1161/STROKEAHA.107.509455
Yamanouchi D, Komori K. Eicosapentaenoic acid as the
gold standard for patients with peripheral artery disease?
Subanalysis of the JELIS trial. Circulation Journal 2010;74
(7):1298–9. DOI: 10.1253/circj.CJ-10-0449
∗ Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y,
Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid
on major coronary events in hypercholesterolaemic patients
(JELIS): a randomised open-label, blinded endpoint
analysis. Lancet 2007;369(9567):1090–8.
Yokoyama M, Origasa H, for the JELIS Investigators.
Effects of eicosapentaenoic acid on cardiovascular events in
Japanese patients with hypercholesterolaemia: rationale,
design, and baseline characteristics of the Japan EPA Lipid
Intervention Study (JELIS). American Heart Journal 2003;
146:613–20.
Lorenz-Meyer 1996 {published and unpublished data}
Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J,
Fleig WE, et al. Omega-3 fatty acids and low carbohydrate
diet for maintenance of remission in Crohn’s disease. A
randomized controlled multicenter trial. Study Group
Members (German Crohn’s Disease Study Group).
Scandinavian Journal of Gastroenterology 1996;31(8):
778–85.
Mansel 1990 {published data only}
∗ Mansel RE, Gateley CA, Harrison BJ, Melhuish J,
Sheridan W, Pye JK, et al. Effects and tolerability of n-
6 essential fatty acid supplementation in patients with
recurrent breast cysts: a randomized double-blind placebo-
controlled trial. Journal of Nutritional Medicine 1990;1(3):
195.
Mansel RE, Harrison BJ, Melhuish J, Sheridan W, Pye
JK, Pritchard G, et al. A randomized trial of dietary
intervention with essential fatty acids in patients with
categorized cysts. Annals of the New York Academy of Sciences
1990;586:288–94.
Mansel RE, Pye JK, Hughes LE. Effects of essential fatty
acids on cyclical mastalgia and noncyclical breat disorders.
In: Horrobin DE editor(s). Omega-6 Essential Fatty
Acids: Pathophysiology and Roles in Clinical Medicine. 1st
Edition. New York: Wiley-Liss, 1990:557–66. ISBN
0–471–SAh93–4]
MAPT 2017 {published data only}
∗ Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M,
Bordes S, et al. Effect of long-term omega 3 polyunsaturated
fatty acid supplementation with or without multidomain
intervention on cognitive function in elderly adults with
memory complaints (MAPT): a randomised, placebo-
controlled trial. Lancet Neurology 2017;16:377–89. DOI:
10.1016/S1474-4422(17)30040-6
Carrie I, Van Kan GA, Gillette-Guyonnet S, Andrieu S,
Dartigues JF, Touchon J, et al. Recruitment strategies
for preventive trials. The MAPT study (MultiDomain
Alzheimer Preventive Trial). Journal of Nutrition, Health &
Aging 2012;16(4):355–9.
Delrieu J, Andrieu S, Pahor M, Cantet C, Cesari M, Ousset
PJ, et al. Neuropsychological profile of “cognitive frailty”
subjects in MAPT study. Journal of Prevention of Alzheimer’s
56Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Disease 2016;3(3):151–9. DOI: 10.14283/jpad.2016.94
Delrieu J, Payoux P, Hitzel A, Peiffer S, Abellan Van Kan G,
Gillette S, et al. Multidomain Alzheimer’s disease preventive
trial: Florbetapir ancillary study. Alzheimer’s & Dementia
2011;1:S419.
Fougere B, Barreto PD, Goisser S, Soriano G, Guyonnet S,
Andrieu S, et al. Red blood cell membrane omega-3 fatty
acid levels and physical performance: cross-sectional data
from the MAPT study. Clinical Nutrition 2017;pii(S0261-
5614(17)30128-0):1–4. DOI: 10.1016/j.clnu.2017.04.005
Gillette S. The multidomain Alzheimer preventive trial
(MAPT): a new approach for the prevention of Alzheimer’s
disease. Alzheimer’s & Dementia 2009;5(4):145.
Gillette-Guyonnet S, Andrieu S, Dantoine T, Dartigues JF,
Touchon J, Vellas B, et al. Commentary on “A roadmap
for the prevention of dementia II. Leon Thal Symposium
2008.” The Multidomain Alzheimer Preventive Trial
(MAPT): a new approach to the prevention of Alzheimer’s
disease. Alzheimer’s & Dementia 2009;5(2):114–21.
Gillette-Guyonnet S, Vellas B, Andrieu S, Dupuy C, Carrié
I. MAPT study: a 3-year randomized trial of omega 3 and/
or multidomain intervention for the prevention of cognitive
decline in frail elderly subjects-rationale, design and baseline
data. Alzheimer’s & Dementia 2011;1:S97–8.
Vellas B, Carrie I, Gillette-Guyonnet S, Touchon J,
Dantoine T, Dartigues JF, et al. MAPT study: a
multidomain approach for preventing ALzheimer’s disease:
design and baseline data. Journal of Prevention of Alzheimers
Disease 2014;1(1):13–22.
Vellas B, Carrie I, Guyonnet S, Touchon J, Dantoine T,
Dartigues JF, et al. MAPT (multi-domain Alzheimer’s
prevention trial): results at 36 months. Alzheimer’s &
Dementia 2015;1:331.
Vellas B, Touchon J, Weiner M. MAPT (multidomain
Alzheimer preventive trial) imaging (MRI, FDG-PET,
amyloid-PET) data. Journal of Nutrition, Health and Aging
2012;16 (9):812–5.
MARGARIN Bemelmans 2002 {published data only (unpublished
sought but not used)}
Bemelmans WJ, Broer J, De Vries JH, Hulshof KF, May
JF, Meyboom-De Jong B. Impact of Mediterranean diet
education versus posted leaflet on dietary habits and serum
cholesterol in a high risk population for cardiovascular
disease. Public Health Nutrition 2000;3(3):273–83.
∗ Bemelmans WJ, Broer J, Feskens EJ, Smit AJ, Muskiet
AJ, Lefrandt JD, et al. Effect of an increased intake of
alpha-linolenic acid and group nutritional education on
cardiovascular risk factors: the Mediterranean alpha-
linolenic enriched Groningen dietary intervention
(MARGARIN) study. American Journal of Clinical Nutrition
2002;75:221–7.
Bemelmans WJ, Lefrandt JD, Feskens EJ, Broer J, Tervaert
JW, May JF, et al. Change in saturated fat intake is
associated with progression of carotid and femoral intima-
media thickness, and with levels of soluble intercellular
adhesion molecule-1. Atherosclerosis 2002;163(1):113–20.
Bemelmans WJ, Lefrandt JD, Feskens EJ, Van Haelst
PL, Broer J, Meyboom-de Jong B, et al. Increased alpha-
linolenic acid intake lowers C-reactive protein, but has no
effect on markers of atherosclerosis. European Journal of
Clinical Nutrition 2004;58(7):1083–9.
Bemelmans WJ, Muskiet FA, Feskens EJ, De Vries JH,
Broer J, May JF, et al. Associations of alpha-linolenic acid
and linoleic acid with risk factors for coronary heart disease.
European Journal of Clinical Nutrition 2000;54(12):865–71.
Siero FW, Broer J, Bemelmans WJ, Meyboom-de Jong
BM. Impact of group nutrition education and surplus
value of Prochaska based stage-matched information on
health-related cognitions and on Mediterranean nutrition
behaviour. Health Education Research 2000;15(5):635–47.
MENU - Rock 2016 {published data only}
Le T, Flatt SW, Natarajan L, Pakiz B, Quintana EL, Heath
DD, et al. Effects of diet composition and insulin resistance
status on plasma lipid levels in a weight loss intervention in
women. Journal of the American Heart Association 2016;5
(1):e002771. DOI: 10.1161/JAHA.115.002771
∗ Rock CL, Flatt SW, Pakiz B, Quintana EL, Heath DD,
Rana BK, et al. Effects of diet composition on weight loss,
metabolic factors and biomarkers in a 1-year weight loss
intervention in obese women examined by baseline insulin
resistance status. Metabolism 2016;65(11):1605–13. DOI:
10.1016/j.metabol.2016.07.008
Michalsen 2006 {published data only}
Michalsen A, Lehmann N, Pithan C, Knoblauch NT,
Moebus S, Kannenberg F, et al. Mediterranean diet has
no effect on markers of inflammation and metabolic risk
factors in patients with coronary artery disease. European
Journal of Clinical Nutrition 2006;60(4):478–85.
Middleton 2002 {published data only}
Middleton SJ, Naylor S, Woolner J, Hunter JO. A double-
blind, randomized, placebo-controlled trial of essential fatty
acid supplementation in the maintenance of remission of
ulcerative colitis. Alimentary Pharmacology & Therapeutics
2002;16(6):1131–5. PUBMED: 12030955]
Minnesota Coronary 1989 {published data only}
Brewer ER, Ashman PL, Kuba K. The Minnesota Coronary
Survey: composition of diets, adherence and serum lipid
response. Circulation 1975;51 and 52(Suppl II):269.
Dawson EA, Gatewood LC. The Minnesota Coronary
Survey: methodology and characteristics of the population.
Circulation 1975;51 and 52(Suppl II):271.
∗ Frantz ID Jr, Dawson EA, Ashman PL, Gatewood LC,
Bartsch GE, Kuba K, et al. Test of effect of lipid lowering
by diet on cardiovascular risk. The Minnesota Coronary
Survey. Arteriosclerosis 1989;9(1):129–35.
Frantz ID, Dawson EA, Kuba K, et al. The Minnesota
Coronary Survey: effect of diet on cardiovascular events and
deaths. Circulation 1975;51 and 52(Suppl II):4.
Ramsden CE, Zamora D, Majchrzak-Hong S, Faurot KR,
Broste SK, Frantz RP, et al. Re-evaluation of the traditional
diet-heart hypothesis: analysis of recovered data from
Minnesota Coronary Experiment (1968-73). BMJ 2016;
353:i1246.
57Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Moy 2001 {published and unpublished data}
Moy TF, Yanek LR, Raqueno JV, Bezirdjian PJ, Blumenthal
RS, Wilder LB, et al. Dietary counseling for high blood
cholesterol in families at risk of coronary disease. Preventive
Cardiology 2001;4(4):158–64.
NAT2 2015 {published data only}
Merle BM, Benlian P, Puche N, Bassols A, Delcourt
C, Souied EH. Circulating omega-3 fatty acids and
neovascular age-related macular degeneration. Investigative
Ophthalmology & Visual Science 2014;55(3):2010–9.
PUBMED: 24557349]
∗ Merle BM, Richard F, Benlian P, Puche N, Delcourt C,
Souied EH.CFHY402H andARMS2A69S polymorphisms
and oral supplementation with docosahexaenoic acid in
neovascular age-related macular degeneration patients: the
NAT2 study. PloS One 2015;10(7):e0130816. PUBMED:
26132079]
Querques G, Merle BM, Pumariega NM, Benlian P,
Delcourt C, Zourdani A, et al. Dynamic drusen remodelling
in participants of the Nutritional AMD Treatment-2 (NAT-
2) randomized trial. PloS One 2016;11(2):e0149219.
PUBMED: 26901353]
Souied EH, Delcourt C, Querques G, Bassols A, Merle
B, Zourdani A, et al. Oral docosahexaenoic acid in the
prevention of exudative age-related macular degeneration:
the Nutritional AMD Treatment 2 study. Ophthalmology
2013;120(8):1619–31. PUBMED: 23395546]
Norouzi 2014 {published data only}
∗ Norouzi Javidan A, Sabour H, Latifi S, Abrishamkar
M, Soltani Z, Shidfar F, et al. Does consumption of
polyunsaturated fatty acids influence on neurorehabilitation
in traumatic spinal cord-injured individuals? A double-
blinded clinical trial. Spinal Cord 2014;52(5):378–82.
PUBMED: 24637568]
Sabour H, Norouzi Javidan A, Latifi S, Shidfar F, Heshmat
R, Emami Razavi SH, et al. Omega-3 fatty acids’ effect
on leptin and adiponectin concentrations in patients with
spinal cord injury: a double-blinded randomized clinical
trial. Journal of Spinal Cord Medicine 2015;38(5):599–606.
PUBMED: 25096818]
Norwegian - Natvig 1968 {published data only}
Natvig H. The effect of unsaturated fatty acids on the
incidence of coronary infarction, etc. Tidsskrift for Den
Norske Laegeforening 1967;87(11):1033–41.
∗ Natvig H, Borchgrevink CF, Dedichen J, Owren PA,
Schiotz EH, Westlund K. A controlled trial of the effect
of linolenic acid on incidence of coronary heart disease.
The Norwegian vegetable oil experiment of 1965-66.
Scandinavian Journal of Clinical & Laboratory Investigation -
Supplement 1968;105:1–20.
NutriStroke 2009 {published data only}
Garbagnati F, Cairella G, De Martino A, Multari M,
Scognamiglio U, Venturiero V, et al. Is antioxidant and
n-3 supplementation able to improve functional status in
post-stroke patients? Results from the Nutristroke Trial.
Cerebrovascular Diseases (Basel, Switzerland) 2009;27(4):
375–83. DOI: 10.1159/000207441
OFAMI - Nilsen 2001 {published and unpublished data}
Aarsetoy H, Brugger-Andersen T, Hetland O, Grundt H,
Nilsen DW. Long term influence of regular intake of high
dose n-3 fatty acids on CD40-ligand, pregnancy-associated
plasma protein A and matrix metalloproteinase-9 following
acute myocardial infarction. Thrombosis & Haemostasis
2006;95(2):329–36.
Grundt H, Hetland O, Nilsen DW. Changes in tissue factor
and activated factor XII following an acute myocardial
infarction were uninfluenced by high doses of n-3
polyunsaturated fatty acids. Thrombosis & Haemostasis
2003;89(4):752–9.
Grundt H, Nilsen DW, Hetland O, Mansoor MA.
Clinical outcome and atherothrombogenic risk profile
after prolonged wash-out following long-term treatment
with high doses of n-3 PUFAs in patients with an acute
myocardial infarction. Clinical Nutrition 2004;23(4):
491–500.
Grundt H, Nilsen DW, Mansoor MA, Hetland O, Nordoy
A. Reduction in homocysteine by n-3 polyunsaturated
fatty acids after 1 year in a randomised double-blind
study following an acute myocardial infarction: no effect
on endothelial adhesion properties. Pathophysiology of
Haemostasis & Thrombosis 2003;33(2):88–95.
Grundt H, Nilsen DW, Mansoor MA, Nordoy A. Increased
lipid peroxidation during long-term intervention with
high doses of n-3 fatty acids (PUFAs) following an acute
myocardial infarction. European Journal of Clinical
Nutrition 2003;57(6):793–800.
Naesgaard PA, Grundt H, Brede C, Nilsen DW. The effect
on vitamin D levels of long-term high-dose treatment
with a concentrated omega-3 compound (Omacor/lovaza)
in patients hospitalized with a myocardial infarction.
Circulation 2014;130(Suppl 2):A17245.
∗ Nilsen DW, Albrektsen G, Landmark K, Moen S, Aarsland
T, Woie L. Effects of a high-dose concentrate of n-3 fatty
acids or corn oil introduced early after an acute myocardial
infarction on serum triacylglycerol and HDL cholesterol.
American Journal of Clinical Nutrition 2001;74(1):50–6.
Poenitz V, Grundt H, Bottazzi B, Cuccovillo I, Mantovani
A, Nilsen DW. Pentraxin 3 is uninfluenced by high doses
of concentrated omega-3 fatty acids administered for
12 months following an acute myocardial infarction.
Circulation 2012;126(21 Suppl 1):A13464.
OMEGA 2014 {published and unpublished data}
∗ Rauch B, Riemer T, Schwaab B, Schneider S, Diller
F, Gohlke H, et al. Short-term comprehensive cardiac
rehabilitation after AMI is associated with reduced 1-year
mortality: results from the OMEGA study. European
Journal of Preventive Cardiology 2014;21(9):1060–9.
Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke
H, et al. OMEGA, a randomized, placebo-controlled trial
to test the effect of highly purified omega-3 fatty acids on
top of modern guideline-adjusted therapy after myocardial
infarction. Circulation 2010;122(21):2152–9. DOI:
10.1161/CIRCULATIONAHA.110.948562
Rauch B, Schiele R, Schneider S, Gohlke H, Diller F,
58Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gottwik M, et al. Highly purified omega-3 fatty acids
for secondary prevention of sudden cardiac death after
myocardial infarction-aims and methods of the OMEGA-
study. Cardiovascular Drugs and Therapy / Sponsored by
the International Society of Cardiovascular Pharmacotherapy
2006;20(5):365–75. DOI: 10.1007/s10557-006-0495-6
OPAL - Dangour 2010 {published and unpublished data}
∗ Dangour AD, Allen E, Elbourne D, Fasey N, Fletcher AE,
Hardy P, et al. Effect of 2-y n-3 long-chain polyunsaturated
fatty acid supplementation on cognitive function in older
people: a randomized, double-blind, controlled trial.
American Journal of Clinical Nutrition 2010;91(6):1725–32.
Dangour AD, Allen E, Elbourne D, Fletcher A, Richards M,
Uauy R. Fish consumption and cognitive function among
older people in the UK: baseline data from the OPAL study.
Journal of Nutrition, Health & Aging 2009;13(3):198–202.
Dangour AD, Allen E, Elbourne D, Fletcher AE, Neveu
MM, Uauy R, et al. N-3 fatty acids and retinal function.
Ophthalmology 2013;120(3):643. DOI: http://dx.doi.org/
10.1016/j.ophtha.2012.09.043
Dangour AD, Clemens F, Elbourne D, Fasey N, Fletcher
AE, Hardy P, et al. A randomised controlled trial
investigating the effect of n-3 long-chain polyunsaturated
fatty acid supplementation on cognitive and retinal function
in cognitively healthy older people: the Older People And
n-3 Long-chain polyunsaturated fatty acids (OPAL) study
protocol [ISRCTN72331636]. Nutrition Journal 2006;5:
20.
ORIGIN 2012 {published data only}
Bordeleau L, Yakubovich N, Dagenais G, Rosenstock J,
Ryden LE, Spinas G, et al. Cancer outcomes in patients
with dysglycemia on basal insulin: results of the ORIGIN
trial. Diabetes 2013;62:A72.
Bordeleau L, Yakubovich N, Dagenais GR, Rosenstock J,
Probstfield J, Chang Yu P, et al. The association of basal
insulin glargine and/or n-3 fatty acids with incident cancers
in patients with dysglycemia. Diabetes Care 2014;37(5):
1360–6.
Lonn EM, Bosch J, Diaz R, Lopez-Jaramillo P,
Ramachandran A, Hancu N, et al. Effect of insulin glargine
and n-3FA on carotid intima-media thickness in people
with dysglycemia at high risk for cardiovascular events: the
glucose reduction and atherosclerosis continuing evaluation
study (ORIGIN-GRACE). Diabetes Care 2013;36(9):
2466–74.
Maggioni AP, Fabbri G, Bosch J, Dyal L, Ryden LE,
Gerstein HC, et al. Effects of n-3 fatty acids on long-term
outcomes of high risk patients with type 2 diabetes mellitus
or IGF/IGT with a recent myocardial infarction. European
Heart Journal 2013;34:352.
∗ Origin Trial Investigators, Bosch J, Gerstein HC, Dagenais
GR, Diaz R, Dyal L, Jung H, et al. N-3 fatty acids and
cardiovascular outcomes in patients with dysglycemia. New
England Journal of Medicine 2012;367(4):309–18.
Origin Trial Investigators, Gerstein H, Yusuf S, Riddle
MC, Ryden L, Bosch J. Rationale, design, and baseline
characteristics for a large international trial of cardiovascular
disease prevention in people with dysglycemia: the
ORIGIN trial (Outcome Reduction with an Initial Glargine
Intervention). American Heart Journal 2008;155(1):26-32,
32.
Origin Trial Investigators, Gerstein HC, Bosch J, Dagenais
GR, Diaz R, Jung H, Maggioni AP, et al. Basal insulin and
cardiovascular and other outcomes in dysglycemia. New
England Journal of Medicine 2012;367(4):319–28.
Punthakee Z, Gerstein HC, Bosch J, Tyrwhitt J, Jung
H, Lee SF, et al. Cardiovascular and other outcomes
postintervention with insulin glargine and omega-3 fatty
acids (ORIGINALE). Diabetes Care 2016;39(5):709–16.
Oslo Diet-Heart 1966 {published and unpublished data}
Leren P. Prevention of coronary heart disease, some results
from the Oslo secondary and primary intervention studies.
Journal of the American College of Nutrition 1989;8:407–10.
Leren P. The Oslo diet-heart study. Eleven year report.
Circulation 1970;42:935–42.
Leren P. The effect of a cholesterol lowering diet in male
survivors of myocardial infarction (a controlled clinical trial)
[Virkningen av cholesterolsenkende diett hos menn som har
gjennomgatt hjerteinfarkt. Et kontrollert klinisk fors/ok].
Nordisk Medicin 1967;77(21):658–61.
∗ Leren P. The effect of plasma cholesterol lowering diet
in male survivors of myocardial infarction. A controlled
clinical trial. Acta Medica Scandinavica. Supplementum
1966;466:1–92.
Leren P. The effect of plasma-cholesterol-lowering diet
in male survivors of myocardial infarction. A controlled
clinical trial. Bulletin of the New York Academy of Medicine
1968;44:1012–20.
Oxford Retinopathy 1978 {published and unpublished data}
Coppack SW, Doll HA, Pim B, Hockaday TDR.
Intravenous glucose tolerance and mortality in non-insulin-
dependant diabetes mellitus. Quarterly Journal of Medicine
1990;75:451–60.
Hillson RM, Hockaday TDR, Mann JI, Newton DJ.
Hyperinsulinaemia is associated with development of ECG
abnormalities in diabetics. Diabetes Research 1984;1:143–9.
∗ Hockaday TD, Hockaday JM, Mann JI, Turner RC.
Prospective comparison of modified fat-high-carbohydrate
with standard low-carbohydrate dietary advice in the
treatment of diabetes: one year follow-up study. British
Journal of Nutrition 1978;39(2):357–62.
Howard-Williams J, Patel P, Jelfs R, Carter RD, Awdry
P, Bron A, et al. Polyunsaturated fatty acids and diabetic
retinopathy. British Journal of Ophthalmology 1985;69(1):
15–8.
Lopez-Espinoza I, Howard WJ, Mann JI, Carter RD,
Hockaday TD. Fatty acid composition of platelet
phospholipids in non-insulin-dependent diabetics
randomized for dietary advice. British Journal of Nutrition
1984;52(1):41–7.
Özaydin 2011 {published data only}
Özaydin M, Erdo an D, Tayyar S, Uysal BA, Do
an A, Içli A, et al. N-3 polyunsaturated fatty acids
59Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
administration does not reduce the recurrence rates of atrial
fibrillation and inflammation after electrical cardioversion:
a prospective randomized study. Anadolu Kardiyoloji Dergisi
2011;11(4):305–9. DOI: 10.5152/akd.2011.080
POUNDS Lost Sacks 2009 {published and unpublished data}
∗ Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH,
Anton SD, et al. Comparison of weight-loss diets with
different compositions of fat, protein, and carbohydrates.
New England Journal of Medicine 2009;360(9):859–73.
de Souza RJ, Bray GA, Carey VJ, Hall KD, LeBoff MS,
Loria CM, et al. Effects of 4 weight-loss diets differing in fat,
protein, and carbohydrate on fat mass, lean mass, visceral
adipose tissue, and hepatic fat: results from the POUNDS
LOST trial. American Journal of Clinical Nutrition 2012;95
(3):614–25. DOI: 10.3945/ajcn.111.026328
Ramirez-Ramirez 2013 {published data only}
∗ Ramirez-Ramirez V, Macias-Islas MA, Ortiz GG, Pacheco-
Moises F, Torres-Sanchez ED, Sorto-Gomez TE, et al.
Efficacy of fish oil on serum of TNF α , IL-1 β , and
IL-6 oxidative stress markers in multiple sclerosis treated
with interferon beta-1b. Oxidative Medicine and Cellular
Longevity 2013;2013:709493. DOI: 10.1155/2013/
709493
Sorto-Gomez TE, Ortiz GG, Pacheco-Moises FP, Torres-
Sanchez ED, Ramirez-Ramirez V, Macias-Islas MA, et al.
Effect of fish oil on glutathione redox system in multiple
sclerosis. American Journal of Neurodegenerative Disease
2016;5(2):145–51.
Reed 2014 {published and unpublished data}
Olendzki BC, Leung K, Van Buskirk S, Reed G, Zurier
RB. Treatment of rheumatoid arthritis with marine and
botanical oils: influence on serum lipids. Evidence-Based
Complementary & Alternative Medicine: eCAM 2011;2011:
827286.
∗ Reed GW, Leung K, Rossetti RG, Vanbuskirk S, Sharp JT,
Zurier RB. Treatment of rheumatoid arthritis with marine
and botanical oils: an 18-month, randomized, and double-
blind trial. Evidence-Based Complementary & Alternative
Medicine: eCAM 2014;2014:857456.
Risk and Prevention {published and unpublished data}
Rischio and Prevenzione Investigators. Efficacy of n-3
polyunsaturated fatty acids and feasibility of optimizing
preventive strategies in patients at high cardiovascular
risk: rationale, design and baseline characteristics of the
Rischio and Prevenzione study, a large randomised trial in
general practice. Trials 2010;11(1):68. DOI: 10.1186/
1745-6215-11-68
∗ Roncaglioni MC, Tombesi M, Avanzini F, Barlera S,
Caimi V, Longoni P, et al. N-3 fatty acids in patients with
multiple cardiovascular risk factors. New England Journal of
Medicine 2013;368(19):1800–8.
Visentin G, Risk & Prevention Study Group. Towards
evidence-based practice via practice-based evidence: the
Italian experience. Family Practice 2008;25 Suppl 1:i71–4.
Sandhu 2016 {published data only}
∗ Sandhu N, Schetter SE, Liao J, Hartman TJ, Richie
JP, McGinley J, et al. Influence of obesity on breast
density reduction by omega-3 fatty acids: evidence from
a randomized clinical trial. Cancer Prevention Research
(Philadelphia, Pa.) 2016;9(4):275–82. PUBMED:
26714774]
Signori C, DuBrock C, Richie JP, Prokopczyk B, Demers
LM, Hamilton C, et al. Administration of omega-3 fatty
acids and Raloxifene to women at high risk of breast cancer:
interim feasibility and biomarkers analysis from a clinical
trial. European Journal of Clinical Nutrition 2012;66(8):
878–84. PUBMED: 22669332]
Schirmer 2007 {published data only}
Schirmer MA, Phinney SD. Gamma-linolenate reduces
weight regain in formerly obese humans. Journal of
Nutrition 2007;137(6):1430–5. PUBMED: 17513402]
SCIMO - von Schacky 1999 {published and unpublished data}
Angerer P, Kothny W, Stork S, von Schacky C. Effect
of dietary supplementation with omega-3 fatty acids
on progression of atherosclerosis in carotid arteries.
Cardiovascular Research 2002;54(1):183–90.
∗ von Schacky C, Angerer P, Kothny W, Theisen K, Mudra
H. The effect of dietary omega-3 fatty acids on coronary
atherosclerosis. A randomized, double-blind, placebo-
controlled trial. Annals of Internal Medicine 1999;130(7):
554–62.
von Schacky C, Baumann K, Angerer P. The effect
of n-3 fatty acids on coronary atherosclerosis: results
from SCIMO, an angiographic study, background and
implications. Lipids 2001;36 Suppl:S99–102.
Shinto 2014 {published data only}
NCT00090402. Fish oil and alpha lipoic acid in
treating Alzheimer’s Disease. clinicaltrials.gov/ct2/show/
NCT00090402 (first posted 26 August 2014).
∗ Shinto L, Quinn J, Montine T, Dodge HH,WoodwardW,
Baldauf-Wagner S, et al. A randomized placebo-controlled
pilot trial of omega-3 fatty acids and alpha lipoic acid in
Alzheimer’s disease. Journal of Alzheimer’s Disease 2014;38
(1):111–20. PUBMED: 24077434]
SHOT - Eritsland 1996 {published and unpublished data}
Eritsland J, Arnesen H, Berg K, Seljeflot I, Abdelnoor M.
Serum Lp(a) lipoprotein levels in patients with coronary
artery disease and the influence of long-term n-3 fatty acid
supplementation. Scandinavian Journal of Clinical and
Laboratory Investigation 1995;55(4):295–300.
∗ Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor
M. Effect of dietary supplementation with n-3 fatty acids
on coronary artery bypass graft patency. American Journal of
Cardiology 1996;77(1):31–6.
Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor
M. Effect of supplementation with n-3 fatty acids on graft
patency in patients undergoing coronary artery bypass
operation. Results from SHOT study. European Heart
Journal 1994;15:29.
Eritsland J, Arnesen H, Seljeflot I, Hostmark AT. Long-
term metabolic effects of n-3 polyunsaturated fatty acids in
60Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
patients with coronary artery disease. American Journal of
Clinical Nutrition 1995;61(4):831–6.
Eritsland J, Arnesen H, Seljeflot I, Kierulf P. Long-term
effects of n-3 polyunsaturated fatty acids on haemostatic
variables and bleeding episodes in patients with coronary
artery disease. Blood Coagulation & Fibrinolysis 1995;6(1):
17–22.
Eritsland J, Seljeflot I, Abdelnoor M, Arnesen H. Long-term
influence of omega-3 fatty acids on fibrinolysis, fibrinogen,
and serum lipids. Fibrinolysis 1994;8(2):120–5.
Eritsland J, Seljeflot I, Abdelnoor M, Arnesen H, Torjesen
PA. Long-term effects of n-3 fatty acids on serum lipids and
glycaemic control. Scandinavian Journal of Clinical and
Laboratory Investigation 1994;54(4):273–80.
Eritsland J, Seljeflot I, Arnesen H, Abdelnoor M. Long-term
effects of fish oil supplementation in patients with coronary
artery disease: influence on lipoproteins, coagulation and
fibrinolysis [abstract]. Thrombosis Research 1992;65:75.
Eritsland J, Seljeflot I, Arnesen H, Abdelnoor M. Long-term
influence of omega-3 fatty acids on fibrinolysis, fibrinogen,
and serum lipids. Thrombosis and Haemostasis 1993;69:
1065.
Eritsland J, Seljeflot I, Arnesen H, Westvik AB, Kierulf P.
Effect of long-term, moderate-dose supplementation with
omega-3 fatty acids on monocyte procoagulant activity and
release of interleukin-6 in patients with coronary artery
disease. Thrombosis Research 1995;77(4):337–46.
Sianni 2013 {published data only}
Sianni A, Matsoukis I, Ganotopoulou A, Paraskevas P,
Asimis A, Tsivilis N, et al. PP128-sun effect of omega 3 fatty
acids in patients with hypertension and atrial fibrillation.
Clinical Nutrition 2013;32(Suppl 1):S70–1.
SMART Tapsell 2013 {published data only}
Anil S, Charlton KE, Tapsell LC, Probst Y, Ndanuko R,
Batterham MJ. Identification of dietary patterns associated
with blood pressure in a sample of overweight Australians.
Journal of Human Hypertension 2016;30(11):672–8. DOI:
10.1038/jhh.2016.10
Tapsell LC, Batterham MJ, Charlton KE. Effect of dietary
restriction and n-3 PUFA supplementation on insulin
resistance in obese adults. FASEB Journal 2010;24:733.9.
∗ Tapsell LC, Batterham MJ, Charlton KE, Neale EP, Probst
YC, O’Shea JE, et al. Foods, nutrients or whole diets:
effects of targeting fish and LCn3PUFA consumption in a
12mo weight loss trial. BMC Public Health 2013;13:1231.
PUBMED: 24369765]
SOFA 2006 {published and unpublished data}
Brouwer IA, Katan MB, Schouten EG, Camm AJ, Hauer
RNW, Wever EFD, et al. Rationale and design of a clinical
trial on n-3 fatty acids and cardiac arrhythmia (SOFA).
Annals of Nutrition & Metabolism 2001;45(Suppl 1):79.
Brouwer IA, Raitt MH, Dullemeijer C, Kraemer DF,
Zock PL, Morris C, et al. Effect of fish oil on ventricular
tachyarrhythmia in three studies in patients with
implantable cardioverter defibrillators. European Heart
Journal 2009;30(7):820–6.
∗ Brouwer IA, Zock PL, Camm AJ, Böcker D, Hauer
RN, Wever EF, et al. Effect of fish oil on ventricular
tachyarrhythmia and death in patients with implantable
cardioverter defibrillators: the Study on Omega-3 Fatty
Acids and Ventricular Arrhythmia (SOFA) randomized
trial. JAMA 2006;295(22):2613–9.
Brouwer IA, Zock PL, Wever EFD, Hauer RNW, Camm
AJ, Bocker D, et al. Rationale and design of a randomised
controlled clinical trial on supplemental intake of n-3 fatty
acids and incidence of cardiac arrhythmia: SOFA. European
Journal of Clinical Nutrition 2003;57:1323–30.
Sofi 2010 {published data only}
Sofi F, Giangrandi I, Cesari F, Corsani I, Abbate R, Gensini
GF, et al. Effects of a 1-year dietary intervention with n-
3 polyunsaturated fatty acid-enriched olive oil on non-
alcoholic fatty liver disease patients: a preliminary study.
International Journal of food Sciences and Nutrition 2010;61
(8):792–802. PUBMED: 20465434]
STARS 1992 {published and unpublished data}
Blann AD, Jackson P, Bath PM, Watts GF. Von Willebrand
factor, a possible indicator of endothelial cell damage,
decreases during long-term compliance with a lipid-lowering
diet. Journal of Internal Medicine 1995;237:557–61.
Watts GF. Nutritional, metabolic, and genetic determinants
of the progression of coronary heart disease. STARS Group.
Journal of Cardiovascular Pharmacology 1995;25(Suppl 4):
S11–9.
Watts GF, Brunt JNH, Coltart DJ, Lewis B. The St.
Thomas Atherosclerosis Regression Study (STARS).
Atherosclerosis 1992;97:231.
Watts GF, Jackson P, Burke V, Lewis B. Dietary fatty acids
and progression of coronary artery disease in men. American
Journal of Clinical Nutrition 1996;64:202–9.
Watts GF, Jackson P, Mandalia S, Brunt JN, Lewis ES,
Coltart DJ, et al. Nutrient intake and progression of
coronary artery disease. American Journal of Cardiology
1994;73(5):328–32.
∗ Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ,
Smith LD, et al. Effects on coronary artery disease of
lipid-lowering diet, or diet plus cholestyramine, in the St
Thomas’ Atherosclerosis Regression Study (STARS). Lancet
1992;339(8793):563–9.
Watts GF, Lewis B, Brunt JNH, Swan AV. Coronary
atheroma regression trials. Lancet 1992;339(i):1241–3.
Watts GF, Lewis B, Jackson P, Burke V, Lewis ES, Brunt
JN, et al. Relationships between nutrient intake and
progression/regression of coronary atherosclerosis as assessed
by serial quantitative angiography. Canadian Journal of
Cardiology 1995;11(Suppl G):110G–4G.
Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltart
DJ, Lewis B. Independent associations between plasma
lipoprotein subfraction levels and the course of coronary
artery disease in the St. Thomas’ Atherosclerosis Regression
Study (STARS). Metabolism: Clinical and Experimental
1993;42:1461–7.
Watts GF, Mandalia S, Slavin BM, Brunt JN, Coltart DJ,
Lewis B. Metabolic determinants of the course of coronary
61Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
artery disease in men. Clinical Chemistry 1994;40(12):
2240–6.
Stoll 2001 {published data only}
NCT00010868. Omega-3 fatty acids in bipolar disorder.
clinicaltrials.gov/ct2/show/NCT00010868 (first posted 5
February 2001).
STRENGTH {published data only}
NCT02104817. Outcomes study to assess statin residual
risk reduction with EpaNova in high CV risk patients with
hypertriglyceridemia (STRENGTH). clinicaltrials.gov/ct2/
show/NCT02104817 2014.
SU.FOL.OM3 Galan 2010 {published and unpublished data}
Ahluwalia N, Blacher J, Szabo De Edelenyi F, Faure P, Julia
C, Hercberg S, et al. Prognostic value of multiple emerging
biomarkers in cardiovascular risk prediction in patients with
stable cardiovascular disease. Atherosclerosis 2013;228(2):
478–84.
Andreeva VA, Galan P, Torres M, Julia C, Hercberg S, Kesse-
Guyot E. Supplementation with B vitamins or n-3 fatty
acids and depressive symptoms in cardiovascular disease
survivors: ancillary findings from the SUpplementation
with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty
acids (SU.FOL.OM3) randomized trial. American Journal
of Clinical Nutrition 2012;96(1):208–14.
Andreeva VA, Kesse-Guyot E, Barberger-Gateau P,
Fezeu L, Hercberg S, Galan P. Cognitive function after
supplementation with B vitamins and long-chain omega-
3 fatty acids: ancillary findings from the SU.FOL.OM3
randomized trial. American Journal of Clinical Nutrition
2011;94(1):278–86.
Andreeva VA, Latarche C, Hercberg S, Briancon S,
Galan P, Kesse-Guyot E. B vitamin and/or n-3 fatty acid
supplementation and health-related quality of life: ancillary
findings from the SU.FOL.OM3 randomized trial. PLoS
One 2014;9(1):e84844.
Andreeva VA, Touvier M, Kesse-Guyot E, Julia C, Galan
P, Hercberg S. B vitamin and/or omega-3 fatty acid
supplementation and cancer: ancillary findings from the
supplementation with folate, vitamins B6 and B12, and/
or omega-3 fatty acids (SU.FOL.OM3) randomized trial.
Archives of Internal Medicine 2012;172(7):540–7.
Arnaud J, Bost M, Vitoux D, Labarere J, Galan P, Faure
H, et al. Effect of low dose antioxidant vitamin and trace
element supplementation on the urinary concentrations of
thromboxane and prostacyclin metabolites. Journal of the
American College of Nutrition 2007;26(5):405–11.
Astorg P, Bertrais S, Alessandri JM, Guesnet P, Kesse-
Guyot E, Linard A, et al. Long-chain n-3 fatty acid levels
in baseline serum phospholipids do not predict later
occurrence of depressive episodes: a nested case-control
study within a cohort of middle-aged French men and
women. Prostaglandins Leukotrienes & Essential Fatty Acids
2009;81(4):265–71.
Astorg P, Couthouis A, Bertrais S, Arnault N, Meneton P,
Guesnet P, et al. Association of fish and long-chain n-3
polyunsaturated fatty acid intakes with the occurrence of
depressive episodes in middle-aged French men and women.
Prostaglandins Leukotrienes & Essential Fatty Acids 2008;78
(3):171–82.
Blacher J, Czernichow S, Paillard F, Ducimetiere P, Hercberg
S, Galan P, et al. Cardiovascular effects of B-vitamins and/
or N-3 fatty acids: the SU.FOL.OM3 trial. International
Journal of Cardiology 2013;167(2):508–13.
Blacher J, Safar ME, Ly C, Szabo De Edelenyi F, Hercberg
S, Galan P. Blood pressure variability: cardiovascular risk
integrator or independent risk factor. Journal of Human
Hypertension 2015;29(2):122–6.
Czernichow S, Bruckert E, Oppert JM, Bertrais S, Paillard F,
Astorg P, et al. Intake of added oils and fats among middle-
aged French adults: relationships with educational level
and region of residence. Journal of the American Dietetic
Association 2005;105(12):1889–94.
Fezeu LK, Laporte F, Kesse-Guyot E, Andreeva VA, Blacher
J, Hercberg S, et al. Baseline plasma fatty acids profile and
incident cardiovascular events in the SU.FOL.OM3 trial:
the evidence revisited. PLoS One 2014;9(4):e92548.
Galan P, Briancon S, Blacher J, Czernichow S, Hercberg
S. The SU.FOL.OM3 study: a secondary prevention trial
testing the impact of supplementation with folate and B-
vitamins and/or Omega-3 PUFA on fatal and non fatal
cardiovascular events, design, methods and participants
characteristics. Trials 2008;9:35.
Galan P, Briancon S, Blacher J, Czernichow S, Hercberg
S. The SU.FOL.OM3 study: a secondary prevention trial
testing the impact of supplementation with folate and B-
vitamins and/or omega-3 PUFA on fatal and non fatal
cardiovascular events, design, methods and participants
characteristics. Trials 2008;9:35. DOI: 10.1186/
1745-6215-9-35
Galan P, Briancon S, Blacher J, Czernichow S, Hercberg
S. The scientific basis of the SU.FOL.OM3 study: a
secondary intervention trial of folate, B6 and B12 vitamins
and/or omega3 fatty acid supplements in the prevention of
recurrent ischemic events. Sang Thrombose Vaisseaux 2009;
21(4):207–13.
Galan P, Briançon S, Blacher J, Czernichow S, Hercberg
S. The scientific basis of the SU.FOL.OM3 study: a
secondary intervention trial of folate, B6 and B12 vitamins
and/or omega3 fatty acid supplements in the prevention
of recurrent ischemic events [Bases scientifiques de l’étude
SUFOLOM3: essai de prévention secondaire visant à tester
l’impact d’une supplémentation en folates, vitamines B6
et B12 et/ ou acides gras oméga–3 dans la prévention de
la récidive de pathologies ischémiques]. Sang Thrombose
Vaisseaux 2009;21(4):207–13.
∗ Galan P, Kesse-Guyot E, Czernichow S, Briancon S,
Blacher J, Hercberg S, SU.FOL.OM3 Collaborative
Group. Effects of B vitamins and omega 3 fatty acids on
cardiovascular diseases: a randomised placebo controlled
trial. BMJ 2010;341:c6273. DOI: 10.1136/bmj.c6273
Galan P, de Bree A, Mennen L, Potier de Courcy G,
Preziozi P, Bertrais S, et al. Background and rationale of the
SU.FOL.OM3 study: double-blind randomized placebo-
controlled secondary prevention trial to test the impact of
62Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
supplementation with folate, vitamin B6 and B12 and/or
omega-3 fatty acids on the prevention of recurrent ischemic
events in subjects with atherosclerosis in the coronary or
cerebral arteries. Journal of Nutrition, Health & Aging 2003;
7(6):428–35.
Julia C, Meunier N, Touvier M, Ahluwalia N, Sapin V,
Papet I, et al. Dietary patterns and risk of elevated C-
reactive protein concentrations 12 years later. British Journal
of Nutrition 2013;110(4):747–54.
Julia C, Touvier M, Meunier N, Papet I, Galan P, Hercberg
S, et al. Intakes of PUFAs were inversely associated with
plasma C-reactive protein 12 years later in a middle-aged
population with vitamin E intake as an effect modifier.
Journal of Nutrition 2013;143(11):1760–6.
Kesse-Guyot E, Peneau S, Hercberg S, Galan P, Vogt L,
Escande M, et al. Thirteen-year prospective study between
fish consumption, long-chain n-3 fatty acids intakes and
cognitive function. Journal of Nutrition, Health and Aging
2011;15(2):115–20.
Latreille J, Kesse-Guyot E, Malvy D, Andreeva V, Galan
P, Tschachler E, et al. Association between dietary intake
of n-3 polyunsaturated fatty acids and severity of skin
photoaging in a middle-aged Caucasian population. Journal
of Dermatological Science 2013;72(3):233–9.
Latreille J, Kesse-Guyot E, Malvy D, Andreeva V, Galan P,
Tschachler E, et al. Dietary monounsaturated fatty acids
intake and risk of skin photoaging. PLoS One 2012;7(9):
e44490.
Pouchieu C, Chajes V, Laporte F, Kesse-Guyot E, Galan P,
Hercberg S, et al. Prospective associations between plasma
saturated, monounsaturated and polyunsaturated fatty
acids and overall and breast cancer risk - modulation by
antioxidants: a nested case-control study. PLoS One 2014;9
(2):e90442.
Szabo De Edelenyi F, Vergnaud AC, Ahluwalia N, Julia C,
Hercberg S, Blacher J, et al. Effect of B-vitamins and n-3
PUFA supplementation for 5 years on blood pressure in
patients with CVD. British Journal of Nutrition 2012;107
(6):921–7.
Touvier M, Kesse-Guyot E, Andreeva VA, Fezeu L,
Charnaux N, Sutton A, et al. Modulation of the association
between plasma intercellular adhesion molecule-1 and
cancer risk by n-3 PUFA intake: a nested case-control study.
American Journal of Clinical Nutrition 2012;95(4):944–50.
Vesin C, Galan P, Gautier B, Czernichow S, Hercberg S,
Blacher J. Control of baseline cardiovascular risk factors in
the SU-FOL-OM3 study cohort: does the localization of
the arterial event matter?. European Journal of Cardiovascular
Prevention & Rehabilitation 2010;17(5):541–8.
de Bree A, Mennen LI, Hercberg S, Galan P. Evidence for a
protective (synergistic?) effect of B-vitamins and omega-3
fatty acids on cardiovascular diseases. European Journal of
Clinical Nutrition 2004;58(5):732–44.
Søndergaard 2003 {published and unpublished data}
Sondergaard E, Moller JE, Egstrup K. Effect of dietary
intervention and lipid-lowering treatment on brachial
vasoreactivity in patients with ischemic heart disease and
hypercholesterolemia. American Heart Journal 2003;145
(5):E19.
Tande 2016 {published data only}
Tande KS, Vo TD, Lynch BS. Clinical safety evaluation of
marine oil derived from Calanus finmarchicus. Regulatory
Toxicology and Pharmacology : RTP 2016;80:25–31.
PUBMED: 27233921]
Tay 2015 {published data only}
∗ Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M,
Buckley JD, Wittert GA, et al. Comparison of low- and
high-carbohydrate diets for type 2 diabetes management:
a randomized trial. American Journal of Clinical Nutrition
2015;102(4):780–90.
Tay J, Thompson CH, Luscombe-Marsh ND, Noakes M,
Buckley JD, Wittert GA, et al. Long-term effects of a very
low carbohydrate compared with a high carbohydrate diet
on renal function in individuals with type 2 diabetes: a
randomized trial. Medicine 2015;94(47):e2181. DOI:
10.1097/MD.0000000000002181
THIS DIET - Tuttle 2008 {published and unpublished data}
Tuttle KR, Shuler LA, Packard DP, Milton JE, Daratha
KB, Bibus DM, et al. Comparison of low-fat versus
Mediterranean-style dietary intervention after first
myocardial infarction (from The Heart Institute of Spokane
Diet Intervention and Evaluation Trial). American Journal of
Cardiology 2008;101(11):1523–30. PUBMED: 18489927]
VITAL {published data only}
Bassuk SS, Manson JE, Lee IM, Cook NR, Christen WG,
Bubes VY, et al. Baseline characteristics of participants in the
VITamin D and OmegA-3 TriaL (VITAL). Contemporary
Clinical Trials 2016;47:235–43.
Gold DR, Litonjua AA, Carey VJ, Manson JE, Buring
JE, Lee IM, et al. Lung VITAL: rationale, design, and
baseline characteristics of an ancillary study evaluating the
effects of vitamin D and/or marine omega-3 fatty acid
supplements on acute exacerbations of chronic respiratory
disease, asthma control, pneumonia and lung function in
adults. Contemporary Clinical Trials 2016;47:185–95.
Gold DR, Luttmann-Gibson H, Litonjua AA, Friedenberg
G, Gordon D, Lee IM, et al. Baseline chronic obstructive
pulmonary disease in the lung vitamin D and omega-3 trial.
American Journal of Respiratory and Critical Care Medicine
2014;189:D44 COPD.
Kang JH, Grodstein F, Manson JAE. Cognitive substudy
of the vitamin d and omega-3 trial (VITAL-Cog): design
of a large randomized trial of omega-3 and vitamin d
supplements in relation to cognitive change. Alzheimer’s &
Dementia 2015;1:608.
LeBoff MS, Yue AY, Copeland T, Cook NR, Buring JE,
Manson JE. VITAL-bone health: rationale and design of
two ancillary studies evaluating the effects of vitamin D
and/or omega-3 fatty acid supplements on incident fractures
and bone health outcomes in the VITamin D and OmegA-
3 TriaL (VITAL). Contemporary Clinical Trials 2015;41:
259–68.
Manson JAE. Vitamin D and cancer and cardiovascular
disease: ready for prime time?. Menopause 2010;17(6):
63Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1215.
Manson JE. Vitamin D and the heart: why we need large-
scale clinical trials. Cleveland Clinic Journal of Medicine
2010;77(12):903–10.
∗ Manson JE, Bassuk SS, Lee IM, Cook NR, Albert MA,
Gordon D, et al. The VITamin D and omegA-3 TriaL
(VITAL): rationale and design of a large randomized
controlled trial of vitamin D and marine omega-3 fatty
acid supplements for the primary prevention of cancer and
cardiovascular disease. Contemporary Clinical Trials 2012;
33(1):159–71.
Pradhan AD, Manson JE. Update on the Vitamin D and
OmegA-3 trial (VITAL). Journal of Steroid Biochemistry &
Molecular Biology 2016;155(Pt B):252–6.
Weinstock-Guttman 2005 {published data only}
Weinstock-Guttman B, Baier M, Park Y, Feichter J, Lee-
Kwen P, Gallagher E, et al. Low fat dietary intervention with
n-3 fatty acid supplementation in multiple sclerosis patients.
Prostaglandins, Leukotrienes and Essential Fatty Acids 2005;
73:397–404. DOI: 10.1016/j.plefa.2005.05.024
WHI 2006 {published data only}
Anderson G, Cummings S, Freedman LS, Furberg C,
Henderson M, Johnson SR, et al. Design of the Women’s
Health Initiative clinical trial and observational study.
Controlled Clinical Trials 1998;19(1):61–109.
Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis
S, et al. Implementation of the Women’s Health Initiative
study design. Annals of Epidemiology 2003;13(9 Suppl):
S5–17.
Beresford SA, Johnson KC, Ritenbaugh C, Lasser NL,
Snetselaar LG, Black HR, et al. Low-fat dietary pattern and
risk of colorectal cancer: the Women’s Health Initiative
Randomized Controlled Dietary Modification Trial. JAMA
2006;295(6):643–54.
Bowen D, Ehret C, Pedersen M, Snetselaar L, Johnson M,
Tinker L, et al. Results of an adjunct dietary intervention
program in the Women’s Health Initiative. Journal of the
American Dietetic Association 2002;102(11):1631–7.
Carty CL, Kooperberg C, Neuhouser ML, Tinker L,
Howard B, Wactawski-Wende J, et al. Low-fat dietary
pattern and change in body-composition traits in the
Women’s Health Initiative Dietary Modification Trial.
American Journal of Clinical Nutrition 2011;93:516–24.
Curb JD, McTiernan A, Heckbert SR, Kooperberg C,
Stanford J, Nevitt M, et al. Outcomes ascertainment and
adjudication methods in the Women’s Health Initiative.
Annals of Epidemiology 2003;13(9 Suppl):S122–8.
Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M,
Allen C, et al. The Women’s Health Initiative recruitment
methods and results. Annals of Epidemiology 2003;13(9
Suppl):S18–77.
Hebert JR, Patterson RE, Gorfine M, Ebbeling CB, St Jeor
ST, Chlebowski RT, et al. Differences between estimated
caloric requirements and self-reported caloric intake in the
Women’s Health Initiative. Annals of Epidemiology 2003;13
(9):629–37.
Howard BV. Dietary fat and cardiovascular disease: putting
the Women’s Health Initiative in perspective. Nutrition
Metabolism & Cardiovascular Diseases 2007;17(3):171–4.
Howard BV, Manson JE, Stefanick ML, Beresford SA,
Frank G, Jones B, et al. Low-fat dietary pattern and weight
change over 7 years: the Women’s Health Initiative Dietary
Modification Trial. JAMA 2006;295(1):39–49.
∗ Howard BV, Van Horn L, Hsia J, Manson JE, Stefanick
ML, Wassertheil-Smoller S, et al. Low-fat dietary pattern
and risk of cardiovascular disease: the Women’s Health
Initiative Randomized Controlled Dietary Modification
Trial. JAMA 2006;295(6):655–66.
Neuhouser ML, Tinker L, Shaw PA, Schoeller D, Bingham
SA, Horn LV, et al. Use of recovery biomarkers to calibrate
nutrient consumption self-reports in the Women’s Health
Initiative. American Journal of Epidemiology 2008;167(10):
1247–59.
Patterson RE, Kristal A, Rodabough R, Caan B, Lillington
L, Mossavar-Rahmani Y, et al. Changes in food sources
of dietary fat in response to an intensive low-fat dietary
intervention: early results from the Women’s Health
Initiative. Journal of the American Dietetic Association 2003;
103(4):454–60.
Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP,
gurs-Collins T, et al. Measurement characteristics of the
Women’s Health Initiative food frequency questionnaire.
Annals of Epidemiology 1999;9(3):178–87.
Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller
LH, Ockene JK, et al. Low-fat dietary pattern and risk
of invasive breast cancer: the Women’s Health Initiative
Randomized Controlled Dietary Modification Trial. JAMA
2006;295(6):629–42.
Prentice RL, Thomson CA, Caan B, Hubbell FA, Anderson
GL, Beresford SA, et al. Low-fat dietary pattern and
cancer incidence in the Women’s Health Initiative Dietary
Modification Randomized Controlled Trial. Journal of the
National Cancer Institute 2007;99(20):1534–43.
Ritenbaugh C, Patterson RE, Chlebowski RT, Caan B,
Fels-Tinker L, Howard B, et al. The Women’s Health
Initiative Dietary Modification trial: overview and baseline
characteristics of participants. Annals of Epidemiology 2003;
13(9 Suppl):S87–97.
Robinson JG, Wallace R, Safford MM, Pettinger M,
Cochrane B, Ko MG, et al. Another treatment gap:
restarting secondary prevention medications: the Women’s
Health Initiative. Journal of Clinical Lipidology 2010;4:
36–45.
Rossouw JE, Finnegan LP, Harlan WR, Pinn VW, Clifford
C, McGowan JA. The evolution of the Women’s Health
Initiative: perspectives from the NIH. Journal of the
American Medical Women’s Association 1995;50(2):50–5.
The Women’s Health Initiative Study Group. Design of the
Women’s Health Initiative clinical trial and observational
study. Controlled Clinical Trials 1998;19(1):61–109.
Tinker LF, Bonds DE, Margolis KL, Manson JE, Howard
BV, Larson J, et al. Low-fat dietary pattern and risk of
treated diabetes mellitus in postmenopausal women: the
Women’s Health Initiative randomized controlled dietary
64Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
modification trial. Archives of Internal Medicine 2008;168
(14):1500–11.
Tinker LF, Perri MG, Patterson RE, Bowen DJ, McIntosh
M, Parker LM, et al. The effects of physical and emotional
status on adherence to a low-fat dietary pattern in the
Women’s Health Initiative. Journal of the American Dietetic
Association 2002;102(6):789–800.
Tinker LF, Rosal MC, Young AF, Perri MG, Patterson
RE, Van Horn L, et al. Predictors of dietary change and
maintenance in the Women’s Health Initiative Dietary
Modification Trial. Journal of the American Dietetic
Association 2007;107(7):1155–66.
Women’s Health Initiative Study Group. Dietary adherence
in the Women’s Health Initiative Dietary Modification
Trial. Journal of the American Dietetic Association 2004;104
(4):654–8.
Zhang 2016 {published data only}
Zhang YP, Miao R, Li Q, Wu T, Ma F. Effects of DHA
supplementation on hippocampal volume and cognitive
function in older adults with mild cognitive impairment: A
12-month randomized, double-blind, placebo-controlled
trial. Journal of Alzheimer’s Disease 2016;55(2):497–507.
References to ongoing studies
AC Omega3 {published data only}
ACTRN12614000732684. The Aboriginal cardiovascular
omega-3 randomised controlled trial [The effect of omega–3
supplementation on adverse cardiovascular (CV) events
among Indigenous Australians with stable coronary artery
disease: a randomized controlled trial]. www.anzctr.org.au/
Trial/Registration/TrialReview.aspx?id=366337 (date
registered 10 July 2014).
ACTRN12610000594022 {published data only}
ACTRN12610000594022. Fish oil as adjunct therapy for
periodontitis [Clinical efficacy of fish oil as adjunct therapy
for patients with chronic periodontitis]. www.anzctr.org.au/
Trial/Registration/TrialReview.aspx?id=335470 (date
registered 23 July 2010).
ACTRN12613000034730 {published data only}
ACTRN12613000034730. Intervention of testosterone
& fish oil as a possible strategy for the prevention of
Alzheimer’s Disease [A 56 week, double–blind, randomised,
placebo–controlled trial to determine the efficacy of
testosterone, with and without DHA supplementation in
PiB positive men with subjective memory complaints as a
strategy to prevent the development of Alzheimer’s disease].
www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=
363372 (date registered 14 January 2013).
AFORRD {published and unpublished data}
Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil
HA, et al. Atorvastatin in factorial with omega-3 EE90 risk
reduction in diabetes (AFORRD): a randomised controlled
trial. Diabetologia 2009;52(1):50–9.
Neil HA, Ceglarek U, Thiery J, Paul S, Farmer A, Holman
RR. Impact of atorvastatin and omega-3 ethyl esters 90 on
plasma plant sterol concentrations and cholesterol synthesis
in type 2 diabetes: a randomised placebo controlled factorial
trial. Atherosclerosis 2010;213(2):512–7.
Beyond Aging Project {published data only}
Cockayne NL, Duffy SL, Bonomally R, English A,
Amminger PG, Mackinnon A, et al. The Beyond Ageing
Project Phase 2--a double-blind, selective prevention,
randomised, placebo-controlled trial of omega-3 fatty acids
and sertraline in an older age cohort at risk for depression:
study protocol for a randomized controlled trial. Trials
2015;16:247.
Chandrakala 2010 {published data only (unpublished sought but not
used)}
Chandrakala G, Arpana G, Rao PV. Long-term effects
of a reduced fat diet intervention in pre-diabetes.
professional.diabetes.org/meeting/scientific-sessions/70th-
scientific-sessions-2010 (accessed before 11 April 2018).
Chandrakala G, Arpana G, Sreenivas T, Rao PV. Low-fat
(<20%) diets prevent type 2 diabetes mellitus. Diabetes
2012;61:A190.
n-3 for Vascular Cognitive Aging {published data only}
Shinto L, Silbert LC, Dodge HH, Quinn JF, Howieson D,
Kaye J, et al. Omega 3 fatty acids for the prevention of
vascular cognitive aging: methods and rationale for a phase
II trial. Alzheimer’s & Dementia 2015:P2–305.
n-3 on plasma lipid {published data only}
ChiCTR-TRC-12002014. Influence of different
source of n-3 fatty acid on plasma lipid in moderately
hypercholesterolemia subject and the valid dosage.
www.chictr.org.cn/hvshowproject.aspx?id=2374 (date last
refreshed on 3 May 2015).
NCT00309439 {published data only}
NCT00309439. ALA and prostate cancer. clinicaltrials.gov/
ct2/show/NCT00309439 (first posted 31 March 2006).
NCT00410020 {published data only}
NCT00410020. Arrhythmia prevention with an alpha-
linolenic enriched diet. clinicaltrials.gov/ct2/show/
NCT00410020 (first posted 12 December 2006).
NCT01047449 {published data only}
NCT01047449. Improving the results of heart
bypass surgery using new approaches to surgery and
medication (SUPERIORSVG). clinicaltrials.gov/ct2/show/
NCT01047449 (first posted 13 January 2010).
NCT01513252 {published data only}
NCT01513252. Long-term effects of interventional
strategies to prevent cognitive decline in elderly (MAPT-
PLUS). clinicaltrials.gov/ct2/show/NCT01513252 (first
posted 20 January 2012).
NCT01784042 {published data only}
NCT01784042. Dietary energy restriction and omega-3
fatty acids on mammary tissue. clinicaltrials.gov/ct2/show/
NCT01784042 (first posted 5 February 2013).
NCT02128763 {published data only}
NCT02128763. Dry eye assessment andmanagement study
(DREAM). clinicaltrials.gov/ct2/show/NCT02128763
(first posted 1 May 2014).
65Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02211560 {published data only}
NCT02211560. Investigating a phosphatidylserine based
dietary approach for the management of mild cognitive
impairment. clinicaltrials.gov/ct2/show/NCT02211560
(first posted 7 August 2014).
NCT02295059 {published data only}
NCT02295059. Omega 3 fatty acids and ERPR(-)HER2
(+/-) breast cancer prevention. clinicaltrials.gov/ct2/show/
NCT02295059 (first posted 20 November 2014).
NCT02676466 {published data only}
NCT02676466. The ENRGISE pilot study (ENRGISE).
clinicaltrials.gov/ct2/show/NCT02676466 (first posted 8
February 2016).
NCT02719327 {published data only}
NCT02719327. Brain amyloid and vascular effects of
eicosapentaenoic acid (BRAVE-EPA). clinicaltrials.gov/ct2/
show/NCT02719327 (first posted 25 March 2016).
OMEMI {published data only}
Laake K, Myhre P, Nordby LM, Seljeflot I, Abdelnoor M,
Smith P, et al. Effects of omega 3 supplementation in
elderly patients with acute myocardial infarction: design of
a prospective randomized placebo controlled study. BMC
Geriatrics 2014;14:74. http://www.biomedcentral.com/
1471–2318/14/74]
∗ Laake K, Seljeflot I, Schmidt EB, Myhre P, Tveit A,
Arnesen H, et al. Serum fatty acids, traditional risk factors,
and comorbidity as related to myocardial injury in an
elderly population with acute myocardial infarction. Journal
of Lipids 2016;2016:4945720. http://dx.doi.org/10.1155/
2016/4945720]
REDUCE-IT {published data only}
Bhatt DL, Steg G, Brinton EA, Jacobson TA, Miller M,
Tardif J-C, et al. Rationale and design of REDUCE-IT:
Reduction of Cardiovascular Events with Icosapent Ethyl-
Intervention Trial. Clinical Cardiology 2017;40:138–48.
DOI: 10.1002/clc.22692
seAFOOD {published data only}
∗ Hull MA, Sandell AC, Montgomery AA, Logan RF,
Clifford GM, Rees CJ, et al. A randomized controlled
trial of eicosapentaenoic acid and/or aspirin for colorectal
adenoma prevention during colonoscopic surveillance in the
NHS Bowel Cancer Screening Programme (The seAFOod
Polyp Prevention Trial): study protocol for a randomized
controlled trial. Trials 2013;14:237.
ISRCTN05926847. The seAFOod (Systematic
Evaluation of Aspirin and Fish Oil) polyp prevention trial.
www.isrctn.com/ISRCTN05926847 (data assigned 6 May
2011).
UMIN000012825 {published data only}
UMIN000012825. Effect of polysaturated fatty acids on
vascular healing process in hyper-cholesterolemic patients
with acute coronary syndrome. upload.umin.ac.jp/cgi-
open-bin/ctr e/ctr view.cgi?recptno=R000014981 (first
posted 1 February 2014).
Additional references
4S Trial 1994
4S trial authors. Randomised trial of cholesterol lowering in
4444 patients with coronary heart disease: the Scandinavian
Simvastatin Survival Study (4S). Lancet 1994;344(8934):
1383–9.
Abdelhamid 2017
Abdelhamid A, Hooper L, Welch A. Polyunsaturated fatty
acids for musculoskeletal health and functional status in




Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe
GC, Moore HJ, et al. Omega-3 fatty acids for the primary
and secondary prevention of cardiovascular disease.
Cochrane Database of Systematic Reviews 2018, Issue 6.
DOI: 10.1002/14651858.CD003177.pub3
Berkley 1995
Berkley CS, Hoaglin DC, Mosteller F, Colditz GA. A
random-effects regression model for meta-analysis. Statistics
in Medicine 1995;14(4):395–411.
Bhatnagar 2016
Bhatnagar P, Wickramasinghe K, Wilkins E, Townsend N.
Trends in the epidemiology of cardiovascular disease in the
UK. Heart 2016;102:1945–1952. DOI: http://dx.doi.org/
10.1136/heartjnl-2016-309573
Brown 2017
Brown T, Song F, Wang X, Brainard J, Hooper L. Dietary
polyunsaturated fat for prevention and treatment of type 2
diabetes mellitus. PROSPERO 2017:CRD42017064110.
Burr 1989
Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM,
Sweetnam PM, et al. Effects of changes in fat, fish, and
fibre intakes on death and myocardial reinfarction: diet and
reinfarction trial (DART). Lancet 1989;2(8666):757–61.
Calder 2012
Calder PC. Mechanisms of action of (n-3) fatty acids.
Journal of Nutrition 2012;142(3):592S–9S. DOI: 10.3945/
%E2%80%8Bjn.111.155259
Carandang 2006
Carandang R, Seshadri S, Beiser A, Kelly-Hayes M, Kase
CS, Kannel WB, Wolf PA. Trends in incidence, lifetime
risk, severity, and 30-day mortality of stroke over the past
50 years. JAMA 2006;296(24):2939–46. DOI: 10.1001/
jama.296.24.2939
Carlisle 2017
Carlisle JB. Data fabrication and other reasons for non-
random sampling in5087 randomised, controlled trials in
anaesthetic and general medical journals. Anaesthesia 2017;
72:944–952. DOI: 10.1111/anae.13938
de Souza 2015
de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V,
Kishibe T, et al. Intake of saturated and trans unsaturated
fatty acids and risk of all cause mortality, cardiovascular
disease, and type 2 diabetes: systematic review and meta-
66Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
analysis of observational studies. BMJ 2015;351:h3978.
DOI: https://doi.org/10.1136/bmj.h3978
Deeks 2011
Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9:
Analysing data and undertaking meta-analyses. In: Higgins
JPT, Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Feigin 2014
Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah
GA, Connor M, Bennett DA, Moran AE, et al. Global and
regional burden of stroke during 1990-2010: findings from




Friedewald WT, Levy RI, Fredrickson DS. Estimation of
the concentration of low-density lipoprotein cholesterol in
plasma, without use of the preparative ultracentrifuge. Clin
Chem 1972;18(6):499–502.
GRADEpro GDT 2015 [Computer program]
McMaster University (developed by Evidence Prime).
GRADEpro GDT. Version accessed 26 August 2016.
Hamilton (ON): McMaster University (developed by
Evidence Prime), 2015.
Hanson 2017a
Hanson S, Biswas P, Jimoh OF, O’Brien A, Hooper L,
Abdelhamid A, et al. Dietary polyunsaturated fat for
prevention and treatment of depression and anxiety.
PROSPERO 2017:CRD42017056092.
Hanson 2017b
Hanson S, Thorpe G,Winstanley L, Abdelhamid A, Hooper
L. Effects of supplementary dietary polyunsaturated fat on
cancer incidence. PROSPERO 2017:CRD42017056109.
Hegsted 1965
Hegsted DM, McGandy RB, Myers ML, Stare FJ.
Quantitative effects of dietary fat on serum cholesterol in
man. American Journal of Clinical Nutrition 1965;17(5):
281–95.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327:
557–60.
Higgins 2011a
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter
8: Assessing risk of bias in included studies. In: Higgins
JPT, Green S (editors). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Higgins 2011b
Higgins JPT, Deeks JJ, Altman DG (editors). Chapter
16: Special topics in statistics. In: Higgins JPT, Green
S (editors), Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Hooper 2006
Hooper L, Thompson RL, Harrison RA, Summerbell CD,
Ness AR, Moore HJ, et al. Risks and benefits of omega
3 fats for mortality, cardiovascular disease, and cancer:
systematic review. BMJ 2006;322:752. DOI: https://
doi.org/10.1136/bmj.38755.366331.2F
Hooper 2015a
Hooper L, Martin N, Abdelhamid A, Davey Smith G.
Reduction in saturated fat intake for cardiovascular disease.
Cochrane Database of Systematic Reviews 2015, Issue 6.
DOI: 10.1002/14651858.CD011737
Hooper 2015b
Hooper L, Abdelhamid A, Bunn D, Brown T, Summerbell
CD, Skeaff DM. Effects of total fat intake on body weight.
Cochrane Database of Systematic Reviews 2015, Issue 8.
DOI: 10.1002/14651858.CD011834
Hooper 2018
Hooper L, Al-Khudairy L, Abdelhamid AS, Rees K, Brainard
JS, Brown TJ, et al. Omega-6 fats for the prevention and
treatment of cardiovascular disease. Cochrane Database
of Systematic Reviews 2018, Issue 6. DOI: 10.1002/
14651858.CD011094.pub3
Jimoh 2017
Jimoh OF, Brainard J, Deane KA, Biswas P, Donaldson D,
Hooper L. Dietary polyunsaturated fat for prevention and
treatment of neurocognitive disorders. PROSPERO 2017:
CRD42017019049.
Keys 1950
Keys A, Mickelsen O, Miller EVO, Carleton B. The relation
in man between cholesterol levels in the diet and in the
blood. Science 1950;112:79–81.
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching
for studies. In: Higgins JP, Green S, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
Lozano 2012
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K,
Aboyans V, Abraham J, et al. Global and regional mortality
from 235 causes of death for 20 age groups in 1990 and
2010: a systematic analysis for the Global Burden of Disease
Study 2010. Lancet 2012;380:2095–128. DOI: 10.1016/
S0140-6736(12)61728-0.
Moher 2009
Moher D, Liberati A, Tetzlaff J, Altman DG, The
PRISMA Group (2009). Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA
Statement. PLoS 2009;6(7):e1000097. DOI: 10.1371/
journal.pmed1000097
67Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mozaffarian 2010
Mozaffarian D, Micha R, Wallace S. Effects on coronary
heart disease of increasing polyunsaturated fat in place of
saturated fat: a systematic review and meta-analysis of
randomized controlled trials. PLoS Medicine 2010;7(3):
e1000252. DOI: 10.1371/journal.pmed.1000252.
Ohwada 2016
Ohwada T, Yokokawa T, Kanno Y, Hotsuki Y, Sakamoto T,
Watanabe K, et al. Vascular composition data supporting the
role of N-3 polyunsaturated fatty acids in the prevention of
cardiovascular disease events. Data Brief 2016;7:1237–47.
DOI: http://dx.doi.org/10.1016/j.dib.2016.03.101
Oliver 1953
Oliver MF, Boyd GS. The plasma lipids in coronary artery
disease. British Heart Journal 1953;15:387–90.
QRISK 2-2017
ClinRisk Ltd. QRISK®2-2017 risk calculator. qrisk.org/
2017/index.php (accessed before 11 April 2018).
Ramsden 2010
Ramsden CE, Hibbeln JR, Majchrzak SF, Davis JM. N-
6 fatty acid-specific and mixed polyunsaturate dietary
interventions have different effects on CHD risk: a meta-
analysis of randomised controlled trials. British Journal
of Nutrition 2010;104(11):1586–600. DOI: 10.1017/
S0007114510004010
RevMan 2014 [Computer program]
The Cochrane Collaboration. Review Manager 5 (RevMan
5). Version 5.3. Copenhagen: The Nordic Cochrane
Centre: The Cochrane Collaboration, 2014.
Ricci 2018
Ricci C, Baumgartner J, Zec M, Kruger HS, Smuts CM.
Type of dietary fat intakes in relation to all-cause and cause-
specific mortality in US adults: an iso-energetic substitution
analysis from the American National Health and Nutrition
Examination Survey linked to the US mortality registry.
British Journal of Nutrition 2018;119(4):456–63. DOI:
10.1017/S0007114517003889
Roberts 2015
Roberts I, Ker K, Edwards P, Beecher D, Manno D,
Sydenham E. The knowledge system underpinning




Russo GL. Dietary n-6 and n-3 polyunsaturated fatty acids:
from biochemistry to clinical implications in cardiovascular
prevention. Biochemical Pharmacology 2009;77(6):937–46.
Savovic 2012
Savovic J, Jones H, Altman D, Harris R, Jüni P, Pildal J, et
al. Influence of reported study design characteristics on
intervention effect estimates from randomised controlled
trials: combined analysis of meta-epidemiological studies.
Health Technology Assessment 2012;16:1–82.
Schultz 1995
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical
evidence of bias. Dimensions of methodological quality
associated with estimates of treatment effects in controlled
trials. JAMA 1995;273(5):408–12.
Schünemann 2011
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT,
Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting
results and drawing conclusions. In: Higgins JPT, Green
S (editors), Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Sharp 1998
Sharp S. Meta-analysis regression. Stata Technical Bulletin
1998;42:16–22.
Simopoulos 2016
Simopoulos AP. An increase in the omega-6/omega-3 fatty
acid ratio increases the risk for obesity. Nutrients 2016;8(3):
128. DOI: 10.3390/nu8030128
Sterne 2011
Sterne JAC, Egger M, Moher D (editors). Chapter 10:
Addressing reporting biases. In: Higgins JPT, Green S
(editors). Cochrane Handbook for Systematic Reviews
of Interventions. Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from
handbook.cochrane.org.
Thorpe 2017
Thorpe G, Ajabnoor S, Ahmed Z, Abdelhamid A, Hooper
L. Dietary polyunsaturated fat for prevention and treatment
of inflammatory bowel disease. PROSPERO 2017:
CRD42017068704.
WHO 2004
World Health Organization. World Health Statistics.
www3.who.int/whosis 2004.
WHO 2016
World Health Organization. Cardiovascular diseases
(CVDs). Fact sheet number 317. www.who.int/
mediacentre/factsheets/fs317/en/ reviewed June 2016:
(accessed 26 July 2016).
WHO/FAO 2008
Joint FAO/WHO Expert Consultation on Fats, Fatty
Acids in Human Nutrition. Interim summary of
conclusions and dietary recommendations on total
fat & fatty acids. www.who.int/nutrition/topics/
FFA interim recommendations/en/ 10 – 14 November
2008; Vol. WHO, Geneva.
Wood 2008
Wood L, Egger M, Gluud LL, Schulz K, Jüni P, Altman
DG, et al. Empirical evidence of bias in treatment effect
estimates in controlled trials with different interventions
and outcomes: meta-epidemiological study. BMJ 2008;
336:601–5.
References to other published versions of this review
68Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Abdelhamid 2016
Abdelhamid A, Martin N, Bridges C, Song F, Deane
KHO, Hooper L. Polyunsaturated fat intake for
prevention of cardiovascular disease. Cochrane Database
of Systematic Reviews 2016, Issue 9. DOI: 10.1002/
14651858.CD012345
∗ Indicates the major publication for the study
69Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ahn 2016
Methods RCT, parallel, (n3 EPA + DHA versus nil, both with statins), 12 months
Summary risk of bias: moderate or high
Participants Statin-treated CAD patients undergoing PCI
N: 38 intervention, 36 control
Level of risk for CVD: high
Male: 63.2% intervention, 72.2% control
Mean age (SD): 59.6 (9.1) intervention, 60.7 (0.8) [sic] control
Age range: unclear
Smokers: 36.8% intervention, 58.3% control
Hypertension: 50% in both groups
Medications taken by ≥ 50% of those in the control group: aspirin, clopidogrel, ACEi/
ARB, beta blockers, atorvastatin
Medications taken by 20%-49% of those in the control group: cilostazol




Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs unclear (nil)
Intervention: 3 g of ω-3 PUFA containing 1395 mg of EPA and 1125 mg of DHA/d.
No further details
Control: unclear whether control group were given placebo or only statins
Dose aim: increase 2.5 g/d EPA + DHA, 1% E n-3
Baseline PUFA unclear
Compliance by biomarkers: no tissue fatty acids reported, but TC was reduced by 31.
5% in intervention and by 20.9% in the control group, supporting greater PUFA intake
in the intervention arm
Compliance by dietary intake: not reported
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, othermethods: unclear how it was measured but reported good compliance
with no numbers
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Ahn 2016 (Continued)
Inclusion basis: planned dose suggested total PUFA intake 2.5 g/d higher in interven-
tion, or 1.13% E PUFA dose. There were no biomarker or dietary intake data to confirm
this, but greater reductions in TC in the intervention arm supports. > 10% increase from
assumed baseline of 6% E PUFA
PUFA dose: 1.13% E
Length of intervention: 12 months
Outcomes Main trial outcome: change in atherosclerotic burden
Dropouts: none
Available outcomes: lipids (TG reported asmedian , IQR so not used), atheroma volume,
neointimal volume index
Response to contact: contact attempted but no response to date
Notes Trial funding: the trial was supported by clinical research grant from Pusan National
University Hospital
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple randomisation was carried out us-
ing random number tables to assign each
participant to the intervention or control
group
Allocation concealment (selection bias) Low risk Participants were assigned randomisation
numbers sequentially on recruitment to the
trial, and the randomisation codes were re-
tained by the clinical research co-ordinator
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The personnel responsible for randomisa-
tion as well as those performing labora-
torymeasurements were blinded to the ran-
domisation assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts reported
Selective reporting (reporting bias) Unclear risk No protocol or trial register entry found
Attention bias Unclear risk No details
Compliance Low risk No fatty acid levels reported, but TC lower
in higher PUFA arm
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Ahn 2016 (Continued)
Other bias High risk It’s unclear whether the trial was placebo
controlled or the control group had no in-
tervention. Also, some of the SDs appear
to be incorrectly reported
AlphaOmega - ALA
Methods RCT, 2 x 2 (n3 ALA vs MUFA), 40 months
Summary risk of bias: low
Participants 60-80 year olds with previous MI
N: intervention 2409 (1197 ALA, 1212 ALA + EPA + DHA), control 2428 (1236
MUFA, 1192 EPA + DHA). All analysed in ITT analysis
Level of risk for CVD: high
Male: 77.9% intervention, 78.7% control
Mean age (SD): 69.0 (5.6) intervention, 68.9 (5.6) control
Age range: 60-80 years
Smokers: 17.4% intervention, 18% control
Hypertension: unclear
Medications taken by ≥ 50% of those in the control group: lipid-lowering medication,
antihypertensives, antithrombotics
Medications taken by 20%-49% of those in the control group: not reported




Interventions Type: supplementary margarine
Comparsion: ALA vs MUFA
Intervention: 20 g/d of enriched margarine incorporating: 2 g ALA. 8 x 250 g margarine
tubs delivered every 12 weeks
Control: 20 g/d of margarine. No additional n-3 PUFAs. Identical margarine (oleic acid)
placebo
Dose aim: increase 2 g/d, 1% E n-3
Baseline PUFA unclear
Compliance by biomarkers: plasma cholesteryl esters had clearly higher ALA in the
two ALA arms, no data for total PUFA, no serum TC reported post-baseline
Compliance by dietary intake:margarine composition data - summing LA, ALA, EPA,
DPA and DHA total PUFA dose in ALA margarine (compared to placebo) was +14.4%
E. As planned intake was 20 g/d, intake was 2.88 g/d total PUFA, or 1.3% E from total
PUFA. Total PUFA in ALA + EPA + DHA (compared to EPA + DHA margarine) was
11.3% E, or 2.26 g/d total PUFA, 1.02% E total PUFA
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
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AlphaOmega - ALA (Continued)
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other methods: unused margarine tubs were returned- daily intakes of
margarine and n-3 fatty acids were calculated on the basis of the amount unused. Ad-
herence was measured by levels of fatty acids in plasma cholesteryl esters, margarine and
questionnaires. 90.5% of participants adhered to the protocol and consumed 20.6 (2.8)
g/d of margarine
Inclusion basis: planned total PUFA intake 1.02 and 1.30% E higher in control than
intervention, > 10% higher than assumed 6% E from total PUFA at baseline
PUFA dose: 1.02% E in ALA + EPA +DHA vs EPA +DHA, 1.3% E in ALAmargarine
vs placebo margarine
Duration of intervention: 40 months
Outcomes Main trial outcome: CVD events
Dropouts: 91 died, 98 discontinued intervention, 93 died, 93 discontinued control
Available outcomes: deaths, MI, CVD events, VF/VT, incident CVD
Response to contact: yes (data provided)
Notes This is a 2 x 2 trial, using ALA margarine vs MUFA margarine (this part) and EPA/
DHA margarine vs MUFA margarine (the next trial). The 4 arms were ALA margarine,
EPA/DHA margarine, mixture of the 2 interventions and MUFA margarine. This ta-
ble represents the AL- only intervention. Where possible data represent the full trial
population for each comparison (ALA margarine plus combined intervention vs MUFA
margarine plus EPA/DHA margarine). As this review assesses effects of total PUFA, and
doses of total PUFA were higher in the ALA arms we have omitted the EPA/DHA data
when pooling would otherwise have meant that each participant was represented twice
in meta-analysis
Trial funding:NetherlandsHeart Foundation,National Institutes ofHealth andUnilever
R&D (latter provided unrestricted grant for distribution of trial margarines)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk On the computer by a random-number
generator before the start of the trial
Allocation concealment (selection bias) Low risk Trial author confirmed allocation was con-
cealed from clinicians/ researchers
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The 4 types of margarine were “similar in
taste, texture and colour”. A trained test
panel did not perceive a fishy taste or odour.
Randomisation tables were stored safely
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AlphaOmega - ALA (Continued)
under supervision
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation tables were stored safely
under supervision. There was an indepen-
dent statistician for data analysis
Quote: “Events were coded by three mem-
bers of the end-point adjudication commit-
tee who were unaware of the identity of the
patient, the identity of the treating physi-
cian and the patients assigned study group”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were followed up for
events. Computerised linkage with munic-
ipal registries. 2531 participants were only
followed up for baseline anthropometric
and medical measurements
Selective reporting (reporting bias) High risk Sudden cardiac death endpoint omitted.
Registered in August 2005, recruitment
was from 2002-2006. Outcomes papers
published in 2010
Attention bias Low risk All participants appear to have had simi-
lar frequency and quantity of attention and
follow-up
Compliance Unclear risk Only plasma cholesteryl esters of ALAwere
reported and were higher in intervention
arms (unclear regarding total PUFA), no
TC reported
Other bias Low risk None noted
Bassey 2000-Post
Methods RCT, (high PUFA GLA+DHA+EPA vs low PUFA, both with Ca), 12 months
Summary risk of bias: moderate or high
Participants Healthy postmenopausal women
N: 21 intervention, 24 control (total randomised 57)
Level of risk for CVD: low
Male: 0% intervention, 0% control
Mean age (SD): 58 (4.6) intervention, 55 (4.6) control
Age range: 50-65 years (inclusion)
Smokers: 20.8% intervention, 19% control
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
74Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bassey 2000-Post (Continued)
Medications taken by some, but < 20% of the control group: not reported (Women on




Comparsion: evening primrose oil + fish oil vs nil
Intervention 10 large capsules/d of efacal (Ca 1.0 g, evening primrose oil 4.0 g (85% or
3.4 g/d PUFA) and marine fish oil 440 mg), divided in doses with meals
Control: large capsules of 1 g Ca
Dose aim: increase ~3.5 g/d PUFA, 1.6% E PUFA
Baseline PUFA unclear
Compliance by biomarkers: neither biomarkers nor TC data reported
Compliance by dietary intake: not reported
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other methods: assessed by counting returned capsules at each visit, re-
ported compliance > 90%
Inclusion basis: no intention to increase total PUFA, planned dose ~3.5 g/d PUFA, 1.
6% E PUFA, > 10% higher than assumed 6% E from total PUFA at baseline
PUFA dose: 1.6% E PUFA
Length of intervention: 12 months
Outcomes Main trial outcome: BMD
Dropouts: 23% (unclear by arm)
Available outcomes: weight
Response to contact: not attempted
Notes Trial funding: Scotia Pharmaceuticals Plc, Guildford, UK
Mortality reported (1 death but unclear in which arm)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “women were randomized by staff
at Scotia Pharmaceuticals Plc”
Allocation concealment (selection bias) Unclear risk No details
75Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bassey 2000-Post (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind stated but no further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessors were blinded for the BMD mea-
surements but unclear for other outcomes
Incomplete outcome data (attrition bias)
All outcomes
High risk 23%were lost to follow-up, unclear by arm
and not all were accounted for
Selective reporting (reporting bias) Unclear risk No protocol or trial registry record
Attention bias Low risk No difference was noted for intervention/
control groups
Compliance Unclear risk Neither biomarkers nor TC data reported
Other bias Low risk None noted
Bassey 2000-Pre
Methods RCT, (high PUFA GLA+DHA+EPA vs low PUFA, both with Ca), 12 months
Summary risk of bias: moderate or high
Participants Healthy pre-menopausal women
N: 19 intervention, 24 control (total randomised 64)
Level of risk for CVD: low
Male: 0% intervention, 0% control
Mean age (SD): 34 (4.4) intervention, 35 (4.9) control
Age range: 25-40 years (inclusion)
Smokers: 0% intervention, 0% control
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported (Women on




Comparsion: evening primrose oil + fish oil vs nil
Intervention 10 large capsules/d of efacal (Ca 1.0 g, evening primrose oil 4.0 g and
marine fish oil 440 mg), divided in doses with meals
Control: large capsules of 1 g Ca
Dose aim: increase ~3.5 g/d PUFA, 1.6% E PUFA
Baseline PUFA unclear
Compliance by biomarkers: neither biomarkers nor TC data reported
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Bassey 2000-Pre (Continued)
Compliance by dietary intake: not reported
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other methods: assessed by counting returned capsules at each visit, re-
ported compliance > 90% (median > 9 capsules/d in both treatment and control groups)
Inclusion basis: no intention to increase total PUFA, planned dose ~3.5 g/d PUFA, 1.
6% E PUFA, > 10% higher than assumed 6% E from total PUFA at baseline
PUFA dose: 1.6% E PUFA
Length of intervention: 12 months
Outcomes Main trial outcome: BMD
Dropouts: 31% (unclear by arm)
Available outcomes: weight
Response to contact: not attempted
Notes Trial funding: Scotia Pharmaceuticals Plc, Guildford, UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “women were randomized by staff
at Scotia Pharmaceuticals Plc”
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind stated but no further details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessors were blinded for the BMD mea-
surements but unclear for other outcomes
Incomplete outcome data (attrition bias)
All outcomes
High risk 31%were lost to follow-up, unclear by arm
and not all were accounted for
Selective reporting (reporting bias) Unclear risk No protocol or trial registry record
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Bassey 2000-Pre (Continued)
Attention bias Low risk No difference was noted for intervention/
control groups
Compliance Unclear risk Neither biomarkers nor TC data reported
Other bias Low risk None noted
Bates 1977
Methods RCT, parallel, 4 arms (n6 GLA+LA vs MUFA), 2 years
Summary risk of bias: moderate to high
Participants People with chronic progressive multiple sclerosis
CVD risk: low
N; intervention A, C: 38 per arm; control B, D: 38 per arm
Mean years in trial: 2
% male: unclear (no statistically significant difference between groups)




Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported




Comparison: GLA + linoleic (n6) vs oleic (MUFA)
Intervention aims A: increase PUFAs with addition of 8 x 0.6 mL/d of Naudicelle oil in
capsules (360 mg/d GLA plus 3.42 g/d linoleic acid plus < 1% ALA)
Control aims B: increase MUFAs with addition of 8 x 0.6 mL/d of oleic acid in capsules
(4.8 g oleic acid/d)
A vs B dose aim: increase 0.34 g/d GLA, 3.78 g/d or 34 kcal or 1.7% E n-6
Intervention aims C: increase linoleic acid with addition of 11.5 g/d in a spread
Control aims D: increase oleic acid with addition of 4 g/d in a spread
C vs D dose aim: increase 11.5 g/d or 104 kcal or 5% E n-6
Baseline PUFA: unclear
Compliance by biomarkers: unclear, no serum TC reported, no tissue fatty acids re-
ported
Compliance by dietary intake assessment: unclear, not reported
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
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Bates 1977 (Continued)
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other methods: not reported
Inclusion basis: aimed to increase total PUFA intake
PUFA dose: A vs B 1.7% E PUFA, C vs D 5% E PUFA
Duration of intervention: 2 years
Outcomes Main trial outcome: progression or regression of multiple sclerosis
Dropouts: unclear in all arms (deaths and dropouts reported together)
Available outcomes: multiple sclerosis progression (deaths occurred but reported with
dropouts, so numbers and arms unclear)
Response to contact: yes, Professor Bates stated that data on mortality are no longer
available
Notes Trial funding: Multiple Sclerosis Society, Van den Berghs provided intervention and
control spreads free
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly allocated”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Paper states “double blind”, capsules of
“identical appearance” and “similar spread”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Paper states “double blind” with no further
details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Deaths and dropouts combined, no reasons
for dropping out provided
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry located
Attention bias Low risk Capsules and spreads provided to all par-
ticipants, no suggestion of attention bias
Compliance Unclear risk Neither tissue PUFA biomarkers nor TC
data reported
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Bates 1977 (Continued)
Other bias Low risk None found
Bates 1978
Methods RCT, parallel, 2 arms (n6 GLA+LA vs MUFA), using supplements (further 2 arms of
n6 LA vs MUFA using supplementary foods not included as no outcome data), 2 years
Summary risk of bias: moderate to high
Participants People with acute remitting multiple sclerosis
CVD risk: low
N; intervention A, C: 29 per arm; control B, D: 29 per arm
Mean years in trial: 2
% male: intervention A 34.48%; intervention C 17.24%; control B 34.48%; control D
37.93%





Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported




Comparison: GLA and linoleic (n6) vs oleic (MUFA)
Intervention aims A: 8 x Naudicelle capsules/d, 2.92 g/d LA plus 0.34 g/d GLA
Control aims B: 8 x capsules/d (4 g/d oleic acid), 4 g/d MUFA
A vs B dose aim: increase 0.34 g/d GLA, 3.26 g/d or 29 kcal or 1.5% E n-6
Intervention aims C: linoleic acid spread (23 g/d linoleic acid)
Control aims D: oleic acid spread (16 g/d oleic acid)
C vs D dose aim: increase 23 g/d LA or 207 kcal or 10.4% E n-6
Baseline PUFA: unclear
Compliance by biomarkers: good for C vs D, poor for A vs B, no serum TC reported,
“estimations of total fatty acids in patients before and after 12-24 months’ treatment
showed that the percentage of linoleic and arachidonic acids increased significantly only
in those patients taking the linoleic acid spread (group C)”
Compliance by dietary intake: unclear, not reported
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
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Bates 1978 (Continued)
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other methods: not reported
Inclusion basis: aimed to increase PUFA intake, but C vs D had no outcome data so
was excluded
PUFA dose: A vs B 1.5% E PUFA, C vs D 10.4% E PUFA (assumed from omega-6
doses)
Duration of intervention: 2 years
Outcomes Main trial outcome: progression or regression of multiple sclerosis
Dropouts: A 0, B 1, C 3, D 6
Available outcomes: multiple sclerosis progression, deaths (nil in arms A, C and D)
Response to contact: contact with Dr Bates
Notes Trial funding: Multiple Sclerosis Society, Van den Berghs provided intervention and
control spreads free
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly allocated”
Allocation concealment (selection bias) Unclear risk Quote: ”randomly allocated”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Paper states “double blind”, capsules of
“identical appearance” and “similar spread”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Paper states “double blind” with no further
details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Fairly well described, from 0-6 dropouts
per arm over 2 years (each 29 randomised)
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry located
Attention bias Low risk Appears equivalent
Compliance High risk No serum TC reported. Paper reports
Quote: “estimations of total fatty acids in
patients before and after 12-24 months’
treatment showed that the percentage of
linoleic and arachidonic acids increased sig-
nificantly only in those patients taking the
linoleic acid spread (group C)”
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Bates 1978 (Continued)
Only A vs B had outcomes for this review,
data suggests poor compliance in this group
Other bias Low risk None found
Bates 1989
Methods RCT, parallel, (n3 EPA + DHA vs MUFA), 24 months
Summary risk of bias: moderate or high
Participants People with multiple sclerosis
N: 155 intervention, 157 control (analysed, int: 145 cont: 147)
Level of risk for CVD: low
Male: 34.2% intervention, 30.6% control
Mean age (SD): 34.0 (6.6) intervention, 33.7 (6.3) control
Age range: not reported but 16-45 years inclusion criteria
Smokers: not reported
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49%: not reported
Medications taken by some, but < 20%: not reported
Location: UK
Ethnicity: not reported
Interventions Type: supplement (fish oil capsule)
Comparison: EPA + DHA vs MUFA
Intervention: 20 x 0.5 g/d capsules MaxEPA fish body oil (10 g/d fish oil providing 1.
71 g/d EPA + 1.14 g/d DHA + 10 IU/d vitamin E), plus all advised to reduce animal fat
and ensure plentiful omega-6 fats. EPA + DHA 2.85 g/d
Control: 20 x 0.5 g/d capsules olive oil (10 g/d olive oil), plus all advised to reduce animal
fat and ensure plentiful omega-6 fats. All capsules contained 0.5 IU vitamin E and 100
ppm dodecylgallate to minimise peroxide formation
Dose aim: intervention increase 2.85 g/d EPA + DHA, 1.3% E n-3, omega-6 dose
unclear. Control assumed to have similar PUFA content to intervention, apart from EPA
+ DHA, dose 1.3% E PUFA
Baseline PUFA not reported
Compliance by biomarkers: adding serum EPA, DHA, LA and AA intervention 51.
5% PUFA, control 47.6% PUFA. TC not reported
Compliance using dietary assessment: not reported
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
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Bates 1989 (Continued)
• Sugars intake: not reported
• Protein intake: intervention 1.07 g/kg/d (0.10), control 1.10 g/kg/d (0.07)
• Alcohol intake: not reported
Compliance, other measures: not reported
Inclusion basis: intended doses suggested total PUFA intake 1.3% E higher in inter-
vention than control > 10% more than assumed 6% E PUFA at baseline
PUFA dose: 1.3% E
Duration of intervention: 24 months (5 years mentioned but outcomes not reported)
Outcomes Main trial outcome: multiple sclerosis progress
Dropouts: 10 intervention, 10 control
Available outcomes: all-cause mortality, progress of multiple sclerosis, rate of multiple
sclerosis relapse
Response to contact: yes (no data provided)
Notes Trial funding: Multiple Sclerosis Society of Great Britain and Northern Ireland but
Marfleet Refining provided fish oil and placebo capsules
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised”
Allocation concealment (selection bias) Unclear risk No further details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Paper states research was “double blind”
and control capsules
Quote: “had the same appearance and
flavour as the fish oil capsules and were
packed and dispensed in identical fashion”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low risk at reported time points
Selective reporting (reporting bias) High risk No protocol or trials registration entries
found. Trial was intended to run for 5 years,
but outcomes only appear to be reported
for the first 2 years
Attention bias Low risk Unlikely as each had capsules
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Bates 1989 (Continued)
Compliance Low risk Adding serum EPA, DHA, LA and AA in-
tervention 51.5% PUFA, control 47.6%
PUFA. TC not reported
Other bias Low risk Not noted
Black 1994
Methods RCT, parallel, (low fat diet vs usual diet), 24 months
Summary risk of bias: moderate or high
Participants People with non-melanoma skin cancer
N: 66 intervention, 67 control (analysed, 57 int, 58 cont)
Level of risk for CVD: low
Male: 54% intervention, 67% control
Mean age (SD): 50.6 (9.7) intervention, 52.3 (13.2) control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: USA
Ethnicity: white 100% (excluded from trial if of Asian, Black, Hispanic or American
Indian ancestry)
Interventions Type: dietary advice
Comparison: reduced fat (lower omega-6 and total PUFA) vs usual diet
Intervention: aims total fat 20% E, protein 15% E, CHO 65% E; methods 8 x weekly
classes plus monthly follow-up sessions, with behavioural techniques being taught fol-
lowing individual approach (not clear if in a group or individual). 4-month intervals
clinic examination by dermatologist. Intervention delivered face to face by a dietitian
Control: aims usual diet; methods no dietary change, 4-month intervals clinic examina-
tion by dermatologist
Dose aim: reduce total fat to 20% E, 15% E protein, 65% ECHO, particularly complex
CHO (fat reduction included reducing omega-6 and total PUFA, no aim provided)
Baseline PUFA 8% E
Compliance by biomarkers: unclear, no serum TC reported, no tissue fatty acids
Compliance by dietary intake: all assessed “during study”, months 4-24, using 7-day
food records verified by a dietitian
• Energy intake, kcal/d: control 2196 (SD 615), intervention 1995 (SD 564)
• Total fat intake, % E: control 37.8 (SD 4.1), intervention 20.7 (SD 5.5) (MD -
17.10, 95% CI -18.88 to -15.320 significant reduction
• SFA intake, % E: control 12.8 (SD 2.0), intervention 6.6 (SD 1.8), (MD -6.20,
95% CI -6.90 to -5.50) significant reduction
• PUFA intake, % E: control 7.8 (SD 1.4), intervention 4.5 (SD 1.3), (MD -3.30,
95% CI -3.79 to -2.81) significant reduction
• PUFA n-3 intake: not reported
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Black 1994 (Continued)
• PUFA n-6 intake: LA, Control 16.9 (SD 5.6) g, intervention 8.5 (SD 3.3) g
• Trans fat intake: not reported
• MUFA intake, % E: control 14.4 (SD 1.7), intervention 7.6 (SD 2.2), (MD -6.
80, 95% CI -7.52 to -6.08) significant reduction
• CHO intake, % E: control 44.6 (SD 6.9), intervention 60.3 (SD 6.3), (MD 15.
70, 95% CI 13.29 to 18.11) significant increase
• Sugars intake: not reported
• Protein intake, % E: control 15.7 (SD 2.4), intervention 17.7 (SD 2.2), (MD 2.
00, 95% CI 1.16 to 2.84) significant increase
• Alcohol intake, % E: control 3.2 (SD 3.9), intervention 3.2 (SD 3.4)
Inclusion basis: dietary intake data suggested total PUFA intake 3.3% E higher in
control than intervention
PUFA dose: -3.3% E
Duration of intervention: 24 months (mean 1.9 years in trial)
Outcomes Main trial outcome: incidence of actinic keratosis and non-melanoma skin cancer
Dropouts: unclear intervention, unclear control
Available outcomes: deaths, CVD deaths, cancer deaths (none), (weight data provided
but without variance)
Response to contact: Prof Black provided data on mortality
Notes Trial funding: National Cancer Institute
NOTE: for this trial the higher PUFA arm is the control, and lower PUFA arm is the
intervention
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “list of randomly generated numbers”
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Dietary advice provided, so participants
not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “examined .... by dermatologists unaware
of their treatment assignments”. Deaths
(all-cause and CVD) not considered rele-
vant to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk For mortality. Unclear for other outcomes
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry found
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Attention bias High risk Weekly classes and monthly follow-up in
intervention group, 4-monthly check-ups
only in control
Compliance Unclear risk Neither tissue PUFA biomarkers nor TC
data reported
Other bias Low risk None noted
Brox 2001
Methods RCT, parallel, 3 arms (n3 EPA + DHA from cod liver oil vs n3 EPA + DHA from seal
oil vs nil), 14 months
Summary risk of bias: moderate or high
Participants People with moderate hypercholesterolaemia
N: 40 seal oil (SO), 40 cod liver oil, 40 control (numbers analysed vary by outcome)
Level of risk for CVD: moderate (dyslipidaemia)
Male: 53% seal oil, 50% cod liver oil, 48% control




Medications taken by ≥ 50% of those in the control group: none allowed
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: Norway
Ethnicity: not reported
Interventions Type: supplement (oil)
Comparison: EPA + DHA vs nil
Intervention: intervention: seal oil, 15 mL/d (2.6 g, 1.1 g/d EPA + 1.5 g/d DHA) (total
n-3 3.9 g/d, total PUFA 4.2 g/d): EPA + DHA 2.6 g/d
Cod liver oil, 15 mL/d (3.3 g, 1.5 g/d EPA + 1.8 g/d DHA) (total n-3 4.1 g/d, total
PUFA 4.35 g/d): EPA + DHA 3.3 g/d
Control: nil, no supplement
PUFA dose seal oil aim: (intended) increase 2.6 g/d EPA + DHA, 1.2% E n-3, 1.9%
E PUFA
PUFA dose cod liver oil aim: (intended) increase 3.3 g/d EPA + DHA, 1.5% E n-3,
2.0% E PUFA
Baseline PUFA unclear
Compliance by biomarkers: serum omega-3 fatty acids, rose from around 1 mmol/L to
2.4 (seal oil), 2.1 (cod liver oil) and 1.2 mmol/L (control). Latest total PUFA in serum
was 10.3 mmol/L seal oil, 9.9 mmol/L cod liver oil, 7.3 mmol/L control. Serum TC
reported in intervention arms but not control, fell from 8.2 mmol/L at baseline to 7.8
mmol/L at 14 months in seal oil, 8.3 to 8.0 in cod liver oil (further data provided by
trial authors)
Compliance by dietary intake: not reported
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Brox 2001 (Continued)
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other measures: no other data
Inclusion basis: intended dose appeared to be 1.9% or 2.0% increase in intervention
arms compared to control, > 10% greater intake than the assumed 6% E from PUFA at
baseline. Supported by serum fatty acid composition being higher in both intervention
arms at 14 months than the control arm
PUFA dose: 1.9% E SO, 2.0% E CLO
Length of intervention: 14 months
Outcomes Main trial outcome: serum lipids
Dropouts: 8 seal oil, 2 cod liver oil, 1 control
Available outcomes: total and CV deaths, MI, combined CV events, TC, TG and HDL,
adverse events (no stroke or SCD occurred, weight reported but too different at baseline
and only reported to 6 months, data also provided by trial authors on apolipoproteins
A1 and B, and Lp(a), but not used)
Response to contact: yes (trial author providedmethodological details and outcome data)
Notes Data of 2 intervention groups combined for dichotomous outcomes and cod liver oil vs
control data used for continuous outcomes
Trial funding: the trial was supported by the program Medical Research in Finnmark
County, University of Tromsø
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk J Brox stated (personal communication,
January 2017)
Quote: ”The randomisation of the 120 par-
ticipants was done by first generating 3
groups (seal oil, cod liver oil, control), then
giving each participant a number (1-120)
, putting all the numbers into the same
hat and blindly drawing one number at the
time from the hat. The first 40 numbers (1-
40) were allocated to the seal oil group, the
next 40 numbers (41-80) to the cod liver
oil group and the rest (81-120) were allo-
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Brox 2001 (Continued)
cated to the control group.“
Allocation concealment (selection bias) Low risk J Brox stated (personal communication,
January 2017)
Quote: ”The researcher/clinician who in-
vited the participants had no knowledge of
to which group the participants would be
allocated“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ”controls were aware - not given a
supplement“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk J Brox stated (personal communication,
2003)
Quote: ”All the persons involved in
the drawing & analysing of blood were
unaware of treatment. The technicians
analysing the blood did not have any per-
sonal contact with the participants except
K. Olaussen who did the FA analysis… she
only had access to the sample numbers not
names and code. The participants did not
know their number” [says elsewhere that K
Olaussen did not know allocations]. “The
only assessor was J Brox who did not have
any personal contact with the participants,
had nothing to do with the randomising or
analysing process, or the collecting of re-
sults.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Seal oil group 10 dropouts, cod liver oil
3 dropouts, control group 3 dropouts. So
substantial differences in rates of dropouts
between the groups
Selective reporting (reporting bias) Unclear risk No trial protocol or trials register entry was
found.
Attention bias Low risk No suggestion of differential attention
Compliance Low risk Latest total PUFA in serum was 10.3
mmol/L seal oil, 9.9 mmol/L cod liver oil,
7.3 mmol/L control. Serum TC reported
in intervention arms but not control
Other bias Low risk No further bias noted
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DART fat 1989
Methods Diet And Reinfarction Trial (DART)
RCT, 2 x 2 x 2 factorial (n6 LA vs mixed fats), also increased fish and increased fibre
arms, 2 years
Summary risk of bias: moderate to high
Participants Men recovering from an MI
CVD risk: high
N: intervention: randomised 1018, analysed unclear; control: randomised 1015, analysed
unclear
Mean years in trial: control 1.9, randomised 1.9
% male: 100%
Age: mean control 56.8, intervention 56.4 years
Age range: all < 70 years
Smokers: control 62.7%, intervention 61.2%
Hypertension: intervention 24%, control 23.3%
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: beta-blockers, other anti-
hypertensives, anti-anginals
Medications taken by some, but < 20% of the control group: anti-coagulant, aspirin,
other anti-platelet, digoxin, other cardiac drugs
Location: UK
Ethenicty: not reported
Interventions Type: dietary advice
Comparison: polyunsaturated oil and margarines (n6) vs usual dietary fats (SFA)
Intervention aims: reduce fat intake to 30% E, increase polyunsaturated to saturated
ratio (P/S) to 1.0 (using polyunsaturated oils and margarines), weight-reducing advice
if BMI > 30 (dietitians provided the participants and their wives with initial individual
advice and a diet information sheet, participants were revisited for further advice, recipes,
encouragement at 1, 3, 6, 9, 12, 15, 18 and 21 months)
Control aims: no dietary advice on fat, weight-reducing advice if BMI > 30 (dietitians
provided ’sensible eating’ advice without specific information on fats)
Dose aim: unclear
Baseline n-6: unclear, but control PUFA intake 6.8% E
Compliance by biomarkers: good, serum TC significantly reduced in intervention
compared to control (-0.26 mmol/L, 95% CI -0.37 to -0.15)
Compliance by dietary intake: assessed using a 7-day weighted food diary, of a 25%
random subsample
• Energy intake, MJ/d: intervention 7.3 (SD 1.8), control 7.7 (SD 1.9)
• Total fat intake, % E: intervention 31 (SD 7), control 35 (SD 6)
• SFA intake: intervention 11% E (SD 3), control 15% E (SD 3), dose -4% E
• PUFA intake: intervention 9.4% E, control 6.6% E, dose +2.8% E (most of
which omega-6)
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported, but PUFA/SFA ratio was 0.85 (SD 0.33) in
intervention, implying PUFA of 9.4% E. In control ratio was 0.45 (SD 0.24),
implying PUFA of 6.8% E
• Trans fat intake: not reported
• MUFA intake: not reported
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DART fat 1989 (Continued)
• CHO intake: intervention 46% E (SD 7), control 44% E (SD 6)
• Sugars intake: not reported
• Protein intake: % E: intervention 18 (SD 4), control 17 (SD 4)
• Alcohol intake: intervention 5% E (SD 6), control 4% E (SD 6)
Compliance, other measures: no other data
Inclusion basis: intended to increase PUFA/SFA ratio, as well as reduce total fat. TC
was lower in intervention than control, and intake data suggest PUFA intake higher by
2.8% E in intervention than control, > 10% greater than baseline of 6.8% E
PUFA dose: 2.8% E
Duration of intervention: 2 years
Outcomes Main trial outcomes: mortality, reinfarction
Dropouts: all followed for events regardless of compliance (ITT)
Available outcomes: CV events (CV deaths plus non-fatal MI), cancer deaths, total MI,
non-fatal MI, TC, HDL
Response to contact: yes, Professor Burr provided additional data and information on
methodology
Notes Note: this was a 2 x 2 x 2 factorial trial, and so some in each group were randomised to
increased fatty fish and/or increased cereal fibre
Trial funding: Welsh Scheme for Development of Health and Social Research, Welsh
Heart Research Foundation, Flora Project (commercial), Health Promotion Research
Trust
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using sealed envelopes
Allocation concealment (selection bias) Unclear risk Unclear if envelopes were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Very difficult to blind trials where par-
ticipants need to make their own dietary
changes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “outcome assessors were not aware
of study allocation” (Prof Burr, personal
communication)
Method of blinding not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk GPs contacted for information on mortal-
ity and morbidity when participants did
not attend, data collected from mortality
register
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry located
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DART fat 1989 (Continued)
Attention bias High risk Those given dietary advice almost certainly
givenmore time and attention than those in
the control group (with no dietary advice)
Compliance Low risk TC significantly reduced in intervention
compared to control (-0.26 mmol/L, 95%
CI -0.37 to -0.15)
Other bias Low risk None found
DIPP-Tokudome 2015
Methods Dietary Intervention for Patients Polypectomized for tumours of the colorectum (DIPP)
RCT, parallel, 2 arms (n3 EPA + DHA + ALA vs nil), 24 months
Summary risk of bias: moderate or high
Participants Poeple previously polypectomised for colorectal tumours
N: 104 intervention, 101 control
Level of risk for CVD: low
Male: 73.1% intervention, 74.3% control
Mean age (SD): 58.3 (9.5) intervention, 59.7 (8.9) control
Age range: 35-75
Smokers: 65.4% intervention, 61.4% control
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: supplements
Medications taken by 20%-49% of those in the control group: none
Medications taken by some, but < 20% of the control group: oral contraceptive pills
Location: Japan
Ethnicity: not reported
Interventions Type: advice plus supplement (fish oil capsules)
Comparison: n3 EPA + DHA + ALA vs nil
Intervention: advice to reduce total fat intake, decrease consumption of n-6 PUFAs,
increase intake of n-3 PUFAs from fish/marine foods, increase intake of n-3 PUFAs from
perilla oil rich in ALA, and take 8 capsules of fish oil/day (equivalent to 96 mg/day of
EPA and 360 mg/day of DHA)
Control: advice to decrease intake of fats/oils as a whole
Dose aim: increase 0.46 g/d EPA + DHA plus EPA + DHA from fish plus ALA from
perilla, unclearn3, unclear PUFA
Baseline PUFA: unclear but control 6.3% E PUFA
Compliance by biomarkers: plasma fatty acid concentrations, fatty acid compositions
in the membranes of red blood cells and the sigmoid colon. Plasma fatty acids suggested
higher total PUFA intakes in intervention group (at 24 months 4.91 mmol/L, SD 1.23
in intervention group, 4.59 mmol/L, SD 0.76 in control). But TC higher in intervention
(5.52 mmol/L, SD 0.9) than control (5.40 mmol/L, SD 0.79) at 24 months
Compliance by dietary intake: assessed using semi-quantitative food frequency ques-
tionnaire
• Energy intake, kcal/d: intervention 2268 (SD 535), control 2131 (SD 563)
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DIPP-Tokudome 2015 (Continued)
• Total fat intake, g/1000 kcal: intervention 28.4 (SD 5.1), control 28.07 (SD 6.27)
• SFA intake, g/1000 kcal: intervention 7.02 (SD 1.74), control 7.27 (SD 2.03)
• PUFA intake, % E: intervention 7.4, control 6.3
• PUFA n-3 intake, g/1000 kcal: intervention 3.24 (SD 1.15), control 1.49 (SD 0.
39)
• PUFA n-6 intake, g/1000 kcal: intervention 4.38 (SD 1.01), control 4.90 (SD 1.
46)
• Trans fat intake: not reported
• MUFA intake, g/1000 kcal: intervention 9.07 (SD 2.05), control 10.09 (SD 2.67)
• CHO intake, g/1000 kcal: intervention 129.5 (SD 15.8), control 133.96 (SD 17.
98)
• Sugars intake: not reported
• Protein intake, g/1000 kcal: intervention 39.0 (SD 5.6), control 36.6 (SD 5.72)
• Alcohol intake: not reported
Compliance, other measures: none
Inclusion basis: no intention to increase total PUFA. Intention was to increase omega-
3 but dose unclear. Total PUFA intakes were higher in intervention than control by 1.
1%E, > 10% more than control
PUFA dose: 1.1% E
Length of intervention: 24 months
Outcomes Main trial outcome: number and size of colorectal tumours
Dropouts: 3 intervention, 5 control
Available outcomes: all-cause mortality, dietary intake, plasma fatty acids, lipids, side
effects, glucose
Response to contact: yes (methodological details provided)
Notes Trial funding: all were either government or charity grants.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated using random digit
number for allocation of participants
Allocation concealment (selection bias) Low risk Trial author confirmed “Allocation infor-
mation was blinded to clinicians and re-
searchers” but no methodology provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk From the 2015 paper, “The attending
physicians as well as the participants were
blinded to the assignment information”.
However in the discussion section they say
“complete participant blinding could not
have been achieved because free-living par-
ticipants might have exchanged informa-
tion on their dietary intervention, say in
the hospital waiting room”
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DIPP-Tokudome 2015 (Continued)
Trial author confirmed blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “physicians, including colono-
scopists, a scientist who conducted blood
and specimen analyses, and pathologists
were blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All those randomised were accounted for.
Selective reporting (reporting bias) High risk The researchers chose not to report data
on the number, size and pathological type
of the colorectal tumours as they said they
would in the trials register. They reported
more outcomes in the paper than initially
stated. UMIN000000461 Registered 03
August 2006, recruitment completed 01
March 2007
Attention bias Low risk Participants were given equal follow-up.
Compliance Unclear risk Plasma fatty acids suggested higher total
PUFA intakes in intervention group (at 24
months 4.91 mmol/L, SD 1.23 in inter-
vention group, 4.59 mmol/L, SD 0.76 in
control). But TC higher in intervention (5.
52 mmol/L, SD 0.9) than control (5.40
mmol/L, SD 0.79) at 24 months
Other bias Low risk None noted
Dodin 2005
Methods RCT, parallel, (n3 ALA vs n6 LA), 12 months
Summary risk of bias: moderate or high
Participants Healthy menopausal women
N: 101 intervention, 98 control (analysed, intervention: 85 control: 94)
Level of risk for CVD: low
Male: 0% intervention, 0% control
Mean age (SD): 54.0 (4.0) intervention, 55.4 (4.5) control
Age range: 49-65
Smokers: 8% intervention, 6% control
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: Canada
Ethnicity: French Canadian
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Dodin 2005 (Continued)
Interventions Type: food supplement (flaxseed)
Comparison: more ALA vs less ALA
Intervention: 40 g/d flaxseed incorporated into diets (providing 21,071 g total lignans,
180 calories, 16 g lipids (57% ALA), and 11 g total dietary fibre): 9.1 g/d ALA
Control: 40 g/d wheat germ incorporated into diets (providing 196 g total lignans, 144
calories, 4 g lipids (6.9% ALA), and 6 g total dietary fibre: 0.26 g/d PUFA
Dose aim: increase 8.8 g/d PUFA, 4.0% E PUFA
Baseline PUFA 5.4% E
Compliance by biomarkers: plasma fatty acid total PUFA (summing LA, GLA, AA,
EPA, DHA, DPA, ALA) increased 3.02% from baseline to 12 months in control, in-
creased 1.99% in intervention
Compliance by dietary intake: assessed by 3-day food diary at baseline and 12 months
• Energy intake, kcal/d: intervention 1878, change -36 SD 413, control baseline
2021, change -138, SD 461
• Total fat intake, change % E: intervention +1.4 (SD 6.5), control -1.4 (SD 7.7)
• SFA intake, change % E: intervention -0.3 (SD 3.5), control -0.5 (SD 3.9)
• PUFA intake, change % E: intervention +2.4 (SD 2.0), control +0.9 (SD 2.2)
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, change % E: intervention -0.3 (SD 3.6), control -1.4 (SD 4.2)
• CHO intake, change % E: intervention -0.9 (SD 5.5), control +2.5 (SD 7.4)
• Sugars intake: not reported
• Protein intake, change % E: intervention -0.2 (SD 3.0), control -0.4 (SD 3.1)
• Alcohol intake, change % E: intervention -0.3 (SD 3.5), control -0.7 (SD 4.1)
Compliance, other methods: first morning urine collection was performed at randomi-
sation and at month 12 to measure urinary lignin levels. In addition, trial participants
recorded their daily intake of seeds on diary cards and were asked to return unused bread
and packages of seeds at each visit. Good compliance reported
Inclusion basis: no intention to increase total PUFA, planned dose ~4.0% E PUFA,
dietary intake data suggested 1.5% E PUFA, biomarkers suggested greater PUFA intake
in control, TC rose in control and fell in intervention. Using dietary intake dose of 1.
5% E PUFA higher in intervention, > 10% higher than 5.6% E from total PUFA at
baseline
PUFA dose: 1.5% E PUFA
Duration of intervention: 12 months
Outcomes Main trial outcome: BMD
Dropouts: 26 intervention, 17 control (but 13/17 had an endpoint evaluation)
Available outcomes: weight, BMI,QoL, BP, lipids, glucose, adverse events, dietary intake,
plasma fatty acids
Response to contact: yes, trial author confirmed that no CV events or deaths occurred
during the trial
Notes Trial authors replied to tell us that there were no deaths or CV events during the trial
Trial funding: not reported
Risk of bias
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Dodin 2005 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation schedule was prepared
by the clinical unit of the research centre us-
ing computer-generated randomisation in
blocks of 4-8
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants, investigators, staff, and statis-
ticians were blinded to dietary assignments
for the duration of the trial
Quote: “a local baker prepared loaves of
bread. Each week, the loaves of bread
were delivered in sealed, opaque unmarked
wrappers to the Department of Food and
Nutrition Sciences at Laval University. The
seeds were ground up and vacuum-packed
in the same laboratory. The Department of
Food and Nutrition Sciences was responsi-
ble for labelling the bags of bread and pack-
ages of seeds with the subject’s randomiza-
tion number. Bread and packages of seeds
were provided on a 3-month basis. The
foods that both groups received was similar
in appearance and packaging and was kept
frozen until consumption to avoid essential
fatty acid.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants, investigators, staff, and statis-
ticians were blinded to dietary assignments
for the duration of the trial
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT. Loss to follow-up 10%, reasons given.
Selective reporting (reporting bias) Unclear risk No protocol or clinical trials registry entry
found
Attention bias Low risk All participants had same number of visits
Compliance High risk Plasma fatty acid total PUFA (summing
LA, GLA, AA, EPA, DHA, DPA, ALA) in-
creased 3.02% from baseline to 12 months
in control, increased 1.99% in intervention
Other bias Low risk None noted
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Doi 2014
Methods RCT, parallel, (n3 EPA vs nil, both with statins), 12 months
Summary risk of bias: moderate or high
Participants Patients having PCI after acute MI
N: 119 intervention, 119 control analysed
Level of risk for CVD: high
Male: 77% intervention, 76% control
Mean age (SD): 70 (11) intervention, 71 (12) control
Age range: unclear
Smokers: 28% intervention, 32% control
Hypertension: 71% intervention, 69% control
Medications taken by ≥ 50% of those in the control group: aspirin, ticlopidine, ß-
blockers, statins (as part of treatment)
Medications taken by 20%-49% of those in the control group: ARB/ ACE inhibitors
Medications taken by some, but < 20% of the control group: none
Location: Japan
Ethnicity: not reported
Interventions Type: supplement (EPA)
Comparison: EPA vs nil
Intervention: purified EPA ethyl esters (> 98%) 1.8 g/d EPA within 24 h after PCI plus
statins
Control: statins with no EPA
Dose aim: increase 1.8 g/d EPA + DHA, 0.8% E n-3, 0.8 %E PUFA
Baseline PUFA: unclear
Compliance by biomarkers: plasmaEPA reported at 6-8months, higher in intervention
(162.8 mg/L) than control (65.5 mg/L). No further biomarker or TC data reported
Compliance by dietary intake: not reported
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other measures: not reported
Inclusion basis: no intention to increase total PUFA. Intention was to increase omega-
3 by 0.8% E. Total PUFA appear to be 0.8% E higher in intervention, > 10%more than
assumed 6% E baseline
PUFA dose: 0.8% E
Length of intervention: 12 months
Outcomes Main trial outcome: CV events
Dropouts: 1 intervention, 2 control
Available outcomes: mortality, stroke, MI, sudden death, CV death, revascularisation
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Doi 2014 (Continued)
Response to contact: contact attempted but no response to date
Notes Trial funding: trial registry states “self-funded”. The trial authors received honoraria from
Mochida Pharmaceutical Co
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer-generated randomisation
plan, which included stratification by age
and sex
Allocation concealment (selection bias) Unclear risk Carried out by research technician but un-
clear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label but blind endpoint
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Data onoutcomeswere collected fromclin-
ical charts. Unclear if blinded. Diagnoses
were confirmed by investigator blind to
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 3 dropouts, similar rates between the
groups and reasons given
Selective reporting (reporting bias) High risk Data collection completed before trial reg-
istry entry. Only 1% dropout
Attention bias Low risk Timing of follow-ups similar
Compliance Unclear risk PlasmaEPA reported at 6-8months, higher
in intervention (162.8 mg/L) than control
(65.5 mg/L). No further biomarker or TC
data reported
Other bias Low risk None observed
Dullaart 1992
Methods RCT, parallel, 2 arms (n6 LA vs mixed fats), 2 years
Summary risk of bias: moderate to high
Participants People with type I diabetes with elevated urinary albumin
CVD risk: moderate
Intervention: randomised 18, analysed 16
Control: randomised 20, analysed 20
97Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dullaart 1992 (Continued)
% male: 81% intervention, 75% control
Age: mean (SD) intervention 44 (12), control 41 (14)
Age range: unclear (21-65 inclusion)
Smokers: intervention 50%, control 55%
Hypertension: intervention 6%, control 10%
Medications taken by ≥ 50% of those in the control group: insulin
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: anti-hypertensives
Location: Netherlands
Ethnicty: not reported
Interventions Type: dietary advice
Comparison: LA (n6) vs usual diet
Intervention: diet advice given at every visit throughout the 2-year period to increase
linoleic acid achieving a polyunsaturated: saturated fatty acid ratio close to 1.0. Advice
to replace butter or saturated margarines by polyunsaturated margarines and to restrict
the intake of SFA from meat and milk products
Control: to continue their usual diet. All participants were urged not to alter total fat
and protein content
Dose: aim unclear
Baseline PUFA: 6.6% E PUFA
Compliance: TC fell more in intervention (-0.45 mmol/L) than control (0.10 mmol/
L) from baseline to 2 years. Significant difference between plasma cholesteryl ester LA
in intervention and control at 2 years
Plasma cholesteryl esters at 2 years
• LA mol%: intervention 62.2 (SD 4.2), control 57.4 (SD 4.9)
• oleic acid mol%: intervention13.7 (SD 1.8), control 16.5 (SD 1.4)
Dietary assessment using 1 week dietary recall, reported at 2 years.
• Energy intake, MJ/d: intervention 7.42 (SD 2.02), control 8.48 (SD 2.48)
• Total fat intake, % E: intervention 37 (SD 4), control 40 (SD 7)
• SFA intake, % E: intervention 13 (SD 2), control 16 (SD 3)
• PUFA intake, % E: (calculated from P/S and SFA intake) intervention 12.5 (SD
not reported), control 9.0 (SD not reported), increase 3.5%E
• PUFA n-3 intake: not reported
• PUFA n-6 intake, % E: not reported, but intervention 11%E LA (SD 2), control
7%E LA (SD 3)
• PUFA/SFA ratio: intervention 0.96 (SD 0.16), control 0.56 (SD 0.25)
• MUFA intake: not reported
• CHO intake, % E: intervention 43 (SD 4), control 41 (SD 7)
• Protein intake, % E: intervention 18 (SD 4), control 17 (SD 3)
• Trans fat intake: not reported
• Cholesterol intake, mg/d: intervention 174 (SD 49), control 245 (SD 120)
Compliance, other methods: not reported
Inclusion basis: aimed to increase LA rather than total PUFA intake. Intake data suggests
3.5% E PUFA dose, > 10% increase from control 9% E intake Supported by plasma
cholesteryl ester LA and TC
PUFA dose: 3.5% E PUFA
Duration of intervention: 2 years
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Dullaart 1992 (Continued)
Outcomes Main trial outcomes: albuminuria and lipids
Dropouts: intervention 2 of 20, control 4 of 20
Available outcomes: weight, HDL , TGs, HbA1c (TC, glucose, insulin reported but too
different at baseline to use, LDL not reported in control group, renal outcomes such as
glomerular filtration rate, albuminuria, mean arterial pressure not used)
Response to contact: yes, trial author confirmed no MI or other CVD events occurred
during trial
Notes Most outcomes are estimated from figures.
Trial funding: Dutch Diabetes Research Fund
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “patients were stratified according
to sex and randomised in blocks of tenmen
and six women”
Allocation concealment (selection bias) Low risk Assigned using opaque sealed envelopes by
independent statistical investigator with no
contact with participants
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No information on blinding. Participants
could not be blinded as they received di-
etary advice
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details on dropouts apart from the ex-
clusion of 2 intervention participants from
the trial due to pregnancy and decision not
to participate
Selective reporting (reporting bias) Unclear risk No protocol or trial registration located
Attention bias High risk Likely that diet-advice group had more
time and attention
Compliance Low risk TC fell more in intervention (-0.45 mmol/
L) than control (0.10 mmol/L) from base-
line to 2 years. Significant difference be-
tween plasma cholesteryl ester LA in inter-
vention and control at 2 years
Other bias Low risk None noted
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EPIC-1 2008
Methods EPANOVA in Crohn’s disease, trial 1 (EPIC-1)
RCT, parallel, 2 arms (n3 EPA + DHA vs mixed fats), 52 weeks
Summary risk of bias: moderate or high
Participants Adults with quiescent Crohn’s Disease Activity Index score < 150
N: 188 intervention, 186 control
Level of risk for CVD: low
Male: 48.1% intervention, 41.1% control
Mean age (SD): 40.5 (15.2) intervention, 38.2 (13.1) control
Age range: 18-70 years
Smokers: 30.6% intervention, 34.4% control
Hypertension: unclear
Medications taken by≥ 50% of those in the control group: oral 5-ASA therapy, systemic
corticosteroids - prednisolone, budesonide
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: antibiotic therapy, topical
rectal therapy, immune-modifying agents, immune modifiers/biologics
Location: Canada, Europe, Israel, USA
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs MCT
Intervention: 2 x 2 1 g gelatine capsules omega-3-free fatty acids (Epanova- 2.2 g EPA,
0.8 g DHA)
Control: 4 x1 g capsules medium-chain triglycerides
Dose aim: increase 3.0 g/d EPA + DHA, 1.4% E n-3, 1.4% E PUFA
Baseline PUFA: unclear
Compliance by biomarkers: not reported, neither fatty acids nor TC
Compliance by dietary intake: not reported
• Energy intake, kcal/d: not reported
• Total fat intake, % E: not reported
• SFA intake, % E: not reported
• PUFA intake, % E: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E: not reported
• Sugars intake: not reported
• Protein intake, % E: not reported
• Alcohol intake, % E: not reported
Compliance, other measures: pill counts, 79.2% adhered intervention, 75.6% adhered
control
Inclusion basis: no intention to increase total PUFA. Intention was to increase 3.0 g/d
EPA + DHA, 1.4% E n-3, 1.4% E PUFA, > 10% greater than assumed baseline of 6%
E.
PUFA dose: 1.4% E
Length of intervention: mean 52 weeks
100Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
EPIC-1 2008 (Continued)
Outcomes Main trial outcome: Crohns relapse-free time
Dropouts: 80 intervention, 91 control
Available outcomes: total deaths, non-fatal arrhythmias, cancer diagnoses, cancer deaths,
adverse events
Response to contact: yes (data provided)
Notes Trial funding: Tillotts Pharma, trial authors had extensive financial disclosures
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by number generator. Used
a centralised randomisation procedure via
interactive voice-recognition system
Allocation concealment (selection bias) Low risk Centralised randomisation (see above)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinding stated, identical capsule
(slow-release capsules). Neither investiga-
tor nor participant knew the allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trial states double-blind but does not state
that outcome assessors were blinded or pro-
vide a mechanism for this
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number of dropouts and reasons provided.
171 of 187 in intervention group and 174
of 184 in control group provided data for
primary outcome, (7% dropout), though
80 in the intervention group and 91 in the
control group terminated early
Selective reporting (reporting bias) High risk Trials registration (NCT00613197) first
received in 2008, but trial started in 2003,
and was published in 2008
Attention bias Low risk As investigators were blinded attention bias
was not possible
Compliance Unclear risk Neither tissue PUFA biomarkers nor TC
data reported
Other bias Low risk No further bias noted
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EPIC-2 2008
Methods EPANOVA in Crohn’s disease, trial 2 (EPIC-2)
RCT, parallel, 2 arms (n3 EPA + DHA vs mixed fats), 58 weeks
Summary risk of bias: moderate or high
Participants Adults with a confirmed diagnosis of Crohn’s disease and a Crohn’s Disease Activity
Index score < 150 who are responding to steroid induction therapy
N: intervention, 189, control 190 (187 intervention, 188 control analysed)
Level of risk for CVD: low (people with quiescent Crohn’s disease)
Male: 48.1% intervention, 41.1% control
Mean age (SD): 38.5 (13.8) intervention, 40.0 (13.6) years control
Age range: > 16 years
Smokers: 25.1% intervention, 37.2% control
Hypertension: unclear
Medications taken by ≥ 50% of those in the control group: systemic corticosteroids -
prednisolone, budesonide (but tapered and discontinued during the trial)
Medications taken by 20%-49% of those in the control group: only reported for prior
12 months
Medications taken by some, but < 20% of the control group: only reported for prior 12
months
Location: Canada, Europe, Israel, USA
Ethnicity: not reported
Interventions Type: supplement (capsule)
Comparison: EPA + DHA vs MCT
Intervention: 2 x 2 1 g gelatine capsules omega-3-free fatty acids (Epanova) providing
total dose ~2.2 g/d EPA, 0.8 g/d DHA: EPA + DHA ~3.0 g/d
Control: 2 x 2 1 g capsules medium-chain triglyceride oil
Dose aim: increase 3.0 g/d EPA + DHA, 1.4% E n-3, 1.4% E PUFA
Baseline PUFA: unclear
Compliance by biomarkers: not reported, neither fatty acids nor TC
Compliance by dietary intake: not reported
• Energy intake, kcal/d: not reported
• Total fat intake, % E: not reported
• SFA intake, % E: not reported
• PUFA intake, % E: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E: not reported
• Sugars intake: not reported
• Protein intake, % E: not reported
• Alcohol intake, % E: not reported
Compliance, other measures: measured by participant interviews and pill counts, 75.
4% adhered intervention, 81.4% adhered control
Inclusion basis: no intention to increase total PUFA. Intention was to increase 3.0 g/d
EPA + DHA, 1.4% E n-3, 1.4% E PUFA, > 10% greater than assumed baseline of 6%
E
PUFA dose: 1.4% E
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EPIC-2 2008 (Continued)
Length of intervention: mean 58 weeks
Outcomes Main trial outcome: maintain Crohns symptomatic remission
Dropouts: 114 intervention, 112 control
Available outcomes: mortality, CV events (nil), cancer diagnoses, adverse events
Response to contact: yes (data provided)
Notes Trial funding: Tillotts Pharma, trial authors had extensive financial disclosures
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by number generator. Used
a centralised randomisation procedure via
interactive voice-recognition system
Allocation concealment (selection bias) Low risk Centralised randomisation (see above)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blinding stated, identical capsule
(slow-release capsules). Neither investiga-
tor nor participant knew the allocation.
However no information provided on cap-
sules taste or smell
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trial states double-blind but does not state
that outcome assessors were blinded or pro-
vide a mechanism for this
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of dropouts and reasons provided,
however 114 of 189 in intervention group
and112of 190 in control group terminated
early
Selective reporting (reporting bias) High risk NCT00074542. First received 2003, trial
start 2002. Published 2008. Some out-
comes, such as quality of life, stated in trials
registry but not in published papers
Attention bias Low risk As investigators were blinded attention bias
was not possible
Compliance Unclear risk Neither tissue PUFA biomarkers nor TC
data reported
Other bias Low risk No further bias noted
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EPOCH 2011
Methods Older People, Omega-3 and Cognitive Health (EPOCH)
RCT, parallel (n3 EPA + DHA vs MUFA), 18 months
Summary risk of bias: low
Participants Healthy older adults with no cognitive impairment
N: 195 intervention, 196 control (reported by trial author)
Level of risk for CVD: low
Male: not reported
Mean age (SD): not reported
Age range: not reported, but 65-90 recruited
Smokers: not reported
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
Interventions Type: supplement (fish oil capsules)
Comparison: high EPA + DHA vs MUFA and low EPA + DHA
Intervention: 4 capsules/d (1.72 g/d DHA and 0.60 g/d EPA): EPA + DHA 2.32 g/d
Control: 4 capsules/d (3.960 g/d olive oil and 40 mg/d fish oil), 0.8 g/d PUFA
(assuming 20% of olive oil is PUFA)
Dose aim: increase 2.28 g/d EPA + DHA, or 1.52 g/d PUFA (subtracting control data)
, 0.68% E PUFA
Baseline PUFA unclear
Compliance by biomarkers: erythrocyte membrane n-3 LC PUFA status assessed but
no useful data reported, no TC data
Compliance by dietary intake: not reported
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other methods: count of all unused supplements returned at 3-monthly
intervals, plus self-report calendars, mailed back on a monthly basis. If compliance fell
below 85% (re calendars), they were contacted by a researcher who noted the reasons
Inclusion basis: no intention to increase total PUFA intake.
Dose aim 1.52 g/d PUFA or 0.68% E total PUFA, > 10% increase from assumed 6%
E PUFA baseline. No data on biomarkers, intake or TC
PUFA dose: 0.68% E
Length of intervention: 18 months
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EPOCH 2011 (Continued)
Outcomes Main trial outcome: change in cognitive performance
Dropouts: not reported
Available outcomes: mortality (nil), MI, stroke, revascularisation, atrial fibrillation, CV
events. Planned outcomes, not reported in publications, included: cognitive outcomes,
functional outcomes, glucose, lipids, plasma fatty acids, BP, inflammation and oxidative
stress
Response to contact: yes (data provided)
Notes Trial authors reported some events, but don’t appear to be published
Trial funding: EPAX donated theOmega-3 concentrate and Blackmores Pty Ltd donated
the placebo and packaging of the Omega-3 concentrate. The trial was supported by the
Brailsford Robertson Award 2007-2008 (University of Adelaide and CSIRO Food and
Nutritional Sciences), and is funded by a National Health and Medical Research Project
Grant (#578800)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Age-stratified, permuted-block randomisa-
tion, with mixed block-sizes (2-8, size un-
known to trial investigators), 1:1 alloca-
tion. Computer-generated randomisation
schedule
Allocation concealment (selection bias) Low risk An independent researcher prepared allo-
cation to treatment.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The researchers, project staff, and partici-
pants remained blinded to treatment allo-
cation until the trial was completed and the
database locked. No information provided
on capsules’ appearance, taste or smell, but
fish oil added to control to make taste sim-
ilar
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No data for each group presented, and no
attrition data presented
Selective reporting (reporting bias) High risk Registered at ACTRN12607000278437.
Only cognitive functions reported for
whole population (not by arm). No sec-
ondary outcomes reported (Mini Mental
State Examination; perceived health status,
depressive symptoms, positive and negative
105Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
EPOCH 2011 (Continued)
affect, life satisfaction, self-reported cogni-
tive functioning, and functional capacity;
BP; biomarkers of glucose, glycated haemo-
globin, TGs, TC, HDL, LDL, homocys-
teine, CRP, Malondialdehyde (MDA), and
telomere length)
Attention bias Low risk All had the same contact and attention
Compliance Unclear risk Compliance assessed by erythrocyte mem-
brane n-3 long-chain PUFA status but re-
sults not reported, noTCor biomarker data
on total PUFA
Other bias Low risk None noted
FAAT - Leaf 2005
Methods Fatty Acid Antiarrhythmia Trial - FAAT
Randomisation: RCT, parallel, 2 arms, (n3 EPA + DHA vs MUFA), 12 months
Summary risk of bias: moderate or high
Participants People with implanted cardioverter defibrillators (ICDs)
N: intervention 200, control 202
Level of risk for CVD: high (participants with ICDs).
Male: intervention 84.5%, control 81.7%
Mean age (SD): intervention 65.7 (11.6), control 65.3 (11.7) years
Age range: unclear
Smokers: intervention 15%, control 11.4%
Hypertension: unclear
Medications taken by ≥ 50% of those in the control group: ACEi, beta-blockers
Medications taken by 20%-49%: diuretics
Medications taken by some, but < 20%: Ca channel blockers, amiodarone, sotalol, type
1 antiarrhythmics
Location: USA
Ethnicity: intervention 95.5% white, control 96.5% white
Interventions Type: supplement/capsule
Comparison: EPA + DHA vs MUFA
Intervention: 4 x 1 g/d fish oil gelatin capsules, 2.6 g EPA + DHA/d (Pronova Biocare,
quantities of EPA + DHA unclear): EPA + DHA 2.6 g/d
Control: 4 x 1 g/d olive oil capsules, 4 g/d (in identical gelatin capsules, < 0.06 g/d EPA
+ < 0.06 g/d DHA)
All were advised to use olive oil rather than the common plant seed oils for cooking,
dressings, and sauces
PUFA Dose: (intended)
Dose aim: intervention 2.6 g/d EPA + DHA, 1.2% E n3, 1.2% E PUFA, control 4 g
olive oil, 20% LA, 0.8 g/d PUFA, 0.36% E PUFA. Difference 0.84% E PUFA
Baseline PUFA: unclear
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FAAT - Leaf 2005 (Continued)
Compliance by biomarkers: platelet phospholipid EPA + DHA higher in intervention
group than control, no data on total PUFA or TC
Compliance by dietary intake: not reported
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other measures: pill counts suggested greater omega-3 intake in interven-
tion participants. 35% were non-compliers (36.5% intervention, 34.2% control)
Inclusion basis: no intention to increase total PUFA. Intention was to increase omega-
3, difference between arms was 0.84% E PUFA, > 10% more than control
PUFA dose: 0.84% E
Duration of intervention: 12 months
Outcomes Main trial outcome: fatal VF/VT
Dropouts: intervention 13 deaths, unclear number of dropouts; control 12 deaths, drop-
outs unclear
Available outcomes: deaths, CV deaths, deaths from heart failure, fatal arrhythmias, MI,
angina
Response to contact: yes (data provided)
Notes Trial funding: the trial was supported in part by a grant from the NHLBI, NIH
(HL62154)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation tables
for each collaborating site, stratified by site
Allocation concealment (selection bias) Low risk Trial author confirmed allocation was con-
cealed from investigators
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Trial referred to as “double blind” and
gelatin capsules (verum and placebo) were
stated as being of identical appearance but
no discussion of taste or smell. Trial au-
thor confirmed that investigators and par-
ticipants were blinded
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FAAT - Leaf 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk VT and VF events were assessed blinded to
allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Large numbers dropped out so some deaths
etc. may have been missed, 35% discontin-
ued early due to non-compliance but were
assessed at trial end, data censored for some
participants
Selective reporting (reporting bias) High risk Trials registry data received September
2005, paper published November 2005
Attention bias Low risk Time and attention appeared similar be-
tween the 2 arms
Compliance High risk Platelet phospholipid EPA + DHA higher
in intervention group than control, no data
on total PUFA or TC
Other bias Low risk None noted
GLAMT 1993
Methods Gamma Linolenic Acid Multicentre Trial (GLAMT)
RCT, 2-arm, parallel (n6 GLA vs non-fat), 1 year
Summary risk of bias: moderate to high
Participants People with mild diabetic neuropathy
CVD risk: moderate
Control: randomised 57, analysed 48 (with ≥ 1 evaluation)
Intervention: randomised 54, analysed 52
Mean years in trial: control 1.0, randomised 1.0
% male: intervention 67%, control 79%,




Medications taken by ≥ 50% of those in the control group: insulin
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: UK and Finland
Ethenicty: not reported
Interventions Type: supplement
Comparison: GLA (n-6) vs placebo (paraffin)
Control aims: 12 capsules/d paraffin
Intervention aims: 12 capsules/d evening primrose oil (EP4, equivalent to Epogam): 0.
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GLAMT 1993 (Continued)
48 g/d GLA plus LA (stated as the major constituent, dose not given, if assume 0.7 g/
capsule then 8.4 g/d*)
Dose aim: increase 0.48 g/d GLA or 4 kcal or 0.2% E GLA, increase ~8.4 g/d LA or
76 kcal or 3.8% E LA, total 4% E n6
Baseline PUFA: unclear
Compliance by biomarkers: unclear, no serum TC or tissue fatty acid levels reported
Compliance by dietary intake: unclear
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other methods: not reported
Inclusion basis: aimed to increase GLA intake rather than total PUFA.
Dose aim appeared to be ~4% E PUFA (from omega-6 data), >10%more than assumed
baseline of 6% E PUFA. No confirmatory biomarker or intake data
PUFA dose: 4% E PUFA (estimated from aim)
Duration of intervention: 1 year
Outcomes Main trial outcome: measures of diabetic neuropathy
Dropouts: intervention 10, control 17
Available outcomes: MI, cancer (no deaths)
Response to contact: contact attempted but no response to date
Notes Trial funding: Scotia Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind, and
Quote: “Active and placebo capsules were
indistinguishable in taste or appearance”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear, though trial described as double-
blind no methods or statement of blinding
of outcome assessors was mentioned
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Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for withdrawal usually given, but
high and dissimilar
Selective reporting (reporting bias) Unclear risk No clear protocol or trials registry entry
found
Attention bias Low risk Appeared similar
Compliance Unclear risk Neither tissue PUFA biomarkers nor TC
data reported
Other bias Low risk None identified
HARP- Sacks 1995
Methods Harvard Atherosclerosis Reversibility Project (HARP)
RCT, (n3 EPA + DHA vs MUFA), 24 months
Summary risk of bias: moderate or high
Participants People with coronary heart disease
N: 41 intervention, 39 control (99.9% follow-up at trial end)
Level of risk for CVD: high
Male: 93.5% intervention, 92.9 % control
Mean age (SD): 62 (7) intervention, 62 (7) years control
Age range: 30-75
Smokers: 0% (exclusion criteria)
Hypertension: 48% intervention, 36% control
Medications taken by ≥ 50% of those in the control group: beta blockers, antiplatelet
agents
Medications taken by 20%-49% of those in the control group: Ca channel blockers,
nitrates




Interventions Type: supplement (capsule)
Comparison: n3 vs MUFA
Intervention: 12 fish oil capsules/d (Promega, Parke-Davis) in divided doses, preferably
after meals. Each fish oil capsule contained 500 mg of n-3 PUFAs composed of EPA
(240 mg), DHA (160 mg) and other (100 mg) (mainly DPA) providing total daily dose
of 6 g/d of n-3 fatty acids.
Control: olive oil capsules identical in appearance to the fish oil capsules, 6 g/d olive oil,
1.2 g/d LA
Dose aim: increase 4.8 g/d PUFA, 2.2% E PUFA
Baseline PUFA: unclear
Compliance by biomarkers: adipose fatty acids (sum of LCn3 fats, AA & LA) were 21.
2% in intervention group, 20.4% in control group.TCwas slightly higher in intervention
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HARP- Sacks 1995 (Continued)
(5.02 mmol/L, SD 0.96) than control (4.99 mmol/L, SD 0.62) at 28 months
Compliance by dietary intake: not reported.
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other measures: capsule counts, adherence averaged 80% intervention,
and 90% control
Inclusion basis: no intention to increase total PUFA. Intention was to increase omega-
3, difference between arms was 4.8 g/d PUFA, 2.2% E PUFA, > 10% increase from
assumed baseline of 6% E PUFA
PUFA dose: 2.2% E PUFA
Duration of intervention: average 28 months
Outcomes Main trial outcome: regression of coronary artery lesions
Dropouts: 10 intervention, 11 control
Available outcomes: total and CV deaths, fatal and non-fatal MI, stroke, angioplasty or
coronary artery bypass graft, unstable angina, CHD, cancer diagnosis, combined CV
events, side effects
Response to contact: yes
Notes Trial funding: National Heart, Lung, and Blood Institute (NHLBI), National Institutes
ofHealth, Bethesda,Maryland,Warner Lambert-ParkeDavis (pharmaceutical company)
, East Hanover, New Jersey; and by an Established Investigator Award to Dr. Sacks from
the American Heart Association, Dallas, Texas
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomization” stratified by clinical man-
agement regime and TC/HDL ratio
Allocation concealment (selection bias) Unclear risk No further details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “patients and personnel responsible
for lab measurements, cardiac catheteriza-
tion, and analysis of angiography filmswere
blinded to the treatment assignment”
Although capsules were identical in appear-
ance, no information on their taste and
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smell
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “patients and personnel responsible
for lab measurements, cardiac catheteriza-
tion, and analysis of angiography filmswere
blinded to the treatment assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low attrition rate over 28 months and all
reasons are well-documented
Selective reporting (reporting bias) High risk Trial registered retrospectively after publi-
cation
Attention bias Low risk Nothing in description implies the arms
were treated differently
Compliance Unclear risk Adipose fatty acids (sum of LCn3 fats, AA
& LA) were 21.2% in intervention group,
20.4% in control group. TC was slightly
higher in intervention (5.02 mmol/L, SD
0.96) than control (4.99 mmol/L, SD 0.
62) at 28 months
Other bias Low risk None noted
HERO-Tapsell 2009
Methods Healthy Eating to Reduce Overweight in people with type 2 diabetes (HERO)
RCT, parallel, (n3 ALA vs low n3), 12 months
Summary risk of bias: moderate or high
Participants Overweight adults with non-insulin treated diabetes
N: 26 intervention, 24 control (analysed, int: 18 cont: 17)
Level of risk for CVD: moderate
Male %: not reported




Medications taken by ≥ 50% of those in the control group: lipid-lowering drugs, oral
hypoglycemics
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
Interventions Type: food supplement (walnuts)
Comparison: ALA vs nil
Intervention: 30 g/d snack portions of walnuts, aim 30% E fat (10% SFA, 10%MUFA,
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HERO-Tapsell 2009 (Continued)
10% PUFA), 20% E protein, 50% E CHO, P/S ratio of 1.0. Advised not to take fish
oil supplements, ALA dose unclear
Control: no supplements, aim 30% E fat (10% SFA, 15% MUFA, 5% PUFA), 20% E
protein, 50% E CHO
Both groups were given low-fat isocaloric dietary advice plus advice to brisk walk 30 min
3 times/week
Dose aim: increase 5% E PUFA
Baseline PUFA: unclear but control 5.5% E PUFA
Compliance by biomarkers: omega-3 fats measured by erythrocyte membrane fatty
acid levels which were similar in both groups, no other PUFAs reported. TC fell by
0.3 mmol/L from baseline to 12 months in control, and fell by 0.1 mmol/L in the
intervention
Compliance by dietary intake: all assessed at 12 months using validated diet history
interview and 3-day food records
• Energy intake, kcal/d: intervention 1914 (SD 443), control 2112 (SD 685)
• Total fat intake, % E: control 29.3 (SD 7.2), int ervention34.1 (SD 5.8)
• SFA intake, % E: intervention 8.1 (SD 2.6)
• PUFA intake, % E: control 5.5 (SD 2.3), intervention 12.0 (SD 2.5)cont 9.6 (SD
3.2),
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: intervention 10.9 (SD 3.0), control 11.2 (SD 2.8)
• CHO intake, % E: intervention 41.4 (SD 6.2), control 42.3 (SD 7.6)
• Sugars intake: not reported
• Protein intake, % E: intervention 21.1 (SD 4.4), control 23.9 (SD 4.3)
• Alcohol intake, % E: not reported
Compliance, other measures: not reported
Inclusion basis: no intention to increase total PUFA. Intention was to increase walnuts,
which included increasing PUFA in place of MUFA. Dietary intake data suggested an
increase of 6.5% E from PUFA compared to control, > 10% increase from control group
baseline of 5.1% E from PUFA
PUFA dose: 6.5% E PUFA
Duration of intervention: 12 months
Outcomes Main trial outcome: change in body weight and % body fat
Dropouts: 8 intervention, 5 control
Available outcomes: all-causemortality (nil deaths), weight, visceral adipose tissue, lipids,
glucose, insulin, HbA1c (body fat % and subcutaneous adipose tissue measured but too
different at baseline to use)
Response to contact: not yet attempted
Notes Body fat % was too different between groups at baseline hence data not used
Trial funding: California Walnuts Commission
Risk of bias
Bias Authors’ judgement Support for judgement
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HERO-Tapsell 2009 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation was conducted using a
computerised random-number generator
by a researcher independent of the subject
interface
Allocation concealment (selection bias) Unclear risk No further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Subjects, but not dietitians, were
blinded to the type of overall diet (a
prepackaged 30 g snack portion of walnuts
was given to the walnut group unbeknown
to the controls)”
However, there was no placebo supplement
so blinding not truly feasible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Paper states “code was concealed from the
researchers collecting data, as well as from
subjects.”
However as participants could not be
blinded outcome assessors may not have
been (problem for measures of adiposity,
not for biochemical measures)
Incomplete outcome data (attrition bias)
All outcomes
High risk High dropout rate, 35 of 50 analysed (30%
attrition rate)
Selective reporting (reporting bias) Unclear risk Trial was registered but post-analysis
Attention bias Low risk Both groups appear to have had same level
of attention
Compliance High risk Omega-3 fats measured by erythrocyte
membrane fatty acid levelswhich were sim-
ilar in both groups, no other PUFAs re-
ported. TC fell by 0.3 mmol/L from base-
line to 12 months in control, and fell by 0.
1 mmol/L in the intervention
Other bias Low risk None noted
Houtsmuller 1979
Methods RCT, parallel, (increase LA vs usual diet), 72 months maximum
Summary risk of bias: moderate or high
Participants Adults with newly diagnosed diabetes
N: 51 intervention, 51 control (analysed unclear intervention, unclear control)
Level of risk for CVD: moderate
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Houtsmuller 1979 (Continued)
Male: 56% overall (not stated by intervention arm)
Mean age (SD): not reported intervention, not reported control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: statins (probably)
Location: Netherlands
Ethenicity: not reported
Interventions Type: dietary advice
Comparison: omega-6 vs SFA and CHO
Intervention: aims total fat 40% E, 1/3 LA, CHO 45% E, protein 15% E; methods
unclear, surveyed by dietitian. Intervention appears to have been delivered by dietitian
but no details on format or frequency
Control: aims SFA 35% E, CHO 50% E, protein 15% E; methods unclear, surveyed by
dietitian
Dose aims: increase ~9% E LA (aims imply no LA in control, but paper states LA was 4
x higher in intervention than control, est 3% E control, 12% E int, so increase of ~9%
E)
Baseline PUFA: unclear
Compliance by biomarkers: good, serum TC significantly reduced in intervention
compared to control (-0.47 mmol/L, 95% CI -0.76 to -0.18), no significant differences
in men, but significant improvements in women from 3 years
Compliance by dietary intake: unclear (not reported)
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other measures: not reported
Inclusion basis: aimed to increase LA, not total PUFA. Appears to have increased LA
by ~9% E so assume increase in total PUFA also ~9% E, > 10% increase from control
group baseline of ~3% E from PUFA
PUFA dose: 9% E PUFA
Duration of intervention: 72 months
Outcomes Main trial outcome: progression of diabetic retinopathy
Dropouts: unclear intervention, unclear control
Available outcomes: CV events (total MI and angina), TC, TGs (data read off graph),
CHD mortality (fatal MI), CHD events (MI, angina), progression of retinopathy
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Houtsmuller 1979 (Continued)
Response to contact: contact attempted but no response to date
Notes Trial funding: Dutch Heart Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants matched in pairs then ran-
domised
Allocation concealment (selection bias) Unclear risk Randomisation method not clearly de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unclear, though unlikely as dietary advice
provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not men-
tioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are
dropouts, trialists asked for data - unclear
if any data missing
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry found
Attention bias Unclear risk No details provided
Compliance Low risk TC significantly reduced in intervention
compared to control (-0.47 mmol/L, 95%
CI -0.76 to -0.18)
Other bias High risk Some concerns around fraud in the first au-
thor’s later research on diet in cancer.No al-
legations found regardinghis research in di-
abetes (but much information is in Dutch)
Kumar 2012
Methods RCT, parallel, (n3 EPA + DHA vs nil), 12 months
Summary risk of bias: moderate or high
Participants People with persistent AF on warfarin
N: 92 intervention, 90 control (91 and 87 analysed ITT)
Level of risk for CVD: high
Male %: 82.4 intervention, 72.4 control
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Mean age (SD): 63 (10) intervention, 61 (13) control
Age range: 18-85 (inclusion criteria)
Smokers: 22.2% intervention, 11.5% control
Hypertension: 45.6% intervention, 58.6% control
Medications taken by≥ 50%of those in the control group: anti-arrhythmic drugs, renin-
angiotensin system inhibitors
Medications taken by 20%-49% of those in the control group: statins
Medications taken by some, but < 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
Interventions Type: fish oil capsule
Comparison: EPA + DHA vs nil
Intervention: 6 capsules/d of a fish oil preparation containing a total dose of 1.02 g of
EPA and 0.72 g DHA. Participants in the omega-3 group were asked to continue fish
oils till a maximum of 1 year or till return of persistent AF
Control: no supplements. Participants were advised not to take any fish oil supplements
All participants underwent cardioversion following randomisation
Dose aim: increase 1.74 g/d EPA + DHA, 0.8% E n-3, 0.8% E PUFA
Baseline PUFA: unclear
Compliance by biomarkers: phospholipid fatty acid status measured at cardioversion,
DHA and EPA higher in intervention (EPA 2.5% fat, DHA 6.3% fat) than control (EPA
1.2% fat, DHA 3.4% fat), both P < 0.001. No other PUFAs, or TC, reported
Compliance by dietary intake: not reported
• Energy intake, kcal/d: not reported
• Total fat intake, % E: not reported
• SFA intake, %E: not reported
• PUFA intake, % E: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E: not reported
• Sugars intake: not reported
• Protein intake, % E: not reported
• Alcohol intake, % E: not reported
Compliance, other measures: monitored on a weekly basis via telephone and during
follow-up by using a pill count, results not reported
Inclusion basis: no intention to increase total PUFA. Intention was to increase 1.74
g/d EPA + DHA, 0.8% E PUFA > 10% greater than assumed baseline of 6% E. No
biomarker, TC or intake data to confirm
PUFA dose: 0.8% E
Duration of intervention: 1 year (or AF recurrence)
Outcomes Main trial outcome: AF recurrence
Dropouts: 4 intervention, 0 control
Available outcomes: all-cause mortality (nil death), AF recurrence, time to AF recurrence,
adverse events
Response to contact: written but no answer yet
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Notes Trial funding: the trial was funded in part by theNational Heart Foundation of Australia
and the Pfizer Cardiovascular Lipid Research Grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised to a control
or an omega-3 group in a 1:1 fashion (no
methodological details)
Allocation concealment (selection bias) Unclear risk No further details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label with no placebo control




Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT conducted
Selective reporting (reporting bias) Unclear risk Trial registered 2005 but data collection
started 2003
Attention bias Unclear risk Intervention group had capsules, while
control group did not. Potential for greater
contact and checking with intervention
group, otherwise groups seem to have had
the same care
Compliance Unclear risk Phospholipid fatty acid status measured at
cardioversion, DHA and EPA higher in in-
tervention (EPA 2.5% fat, DHA 6.3% fat)
than control (EPA 1.2% fat, DHA 3.4%
fat), both P < 0.001. No other PUFAs, or
TC, reported
Other bias Low risk None noted
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Methods RCT, parallel, (n3 EPA + DHA vs nil), 12 months
Summary risk of bias: moderate or high
Participants Adults > 60 years with sinoatrial node disease and dual chamber pacemakers
N: 39 intervention, 39 control (only 18 vs 39 for 12-month analyses)
Level of risk for CVD: moderate/high
Male %: 46% intervention, 56% control
Mean age (SD): 78 (7) intervention, 77 (8) control
Age range: not reported
Smokers: not reported
Hypertension: 72%
Medications taken by ≥ 50% of those in the control group: statins, renin-angiotensin
system inhibitors
Medications taken by 20%-49% of those in the control group: anti-arrhythmic drugs
Medications taken by some, but < 20% of the control group: not reported
Location: Australia
Ethnicity: not reported
Interventions Type: omega-3 capsule
Comparison: EPA + DHA vs nil
Intervention: a triglyceride preparation containing a total of 6 g/day of omega-3 PUFAs
of which 1.8 g/day were n-3 (1.02 g EPA and 0.72 g DHA)
Control: no supplements
Dose aim: increase 1.74 g/d EPA + DHA, 0.8% E n-3, 0.8% E PUFA
Baseline PUFA: unclear
Compliance by biomarkers: phospholipid fatty acid status measured at randomisation
and at 1-3 months, DHA and EPA increased in intervention, not in control. No other
PUFAs, or TC, reported
Compliance by dietary intake:measured via weekly diet history, but no results reported
• Energy intake, kcal/d: not reported
• Total fat intake, % E: not reported
• SFA intake, %E: not reported
• PUFA intake, % E: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E: not reported
• Sugars intake: not reported
• Protein intake, % E: not reported
• Alcohol intake, % E: not reported
Compliance, other measures: measured by weekly pill count, results not reported
Inclusion basis: no intention to increase total PUFA. Intention was to increase 1.74
g/d EPA + DHA, 0.8% E PUFA >10% greater than assumed baseline of 6% E. No
biomarker, TC or intake data to confirm
PUFA dose: 0.8% E
Duration of intervention: median 378 days
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Outcomes Main trial outcome: AF burden
Dropouts: 1 intervention, 0 control
Available outcomes: all-cause mortality, CV mortality, AF (frequency and duration but
not recurrence so not used), adverse events
Response to contact: written, no reply to date
Notes Trial funding: unclear
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed using se-
quentially numbered, opaque, sealed en-
velopes
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label design
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “At each visit, stored AT/AF diag-
nostic data were retrieved in an un-blinded
fashion”
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 1 lost, and reason explained. But
group baseline size to cross-over is huge.
Doesn’t report just the 17 or 18 metrics at
baseline, no idea why the 21 were the ones
switched and mixed with the control
Selective reporting (reporting bias) Low risk Trial prospectively registered and outcomes
stated were reported
Attention bias Unclear risk Only difference would be handing out the
capsules, rest seems the same.However, one
group is getting supplements and the other
nil
Compliance Unclear risk Phospholipid fatty acid status measured at
randomisation and at 1-3 months, DHA
and EPA increased in intervention, not in
control. No other PUFAs, or TC, reported
Other bias High risk 21of the 39 randomised to the intervention
were crossed over to control at six months
so 12-month outcomes are reported for 17/
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18 intervention group while baseline char-
acteristics are reported for all 39 partici-
pants
Ley 2004
Methods RCT, parallel, (reduced total fat vs usual diet), 12 months
Summary risk of bias: low (dietary advice trial)
Participants Adults with impaired glucose intolerance or high normal blood glucose
N: 85 intervention, 90 control (176 between both groups) (analysed 66 intervention:
70 control at 1 year, 112 between both groups at 5 years)
Level of risk for CVD: moderate
Male: 80% intervention, 68% control
Mean age (SD): 52.5 (SE 0.8) intervention, 52.0 (SE 0.8) control
Age range: not reported
Smokers: 23% intervention, 9% control
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: BP medication taken by
27% intervention, 18% control
Location: New Zealand
Ethnicity: European 67% intervention, 77% control, Maori 11% intervention, 7%
control, Pacific islander 20% intervention, 13% control, other 3% intervention, 4%
control (outcomes not provided by ethnicity)
Interventions Type: diet advice
Comparison: reduced fat vs usual diet
Intervention: aim reduced fat diet (no specific goal stated);methodsmonthly small group
meetings to follow a 1-year structured programme aimed at reducing dietary fat, includes
education, personal goal setting, self-monitoring
Control: aim usual diet; methods usual intake plus general advice on healthy eating
consistent with the New Zealand guidelines and standard dietary information for people
with nutrition-related problems upon entering the trial
Dose aim: no goal stated
Baseline PUFA: unclear but lower PUFA arm 4% E PUFA
Compliance by biomarkers: erythrocyte ALA increased by 28% in control, reduced by
17% in intervention (in a subsample of participants, % of total fatty acids in red blood
cells also increased in control group compared to intervention), no other erythrocyte
fatty acids reported. TC fell by 0.15 mmol/L (SE 0.09) in control, and by 0.05 mmol/
L (SE 0.17) in intervention to 1 year
Compliance by dietary intake: mean of five, 24-h diet recalls over 2 years of trial
• Energy intake, kcal/d: intervention 1821 (SD not reported), control 1593 (SD
not reported)
• Total fat intake, % E: intervention 33.6 (SE 7.8), control 26.1 (SE 7.7)
• SFA intake, %E: intervention 10.0 (SE 0.6), control 13.4 (SE 0.6)
• PUFA intake, % E: intervention 4.0 (SE 0.2), control 4.8 (SE 0.2)
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• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: intervention 8.9 (SE 0.4), control 11.8 (SE 0.4)
• CHO intake, % E: intervention 54.2 (SE 1.5), control 45.8 (SE 1.4)
• Sugars intake: not reported
• Protein intake, % E: intervention 18.4 (SE 0.5), control 16.6 (SE 0.5)
• Alcohol intake, % E: intervention 3.6 (SE 1.0), control 5.7 (SE 0.9)
Compliance, other methods: not reported
Inclusion basis: aimed to reduce total fat, not to alter total PUFA. Resulted in fall of 0.
8% E total PUFA in intervention, > 10% increase from 5.3% E PUFA at baseline
PUFA dose: 0.8% E PUFA (from dietary intake data)
Duration of intervention: 12 months (later data reported, but intervention only lasted
1 year)
Outcomes Main trial outcome: lipids, glucose, BP
Dropouts: unclear intervention, unclear control
Available outcomes: mortality, CVD mortality, combined CV events (including MI,
angina, stroke, heart failure), diabetes diagnosis, totalMI, stroke, cancer diagnoses, cancer
deaths, CHD events (MI or angina), weight, total, LDL and HDL, TGs, BP
Author contact: Dr Metcalf provided additional methodology and outcome data
Notes Trial funding: National Heart Foundation of New Zealand, Aukland Medical Research
Foundation, Lotteries Medical Board and the Health Research Council of New Zealand
NOTE: total PUFA intake lower in intervention than control group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Unmarked opaque envelopes were opened
by the person recruiting, unable to alter al-
location later (trial author stated in their
reply to us that randomisation and prepa-
ration of the envelopes was by people not
involved in recruitment)
Allocation concealment (selection bias) Low risk Unmarked opaque envelopes were opened
by the person recruiting, unable to alter al-
location later
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Dietary advice, not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial authors stated that those assessing
lipids were blinded
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are
dropouts, trialists asked for data but they
were unable to provide any - unclear if any
data missing
Selective reporting (reporting bias) Low risk No protocol or trials registry entry found
Attention bias High risk Regular meetings in intervention group,
not in control
Compliance Low risk Erythrocyte ALA increased by 28% in con-
trol, reduced by 17% in intervention (in a
subsample of participants, % of total fatty
acids in red blood cells also increased in
control group compared to intervention),
no other erythrocyte fatty acids reported.
TC fell by 0.15 mmol/L (SE 0.09) in con-
trol (the arm higher in PUFA), and by 0.05
mmol/L (SE 0.17) in intervention to 1 year
(control group should have been higher in
total PUFA in this trial)
Other bias Low risk None noted
MARINA - Sanders 2011
Methods Modulation of Atherosclerosis Risk by Increasing dose of N-3 fatty Acids (MARINA)
RCT, parallel, 4 arms (n3 EPA + DHA at 3 doses vs MUFA), G2 vs control included,
12 months
Summary risk of bias: low
Participants Non-smoking men and women aged 45-70 years
N: intervention 279 in 3 groups (G1 0.45 g/d N = 94, G2 0.9 g/d N = 93, G3 1.8 g/d
N = 92), control: 88 (analysed G1 0.45 g/d N = 81, G2 0.9 g/d N = 80, G3 1.8 g/d N
= 80, control 71)
Level of risk for CVD: low
Male: 38.7% intervention, 38.6% control
Mean age (CI): G1:55 (53, 56), G2:55 (54, 56), G3: 55 (54, 57) intervention 55 (54,
57) control
Age range: 45-70
Smokers: 0% intervention, 0% control
Hypertension: 5.4% intervention, 5% control
Medications taken by ≥ 50% of those in the control group: none
Medications taken by 20%-49% of those in the control group: none
Medications taken by some, but < 20% of the control group: statins, antihypertensives,
hormone replacement therapy, thyroxine
Location: UK
Ethnicity: G1: white 80.9%, black 4.3%, Asian 6.4%, Far Eastern 4.3%, other 4.3%
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G2: white 78.5%, black 6.5%, Asian 10.8%, Far Eastern 0%, other 4.3%
G3: white 85.9%, black 1.1%, Asian 2.2%, Far Eastern 4.3%, other 6.5%
Control: white 77.3%, black 10.2%, Asian 6.8%, Far Eastern 2.3%, other 3.4%
Interventions Type: supplement (fish oil capsules)
Comparison 1: EPA + DHA vs MUFA
Comparison 2: high EPA + DHA vs low EPA + DHA
Intervention: 3 x 1 g oil gelatin capsule/day consisting of blend of EPA concentrate,
DHA concentrate, refined olive oil and 0.1 wt% peppermint oil Providing a daily dose
of; 0.45 g, 0.9 g, or 1.8 g/d (all with EPA/DHA ratio of 1.51)
Control: 3 gelatin capsules/d containing refined olive oil + 0.1% peppermint oil
Dose aim: (intended) increase 0.45 g/d EPA + DHA, 0.2% E n-3 or increase 0.9 g/d
EPA + DHA, 0.4% E n-3 or increase 1.8 g/d EPA + DHA, 0.8% E n-3
Baseline PUFA 6.2% E
Compliance by biomarkers: EPA and DHA in erythrocyte lipids increased in dose-
dependent manner compared with placebo, indicating long-term compliance with in-
tervention. TC rose by 0.1 mmol/L in both the control and intervention (G2, 0.9 g/d
group) from baseline to end. No other biomarkers reported
Compliance by dietary intake: all assessed after treatment (assumed at 12 months)
, using food frequency questionnaire (checked for completeness). Intervention group
refers to G2 (0.9 g/d):
• Energy intake, MJ/d (95% CI): intervention 7.98 (7.28 to 8.68), control 7.79 (6.
92 to 8.67)
• Total fat intake, % E (95% CI): intervention 34.0 (32.4 to 35.5), control 30.8
(28.9 to 32.6)
• SFA intake, %E (95% CI): intervention 12.1 (11.5 to 12.8), control 11.1 (10.3
to 11.9)
• PUFA intake, % E (95% CI): intervention 6.4 (6.0 to 6.8), control 5.7 (5.3 to 6.
1)
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E (95% CI): control 49.5 (47.4 to 51.6), intervention 46.6 (44.9
to 48.3)
• Sugars intake: not reported
• Protein intake, % E (95% CI): intervention 16.3 (15.7 to 16.9), control 15.8 (15.
1 to 16.6)
• Alcohol intake, % E: not reported
Compliance by other measures: measured by capsule counting, 88.5% of participants
consumed > 90% of capsules provided
Inclusion basis: dietary intake data suggested total PUFA intake 0.7% E higher in
control than intervention (> 10% increase from baseline of 6.2% E from PUFA)
PUFA dose: 0.7% E
Length of intervention: 12 months
Outcomes Main trial outcome: endothelial function, arterial stiffness
Dropouts: 38 intervention (13,13,12), 17 control
Available outcomes (for G2 vs control used): lipids, dietary intake, CRP, BP (supine and
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ambulatory - numeric data not provided, but trial states that there were no significant
differences between arms). Weight data not used, as baseline is different between groups
(FMD, arterials stiffness, carotid intimamedia thickness, heart rate variability, heart rate,
endothelial progenitor cells reported but not used)
Contact with authors: yes (many outcomes above provided in end of trial report from
authors)
Notes NOTE: outcome data used G2 (0.9 g/d EPA + DHA) vs placebo for continuous out-
comes, as this was the comparisonwhere dietary data suggested that total PUFA increased
by > 10% compared with placebo
Trial funding: Food Standards Agency
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the random allocation sequence
was generated with a computer program by
using the process of minimisation to bal-
ance age, sex and ethnicity between treat-
ment groups.”
Allocation concealment (selection bias) Low risk Quote: “We enrolled eligible participants
and the trial database program allocated a
series of capsules to the participant”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “blends of the test fat with 0.1wt%
peppermint oil to disguise the fish taste of
the EPA and DHA”
Peppermint oil in both intervention and
control capsules.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The treatments associatedwith the
capsule codes were concealed from all in-
vestigators and associated clinical staff until
the data analysis was complete. The code
breaker was an employee of MedSciNet
who constructed the trial database.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 15% withdrawal, reasons for attrition re-
ported
Selective reporting (reporting bias) Low risk Outcomes published match trials register.
Registered September 2008, trial started
June 2008, ended December 2010, main
publication 2011
Attention bias Low risk No difference between groups
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Compliance High risk EPA and DHA in erythrocyte lipids in-
creased in dose-dependent manner com-
pared with placebo, indicating long-term
compliance with intervention. TC rose by
0.1 mmol/L in both the control and inter-
vention (G2, 0.9 g/d group) from baseline
to end. No other biomarkers reported
Other bias Low risk None noted
McIllmurray 1987
Methods RCT, parallel, 2 arms (GLA vs “inert placebo”), 40 months
Summary risk of bias: moderate to high
Participants People within 1 month following operation to remove Dukes’s C colorectal cancer
N: intervention 25 (plus some dropouts), control: 24 (plus some dropouts (analysed
intervention 25, control 24). 5 dropped out, but arms unclear
Level of risk for CVD: low
Male: not reported
Mean age (SD) years: intervention 62.1 (not reported), control 64.8 (not reported)
Age range: intervention 48-81, control 45-77
Smokers: not reported
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: UK
Ethnicity: not reported
Interventions Type: supplement (Efamol)
Comparison: GLA vs “inert placebo” (unclear what)
Intervention: 6 capsules/d containing 500 mg GLA plus 10 mg natural vitamin E
(Efamol). GLA 0.5 g/d, 60mg/d vitamin E. Plus vitamin supplements including vitamin
C, zinc sulphate and pyridoxine
Control: 6 capsules/d containing an inert placebo, identical in appearance (not specified
what). Plus vitamin supplements including vitamin C, zinc sulphate and pyridoxine
Dose aim: (assuming placebo contains no PUFA) increase 0.5 g/d GLA, 5 kcal or 0.
2% E GLA, assume 70% LA*, 4.2 g/d or 37.8 kcal/d or 1.9% E LA, 2.1% E n6
Baseline PUFA: unclear
Compliance by biomarkers: unclear, no serum TC or tissue fatty acid levels reported.
Compliance by dietary intake: unclear, states that one participant stopped taking the
supplements at 12 months
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
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• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other methods: not reported
Inclusion basis: aimed to increase GLA rather than total PUFA. Aimed to increase
omega-6 by 2.1% E, assume 2.2% E increase for PUFA, > 10% of assumed 6% E PUFA
baseline. No confirmatory biomarker, TC or intake data
PUFA dose: 2.2% E PUFA
Duration of intervention: 40 months
Outcomes Main trial outcome: unclear, “survival”, probably mortality
Dropouts: 5 (unclear from which groups)
Available outcomes: mortality, cancer mortality (face flushing reported as a side effect,
but no numbers provided and assumed due to concomitant pyridoxine)
Response to contact: Professor McIllmurray replied, “I don’t have the records...so I have
nothing more than what appears in the publication. I do not recall there being any
cardiovascular events.”
Notes Trial funding: not stated, Efamol Ltd provided the Efamol capsules and inert capsules
*EPO described as being ~70% LA in some publications, this and a 1 g capsule size have
been assumed where no other details are provided
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “assigned at random”
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No details apart from the placebowas iden-
tical in appearance to the Efamol capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5 dropouts, unclear from which arms
Selective reporting (reporting bias) Unclear risk No protocol or trials register entry found
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Attention bias Low risk Supplement provided, no suggestion of at-
tention bias
Compliance Unclear risk Neither tissue PUFA biomarkers nor TC
data reported
Other bias Unclear risk None noted, but contents of placebo cap-
sules unclear
Mendis 2001
Methods RCT, 2 arms, parallel (n6 LA vs non-fat) dietary advice, 1 year
Summary risk of bias: moderate to high
Participants Healthy volunteers responding to survey. Some had hyperlipidaemia.
CVD risk: low
N: 30 intervention, 30 control (analysed 26 intervention, 28 control)
% male: 78% (total)
Mean age: not reported
Age range: 20-65 years
Smokers: not reported
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
*lipid-lowering medications as well as many others were not allowed
Location: Sri Lanka
Ethnicty: 100% Sri Lanakan
Interventions Type: diet advice plus test fat supplement
Comparison: n-6 vs non-fat (unclear if CHO, protein or both)
Intervention: group B received a diet containing 20% E as fat (4.7% coconut fat) plus 7.
5 g/d test fat containing soybean fat-sesame fat (3:1, v/v containing PUFA:MUFA ratio
2). Fat intake in group B was, therefore, 24% energy intake. (test fat provided additional
5 g/d PUFA mainly LA)
Control: Group A received a diet containing 20% E as fat (4.7% E coconut fat)
Dose aim: increase 5 g/d PUFA, 2.2% E PUFA
Baseline PUFA: unclear
Compliance by biomarkers: poor, serum TC was not significantly reduced in inter-
vention compared to control (0.16 mmol/L, 95% CI -0.18 to 0.50). The intervention
group were stated as having higher dietary PUFA:SFA ratio than controls, but no blood
levels of fatty acids were reported
Compliance by dietary intake: unclear, measured by field workers’ visits and using food
diaries
• Energy intake, kJ/d: intervention 7962 (SD 1568), control 8030 (SD 1465)
• Total fat intake, % E: intervention 24 (SD not reported), control 20 (SD not
reported)
• SFA intake % E: intervention 11.4 (SD not reported), control 11.8 (SD not
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reported)
• PUFA intake: not reported (unsaturated fat intake intervention 12.6% E, control
8.2% E, test fat reported as mainly LA)
• PUFA n-3 intake: not reported
• PUFA n-6 intake: (unsaturated fat intake intervention 12.6% E, control 8.2% E,
test fat reported as mainly LA)
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake, % E: intervention 64 (SD not reported), control 67 (SD not
reported)
• Sugars intake: not reported
• Protein intake, % E: intervention 12.2 (SD not reported), control 12.1 (SD not
reported)
• Alcohol intake: not reported
Compliance, other methods: not reported
Inclusion basis: did not aim to increase PUFA (but replace SFA with unsaturated fats)
. Did appear to increase unsaturated fat by 4.4% E, and test fat reported as mainly LA.
Aim was to increase PUFA by 2.2% E, assume this achieved though no biomarker or
dietary intake data and TC was not reduced in intervention
PUFA dose: 2.2% E PUFA
Duration of intervention: 1 year
Outcomes Main trial outcome: serum lipids
Dropouts: intervention 4, control 2
Available outcomes: lipids
Response to contact: contact attempted but no response to date
Notes Trial funding: funded by the National Science Foundation of Sri Lanka
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomised to 2 groups
(groups A and B). This was done in such
a way that the 38 hyperlipidaemic partici-
pants were equally
divided between the two groups.
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The groups had different diets with test fat
added to intervention group
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
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Incomplete outcome data (attrition bias)
All outcomes
High risk Six participants dropped out at 6 months
but their data are not included in the anal-
ysis at all
Selective reporting (reporting bias) Unclear risk No protocol or trial register entry found
Attention bias Low risk Appeared similar
Compliance High risk TCwas higher in intervention than control
(0.16mmol/L, 95%CI -0.18 to 0.50). The
intervention group were stated as having
higher dietary PUFA:SFA ratio than con-
trols, but no blood levels of FAs were re-
ported
Other bias Unclear risk No details provided on the form or method
of supply of diet or test fat
Mita 2007
Methods RCT, parallel, (n3 EPA vs nil), 2 years
Summary risk of bias: moderate or high
Participants Japanese people with type 2 diabetes
N: intervention 40, control 41 (analysed 30, 30)
Level of risk for CVD: moderate
Male: 53% intervention, 67% control
Mean age (SD): 59 (11.2) intervention 61.2 (8.4) control
Age range: not reported
Smokers: 40% intervention, 43% control
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: oral hypoglycemics
Medications taken by 20%-49% of those in the control group: insulin, lipid-lowering
drugs, antihypertensives
Medications taken by some, but < 20% of the control group: antithrombotics
Location: Japan
Ethnicity: 100% Japanese
Interventions Type: supplement (EPA oil capsules)
Comparison: EPA vs nil
Intervention: 1.8 g/d EPA as EPADEL capsules (Mochida Pharmaceutical Co Ltd Japan)
98% pure ethyl-ester EPA (unclear how many capsules)
Control: no intervention
Dose aim: increase 1.8 g/d EPA +DHA, 0.8% E n-3, assumed 0.8% E from total PUFA
as no control
Baseline PUFA not reported
Compliance by biomarkers: no tissue fatty acids reported, but TC lower in intervention
arm (5.37 mmol/L SD 0.74 at baseline, 5.15 mmol/L SD 0.83 at 2 years), than control
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(5.37 mmol/L SD 1.03 at baseline, 5.27 mmol/L SD 0.99 at 2 years)
Compliance by dietary intake: not reported
• Energy intake, kcal/d: not reported
• Total fat intake, % E: not reported
• SFA intake, %E: not reported
• PUFA intake, % E: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E: not reported
• Sugars intake: not reported
• Protein intake, % E: not reported
• Alcohol intake, % E: not reported
Compliance, other methods: checked during 3-month reviews throughout trial and 5
participants were excluded for poor compliance but no details on method or results
Inclusion basis: planned dose suggested in increase in total PUFA (by 0.8% E, > 10%
increase from an assumed baseline of 6% E), and higher PUFA in the intervention is
backed up by TC data
PUFA dose: 0.8% E
Length of intervention: mean 2.1 (0.2) years
Outcomes Main trial outcome: progression of diabetic macroangiopathy measured by carotid in-
tima-media thickness and brachial-ankle pulse wave velocity
Dropouts: 10 intervention, 11 control
Available outcomes: BMI, lipids, BP, HbA1c, cancer diagnosis (BP data not used as
groups very different at baseline)
Response to contact: not yet attempted
Notes Trial funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomly divided into 2
groups matched for age and gender
Allocation concealment (selection bias) Unclear risk No details




Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors of main trial outcomes were
blinded to the treatment
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout rate (26%) over 2 years. All drop-
outs explained, however, 5 were excluded
for poor compliance but no clear prede-
fined protocol for exclusion
Selective reporting (reporting bias) Unclear risk No protocol
Attention bias Low risk All participants had the same contact
Compliance Low risk No tissue fatty acids reported, butTC lower
in intervention arm (5.37 mmol/L SD 0.
74 at baseline, 5.15 mmol/L SD 0.83 at 2
years), than control (5.37 mmol/L SD 1.
03 at baseline, 5.27 mmol/L SD 0.99 at 2
years)
Other bias Low risk None noted
MRC 1968
Methods Medical Research Council (MRC)
RCT, 2 arm, parallel (n6 LA vs mixed fats), 4 years
Summary risk of bias: moderate to high
Participants Free-living men who have survived a first MI (UK)
CVD risk: high
Control: randomised 194, analysed 181 at 2 years
Intervention: randomised 199, analysed 172 at 2 years
Mean years in trial: control 3.7, intervention 3.8
% male: 100
Age: unclear
Age range: all < 60 years
Smokers: control 84%, intervention 81%
Hypertension: control 12%, intervention 8%
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: UK
Ethnicty: not reported
Interventions Type: diet advice plus supplement
Comparison: soya oil (n-6) vs usual diet (some SFA replacement, otherwise unclear)
Control aims: usual diet
Intervention aims: reduce dietary fat to 35 g/d fat, add 84 g/d soya oil
Dose aim: increase 84 g/d soya oil or 756 kcal or 37.8% E soya (assume 50% LA, so
18.9% E LA, assume 58% PUFA so21.9% E PUFA)
Baseline PUFA: unclear
Compliance by biomarkers: serum TC reported but without variance info, but TC
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lower in intervention than control consistently post-baseline. Report stated that, “tissue
fat of the men on the soya-bean oil diet was less saturated than that of the controls”
and that further information would be published elsewhere. No statistical significance
or variance data mentioned
Compliance by dietary intake: unclear
• Energy intake, kcal/d: intervention 2380 (SD not reported), control 2274 (SD
not reported)
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake, g/d: intervention 243 (SD not reported), control 228 (SD not
reported)
• Sugars intake, g/d: intervention 66 (SD not reported), control 60 (SD not
reported)
• Protein intake, g/d: intervention 80 (SD not reportedR), control 88 (SD not
reported)
• Alcohol intake: not reported
Compliance, other methods: not reported
Inclusion basis: aimed to replace SFA with PUFA.
PUFA dose: 21.9% E PUFA (aim)
Duration of intervention: 4 years
Outcomes Main trial outcomes: MI or sudden death
Dropouts: intervention 199 randomised, 181 at 2 years, 91 at 4 years. Control: 194
randomised, 172 at 2 years, 85 at 4 years
Available outcomes: mortality, CV mortality (CV deaths plus non-fatal MI), total MI,
non-fatal MI (data for weight, TC and BP, but no variance info)
Response to contact: reply from trial statistician, JA Heady, in 1999
Notes Some data not usable due to lack of variance. For all, data at 4 years, control N = 89,
intervention N = 88
Weight change: intervention 0 kg, control -3 kg
TC change: intervention -1.11 mmol/L, control -0.47 mmol/L
Systolic BP change: intervention +2 mmHg, control 0 mmHg
Diastolic BP change: intervention -1 mmHg, control +3 mmHg
Trial funding: Medical Research Council
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “using random numbers, by blocks
within hospitals”
Allocation concealment (selection bias) Unclear risk Not described
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Big changes to fat intake in intervention
group while control group ate their usual
diet
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Suspected relapses were assessed at
regular intervals by a review committee un-
aware of the patients diet group”
Incomplete outcome data (attrition bias)
All outcomes
High risk Data collection was thorough, but some
participants dropped out and contact was
lost
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry located
Attention bias High risk Dietary intervention, control ate usual diet,
so likely that intervention group received
more time and support, though this is not
clear from paper
Compliance Low risk TC lower in intervention than control con-
sistently post-baseline. Report stated that
“tissue fat of the men on the soya-bean oil
diet was less saturated than that of the con-
trols” and that further information would
be published elsewhere
Other bias Low risk None noted
NDHS Faribault 1968
Methods National Diet-Heart Study (NDHS) - Faribault site
RCT, several arms, parallel (n6 LA vs SFA), 1 year
Summary risk of bias: low
Participants Men living in a mental health institute
CVD risk: low
N: interventions B, C, E combined: randomised 167, analysed 143; control: randomised
57, analysed 52
Mean years in trial: interventions 0.9, control 1.0,
% male: 100
Age: unclear
Age range: all 45-54 years
Smokers: 55%-59% current smokers in each arm
Hypertension: unclear
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: USA
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Ethnicty: not reported
Interventions Type: diet provided (residential institution)
Comparison: PUFA (n-6) vs usual institutional diet (SFA and MUFA)
Control aims: total fat 40% E, SFA 16%-18% E, dietary cholesterol 650-750 mg/d, P/
S 0.4 (so PUFA 6.8% E) (whole diet provided)
Intervention aims: B (C, E) total fat 30% E (40% E, 40% E), SFA < 9% E (< 9% E,
not stated), dietary cholesterol 350-450 mg/d (350-450 mg/d, not stated), PUFA 15%
E (18-20% E, not stated), P/S 1.5 (2.0, 4.4) (equivalent to Minnesota Coronary Trial
diet) (whole diet provided)
Dose aim: increase B 8.2% E, C 12.2% E, E unclear n-6
Baseline n-6 (table IX2): 4.4% E LA, 4.8% E PUFA
Compliance by biomarkers: serum TC significantly reduced in intervention compared
to control (-0.91 mmol/L, 95% CI -1.17 to -0.65). Fatty acid composition of red blood
cells suggests that LA was higher in intervention arms (table X6: LA rose by 4 in control,
by 5-7 in other arms, at the expense of MUFA, which rose by 1 in control, fell by 4 or 5
in other arms. Palmitic acid fell by 5 in control, and fell by 4 in intervention arms, stearic
did not alter in control, rose by 1 or 2 in intervention arms - no statistical significance
or variance info provided, units unclear, probably % of LA+oleic+palmitic+stearic)
Compliance by dietary intake: good. Assessed from 7-day food records after 28 and
44 weeks combined (tables IX8&9)
• Energy intake, kcal/d: intervention B 2549, intervention C 2599, intervention E
2560, control D 2593
• Total fat intake, % E: intervention B 29.0, intervention C 38.5, intervention E
37.1, control 39.5 (decrease B 10.5% E, C 1.0% E, E 2.4 total fat)
• SFA intake, % E: intervention B 6.1, intervention C 7.0, intervention E 4.6,
control D 15.6 (decrease B 9.5% E, C 8.6% E, E 11.0% E SFA)
• PUFA intake, % E: intervention B 12.1, intervention C 17.8, intervention E 22.
3, control D 4.6 (increase B 7.5%E, C 13.2% E, E 17.7% E PUFA)
• PUFA n-3 intake: not reported
• PUFA n-6 intake, % E LA: intervention B 11.6, intervention C 16.9,
intervention E 21.9, control D 4.3 (increase B 7.3% E, C 12.6% E, E 17.6% E LA)
• Trans fat intake: not reported
• MUFA intake, % E: intervention B 10.8, intervention C 13.7, intervention E 10.
2, control D 19.3 (decrease B 8.5% E, C 5.6% E, E 9.1% E MUFA)
• CHO intake, % E: intervention B 55.3, intervention C 45.8, intervention E 48.
6, control D 45.1 (increase B 10.1% E, C 0.7% E, E 3.5% E CHO)
• Sugars intake: not reported
• Protein intake, % E: intervention B 17.0, intervention C 16.7, intervention E 15.
7, control D 16.4 (increase B 0.6% E, C 0.3% E, E -0.7% E protein)
• Alcohol intake: not reported
Compliance, other methods: 3.6% of days were lost (diet not eaten)
Inclusion basis: aimed to increase PUFA intake as well as increase PUFA/SFA, reduce
SFA slightly and reduce dietary cholesterol
PUFA dose: B 7.5% E, C 13.2% E, E 17.7% E PUFA
Duration of intervention: 1 year
Outcomes Main trial outcomes: lipid levels and dietary assessment
Dropouts: B 7, C 10, E 7, D (control) 5
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Available outcomes: mortality, TC (weight and TG data available but without SDs)
Response to contact: not attempted as trial completed in 1967
Notes Data entered as all interventions combined (B+C+E) vs control (D)
Dose calculations
Interventions: B PUFA 15% E, 8.2% E
Control: 17% E SFA, P/S 0.4 so PUFA 6.8% E
C PUFA 19% E, 12.2% E
D unclear % E?
Mean for all interventions 10.2% E
Trial funding: National Heart Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation by the statistical
centre
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Institution so all participants and trial staff
blinded to allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were reported as
blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Institution so able to follow-up all partici-
pants through trial
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry found
Attention bias Low risk Equivalent, diet provided to both groups
Compliance Low risk TC significantly reduced in intervention
compared to control (-0.91 mmol/L, 95%
CI -1.17 to -0.65). Fatty acid composition
of red blood cells suggests LA was higher in
intervention arms
Other bias Low risk None found
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Methods National Diet-Heart Study (NDHS) - open first phase
RCT, several arms, parallel (n6 LA vs SFA), 1 year
Summary risk of bias: low
Participants Free-living men aged 45-54 years
CVD risk: low
Interventions B, C, X combined: randomised 829, analysed 726
Control: randomised 382, analysed 341
Mean years in trial: control 0.95, Interventions 0.93
% male: 100
Age: unclear
Age range: all 45-54 years
Smokers: 39%-40% current smokers in each arm
Hypertension: unclear
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: USA
Ethnicty: white 98.2%, non-white 1.8% (not reported by intervention arm)
Interventions Type: diet provided (bought from a trial shop)
Comparison: PUFA (n-6) vs usual diet (replacement of SFA and MUFA)
Control aims: total fat 40% E, dietary cholesterol 650-750 mg/d, P/S 0.4 (assume PUFA
6.8% E as at Faribault) (foods bought from a trial shop - normal foods)
Intervention aims: B (C, X) total fat 30% E (40% E, 30% E), SFA < 9% E (< 9% E, <
9% E), dietary cholesterol 350-450 mg/d (350-450 mg/d, 350-450 mg/d), PUFA 15%
E (18% E-20% E, 15% E), P/S 1.5 (2.0, 1.5) (foods bought from a trial shop - SFAs
removed and replaced by polyunsaturated oils and fats)
Dose aim: increase B 8.2% E, C 12.2% E, X 8.2% E n-6
Baseline n-6 (tables IX 1&3): 3.7% LA, 3.9% PUFA
Compliance by biomarkers: serum TC significantly reduced in intervention compared
to control (-0.45 mmol/L, 95% CI -0.55 to -0.35). Data on fatty acid composition of
red blood cells provided in chapter 10 (table X6: LA rose by 1 in control, by 2-3 in
other arms, at the expense of MUFA which did not alter in control, fell by 2-3 in other
arms. Palmitic acid remained constant in control and remained constant or fell by 1 in
intervention arms, stearic did not alter in control and remained constant or rose by 1
in intervention arms - no statistical significance or variance info provided, units unclear,
probably % of LA+oleic+palmitic+stearic)
Compliance by dietary intake: good. Nutritionists’ subjective adherence ratings of
excellent or good (as compared to fair or poor) intervention B 58%, intervention C 60%,
control D 55%. Dietary intake computed from 7-day food records at 28 weeks (table
IX3, no later data found):
• Energy intake, kcal/d: intervention B 2154 (SD432), intervention C 2262
(SD435), intervention X 2117 (SD447), control D 2228 (SD456)
• Total fat intake, % E: intervention B 29.7, intervention C 34.4, intervention X
31.7, control D 34.9 (decrease B 5.2% E, C 0.5% E, X 3.2 total fat)
• SFA intake, % E: intervention B 7.1, intervention C 7.4, intervention X 8.9,
control D 11.6 (decrease B 4.5% E, C 4.2% E, X 2.7% E SFA)
• PUFA intake, % E: intervention B 9.9, intervention C 13.2, intervention X 6.5,
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control D 4.9 (increase B 5.0% E, C 8.3% E, X 1.6 PUFA)
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported, probably similar to PUFA
• Trans fat intake: not reported
• MUFA intake, % E (by subtraction of SFA and PUFA from total fat):
intervention B 12.7, intervention C 13.8, intervention X 16.3, control D 18.4
(decrease B 5.7% E, C 4.6% E, X 2.1% E MUFA)
• CHO intake, % E: intervention B 48.7, intervention C 45.3, intervention X 49.
5, control D 44.7 (increase B 4.0% E, C 0.6% E, X 4.8% E CHO)
• Sugars intake: not reported
• Protein intake, % E: intervention B 18.6, intervention C 17.6, intervention X 17.
1, control D 17.4 (increase B 1.2% E, C 0.2% E, X -0.3% E protein, little change)
• Alcohol intake, % E: intervention B 2.1, intervention C 2.1, intervention X 1.7,
control D 2.2 (minimal change)
Compliance, other methods: also assessed adherence ratings by nutritionists, subjec-
tively, by recall and by food records. Poor adherence by 17%-29%, others were fair, good
or excellent
Inclusion basis: aimed to increase PUFA intake as well as increase PUFA/SFA, reduce
SFA slightly and reduce dietary cholesterol
PUFA dose: achieved B 5.0% E, C 8.3% E, X 1.6 PUFA
Duration of intervention: 1 year
Outcomes Main trial outcomes: lipid levels and dietary assessment
Dropouts: intervention B 42, C 34, X 5, control D 36
Available outcomes: CV events (MI and PAD events), cancer diagnoses, TC (weight,
diastolic BP and TG data available but without SDs)
Response to contact: not attempted as trial completed in 1967
Notes All intervention arms combined for data analysis
Aim was to replace saturates with polyunsaturates, but oils used were omega-6 fats
Dose calculations
Control: assume from Faribault 17% E SFA, P/S 0.4 so PUFA 6.8% E
Interventions: B PUFA 15% E, 8.2% E
C PUFA 19% E, 12.2% E
X PUFA 15% E, 8.2% E Mean for all interventions 10% E
Trial funding: National Heart Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation by the statistical
centre
Allocation concealment (selection bias) Low risk Stratified randomisation by the statistical
centre
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and trial personnel (aside from
the store manager) were blinded to alloca-
tion. Blinding of participants was checked
using a questionnaire, which found no dif-
ference between intervention and control
participants in guesses at dietary composi-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were reported as
blinded to treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12% dropouts, well described
Selective reporting (reporting bias) Unclear risk No protocol or trial registry entry found
Attention bias Low risk Equivalent, both groups bought special
foods from trial shop
Compliance Low risk TC significantly reduced in intervention
compared to control (-0.45 mmol/L, 95%
CI -0.55 to -0.35). Data on fatty acid com-
position of red blood cells shows LA rose
by 1 in control, by 2-3 in other arms, at the
expense of MUFA, which did not alter in
control, fell by 2 or 3 in other arms
Other bias Low risk None noted
Nodari 2011 AF
Methods RCT, parallel, (n3 DHA + EPA vs MUFA), 12 months
Summary risk of bias: moderate or high
Participants Adults with persistent AF with ≥ 1 relapse after cardioversion
N: 102 intervention, 103 control (analysed, intervention: 94 control: 94)
Level of risk for CVD: high
Male: 70% intervention, 63% control
Mean age (SD): 70 (6) intervention, 69 (9) control
Age range: not reported (18-80 inclusion criteria)
Smokers: 10% intervention, 9.1% control
Hypertension: 47% intervention, 40% control
Medications taken by ≥ 50% of those in the control group: beta-blockers, ACE in-
hibitors, anticoagulant therapy, amiodarone
Medications taken by 20%-49% of those in the control group: diuretics, antiplatelet,
statins
Medications taken by some, but < 20% of the control group: Ca channel blockers
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Location: Italy
Ethnicity: not reported
Interventions Type: supplement (Omacor)
Comparison: EPA and DH+A vs MUFA
Intervention: 2 x1 g/d Omacor (total 1.7 g/d EPA + DHA at a ratio of 0.9-1.5)
Control: 2 x1 g/d olive oil (gelatin capsules identical in appearance to Omacor)
Dose aim: increase 1.7 g/d EPA + DHA, 0.8% E n-3, 0.8% E PUFA
Baseline PUFA not reported
Compliance by biomarkers: unclear, no biomarkers, no TC reported.
Compliance by dietary intake: not reported
• Energy intake, kcal/d: not reported
• Total fat intake, % E: not reported
• SFA intake, %E: not reported
• PUFA intake, % E: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E: not reported
• Sugars intake: not reported
• Protein intake, % E: not reported
• Alcohol intake, % E: not reported
Compliance, other measures: none reported
Inclusion basis: intended dose was an increase 1.7 g/d EPA + DHA without differences
in other PUFAs, so assumed dose 0.8% E PUFA, > 10% increase in total PUFA from
assumed baseline of 6% E. No biomarker, TC or dietary intake data to support this
PUFA dose: 0.8% E
Duration of intervention: 12 months
Outcomes Main trial outcome: probability of maintenance of sinus rhythm
Dropouts: 6 intervention, 5 control
Available outcomes: adverse events, AF recurrence (nil death)
Response to contact: no (contact established with trial author but no data received in
this trial)
Notes Trial funding: ‘Centro per lo Studio ed il Trattamento dello Scompenso Cardiaco’ of the
University of Brescia, Brescia, Italy. The work of Dr Campia was supported by National
Institutes of Health grant K12 HL083790-01a1
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random assignment followed a computer-
generated randomisation list obtained us-
ing blocks of size 4
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Allocation concealment (selection bias) Low risk The randomisation schedule was kept in
the research pharmacy area and was avail-
able only to unblinded pharmacy person-
nel until after the database was locked. At
that time, the unblinded patient treatment
information was made available to the in-
vestigators
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Placebo gelatin capsules identical in ap-
pearance toOmacor.However no informa-
tion provided as to their smell and taste
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised were accounted for. ITT
for main outcomes
Selective reporting (reporting bias) Unclear risk NCT01198275. Registered retrospectively
in September 2010, trial started January
2006, completed May 2008, main publi-
cation 2011
Attention bias Low risk No difference between groups
Compliance Unclear risk No biomarkers, no TC reported
Other bias Low risk None noted
Nodari 2011 HF
Methods RCT, parallel, (n3 DHA + EPA vs MUFA), 12 months
Summary risk of bias: moderate or high
Participants People with heart failure (non-ischaemic dilated cardiomyopathy)
N: 67 intervention, 66 control (analysed, intervention: 67 control: 66)
Level of risk for CVD: high
Male: 95.5% intervention, 84.9% control
Mean age (SD): 61 (11) intervention, 64 (9) control
Age range: not reported (18-75 inclusion criteria)
Smokers: not reported
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: beta-blockers, ACEi,
furosemide, amiodarone, aldosterone blockers
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: statins, ARB
Location: Italy
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Ethnicity: not reported
Interventions Type: supplement (Omacor)
Comparison: EPA + DHA vs MUFA
Intervention: 2 x1 g/d Omacor (1.7 g/d EPA + DHA at a ratio of 0.9:1.5)
Control: 2 x1 g/d olive oil (gelatin capsules identical in appearance to Omacor)
Dose aim: increase 1.7 g/d EPA + DHA, 0.8% E n-3, 0.8% E PUFA
Baseline PUFA not reported
Compliance by biomarkers: circulating free fatty acid EPA +DHA0.83%of circulating
FFAs in intervention group, 0.41% in control group, but no omega-6 or total PUFA
reported. TC equivalent at baseline (187 mg/dL) and similar at 1 year (4.8 mmol/L, SD
0.62 intervention, 4.9 mmol/L, SD 0.62 control)
Compliance by dietary intake: not reported
• Energy intake, kcal/d: not reported
• Total fat intake, % E: not reported
• SFA intake, %E: not reported
• PUFA intake, % E: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E: not reported
• Sugars intake: not reported
• Protein intake, % E: not reported
• Alcohol intake, % E: not reported
Compliance, other measures: pill counts - participants were withdrawn if < 80% capsules
taken (none were withdrawn)
Inclusion basis: intended dose was an increase 1.7 g/d EPA + DHA without differences
in other PUFAs, so assumed dose 0.8% E PUFA, > 10% increase in total PUFA from
assumed baseline of 6% E. No biomarker or dietary intake data but supported by TC
PUFA dose: 0.8% E
Duration of intervention: 12 months
Outcomes Main trial outcome: left ventricular function and functional capacity
Dropouts: 0 intervention, 0 control
Available outcomes: mortality (nil death), combined CVD events, AF, BMI, hospitali-
sation for CV reasons, hospitalisation for worsening heart failure, lipids, blood glucose
(but too different at baseline to use), serum cytokine
Response to contact: yes, additional data and methodological data provided
Notes Trial funding: Centro per lo Studio ed il Trattamento dello Scompenso Cardiaco, one
author was a consultant for 8 pharmaceutical companies
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised”
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Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Paper states that placebo and verum were
identical and that the trial was double-
blind, but blinding of participants not
checked. Trial author confirmed investiga-
tors not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Trial author confirmed assessors not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear whether all participants were as-
sessed for all outcomes (e.g. hospitalisation)
, but some outcomes report no attrition
Selective reporting (reporting bias) Unclear risk NCT01223703 - trial registration Octpber
2010, recruitment November 2007-June
2009. Retrospective
Attention bias Low risk No suggestion of this, and investigators ap-
peared blinded (so could not differ in at-
tention provided by allocation)
Compliance High risk Circulating free fatty acid EPA + DHA
0.83% of circulating FFAs in interven-
tion group, 0.41% in control group, but
no omega-6 or total PUFA reported. TC
equivalent at baseline (187 mg/dL) and
similar at 1 year (4.8 mmol/L, SD 0.62 in-
tervention, 4.9 mmol/L, SD 0.62 control)
Other bias Low risk None noted
Nye 1990
Methods Randomisation: parallel, 3 groups (n3 EPA vs MUFA vs aspirin and dipyridamole), 1
year
Risk of bias: moderate or high
Participants People undergoing percutaneous transluminal coronary angioplasty
N: 36 intervention, 37 control (also 35 allocated to arm 3, aspirin and dipyridamole)
Level of risk for CVD: high (people undergoing angioplasty)
Male: 78% intervention, 76% control
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Nye 1990 (Continued)
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: New Zealand
Ethnicity: unclear
Interventions Type: supplement (capsules)
Comparison: EPA vs MUFA
Intervention: maxEPA capsules 12/d (2.2 g EPA)
Control: olive oil capsules, 12/d, identical to MaxEPA. Both capsules had vit E
Dose aim: increase 2.2 g/d EPA + DHA, 1.0% E n-3, 1.0% E PUFA
Baseline PUFA not reported
Compliance by biomarkers: plasma EPA increased in the intervention group by 0.49
mmol/L (95%CI 0.34-0.64), while were ”unchanged“ in the control group, but no other
PUFA data were presented. However, TC appeared higher in the intervention group (6.
55 mmol/L, SD 1.09 in intervention, 6.07 mmol/L, SD 1.33 in control, presumably at
the end of the intervention)
Compliance by dietary intake: not reported
• Energy intake, kcal/d: not reported
• Total fat intake, % E: not reported
• SFA intake, % E: not reported
• PUFA intake, % E: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E: not reported
• Sugars intake: not reported
• Protein intake, % E: not reported
• Alcohol intake, % E: not reported
Compliance, other measures: none reported
Inclusion basis: intended dose was an increase 2.2 g/d EPA +DHA.With no suggestion
of differences in other PUFAs assumed dose was 1.0% E PUFA, > 10% increase in
total PUFA from assumed baseline of 6%E. No biomarker or dietary intake data but
challenged by TC
PUFA dose: 1.0% E
Duration of intervention: 12 months
Outcomes Main trial outcome: angina, restenosis
Dropouts: none
Available outcomes: angina, interventions, lipids (nil death)
Response to contact: not attempted
Notes Trial funding: Medical Rsearch Council of New Zealand and Scherer Ltd (who supplied
MaxEPA and the olive oil capsules)
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: ”randomly divided without exclu-
sions into 3 groups“
Allocation concealment (selection bias) Unclear risk Unclear, no further info
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States that placebo capsules were identical
to the MaxEPA, and
Quote: ”neither the patient nor the attend-
ing cardiologist knew which capsules were
being used“
But no masking of taste was reported, and
participant guesses as to allocationwere not
reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: ”Neither the patient, nor the at-
tending cardiologist knew which capsules
were being used” ... “Angioplasty was re-
peated electively at one year or before where
symptoms recurred, and assessed without
knowledge of the patient’s treatment group.
”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some participants were lost to follow-up
and reasons for this were unclear
Selective reporting (reporting bias) Unclear risk No protocol or trials registration found
Attention bias Low risk No suggestion of attention bias, symp-
tomatic participants were reviewed be-
tween scheduled visits, otherwise all on the
same schedule
Compliance High risk Plasma EPA increased in the intervention
group by 0.49 mmol/L (95% CI 0.34-0.
64), while were “unchanged” in the control
group, but no other PUFA data were pre-
sented. However, TC appeared higher in
the intervention group (6.07 mmol/L, SD
1.33 in control, 6.55 mmol/L, SD 1.09 in
intervention, presumably at the end of the
intervention)
Other bias Low risk No further bias noted
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Methods RCT- parallel, 3 arms (n3 EPA + DHA high dose vs n3 EPA + DHA low dose vs n3
EPA), 12 months
Summary risk of bias: moderate or high
Participants Population: Japanese adults with hypertriglyceridaemia
N: 171 intervention (4 g TAK), 165 control (2 g TAK)
Level of risk for CVD: moderate
Male: 70.8% intervention, 71.5% control
Mean age (SD): 55.9 (10.12) intervention, 56 (10.95) control
Age range: 20-74
Smokers (current): 27.5% intervention, 31.5% control
Hypertension: 66.7% intervention, 67.3% control
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49%: statin
Medications taken by some, but < 20%: not reported
Location: Japan
Ethnicity: unclear
Interventions Type: supplement (TAK-085 capsules)
Comparison: EPA + DHA higher vs lower dose
Intervention: 1 x2 /d capsule each containing 2 g of TAK-085 (1 g of fatty acid in TAK-
085 capsules contains approximately 465 mg of EPA-E plus 375 mg of DHA-E). Total
dose of 1.86 g/d EPA & 1.5 g/d DHA
Control: 1 capsule/d containing 2 g of TAK-085 (1 g of fatty acid in TAK-085 capsules
contains approximately 465 mg of EPA-E plus 375 mg of DHA-E) Total dose of 0.93
g/d EPA and 0.75 g/d DHA
Dose aim high TAK vs low TAK: increase 1.68 g/d EPA + DHA, 0.8% E n3, 0.8% E
PUFA assumed (no details of other capsule components provided)
Baseline PUFA not reported
Compliance by biomarkers: plasma free fatty acids did not differ between high and low
TAK for AA, while EPA and DHA were higher in high TAK by 52 weeks. There was
a small difference in change in TC between high and low TAK, statistical significance
unclear
Compliance by dietary intake: not reported
• Energy intake, kcal/d: not reported
• Total fat intake, % E: not reported
• SFA intake, % E: not reported
• PUFA intake, % E: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E: not reported
• Sugars intake: not reported
• Protein intake, % E: not reported
• Alcohol intake, % E: not reported
Compliance by pill count or equivalent: monitored every 4 weeks, mean rate of compli-
ance reported as > 96% in each group
Inclusion basis: intended omega-3 increase in high TAK was 0.8% E greater than low
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TAK, and no suggestion of different intakes of other PUFAs between arms
PUFA dose: 0.8% E
Duration of intervention: 12 months
Outcomes Main trial outcome: safety outcomes and adverse events
Dropouts: 8 G1, 14 G2, 21 G3
Available outcomes: adverse events (including CVD events, cancers), CRP, waist cir-
cumference, weight, BP (nil death), lipids provided as % change from baseline, but no
baseline data available, so not used in meta-analyses
Response to contact: contact attempted but no response to date
Notes A third arm of EPA-E 1.8 g supplementation is not used here. Outcome data used TAK-
4 vs TAK-2
Trial funding: funded by Takeda Pharmaceutical Company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was stratified according to
statin use and performed by an indepen-
dent registration centre
Allocation concealment (selection bias) Low risk Randomisation was stratified according to
statin use and performed by an indepen-
dent registration centre




Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open- label
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were accounted for and
analysed for main outcomes
Selective reporting (reporting bias) Low risk Trials registry entry May 2011, trial start
date November 2009, completion Novem-
ber 2011, so partially retrospective. How-
ever, entry appears to reflect reported out-
comes
Attention bias Low risk Capsules, appeared equivalent
Compliance Unclear risk Plasma free fatty acids did not differ be-
tween high and low TAK for AA, while
EPA and DHA were higher in high TAK
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by 52 weeks. There was a 1% difference in
change in TC between high and low TAK,
statistical significance unclear
Other bias Low risk None noted
PREDIMED 2013
Methods PREvención con Dieta MEDiterránea (PREDIMED)
RCT, parallel, 3 arms (high PUFA vs low PUFA, Mediterranean diet with nuts or olive
oil), also low-fat arm, 60 months
Summary risk of bias: moderate to high
Participants Men aged 55-80 years and women aged 60-80 years, free of CVD but with diabetes or
≥ 3 CVD risk factors
N: intervention (Med with nuts) 2454, control (Med with olive oil) 2543 - also low-fat
arm, not discussed here, 2450
Level of risk for CVD: moderate
Male: intervention 46%, control 41.3%
Mean age (SD): intervention 67 (6), control 67 (6) years
Age range: 55-80 years
Smokers: intervention 14.5%, control 13.9% (current smokers)
Hypertension: intervention 82.4%, control 82.1%
Medications taken by ≥ 50% of those in the control group: nil
Medications taken by 20%-49% of those in the control group: ACEi, diuretics, other
antihypertensives, statins, oral hypoglycaemics, antiplatelet therapy
Medications taken by some, but < 20% of the control group: insulin, non-statin lipid-
lowering, hormone replacement therapy
Location: Spain
Ethinicty: white from Europe 97%, Hispanic from Central or South America 1%-2%,
other 1.5%
Interventions Type: dietary advice and food supplement
Comparison: PUFA vs MUFA
Intervention: Mediterranean dietary advice plus 30 g/d mixed nuts (15 g walnuts, 7.5 g
hazelnuts, 7.5 g almonds, provided, rich in ALA and linoleic) - intensive education on
diet with individual and up to 20 group sessions with dietitian
Control: Mediterranean dietary advice plus 1 L/week extra-virgin olive oil (provided) -
intensive education on diet with individual and up to 20 group sessions with dietitian
Dose aim: unclear, food rather than nutrient goals provided, nuts (PUFA) vs olive oil
(MUFA)
Baseline PUFA 6.4% E in intervention, 6.1% E in control
Compliance by biomarkers: unclear, no serum TC reported, no tissue fatty acids
Compliance by dietary intake: all assessed at end of trial using a 137-item food fre-
quency questionnaire
• Energy intake, kcal/d: intervention 2229 (SD 477), control 2172 (SD 475)
• Total fat intake, % E: intervention 41.5 (SD 6.1) (MD +0.4% E), control 41.2
(SD 5.4)
• SFA intake, % E: intervention 9.3 (SD 2.0), (MD -0.1% E), control 9.4 (SD 2.0),
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• PUFA intake, % E: intervention 7.7 (SD 1.8), (MD +1.6% E), control 6.1 (SD
1.4)
• PUFA n-3 intake (ALA plus marine omega-3), g/d: intervention 2.7 (SD not
reported), (MD +0.5 g/d), control 2.2 (SD not reported)
• PUFA n-6 intake, g/d: LA, intervention 16.0 (SD 5.5), (MD +3.8 g/d), control
12.2 (SD 4.6) g
• Trans fat intake: not reported
• MUFA intake, % E: intervention 20.9 (SD 4.1), (MD -1.2% E), control 22.1
(SD 3.7)
• CHO intake, % E: intervention 39.7 (SD 6.3), (MD -0.7% E), control 40.4 (SD
5.9)
• Sugars intake: not reported
• Protein intake, % E: intervention 16.4 (SD 2.5), (MD 0.2% E), control 16.2 (SD
2.4)
• Alcohol intake, % E: not reported
Compliance by other methods: scores on the 14-item Mediterranean-diet screener in-
creased for the participants in both Mediterranean diet groups. Participants assigned to
a Mediterranean diet with extra-virgin olive oil and those assigned to a Mediterranean
diet with nuts significantly increased their consumption of extra virgin olive oil (to 50
g/d and 32 g/d, respectively) and nuts (to 0.9 and 6 servings/week, respectively)
Inclusion basis: dietary intake data suggested total PUFA intake 1.6% E higher in
intervention than control
PUFA dose: 1.6% E
Duration of intervention: 56 months median
Outcomes Main trial outcome: CVD events
Dropouts: intervention 6.3% lost to follow-up for≥ 2 years, control 3.6% lost to follow-
up for ≥ 2 years
Available outcomes: deaths, CV mortality, stroke, MI, CV events. Outcome data not
altered in the republication of the main paper (Estruch 2018)
Response to contact: contact established but no additional data provided
Notes All data used were for the Mediterranean diet with nuts vs Mediterranean diet with olive
oil, which is higher vs lower PUFA. As nuts were mixed it is not clear whether they were
high in ALA or not (probably varied)
Trial funding: mainly governmental funding, but olive oil and nuts were provided by
companies
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Tables of random allocation were centrally
elaborated. However the main paper (Es-
truch 2013) was retracted and republished
(as Estruch 2018) following a statistical
analysis suggesting that baseline variables
did not appear consistent with randomi-
sation (Carlisle 2017). The republication
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states that partners were included in the
trial without randomisation (in the same
arms as family members) and that some
clinics allocated by clinic rather than apply-
ing the protocol specified individual ran-
domisation. This puts allocation conceal-
ment of some participants at high risk
Allocation concealment (selection bias) High risk Trial nurses in charge of the random alloca-
tion were independent of the nursing staff,
allocation was performed centrally. How-
ever, see note on random sequence genera-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Olive oil and nuts arms could not be
blinded to participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All medical records related to end
points were examined by the end-point
adjudication committee, whose members
were unaware of the trial-group assign-
ments.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “We used four sources of informa-
tion to identify end points: repeated con-
tacts with participants, contacts with fam-
ily physicians, a yearly review of medical
records, and consultation of the National
Death Index.”
Attritionwas < 10%per year, explained and
balanced.
Selective reporting (reporting bias) High risk Many outcomes in the trials registry entry
are not reported by allocated group for the
full set of trial participants (for example,
cognition)
Attention bias Low risk These appear very similar between the two
Mediterranean diet groups
Compliance Unclear risk Neither tissue PUFA biomarkers nor TC
data reported
Other bias High risk Retraction and republication in 2018 due
to randomisation problems not reported in
the initial publication. However, new out-
come data not provided
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Methods RCT, parallel, (n3 EPA + DHA high dose vs n3 EPA + DHA low dose), 12 months
Summary risk of bias: low
Participants People with rheumatoid arthritis < 12 months’ duration, disease-modifying anti-
rheumatic drugs (DMARD)-naive
N: 87 intervention, 53 control (analysed, intervention: 75 control: 47)
Level of risk for CVD: low
Male: 29% intervention, 25% control
Mean age (SD): 56.1 (15.9) intervention, 55.5 (14.1) control
Age range: unclear
Smokers: 65.1% intervention, 54.7% control (includes current & previous smokers)
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: triple DMARD therapy
(sulfasalazine 0.5 g/d, hydroxychloroquine 200 mg twice/day and methotrexate 10 mg
once/week)
Medications taken by 20%-49% of those in the control group: NSAIDS
Medications taken by some, but < 20% of the control group: oral or parenteral steroids
Location: Australia
Ethnicity: not reported
Interventions Type: supplement (fish oil)
Comparison: high EPA + DHA vs low EPA + DHA + MUFA
Intervention: 10 mL/d fish oil concentrate (BLT Incromega TG3525) providing 5.5 g/
d (3.2 EPA + 2.3 DHA)
Control: 10 mL/d Sunola oil:capelin oil (2:1) providing 0·21 g EPA + 0·19 g/d DHA
as TG (0.40 g/d EPA + DHA). Sunola oil was stated to be a monounsaturated oil
Dose aim: increase 5.1 g/d EPA + DHA, 2.3% E n-3, 2.3% E PUFA
Baseline PUFA not reported
Compliance by biomarkers: unclear, no serumTC reported, plasma phospholipid EPA
and DHA reported, but not by intervention group, no other tissue fatty acids reported
Compliance by dietary intake: not reported
• Energy intake, kcal/d: not reported
• Total fat intake, % E: not reported
• SFA intake, %E : not reported
• PUFA intake, % E: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E: not reported
• Sugars intake: not reported
• Protein intake, % E: not reported
• Alcohol intake, % E: not reported
Compliance by other methods: consumption checked at each visit. 100% compliance
would be consumptionof 3650mLoil at 12months. The fish oil groupwas less compliant
than the control group with median intakes of 2482 mL and 3248 mL, respectively (P
= 0.015, Mann-Whitney U test). This provided an average daily intake of EPA + DHA
of 3.7 g and 0.36 g in the fish oil and control groups, respectively
Inclusion basis: compliance data suggested that omega-3 fats increased by 3.3 g/d EPA
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+ DHA, or 29.7 kcal/d, or 1.5% E. This is > 10% increase of assumed 6% E total PUFA
intake at baseline, assuming no or minor PUFA in control (described as MUFA oil)
PUFA dose: 1.5% E total PUFA
Duration of intervention: 12 months
Outcomes Main trial outcome: DMARD failure and remission
Dropouts: 11 intervention, 6 control
Available outcomes: mortality (nil death), adverse events including CVD, Disease Ac-
tivity Score, diabetes, BMI change
Response to contact: yes, trial authors supplied methodology data plus BMI change
Notes DAS scores are reported as median and IQR in Proudman 2012 abstract (see Proudman
2015)
Trial funding: the trial was supported by ‘theNational HealthMedical Research Council
of Australia and Royal Adelaide Hospital Research Committee. Melrose Health has
provided support for ongoing studies.’ The oil used in the trial was made by the Royal
Adelaide Hospital Pharmacy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation schedule was
prepared using an online random num-
ber generator and involved randomly per-
muted blocks of size six.”
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed by
the RAH pharmacy, which also prepared
andprovided the study oils in 500mL iden-
tical dark brown bottles labelled with con-
secutive study numbers”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Both participants and investiga-
tors/assessors were blinded to the group al-
location. Although the control oil was paler
in colour than the fish oil, this was not evi-
dent in the brown bottles. The ‘fishy’ odour
of each oil was similar.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Both participants and investiga-
tors/assessors were blinded to the group al-
location”’
Quote: “Investigators and subjects re-
mained blinded for all withdrawals.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk The flow of all trial participants shown in
FIGURE 2
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Selective reporting (reporting bias) Unclear risk Outcomes reported
in trial register matched with the outcomes
reported in publications. However, the trial
was retrospectively registered - registered in
2013, recruitment began in 2001
Attention bias Low risk No difference between groups
Compliance Unclear risk NoTCreported, plasmaphospholipidEPA
and DHA reported, but not by interven-
tion group, no other tissue fatty acids re-
ported
Other bias Low risk None noted
Puri 2005
Methods RCT, parallel (n3 EPA vs non-fat), 2 arms, 12 months
Summary risk of bias: low
Participants People with Huntington’s disease
N: 67 intervention, 68 control (analysed, intervention: 39 control: 44)
Level of risk for CVD: low
Male: 57% intervention, 44% control
Mean age (SD): 50 (9.3) intervention, 49 (9.0) control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: antidepressants
Medications taken by some, but < 20%: neuroleptics
Location: Australia, Canada, UK, USA
Ethnicity: white (black, Asian) 94% (4%, 1%) intervention, 97% (3%, 0%) control
Interventions Type: supplement (ethyl-EPA)
Comparison: EPA vs paraffin (non-fat)
Intervention: 2 x 2 x 500 mg capsules/d, total dose of 2 g/d ethyl-EPA (code name LAX-
101, purity 95%)
Control: 2 x 2 x 500 mg capsules/d liquid paraffin
Dose aim: increase 1.9 g/d EPA + DHA, 0.86% E n-3, 0.86% E PUFA
Baseline PUFA not reported
Compliance by biomarkers: no serum TC reported, no tissue fatty acids reported
Compliance by dietary intake: not reported
• Energy intake, kcal/d: not reported
• Total fat intake, % E: not reported
• SFA intake, % E: not reported
• PUFA intake, % E: not reported
• PUFA n-3 intake: not reported
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• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E: not reported
• Sugars intake: not reported
• Protein intake, % E: not reported
• Alcohol intake, % E: not reported
Compliance by othermethods: 38were excluded for protocol violations, 4 intervention
and 16 control were non-compliant with capsules
Inclusion basis: intended that omega-3 fats increased by 1.9 g/d EPA +DHA, or 0.86%
E from omega-3 fats. This was compared to paraffin (no fat), so dose of total PUFA was
0.86% E. This is > 10% increase of assumed 6% E total PUFA intake at baseline
PUFA dose: 0.86% E total PUFA
Duration of intervention: 12 months
Outcomes Main trial outcome: functional status in Huntington’s disease
Dropouts: 7 intervention, 7 control
Available outcomes: measures of functional capacity, CV events, cancers (no deaths)
Response to contact: yes (replied to say that no CV mortality or fatal MI occurred)
Notes Trial funding: “Amarin Neuroscience Ltd. (formerly known as Laxdale Ltd.) was respon-
sible for organizing and funding this clinical trial” as well as paying the salaries of several
investigators
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “After screening and acceptance...
patients were assigned to treatment by re-
ceiving a numbered pack
supplied by a clinical trials packaging orga-
nization ... independent of all other aspects
of the trial. Randomization was stratified
in a block size of four,
with the appropriate number of blocks al-
located to each centre. PCI Clinical Ser-
vices held the randomization code until the
database had been closed and all patients
had been assigned”
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Placebo and ethyl-EPA capsules
were of identical appearance” (though taste
and smell not reported)
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation described as “double-
blind”, “neither the participants nor the
participatingmedical staff had access to this
code during the course of the study”
Incomplete outcome data (attrition bias)
All outcomes
High risk Clearly reported and complete, however >
20% attrition
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry identi-
fied
Attention bias Low risk Unlikely
Compliance Unclear risk No TC or tissue fatty acids reported
Other bias Low risk None noted
Raitt 2005
Methods RCT, parallel, (n3 EPA + DHA vs MUFA), 24 months
Summary risk of bias: moderate or high
Participants People with implantable cardioverter defibrillators and recent sustained VT/VF
N: 100 intervention, 100 control
Level of risk for CVD: high
Male: 86% intervention, 86% control
Mean age (SD): 63 (13) intervention, 62 (13) control
Age range: not reported but 18-75 inclusion criteria
Smokers: not reported
Hypertension: 46% intervention, 55% control
Medications taken by≥ 50% of those in the control group: diuretic, beta blockers, ACEi
Medications taken by 20%-49% of those in the control group: digoxin, statins
Medications taken by some, but < 20% of the control group: Ca channel blocker
Location: USA
Ethnicity: white 94% intervention, 97% control
Interventions Type: supplement (fish oil capsules vs olive oil capsules)
Comparison: EPA + DHA vs MUFA
Intervention: 1.8 g/d fish oil capsules (Hoffman LaRoche, including ethyl esters of EPA
and DHA, 0.76 g/d EPA, 0.54 g/d DHA)
Control: 1.8 g/d olive oil capsules (Hoffman LaRoche, 73% oleic acid)
Dose aim: increase 1.3 g/d EPA + DHA, 0.6% E n-3, 0.6% E PUFA
Baseline PUFA not reported
Compliance by biomarkers: while control group plasma and platelet DHA and EPA
did not change, there were increases of 2%-8.3% in the intervention group. Plasma and
red blood cell omega-3 fats were higher in intervention than control participants at all
time points (P < 0.001). No data on total PUFA or LA plasma or red blood cell fats, and
no TC reported
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Compliance by dietary intake: not reported
• Energy intake, kcal/d: not reported
• Total fat intake, % E: not reported
• SFA intake, %E: not reported
• PUFA intake, % E: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: not reported
• CHO intake, % E: not reported
• Sugars intake: not reported
• Protein intake, % E: not reported
• Alcohol intake, % E: not reported
Compliance by other methods: no others reported
Inclusion basis: aims suggested total PUFA intake 0.6% E higher in intervention than
control, a 10% increase on assumed 6% E from PUFA at baseline
PUFA dose: 0.6% E
Duration of intervention: 24 months (median 718 days)
Outcomes Main trial outcome: time to first episode of VT/VF
Dropouts: 17 intervention, 26 control
Available outcomes: deaths, CV death, MI, angina, revascularisation, atrial fibrillation,
sudden cardiac death, cancer
Response to contact: contact attempted but no response to date
Notes Trial funding: NIH and Hoffman LaRoche
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer generated block ran-
domisation scheme”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participant blinding unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ICD traces were viewed by researchers
blinded to allocation, “double blind
placebo-controlled”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Almost all participants were included in
outcome assessment, well described
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Selective reporting (reporting bias) High risk NCT registered in February 2000, trial car-
ried out from February 1999 to January
2004. Most outcomes stated in registry en-
try reported, but quality of life missing
Attention bias Low risk Capsules were the only different interven-
tions between arms, little opportunity for
attention bias
Compliance Unclear risk No data on total PUFA or LA plasma or
red blood cell fats, and no TC reported
Other bias Low risk None noted
Rose 1965
Methods RCT, 2 arms, parallel (n6 LA vs MUFA), 24 months
Summary risk of bias: moderate to high
Participants People with ischaemic heart disease
CVD risk: high
N: 28 intervention, 26 control (analysed 15 intervention, 12 control)
% male: not reported
Mean age: 52.6 intervention, 55 control (no SDs)
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: UK
Ethnicty: not reported
Interventions Type: test oil provided (equivalent advice to both arms)
Comparison: n-6 vs MUFA
Intervention: 80 g/day corn oil to be taken in 3 equal doses atmeal-times plus participants
were instructed to avoid fried foods. Fattymeat, sausages, pastry, ice-cream, cheese, cakes,
milk, eggs, butter were restricted: assuming 80% LA in corn oil, 64 g/d LA or 576 kcal/
d or 28.8% E from LA
Control: 80 g/day olive oil plus participants were instructed to avoid fried foods, fatty
meat, sausages, pastry, ice-cream, cheese, cakes, milk, eggs, butter were restricted. as-
suming 12% LA and 69% MUFA in olive oil, 9.6 g/d LA or 4.3% E LA and 55.2 g/d
MUFA or 24.8% E
Dose aim: +24.5% E from LA, -24.8% E MUFA
Baseline PUFA: unclear
Compliance using biomarkers: serum TC reduced, but not statistically significantly
reduced in intervention compared to control (-0.49 mmol/L, 95% CI -1.34 to 0.36).
No fatty acid biomarkers reported
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Compliance using dietary assessment: poor. Measured using questionnaire. Mean in-
take of oil in intervention was 595 kcal/d or 476 kcal/d LA or 23.8% E, in control 540
kcal/d or 3.2% E LA and 18.6% E MUFA, achieved: +20.6% E from LA, -18.6% E
MUFA within the oils, unclear how diet altered
• Energy intake: intervention 2070 kcal/d control 2045 kcal/d
• Total fat intake: intervention 50 g/d + 595 kcal from oil or 1045 kcal/d or 52% E,
control 45 g/d + 540 kcal from oil or 945 kcal/d or 47.3% E
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: +20.6% E (higher in intervention than control)
• Trans fat intake: not reported (oils provided so not likely to be a problem)
• MUFA intake: -18.6% E (lower in intervention than control)
• CHO intake: intervention 189 g/d or 756 kcal/d or 37.8% E, control 216 g/d or
864 kcal/d or 43.2% E
• Sugars intake: not reported
• Protein intake: intervention 57 g/d or 228 kcal/d or 11.4% E, control 49 g/d or
196 kcal/d or 9.8% E
• Alcohol intake: not reported
Compliance by other methods: no others reported
Inclusion basis: aim was to increase omega-6 fats, not total PUFA. Total PUFA not
reported but LA dose so big that total PUFA must have been increased in intervention
compared to control. Best estimate 20.6% E total PUFA dose, > 10% increase from
baseline
PUFA dose: according to questionnaire 20.6% E from LA, assume equivalent to 20.6%
E from total PUFA
Duration of intervention: 2 years
Outcomes Main trial outcome: occurrence of infraction
Dropouts: 6 intervention, 11 control?, details provided in table but unclear how many
dropped out.
Available outcomes: major CVD events, MI (fatal and non-fatal), sudden death, serum
cholesterol
Response to contact: not attempted as published in the 1960s
Notes Trial funding: no details
The trial had a 3rd control arm (no intervention), which has not been used here
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk When a new participant was accepted for
the trial a sealed envelope was opened con-
taining the allocation instructions. In the
case of participants allocated to an oil group
the instructions referred only to a code
number
158Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rose 1965 (Continued)
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The physicians in charge knew which par-
ticipants were receiving oil, but they did
not know until the end of the trial the kind
of oil that they were receiving
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The electrocardiograms were assessed with-
out the knowledge of the participant’s treat-
ment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk 52% intervention, and 57% control re-
mained in the trial after 24 months. How-
ever, the list of reasons and complications
is provided
Selective reporting (reporting bias) Unclear risk No trial registry record or protocol found
Attention bias Low risk Oil provided to both groups, appeared sim-
ilar
Compliance Low risk TC somewhat reduced in intervention
compared to control (-0.49 mmol/L, 95%
CI -1.34 to 0.36). No fatty acid biomarkers
reported
Other bias Low risk None noted
Rossing 1996
Methods RCT, parallel, (n3 EPA + DHA vs MUFA), 12 months
Summary risk of bias: moderate or high
Participants Adults with insulin-dependant diabetes mellitus, diabetic nephropathy and normal BP
N: 18 intervention, 18 control (analysed, 17 intervention, 15 control)
Level of risk for CVD: moderate
Male: 64% intervention, 67% control
Mean age (SD) years: 32 (7) intervention, 34 (10) control
Age range: 18-55 years
Smokers: 50% intervention, 47% control
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: insulin
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: Denmark
Ethnicity: not reported
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Interventions Type: supplement
Comparison: fish oil vs olive oil
Intervention: cod-liver oil emulsion (Pharma-Vinci A/S Denmark). EPA 2 g/d, DHA 2.
6 g/d, plus 24.1% SFA, 45.6% MUFA, 23.6% EPA + DHA, 6.7% other fats. Assumed
total PUFA 4.6 g/d
Control: olive oil emulsion (Pharma-Vinci A/S Denmark). 15.1% SFA, 76.9% MUFA,
8.0% other fats. Assumed total PUFA 0 g/d
Dose aim: increase 4.6 g/d EPA + DHA, 2.1% E n-3, 2.1% E PUFA
Baseline PUFA: unclear
Compliance using biomarkers: assessed through omega-3 incorporation in platelets,
and the paper reports significantly higher omega-3 levels in platelets at 12 months. EPA
% was 0.59 (SE 0.07) in control, 2.70 (SE 0.29) in intervention arm latest reading.
DHA % was 1.99 (SE0.13) control, 3.57 (SE 0.18) intervention (P < 0.001 between
intervention and control for both). Total PUFA not reported. HOWEVER serum TC
rosemore in the intervention arm (+ 0.46mmol/L) than control (+ 0.13mmol/L) during
the trial
Compliance using dietary assessment: poor. Unclear how measured, only protein re-
ported
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: intervention 1.07 g/kg/d (0.10), control 1.10 g/kg/d (0.07)
• Alcohol intake: not reported
Compliance by other methods: no others reported
Inclusion basis: aim was to increase omega-3 fats, not total PUFA. Total PUFA not
reported but omega-3 dose rose by 2.1%E, so assume total PUFAdid also as compared to
MUFA. Best estimate 2.1% E total PUFA dose, more than 10% increase from assumed
baseline of 6% E
PUFA dose: intended dose only, 2.1% E
Duration of intervention: 12 months
Outcomes Main trial outcome: diabetic nephropathy
Dropouts: 1 intervention, 3 control (though 3 further intervention participants are not
included in all data)
Available outcomes: mortality (nil), breast cancer, TC, LDL, systolic BP (TGs reported
as medians so not used, albuminuria, fractional albumin clearance, transcapillary escape
rate of albumin, prothrombin fragment reported as geometricmeans ormedians,HbA1c,
HDL and diastolic BP too different at baseline to include, glomerular filtration rate
(GFR), plasminogen activator inhibitor-1 (PAI1), tissue plasminogen activator (TPA),
fibrinogen etc. not relevant)
Trial author reply: yes
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Notes Trial funding: supported by The Danish Heart Association. Eskisol Fish oil and placebo
oil emulsions were provided by Pharma-Vinci A/S, Frederiksvaerk, Denmark
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised using “con-
cealed randomization to receive either fish
oil or olive oil in blocks of 4 according to
their glomerular filtration rate.”
Allocation concealment (selection bias) Unclear risk No further details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”Active and placebo (olive oil) were
given as emulsions with orange flavour.
At the end patients were allowed to guess
about treatment and ~50% were right”
(from trial author response)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts similar between groups although
relatively high for small sample size. 3 drop-
outs from fish oil and 1 from control due
to side effects. ITT appears to have been
given for albuminuria only
Selective reporting (reporting bias) Unclear risk No trials registry entry or protocol found
Attention bias Low risk Time and attention appear to be the same.
All participants were given dietary advice
Compliance High risk Total PUFA in body fractions not reported.
However, serumTC rose more in the inter-
vention arm (+0.46 mmol/L) than control
(+0.13 mmol/L) during the trial
Other bias Low risk None noted
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Simon 1997
Methods RCT, parallel, (low fat with low PUFA vs usual diet), 24 months
Summary risk of bias: moderate or high
Participants Women with a high risk of breast cancer
N: 98 intervention, 96 control (analysed 72 intervention: 75 control)
Level of risk for CVD: low
Male: 0% intervention, 0% control
Mean age (SD): 46 (not reported) intervention, 46 (not reported) control
Age range: not reported
Smokers: not reported
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported (those on
statins excluded)
Location: USA
Ethenicity: white 89%, African American 9%, Hispanic 2%
Interventions Type: dietary advice
Comparison: reduced fat including PUFA (intervention) vs usual diet
Intervention: aims total fat 15% E; methods biweekly individual dietetic appointments
over 3 months followed by monthly individual or group appointments, including ed-
ucation, goal setting, evaluation, feedback and self-monitoring. Intervention delivered
face to face by a dietitian
Control: aim usual diet, no stated intervention(s)
Dose aim: unclear PUFA
Baseline 7.7% E PUFA
Compliance by biomarkers: no fatty acid biomarkers reported, TC reported in a sub-
group and fell by 0.34 mmol/L in intervention and fell by 0.08 mmol/L in control over
1 year
Compliance by dietary intake: assessed using 3-day 24-h recalls every 3 months, 1 year
data reported
• Energy intake, kcal/d: intervention 1570 (SE 47.0), control 1594 (SE 63.6)
• Total fat intake, % E: intervention 17.6 (SD 5.8), control 33.8 (SD 7.4)
• SFA intake, % E: intervention 6.0 (SD 3.0), control 12.1 (SD 5.2)
• PUFA intake, % E: intervention 3.8 (SD 1.7), control 7.3 (SD 4.1)
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: intervention 6.1 (SD 3.0), control 12.8 (SD 6.3)
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake, not reported
• Alcohol intake: not reported
Compliance, other methods: not reported
Inclusion basis: no intention to increase total PUFA stated. Acheived total PUFA re-
duction of 6.7% E in intervention compared to control at 1 year, > 10% higher than
baseline 7.7% E from total PUFA
PUFA dose: -6.7% E PUFA
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Simon 1997 (Continued)
Compliance: dietary assessment
Duration of intervention: 24 months (mean years in trial: control 1.8, intervention 1.7)
Outcomes Main trial outcome: intervention feasibility
Dropouts: unclear intervention, unclear control
Available outcomes: TC, TG, LDL and HDL (2 deaths, but unclear in which arms, 8
cancer diagnosis but not clear in which arms), (weight, BMI, % body fat and waist-hip
ratio reported but all too unbalanced at baseline to use)
Trial author contact: Dr Simon confirmed that some deaths occurred (but not in which
arms) and sent a further reference
Notes Trial funding: Marilyn J Smith Fund, Harper-Grace Hospitals, the Wesley Foundation,
National Cancer Institute, Karmanos Cancer Institute Core Grant, the United Founda-
tion of Detroit
Trialaim was to reduce total fat to 15% E (SFA not mentioned), but PUFA fat intake in
the intervention group was significantly lower than in the control group
Note: PUFA lower in intervention arm, so higher PUFA arm is the control
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified by age and randomised (block size
2)
Allocation concealment (selection bias) Unclear risk Allocation method not clearly enough de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants not blinded (as given dietary
advice or not), personnel unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear, deaths, cancer and CV events are
dropouts - unclear if any data missing
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry found
Attention bias High risk Time and attention in the intervention
group not mirrored in control
Compliance High risk No fatty acid biomarkers reported, TC re-
ported in a subgroup and fell by 0.34
mmol/L in intervention and fell by 0.08
mmol/L in control over 1 year (but control
group should have been higher in PUFA in
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this trial)
Other bias Low risk None noted
Sydney Diet-Heart 1978
Methods Sydney Diet-Heart Study
RCT, 2 arm, parallel (n6 LA vs SFA), 4.3 years
Summary risk of bias: low (as diet advice trial)
Participants Men with previous MI
CVD risk: high
Control: randomised 237, analysed 221 at 2 years
Intervention: randomised 221, analysed 205 at 2 years
Mean years in trial: control 4.3, intervention 4.3
% male: 100
Age: mean intervention 48.7 (SD 6.8), control 49.1 (SD 6.5)
Age range: 30-59 years
Smokers: intervention 71.5%, control 68.8%
Hypertension: unclear
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: Australia
Ethenicty: not reported
Interventions Type: diet advice and supplemental foods
Comparison: safflower oil and safflower oil-based margarine (n-6) vs usual diet (reduced
SFA and MUFA)
Control aims: reduction in energy if overweight, no other specific dietary advice, allowed
touse PUFAmargarine instead of butter (no specific dietary instruction, except reweight)
Intervention aims: SFA 10% E, PUFA 15% E, reduction in energy if overweight, dietary
cholesterol < 300 mg/day through provision of safflower oil and safflower margarine
(advised and tutored individually, diet assessed 3 times in first year, twice annually
thereafter)
Dose aim: increase 6.6% E PUFA, most of which n6
Baseline n-6: unclear, 6.1% E PUFA, mostly n6
Compliance by biomarkers: serum TC significantly reduced in intervention compared
to control (-0.30 mmol/L, 95% CI -0.51 to -0.09). No body fatty acid markers reported
Compliance by dietary intake: good. From diet records, medians provided
• Energy intake, kcal/d: intervention 2256, control 2194
• Total fat intake, % E: intervention -1.9, control -1.1 (reduction of 0.8% E total
fat, not statistically significant)
• SFA intake, % E: intervention -6.9, control -2.1 (reduction of 4.8% E SFA,
statistically significant)
• PUFA intake, % E: intervention +9.3, control +2.2 (increase of 7.1% E PUFA,
statistically significant)
• PUFA n-3 intake: not reported
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Sydney Diet-Heart 1978 (Continued)
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake, % E: intervention -3.4, control -0.7 (reduction of 2.7% E MUFA,
statistically significant)
• CHO intake, % E: intervention +1.4, control +0.1 (increase of 1.3% E CHO,
not statistically significant)
• Sugars intake: not reported
• Protein intake, % E: intervention +0.4, control +1.2 (decrease of 0.8% E protein,
not statistically significant)
• Alcohol intake, % E: intervention +0.7, control +1.7 (decrease of 1.0% E
alcohol, not statistically significant)
Compliance, other methods: not reported
Inclusion basis: aimed to increase total PUFA intake as well as reduce SFA
PUFA dose: 7.1% E PUFA (from dietary intake data)
Duration of intervention: 2-7 years
Outcomes Main trial outcomes: CV mortality and morbidity
Dropouts: unclear, probably 16 dropouts in each arm, but participants were included
from 2-7 years
Available outcomes: mortality, TC, TG
Response to contact: yes, further data provided
Notes Trial funding: Life Insurance Medical Research Fund of Australia and New Zealand
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “table of random numbers ... gen-
erated by a research assistant and was con-
cealed until after medical evaluations and
testing at baseline were completed”
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Very difficult to blind trials where par-
ticipants need to make their own dietary
changes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Initially masked to group assignment
(though success of blinding not checked)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Survival analysis used
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry located
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Attention bias High risk Different levels of dietary support (non-di-
etary aspects were equivalent)
Compliance Low risk TC significantly reduced in intervention
compared to control (-0.30 mmol/L, 95%
CI -0.51 to -0.09). No body fatty acid
markers reported
Other bias Low risk None noted
Veterans Admin 1969
Methods Veterans Administration Trial
RCT, 2 arms, parallel (n6 LA vs SFA), up to 8 years
Summary risk of bias: moderate to high
Participants Men living at the Veterans Administration Centre
CVD risk: low
Control: randomised 422, analysed 422
Intervention: randomised 424, analysed 424
Mean years in trial: control 3.7, intervention 3.7
% male: 100
Age: mean control 65.6, intervention 65.4
Age range: all 54-88 years
Smokers: intervention 283, control 279 (unknown intervention 41, control 58)
Hypertension: unclear
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: digitalis, diuretics, oestro-
gens, corticoids, androgens, coumarins, nicotinic acid
Location: USA
Ethnicity: white 90%, black 7%, Asian 1%, Hispanic 1%, other 1%
Interventions Type: diet provided (residential institution)
Comparison: corn, soybean, safflower and cottonseed oils (n-6) vs usual institutional
diet
Control aims: provided, total fat 40% E (whole diet provided)
Intervention aims: total fat 40% E, 2/3 of SFA replaced by unsaturated fats (from corn,
soybean, safflower and cottonseed oils), dietary cholesterol reduced (whole diet provided)
Dose aim: 2/3 of baseline SFA is increase of ~12%E PUFA
Baseline n-6: 4% E LA, control arm 4.8% E PUFA
Compliance by biomarkers: subcutaneous 18:2 + 18:3 11.7% fat at baseline, rising
to 12.8% fat in control and 34.8% fat in intervention (after “prolonged” adherence to
diet). Serum TC reduced, but not statistically significantly in intervention compared to
control (-0.37 mmol/L, 95% CI -0.77 to 0.03)
Compliance by dietary intake: unclear,checked using coloured tickets to assess dining
room attendance - described as 49% in intervention and 56% in controls. Laboratory
analysis of the mean of over 400 weekly collections of diet provided:
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Veterans Admin 1969 (Continued)
• Energy intake, kcal/d: intervention 2496, control 2496
• Total fat intake, % E: intervention 38.9 (SD 1.9), control 40.1 (SD 2.2)
• SFA intake, % E: intervention 8.3, control 18.5 (decrease 10.2% E SFA)
• PUFA intake: not reported but shown in graph as 18:2 + 18:3 ~12% of dietary fat
(4.8% E) in control and 43% in intervention (17.2% E), increase 12.4% E
• PUFA n-3 intake, % E: not reported
• PUFA n-6 intake, % E: intervention 16.1, control 4.4 (increase 11.7% E LA)
• Trans fat intake: not reported
• MUFA intake, % E: intervention 14.6, control 17.1 (decrease 2.5% E MUFAs)
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake, % E: intervention 15.6 (SD not reported), control 15.4 (SD not
reported)
• Alcohol intake: not reported
Compliance by other methods: no others reported
Inclusion basis: aim was to increase unsaturated fats, not total PUFA. Total PUFA not
reported but LA dose 11.7% E (best estimate), > 10% increase from baseline of ~5% E
PUFA dose: 11.7% E from total PUFA (best estimate from food composition data)
Duration of intervention: up to 8-9 years
Outcomes Main trial outcomes: mortality, heart disease
Dropouts: intervention 117, control 58 withdrawals over whole trial, a few participants
were involved for up to 8-9 years
Available outcomes: mortality, CVmortality (sudden death, definite MI, definite stroke,
angina, PAD events), cancer deaths, cancer diagnoses, stroke, non-fatal MI, total MI,
CHD deaths (fatal MI and sudden death due to CHD), CHD events (any MI or sudden
death due to CHD), some data on TC, but no variance info
Response to contact: attempted but no author contact established (trial published in
1969)
Notes Trial dates: recruitment 1959-1967
Trial funding:mainlyUS PublicHealth Service, Los Angeles CountyHeart Assoc, Arthur
Dodd Fuller Assoc, but Corn Products Co (provided Corn oil and margarine), National
Soybean Processors Assoc (provided soybean oil), Pitman-Moore Co (provided mar-
garine), Frozen Desserts Co (imitation ice cream). All trial authors worked for academic
or health institutions
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “table of random numbers used”
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Institution provided diet in a masked fash-
ion
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Physician knowledge of allocation was as-
sessed and found not much better than ran-
dom
Incomplete outcome data (attrition bias)
All outcomes
Low risk All followed up via Veterans Admin system
Selective reporting (reporting bias) Unclear risk No protocol or trials registry entry located
Attention bias Low risk Appeared equivalent, diet provided to both
arms
Compliance Low risk Subcutaneous 18:2 + 18:3 11.7% fat at
baseline, rising to 12.8% fat in control
and 34.8% fat in intervention (after “pro-
longed” adherence to diet). TC reduced,
but not statistically significantly in inter-
vention compared to control (-0.37 mmol/
L, 95% CI -0.77 to 0.03)
Other bias Low risk None found
Vijayakumar 2014
Methods RCT, 2 arms, parallel (n6 LA vs SFA), 2 years
Summary risk of bias: moderate to high
Participants People with stable coronary artery disease
CVD risk: high
N: intervention (sunflower oil): 100 randomised, analysed at 2 years 94; control (coconut
oil): 100 randomised, analysed at 2 years 96
Mean years in trial: 2
% male: intervention 92.9%, control 93.9%
Age, mean (SD) years: intervention 59.0 (8.9), control 59.0 (8.4)
Age range: unclear
Smokers, ex: intervention 57.1%, control 54.1%
Hypertension: intervention 55.1%, control 58.2%
Medications taken by ≥ 50% of those in the control group: statins
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: fibrates, nicotinic acid
Location: India
Ethnicity: not reported
Interventions Type: food (cooking oil) provided
Comparison: sunflower oil (n6) vs coconut oil (SFA)
Intervention aims: whole family to use branded sunflower oil for cooking (15% E pro-
vided in form of sunflower oil, ~66% PUFA)
Control aims: whole family to use branded coconut oil for cooking (15% E provided in
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form of coconut oil, ~5% PUFA)
Dose aim: increase 9.2% E PUFA
Baseline PUFA: unclear
Compliance by biomarkers: Serum TC reduced but not significantly reduced in inter-
vention compared to control (-0.06 mmol/L, 95% CI -0.22 to 0.34) though rose slightly
in control, fell slightly in intervention. No biomarker data reported
Compliance by dietary intake: unclear. Reports that 7-day recall and diet diaries were
used to monitor intake, but results not provided
• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other methods: oils were provided for family members to encourage
compliance
Inclusion basis: did not aim to increase total PUFA intake. Quantity and standard
compositions suggest dose ~9.2% E total PUFA, > 10% more than assumed baseline of
6% E PUFA
PUFA dose: 9.2% E PUFA
Duration of intervention: 2 years
Outcomes Main trial outcome: CV risk factors
Dropouts: intervention 6 lost, control 4 lost
Available outcomes: lipids, death, revascularisation, (glycaemic control, weight, BMI
available but unbalanced at baseline)
Response to contact: author replied and provided additional outcome data
Notes Trial funding: coconut development board, Amrita Institute of Medical Science and
Research. Sponsors had no role in trial design or analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation with 5 blocks of 40
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Unlikely as participants and their families
used branded oils
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 5% withdrawals. Clear, with reasons
Selective reporting (reporting bias) Unclear risk Unclear, no protocol or trials register entry
found
Attention bias Low risk Appeared equivalent
Compliance Low risk TC reduced in intervention compared to
control (-0.06 mmol/L, 95% CI -0.22 to
0.34, rose slightly in control, fell slightly in
intervention). No biomarker data reported
Other bias Low risk None noted
WAHA - Ros 2016
Methods The Walnut and Healthy Aging Study (WAHA)
2 arms, parallel RCT (n3 ALA vs mixed fats, ALA provided as walnuts), 2 years
Summary risk of bias: moderate to high
Participants Middle-aged, healthy adults
N: 362 intervention, 346 control (only preliminary data on 260 intervention, and 254
control available)
Level of risk for CVD: low
Male: 32.6% intervention, 31.5% control
Mean age (SD): 69.4 (3.8) intervention, 68.9 (3.5) control
Age range: 63-79 (inclusion criteria)
Smokers: 4.4% intervention, 1.2% control
Hypertension: 52.8% intervention, 52.9% control
Medications taken by ≥ 50% of those in the control group: not reported
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: Spain and USA
Ethnicity: not reported
Interventions Type: supplement (food)
Comparison: ALA vs nil
Intervention: 15% of daily energy intake as walnuts. The estimated amount of walnuts
ranged from 1-2 oz/d (~30-60 g/day). Sachets for daily consumption containing 30, 45,
or 60 g of raw, pieced walnuts were provided as 8-week allotments to be eaten daily,
preferably as the raw product, either as a snack or by incorporating them into shakes,
yogurts, cereals, or salads. To improve participants’ compliance, 1- kg extra walnut
allowances were provided every 2 months to take into account family needs
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Control: usual diet without walnuts
Compliance: assessed by dietitians through Food Frequency Questionnaires, recount of
empty packages, and changes in fatty acids concentrations. 95% consumed ≥ 1 oz./
d. The proportion of α-linolenic acid in red blood cell counts increased in the walnut
group by 0.162% (95% CI 0.143 to 0.181) and in the control group by 0.015% (95%
CI −0.005 to 0.035) (P < 0.001)
Dose aim: increase (assuming 10% E in walnuts is ALA) 1.5% E n3 ALA. 45 g walnut
gives ~65% or 29.3 g oil, of which ~68% PUFA, 19.9 g/d oil, 9% E PUFA
Baseline PUFA: unclear, control 7.9% E PUFA
Compliance by biomarkers: erythrocyte ALA increased by 28% in intervention, re-
duced by 17% in control (in a subsample of participants, percentage of total fatty acids
in red blood cells also increased in intervention group compared to control, no other
erythrocyte fatty acids reported. TC fell by 0.19 mmol/L (SD 0.04) in intervention, and
by 0.01 mmol/L (SD 0.04) in control to 1 year
Compliance by dietary intake: mean of five, 24-h diet recalls over 2 years of trial
• Energy intake, kcal: intervention 1821 (SD not reported), control 1593 (SD not
reported)
• Total fat intake, % E: intervention 41.5 (SD not reported), control 35.6 (SD not
reported) (increase of 5.9% E)
• SFA intake, % E: intervention 10.9 (SD not reported), control 11.9 (SD not
reported) (reduction of 1.0%E SFA)
• PUFA intake, % E: intervention 15.3 (SD not reported), control 7.9 (SD not
reported) (increase of 7.4% E PUFA)
• PUFA n-3 intake, % E: intervention 2.5 (SD not reported), control 0.9 (SD not
reported) (increase of 1.6% E)
• PUFA n-6 intake, % E: intervention 12.9 (SD not reported), control 7.0 (SD not
reported (increase of 5.9% E)
• Trans fat intake: not reported
• MUFA intake, % E: intervention 12.4 (SD not reported), control 12.4 (SD not
reported (0% E)
• CHO intake, % E: intervention 44.8 (SD NRnot reported, control 48.2 (SD not
reported) (reduction of 3.4% E)
• Sugars intake: not reported
• Protein intake, % E: intervention 15.4 (SD not reported), control 16.3 (SD not
reported) (decrease of 0.9% E)
• Alcohol intake, not reported
• (Also slightly higher intakes of most micronutrients reported)
Compliance, other methods: assessed by dietitians through Food Frequency Question-
naires and recount of empty packages, 95% consumed ≥ 28g/d
Inclusion basis: aimed to increase walnuts, not total PUFA. Resulted in increase of 7.
4% E total PUFA
PUFA dose: 7.4% E PUFA (from dietary intake data)
Duration of intervention: 2 years
Outcomes Main trial outcome: change in cognitive decline (results not yet published)
Dropouts: 36 intervention, 21 control (after 1 year)
Available outcomes: CVD events, cancers, lipids (for TG and HDL only data states ”no
between diet differences were observed“), weight (waist circumference was provided but
without variance, abstract stated that ”there were no significant changes in body fat and
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waist-to-hip ratio over time and between the two groups“). Cognitive, ophthalmological,
inflammatory markers, glycaemic status and other outcomes are not yet available.
Response to contact: author replied and provided additional outcome and methodolog-
ical data
Notes Trial funding: funding was provided by the Calfornia Walnut Commission
The 2-year results as well the full 1-year results are yet to be published
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”randomized to either the control
or walnut group using a computerized ran-
dom number table with stratification by
center, sex, and age range. Couples entering
the trial were treated as one number and
were randomized into the same group“
Allocation concealment (selection bias) Low risk Author reply stated ”Baseline subject data
was collected before randomization. Ran-
domization was done by the clinician,
pressing the key on the computer“




Quote: ”An unavoidable limitation of the
study is not being able to blind participants
to the intervention since it consists of a
whole food” Rajaram 2017
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Single-blind. Author reply stated “Study
personnel not in contact with the sub-
jects were blind to the treatment assign-
ment. So (lab technicians, ophthalmology
technician, neuro cognitive testers) were
not aware of the treatment assignment. Of
course clinicians who were visited by sub-
jects every twomonths, knew the treatment
assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 38/362 dropouts in intervention group =
10.5%. 34/346 dropouts in control group
= 9.8%. Similar dropout in groups over 2
years
Selective reporting (reporting bias) Unclear risk Although prospectively registered, no full
results paper published - results from con-
ference abstracts and papers only report
some secondary outcomes and dietary data
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Attention bias Unclear risk Not enough detail to assess
Compliance Low risk Erythrocyte ALA increased by 28% in in-
tervention, reduced by 17% in control (in
a subsample of participants), percentage of
total fatty acids in red blood cells also in-
creased in intervention group compared to
control, no other erythrocyte fatty acids re-
ported. TC fell by 0.19 mmol/L (SD 0.04)
in intervention, and by 0.01 mmol/L (SD
0.04) in control to 1 year
Other bias Low risk None noted
WELCOME 2015
Methods RCT, parallel, (n3 EPA + DHA vs MUFA), 15-18 months
Summary risk of bias: low
Participants Patients with NAFLD
N: 51 intervention, 52 control (analysed, 47 intervention, 48 control)
Level of risk for CVD: moderate
Male: 49% intervention, 67% control
Mean age (SD): 48.6 (11.1) intervention, 54 (9.6) control
Age range: not reported (18-75 inclusion criteria)
Smokers: 14.3% intervention, 11.8% control
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: lipid-lowering drugs
Medications taken by 20%-49% of those in the control group: antihypertensives, met-
formin (data not provided by group)
Medications taken by some, but < 20% of the control group: none reported
Location: UK
Ethenicity: not reported
Interventions Type: supplement (Omacor capsules)
Comparison: DHA + EPA vs MUFA
Intervention: 4 g Omacor/d (providing 1.84 g EPA, 1.52 g DHA as ethyl esters)), 3.36
g/d EPA + DHA
Control: 4 g olive oil capsules/d (providing; ALA 1%, oleic acid 67%, palmitic acid
15%, stearic acid 2%, n-6 fat: 15%), 0.64 g/d PUFA
Dose aim: increase 2.72 g/d PUFA, 1.22% E PUFA
Baseline PUFA unclear
Compliance by biomarkers: erythrocyte EPA + DHA both increased in intervention,
not in control (EPA% 1.0%, SD 0.2% in control vs 2.4% SD 1.8% in intervention at
latest point, DHA% 5.0 SD 1.0 in control, 7.1% SD 1.3% in intervention), no other
fatty acids reported. TC remained 4.8 mmol/L in control but fell by 0.2 mmol/L to 4.7
mmol/L in intervention at 15-18 months
Compliance by dietary intake: not reported
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• Energy intake: not reported
• Total fat intake: not reported
• SFA intake: not reported
• PUFA intake: not reported
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: not reported
• CHO intake: not reported
• Sugars intake: not reported
• Protein intake: not reported
• Alcohol intake: not reported
Compliance, other methods: assessed by recording the returned unused capsules, but
results not reported
Inclusion basis:no intention to increase total PUFA stated. Planned total PUFA increase
2.72 g/d PUFA, 1.22% E PUFA, > 10% higher than assumed 6% E from total PUFA
at baseline. Confirmed by TC fall in intervention, no other biomarker or intake data
PUFA dose: 1.22%E PUFA
Duration of intervention: 15-18 months
Outcomes Main trial outcome: changes in mean liver fat%, changes in 2 liver fibrosis scores, change
in serum biomarkers
Dropouts: 4 intervention, 4 control
Available outcomes: weight, BMI, lipids, BP, glucose, insulin sensitivity, body fat mea-
sures, liver enzymes, HbA1c, serum n-3 fatty acids, trial authors provided details of di-
abetes diagnoses, % body fat, BP and carotid intima media thickness
Response to contact: yes
Notes Trial funding: Omacor and placebo were provided by Pronova Biopharma through Ab-
bott Laboratories, Southampton, UK. This work was supported by a National Institute
for Health Research (NIHR) Southampton Biomedical Research Unit grant and by a
Diabetes UK Allied Health Research training fellowship awarded to KGM (Diabetes
UK. BDA 09/ 0003937). CDB, PCC and ES were supported in part by the NIHR
Southampton Biomedical Research Centre (McCormick-2015, p9; see WELCOME
2015)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were block randomised by an
independent clinical trials pharmacist ....
randomised according to standardised pro-
cedures (computerised block randomisa-
tion) by a research pharmacist at University
Hospital Southampton NHS Foundation
Trust. Simple randomisation in blocks of
4..
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Allocation concealment (selection bias) Low risk Only the clinical trials pharmacist was un-
blinded, and randomisation group alloca-
tion was concealed from all trial members
throughout the trial. (McCormick-2015,
p2)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Paper states that only the clinical trials
pharmacist was unblinded, and randomi-
sation group allocation was concealed from
all trial members throughout the trial.
However, the trial register record states
“single blind (investigator)”. Although the
capsules were identical, no information
provided as to their smell and taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
All outcomes
Low risk The ITT included all participants ran-
domised who had complete data (baseline
and end-of-trial measurements), regardless
of whether they were later found to be inel-
igible, a protocol violator, given the wrong
treatment allocation, or never treated).
(Scorletti 2014, p4; seeWELCOME2015)
Selective reporting (reporting bias) Unclear risk Prospectively registered September 2008,
trial start September 2009, end February
2017. Outcome data for cardiac function
not yet published (may be ongoing as trial
only recently completed), though other CV
measures reported
Attention bias Low risk Both groups had the same attention
Compliance Low risk Erythrocyte EPA + DHA both increased in
intervention, not in control (EPA% 1.0%,
SD 0.2% in control vs 2.4% SD 1.8% in
intervention at latest point,DHA%5.0 SD
1.0 in control, 7.1% SD 1.3% in interven-
tion), no other fatty acids reported. TC re-
mained 4.8 mmol/L in control but fell by
0.2mmol/L to 4.7mmol/L in intervention
at 15-18 months
Other bias Low risk None noted
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Methods Women’s Intervention Nutrition Study (WINS)
RCT, parallel, (reduced fat with reduced PUFA vs usual diet), 60 months
Summary risk of bias: low (as diet advice trial)
Participants Women with localised resected breast cancer
N: 975 intervention, 1462 control (analysed 975 int, 1462 cont)
Level of risk for CVD: low
Male: 0% intervention, 0% control
Mean age (95% CI): 58.6 (44.4-72.8) intervention, 58.5 (43.6-73.4) control
Age range: not reported, all postmenopausal
Smokers: 49.9% intervention, 48.7% control never smokers
Hypertension: not reported
Medications taken by ≥ 50% of those in the control group: menopausal hormone
therapy (65.3% intervention, 64.0% control), tamoxifen (47.7% tamoxifen alone, 38.
5% tamoxifen plus chemotherapy in intervention, 47.4% and 38.0% respectively in
control), all were on chemotherapy, most on radiotherapy
Medications taken by 20%-49% of those in the control group: not reported
Medications taken by some, but < 20% of the control group: not reported
Location: USA
Ethnicity: 85% white, 5% black, 4% Hispanic, 5% Asian or Pacific Islander, < 1%
American Indian or unknown (no outcome data based on ethnicity)
Interventions Type: dietary advice
Comparison: reduced fat intake (with reduced PUFA) vs usual diet
Intervention: aims total fat 15%-20% E;methods 8 biweekly individual dietetic sessions
plus 3-monthly contact and optional monthly group sessions, incorporating individual
fat gram goals, social cognitive theory, self-monitoring, goal setting, modelling, social
support and relapse prevention and management. Intervention was delivered face to face
individually by trained dietitian
Control: aims minimal nutritional counselling focused on nutritional adequacy; meth-
ods one baseline dietetic session plus 3-monthly sessions
Dose aim: unclear PUFA
Baseline 5.4% E PUFA
Compliance by biomarkers: no fatty acid biomarkers reported, TC reported but only
in a subgroup (N = 18 at 2 years) and unbalanced at baseline so not used in analyses,
little change but TC fell by 6 mg/dL in intervention and increased by 0.8 mg/dL in
control over 2 years
Compliance by dietary intake: assessed using unannounced phone calls over several
days, 1-year data reported apart from protein and carbohydrate which were 6-month
data
• Energy intake, MJ/d: intervention 7.3 (SD 1.8), control 7.7 (SD 1.9)
• Total fat intake, % E: intervention 20.3 (SD 8.1), control 29.2 (SD 7.4)
• SFA intake: intervention 6.4 (SD 0.14 (4.4)), control 9.8 (SD 0.15 (5.7))
• PUFA intake: intervention 4.5 (SD 0.09 (2.8)), control 6.4 (SD 0.10 (3.8))
• PUFA n-3 intake: not reported
• PUFA n-6 intake: not reported
• Trans fat intake: not reported
• MUFA intake: intervention 7.6 (SD 0.14 (4.4)), control 11.5 (SD 0.16 (6.1))
• CHO intake: intervention 60.8 (SD 19.6), control 50.5 (SD 14.8)
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• Sugars intake: not reported
• Protein intake, % E: intervention 19.1 (SD 5.2), control 17.6 (SD 4.1)
• Alcohol intake: intervention 5% E (SD 6), control 4% E (SD 6)
Compliance, other methods: not reported
Inclusion basis: no intention to increase total PUFA stated. Acheived total PUFA re-
duction of 1.9% E in intervention compared to control at 1 year, > 10% higher than
baseline 5.4% E from total PUFA
PUFA dose: -1.9% E PUFA
Duration of intervention: 60 months
Outcomes Main trial outcome: dietary fat intake, TC, weight and waist
Dropouts: 45 lost to follow-up, 170 discontinued intervention, 66 lost and 106 discon-
tinued control
Available outcomes: all-cause mortality, cancer diagnoses (including recurrences), new
breast cancer diagnoses, weight, BMI (TC, TG, HDL, insulin provided in tiny subgroup
- 9 participants in each group at 2 years - and unbalanced at baseline, not useable)
Author contact: limited information received
Notes Trial funding: National Cancer Institute, Breast Cancer Research Foundation, American
Institute for Cancer Research
*SDs appear incorrect, probably SEs?
NOTE: control arm is the arm higher in PUFA, intervention arm lower in PUFA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random stratified permuted block design,
carried out at the statistical co-ordinating
centre of WINS
Allocation concealment (selection bias) Low risk Random stratified permuted block design,
carried out at the statistical co-ordinating
centre of WINS
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not for dietary advice and participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All outcomes assessed by the blinded out-
come committee
Incomplete outcome data (attrition bias)
All outcomes
Low risk All assessed
Selective reporting (reporting bias) Low risk Outcomes stated in protocol all appear to
have been published
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Attention bias High risk Intervention group appear to have received
more time and attention
Compliance Unclear risk No fatty acid biomarkers reported, TC re-
ported but only in a subgroup (n = 18 at
2 years) and unbalanced at baseline so not
used in analyses, little change but TC fell
by 6 mg/dL in intervention and increased
by 0.8 mg/dL in control over 2 years (note,
control group should be higher in PUFA in
this trial). Overall changes not reported
Other bias Low risk None noted
AA: arachidonic acid; ACEi: angiotensin-converting-enzyme inhibitor; AF: atrial fibrillation; ALA: alpha-linolenic acid (a plant-based
omega-3 fat); ARB: Angiotensin II receptor blockers; BMD: bone mineral density; BMI: body mass index (weight in kg divided
by height in m squared); BP: blood pressure; Ca: calcium; CAD: coronary artery disease; CHO: carbohydrate; CLO: cod-liver
oil; CRP: C-reactive protein; CV: cardiovascular; CVD: cardiovascular diseases; DHA: docosahexaenoic acid (a fish-based omega-
3 polyunsaturated fatty acid); DPA: docosapentaenoic acid (a fish-based omega-3 polyunsaturated fatty acid); E: energy; EPA:
eicosapentaenoic acid (a fish-based omega-3 polyunsaturated fatty acid); FMD: fibromuscular dysplasia; GLA: gamma linolenic
acid (an omega-6 polyunsaturated fatty acid); HDL: high density lipoprotein (a fraction of TC, measured in human blood); ICD:
implanted cardioverter defibrillator; ITT: intention to treat analysis; IQR: interquartile range; kcal: calories; LDL: low density
lipoprotein (a fraction of TC, measured in human blood); LA: linoleic acid (an omega-6 polyunsaturated fatty acid); MD: mean
difference; MI: myocardial infarction; MUFA: monounsaturated fatty acid or monounsaturated fat; IQR: interquartile range; N:
number or participants; NAFLD: non-alcoholic fatty liver disease; NSAIDs: nonsteroidal antiflammatory drugs; P: P value; PCI:
percutaneous coronary intervention; PUFA: polyunsaturated fatty acid; P/S: polyunsaturated to saturated fatty acid ratio; PAD:
peripheral arterial disease;QoL: quality of life;RCT: randomised controlled trial;SCD: sudden cardiac death;SD: standard deviation;
SE: standard error; SFA: saturated fatty acid or saturated fat; SO: seal oil; TC: total cholesterol (measured in human blood); TG:
triglycerides (measured in human blood); VF: ventricular fibrillation; VT: ventricular tachycardia
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ADCS-Quinn 2010 Compared DHA vs omega-6, no intention to increase total PUFA. Intervention 1.02 g/d algal-
derived DHA compared to 2 g of soy or corn oil. Biggest difference would be 1 g/d total PUFA,
0.45% E, < 10% change from assumed 6% E baseline PUFA
AFFORD 2014 Aim was to assess effects of high-dose fish oils, compared EPA + DHA (1.6 g/d EPA + 0.8 g/
d DHA) vs omega-6 safflower oil (4 g/d, ~80% LA). Assumed 2.4 g/d or 1.08% E omega-3 in
intervention, 3.2 g/d or 1.44% E omega-6 fats in control, difference 0.8 g/d or 0.36% E total
PUFA. This was < 10% increase from assumed baseline of 6% E total PUFA. No biomarker, lipid
or dietary intake data to support
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AlphaOmega - EPA+DHA Aim was to increase omega-3 fats. Margarine composition data - summing LA, ALA, EPA, DPA
and DHA total PUFA suggested dose in EPA + DHA margarine (compared to placebo) was 3.8%
E. As planned intake was 20 g/d, intake was 0.76 g/d total PUFA, or 0.3% E from total PUFA.
Total PUFA in ALA + EPA + DHA (compared to ALA margarine) was 0.7% E, or 0.14 g/d total
PUFA, 0.06%E total PUFA. These were both < 10% higher than assumed 6% E from PUFA at
baseline. TC levels did not alter by intervention
AREDS2 2014 Aimed to increase omega-3 fats, compared EPA + DHA (350 mg/d DHA plus 650 mg/d EPA) vs
nil. Intended increase 1.0 g/d, 0.5% E n-3, assume 0.5% E PUFA (< 10% increase from assumed
6% E PUFA at baseline). No biomarker, lipid or dietary intake data to support or refute
ASCEND Ongoing trial. Intervention omega-3 (1 g/d: 0.41 g EPA, 0.34 g DHA) vs olive oil placebo (plus
or minus aspirin). Dose appears < 1.33 g/d total PUFA, < 0.6% E PUFA, so excluded
Azadbakht 2007 Weight reduction goals as well as fat modification, multifactorial
Baldassarre 2006 Aim to increase omega-3. Compared LCn3 (1.8 g/d EPA + DHA, 0.12 g LA, 1.92 g/d PUFA)
vs MUFA (~20% LA or 1.2 g/d PUFA). Dose 0.72 g/d PUFA, 0.3% E total PUFA, < 10% of
baseline assumed 6% E PUFA. No biomarker data except on EPA + DHA, no dietary intake data
presented, no postbaseline TC data but LDL increased in intervention arm and remained static in
control
Berson 2004 DHA vs omega-6, there appeared to be roughly the same amount of PUFA in both intervention
and control supplements, but exact composition unclear (1.2g/d DHA plus 1.8 g vegetable oil vs
3 g/d mixed soy and corn oils (half each). Appeared to be < 10% difference in total PUFA between
arms
Caldwell 2011 Compared EPA + DHA vs omega-6, did not report intention to increase total PUFA. Intervention
2.1 g/d n3 (1050 mg EPA, 750 mg DHA and 300 mg other n3), control 3 g/d soybean oil (approx
60% PUFA plus 8% fish oil, 2.04 g/d), PUFA Dose 0.06 g/d, 0.03% E PUFA, < 10% increase
from assumed 6% E baseline. Only erythrocyte fatty acid ratio reported, no TC or dietary intake
data reported
DART 2 - Burr 2003 Aimed to increase oily fish intake or update of fish oil capsules. NoPUFA aim, noPUFAbiomarkers
(though plasma EPA rose 1.23 mg/dl in intervention, fell 0.16 mg/dL in control over 6 months)
or intake data reported. Aim for those on capsules was increase 0.5 g/d EPA + DHA, 0.2% E n-
3, 0.2% E PUFA. < 10% increase from assumed 6% E from PUFA baseline
DART fish Burr 1989 EPA + DHA vs nil, aimed to increase omega-3 intake by increasing fatty fish intake. No total
PUFA goals or data on intake, serum fatty acids or serum cholesterol. Dose aim increase 0.5 g/d
EPA + DHA, 0.2% E n-3, 0.2% E PUFA. < 10% increase over assumed 6% E PUFA at baseline
Derosa 2016 Compared EPA + DHA vs filler (non-fat), no intention to increase total PUFA. Omega-3 dose
unclear, states intention in intervention of 3 x 1 g capsule/d n-3 PUFAs (ethylic esters, each 1-g
capsule of n-3 PUFAs contains highly concentrated ethyl esters of omega-3 fatty acids, primarily
EPA, and DHA in the proportion of 0.9-1.5), compared to placebo of “sucrose, mannitol and
mineral salts magnesium stearate and silicon dioxide, used as anti-caking agents”. Both groups
were given diet and exercise advice. No biomarker or intake data provided on omega-3 or total
PUFAs, TC not significantly different between arms. If omega-3 dose was 1 g/d, or 0.45% E this
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would be < 10% E increase from an assumed baseline of 6% E
Deslypere 1992 Compared LCN3 vsMUFA, no intention to increase total PUFA. Intended dose appeared relevant
for 6 and 6 capsule arms (increase 1.12 g/d EPA + DHA, 0.5% E n-3, 0.5% E PUFA or 2.24g/d
EPA + DHA, 1.0% E n-3, 1.0% E PUFA or 3.4 g/d EPA + DHA, 1.5% E n-3, 1.5% E PUFA)
but total PUFA intake appeared equal in all arms (subtracting SFA and MUFA from total fat),
and erythrocyte membrane fatty acids similar in all arms (summing EPA, DHA, DPA, LA and
AA, 30.6% fatty acids for 9-capsule arm, 30.5% 6 capsules, 29.9% 3 capsules and 29.1% fatty
acids in control arm. Did not appear to be > 10% increase in total PUFA between intervention
and control arms
DISAF - Harrison 2005 Compared EPA + DHA vs nil, did not aim to increase total PUFA. Aimed to increase 1.4 g/d EPA
+ DHA, 0.6% E n-3, this equates to 0.6% E PUFA in intervention arm, no change in control.
While red cell membrane EPA and DHA increased in the intervention group, not in control,
AA was reported as falling in intervention. PUFA (summed EPA + DHA and AA was 17.8% in
intervention, 17.6% in control. Other PUFAs and TC not reported. Difference in total PUFA
between intervention and control < 10% control
DO Health Ongoing trial. Intervention omega-3 (1 g/d, ratio EPA:DHA = 1:2) vs placebo capsules (plus or
minus vitamin D3 and strength home exercise). Dose of total PUFA appears < 1.33 g/d, < 0.6%
E PUFA, so excluded
DO IT - Einvik 2010 Compared EPA + DHA vs omega-6, no aim to increase total PUFA. Intervention aim 2.4 g/d of
omega-3 PUFA (EPA + DHA 1.32 g/d, assume 1.08 g/d ALA or other omega-3) vs corn oil (2.24
g/d LA). 2.4 g/d omega-3, 1.1% E n3 vs 2.24 g/d LA or 1.0% E LA, PUFA dose 0.1% E. < 10%
increase from assumed 6% E baseline. Serum fatty acids suggest < 10% more total PUFA in both
intervention arms than controls, no difference in TC between arms
DO IT 2006 Dietary advice arm provided multifactorial dietary advice, while the supplementary arm was a
specifically omega-3 intervention (so included in the omega-3 review)
EPE-A study 2014 Compared: high EPA vs low EPA vs placebo (contents not reported). PUFA content of placebo
unknown. High EPA (increase 2.7 g/d EPA + DHA, 1.2% E omega-3, 1.2% E PUFA) vs low EPA
(increase 1.8 g/d EPA + DHA, 0.8% E omega-3, 0.8% E PUFA), PUFA dose 0.4% E, < 10%
increase from assumed 6% E at baseline. Serum EPA to AA (0.57 in high dose, 0.40 in low dose,
0.09 in control), TC rose by 8 mg/dL in control, by 4 mg/dL in high dose and by 3 mg/dL in
moderate dose)
Erdogan 2007 Intervention and control group contents unclear, so unclear if more PUFA vs less
Finnish Mental Hosp 1972 Not randomised (cluster-randomised, but < 6 clusters)
FLAX-PAD 2013 Compared ALA (in milled flaxseed) vs mixed dietary oils (composition unclear). No intention to
increase total PUFA. Quantity of ALA and other PUFA unclear in both arms. Plasma levels of
enterolignans and ALA rose in ALA arm, no details for control. No suggestion that total PUFA
intake was higher in either arm, exclude
FORWARD 2013 Compared EPA + DHA vs MUFA, no aim to increase total PUFA. Intervention provided 0.86 g/
d EPA + DHA, 0.4% E n-3, 0.4% E PUFA, control provided 1 g/d olive oil, or 0.2 g/d LA. Total
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PUFA dose 0.66 g/d PUFA, 0.3% E, < 10% higher than assumed 6% E PUFA baseline
FOSTAR 2016 Compared high EPA + DHA vs low EPA + DHA plus ALA. Intervention fruit juice mixed with
fish oil supplement (18% EPA, 12% DHA, 4.5 g/day total omega-3), control 15 mL Sunola oil/d
(fish oil 2 mL plus 13 mL canola oil, omega-3≤ 0.45 g EPA + DHA plus 3.9 g/d PUFA in canola,
4.4 g/d PUFA). ~0.1 g/d PUFA more in intervention, < 10% more than assumed 6% E PUFA at
baseline
Franzen 1993 Compared EPA + DHA vs MUFA. No intention to increase total PUFA stated but increased
omega-3 (20%EPA, 15%DHA, 3.15 g/day total omega-3) vs increased olive oil (6.3 g/dayMUFA,
1.35 g/day SFA, 1.35 g/d total omega-6 fat). This suggests increase 1.8 g/d PUFA, 0.8% E PUFA,
but serum fatty acids (summing EPA, DHA, ALA, LA, AA, DPA) suggested higher total PUFA
in control (182 mg/dL PUFA in intervention, 195 mg/dL in control). However, TC rose more in
control than intervention. Change in total PUFA unclear, exclude
Gill 2012 Compared omega-3 with placebo (unclear what), no aim to increase total PUFA. Control group
contents unclear, so unclear if more PUFA vs less, no biomarker or intake data, TC reported only
as “no significant change”. Change in total PUFA unclear, exclude
GISSI-HF 2008 Compared EPA + DHA vs MUFA, no aim to increase total PUFA. Intervention increased 1 g/
d omega-3, 1 g/d olive oil, or 0.2 g/d LA in control, dose 0.8 g/d total PUFA, 0.36% E PUFA,
< 10% increase from assumed 6% E PUFA. Fatty acid status did not provide total PUFA or any
omega-6 PUFAs, TC data provided for intervention but not control
GISSI-P 1999 Compared EPA + DHA vs nil, no aim to increase total PUFA. Intervention dose 0.86 g/d EPA +
DHA, 0.4% E n-3, 0.4% E PUFA, < 10% increase from assumed 6% E PUFA. No biomarker or
intake data, TC appeared to rise slightly more in intervention than control arms to 6 months
JELIS 2007 Compared EPA fats with nil, no intention to increase total PUFA. Intended omega-3 dose was 1.
8 g/d EPA, compared to nil, and both groups received “appropriate” dietary advice (not described
further). This suggests increases in total PUFA (0.8%E n-3, 0.8% E PUFA), but increase in plasma
PUFAs (sum of omega-3 and omega-6 fats, including EPA, DHA, DPA, ALA, LA, GLA, AA),
was higher in control (+26.2 mg/mL) than intervention (+ 20 mg/mL). TC not reported, LDL
change was equivalent (but all on statins). Difference in total PUFA appears < 10% of baseline
PUFA intake assumed to be 6% E
Lorenz-Meyer 1996 Compared EPA + DHA vs omega-6, no intention to increase total PUFA. Intervention increased
EPA + DHA 5.1 g/d vs 6 g/d LA, 0.9 g/d or 0.45% E difference, < 10% increase over assumed
6% E PUFA. No biomarker or TC or intake data reported
Mansel 1990 Did not aim to alter total PUFA, aimed to increase 0.48 g/d GLA or 4 kcal or 0.2%EGLA, increase
~8.4 g/d LA or 76 kcal or 3.8% ELA, total 4% En6, estimated total PUFA dose 4% E. No
serum TC or tissue fatty acid levels reported, no dietary intake data. No deaths or cardiovascular
events occurred, only breast cancer diagnoses reported
MAPT 2017 Compared EPA + DHA vs paraffin oil (non fat). Intervention 1.025 g/d DHA + EPA compared
to flavoured paraffin oil. (Also aims 3 and 4 as above plus multi-domain intervention (nutrition,
physical exercise, cognitive stimulation, social activities). Intended increase 1.03 g/d EPA + DHA,
0.5% E n3, 0.5% E PUFA, < 10% more than assumed 6% E PUFA baseline
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MARGARIN Bemelmans 2002 Omega-3 vs omega-6. Compared omega-3 (ALA-rich margarine, 80% fat of which 15% was ALA
and 46% LA) with omega-6 (LA-rich margarine, 80% fat of which 0.3% was ALA and 58% LA)
. Margarines eaten as desired, so doses unclear. Serum cholesterol ester fatty acid changes suggest
rises in ALA in omega-3 arm and rises in LA in the LA arm, with rough equivalence in total PUFA
between arms. TC fell slightly more in LA arms than ALA arms, but fell in all arms. Arms appear
equivalent in total PUFA intake
MENU - Rock 2016 Compared walnut-rich moderate fat diet (ALA) vs moderate fat diet (MUFA), did not aim to
increase total PUFA. Intervention was advice to follow walnut-rich higher fat diet (35% E fat with
limited SFA, MUFA encouraged, including 42 g/d walnuts, 45% E CHO, 20% E protein) vs
exactly as intervention goals without walnuts. Unclear how total PUFA altered in each arm, mean
LDL at 1 year was 2.97 mmol/L in both arms, TC not reported. Red blood cell fatty acid ALA and
LA reported at 1 year (summed 12.5% in intervention, 12.2% in control) but other fatty acids
not reported. PUFA dose unclear, excluded
Michalsen 2006 Multifactorial - combination of diet (focusing on ALA and oily fish as well as Mediterranean
diet more generally), exercise and stress-reduction programme and advice in intervention, general
written dietary and stress advice in control
Middleton 2002 Intervention and control descriptions unclear. Compared EPA + DHA + GLA vs LA, but unclear
which arm was higher in PUFA, or quantity of PUFA in either arm
Minnesota Coronary 1989 While participants were involved in this trial for over 1 year on average they could move in and
out of the institution in which the trial took place, and therefore in and out of the trial over the
duration of the trial. Most participants were not involved in the trial continuously for ≥ 1 year
Moy 2001 Aim was to reduce dietary fat (total and saturated fat reductions appear to have been achieved) but
effects on PUFAs unclear (total PUFA, omega-6 and omega-3 intakes not reported)
NAT2 2015 No aim to increase total PUFA, aimed to increase omega-3 fats. Intervention was 1110 mg/d n-
3 FAs (EPA: 270 mg/day DHA: 840 mg/day) vs olive oil capsules (containing 0.2 g total PUFA)
. Total PUFA dose would be 0.91 g/d, or 0.4% E PUFA. Red blood cell lipid EPA and DHA
presented, but not total PUFA. Dietary intake data suggest 0.5% E difference in total PUFA
between arms (< 10% increase from assumed 6% E from PUFA at baseline)
Norouzi 2014 Compared LCn3 with placebo (no details). Intervention 1.056 g/d LCn3 plus 0.056 g/d omega-6,
1.112 g/d PUFA in intervention, control group contents unclear, so unclear whether more PUFA
vs less. No biomarker, TC or dietary intake data to help. No intention to increase total PUFA and
no information on whether PUFA was increased substantially in one arm compared to the other,
exclude
Norwegian - Natvig 1968 Aimwas to increase vegetable oil intake, comparing ALA (linseed oil) with omega-6 (sunflower oil)
. Intervention was linseed oil, 10 mL/d (55% ALA), 5.5 g/d ALA, 1.5g/d LA (7.04 g total PUFA)
, control was sunflower oil, 10 mL/d (1.4% ALA), 0.14 g/d ALA, 6.3 g/d LA or 6.42 g/d omega-
6 (6.56 g/d total PUFA). Intended total PUFA dose was 0.48 g/d lower total PUFA or 0.22% E
from PUFA lower in intervention (< 10% change from assumed 6% E baseline). No biomarker or
dietary intake data, except slightly lower TC at 6 months in intervention arm
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NutriStroke 2009 Compared LCn3 with unclear placebo. No intention to increase total PUFA. Intervention 0.5 g/
d LCn3, assume 0.5 g/d PUFA. Control group contents unclear, but state no PUFA. PUFA dose
0.5 g/d or 0.23% E PUFA, < 10% increase from assumed 6% E PUFA baseline. No biomarker,
TC or dietary intake data to confirm
OFAMI - Nilsen 2001 Omega-3 vs omega-6 comparison, aim to assess effects of omega-3 increase, total PUFA doses in
each arm unclear, no dietary intake data provided
OMEGA 2014 Did not aim to alter total PUFA. Aimed to increase omega-3 fats, vs MUFA control, but only
increased omega-3 fats by 0.4% E (< 10% of assumed baseline of 6% E from PUFA). No dietary
intake data provided
OPAL - Dangour 2010 Aimed to increase omega-3 fats, not total PUFA, compared omega-3 supplement with olive oil,
omega-3 dose 0.7 g/d or 0.3% E (< 10% of assumed baseline of 6% E from PUFA). No dietary
intake data provided
ORIGIN 2012 Aimed to increase omega-3 fats, not total PUFA. Compared omega-3 supplement with olive oil
placebo, EPA + DHA vs MUFA. Aimed to increase 0.84 g/d EPA + DHA, 0.4% E n-3, 0.4% E
PUFA (< 10% of assumed baseline of 6% E from PUFA). No dietary intake data provided
Oslo Diet-Heart 1966 Multifactorial dietary intervention (cannot separate out the effects of PUFAs from other dietary
interventions)
Oxford Retinopathy 1978 Multifactorial dietary intervention (cannot separate out the effects of PUFAs from other dietary
interventions)
POUNDS Lost Sacks 2009 Manipulation of total fat intake, but no details of fat types aimed for or achieved in any arms
Ramirez-Ramirez 2013 Omega-3 vs omega-6 (DHA +EPA vs sunflower oil). Quantities of total PUFA in each arm unclear,
but likely to have been similar (< 10% of assumed baseline of 6% E from PUFA). Aimed to assess
omega-3 effects, no dietary intake data provided
Reed 2014 Omega-3 vs omega-6 (EPA + DHA vs GLA + sunflower oil). Doses of total PUFA in each arm
unclear but likely to have been similar (< 10% of assumed baseline of 6% E from PUFA). Aimed
to assess omega-3 effects and omega-6 effects, not total PUFA. Paper states that there were no
differences between arms for TC or dietary intake
Risk and Prevention Omega-3 vs MUFA, but small PUFA dose (intended to increase 0.86 g/d EPA + DHA, 0.4% E
n3, 0.4% E PUFA). Aimed to assess effects of omega-3 fats, not total PUFA, intended dose too
small (< 10% of assumed baseline of 6% E from PUFA). No difference between arms for change
in TC from baseline to 5 years (P = 0.52)
Sandhu 2016 Aimed to increase omega-3 fats. Intended dose suggested higher omega-3 fats in Lovaza and Lovaza
& Raloxifee compared to control and Raloxifene 30 mg (as no placebo was provided. However,
plasma fatty acid concentration suggested that total PUFA was not higher in these arms. Mean
summed plasma fatty acid omega-3 fats higher in Lovaza and Lovaza & Raloxifee arms compared
to control and Raloxifene 30 mg at 2 years. However omega-6 fats were equivalently lower, mean
total PUFA (summing omega-3 and omega-6) similar in both arms
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Schirmer 2007 Compared n-6 (GLA) vs MUFA, did not aim to increase total PUFA. Intervention included 0.89
g/d GLA plus ~0.9 g/d LA or 0.8% E n6. control included 1 g/d LA, 0.45% E LA. Difference 0.
35% E omega-6, assume same for PUFA, < 10% more than assumed 6% E baseline total PUFA.
No biomarker, TC or dietary intake data
SCIMO - von Schacky 1999 Aimed to increase omega-3 fats. Intended omega-3 dose was 1.03 g/d EPA + DHA, 0.5% E
n-3. This would translate to 0.5% E PUFA, but the placebo was probably fairly rich in total
PUFA. Excluded as probably < 10% increase in total PUFA in intervention compared to control.
Erythrocyte phospholipid fatty acid composition confirmed rise in EPA andDHA but didn’t report
further PUFAs. Serum total cholesterol dropped very slightly more in intervention than control
(TC -0.1mmol/L in int, -0.05mmol/L in cont from baseline to 24 months)
Shinto 2014 Compared EPA + DHA vs n-6, did not intend to increase total PUFA. Intervention 1.650 g/d
LCn3, 1.65 g/d PUFA vs 3 g/d soybean oil (~60% PUFA), 1.8 g/d PUFA. Dose is 0.15 g/d PUFA,
0.07% E PUFA, < 10% change from assumed 6% E PUFA baseline. No biomarker (except red
blood cell EPA + DHA), dietary intake or TC data
SHOT - Eritsland 1996 Aim was to increase omega-3 fats. Intervenion was omega-3 vs nil, and provided 3.3 g/d EPA +
DHA, or 1.5% E from omega-3 fats. This suggests increase of 1.5% E from PUFA, but serum
fatty acid PUFA assessments were 645 mg/L in the control (up 43 mg/L from 603 at baseline),
and 621 mg/L (up 28 mg/L from 593) in the intervention group at 9 months, suggesting lower
or equivalent total PUFA intake in the intervention compared with control. Serum TC remained
constant over the trial in both arms
Sianni 2013 Control group contents unclear, so unclear if more PUFA vs less. Aimed to increase omega-3 fats,
intervention group received 4 g/d omega-3 fats, placebo not described. As only an abstract could
be found, and contact could not be established with the authors we excluded this trial
SMART Tapsell 2013 Compared fish + fish oil supplements vs fish + olive oil supplements vs olive oil supplements. Did
not aim to increase total PUFA. Comparisons with olive oil supplement arm are multifactorial so
excluded. Fish + fish oil supplements (capsules including 420 mg/d EPA + 210 mg/d DHA, 0.63
g/d EPA + DHA) vs fish plus olive oil supplements (1 g olive oil/d, assume 0.2 g/d PUFA) has
equivalent diets with differing supplements between arms. Dose 0.43 g/d PUFA, 0.2% E from
PUFA, < 10% increase from assumed 6% E PUFA at baseline
SOFA 2006 Aimed to increase omega-3 fats. Comparison was EPA + DHA (961 mg n-3 PUFAS) vs MUFA +
omega-6 (2 g/d high-oleic acid sunflower oil). Omega-3 dose was only 0.96 g/d, or 0.4% E from
omega-3. As there was some PUFA in the placebo it was unlikely that total PUFA was increased
more than 10% of baseline. No biomarker data found to confirm or refute this
Sofi 2010 Aimed to increase omega-3 fats. Comparison was EPA + DHA (6.5 mL/d olive oil enriched with
n-3 plus dietary recommendations, 0.83 g n-3/d of which 0.47 g/d EPA & 0.24 g/d DHA) vs
MUFA (6.5 mL/d olive oil plus dietary recommendations). Omega-3 dose was 0.71 g/d EPA +
DHA, 0.3% E n-3, equivalent to 0.3% E PUFA (< 10% increase from assumed 6% E PUFA
baseline). No fatty acid biomarker data, TC fell more in control than intervention
STARS 1992 Intervention encouraged to increase plant-derived soluble fibre as well as alter dietary fats, multi-
factorial
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Stoll 2001 Ongoing trial. NCT00010868. The PI, Andrew Stoll, appears to have been struck off the medical
register in Massachusetts in 2011 (Commonwealth of Massachusetts Board of Registration in
Medicine, Adjudicatory Case number 2011-026) so it has not been possible to contact him and
no publication of results has been found
STRENGTH Ongoing trial. Intervention omega-3 carboxylic acid capsule (Epanova, not less than 800 mg/g)
and statin vs corn oil placebo capsule and statin. Omega-3 vs omega-6, unlikely to reach PUFA
dose of > 1.33 g/d or 0.6% E
SU.FOL.OM3 Galan 2010 Compared EPA + DHA vs non-fat placebo, no intention to increase total PUFA. Intervention 400
mg/d EPA and 200 mg/d DHA compared to liquid paraffin with fish flavour. Intended dose 0.6 g/
d EPA + DHA, 0.3% E PUFA, < 10% change from assumed 6% E PUFA baseline. No biomarker
(aside from plasma EPA + DHA), TC (apart from baseline) or dietary intake data provided
Søndergaard 2003 Multifactorial dietary intervention (cannot separate out the effects of PUFAs from other dietary
interventions)
Tande 2016 Compared EPA + DHA vs MUFA, did not intend to increase total PUFA. Intervention 2 g/d
calanus oil (85% wax ester with a sum of neutral lipids > 90%, 11% oil is EPA + DHA, or 0.22
g/d EPA + DHA), control 2 g/d olive oil (analysis indicated this olive oil was primarily oleic acid
(76.9%), palmitic acid (10.2%), and linoleic acid (7.7%), assumed 0.14 g/d LA), overall dose 0.
08 g/d PUFA, 0.04% PUFA. < 10% increase from assumed 6% E PUFA. TC increased by 0.02
mmoL/L in intervention to 1 year, fell 0.08 mmoL/L in control, no further biomarker or intake
data
Tay 2015 Multifactorial dietary intervention (cannot separate out the effects of PUFAs from other dietary
interventions)
THIS DIET - Tuttle 2008 Aim was to achieve a Mediterranean-style diet, and compare it to a low-fat diet. All intervention
and control participants were advised to reduce SFA and dietary cholesterol, increase fruits and
vegetables andwhole grains. In addition intervention participantswere encouraged to increase cold-
water fish and oils from olives, canola and soybeans. Plasma fatty acid composition suggested that
omega-3 increased in the intervention arm compared to control (rising 0.1% in control, rising 0.
6% in intervention) while omega-6 fats reduced in the intervention (rising 0.7% in control, falling
0.1% in intervention). This confirms dietary intake data suggesting that total PUFA increased by
0.9% E in control, and increased by only 0.1% E in intervention, to equivalence at 24 months
(total PUFA intake at 24 months 5.7% E, SD 3.1 in control, 5.7% E, SD 2.4 in intervention).
No total PUFA difference between arms during trial, so excluded
VITAL Ongoing trial. Intervention omega-3 (Omacor fish oil, EPA + DHA 1 g/d: 465 mg EPA; 375 mg
DHA) vs placebo (plus or minus vitamin D3). Placebo unclear but very unlikely to attain a dose
of > 1.33 g/d PUFA or 0.6% E
Weinstock-Guttman 2005 Aim was to compare low fat diet (15% E from fat) plus EPA + DHA supplements (3.3 g/d EPA +
DHA, 1.5% E n3) with low-fat diet (30% E from fat) plus olive oil capsules. Total PUFA in each
arm (aimed or achieved) is not clear. Serum fatty acids were assessed, data reported on MUFA,
EPA, DHA, DPA, combined omega-3 fats and SFA, but not total fat intake or total PUFAs. TC
was not reported and LDL rose slightly in both groups, more in the control (30% E fat) than
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intervention (15% E fat). Dietary intake not reported
WHI 2006 Dietary intervention was of dietary fat and also fruit and vegetables, multifactorial
Zhang 2016 ComparedDHAvs cornoil (n6).No aim to increase total PUFA, intervention1.0 g/dDHA, 0.45%
E n3, control 1.1 g/d PUFA, 0.5% E PUFA, dose 0.05% E PUFA, < 10% increase from assumed
6% E PUFA baseline. No fatty acid (except very small increase in serum DHA in intervention,
unclear if statistically significant), TC or dietary intake data
Özaydin 2011 Compared omega-3 supplement with nil (no placebo). Intended omega-3 dose was increase 0.6
g/d EPA + DHA, 0.3% E n-3, 0.3% E PUFA. Baseline total PUFA not reported, nor intake or
body marker data. Assume baseline 6% E PUFA, dose < 10% increase
AA: arachidonic acid; ALA: alpha-linolenic acid (a plant-based omega-3 fat); CHO: carbohydrate;DHA: docosahexaenoic acid (a fish-
based omega-3 polyunsaturated fat);DPA: docosapentaenoic acid (a fish-based omega-3 polyunsaturated fat);EPA: eicosapentaenoic
acid (a fish-based omega-3 polyunsaturated fat);GLA: gamma linolenic acid (an omega-6 polyunsaturated fat); LA: linoleic acid (an
omega-6 polyunsaturated fat);LDL: lowdensity lipoprotein (a fraction of TC,measured in human blood);MUFA: monounsaturated
fatty acid or monounsaturated fat; PUFA: polyunsaturated fatty acid or polyunsaturated fat; SFA: saturated fatty acid or saturated
fat; TC: total cholesterol (measured in human blood)
Characteristics of ongoing studies [ordered by study ID]
AC Omega3
Trial name or title The Aboriginal cardiovascular omega-3 randomised controlled trial (AC Omega3)
Methods RCT
Participants Indigenous Australian adults with stable coronary artery disease
Interventions Each for 12 months:
Arm 1: omega-3 (1800 mg/d AlaskOmega: 3 capsules/d: 400 mg EPA and 200 mg DHA)
Arm 2: placebo mixed oil capsules (1000 mg/d: 3 capsules/d containing palm oil, gelatin, glycerol, sunflower
oil, rapeseed oil, mixed tocopherols, and a “small amount” of fish oil ((or taste) to aid blinding)
Outcomes Primary: serum non-HDL cholesterol
Secondary: triglycerides, total cholesterol, LDL, HDL, lipid functionality by cholesterol efflux and CETP,
heart rate variability, platelet function and thrombosis markers, inflammation markers, cumulative combined
rate of major adverse cardiac events (including death, non-fatal MI, unstable angina, non-fatal stroke, revas-
cularisation and cardiac-related hospital admissions)
Starting date Registered on Trials Registry: 10 July 2014
Trial start date: 1 October 2014
Trial completion date est: unclear
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Contact information Alex Brown (PI), Wardliparingga Aboriginal Unit, Adelaide, Australia, alex.brown@sahmri.com
Notes ACTRN12614000732684
Alex Brown contacted in 2016: confirmed trial is actively recruiting
ACTRN12610000594022
Trial name or title Clinical efficacy of fish oil as adjunct therapy for patients with chronic periodontitis
Methods RCT
Participants Adults (25-80 years, non-smokers) with newly diagnosed severe but non aggressive periodontitis
Interventions Each for 13 months:
Arm 1: fish oil rich in EPA (6 x 500 mg capsules/d: 277 mg EPA; 27 mg DHA) and standard periodontal
treatment (scaling and debridement)
Arm 2: fish oil rich in DHA (6 x 500 mg capsules/d: 66 mg EPA; 258 mg DHA) and standard periodontal
treatment
Arm 3: soya oil placebo (6 x 500 mg capsules/d) and standard periodontal treatment
Outcomes Primary: probing pocket depth, clinical attachment level (CAL)
Secondary: inflammatory biomarkers in gingival crevicular fluid, erythrocyte omega-3, C-reactive protein
Starting date Registered on Trials Registry: 23 July 2010
Trial start date: July 2010
Trial completion date est: unclear
Contact information Mark Bartold, University of Adelaide, mark.bartold@adelaide.edu.au
Notes ACTRN12610000594022
PhD, Boram Park, available giving 4-month outcome data for pilot trial n = 33 participants
Mark Bartold written to in 2016. Confirmed preparing full publications for submission
ACTRN12613000034730
Trial name or title Intervention of testosterone & fish oil for the prevention of Alzheimer’s disease: InTrePad
Methods RCT
Participants PiB-PET (Pittsburgh compound B)-positive men aged ≥ 60 years with subjective memory complaints
Interventions Each for 56 weeks:
Arm 1: DHA capsules (1720 mg/d) and testosterone undecanoate (intramuscular injection 1000 mg/4 mL
every 8 weeks)
Arm 2: placebo DHA and testosterone undecanoate (intramuscular injection 1000 mg/4 mL every 8 weeks)
Arm 3: placebo DHA and placebo testosterone
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Outcomes Primary: PiB score
Secondary: neuropsychological, mood and daily functioning questionnaires, beta amyloid levels, fluo-
rodeoxyglucose to assess brain glucose metabolism, inflammatory and oxidative biomarkers, hippocampal
volume, quality of life, safety and tolerability of treatment
Starting date Registered on Trials Registry: 14 January 2013
Trial start date: 28 February 2013
Trial completion date est:
Contact information Ralph Martins (PI), Sir James McCusker Alzheimer’s Disease Research Unit, Hollywood Medical Centre,
Nedlands, Australia, r.martins@ecu.edu.au
Notes ACTRN12613000034730
Ralph Martins written to in 2016- no response
AFORRD
Trial name or title Atorvastatin in factorial with omega-3 fatty acid risk reduction in diabetes (AFORRD)
Methods RCT
Participants People with type 2 diabetes with no known CVD and not taking lipid-lowering therapy, adults (> 18 years)
N: intervention 397, control 403 (analysed intervention 371, control 361)
Interventions Each for 12 months:
Arm 1: atorvastatin (Lipitor 20 mg/d) and olive oil placebo (2 g/d)
Arm 2: omega-3 (Omacor 2 g/d: 46% EPA, 38% DHA) and placebo tablets for atorvastatin
Arm 3: atorvastatin (Lipitor 20 mg/d) and Omega-3 (Omacor 2 g/d: 46% EPA, 38% DHA)
Arm 4: placebo tablets for atorvastatin and olive oil placebo (2 g/d)
Outcomes Primary: lipid profiles
Secondary: phytosterol changes, HbA1c ,estimated CVD risk using the UK Prospective Diabetes Study risk
engine
Starting date Registered on Trials Registry: 4 April 2004
Trial start date: 1 November 2004
Trial completion date est: 31 July 2006
Contact information Rury Holman, Oxford Centre for Diabetes
Notes ISRCTN76737502
Rury Holman contacted in 2016: confirmed results are not yet published, but planned
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Trial name or title The Beyond Ageing Project phase 2: a selective prevention trial using novel pharmacotherapies in an older
age cohort at risk for depression
Methods RCT
Participants Older adults (≥ 60 years) at risk of depression (K-10 score ranging from 16-29) who initially participated in
the first Beyond Ageing Project
Interventions Each for 12 months:
Arm 1: omega-3 (4 capsules, total 2 g/d: 1200 mg EPA and 800 mg DHA) and placebo microcrystalline
cellulose (1 capsule)
Arm 2: paraffin oil placebo (4 capsules) and sertraline hydrochloride (1 capsule, 50 mg)
Arm 3: paraffin oil placebo (4 capsules) and placebo microcrystalline cellulose (1 capsule)
Outcomes Primary: depressive symptoms (PHQ-9)
Secondary: cognitive decline, Mini Mental State Exam, brain metabolism, hippocampal volume, anxiety
(Generalized Anxiety Disorder-7 (GAD-7)), disability (World Health Organziation Disability Assessment
Schedule-II (WHODAS-II)), sleeping problems (Pittsburgh Sleep Quality Index (PSQI)), exercise (Active
Australian Survey)
Starting date Registered on Trials Registry: 12 January 2010
Trial start date: June 2011
Trial completion date est: Main results expected in 2017
Contact information Ian Hickie (PI), Brain and Mind Centre, University of Sydney, ian.hickie@sydney.adu.au
Notes ACTRN12610000032055
Chandrakala 2010
Trial name or title Long-term effects of a reduced fat diet intervention in pre-diabetes
Methods RCT
Participants Participants with pre-diabetes (IFG/IGT), 201 participants discussed in 1 abstract, 134 in a later abstract
Interventions Each for 3 years:
Arm 1: reduced-fat diet (fat content ≤ 20% total energy, ratio of PUFA/SFA 0.8 to 1.0)
Arm 2: normal/control diet
Outcomes Incidence of diabetes, BMI, lipids, insulin, plasma glucose, HbA1c, BP, nutritional intake
Starting date Registered on Trials Registry: no registration found
Trial start date: not stated
Trial completion date est: not stated
Contact information Chandrakala Galla, chandrakala.galla@gmail.com; Arpana Gaddam, dr.arpanag@gmail.com
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Chandrakala 2010 (Continued)
Notes We wrote to trial authors in 2016: Dr Gaddam confirmed work submitted as a PhD but not published in
full. Requested copy of PhD thesis, but no reply to date
Funding: DiabetOmics India
n-3 for Vascular Cognitive Aging
Trial name or title n-3 PUFA for vascular cognitive aging
Methods RCT
Participants Older adults (≥ 80 years) at high risk for cognitive decline and dementia of Alzheimer’s type
Interventions Each for 3 years:
Arm 1: omega-3 fish oil (1.65 g/d EPA + DHA)
Arm 2: soybean oil placebo (1.65 g/d)
Outcomes Primary: total cerebral white matter volume
Secondary: biomarkers of endothelial health, total brain atrophy, medial temporal lobe atrophy, ventricular
expansion, Trail Making Test part B, digit symbol Wechsler Adult Intelligence Scale-Revised (WAIS-R),
cerebral blood flow, fractional anisotropy within frontal gyri
Starting date Registered on Trials Registry: 24 September 2013
Trial start date: May 2014
Trial completion date est: March 2019
Contact information Alena Borgatti, borgatti@ohsu.edu; James Dursch, dursch@ohsu.edu; Gene Bowman and Lynne Shinto (PIs)
, Oregon Health and Science University
Notes NCT01953705
n-3 on plasma lipid
Trial name or title Influence of different sources of n-3 fatty acid on plasma lipid in moderately hypercholesterolaemic subjects
Methods RCT
Participants Adults (40-65 years) with mild to moderate hypercholesterolaemia
Interventions Arm 1: EPA/DHA 1.8 g/d
Arm 2: EPA/DHA 3.6 g/d
Arm 3: ALA 4 g/d
Arm 4: placebo
Outcomes Fatty acids, lipids, cytokines (IL-6, IL-1a)
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n-3 on plasma lipid (Continued)
Starting date Registered on Trials Registry: 13 March 2012
Trial start date: unclear
Trial completion date est: unclear
Contact information Su Yixiang, Sun-Yat Sen University, China, suyx@mail.sysu.edu.cn; Zhou Quan, Guangzhou Medical Uni-
versity, joan zq@126.com
Notes ChiCTR-TRC-12002014
Su Yixiang and Zhou Quan contacted in 2016: no response
NCT00309439
Trial name or title Studies of serum PSA to help resolve the current implication of alpha-linolenic acid and prostate cancer
Methods RCT
Participants Adults 18-77 years
Interventions Arm 1: ALA-rich diet
Arm 2: control (not detailed)
Outcomes PSA, atrial fibrillation
Starting date Registered on Trials Registry: 29 March 2006
Trial start date: unclear
Trial completion date est: unclear
Contact information David Jenkins, University of Toronto, nutritionproject@smh.toronto.on.ca
Notes NCT00309439
David Jenkins written to in 2016: confirmed not published in full and data incomplete
NCT00410020
Trial name or title Arrhythmia prevention with an alpha-linolenic enriched diet
Methods RCT, parallel, 2 arms, 12 months
Participants 98 people with successful atrial fibrillation electrical cardioversion
Interventions Canola margarine and oil, rich in ALA, versus a conventional diet (control), for 1 year
Outcomes Length of time to first recurrence of atrial fibrillation
Starting date June 1999, expected finish date June 2003, registered December 2006 so appears to have been carried out
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NCT00410020 (Continued)
Contact information Principal Investigator: Jean-Paul Broustet, MD, PhD, Universitary Hospital Haut-Lévêque Bordeaux France
Notes NCT00410020, registered Dec 2006, no publication found
NCT01047449
Trial name or title Improving the results of heart bypass surgery using new approaches to surgery and medication (SUPERI-
ORSVG)
Methods RCT
Participants Adults having coronary artery bypass graft (CABG) using saphenous vein graft (SVG)
Interventions Each for 12 months:
Arm 1: fish oil supplements (2 x 1 g/d Ocean Nutrition capsules: 55% fish oils EPA:DHA 33%:22%) and
SVG conventionally harvested
Arm 2: placebo and SVG conventionally harvested
Arm 3: fish oil supplements (2 x 1 g/d Ocean Nutrition capsules: 55% fish oils EPA:DHA 33%:22%) and
SVG no-touch harvest
Arm 4: placebo and SVG no-touch harvest
Outcomes Primary: proportion of grafts occluded
Secondary: significant stenosis, adverse SVG harvesting events, composite outcome of all-cause mortality,
non-fatal MI and repeat revascularisation
Starting date Registered on Trials Registry: 12 Jan 2010
Trial start date: July 2011
Trial completion date est: Dec 2016
Contact information Stephen Fremes, Sunnybrook Health Sciences Centre (PI)
Notes NCT01047449
NCT01513252
Trial name or title Long-term effects of interventional strategies to prevent cognitive decline in elderly (MAPT PLUS)
Methods RCT - extension of MAPT trial
Participants Participants of MAPT trial
Interventions Follow-up, 2-year extension of participants in MAPT, after completion of MAPT interventions
Outcomes Primary: cognitive and functional status (Grober and Buschke test)
Secondary: markers of cerebral atrophy, cost effectiveness
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NCT01513252 (Continued)
Starting date Registered on Trials Registry: 30 December 2011
Trial start date: December 2011
Trial completion date est: November 2016
Contact information Bruno Vellas (PI), University Hospital, Toulouse, vellas.b@chu-toulouse.fr
Notes NCT01513252
Bruno Vellas written to in 2016- no response
NCT01784042
Trial name or title Dietary energy restriction and omega-3 fatty acids on mammary tissue
Methods RCT
Participants Overweight women (30-55 years) with increased breast cancer risk
Interventions For 1 year:
Arm 1: Lovaza (omega-3-acid ethyl esters)
Arm 2: Lovaza and dietary energy restriction
Arm 3: placebo
Arm 4: placebo and dietary energy restriction
Outcomes Ki67 expression at 1 year
Starting date Registered on Trials Registry: 31 January 2013
Trial start date: March 2013
Trial completion date est: March 2018




Trial name or title Dry eye assessment and management trial (DREAM)
Methods RCT
Participants Adults with dry eye
Interventions Each for 2 years
Arm 1: omega-3 supplements (2000 mg EPA + 1000 mg DHA/d as 5 gelcaps)
Arm 2: olive oil supplements (5 gelcaps)
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NCT02128763 (Continued)
Outcomes Primary: Ocular Surface Disease Index (OSDI) score
Secondary: other eye health measures, SF-36, healthcare utilisation costs, cost effectiveness
Starting date Registered on Trials Registry 28 April 2014
Trial start date: November 2014
Trial completion date est: July 2017




Trial name or title Investigating a phosphatidylserine based dietary approach for the management of mild cognitive impairment
Methods RCT
Participants People with mild cognitive impairment (MCI) aged 65-85 years
Interventions Each for 24 months:
Arm 1: phosphatidylserine omega-3 (DHA enriched)
Arm 2: placebo cellulose capsules
Outcomes Primary: selective reminding test (SRT)
Secondary: MMSE, neurological battery test (NBT), dementia (DSM-4 criteria), mini sleep questionnaire
(MSQ), Hamilton Anxiety rating scale (HAM-A), safety and adverse events
Starting date Registered on Trials Registry: 6 August 2014
Trial start date: September 2014
Trial completion date est: September 2019
Contact information Nadia Niemerzyanski, nadiaN@enzymotec.com; Yael Richter, yaelr@enzymotec.com
Notes NCT02211560
NCT02295059
Trial name or title Omega-3 fatty acids and ERPR(-)HER2(+/-) breast cancer prevention
Methods RCT
Participants Women at risk for recurrent breast cancer- with prior diagnosis of stage 0-III breast cancer and completion
of surgery, chemotherapy or trastuzumab or radiation therapy
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NCT02295059 (Continued)
Interventions Each for 12 months:
Arm 1: omega-3 high-dose capsules (5 g/d EPA + DHA)
Arm 2: omega-3 low-dose capsules (0.9 g/d EPA + DHA)
Outcomes Primary: breast adipose tissue metabolites
Secondary: cytomorphology or cell proliferation of mammary epithelial cells, DNA promoter methylation
and pro-inflammatory gene expression in mammary epithelial and adipose tissue
Starting date Registered on Trials Registry: 14 October 2014
Trial start date: August 2014
Trial completion date est: January 2019
Contact information Anitra Sumbry, anitra.sumbry@osumc.edu; Lisa Yee (PI), Ohio State University
Notes NCT02295059
NCT02676466
Trial name or title Enabling reduction of low-grade inflammation in seniors (ENRGISE)
Methods RCT
Participants People aged 70+ years with self-reported walking or stair-climbing difficulty
Interventions Each for 1 year
Arm 1: omega-3 fish oil (1.4 g/d for 6 months, possibly increasing to 2.8 g/d)
Arm 2: losartan 25 mg/d
Arm 3: placebo corn oil (for omega-3) plus placebo cellulose (for losartan)
Arm 4: omega-3 plus losartan
Arm 5: placebo corn oil (for omega-3)
Arm 6: placebo cellulose (for losartan)
Outcomes Primary: IL6, 400-meter walk test
Secondary: short physical performance battery, frailty, hand grip strength, knee dynamometry, Short Form
(SF)-36
Starting date Registered on Trials Registry 3 February 2016
Trial start date: February 2016
Trial completion date est: March 2018
Contact information Jane Lu janelu@ufl.edu
Michael Stancil mstancil@ufl.edu
Notes NCT02676466
195Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02719327
Trial name or title Impact of icosapent ethyl on Alzheimer’s disease (AD) biomarkers in preclinical adults
Methods RCT
Participants Cognitively healthy adults aged 50-70 years whose parents had AD
Interventions Each for 18 months:
Arm 1: icosapent ethyl EPA (Vascepa) 4 g/d gel cap
Arm 2: matching gel cap placebo
Outcomes Primary: cerebral blood flow by magnetic resonance imaging
Secondary: cerebrospinal fluid biomarkers of Alzheimer’s disease, cognitive performance (preclinical
Alzheimer’s cognitive composite, PACC)
Starting date Registered on Trials Registry: 21 March 2016
Trial start date: December 2016
Trial completion date est: November 2021
Contact information Cynthia Carlsson, cynthia.carlsson@va.gov; Elena Beckman, elena.beckman@va.gov
Notes NCT02719327
OMEMI
Trial name or title Omega-3 fatty acids in elderly patients with myocardial infarction trial (OMEMI)
Methods RCT
Participants Elderly patients (70-82 years) with acute MI
Interventions Each for 24 months:
Arm 1: omega-3 capsules, 3/d (Pikasol, total of 1.8 g/d EPA + DHA) and standard therapy
Arm 2: corn oil placebo, 3/d and standard therapy
Outcomes Primary: composite of total mortality, first non-fatal recurring acute MI, stroke and revascularisation
Secondary: new onset atrial fibrillation, adipose tissue, serum fatty acids, makers of endothelial function,
inflammation, coagulation and fibrinolytic activity, genes associated with atherothrombosis
Starting date Registered on Trials Registry: 16 April 2013
Trial start date: November 2012
Trial completion date est: November 2019
Contact information Svein Solheim, Center for Clinical Heart Research, Oslo University Hospital, arnljot.tveit@vestreviken.no
Notes NCT01841944
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REDUCE-IT
Trial name or title Reduction of cardiovascular events with EPA-intervention trial (REDUCE-IT)
Methods RCT
Participants Patients (45 years or over) with hypertriglyceridaemia, with cardiovascular disease or at high risk for cardio-
vascular disease, and on statin
Interventions Each for 4-6 years:
Arm 1: EPA ethyl ester (AMR101 4 g/d)
Arm 2: placebo
Outcomes Primary: composite of CV death, MI, stroke, coronary revascularisation and hospitalisation for unstable
angina
Secondary: incidence of additional cardiovascular events, lipid and lipoprotein levels
Starting date Registered on Trials Registry: 13 December 2011
Trial start date: November 2011
Trial completion date est: December 2017
Contact information Deepak Bhatt (PI), Brigham and Women’s Hospital
Notes NCT01492361
seAFOOD
Trial name or title The seafood (systematic evaluation of aspirin and fish oil) polyp prevention trial
Methods RCT
Participants NHSBowelCancer ScreeningProgrammepatients (55-73 years) identified as “high risk” (≥ 5 small adenomas;
or ≥ 3 adenomas with at least one being ≥ 10 mm in diameter) after their 1st screening colonoscopy
Interventions Each for 12 months:
Arm 1: EPA (ALFA capsules: 2 x 500 mg/d = 2 g/d) and aspirin placebo (1/d)
Arm 2: EPA placebo (capric and caprylic acid triglycerides: 2/d) and aspirin EC (1/d = 300 mg/d)
Arm 3: EPA (ALFA capsules: 2 x 500 mg/d = 2 g/d) and aspirin EC (1/d = 300 mg/d)
Arm 4: EPA placebo (capric and caprylic acid triglycerides: 2/d) and aspirin placebo (1/d)
Outcomes Primary: number of participants with ≥ 1 adenomas at 12 months
Secondary: adverse events, number of “advanced” adenomas per participant, number of “high risk” participants
re-classified as “intermediate risk”, number participants with≥ 1 advanced adenomas, adenoma region in the
colorectum, total number of adenomas per participant, number of participants with colorectal cancer, levels
of bioactive lipid mediators e.g. omega-3
Starting date Trial Registration entry: 6 May 2011
Trial start date: 30 May 2011
Estimated trial completion: 31 July 2017
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seAFOOD (Continued)





Trial name or title Effect of PUFA on vascular healing process in hypercholesterolemic patients with ACS
Methods RCT
Participants Hypercholesterolemic patients (20-80 years) with acute coronary syndrome who have received successful
optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI)
Interventions Each for 12 months:
Arm 1: intensive lipid-lowering therapy with both statin and EPA + DHA
Arm 2: intensive lipid-lowering therapy with both statin and EPA
Arm 3: standard lipid-lowering therapy with statins
Outcomes Primary: changes in OCT parameter
Secondary: lipids, serum plasma profile, inflammatory parameters, adverse cardiovascular events
Starting date Registered on Trials Registry: 1 February 2014
Trial start date: 1 February 2014
Trial completion date est: 30 June 2019
Contact information Shiro Uemura (PI), Nara Medical University, Japan, suemura@naramed-u.ac.jp
Notes UMIN000012825
BMI: Body Mass Index; CETP: cholesteryl ester transfer protein; CVD: cardiovascular disease; DHA: docosahexaenoic acid;EPA:
eicosapentaenoic acid;HDL: high density lipoprotein: LDL: low density lipoprotein:MI: myocardial infarction; MMSE: Mini
Mental State Examination; PSA: prostate-specific antigen; RCT: randomised controlled trial;
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D A T A A N D A N A L Y S E S
Comparison 1. Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes




participants Statistical method Effect size
1 ALL-CAUSE MORTALITY 24 19290 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.07]
2 All-cause mortality - SA 24 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Low risk of bias for
allocation concealment
11 9639 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.87, 1.22]
2.2 Low risk of bias for
attention
17 13622 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.87, 1.07]
2.3 Low risk of bias for
compliance
10 4776 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.89, 1.14]
2.4 Low summary risk of bias 5 8092 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.87, 1.26]
2.5 Trials registry or pre-2010 22 18852 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.90, 1.08]
2.6 No industry funding 9 4508 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.84, 1.42]
2.7 Randomised 100+
participants
20 19029 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.08]
2.8 Randomised 250+
participants
11 17457 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.91, 1.10]
3 All-cause mortality - SA
fixed-effect
24 19290 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.89, 1.07]
4 All-cause mortality - subgroup
by PUFA dose
24 19290 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.07]
4.1 total PUFA < 1.0% E 5 1054 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.33, 1.34]
4.2 total PUFA 1.0 to < 2.0%
E
9 13766 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.84, 1.13]
4.3 total PUFA 2.0 to < 5.0%
E
4 2295 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.76, 1.20]
4.4 total PUFA ≥ 5.0% E 6 2175 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.86, 1.26]
5 All-cause mortality - subgroup
by duration
24 19290 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.07]
5.1 Medium duration 1 to < 2
years
8 1940 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.48, 1.55]
5.2 Medium-long duration 2
to < 4 years
11 8219 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.82, 1.10]
5.3 Long duration 4+ years 5 9131 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.89, 1.14]
6 All-cause mortality - subgroup
by primary or secondary
prevention
24 19290 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.07]
6.1 Primary prevention of
CVD
13 9549 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.78, 1.20]
6.2 Secondary prevention of
CVD
11 9741 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.86, 1.12]
7 All-cause mortality - subgroup
by baseline PUFA dose
24 19290 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.07]
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7.1 Baseline total PUFA < 6%
E
4 3643 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.84, 1.14]
7.2 Baseline total PUFA 6 to
< 11% E
5 7826 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.89, 1.24]
7.3 Baseline total PUFA
11+% E
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Baseline total PUFA
unclear
15 7821 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.78, 1.08]
8 All-cause mortality - subgroup
by replacement
24 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 PUFA replaced SFA 6 4154 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.15]
8.2 PUFA replaced
monounsaturated fats
11 12526 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.90, 1.12]
8.3 PUFA replaced
carbohydrate
5 2965 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.58, 1.70]
8.4 PUFA replaced protein 2 529 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.57, 1.44]
8.5 PUFA replaced unclear 6 1227 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.39, 1.14]
9 All-cause mortality - subgroup
by sex
24 19290 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.07]
9.1 > 70% men 13 10252 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.88, 1.10]
9.2 > 70% women 1 2437 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.43, 1.65]
9.3 men & women 8 6498 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.79, 1.29]
9.4 sex not reported 2 103 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.51, 1.59]
10 All-cause mortality - subgroup
by age
24 19290 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.07]
10.1 Mean age < 50 years 6 1852 Risk Ratio (M-H, Random, 95% CI) 1.47 [0.95, 2.27]
10.2 Mean age 50 to < 65
years
12 6040 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.75, 1.10]
10.3 Mean age 65+ years 6 11398 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.88, 1.09]
11 All-cause mortality - subgroup
by statin use
24 19290 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.07]
11.1 < 50% on statins 18 13399 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.89, 1.10]
11.2 50+% on statins 4 5353 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.26, 1.51]
11.3 Percentage on statins
unclear
2 538 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.56, 2.37]
12 All-cause mortality - subgroup
by intervention type
24 19290 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.89, 1.07]
12.1 Dietary advice 4 4739 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.77, 1.23]
12.2 Supplemental foods &
diet provided
5 11104 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.88, 1.10]
12.3 Supplements (capsules &
unusual foods)
12 2391 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.52, 1.11]
12.4 Any combination 3 1056 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.72, 1.74]
13 CORONARY HEART
DISEASE (CHD) EVENTS:
myocardial infarction (fatal or
non-fatal) or angina
15 10076 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
14 CHD events - SA 15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 Low risk of bias for
allocation concealment
5 5946 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.73, 1.78]
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14.2 Low risk of bias for
attention
11 7090 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.72, 1.02]
14.3 Low risk of bias for
compliance
7 4006 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.65, 1.17]
14.4 Low summary risk of
bias
4 5826 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.76, 1.81]
14.5 Trials registry or pre-
2010
15 10076 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
14.6 No industry funding 4 1073 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.31, 1.63]
14.7 Randomised 100+
participants
12 9869 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.70, 1.08]
14.8 Randomised 250+
participants
6 8958 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.82, 1.09]
15 CHD events - SA fixed-effect 15 10076 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.82, 0.99]
16 CHD events - subgroup by
PUFA dose
15 10076 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
16.1 total PUFA < 1.0% E 3 829 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.20, 4.89]
16.2 total PUFA 1.0 to < 2.
0% E
4 5170 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.66, 1.13]
16.3 total PUFA 2.0 to < 5.
0% E
3 2224 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.82, 1.04]
16.4 total PUFA > 5.0% E 5 1853 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.54, 1.36]
17 CHD events - subgroup by
duration
15 10076 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
17.1 Medium duration 1 to <
2 years
6 1073 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.27, 1.30]
17.2 Medium-long duration 2
to < 4 years
5 7204 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.84, 1.03]
17.3 Long duration 4+ years 4 1799 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.46, 1.35]
18 CHD events - subgroup
by primary or secondary
prevention
15 10076 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
18.1 Primary prevention of
CVD
6 1710 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.25, 1.11]
18.2 Secondary prevention of
CVD
9 8366 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.85, 1.09]
19 CHD events - subgroup by
baseline PUFA dose
15 10076 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
19.1 Baseline total PUFA <
6% E
1 846 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.56, 1.04]
19.2 Baseline total PUFA 6 to
< 11% E
2 2491 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.68, 2.01]
19.3 Baseline total PUFA
11+% E
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19.4 Baseline total PUFA
unclear
12 6739 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.55, 1.06]
20 CHD events - subgroup by
replacement
15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 PUFA replaced saturated
fats
4 3730 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.78, 1.19]
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20.2 PUFA replaced
monounsaturated fats
9 7079 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.75, 1.20]
20.3 PUFA replaced
carbohydrate
2 156 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.12, 2.65]
20.4 PUFA replaced protein 1 393 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.69, 1.37]
20.5 PUFA replaced unclear 3 469 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.09, 3.52]
21 CHD events - subgroup by sex 15 10076 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
21.1 > 70% men 10 9269 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.82, 1.05]
21.2 > 70% women 1 140 Risk Ratio (M-H, Random, 95% CI) 1.84 [0.08, 44.38]
21.3 men & women 2 222 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.13, 0.51]
21.4 sex not reported 2 445 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.66, 2.50]
22 CHD events - subgroup by age 15 10076 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
22.1 Mean age < 50 years 1 458 Risk Ratio (M-H, Random, 95% CI) 1.63 [1.00, 2.67]
22.2 Mean age 50 to < 65
years
9 3204 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.83, 1.03]
22.3 Mean age 65+ years 3 5921 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.71, 1.04]
22.4 Mean age unclear 2 493 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.06, 4.64]
23 CHD events - subgroup by
statin use
15 10076 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
23.1 < 50% on statins 13 5001 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.66, 1.09]
23.2 50+% on statins 2 5075 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.73, 1.17]
24 CHD events - subgroup by
intervention type
15 10076 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
24.1 Dietary advice 2 2135 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.15, 1.77]
24.2 Supplemental foods &
diet provided
2 5683 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.71, 1.04]
24.3 Supplements (capsules &
unusual foods)
9 1407 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.56, 1.37]
24.4 Any combination 2 851 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.74, 2.02]
25 STROKE - fatal & non fatal 11 14742 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.58, 1.44]
26 Stroke - SA 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
26.1 Low risk of bias for
allocation concealment
4 6022 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.55, 2.38]
26.2 Low risk of bias for
attention
8 11858 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.51, 0.98]
26.3 Low risk of bias for
compliance
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.45, 4.11]
26.4 Low summary risk of
bias
3 5686 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.49, 2.23]
26.5 Trials registry or pre-
2010
11 14742 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.58, 1.44]
26.6 No industry funding 2 851 Risk Ratio (M-H, Random, 95% CI) 1.67 [0.32, 8.62]
26.7 Randomised 100+
participants
10 14662 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.56, 1.45]
26.8 Randomised 250+
participants
8 14291 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.60, 1.60]
27 Stroke - SA fixed-effect 11 14742 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.61, 1.11]
28 Stroke - subgroup by PUFA
dose
11 14742 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.58, 1.44]
28.1 total PUFA < 1.0% E 4 1098 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.14, 6.55]
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28.2 total PUFA 1.0 to < 2.
0% E
2 9834 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.49, 1.07]
28.3 total PUFA 2.0 to < 5.
0% E
2 2113 Risk Ratio (M-H, Random, 95% CI) 3.25 [0.99, 10.72]
28.4 total PUFA > 5.0% E 3 1697 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.36, 1.33]
29 Stroke - subgroup by duration 11 14742 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.58, 1.44]
29.1 Medium duration 1 to <
2 years
4 1098 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.14, 6.55]
29.2 Medium-long duration 2
to < 4 years
3 6950 Risk Ratio (M-H, Random, 95% CI) 1.60 [0.61, 4.16]
29.3 Long duration 4+ years 4 6694 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.47, 0.97]
30 Stroke - subgroup by primary
or secondary prevention
11 14742 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.58, 1.44]
30.1 Primary prevention of
cardiovascular disease (CVD)
4 6570 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.45, 1.11]
30.2 Secondary prevention of
CVD
7 8172 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.59, 2.62]
31 Stroke - subgroup by baseline
PUFA dose
11 14742 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.58, 1.44]
31.1 Baseline total PUFA <
6% E
1 846 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.30, 1.15]
31.2 Baseline total PUFA 6 to
< 11% E
3 7488 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.41, 3.59]
31.3 Baseline total PUFA
11+% E
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
31.4 Baseline total PUFA
unclear
7 6408 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.51, 2.41]
32 Stroke - subgroup by
replacement
11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
32.1 PUFA replaced saturated
fats
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.45, 4.11]
32.2 PUFA replaced
monounsaturated fats
7 11742 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.52, 0.99]
32.3 PUFA replaced
carbohydrates
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32.4 PUFA replaced protein 1 393 Risk Ratio (M-H, Random, 95% CI) 4.88 [0.24, 100.89]
32.5 PUFA replaced unclear 2 574 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.02, 29.08]
33 Stroke - subgroup by sex 11 14742 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.58, 1.44]
33.1 > 70% men 9 9354 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.56, 1.93]
33.2 > 70% women 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.3 men & women 1 4997 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.43, 1.05]
33.4 sex not reported 1 391 Risk Ratio (M-H, Random, 95% CI) 5.03 [0.24, 104.01]
34 Stroke - subgroup by age 11 14742 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.58, 1.44]
34.1 Mean age < 50 years 1 458 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.15, 7.55]
34.2 Mean age 50 to < 65
years
5 2975 Risk Ratio (M-H, Random, 95% CI) 2.84 [1.05, 7.64]
34.3 Mean age 65+ years 4 10918 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.48, 0.94]
34.4 Mean age unclear 1 391 Risk Ratio (M-H, Random, 95% CI) 5.03 [0.24, 104.01]
35 Stroke - subgroup by statin use 11 14742 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.58, 1.44]
35.1 < 50% on statins 9 9667 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.59, 1.78]
35.2 50+% on statins 2 5075 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.07, 3.40]
203Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
36 Stroke - subgroup by
intervention type
11 14742 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.58, 1.44]
36.1 Dietary advice 1 2033 Risk Ratio (M-H, Random, 95% CI) 3.32 [0.92, 12.04]
36.2 Supplemental foods &
diet provided
3 10680 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.49, 0.96]
36.3 Supplements (capsules &
unusual foods)
5 1178 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.25, 5.62]
36.4 Any combination 2 851 Risk Ratio (M-H, Random, 95% CI) 1.67 [0.32, 8.62]
37 Stroke - subgroup by fatal &
non fatal
11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
37.1 Fatal stroke 4 6534 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.38, 1.60]
37.2 Non-fatal stroke 2 1084 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.09, 2.51]
37.3 Only combined fatal &
non fatal data provided
6 7970 Risk Ratio (M-H, Random, 95% CI) 1.51 [0.56, 4.07]
38 Stroke - subgroup by ischaemic
& haemorrhagic
11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
38.1 Ischaemic stroke 3 2762 Risk Ratio (M-H, Random, 95% CI) 4.66 [1.00, 21.63]









2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
40 MACCEs - SA 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
40.1 Low risk of bias for
allocation concealment
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40.2 Low risk of bias for
attention
1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
40.3 Low risk of bias for
compliance
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
40.4 Low summary risk of
bias
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40.5 Trials registry or pre-
2010
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
40.6 No industry funding 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40.7 Randomised 100+
participants
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
40.8 Randomised 250+
participants
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
41 MACCEs - SA fixed-effect 2 2879 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.82, 1.04]
42 MACCEs - subgroup by PUFA
dose
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
42.1 total PUFA < 1.0% E 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
42.2 total PUFA 1.0 to < 2.
0% E
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
42.3 total PUFA 2.0 to < 5.
0% E
1 2033 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
42.4 total PUFA > 5.0% E 1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
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43 MACCEs - subgroup by
duration
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
43.1 Medium duration 1 to <
2 years
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
43.2 Medium-long duration 2
to < 4 years
1 2033 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
43.3 Long duration 4+ years 1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
44 MACCEs - subgroup
by primary or secondary
prevention
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
44.1 Primary prevention of
CVD
1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
44.2 Secondary prevention of
CVD
1 2033 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
45 MACCEs - subgroup by
baseline PUFA dose
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
45.1 Baseline total PUFA <
6% E
1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
45.2 Baseline total PUFA 6 to
< 11% E
1 2033 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
45.3 Baseline total PUFA
11+% E
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
45.4 Baseline total PUFA
unclear
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
46 MACCEs - subgroup by
replacement
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
46.1 PUFA replaced saturated
fats
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
46.2 PUFA replaced
monounsaturated fats
1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
46.3 PUFA replaced
carbohydrates
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
46.4 PUFA replaced protein 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
46.5 PUFA replaced unclear 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47 MACCEs - subgroup by sex 2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
47.1 > 70% men 2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
47.2 > 70% women 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47.3 men & women 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
47.4 sex not reported 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
48 MACCEs - subgroup by age 2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
48.1 Mean age < 50 years 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
48.2 Mean age 50 to < 65
years
1 2033 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
48.3 Mean age 65+ years 1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
49 MACCEs - subgroup by statin
use
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
49.1 < 50% on statins 2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
49.2 50+% on statins 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
50 MACCEs - subgroup by
intervention type
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.59, 1.20]
50.1 Dietary advice 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.12]
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50.2 Supplemental foods &
diet provided
1 846 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
50.3 Supplements (capsules &
unusual foods)
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
50.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Higher PUFA vs lower PUFA - dichotomous secondary outcomes




participants Statistical method Effect size
1 CARDIOVASCULAR
MORTALITY
16 15107 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.26]
2 Cardiovascular mortality - SA 16 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Low risk of bias for
allocation concealment
6 6031 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.85, 1.38]
2.2 Low risk of bias for
attention
9 11774 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.69, 1.07]
2.3 Low risk of bias for
compliance
8 4142 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.75, 1.49]
2.4 Low summary risk of bias 3 5431 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.77, 1.83]
2.5 Trials registry or pre-2010 16 15107 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.26]
2.6 No industry funding 7 1744 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.79, 1.79]
2.7 Randomised 100+
participants
13 14895 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.80, 1.28]
2.8 Randomised 250+
participants
7 13966 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.85, 1.32]
3 Cardiovascular mortality - SA
fixed-effect
16 15107 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.88, 1.16]
4 Cardiovascular mortality -
subgroup by PUFA dose
16 15107 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.26]
4.1 total PUFA < 1.0% E 5 1054 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.38, 1.51]
4.2 total PUFA 1.0 to < 2.0%
E
3 9954 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.76, 1.30]
4.3 total PUFA 2.0 to < 5.0%
E
3 2246 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.96, 1.62]
4.4 total PUFA > 5.0% E 5 1853 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.62, 1.63]
5 Cardiovascular mortality -
subgroup by duration
16 15107 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.26]
5.1 Medium duration 1 to <2
years
5 974 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.39, 1.67]
5.2 Medium-long duration 2
to < 4 years
6 7337 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.88, 1.36]
5.3 Long duration 4+ years 5 6796 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.67, 1.55]
6 Cardiovascular mortality -
subgroup by primary or
secondary prevention
16 15107 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.26]
6.1 Primary prevention of
cardiovascular disease (CVD)
7 6412 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.54, 1.41]
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6.2 Secondary prevention of
CVD
9 8695 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.92, 1.36]
7 Cardiovascular mortality -
subgroup by baseline PUFA
dose
16 15107 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.26]
7.1 Baseline total PUFA < 6%
E
2 982 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.52, 0.97]
7.2 Baseline total PUFA 6 to
< 11% E
4 7621 Risk Ratio (M-H, Random, 95% CI) 1.32 [1.07, 1.62]
7.3 Baseline total PUFA
11+% E
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Baseline total PUFA
unclear
10 6504 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.72, 1.16]
8 Cardiovascular mortality -
subgroup by replacement
16 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 PUFA replaced saturated
fats
4 3730 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.76, 1.54]
8.2 PUFA replaced
monounsaturated fats
8 11874 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.76, 1.30]
8.3 PUFA replaced
carbohydrates
4 425 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.30, 4.71]
8.4 PUFA replaced protein 2 529 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.66, 1.77]
8.5 PUFA replaced unclear 3 436 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.07, 1.37]
9 Cardiovascular mortality -
subgroup by sex
16 15107 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.26]
9.1 > 70% men 10 9623 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.78, 1.27]
9.2 > 70% women 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.3 men & women 5 5430 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.30, 2.47]
9.4 sex not reported 1 54 Risk Ratio (M-H, Random, 95% CI) 1.55 [0.41, 5.84]
10 Cardiovascular mortality -
subgroup by age
16 15107 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.26]
10.1 Mean age < 50 years 1 458 Risk Ratio (M-H, Random, 95% CI) 1.59 [0.99, 2.55]
10.2 Mean age 50 to < 65
years
8 3149 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.95, 1.48]
10.3 Mean age 65+ years 6 11398 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.69, 1.09]
10.4 Mean age unclear 1 102 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.01, 1.60]
11 Cardiovascular mortality -
subgroup by statin use
16 15107 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.26]
11.1 < 50% on statins 11 9416 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.78, 1.40]
11.2 50+% on statins 3 5153 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.67, 1.22]
11.3 Percentage on statins
unclear
2 538 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.47, 2.54]
12 Cardiovascular mortality -
subgroup by intervention type
16 15107 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.82, 1.26]
12.1 Dietary advice 4 2404 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.42, 3.12]
12.2 Supplemental foods &
diet provided
3 10680 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.66, 1.19]
12.3 Supplements (capsules &
unusual foods)
7 1172 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.42, 1.40]
12.4 Any combination 2 851 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.87, 1.95]
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13 CARDIOVASCULAR
EVENTS
21 17799 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.79, 1.01]
14 CVD events - SA 21 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 Low risk of bias for
allocation concealment
11 8714 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.84, 1.08]
14.2 Low risk of bias for
attention
16 14111 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.72, 0.97]
14.3 Low risk of bias for
compliance
8 5697 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.81, 1.14]
14.4 Low summary risk of
bias
6 7014 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.83, 1.67]
14.5 Trials registry or pre-
2010
21 17799 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.79, 1.01]
14.6 No industry funding 5 2440 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.67, 1.44]
14.7 Randomised 100+
participants
18 17587 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.77, 1.00]
14.8 Randomised 250+
participants
11 16524 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.85, 1.02]
15 CVD events - SA fixed-effect 21 17799 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.86, 0.98]
16 CVD events - subgroup by
PUFA dose
21 17799 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.79, 1.01]
16.1 total PUFA < 1.0% E 7 1563 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.42, 0.96]
16.2 total PUFA 1.0 to < 2.
0% E
5 10468 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.80, 1.03]
16.3 total PUFA 2.0 to < 5.
0% E
3 2224 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.90, 1.09]
16.4 total PUFA > 5.0% E 6 3544 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.76, 1.29]
17 CVD events - subgroup by
duration
21 17799 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.79, 1.01]
17.1 Medium duration 1 to <
2 years
11 3175 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.47, 0.99]
17.2 Medium-long duration 2
to < 4 years
6 7930 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.90, 1.05]
17.3 Long duration 4+ years 4 6694 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.73, 1.16]
18 CVD events - subgroup
by primary or secondary
prevention
21 17799 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.79, 1.01]
18.1 Primary prevention of
CVD
10 8893 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.72, 1.01]
18.2 Secondary prevention of
CVD
11 8906 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.75, 1.05]
19 CVD events - subgroup by
baseline PUFA dose
21 17799 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.79, 1.01]
19.1 Baseline total PUFA <
6% E
2 1913 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.64, 1.01]
19.2 Baseline total PUFA 6 to
< 11% E
4 8214 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.85, 1.22]
19.3 Baseline total PUFA
11+% E
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
19.4 Baseline total PUFA
unclear
15 7672 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.69, 0.98]
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20 CVD events - subgroup by
replacement
21 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 PUFA replaced saturated
fats
6 5523 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.79, 1.14]
20.2 PUFA replaced
monounsaturated fats
12 13605 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.76, 1.08]
20.3 PUFA replaced
carbohydrates
2 780 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.70, 2.01]
20.4 PUFA replaced protein 2 1119 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.62, 1.07]
20.5 PUFA replaced unclear 6 1042 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.29, 0.95]
21 CVD events - subgroup by sex 21 17799 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.79, 1.01]
21.1 > 70% men 12 10798 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.74, 1.00]
21.2 > 70% women 1 140 Risk Ratio (M-H, Random, 95% CI) 1.84 [0.08, 44.38]
21.3 men & women 6 6416 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.68, 1.18]
21.4 sex not reported 2 445 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.80, 2.20]
22 CVD events - subgroup by age 21 17799 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.79, 1.01]
22.1 Mean age < 50 years 4 2020 Risk Ratio (M-H, Random, 95% CI) 1.66 [1.05, 2.61]
22.2 Mean age 50 to < 65
years
9 3264 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.66, 1.08]
22.3 Mean age 65+ years 7 12124 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.78, 0.96]
22.4 Mean age unclear 1 391 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.54, 4.83]
23 CVD events - subgroup by
statin use
21 17799 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.79, 1.01]
23.1 < 50% on statins 16 11518 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.78, 1.08]
23.2 50+% on statins 3 5153 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.43, 1.25]
23.3 Percentage on statins
unclear
2 1128 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.53, 1.21]
24 CVD events - subgroup by
intervention type
21 17799 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.79, 1.01]
24.1 Dietary advice 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.91, 1.09]
24.2 Supplemental foods &
diet provided
5 12473 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.79, 0.99]
24.3 Supplements (capsules &
unusual foods)
13 2442 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.54, 1.04]




9 8810 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
26 CHD mortality - SA 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
26.1 Low risk of bias for
allocation concealment
3 5359 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.68, 1.25]
26.2 Low risk of bias for
attention
8 6777 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.70, 1.18]
26.3 Low risk of bias for
compliance
4 3053 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.76, 1.10]
26.4 Low summary risk of
bias
1 4837 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.66, 1.28]
26.5 Trials registry or pre-
2010
9 8810 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
26.6 No industry funding 2 522 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.25, 2.58]
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26.7 Randomised 100+
participants
7 8676 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.77, 1.06]
26.8 Randomised 250+
participants
4 8118 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.79, 1.08]
27 CHD mortality - SA
fixed-effect
9 8810 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.77, 1.05]
28 CHD mortality - subgroup by
PUFA dose
9 8810 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
28.1 total PUFA < 1.0% E 3 840 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.35, 1.59]
28.2 total PUFA 1.0 to < 2.
0% E
2 4957 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.41, 1.76]
28.3 total PUFA 2.0 to < 5.
0% E
2 2113 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.74, 1.10]
28.4 total PUFA > 5.0% E 2 900 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.60, 1.78]
29 CHD mortality - subgroup by
duration
9 8810 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
29.1 Medium duration 1 to <
2 years
3 760 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.34, 1.83]
29.2 Medium-long duration 2
to < 4 years
5 7204 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.77, 1.07]
29.3 Long duration 4+ years 1 846 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.57, 1.75]
30 CHD mortality - subgroup
by primary or secondary
prevention
9 8810 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
30.1 Primary prevention of
CVD
2 966 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.30, 2.34]
30.2 Secondary prevention of
CVD
7 7844 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.77, 1.06]
31 CHD mortality - subgroup by
baseline PUFA dose
9 8810 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
31.1 Baseline total PUFA <
6% E
1 846 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.57, 1.75]
31.2 Baseline total PUFA 6 to
< 11% E
1 2033 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.75, 1.10]
31.3 Baseline total PUFA
11+% E
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
31.4 Baseline total PUFA
unclear
7 5931 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.66, 1.19]
32 CHD mortality - subgroup by
replacement
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
32.1 PUFA replaced saturated
fats
2 2879 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.76, 1.10]
32.2 PUFA replaced
monounsaturated fats
6 6419 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.71, 1.21]
32.3 PUFA replaced
carbohydrates
1 54 Risk Ratio (M-H, Random, 95% CI) 1.86 [0.18, 19.29]
32.4 PUFA replaced protein 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
32.5 PUFA replaced unclear 2 358 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.02, 1.65]
33 CHD mortality - subgroup by
sex
9 8810 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
33.1 > 70% men 7 8636 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
210Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
33.2 > 70% women 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
33.3 men & women 1 120 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.01, 4.05]
33.4 sex not reported 1 54 Risk Ratio (M-H, Random, 95% CI) 1.86 [0.18, 19.29]
34 CHD mortality - subgroup by
age
9 8810 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
34.1 Mean age < 50 years 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
34.2 Mean age 50 to < 65
years
5 2487 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.74, 1.08]
34.3 Mean age 65+ years 4 6323 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.71, 1.23]
35 CHD mortality - subgroup by
statin use
9 8810 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
35.1 < 50% on statins 6 3333 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.75, 1.08]
35.2 50+% on statins 2 5075 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.65, 1.26]
35.3 Percentage on statins
unclear
1 402 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.41, 2.49]
36 CHD mortality - subgroup by
intervention type
9 8810 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.78, 1.06]
36.1 Dietary advice 1 2033 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.75, 1.10]
36.2 Supplemental foods &
diet provided
2 5683 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.71, 1.25]
36.3 Supplements (capsules &
unusual foods)
6 1094 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.36, 1.43]
36.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
37 MYOCARDIAL
INFARCTION (MI) - fatal
and non fatal
15 15609 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.78, 0.99]
38 SUDDEN CARDIAC
DEATH (SCD)






11 11692 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
39.1 Recurrent arrhythmia 4 979 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.65, 1.01]
39.2 New arrhythmia 7 10713 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.70, 1.46]
40 AF - SA 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
40.1 Low risk of bias for
allocation concealment
7 6679 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.63, 0.88]
40.2 Low risk of bias for
attention
10 11514 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.72, 1.13]
40.3 Low risk of bias for
compliance
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
40.4 Low summary risk of
bias
3 5368 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.59, 1.12]
40.5 Trials registry or pre-
2010
11 11692 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
40.6 No industry funding 2 601 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.58, 0.88]
40.7 Randomised 100+
participants
11 11692 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
40.8 Randomised 250+
participants
6 10842 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.69, 1.28]
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41 AF - SA fixed-effect 11 11692 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.80, 1.00]
41.1 Recurrent arrhythmia 4 979 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.72, 0.91]
41.2 New arrhythmia 7 10713 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.83, 1.28]
42 AF - subgroup by PUFA dose 11 11692 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
42.1 total PUFA < 1.0% E 7 1839 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.65, 0.99]
42.2 total PUFA 1.0 to < 2.
0% E
4 9853 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.70, 1.60]
42.3 total PUFA 2.0 to < 5.
0% E
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
42.4 total PUFA 5.0+% E 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
43 AF - subgroup by duration 11 11692 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
43.1 Medium duration 1 to <
2 years
8 2153 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.65, 0.83]
43.2 Medium-long duration 2
to < 4 years
2 5037 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.66, 1.36]
43.3 Long duration 4+ years 1 4502 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.98, 1.79]
44 AF - subgroup by primary or
secondary prevention
11 11692 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
44.1 Primary prevention of
CVD
5 5743 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.99, 1.79]
44.2 Secondary prevention of
CVD
6 5949 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.67, 0.96]
45 Atrial fibrillation - subgroup by
baseline PUFA dose
11 11692 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
45.1 Baseline total PUFA <
6% E
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
45.2 Baseline total PUFA 6 to
< 11% E
1 4502 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.98, 1.79]
45.3 Baseline total PUFA
11+% E
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
45.4 Baseline total PUFA
unclear
10 7190 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.69, 0.95]
46 AF - subgroup by replacement 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
46.1 PUFA replaced saturated
fats
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
46.2 PUFA replaced
monounsaturated fats
8 10804 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.71, 1.14]
46.3 PUFA replaced
carbohydrates
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
46.4 PUFA replaced protein 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
46.5 PUFA replaced unclear 3 888 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.64, 0.88]
47 Atrial fibrillation - subgroup by
sex
11 11692 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
47.1 > 70% men 6 6086 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.69, 1.01]
47.2 > 70% women 1 140 Risk Ratio (M-H, Random, 95% CI) 1.84 [0.08, 44.38]
47.3 men & women 3 5075 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.50, 1.93]
47.4 sex not reported 1 391 Risk Ratio (M-H, Random, 95% CI) 2.01 [0.18, 21.99]
48 AF - subgroup by age 11 11692 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
48.1 Mean age < 50 years 1 374 Risk Ratio (M-H, Random, 95% CI) 2.97 [0.12, 72.40]
48.2 Mean age 50 to < 65
years
5 987 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.62, 1.23]
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48.3 Mean age 65+ years 4 9940 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.63, 1.15]
48.4 Mean age unclear 1 391 Risk Ratio (M-H, Random, 95% CI) 2.01 [0.18, 21.99]
49 AF - subgroup by statin use 11 11692 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
49.1 < 50% on statins 9 6453 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.68, 1.21]
49.2 50+% on statins 1 4837 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.57, 1.10]
49.3 Percentage on statins
unclear
1 402 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.58, 1.01]
50 AF - subgroup by intervention
type
11 11692 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.72, 1.06]
50.1 Dietary advice 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
50.2 Supplemental foods &
diet provided
2 9339 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.62, 1.70]
50.3 Supplements (capsules &
unusual foods)
9 2353 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.67, 0.98]
50.4 Any combination 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
51 ANGINA 7 2070 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.35, 1.16]
52 HEART FAILURE 7 25257 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.40, 1.36]
53 PERIPHERAL ARTERIAL
DISEASE (PAD)




6 1182 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.40, 1.24]
Comparison 3. Higher PUFA vs lower PUFA - continuous secondary outcomes




participants Statistical method Effect size
1 ADIPOSITY - BODY
WEIGHT, kg
13 7100 Mean Difference (IV, Random, 95% CI) 0.76 [0.34, 1.19]
2 Body weight, kg - SA 13 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Low risk of bias for
allocation concealment
5 2586 Mean Difference (IV, Random, 95% CI) 1.72 [0.29, 3.15]
2.2 Low risk of bias for
attention
7 4156 Mean Difference (IV, Random, 95% CI) 0.57 [0.08, 1.06]
2.3 Low risk of bias for
compliance
5 756 Mean Difference (IV, Random, 95% CI) 1.59 [-0.11, 3.28]
2.4 Low summary risk of bias 4 2550 Mean Difference (IV, Random, 95% CI) 1.81 [0.23, 3.38]
2.5 Trials registry or pre-2010 13 7100 Mean Difference (IV, Random, 95% CI) 0.76 [0.34, 1.19]
2.6 No industry funding 6 2783 Mean Difference (IV, Random, 95% CI) 1.62 [0.11, 3.14]
2.7 Randomised 100+
participants
8 6885 Mean Difference (IV, Random, 95% CI) 0.89 [0.41, 1.36]
2.8 Randomised 250+
participants
5 6539 Mean Difference (IV, Random, 95% CI) 0.81 [0.34, 1.28]
3 Body weight, kg - SA fixed-effect 13 7100 Mean Difference (IV, Fixed, 95% CI) 1.08 [0.96, 1.21]
4 Body weight, kg - subgroup by
PUFA dose
13 7100 Mean Difference (IV, Random, 95% CI) 0.76 [0.34, 1.19]
4.1 total PUFA < 1.0% E 2 287 Mean Difference (IV, Random, 95% CI) 1.78 [-1.46, 5.01]
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4.2 total PUFA 1.0 to < 2.0%
E
5 6079 Mean Difference (IV, Random, 95% CI) 0.74 [0.18, 1.30]
4.3 total PUFA 2.0 to < 5.0%
E
3 210 Mean Difference (IV, Random, 95% CI) 1.47 [-3.60, 6.53]
4.4 total PUFA 5.0+% E 3 524 Mean Difference (IV, Random, 95% CI) 0.75 [-0.10, 1.60]
5 Body weight, kg - subgroup by
duration
13 7100 Mean Difference (IV, Random, 95% CI) 0.76 [0.34, 1.19]
5.1 Medium duration 1 to < 2
years
6 502 Mean Difference (IV, Random, 95% CI) 0.47 [-0.20, 1.14]
5.2 Medium-long duration 2
to < 4 years
4 522 Mean Difference (IV, Random, 95% CI) 0.78 [-0.06, 1.62]
5.3 Long duration 4+ years 3 6076 Mean Difference (IV, Random, 95% CI) 0.90 [0.27, 1.54]
6 Body weight, kg - subgroup
by primary or secondary
prevention
13 7100 Mean Difference (IV, Random, 95% CI) 0.76 [0.34, 1.19]
6.1 Primary prevention of
CVD
11 6864 Mean Difference (IV, Random, 95% CI) 0.76 [0.33, 1.19]
6.2 Secondary prevention of
CVD
2 236 Mean Difference (IV, Random, 95% CI) 2.0 [-5.43, 9.43]
7 Body weight, kg - subgroup by
baseline PUFA dose
13 7100 Mean Difference (IV, Random, 95% CI) 0.76 [0.34, 1.19]
7.1 Baseline total PUFA < 6%
E
3 2339 Mean Difference (IV, Random, 95% CI) 2.37 [1.18, 3.56]
7.2 Baseline total PUFA 6 to
< 11% E
5 4345 Mean Difference (IV, Random, 95% CI) 0.68 [0.21, 1.15]
7.3 Baseline total PUFA
11+% E
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Baseline total PUFA
unclear
5 416 Mean Difference (IV, Random, 95% CI) 0.18 [-0.68, 1.03]
8 Body weight, kg - subgroup by
replacement
13 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 PUFA replaced saturated
fats
3 248 Mean Difference (IV, Random, 95% CI) 0.59 [-5.15, 6.34]
8.2 PUFA replaced
monounsaturated fats
4 4036 Mean Difference (IV, Random, 95% CI) 0.69 [0.15, 1.23]
8.3 PUFA replaced
carbohydrates
5 2882 Mean Difference (IV, Random, 95% CI) 1.23 [0.27, 2.20]
8.4 PUFA replaced protein 4 660 Mean Difference (IV, Random, 95% CI) 1.56 [-0.64, 3.75]
8.5 unclear 2 85 Mean Difference (IV, Random, 95% CI) 0.08 [-0.80, 0.95]
9 Body weight, kg - subgroup by
sex
13 7100 Mean Difference (IV, Random, 95% CI) 0.76 [0.34, 1.19]
9.1 > 70% men 4 408 Mean Difference (IV, Random, 95% CI) 3.14 [0.31, 5.98]
9.2 > 70% women 3 2253 Mean Difference (IV, Random, 95% CI) 0.78 [-0.60, 2.17]
9.3 men & women 5 4404 Mean Difference (IV, Random, 95% CI) 0.70 [0.22, 1.18]
9.4 sex not reported 1 35 Mean Difference (IV, Random, 95% CI) -0.30 [-10.57, 9.97]
10 Body weight, kg - subgroup by
age
13 7100 Mean Difference (IV, Random, 95% CI) 0.76 [0.34, 1.19]
10.1 Mean age < 50 years 2 79 Mean Difference (IV, Random, 95% CI) 0.21 [-1.12, 1.54]
10.2 Mean age 50 to < 65
years
9 2978 Mean Difference (IV, Random, 95% CI) 1.15 [0.12, 2.18]
10.3 Mean age 65+ years 2 4043 Mean Difference (IV, Random, 95% CI) 0.71 [0.16, 1.26]
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11 Body weight, kg - subgroup by
statin use
13 7100 Mean Difference (IV, Random, 95% CI) 0.76 [0.34, 1.19]
11.1 < 50% on statins 9 6522 Mean Difference (IV, Random, 95% CI) 0.69 [0.21, 1.17]
11.2 50+% on statins 2 130 Mean Difference (IV, Random, 95% CI) 2.70 [-2.43, 7.83]
11.3 Percentage on statins
unclear
2 448 Mean Difference (IV, Random, 95% CI) 1.88 [-1.08, 4.84]
12 Body weight, kg - subgroup by
intervention type
13 7100 Mean Difference (IV, Random, 95% CI) 0.76 [0.34, 1.19]
12.1 Dietary advice 4 2455 Mean Difference (IV, Random, 95% CI) 2.37 [1.19, 3.55]
12.2 Supplemental foods &
diet provided
3 4078 Mean Difference (IV, Random, 95% CI) 0.71 [0.18, 1.25]
12.3 Supplements (capsules &
unusual foods)
5 390 Mean Difference (IV, Random, 95% CI) 0.37 [-0.18, 0.91]
12.4 Any combination 1 177 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 ADIPOSITY - Body Mass
Index (BMI), kg/m2
8 4798 Mean Difference (IV, Random, 95% CI) 0.17 [-0.08, 0.42]
14 BMI, kg/m2 - SA 8 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 Low risk of bias for
allocation concealment
4 3894 Mean Difference (IV, Random, 95% CI) 0.37 [-0.15, 0.88]
14.2 Low risk of bias for
attention
6 2259 Mean Difference (IV, Random, 95% CI) 0.15 [-0.12, 0.42]
14.3 Low risk of bias for
compliance
3 526 Mean Difference (IV, Random, 95% CI) 0.96 [-0.86, 2.78]
14.4 Low summary risk of
bias
4 3894 Mean Difference (IV, Random, 95% CI) 0.37 [-0.15, 0.88]
14.5 Trials registry or pre-
2010
8 4798 Mean Difference (IV, Random, 95% CI) 0.17 [-0.08, 0.42]
14.6 No industry funding 2 2539 Mean Difference (IV, Random, 95% CI) 0.28 [-0.70, 1.26]
14.7 Randomised 100+
participants
7 4738 Mean Difference (IV, Random, 95% CI) 0.16 [-0.09, 0.41]
14.8 Randomised 250+
participants
4 4331 Mean Difference (IV, Random, 95% CI) 0.21 [-0.04, 0.46]
15 BMI, kg/m2 - SA fixed-effect 8 4798 Mean Difference (IV, Fixed, 95% CI) 0.27 [0.20, 0.35]
16 BMI, kg/m2 - subgroup by
PUFA dose
8 4798 Mean Difference (IV, Random, 95% CI) 0.17 [-0.08, 0.42]
16.1 total PUFA < 1.0% E 2 193 Mean Difference (IV, Random, 95% CI) 0.01 [-0.17, 0.18]
16.2 total PUFA 1.0 to < 2.
0% E
5 4234 Mean Difference (IV, Random, 95% CI) 0.26 [-0.03, 0.55]
16.3 total PUFA 2.0 to < 5.
0% E
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.4 total PUFA 5.0+% E 1 371 Mean Difference (IV, Random, 95% CI) -0.20 [-0.56, 0.16]
17 BMI, kg/m2 - subgroup by
duration
8 4798 Mean Difference (IV, Random, 95% CI) 0.17 [-0.08, 0.42]
17.1 Medium duration 1 to <
2 years
3 407 Mean Difference (IV, Random, 95% CI) 0.21 [-1.40, 1.81]
17.2 Medium-long duration 2
to < 4 years
2 1320 Mean Difference (IV, Random, 95% CI) 0.16 [-0.03, 0.34]
17.3 Long duration 4+ years 3 3071 Mean Difference (IV, Random, 95% CI) 0.22 [-0.12, 0.55]
18 BMI, kg/m2 - subgroup
by primary or secondary
prevention
8 4798 Mean Difference (IV, Random, 95% CI) 0.17 [-0.08, 0.42]
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18.1 Primary prevention of
CVD
5 3034 Mean Difference (IV, Random, 95% CI) 0.30 [-0.09, 0.69]
18.2 Secondary prevention of
CVD
3 1764 Mean Difference (IV, Random, 95% CI) 0.03 [-0.13, 0.19]
19 BMI, kg/m2 - subgroup by
baseline PUFA dose
8 4798 Mean Difference (IV, Random, 95% CI) 0.17 [-0.08, 0.42]
19.1 Baseline total PUFA <
6% E
2 2347 Mean Difference (IV, Random, 95% CI) -0.26 [-2.51, 1.99]
19.2 Baseline total PUFA 6 to
< 11% E
2 903 Mean Difference (IV, Random, 95% CI) 0.10 [-0.27, 0.47]
19.3 Baseline total PUFA
11+% E
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.4 Baseline total PUFA
unclear
4 1548 Mean Difference (IV, Random, 95% CI) 0.16 [-0.16, 0.48]
20 BMI, kg/m2 - subgroup by
replacement
8 Mean Difference (IV, Random, 95% CI) Subtotals only
20.1 PUFA replaced saturated
fats
1 371 Mean Difference (IV, Random, 95% CI) -0.20 [-0.56, 0.16]
20.2 PUFA replaced
monounsaturated fats
5 2391 Mean Difference (IV, Random, 95% CI) 0.14 [-0.11, 0.39]
20.3 PUFA replaced
carbohydrates
2 2347 Mean Difference (IV, Random, 95% CI) -0.26 [-2.51, 1.99]
20.4 PUFA replaced protein 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20.5 PUFA replaced unclear 1 60 Mean Difference (IV, Random, 95% CI) 1.0 [-1.18, 3.18]
21 BMI, kg/m2 - subgroup by sex 8 4798 Mean Difference (IV, Random, 95% CI) 0.17 [-0.08, 0.42]
21.1 > 70% men 3 1764 Mean Difference (IV, Random, 95% CI) 0.03 [-0.13, 0.19]
21.2 > 70% women 2 2347 Mean Difference (IV, Random, 95% CI) -0.26 [-2.51, 1.99]
21.3 men & women 3 687 Mean Difference (IV, Random, 95% CI) 0.31 [-0.08, 0.71]
22 BMI, kg/m2 - subgroup by age 8 4798 Mean Difference (IV, Random, 95% CI) 0.17 [-0.08, 0.42]
22.1 Mean age < 50 years 1 371 Mean Difference (IV, Random, 95% CI) -0.20 [-0.56, 0.16]
22.2 Mean age 50 to < 65
years
5 2635 Mean Difference (IV, Random, 95% CI) 0.38 [-0.42, 1.18]
22.3 Mean age 65+ years 2 1792 Mean Difference (IV, Random, 95% CI) 0.21 [-0.04, 0.47]
23 BMI, kg/m2 - subgroup by
statin use
8 4798 Mean Difference (IV, Random, 95% CI) 0.17 [-0.08, 0.42]
23.1 < 50% on statins 6 3443 Mean Difference (IV, Random, 95% CI) 0.12 [-0.17, 0.42]
23.2 50+% on statins 2 1355 Mean Difference (IV, Random, 95% CI) 1.19 [-1.19, 3.56]
23.3 Percentage on statins
unclear
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
24 BMI, kg/m2 - subgroup by
intervention type
8 4798 Mean Difference (IV, Random, 95% CI) 0.17 [-0.08, 0.42]
24.1 Dietary advice 1 2168 Mean Difference (IV, Random, 95% CI) 0.80 [0.30, 1.30]
24.2 Supplemental foods &
diet provided
2 1792 Mean Difference (IV, Random, 95% CI) 0.21 [-0.04, 0.47]
24.3 Supplements (capsules &
unusual foods)
4 467 Mean Difference (IV, Random, 95% CI) 0.33 [-0.99, 1.64]
24.4 Any combination 1 371 Mean Difference (IV, Random, 95% CI) -0.20 [-0.56, 0.16]
25 Adiposity - waist circumference,
cm
3 1298 Mean Difference (IV, Random, 95% CI) 0.25 [-0.32, 0.83]
26 Adiposity - % body fat 2 309 Mean Difference (IV, Random, 95% CI) 1.90 [-1.41, 5.21]
27 Adiposity - body fat, kg 1 214 Mean Difference (IV, Random, 95% CI) 0.0 [-1.12, 1.12]
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27 8072 Mean Difference (IV, Random, 95% CI) -0.12 [-0.23, -0.02]
29 TC, mmoL/L - SA 27 Mean Difference (IV, Random, 95% CI) Subtotals only
29.1 Low risk of bias for
allocation concealment
10 3548 Mean Difference (IV, Random, 95% CI) -0.16 [-0.36, 0.03]
29.2 Low risk of bias for
attention
19 4830 Mean Difference (IV, Random, 95% CI) -0.10 [-0.23, 0.04]
29.3 Low risk of bias for
compliance
15 5642 Mean Difference (IV, Random, 95% CI) -0.27 [-0.39, -0.14]
29.4 Low summary risk of
bias
7 3204 Mean Difference (IV, Random, 95% CI) -0.23 [-0.46, 0.01]
29.5 Trials registry or pre-
2010
25 7808 Mean Difference (IV, Random, 95% CI) -0.13 [-0.24, -0.03]
29.6 No industry funding 11 2570 Mean Difference (IV, Random, 95% CI) -0.19 [-0.39, 0.01]
29.7 Randomised 100+
participants
19 7711 Mean Difference (IV, Random, 95% CI) -0.16 [-0.27, -0.05]
29.8 Randomised 250+
participants
9 6348 Mean Difference (IV, Random, 95% CI) -0.17 [-0.30, -0.05]
30 TC, mmoL/L - SA fixed-effect 27 8072 Mean Difference (IV, Fixed, 95% CI) -0.22 [-0.26, -0.18]
31 TC, mmoL/L - subgroup by
PUFA dose
27 8072 Mean Difference (IV, Random, 95% CI) -0.12 [-0.23, -0.02]
31.1 total PUFA < 1.0% E 4 480 Mean Difference (IV, Random, 95% CI) -0.01 [-0.15, 0.13]
31.2 total PUFA 1.0 to < 2.
0% E
8 2170 Mean Difference (IV, Random, 95% CI) -0.06 [-0.16, 0.04]
31.3 total PUFA 2.0 to < 5.
0% E
4 1857 Mean Difference (IV, Random, 95% CI) -0.03 [-0.31, 0.25]
31.4 total PUFA 5.0+% E 11 3565 Mean Difference (IV, Random, 95% CI) -0.28 [-0.45, -0.10]
32 TC, mmoL/L - subgroup by
duration
27 8072 Mean Difference (IV, Random, 95% CI) -0.12 [-0.23, -0.02]
32.1 Medium duration 1 to <
2 years
13 2168 Mean Difference (IV, Random, 95% CI) -0.11 [-0.30, 0.08]
32.2 Medium-long duration 2
to < 4 years
9 4012 Mean Difference (IV, Random, 95% CI) -0.07 [-0.19, 0.05]
32.3 Long duration 4+ years 5 1892 Mean Difference (IV, Random, 95% CI) -0.23 [-0.40, -0.06]
33 TC, mmoL/L - subgroup
by primary or secondary
prevention
27 8072 Mean Difference (IV, Random, 95% CI) -0.12 [-0.23, -0.02]
33.1 Primary prevention of
CVD
17 4006 Mean Difference (IV, Random, 95% CI) -0.12 [-0.26, 0.02]
33.2 Secondary prevention of
CVD
10 4066 Mean Difference (IV, Random, 95% CI) -0.12 [-0.24, -0.00]
34 TC, mmoL/L - subgroup by
baseline PUFA dose
27 8072 Mean Difference (IV, Random, 95% CI) -0.12 [-0.23, -0.02]
34.1 Baseline total PUFA <
6% E
6 2347 Mean Difference (IV, Random, 95% CI) -0.33 [-0.56, -0.09]
34.2 Baseline total PUFA 6 to
< 11% E
7 3394 Mean Difference (IV, Random, 95% CI) -0.09 [-0.21, 0.04]
34.3 Baseline total PUFA
11+% E
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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34.4 Baseline total PUFA
unclear
14 2331 Mean Difference (IV, Random, 95% CI) -0.06 [-0.16, 0.04]
35 TC, mmoL/L - subgroup by
replacement
27 Mean Difference (IV, Random, 95% CI) Subtotals only
35.1 PUFA replaced saturated
fats
8 4572 Mean Difference (IV, Random, 95% CI) -0.32 [-0.50, -0.14]
35.2 PUFA replaced
monounsaturated fats
13 4500 Mean Difference (IV, Random, 95% CI) -0.17 [-0.33, -0.00]
35.3 PUFA replaced
carbohydrates
9 1394 Mean Difference (IV, Random, 95% CI) -0.06 [-0.23, 0.10]
35.4 PUFA replaced protein 4 862 Mean Difference (IV, Random, 95% CI) -0.03 [-0.30, 0.24]
35.5 PUFA replaced unclear 3 238 Mean Difference (IV, Random, 95% CI) -0.09 [-0.29, 0.12]
36 TC, mmoL/L - subgroup by sex 27 8072 Mean Difference (IV, Random, 95% CI) -0.12 [-0.23, -0.02]
36.1 > 70% men 15 6393 Mean Difference (IV, Random, 95% CI) -0.15 [-0.30, -0.01]
36.2 > 70% women 2 251 Mean Difference (IV, Random, 95% CI) -0.01 [-0.64, 0.61]
36.3 men & women 8 1367 Mean Difference (IV, Random, 95% CI) -0.11 [-0.22, 0.01]
36.4 sex not reported 2 61 Mean Difference (IV, Random, 95% CI) -0.04 [-0.80, 0.73]
37 TC, mmoL/L - subgroup by
age
27 8072 Mean Difference (IV, Random, 95% CI) -0.12 [-0.23, -0.02]
37.1 Mean age < 50 years 5 1713 Mean Difference (IV, Random, 95% CI) -0.30 [-0.59, -0.02]
37.2 Mean age 50 to < 65
years
15 3250 Mean Difference (IV, Random, 95% CI) -0.05 [-0.17, 0.06]
37.3 Mean age 65+ years 4 2885 Mean Difference (IV, Random, 95% CI) -0.10 [-0.21, 0.00]
37.4 Mean age unclear 3 224 Mean Difference (IV, Random, 95% CI) -0.16 [-0.52, 0.20]
38 TC, mmoL/L - subgroup by
statin use
27 8072 Mean Difference (IV, Random, 95% CI) -0.12 [-0.23, -0.02]
38.1 < 50% on statins 20 5818 Mean Difference (IV, Random, 95% CI) -0.15 [-0.28, -0.03]
38.2 50+% on statins 5 1604 Mean Difference (IV, Random, 95% CI) -0.02 [-0.11, 0.08]
38.3 Percentage on statins
unclear
2 650 Mean Difference (IV, Random, 95% CI) -0.10 [-0.35, 0.15]
39 TC, mmoL/L - subgroup by
intervention type
27 8072 Mean Difference (IV, Random, 95% CI) -0.12 [-0.23, -0.02]
39.1 Dietary advice 4 2019 Mean Difference (IV, Random, 95% CI) -0.13 [-0.41, 0.15]
39.2 Supplemental foods &
diet provided
8 4264 Mean Difference (IV, Random, 95% CI) -0.19 [-0.37, -0.01]
39.3 Supplements (capsules &
unusual foods)
11 934 Mean Difference (IV, Random, 95% CI) -0.09 [-0.19, 0.02]




20 3905 Mean Difference (IV, Random, 95% CI) -0.12 [-0.20, -0.04]
41 TG, mmoL/L - SA 20 Mean Difference (IV, Random, 95% CI) Subtotals only
41.1 Low risk of bias for
allocation concealment
9 2686 Mean Difference (IV, Random, 95% CI) -0.17 [-0.28, -0.06]
41.2 Low risk of bias for
attention
15 3108 Mean Difference (IV, Random, 95% CI) -0.11 [-0.20, -0.01]
41.3 Low risk of bias for
compliance
8 1175 Mean Difference (IV, Random, 95% CI) -0.08 [-0.19, 0.03]
41.4 Low summary risk of
bias
5 2050 Mean Difference (IV, Random, 95% CI) -0.14 [-0.26, -0.03]
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41.5 Trials registry or pre-
2010
19 3715 Mean Difference (IV, Random, 95% CI) -0.13 [-0.21, -0.05]
41.6 No industry funding 8 1196 Mean Difference (IV, Random, 95% CI) -0.08 [-0.25, 0.09]
41.7 Randomised 100+
participants
14 3637 Mean Difference (IV, Random, 95% CI) -0.12 [-0.19, -0.06]
41.8 Randomised 250+
participants
5 2472 Mean Difference (IV, Random, 95% CI) -0.17 [-0.27, -0.07]
42 TG, mmoL/L - SA fixed-effect 20 3905 Mean Difference (IV, Fixed, 95% CI) -0.11 [-0.16, -0.06]
43 TG, mmoL/L - subgroup by
PUFA dose
20 3905 Mean Difference (IV, Random, 95% CI) -0.12 [-0.20, -0.04]
43.1 total PUFA < 1.0% E 5 815 Mean Difference (IV, Random, 95% CI) -0.20 [-0.37, -0.02]
43.2 total PUFA 1.0 to < 2.
0% E
7 2091 Mean Difference (IV, Random, 95% CI) -0.08 [-0.15, -0.01]
43.3 total PUFA 2.0 to < 5.
0% E
3 149 Mean Difference (IV, Random, 95% CI) -0.08 [-0.91, 0.75]
43.4 total PUFA 5.0+% E 5 850 Mean Difference (IV, Random, 95% CI) -0.07 [-0.20, 0.06]
44 TG, mmoL/L - subgroup by
duration
20 3905 Mean Difference (IV, Random, 95% CI) -0.12 [-0.20, -0.04]
44.1 Medium duration 1 to <
2 years
10 1246 Mean Difference (IV, Random, 95% CI) -0.12 [-0.28, 0.04]
44.2 Medium-long duration 2
to < 4 years
7 1787 Mean Difference (IV, Random, 95% CI) -0.06 [-0.18, 0.07]
44.3 Long duration 4+ years 3 872 Mean Difference (IV, Random, 95% CI) -0.13 [-0.23, -0.03]
45 TG, mmoL/L - subgroup
by primary or secondary
prevention
20 3905 Mean Difference (IV, Random, 95% CI) -0.12 [-0.20, -0.04]
45.1 Primary prevention of
CVD
14 1831 Mean Difference (IV, Random, 95% CI) -0.10 [-0.21, 0.01]
45.2 Secondary prevention of
CVD
6 2074 Mean Difference (IV, Random, 95% CI) -0.11 [-0.22, 0.00]
46 TG, mmoL/L - subgroup by
baseline PUFA dose
20 3905 Mean Difference (IV, Random, 95% CI) -0.12 [-0.20, -0.04]
46.1 Baseline total PUFA <
6% E
3 350 Mean Difference (IV, Random, 95% CI) 0.01 [-0.16, 0.17]
46.2 Baseline total PUFA 6 to
< 11% E
6 1195 Mean Difference (IV, Random, 95% CI) -0.14 [-0.23, -0.06]
46.3 Baseline total PUFA
11+% E
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
46.4 Baseline total PUFA
unclear
11 2360 Mean Difference (IV, Random, 95% CI) -0.13 [-0.27, 0.01]
47 TG, mmoL/L - subgroup by
replacement
20 Mean Difference (IV, Random, 95% CI) Subtotals only
47.1 PUFA replaced saturated
fats
4 719 Mean Difference (IV, Random, 95% CI) -0.02 [-0.13, 0.09]
47.2 PUFA replaced
monounsaturated fats
8 2448 Mean Difference (IV, Random, 95% CI) -0.16 [-0.24, -0.08]
47.3 PUFA replaced
carbohydrates
7 848 Mean Difference (IV, Random, 95% CI) -0.05 [-0.23, 0.14]
47.4 PUFA replaced protein 2 171 Mean Difference (IV, Random, 95% CI) 0.12 [-0.26, 0.51]
47.5 PUFA replaced unclear 3 499 Mean Difference (IV, Random, 95% CI) -0.14 [-0.50, 0.21]
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48 TG, mmoL/L - subgroup by
sex
20 3905 Mean Difference (IV, Random, 95% CI) -0.12 [-0.20, -0.04]
48.1 > 70% men 11 2796 Mean Difference (IV, Random, 95% CI) -0.10 [-0.23, 0.03]
48.2 > 70% women 2 250 Mean Difference (IV, Random, 95% CI) -0.03 [-0.20, 0.13]
48.3 men & women 6 824 Mean Difference (IV, Random, 95% CI) -0.19 [-0.28, -0.09]
48.4 sex not reported 1 35 Mean Difference (IV, Random, 95% CI) 0.30 [-0.39, 0.99]
49 TG, mmoL/L - subgroup by
age
20 3905 Mean Difference (IV, Random, 95% CI) -0.12 [-0.20, -0.04]
49.1 Mean age < 50 years 3 565 Mean Difference (IV, Random, 95% CI) -0.11 [-0.26, 0.04]
49.2 Mean age 50 to < 65
years
13 1662 Mean Difference (IV, Random, 95% CI) -0.15 [-0.26, -0.03]
49.3 Mean age 65+ years 2 1528 Mean Difference (IV, Random, 95% CI) -0.08 [-0.17, 0.01]
49.4 Mean age unclear 2 150 Mean Difference (IV, Random, 95% CI) 0.14 [-0.68, 0.96]
50 TG, mmoL/L - subgroup by
statin use
20 3905 Mean Difference (IV, Random, 95% CI) -0.12 [-0.20, -0.04]
50.1 < 50% on statins 15 2239 Mean Difference (IV, Random, 95% CI) -0.14 [-0.24, -0.04]
50.2 50+% on statins 4 1530 Mean Difference (IV, Random, 95% CI) -0.03 [-0.15, 0.08]
50.3 Percentage on statins
unclear
1 136 Mean Difference (IV, Random, 95% CI) 0.04 [-0.42, 0.50]
51 TG, mmoL/L - subgroup by
intervention type
20 3905 Mean Difference (IV, Random, 95% CI) -0.12 [-0.20, -0.04]
51.1 Dietary advice 4 339 Mean Difference (IV, Random, 95% CI) -0.18 [-0.37, 0.00]
51.2 Supplemental foods &
diet provided
4 1753 Mean Difference (IV, Random, 95% CI) -0.04 [-0.12, 0.03]
51.3 Supplements (capsules &
unusual foods)
9 1140 Mean Difference (IV, Random, 95% CI) -0.22 [-0.35, -0.10]
51.4 Any combination 3 673 Mean Difference (IV, Random, 95% CI) 0.12 [-0.22, 0.46]
52 Serum HIGH DENSITY
LIPOPROTEIN (HDL,
mmoL/L)
18 4674 Mean Difference (IV, Random, 95% CI) -0.01 [-0.02, 0.01]
53 HDL, mmoL/L - SA 18 Mean Difference (IV, Random, 95% CI) Subtotals only
53.1 Low risk of bias for
allocation concealment
8 1968 Mean Difference (IV, Random, 95% CI) -0.01 [-0.04, 0.01]
53.2 Low risk of bias for
attention
13 2641 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.01]
53.3 Low risk of bias for
compliance
8 2410 Mean Difference (IV, Random, 95% CI) -0.00 [-0.02, 0.02]
53.4 Low summary risk of
bias
4 1592 Mean Difference (IV, Random, 95% CI) -0.01 [-0.04, 0.01]
53.5 Trials registry or pre-
2010
16 4410 Mean Difference (IV, Random, 95% CI) -0.01 [-0.02, 0.01]
53.6 No industry funding 7 717 Mean Difference (IV, Random, 95% CI) 0.01 [-0.04, 0.05]
53.7 Randomised 100+
participants
11 4332 Mean Difference (IV, Random, 95% CI) -0.01 [-0.02, 0.01]
53.8 Randomised 250+
participants
4 3394 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.01]
54 HDL, mmoL/L - SA
fixed-effect
18 4674 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.02, 0.01]
55 HDL, mmoL/L - subgroup by
PUFA dose
18 4674 Mean Difference (IV, Random, 95% CI) -0.01 [-0.02, 0.01]
55.1 total PUFA < 1.0% E 3 347 Mean Difference (IV, Random, 95% CI) 0.02 [-0.05, 0.09]
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55.2 total PUFA 1.0 to < 2.
0% E
8 2166 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.01]
55.3 total PUFA 2.0 to < 5.
0% E
4 1864 Mean Difference (IV, Random, 95% CI) -0.01 [-0.04, 0.02]
55.4 total PUFA 5.0+% E 3 297 Mean Difference (IV, Random, 95% CI) 0.05 [-0.04, 0.14]
56 HDL, mmoL/L - subgroup by
duration
18 4674 Mean Difference (IV, Random, 95% CI) -0.01 [-0.02, 0.01]
56.1 Medium duration 1 to <
2 years
9 852 Mean Difference (IV, Random, 95% CI) -0.00 [-0.04, 0.04]
56.2 Medium-long duration 2
to < 4 years
8 3504 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.01]
56.3 Long duration 4+ years 1 318 Mean Difference (IV, Random, 95% CI) 0.03 [-0.02, 0.09]
57 HDL, mmoL/L - subgroup
by primary or secondary
prevention
18 4674 Mean Difference (IV, Random, 95% CI) -0.01 [-0.02, 0.01]
57.1 Primary prevention of
CVD
12 1402 Mean Difference (IV, Random, 95% CI) 0.01 [-0.02, 0.04]
57.2 Secondary prevention of
CVD
6 3272 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.01]
58 HDL, mmoL/L - subgroup by
baseline PUFA dose
18 4674 Mean Difference (IV, Random, 95% CI) -0.01 [-0.02, 0.01]
58.1 Baseline total PUFA <
6% E
3 350 Mean Difference (IV, Random, 95% CI) -0.01 [-0.11, 0.09]
58.2 Baseline total PUFA 6 to
< 11% E
6 2454 Mean Difference (IV, Random, 95% CI) -0.00 [-0.03, 0.02]
58.3 Baseline total PUFA
11+% E
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
58.4 Baseline total PUFA
unclear
9 1870 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.01]
59 HDL, mmoL/L - subgroup by
replacement
18 Mean Difference (IV, Random, 95% CI) Subtotals only
59.1 PUFA replaced saturated
fats
4 1976 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.02]
59.2 PUFA replaced
monounsaturated fats
6 1857 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.02]
59.3 PUFA replaced
carbohydrates
6 754 Mean Difference (IV, Random, 95% CI) -0.02 [-0.06, 0.03]
59.4 PUFA replaced protein 2 171 Mean Difference (IV, Random, 95% CI) 0.04 [-0.06, 0.14]
59.5 PUFA replaced unclear 3 238 Mean Difference (IV, Random, 95% CI) 0.05 [-0.04, 0.14]
60 HDL, mmoL/L - subgroup by
sex
18 4674 Mean Difference (IV, Random, 95% CI) -0.01 [-0.02, 0.01]
60.1 > 70% men 10 3660 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.01]
60.2 > 70% women 2 251 Mean Difference (IV, Random, 95% CI) -0.02 [-0.21, 0.17]
60.3 men & women 5 728 Mean Difference (IV, Random, 95% CI) 0.03 [-0.02, 0.07]
60.4 sex not reported 1 35 Mean Difference (IV, Random, 95% CI) 0.10 [-0.17, 0.37]
61 HDL, mmoL/L - subgroup by
age
18 4674 Mean Difference (IV, Random, 95% CI) -0.01 [-0.02, 0.01]
61.1 Mean age < 50 years 2 108 Mean Difference (IV, Random, 95% CI) 0.05 [-0.13, 0.23]
61.2 Mean age 50 to < 65
years
12 2910 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.02]
61.3 Mean age 65+ years 2 1528 Mean Difference (IV, Random, 95% CI) -0.00 [-0.04, 0.03]
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61.4 Mean age unclear 2 128 Mean Difference (IV, Random, 95% CI) 0.01 [-0.08, 0.10]
62 HDL, mmoL/L - subgroup by
statin use
18 4674 Mean Difference (IV, Random, 95% CI) -0.01 [-0.02, 0.01]
62.1 < 50% on statins 12 2934 Mean Difference (IV, Random, 95% CI) -0.00 [-0.03, 0.02]
62.2 50+% on statins 5 1604 Mean Difference (IV, Random, 95% CI) -0.01 [-0.04, 0.01]
62.3 Percentage on statins
unclear
1 136 Mean Difference (IV, Random, 95% CI) 0.03 [-0.08, 0.14]
63 HDL, mmoL/L - subgroup by
intervention type
18 4674 Mean Difference (IV, Random, 95% CI) -0.01 [-0.02, 0.01]
63.1 Dietary advice 4 1959 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.02]
63.2 Supplemental foods &
diet provided
4 1753 Mean Difference (IV, Random, 95% CI) -0.01 [-0.03, 0.02]
63.3 Supplements (capsules &
unusual foods)
8 746 Mean Difference (IV, Random, 95% CI) -0.01 [-0.05, 0.04]
63.4 Any combination 2 216 Mean Difference (IV, Random, 95% CI) -0.02 [-0.10, 0.06]
64 Serum LOW DENSITY
LIPOPROTEIN (LDL,
mmoL/L)
15 3362 Mean Difference (IV, Random, 95% CI) -0.01 [-0.09, 0.06]
65 LDL, mmoL/L - SA 15 Mean Difference (IV, Random, 95% CI) Subtotals only
65.1 Low risk of bias for
allocation concealment
6 1915 Mean Difference (IV, Random, 95% CI) 0.04 [-0.03, 0.10]
65.2 Low risk of bias for
attention
11 2566 Mean Difference (IV, Random, 95% CI) -0.01 [-0.09, 0.07]
65.3 Low risk of bias for
compliance
5 1009 Mean Difference (IV, Random, 95% CI) -0.05 [-0.17, 0.06]
65.4 Low summary risk of
bias
4 1506 Mean Difference (IV, Random, 95% CI) 0.02 [-0.06, 0.09]
65.5 Trials registry or pre-
2010
13 3098 Mean Difference (IV, Random, 95% CI) -0.02 [-0.10, 0.07]
65.6 No industry funding 4 415 Mean Difference (IV, Random, 95% CI) 0.05 [-0.11, 0.21]
65.7 Randomised 100+
participants
10 3114 Mean Difference (IV, Random, 95% CI) -0.03 [-0.11, 0.06]
65.8 Randomised 250+
participants
5 2442 Mean Difference (IV, Random, 95% CI) -0.04 [-0.15, 0.08]
66 LDL, mmoL/L - SA fixed-effect 15 3362 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.07, 0.02]
67 LDL, mmoL/L - subgroup by
PUFA dose
15 3362 Mean Difference (IV, Random, 95% CI) -0.01 [-0.09, 0.06]
67.1 total PUFA < 1.0% E 3 622 Mean Difference (IV, Random, 95% CI) 0.08 [-0.03, 0.19]
67.2 total PUFA 1.0 to < 2.
0% E
5 1790 Mean Difference (IV, Random, 95% CI) -0.05 [-0.19, 0.09]
67.3 total PUFA 2.0 to < 5.
0% E
3 142 Mean Difference (IV, Random, 95% CI) 0.12 [-0.13, 0.38]
67.4 total PUFA 5.0+% E 4 808 Mean Difference (IV, Random, 95% CI) -0.06 [-0.21, 0.09]
68 LDL, mmoL/L - subgroup by
duration
15 3362 Mean Difference (IV, Random, 95% CI) -0.01 [-0.09, 0.06]
68.1 Medium duration 1 to <
2 years
9 1085 Mean Difference (IV, Random, 95% CI) 0.01 [-0.07, 0.10]
68.2 Medium-long duration 2
to < 4 years
5 1959 Mean Difference (IV, Random, 95% CI) -0.00 [-0.13, 0.12]
68.3 Long duration 4+ years 1 318 Mean Difference (IV, Random, 95% CI) -0.11 [-0.49, 0.28]
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69 LDL, mmoL/L - subgroup
by primary or secondary
prevention
15 3362 Mean Difference (IV, Random, 95% CI) -0.01 [-0.09, 0.06]
69.1 Primary prevention of
CVD
11 1915 Mean Difference (IV, Random, 95% CI) -0.03 [-0.14, 0.07]
69.2 Secondary prevention of
CVD
4 1447 Mean Difference (IV, Random, 95% CI) 0.02 [-0.05, 0.09]
70 LDL, mmoL/L - subgroup by
baseline PUFA dose
15 3362 Mean Difference (IV, Random, 95% CI) -0.01 [-0.09, 0.06]
70.1 Baseline total PUFA <
6% E
3 347 Mean Difference (IV, Random, 95% CI) -0.07 [-0.30, 0.15]
70.2 Baseline total PUFA 6 to
< 11%E
4 1055 Mean Difference (IV, Random, 95% CI) -0.05 [-0.22, 0.12]
70.3 Baseline total PUFA
11+% E
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
70.4 Baseline total PUFA
unclear
8 1960 Mean Difference (IV, Random, 95% CI) 0.03 [-0.03, 0.10]
71 LDL, mmoL/L - subgroup by
replacement
15 Mean Difference (IV, Random, 95% CI) Subtotals only
71.1 PUFA replaced saturated
fats
2 222 Mean Difference (IV, Random, 95% CI) -0.04 [-0.21, 0.14]
71.2 PUFA replaced
monounsaturated fats
6 1776 Mean Difference (IV, Random, 95% CI) -0.00 [-0.12, 0.12]
71.3 PUFA replaced
carbohydrates
6 1106 Mean Difference (IV, Random, 95% CI) -0.06 [-0.18, 0.06]
71.4 PUFA replaced protein 3 682 Mean Difference (IV, Random, 95% CI) -0.08 [-0.26, 0.10]
71.5 PUFA replaced unclear 2 409 Mean Difference (IV, Random, 95% CI) 0.10 [-0.03, 0.23]
72 LDL, mmoL/L - subgroup by
sex
15 3362 Mean Difference (IV, Random, 95% CI) -0.01 [-0.09, 0.06]
72.1 > 70% men 7 1972 Mean Difference (IV, Random, 95% CI) 0.04 [-0.03, 0.10]
72.2 > 70% women 2 251 Mean Difference (IV, Random, 95% CI) 0.02 [-0.46, 0.49]
72.3 men & women 5 1107 Mean Difference (IV, Random, 95% CI) -0.07 [-0.21, 0.06]
72.4 sex not reported 1 32 Mean Difference (IV, Random, 95% CI) -0.10 [-0.59, 0.39]
73 LDL, mmoL/L - subgroup by
age
15 3362 Mean Difference (IV, Random, 95% CI) -0.01 [-0.09, 0.06]
73.1 Mean age < 50 years 2 101 Mean Difference (IV, Random, 95% CI) 0.25 [-0.11, 0.61]
73.2 Mean age 50 to < 65
years
8 1177 Mean Difference (IV, Random, 95% CI) 0.01 [-0.08, 0.10]
73.3 Mean age 65+ years 3 1956 Mean Difference (IV, Random, 95% CI) -0.08 [-0.23, 0.07]
73.4 Mean age unclear 2 128 Mean Difference (IV, Random, 95% CI) 0.05 [-0.26, 0.36]
74 LDL, mmoL/L - subgroup by
statin use
15 3362 Mean Difference (IV, Random, 95% CI) -0.01 [-0.09, 0.06]
74.1 < 50% on statins 8 1197 Mean Difference (IV, Random, 95% CI) 0.00 [-0.13, 0.13]
74.2 50+% on statins 5 1515 Mean Difference (IV, Random, 95% CI) 0.01 [-0.07, 0.08]
74.3 Percentage on statins
unclear
2 650 Mean Difference (IV, Random, 95% CI) -0.04 [-0.33, 0.25]
75 LDL, mmoL/L - subgroup by
intervention type
15 3362 Mean Difference (IV, Random, 95% CI) -0.01 [-0.09, 0.06]
75.1 Dietary advice 2 208 Mean Difference (IV, Random, 95% CI) 0.22 [-0.05, 0.48]
75.2 Supplemental foods &
diet provided
5 2178 Mean Difference (IV, Random, 95% CI) -0.07 [-0.18, 0.05]
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75.3 Supplements (capsules &
unusual foods)
7 922 Mean Difference (IV, Random, 95% CI) 0.02 [-0.09, 0.13]
75.4 Any combination 1 54 Mean Difference (IV, Random, 95% CI) -0.07 [-0.51, 0.37]
Comparison 4. Higher PUFA vs lower PUFA intake - tertiary outcomes




participants Statistical method Effect size
1 SYSTOLIC BLOOD
PRESSURE (sBP, mmHg)
10 7356 Mean Difference (IV, Random, 95% CI) -0.47 [-2.20, 1.26]
2 DIASTOLIC BLOOD
PRESSURE (dBP, mmHg)
9 7327 Mean Difference (IV, Random, 95% CI) 0.24 [-0.55, 1.02]
3 SERIOUS ADVERSE EVENTS
(SAEs)
8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Pulmonary embolism 2 2087 Risk Ratio (M-H, Random, 95% CI) 2.15 [0.48, 9.57]
3.2 Multiple Sclerosis
worsened or had acute attack -
GLA supplement
2 268 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.95, 1.30]
3.3 Bleeding 2 748 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.34, 1.85]
3.4 GI hospitalisation 1 200 Risk Ratio (M-H, Random, 95% CI) 1.75 [0.53, 5.79]
3.5 Retinopathy 1 2424 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.56, 1.86]
4 DROPOUTS 27 8574 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.87, 1.13]
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Analysis 1.1. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 1 ALL-CAUSE MORTALITY.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 1 ALL-CAUSE MORTALITY








AlphaOmega - ALA 182/2409 188/2428 22.3 % 0.98 [ 0.80, 1.19 ]
Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
Black 1994 2/67 1/66 0.2 % 1.97 [ 0.18, 21.21 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 111/1018 113/1015 14.0 % 0.98 [ 0.76, 1.25 ]
DIPP-Tokudome 2015 2/104 3/101 0.3 % 0.65 [ 0.11, 3.79 ]
Doi 2014 2/119 9/119 0.4 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
FAAT - Leaf 2005 13/200 12/202 1.5 % 1.09 [ 0.51, 2.34 ]
HARP- Sacks 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.2 % 1.89 [ 0.18, 20.31 ]
McIllmurray 1987 10/25 12/24 2.2 % 0.80 [ 0.43, 1.49 ]
MRC 1968 28/199 31/194 3.9 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
PREDIMED 2013 116/2454 118/2543 13.7 % 1.02 [ 0.79, 1.31 ]
Raitt 2005 4/100 10/100 0.7 % 0.40 [ 0.13, 1.23 ]
Rose 1965 5/28 3/26 0.5 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 4.1 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 33.5 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.1 % 0.20 [ 0.01, 4.11 ]
WINS 2006 19/1462 15/975 1.9 % 0.84 [ 0.43, 1.65 ]
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Total (95% CI) 9912 9378 100.0 % 0.98 [ 0.89, 1.07 ]
Total events: 715 (Higher PUFA), 728 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.59, df = 23 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 2 All-cause mortality - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 2 All-cause mortality - SA








1 Low risk of bias for allocation concealment
AlphaOmega - ALA 182/2409 188/2428 72.8 % 0.98 [ 0.80, 1.19 ]
Brox 2001 0/80 1/40 0.3 % 0.17 [ 0.01, 4.05 ]
DIPP-Tokudome 2015 2/104 3/101 0.9 % 0.65 [ 0.11, 3.79 ]
EPIC-1 2008 1/183 0/180 0.3 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.3 % 0.34 [ 0.01, 8.17 ]
FAAT - Leaf 2005 13/200 12/202 4.8 % 1.09 [ 0.51, 2.34 ]
Kumar 2013 1/39 1/39 0.4 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.5 % 1.89 [ 0.18, 20.31 ]
NDHS Faribault 1968 4/167 0/57 0.3 % 3.11 [ 0.17, 56.84 ]
Sydney Diet-Heart 1978 38/221 27/237 13.3 % 1.51 [ 0.95, 2.39 ]
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WINS 2006 19/1462 15/975 6.2 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 5124 4515 100.0 % 1.03 [ 0.87, 1.22 ]
Total events: 262 (Higher PUFA), 249 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.53, df = 10 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
2 Low risk of bias for attention
AlphaOmega - ALA 182/2409 188/2428 29.5 % 0.98 [ 0.80, 1.19 ]
Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DIPP-Tokudome 2015 2/104 3/101 0.4 % 0.65 [ 0.11, 3.79 ]
Doi 2014 2/119 9/119 0.5 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
FAAT - Leaf 2005 13/200 12/202 2.0 % 1.09 [ 0.51, 2.34 ]
HARP- Sacks 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
McIllmurray 1987 10/25 12/24 2.9 % 0.80 [ 0.43, 1.49 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
PREDIMED 2013 116/2454 118/2543 18.1 % 1.02 [ 0.79, 1.31 ]
Raitt 2005 4/100 10/100 0.9 % 0.40 [ 0.13, 1.23 ]
Rose 1965 5/28 3/26 0.6 % 1.55 [ 0.41, 5.84 ]
Veterans Admin 1969 174/424 177/422 44.2 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.1 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 6836 6786 100.0 % 0.96 [ 0.87, 1.07 ]
Total events: 514 (Higher PUFA), 539 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 13.08, df = 16 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
3 Low risk of bias for compliance
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
Brox 2001 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 111/1018 113/1015 24.9 % 0.98 [ 0.76, 1.25 ]
Ley 2004 2/70 1/66 0.3 % 1.89 [ 0.18, 20.31 ]
MRC 1968 28/199 31/194 6.8 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
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Rose 1965 5/28 3/26 0.9 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 7.2 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 59.3 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 2462 2314 100.0 % 1.01 [ 0.89, 1.14 ]
Total events: 363 (Higher PUFA), 355 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.51, df = 9 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
4 Low summary risk of bias
AlphaOmega - ALA 182/2409 188/2428 75.3 % 0.98 [ 0.80, 1.19 ]
Ley 2004 2/70 1/66 0.6 % 1.89 [ 0.18, 20.31 ]
NDHS Faribault 1968 4/167 0/57 0.4 % 3.11 [ 0.17, 56.84 ]
Sydney Diet-Heart 1978 38/221 27/237 16.1 % 1.51 [ 0.95, 2.39 ]
WINS 2006 19/1462 15/975 7.6 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 4329 3763 100.0 % 1.04 [ 0.87, 1.26 ]
Total events: 245 (Higher PUFA), 231 (Lower PUFA)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.10, df = 4 (P = 0.39); I2 =2%
Test for overall effect: Z = 0.45 (P = 0.65)
5 Trials registry or pre-2010
AlphaOmega - ALA 182/2409 188/2428 22.4 % 0.98 [ 0.80, 1.19 ]
Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
Black 1994 2/67 1/66 0.2 % 1.97 [ 0.18, 21.21 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 111/1018 113/1015 14.1 % 0.98 [ 0.76, 1.25 ]
DIPP-Tokudome 2015 2/104 3/101 0.3 % 0.65 [ 0.11, 3.79 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
FAAT - Leaf 2005 13/200 12/202 1.5 % 1.09 [ 0.51, 2.34 ]
HARP- Sacks 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.2 % 1.89 [ 0.18, 20.31 ]
McIllmurray 1987 10/25 12/24 2.2 % 0.80 [ 0.43, 1.49 ]
MRC 1968 28/199 31/194 3.9 % 0.88 [ 0.55, 1.41 ]
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NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
PREDIMED 2013 116/2454 118/2543 13.8 % 1.02 [ 0.79, 1.31 ]
Raitt 2005 4/100 10/100 0.7 % 0.40 [ 0.13, 1.23 ]
Rose 1965 5/28 3/26 0.5 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 4.1 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 33.6 % 0.98 [ 0.83, 1.15 ]
WINS 2006 19/1462 15/975 1.9 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 9693 9159 100.0 % 0.99 [ 0.90, 1.08 ]
Total events: 713 (Higher PUFA), 717 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.79, df = 21 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
6 No industry funding
Black 1994 2/67 1/66 1.3 % 1.97 [ 0.18, 21.21 ]
Brox 2001 0/80 1/40 0.7 % 0.17 [ 0.01, 4.05 ]
DIPP-Tokudome 2015 2/104 3/101 2.3 % 0.65 [ 0.11, 3.79 ]
FAAT - Leaf 2005 13/200 12/202 12.3 % 1.09 [ 0.51, 2.34 ]
Ley 2004 2/70 1/66 1.3 % 1.89 [ 0.18, 20.31 ]
MRC 1968 28/199 31/194 31.9 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.8 % 3.11 [ 0.17, 56.84 ]
Sydney Diet-Heart 1978 38/221 27/237 33.8 % 1.51 [ 0.95, 2.39 ]
WINS 2006 19/1462 15/975 15.7 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 2570 1938 100.0 % 1.09 [ 0.84, 1.42 ]
Total events: 108 (Higher PUFA), 91 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.88, df = 8 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
7 Randomised 100+ participants
AlphaOmega - ALA 182/2409 188/2428 23.0 % 0.98 [ 0.80, 1.19 ]
Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
Black 1994 2/67 1/66 0.2 % 1.97 [ 0.18, 21.21 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 111/1018 113/1015 14.5 % 0.98 [ 0.76, 1.25 ]
DIPP-Tokudome 2015 2/104 3/101 0.3 % 0.65 [ 0.11, 3.79 ]
Doi 2014 2/119 9/119 0.4 % 0.22 [ 0.05, 1.01 ]
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EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
FAAT - Leaf 2005 13/200 12/202 1.5 % 1.09 [ 0.51, 2.34 ]
Ley 2004 2/70 1/66 0.2 % 1.89 [ 0.18, 20.31 ]
MRC 1968 28/199 31/194 4.0 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
PREDIMED 2013 116/2454 118/2543 14.1 % 1.02 [ 0.79, 1.31 ]
Raitt 2005 4/100 10/100 0.7 % 0.40 [ 0.13, 1.23 ]
Sydney Diet-Heart 1978 38/221 27/237 4.2 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 34.5 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.1 % 0.20 [ 0.01, 4.11 ]
WINS 2006 19/1462 15/975 2.0 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 9779 9250 100.0 % 0.98 [ 0.89, 1.08 ]
Total events: 699 (Higher PUFA), 711 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 16.24, df = 19 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
8 Randomised 250+ participants
AlphaOmega - ALA 182/2409 188/2428 23.5 % 0.98 [ 0.80, 1.19 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
DART fat 1989 111/1018 113/1015 14.8 % 0.98 [ 0.76, 1.25 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
FAAT - Leaf 2005 13/200 12/202 1.6 % 1.09 [ 0.51, 2.34 ]
MRC 1968 28/199 31/194 4.1 % 0.88 [ 0.55, 1.41 ]
PREDIMED 2013 116/2454 118/2543 14.4 % 1.02 [ 0.79, 1.31 ]
Sydney Diet-Heart 1978 38/221 27/237 4.3 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 35.2 % 0.98 [ 0.83, 1.15 ]
WINS 2006 19/1462 15/975 2.0 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 8914 8543 100.0 % 1.00 [ 0.91, 1.10 ]
Total events: 683 (Higher PUFA), 682 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.22, df = 10 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
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Analysis 1.3. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 3 All-cause mortality - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 3 All-cause mortality - SA fixed-effect
Study or subgroup Higher PUFA Lower PUFA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - ALA 182/2409 188/2428 25.5 % 0.98 [ 0.80, 1.19 ]
Bates 1978 0/58 2/58 0.3 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
Black 1994 2/67 1/66 0.1 % 1.97 [ 0.18, 21.21 ]
Brox 2001 0/80 1/40 0.3 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 111/1018 113/1015 15.4 % 0.98 [ 0.76, 1.25 ]
DIPP-Tokudome 2015 2/104 3/101 0.4 % 0.65 [ 0.11, 3.79 ]
Doi 2014 2/119 9/119 1.2 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.2 % 0.34 [ 0.01, 8.17 ]
FAAT - Leaf 2005 13/200 12/202 1.6 % 1.09 [ 0.51, 2.34 ]
HARP- Sacks 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.1 % 1.89 [ 0.18, 20.31 ]
McIllmurray 1987 10/25 12/24 1.7 % 0.80 [ 0.43, 1.49 ]
MRC 1968 28/199 31/194 4.3 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
PREDIMED 2013 116/2454 118/2543 15.8 % 1.02 [ 0.79, 1.31 ]
Raitt 2005 4/100 10/100 1.4 % 0.40 [ 0.13, 1.23 ]
Rose 1965 5/28 3/26 0.4 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 3.6 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 24.2 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.3 % 0.20 [ 0.01, 4.11 ]
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Study or subgroup Higher PUFA Lower PUFA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
WINS 2006 19/1462 15/975 2.5 % 0.84 [ 0.43, 1.65 ]
Total (95% CI) 9912 9378 100.0 % 0.98 [ 0.89, 1.07 ]
Total events: 715 (Higher PUFA), 728 (Lower PUFA)
Heterogeneity: Chi2 = 17.59, df = 23 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 4 All-cause mortality - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 4 All-cause mortality - subgroup by PUFA dose








1 total PUFA < 1.0% E
Doi 2014 2/119 9/119 0.4 % 0.22 [ 0.05, 1.01 ]
FAAT - Leaf 2005 13/200 12/202 1.5 % 1.09 [ 0.51, 2.34 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.2 % 1.89 [ 0.18, 20.31 ]
Raitt 2005 4/100 10/100 0.7 % 0.40 [ 0.13, 1.23 ]
Subtotal (95% CI) 528 526 2.8 % 0.66 [ 0.33, 1.34 ]
Total events: 22 (Higher PUFA), 33 (Lower PUFA)
Heterogeneity: Tau2 = 0.16; Chi2 = 5.27, df = 4 (P = 0.26); I2 =24%
Test for overall effect: Z = 1.15 (P = 0.25)
2 total PUFA 1.0 to < 2.0% E
AlphaOmega - ALA 182/2409 188/2428 22.3 % 0.98 [ 0.80, 1.19 ]
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Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DIPP-Tokudome 2015 2/104 3/101 0.3 % 0.65 [ 0.11, 3.79 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
PREDIMED 2013 116/2454 118/2543 13.7 % 1.02 [ 0.79, 1.31 ]
WINS 2006 19/1462 15/975 1.9 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 7094 6672 38.6 % 0.98 [ 0.84, 1.13 ]
Total events: 321 (Higher PUFA), 328 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.11, df = 8 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
3 total PUFA 2.0 to < 5.0% E
Black 1994 2/67 1/66 0.2 % 1.97 [ 0.18, 21.21 ]
DART fat 1989 111/1018 113/1015 14.0 % 0.98 [ 0.76, 1.25 ]
HARP- Sacks 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
McIllmurray 1987 10/25 12/24 2.2 % 0.80 [ 0.43, 1.49 ]
Subtotal (95% CI) 1151 1144 16.5 % 0.95 [ 0.76, 1.20 ]
Total events: 123 (Higher PUFA), 127 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.17, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.69)
4 total PUFA≥ 5.0% E
MRC 1968 28/199 31/194 3.9 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
Rose 1965 5/28 3/26 0.5 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 4.1 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 33.5 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.1 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 1139 1036 42.1 % 1.04 [ 0.86, 1.26 ]
Total events: 249 (Higher PUFA), 240 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.53, df = 5 (P = 0.35); I2 =10%
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI) 9912 9378 100.0 % 0.98 [ 0.89, 1.07 ]
Total events: 715 (Higher PUFA), 728 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.59, df = 23 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
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Test for subgroup differences: Chi2 = 1.61, df = 3 (P = 0.66), I2 =0.0%
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Analysis 1.5. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 5 All-cause mortality - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 5 All-cause mortality - subgroup by duration








1 Medium duration 1 to < 2 years
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
Doi 2014 2/119 9/119 0.4 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
FAAT - Leaf 2005 13/200 12/202 1.5 % 1.09 [ 0.51, 2.34 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.2 % 1.89 [ 0.18, 20.31 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
Subtotal (95% CI) 1047 893 2.5 % 0.86 [ 0.48, 1.55 ]
Total events: 23 (Higher PUFA), 25 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.59, df = 7 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
2 Medium-long duration 2 to < 4 years
AlphaOmega - ALA 182/2409 188/2428 22.3 % 0.98 [ 0.80, 1.19 ]
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Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
Black 1994 2/67 1/66 0.2 % 1.97 [ 0.18, 21.21 ]
DART fat 1989 111/1018 113/1015 14.0 % 0.98 [ 0.76, 1.25 ]
DIPP-Tokudome 2015 2/104 3/101 0.3 % 0.65 [ 0.11, 3.79 ]
HARP- Sacks 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
McIllmurray 1987 10/25 12/24 2.2 % 0.80 [ 0.43, 1.49 ]
Raitt 2005 4/100 10/100 0.7 % 0.40 [ 0.13, 1.23 ]
Rose 1965 5/28 3/26 0.5 % 1.55 [ 0.41, 5.84 ]
Vijayakumar 2014 0/100 2/100 0.1 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 4105 4114 40.5 % 0.95 [ 0.82, 1.10 ]
Total events: 317 (Higher PUFA), 335 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.77, df = 10 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
3 Long duration 4+ years
MRC 1968 28/199 31/194 3.9 % 0.88 [ 0.55, 1.41 ]
PREDIMED 2013 116/2454 118/2543 13.7 % 1.02 [ 0.79, 1.31 ]
Sydney Diet-Heart 1978 38/221 27/237 4.1 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 33.5 % 0.98 [ 0.83, 1.15 ]
WINS 2006 19/1462 15/975 1.9 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 4760 4371 57.0 % 1.01 [ 0.89, 1.14 ]
Total events: 375 (Higher PUFA), 368 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.72, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
Total (95% CI) 9912 9378 100.0 % 0.98 [ 0.89, 1.07 ]
Total events: 715 (Higher PUFA), 728 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.59, df = 23 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 0.55, df = 2 (P = 0.76), I2 =0.0%
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Analysis 1.6. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 6 All-cause mortality - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 6 All-cause mortality - subgroup by primary or secondary prevention








1 Primary prevention of CVD
Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
Black 1994 2/67 1/66 0.2 % 1.97 [ 0.18, 21.21 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DIPP-Tokudome 2015 2/104 3/101 0.3 % 0.65 [ 0.11, 3.79 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.2 % 1.89 [ 0.18, 20.31 ]
McIllmurray 1987 10/25 12/24 2.2 % 0.80 [ 0.43, 1.49 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
PREDIMED 2013 116/2454 118/2543 13.7 % 1.02 [ 0.79, 1.31 ]
WINS 2006 19/1462 15/975 1.9 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 5053 4496 19.0 % 0.97 [ 0.78, 1.20 ]
Total events: 158 (Higher PUFA), 155 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.74, df = 12 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
2 Secondary prevention of CVD
AlphaOmega - ALA 182/2409 188/2428 22.3 % 0.98 [ 0.80, 1.19 ]
DART fat 1989 111/1018 113/1015 14.0 % 0.98 [ 0.76, 1.25 ]
Doi 2014 2/119 9/119 0.4 % 0.22 [ 0.05, 1.01 ]
FAAT - Leaf 2005 13/200 12/202 1.5 % 1.09 [ 0.51, 2.34 ]
HARP- Sacks 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
MRC 1968 28/199 31/194 3.9 % 0.88 [ 0.55, 1.41 ]
Raitt 2005 4/100 10/100 0.7 % 0.40 [ 0.13, 1.23 ]
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Rose 1965 5/28 3/26 0.5 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 4.1 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 33.5 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.1 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 4859 4882 81.0 % 0.98 [ 0.86, 1.12 ]
Total events: 557 (Higher PUFA), 573 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 11.85, df = 10 (P = 0.29); I2 =16%
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 9912 9378 100.0 % 0.98 [ 0.89, 1.07 ]
Total events: 715 (Higher PUFA), 728 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.59, df = 23 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 1.7. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 7 All-cause mortality - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 7 All-cause mortality - subgroup by baseline PUFA dose








1 Baseline total PUFA < 6% E
Ley 2004 2/70 1/66 0.2 % 1.89 [ 0.18, 20.31 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
Veterans Admin 1969 174/424 177/422 33.5 % 0.98 [ 0.83, 1.15 ]
WINS 2006 19/1462 15/975 1.9 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 2123 1520 35.6 % 0.98 [ 0.84, 1.14 ]
Total events: 199 (Higher PUFA), 193 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.08, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
2 Baseline total PUFA 6 to < 11% E
Black 1994 2/67 1/66 0.2 % 1.97 [ 0.18, 21.21 ]
DART fat 1989 111/1018 113/1015 14.0 % 0.98 [ 0.76, 1.25 ]
DIPP-Tokudome 2015 2/104 3/101 0.3 % 0.65 [ 0.11, 3.79 ]
PREDIMED 2013 116/2454 118/2543 13.7 % 1.02 [ 0.79, 1.31 ]
Sydney Diet-Heart 1978 38/221 27/237 4.1 % 1.51 [ 0.95, 2.39 ]
Subtotal (95% CI) 3864 3962 32.2 % 1.05 [ 0.89, 1.24 ]
Total events: 269 (Higher PUFA), 262 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.33, df = 4 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
AlphaOmega - ALA 182/2409 188/2428 22.3 % 0.98 [ 0.80, 1.19 ]
Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
0.1 0.2 0.5 1 2 5 10
Favours higher PUFA Favours lower PUFA
(Continued . . . )
238Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)








Doi 2014 2/119 9/119 0.4 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
FAAT - Leaf 2005 13/200 12/202 1.5 % 1.09 [ 0.51, 2.34 ]
HARP- Sacks 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
McIllmurray 1987 10/25 12/24 2.2 % 0.80 [ 0.43, 1.49 ]
MRC 1968 28/199 31/194 3.9 % 0.88 [ 0.55, 1.41 ]
Raitt 2005 4/100 10/100 0.7 % 0.40 [ 0.13, 1.23 ]
Rose 1965 5/28 3/26 0.5 % 1.55 [ 0.41, 5.84 ]
Vijayakumar 2014 0/100 2/100 0.1 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 3925 3896 32.1 % 0.92 [ 0.78, 1.08 ]
Total events: 247 (Higher PUFA), 273 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.81, df = 14 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 9912 9378 100.0 % 0.98 [ 0.89, 1.07 ]
Total events: 715 (Higher PUFA), 728 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.59, df = 23 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 1.38, df = 2 (P = 0.50), I2 =0.0%
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Analysis 1.8. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 8 All-cause mortality - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 8 All-cause mortality - subgroup by replacement








1 PUFA replaced SFA
DART fat 1989 111/1018 113/1015 26.4 % 0.98 [ 0.76, 1.25 ]
MRC 1968 28/199 31/194 7.6 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.2 % 3.11 [ 0.17, 56.84 ]
Sydney Diet-Heart 1978 38/221 27/237 8.1 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 57.5 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.2 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 2129 2025 100.0 % 1.00 [ 0.88, 1.15 ]
Total events: 355 (Higher PUFA), 350 (Lower PUFA)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.16, df = 5 (P = 0.40); I2 =3%
Test for overall effect: Z = 0.07 (P = 0.94)
2 PUFA replaced monounsaturated fats
AlphaOmega - ALA 182/2409 188/2428 29.2 % 0.98 [ 0.80, 1.19 ]
Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
FAAT - Leaf 2005 13/200 12/202 1.9 % 1.09 [ 0.51, 2.34 ]
HARP- Sacks 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
PREDIMED 2013 116/2454 118/2543 17.9 % 1.02 [ 0.79, 1.31 ]
Raitt 2005 4/100 10/100 0.9 % 0.40 [ 0.13, 1.23 ]
Rose 1965 5/28 3/26 0.6 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 5.3 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 43.7 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 6257 6269 100.0 % 1.00 [ 0.90, 1.12 ]
Total events: 537 (Higher PUFA), 538 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.91, df = 10 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
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3 PUFA replaced carbohydrate
Black 1994 2/67 1/66 5.1 % 1.97 [ 0.18, 21.21 ]
DIPP-Tokudome 2015 2/104 3/101 9.3 % 0.65 [ 0.11, 3.79 ]
Ley 2004 2/70 1/66 5.1 % 1.89 [ 0.18, 20.31 ]
Rose 1965 5/28 3/26 16.4 % 1.55 [ 0.41, 5.84 ]
WINS 2006 19/1462 15/975 64.1 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 1731 1234 100.0 % 0.99 [ 0.58, 1.70 ]
Total events: 30 (Higher PUFA), 23 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.47, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.97)
4 PUFA replaced protein
Ley 2004 2/70 1/66 3.8 % 1.89 [ 0.18, 20.31 ]
MRC 1968 28/199 31/194 96.2 % 0.88 [ 0.55, 1.41 ]
Subtotal (95% CI) 269 260 100.0 % 0.91 [ 0.57, 1.44 ]
Total events: 30 (Higher PUFA), 32 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
5 PUFA replaced unclear
Brox 2001 0/80 1/40 2.9 % 0.17 [ 0.01, 4.05 ]
Doi 2014 2/119 9/119 12.8 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 2.9 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 2.9 % 0.34 [ 0.01, 8.17 ]
Kumar 2013 1/39 1/39 3.9 % 1.00 [ 0.06, 15.43 ]
McIllmurray 1987 10/25 12/24 74.7 % 0.80 [ 0.43, 1.49 ]
Subtotal (95% CI) 635 592 100.0 % 0.66 [ 0.39, 1.14 ]
Total events: 14 (Higher PUFA), 24 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.43, df = 5 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Chi2 = 2.37, df = 4 (P = 0.67), I2 =0.0%
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Analysis 1.9. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 9 All-cause mortality - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 9 All-cause mortality - subgroup by sex








1 > 70% men
AlphaOmega - ALA 182/2409 188/2428 22.3 % 0.98 [ 0.80, 1.19 ]
DART fat 1989 111/1018 113/1015 14.0 % 0.98 [ 0.76, 1.25 ]
DIPP-Tokudome 2015 2/104 3/101 0.3 % 0.65 [ 0.11, 3.79 ]
Doi 2014 2/119 9/119 0.4 % 0.22 [ 0.05, 1.01 ]
FAAT - Leaf 2005 13/200 12/202 1.5 % 1.09 [ 0.51, 2.34 ]
HARP- Sacks 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Ley 2004 2/70 1/66 0.2 % 1.89 [ 0.18, 20.31 ]
MRC 1968 28/199 31/194 3.9 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
Raitt 2005 4/100 10/100 0.7 % 0.40 [ 0.13, 1.23 ]
Sydney Diet-Heart 1978 38/221 27/237 4.1 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 33.5 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.1 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 5172 5080 81.0 % 0.98 [ 0.88, 1.10 ]
Total events: 560 (Higher PUFA), 574 (Lower PUFA)
Heterogeneity: Tau2 = 0.00; Chi2 = 12.50, df = 12 (P = 0.41); I2 =4%
Test for overall effect: Z = 0.34 (P = 0.73)
2 > 70% women
WINS 2006 19/1462 15/975 1.9 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 1462 975 1.9 % 0.84 [ 0.43, 1.65 ]
Total events: 19 (Higher PUFA), 15 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
3 men % women
Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
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Black 1994 2/67 1/66 0.2 % 1.97 [ 0.18, 21.21 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
PREDIMED 2013 116/2454 118/2543 13.7 % 1.02 [ 0.79, 1.31 ]
Subtotal (95% CI) 3225 3273 14.4 % 1.01 [ 0.79, 1.29 ]
Total events: 121 (Higher PUFA), 124 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.98, df = 7 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
4 sex not reported
McIllmurray 1987 10/25 12/24 2.2 % 0.80 [ 0.43, 1.49 ]
Rose 1965 5/28 3/26 0.5 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 53 50 2.7 % 0.90 [ 0.51, 1.59 ]
Total events: 15 (Higher PUFA), 15 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 9912 9378 100.0 % 0.98 [ 0.89, 1.07 ]
Total events: 715 (Higher PUFA), 728 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.59, df = 23 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 0.33, df = 3 (P = 0.95), I2 =0.0%
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Analysis 1.10. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 10 All-cause mortality - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 10 All-cause mortality - subgroup by age








1 Mean age < 50 years
Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
Sydney Diet-Heart 1978 38/221 27/237 4.1 % 1.51 [ 0.95, 2.39 ]
Subtotal (95% CI) 973 879 4.5 % 1.47 [ 0.95, 2.27 ]
Total events: 44 (Higher PUFA), 30 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.16, df = 5 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
2 Mean age 50 to < 65 years
Black 1994 2/67 1/66 0.2 % 1.97 [ 0.18, 21.21 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 111/1018 113/1015 14.0 % 0.98 [ 0.76, 1.25 ]
DIPP-Tokudome 2015 2/104 3/101 0.3 % 0.65 [ 0.11, 3.79 ]
HARP- Sacks 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Ley 2004 2/70 1/66 0.2 % 1.89 [ 0.18, 20.31 ]
McIllmurray 1987 10/25 12/24 2.2 % 0.80 [ 0.43, 1.49 ]
MRC 1968 28/199 31/194 3.9 % 0.88 [ 0.55, 1.41 ]
Raitt 2005 4/100 10/100 0.7 % 0.40 [ 0.13, 1.23 ]
Rose 1965 5/28 3/26 0.5 % 1.55 [ 0.41, 5.84 ]
Vijayakumar 2014 0/100 2/100 0.1 % 0.20 [ 0.01, 4.11 ]
WINS 2006 19/1462 15/975 1.9 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 3294 2746 24.0 % 0.91 [ 0.75, 1.10 ]
Total events: 183 (Higher PUFA), 193 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.61, df = 11 (P = 0.83); I2 =0.0%
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Test for overall effect: Z = 1.00 (P = 0.32)
3 Mean age 65+ years
AlphaOmega - ALA 182/2409 188/2428 22.3 % 0.98 [ 0.80, 1.19 ]
Doi 2014 2/119 9/119 0.4 % 0.22 [ 0.05, 1.01 ]
FAAT - Leaf 2005 13/200 12/202 1.5 % 1.09 [ 0.51, 2.34 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
PREDIMED 2013 116/2454 118/2543 13.7 % 1.02 [ 0.79, 1.31 ]
Veterans Admin 1969 174/424 177/422 33.5 % 0.98 [ 0.83, 1.15 ]
Subtotal (95% CI) 5645 5753 71.5 % 0.98 [ 0.88, 1.09 ]
Total events: 488 (Higher PUFA), 505 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.89, df = 5 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 9912 9378 100.0 % 0.98 [ 0.89, 1.07 ]
Total events: 715 (Higher PUFA), 728 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.59, df = 23 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 3.94, df = 2 (P = 0.14), I2 =49%
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Analysis 1.11. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 11 All-cause mortality - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 11 All-cause mortality - subgroup by statin use








1 < 50% on statins
Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
Black 1994 2/67 1/66 0.2 % 1.97 [ 0.18, 21.21 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 111/1018 113/1015 14.0 % 0.98 [ 0.76, 1.25 ]
DIPP-Tokudome 2015 2/104 3/101 0.3 % 0.65 [ 0.11, 3.79 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
HARP- Sacks 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
McIllmurray 1987 10/25 12/24 2.2 % 0.80 [ 0.43, 1.49 ]
MRC 1968 28/199 31/194 3.9 % 0.88 [ 0.55, 1.41 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
PREDIMED 2013 116/2454 118/2543 13.7 % 1.02 [ 0.79, 1.31 ]
Raitt 2005 4/100 10/100 0.7 % 0.40 [ 0.13, 1.23 ]
Rose 1965 5/28 3/26 0.5 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 38/221 27/237 4.1 % 1.51 [ 0.95, 2.39 ]
Veterans Admin 1969 174/424 177/422 33.5 % 0.98 [ 0.83, 1.15 ]
WINS 2006 19/1462 15/975 1.9 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 6975 6424 75.4 % 0.99 [ 0.89, 1.10 ]
Total events: 515 (Higher PUFA), 515 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.42, df = 17 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
2 50+% on statins
AlphaOmega - ALA 182/2409 188/2428 22.3 % 0.98 [ 0.80, 1.19 ]
Doi 2014 2/119 9/119 0.4 % 0.22 [ 0.05, 1.01 ]
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Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
Vijayakumar 2014 0/100 2/100 0.1 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 2667 2686 22.9 % 0.62 [ 0.26, 1.51 ]
Total events: 185 (Higher PUFA), 200 (Lower PUFA)
Heterogeneity: Tau2 = 0.32; Chi2 = 4.67, df = 3 (P = 0.20); I2 =36%
Test for overall effect: Z = 1.04 (P = 0.30)
3 Percentage on statins unclear
FAAT - Leaf 2005 13/200 12/202 1.5 % 1.09 [ 0.51, 2.34 ]
Ley 2004 2/70 1/66 0.2 % 1.89 [ 0.18, 20.31 ]
Subtotal (95% CI) 270 268 1.6 % 1.15 [ 0.56, 2.37 ]
Total events: 15 (Higher PUFA), 13 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Total (95% CI) 9912 9378 100.0 % 0.98 [ 0.89, 1.07 ]
Total events: 715 (Higher PUFA), 728 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.59, df = 23 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 1.20, df = 2 (P = 0.55), I2 =0.0%
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Analysis 1.12. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 12 All-cause mortality - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 12 All-cause mortality - subgroup by intervention type









Black 1994 2/67 1/66 0.2 % 1.97 [ 0.18, 21.21 ]
DART fat 1989 111/1018 113/1015 14.0 % 0.98 [ 0.76, 1.25 ]
Ley 2004 2/70 1/66 0.2 % 1.89 [ 0.18, 20.31 ]
WINS 2006 19/1462 15/975 1.9 % 0.84 [ 0.43, 1.65 ]
Subtotal (95% CI) 2617 2122 16.2 % 0.97 [ 0.77, 1.23 ]
Total events: 134 (Higher PUFA), 130 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.81, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
2 Supplemental foods % diet provided
AlphaOmega - ALA 182/2409 188/2428 22.3 % 0.98 [ 0.80, 1.19 ]
NDHS Faribault 1968 4/167 0/57 0.1 % 3.11 [ 0.17, 56.84 ]
PREDIMED 2013 116/2454 118/2543 13.7 % 1.02 [ 0.79, 1.31 ]
Veterans Admin 1969 174/424 177/422 33.5 % 0.98 [ 0.83, 1.15 ]
Vijayakumar 2014 0/100 2/100 0.1 % 0.20 [ 0.01, 4.11 ]
Subtotal (95% CI) 5554 5550 69.7 % 0.98 [ 0.88, 1.10 ]
Total events: 476 (Higher PUFA), 485 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.75, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
3 Supplements (capsules % unusual foods)
Bates 1978 0/58 2/58 0.1 % 0.20 [ 0.01, 4.08 ]
Bates 1989 1/155 0/157 0.1 % 3.04 [ 0.12, 74.02 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
Doi 2014 2/119 9/119 0.4 % 0.22 [ 0.05, 1.01 ]
EPIC-1 2008 1/183 0/180 0.1 % 2.95 [ 0.12, 71.97 ]
EPIC-2 2008 0/189 1/190 0.1 % 0.34 [ 0.01, 8.17 ]
FAAT - Leaf 2005 13/200 12/202 1.5 % 1.09 [ 0.51, 2.34 ]
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HARP- Sacks 1995 0/41 1/39 0.1 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
McIllmurray 1987 10/25 12/24 2.2 % 0.80 [ 0.43, 1.49 ]
Raitt 2005 4/100 10/100 0.7 % 0.40 [ 0.13, 1.23 ]
Rose 1965 5/28 3/26 0.5 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 1217 1174 5.8 % 0.76 [ 0.52, 1.11 ]
Total events: 37 (Higher PUFA), 52 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.53, df = 11 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
4 Any combination
DIPP-Tokudome 2015 2/104 3/101 0.3 % 0.65 [ 0.11, 3.79 ]
MRC 1968 28/199 31/194 3.9 % 0.88 [ 0.55, 1.41 ]
Sydney Diet-Heart 1978 38/221 27/237 4.1 % 1.51 [ 0.95, 2.39 ]
Subtotal (95% CI) 524 532 8.2 % 1.12 [ 0.72, 1.74 ]
Total events: 68 (Higher PUFA), 61 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 2.99, df = 2 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.50 (P = 0.62)
Total (95% CI) 9912 9378 100.0 % 0.98 [ 0.89, 1.07 ]
Total events: 715 (Higher PUFA), 728 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 17.59, df = 23 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 2.11, df = 3 (P = 0.55), I2 =0.0%
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Analysis 1.13. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 13 CORONARY HEART DISEASE (CHD) EVENTS: myocardial infarction (fatal or non-
fatal) or angina.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 13 CORONARY HEART DISEASE (CHD) EVENTS: myocardial infarction (fatal or non-fatal) or angina








AlphaOmega - ALA 121/2409 133/2428 17.5 % 0.92 [ 0.72, 1.17 ]
Brox 2001 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 339/1018 364/1015 21.8 % 0.93 [ 0.82, 1.05 ]
Doi 2014 (1) 1/119 0/119 0.4 % 3.00 [ 0.12, 72.91 ]
EPOCH 2011 (2) 1/195 0/196 0.4 % 3.02 [ 0.12, 73.57 ]
GLAMT 1993 0/54 1/57 0.4 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 3.6 % 0.95 [ 0.37, 2.46 ]
Houtsmuller 1979 8/51 30/51 6.2 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 13.9 % 0.97 [ 0.69, 1.37 ]
Nye 1990 (3) 5/36 11/37 3.6 % 0.47 [ 0.18, 1.21 ]
Proudman 2015 (4) 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (5) 1/100 3/100 0.7 % 0.33 [ 0.04, 3.15 ]
Rose 1965 12/28 9/26 6.2 % 1.24 [ 0.63, 2.44 ]
Sydney Diet-Heart 1978 35/221 23/237 9.5 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 15.0 % 0.77 [ 0.56, 1.04 ]
Total (95% CI) 5062 5014 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 641 (Higher PUFA), 710 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 25.69, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 14 CHD events - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 14 CHD events - SA








1 Low risk of bias for allocation concealment
AlphaOmega - ALA 121/2409 133/2428 57.2 % 0.92 [ 0.72, 1.17 ]
Brox 2001 (1) 0/80 1/40 1.9 % 0.17 [ 0.01, 4.05 ]
EPOCH 2011 (2) 1/195 0/196 1.9 % 3.02 [ 0.12, 73.57 ]
Proudman 2015 (3) 1/87 0/53 1.9 % 1.84 [ 0.08, 44.38 ]
Sydney Diet-Heart 1978 35/221 23/237 37.2 % 1.63 [ 1.00, 2.67 ]
Subtotal (95% CI) 2992 2954 100.0 % 1.14 [ 0.73, 1.78 ]
Total events: 158 (Higher PUFA), 157 (Lower PUFA)
Heterogeneity: Tau2 = 0.07; Chi2 = 6.05, df = 4 (P = 0.20); I2 =34%
Test for overall effect: Z = 0.58 (P = 0.56)
2 Low risk of bias for attention
AlphaOmega - ALA 121/2409 133/2428 52.8 % 0.92 [ 0.72, 1.17 ]
Brox 2001 (4) 0/80 1/40 0.3 % 0.17 [ 0.01, 4.05 ]
Doi 2014 (5) 1/119 0/119 0.3 % 3.00 [ 0.12, 72.91 ]
EPOCH 2011 (6) 1/195 0/196 0.3 % 3.02 [ 0.12, 73.57 ]
GLAMT 1993 0/54 1/57 0.3 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 3.3 % 0.95 [ 0.37, 2.46 ]
Nye 1990 (7) 5/36 11/37 3.3 % 0.47 [ 0.18, 1.21 ]
Proudman 2015 (8) 1/87 0/53 0.3 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (9) 1/100 3/100 0.6 % 0.33 [ 0.04, 3.15 ]
Rose 1965 12/28 9/26 6.6 % 1.24 [ 0.63, 2.44 ]
Veterans Admin 1969 60/424 78/422 31.9 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 3573 3517 100.0 % 0.86 [ 0.72, 1.02 ]
Total events: 209 (Higher PUFA), 243 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.95, df = 10 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.090)
3 Low risk of bias for compliance
Brox 2001 (10) 0/80 1/40 0.8 % 0.17 [ 0.01, 4.05 ]
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DART fat 1989 339/1018 364/1015 24.3 % 0.93 [ 0.82, 1.05 ]
Houtsmuller 1979 8/51 30/51 10.8 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 18.9 % 0.97 [ 0.69, 1.37 ]
Rose 1965 12/28 9/26 10.7 % 1.24 [ 0.63, 2.44 ]
Sydney Diet-Heart 1978 35/221 23/237 14.7 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 19.8 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 2021 1985 100.0 % 0.87 [ 0.65, 1.17 ]
Total events: 504 (Higher PUFA), 555 (Lower PUFA)
Heterogeneity: Tau2 = 0.09; Chi2 = 21.41, df = 6 (P = 0.002); I2 =72%
Test for overall effect: Z = 0.92 (P = 0.36)
4 Low summary risk of bias
AlphaOmega - ALA 121/2409 133/2428 59.1 % 0.92 [ 0.72, 1.17 ]
EPOCH 2011 (11) 1/195 0/196 1.8 % 3.02 [ 0.12, 73.57 ]
Proudman 2015 (12) 1/87 0/53 1.8 % 1.84 [ 0.08, 44.38 ]
Sydney Diet-Heart 1978 35/221 23/237 37.3 % 1.63 [ 1.00, 2.67 ]
Subtotal (95% CI) 2912 2914 100.0 % 1.18 [ 0.76, 1.81 ]
Total events: 158 (Higher PUFA), 156 (Lower PUFA)
Heterogeneity: Tau2 = 0.07; Chi2 = 4.81, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 0.73 (P = 0.46)
5 Trials registry or pre-2010
AlphaOmega - ALA 121/2409 133/2428 17.5 % 0.92 [ 0.72, 1.17 ]
Brox 2001 (13) 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 339/1018 364/1015 21.8 % 0.93 [ 0.82, 1.05 ]
Doi 2014 (14) 1/119 0/119 0.4 % 3.00 [ 0.12, 72.91 ]
EPOCH 2011 (15) 1/195 0/196 0.4 % 3.02 [ 0.12, 73.57 ]
GLAMT 1993 0/54 1/57 0.4 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 3.6 % 0.95 [ 0.37, 2.46 ]
Houtsmuller 1979 8/51 30/51 6.2 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 13.9 % 0.97 [ 0.69, 1.37 ]
Nye 1990 (16) 5/36 11/37 3.6 % 0.47 [ 0.18, 1.21 ]
Proudman 2015 (17) 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (18) 1/100 3/100 0.7 % 0.33 [ 0.04, 3.15 ]
Rose 1965 12/28 9/26 6.2 % 1.24 [ 0.63, 2.44 ]
Sydney Diet-Heart 1978 35/221 23/237 9.5 % 1.63 [ 1.00, 2.67 ]
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Veterans Admin 1969 60/424 78/422 15.0 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 5062 5014 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 641 (Higher PUFA), 710 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 25.69, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 1.35 (P = 0.18)
6 No industry funding
Brox 2001 (19) 0/80 1/40 5.6 % 0.17 [ 0.01, 4.05 ]
Houtsmuller 1979 8/51 30/51 28.8 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 33.8 % 0.97 [ 0.69, 1.37 ]
Sydney Diet-Heart 1978 35/221 23/237 31.7 % 1.63 [ 1.00, 2.67 ]
Subtotal (95% CI) 551 522 100.0 % 0.72 [ 0.31, 1.63 ]
Total events: 93 (Higher PUFA), 104 (Lower PUFA)
Heterogeneity: Tau2 = 0.49; Chi2 = 19.31, df = 3 (P = 0.00024); I2 =84%
Test for overall effect: Z = 0.80 (P = 0.42)
7 Randomised 100+ participants
AlphaOmega - ALA 121/2409 133/2428 20.0 % 0.92 [ 0.72, 1.17 ]
Brox 2001 (20) 0/80 1/40 0.5 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 339/1018 364/1015 24.4 % 0.93 [ 0.82, 1.05 ]
Doi 2014 (21) 1/119 0/119 0.5 % 3.00 [ 0.12, 72.91 ]
EPOCH 2011 (22) 1/195 0/196 0.5 % 3.02 [ 0.12, 73.57 ]
GLAMT 1993 0/54 1/57 0.5 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 8/51 30/51 7.5 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 16.2 % 0.97 [ 0.69, 1.37 ]
Proudman 2015 (23) 1/87 0/53 0.5 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (24) 1/100 3/100 0.9 % 0.33 [ 0.04, 3.15 ]
Sydney Diet-Heart 1978 35/221 23/237 11.3 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 17.3 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 4957 4912 100.0 % 0.87 [ 0.70, 1.08 ]
Total events: 617 (Higher PUFA), 683 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 22.99, df = 11 (P = 0.02); I2 =52%
Test for overall effect: Z = 1.25 (P = 0.21)
8 Randomised 250+ participants
AlphaOmega - ALA 121/2409 133/2428 22.0 % 0.92 [ 0.72, 1.17 ]
DART fat 1989 339/1018 364/1015 41.5 % 0.93 [ 0.82, 1.05 ]
EPOCH 2011 (25) 1/195 0/196 0.2 % 3.02 [ 0.12, 73.57 ]
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MRC 1968 50/199 50/194 13.5 % 0.97 [ 0.69, 1.37 ]
Sydney Diet-Heart 1978 35/221 23/237 7.3 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 15.6 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 4466 4492 100.0 % 0.94 [ 0.82, 1.09 ]
Total events: 606 (Higher PUFA), 648 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.13, df = 5 (P = 0.21); I2 =30%
Test for overall effect: Z = 0.79 (P = 0.43)
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Analysis 1.15. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 15 CHD events - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 15 CHD events - SA fixed-effect
Study or subgroup Higher PUFA Lower PUFA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - ALA 121/2409 133/2428 18.6 % 0.92 [ 0.72, 1.17 ]
Brox 2001 (1) 0/80 1/40 0.3 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 339/1018 364/1015 51.1 % 0.93 [ 0.82, 1.05 ]
Doi 2014 (2) 1/119 0/119 0.1 % 3.00 [ 0.12, 72.91 ]
EPOCH 2011 (3) 1/195 0/196 0.1 % 3.02 [ 0.12, 73.57 ]
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 1.0 % 0.95 [ 0.37, 2.46 ]
Houtsmuller 1979 8/51 30/51 4.2 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 7.1 % 0.97 [ 0.69, 1.37 ]
Nye 1990 (4) 5/36 11/37 1.5 % 0.47 [ 0.18, 1.21 ]
Proudman 2015 (5) 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (6) 1/100 3/100 0.4 % 0.33 [ 0.04, 3.15 ]
Rose 1965 12/28 9/26 1.3 % 1.24 [ 0.63, 2.44 ]
Sydney Diet-Heart 1978 35/221 23/237 3.1 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 11.0 % 0.77 [ 0.56, 1.04 ]
Total (95% CI) 5062 5014 100.0 % 0.90 [ 0.82, 0.99 ]
Total events: 641 (Higher PUFA), 710 (Lower PUFA)
Heterogeneity: Chi2 = 25.69, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 16 CHD events - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 16 CHD events - subgroup by PUFA dose








1 total PUFA < 1.0% E
Doi 2014 (1) 1/119 0/119 0.4 % 3.00 [ 0.12, 72.91 ]
EPOCH 2011 (2) 1/195 0/196 0.4 % 3.02 [ 0.12, 73.57 ]
Raitt 2005 (3) 1/100 3/100 0.7 % 0.33 [ 0.04, 3.15 ]
Subtotal (95% CI) 414 415 1.5 % 1.00 [ 0.20, 4.89 ]
Total events: 3 (Higher PUFA), 3 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.83, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 1.0)
2 total PUFA 1.0 to < 2.0% E
AlphaOmega - ALA 121/2409 133/2428 17.5 % 0.92 [ 0.72, 1.17 ]
Brox 2001 (4) 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
Nye 1990 (5) 5/36 11/37 3.6 % 0.47 [ 0.18, 1.21 ]
Proudman 2015 (6) 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 2612 2558 21.9 % 0.86 [ 0.66, 1.13 ]
Total events: 127 (Higher PUFA), 145 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 1.07 (P = 0.29)
3 total PUFA 2.0 to < 5.0% E
DART fat 1989 339/1018 364/1015 21.8 % 0.93 [ 0.82, 1.05 ]
GLAMT 1993 0/54 1/57 0.4 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 3.6 % 0.95 [ 0.37, 2.46 ]
Subtotal (95% CI) 1113 1111 25.8 % 0.93 [ 0.82, 1.04 ]
Total events: 346 (Higher PUFA), 372 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
4 total PUFA > 5.0% E
Houtsmuller 1979 8/51 30/51 6.2 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 13.9 % 0.97 [ 0.69, 1.37 ]
Rose 1965 12/28 9/26 6.2 % 1.24 [ 0.63, 2.44 ]
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Sydney Diet-Heart 1978 35/221 23/237 9.5 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 15.0 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 923 930 50.8 % 0.86 [ 0.54, 1.36 ]
Total events: 165 (Higher PUFA), 190 (Lower PUFA)
Heterogeneity: Tau2 = 0.21; Chi2 = 20.13, df = 4 (P = 0.00047); I2 =80%
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 5062 5014 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 641 (Higher PUFA), 710 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 25.69, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 0.32, df = 3 (P = 0.96), I2 =0.0%
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Analysis 1.17. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 17 CHD events - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 17 CHD events - subgroup by duration








1 Medium duration 1 to < 2 years
Brox 2001 (1) 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
Doi 2014 (2) 1/119 0/119 0.4 % 3.00 [ 0.12, 72.91 ]
EPOCH 2011 (3) 1/195 0/196 0.4 % 3.02 [ 0.12, 73.57 ]
GLAMT 1993 0/54 1/57 0.4 % 0.35 [ 0.01, 8.45 ]
Nye 1990 (4) 5/36 11/37 3.6 % 0.47 [ 0.18, 1.21 ]
Proudman 2015 (5) 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 571 502 5.5 % 0.59 [ 0.27, 1.30 ]
Total events: 8 (Higher PUFA), 13 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.45, df = 5 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
2 Medium-long duration 2 to < 4 years
AlphaOmega - ALA 121/2409 133/2428 17.5 % 0.92 [ 0.72, 1.17 ]
DART fat 1989 339/1018 364/1015 21.8 % 0.93 [ 0.82, 1.05 ]
HARP- Sacks 1995 7/41 7/39 3.6 % 0.95 [ 0.37, 2.46 ]
Raitt 2005 (6) 1/100 3/100 0.7 % 0.33 [ 0.04, 3.15 ]
Rose 1965 12/28 9/26 6.2 % 1.24 [ 0.63, 2.44 ]
Subtotal (95% CI) 3596 3608 49.9 % 0.93 [ 0.84, 1.03 ]
Total events: 480 (Higher PUFA), 516 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.50, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
3 Long duration 4+ years
Houtsmuller 1979 8/51 30/51 6.2 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 13.9 % 0.97 [ 0.69, 1.37 ]
Sydney Diet-Heart 1978 35/221 23/237 9.5 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 15.0 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 895 904 44.6 % 0.79 [ 0.46, 1.35 ]
Total events: 153 (Higher PUFA), 181 (Lower PUFA)
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Heterogeneity: Tau2 = 0.24; Chi2 = 19.08, df = 3 (P = 0.00026); I2 =84%
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 5062 5014 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 641 (Higher PUFA), 710 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 25.69, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 1.56, df = 2 (P = 0.46), I2 =0.0%
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Analysis 1.18. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 18 CHD events - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 18 CHD events - subgroup by primary or secondary prevention








1 Primary prevention of CVD
Brox 2001 (1) 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
EPOCH 2011 (2) 1/195 0/196 0.4 % 3.02 [ 0.12, 73.57 ]
GLAMT 1993 0/54 1/57 0.4 % 0.35 [ 0.01, 8.45 ]
Houtsmuller 1979 8/51 30/51 6.2 % 0.27 [ 0.14, 0.52 ]
Proudman 2015 (3) 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Veterans Admin 1969 60/424 78/422 15.0 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 891 819 22.7 % 0.53 [ 0.25, 1.11 ]
Total events: 70 (Higher PUFA), 110 (Lower PUFA)
Heterogeneity: Tau2 = 0.30; Chi2 = 9.88, df = 5 (P = 0.08); I2 =49%
Test for overall effect: Z = 1.68 (P = 0.094)
2 Secondary prevention of CVD
AlphaOmega - ALA 121/2409 133/2428 17.5 % 0.92 [ 0.72, 1.17 ]
DART fat 1989 339/1018 364/1015 21.8 % 0.93 [ 0.82, 1.05 ]
Doi 2014 (4) 1/119 0/119 0.4 % 3.00 [ 0.12, 72.91 ]
HARP- Sacks 1995 7/41 7/39 3.6 % 0.95 [ 0.37, 2.46 ]
MRC 1968 50/199 50/194 13.9 % 0.97 [ 0.69, 1.37 ]
Nye 1990 (5) 5/36 11/37 3.6 % 0.47 [ 0.18, 1.21 ]
Raitt 2005 (6) 1/100 3/100 0.7 % 0.33 [ 0.04, 3.15 ]
Rose 1965 12/28 9/26 6.2 % 1.24 [ 0.63, 2.44 ]
Sydney Diet-Heart 1978 35/221 23/237 9.5 % 1.63 [ 1.00, 2.67 ]
Subtotal (95% CI) 4171 4195 77.3 % 0.96 [ 0.85, 1.09 ]
Total events: 571 (Higher PUFA), 600 (Lower PUFA)
Heterogeneity: Tau2 = 0.00; Chi2 = 8.92, df = 8 (P = 0.35); I2 =10%
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 5062 5014 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 641 (Higher PUFA), 710 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 25.69, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 2.41, df = 1 (P = 0.12), I2 =58%
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Analysis 1.19. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 19 CHD events - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 19 CHD events - subgroup by baseline PUFA dose








1 Baseline total PUFA < 6% E
Veterans Admin 1969 60/424 78/422 15.0 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 424 422 15.0 % 0.77 [ 0.56, 1.04 ]
Total events: 60 (Higher PUFA), 78 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.090)
2 Baseline total PUFA 6 to < 11% E
DART fat 1989 339/1018 364/1015 21.8 % 0.93 [ 0.82, 1.05 ]
Sydney Diet-Heart 1978 35/221 23/237 9.5 % 1.63 [ 1.00, 2.67 ]
Subtotal (95% CI) 1239 1252 31.3 % 1.17 [ 0.68, 2.01 ]
Total events: 374 (Higher PUFA), 387 (Lower PUFA)
Heterogeneity: Tau2 = 0.13; Chi2 = 4.78, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.56 (P = 0.58)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
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4 Baseline total PUFA unclear
AlphaOmega - ALA 121/2409 133/2428 17.5 % 0.92 [ 0.72, 1.17 ]
Brox 2001 (1) 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
Doi 2014 (2) 1/119 0/119 0.4 % 3.00 [ 0.12, 72.91 ]
EPOCH 2011 (3) 1/195 0/196 0.4 % 3.02 [ 0.12, 73.57 ]
GLAMT 1993 0/54 1/57 0.4 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 3.6 % 0.95 [ 0.37, 2.46 ]
Houtsmuller 1979 8/51 30/51 6.2 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 13.9 % 0.97 [ 0.69, 1.37 ]
Nye 1990 (4) 5/36 11/37 3.6 % 0.47 [ 0.18, 1.21 ]
Proudman 2015 (5) 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (6) 1/100 3/100 0.7 % 0.33 [ 0.04, 3.15 ]
Rose 1965 12/28 9/26 6.2 % 1.24 [ 0.63, 2.44 ]
Subtotal (95% CI) 3399 3340 53.7 % 0.77 [ 0.55, 1.06 ]
Total events: 207 (Higher PUFA), 245 (Lower PUFA)
Heterogeneity: Tau2 = 0.09; Chi2 = 18.47, df = 11 (P = 0.07); I2 =40%
Test for overall effect: Z = 1.60 (P = 0.11)
Total (95% CI) 5062 5014 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 641 (Higher PUFA), 710 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 25.69, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 1.97, df = 2 (P = 0.37), I2 =0.0%
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Analysis 1.20. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 20 CHD events - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 20 CHD events - subgroup by replacement








1 PUFA replaced saturated fats
DART fat 1989 339/1018 364/1015 41.6 % 0.93 [ 0.82, 1.05 ]
MRC 1968 50/199 50/194 21.5 % 0.97 [ 0.69, 1.37 ]
Sydney Diet-Heart 1978 35/221 23/237 13.3 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 23.7 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 1862 1868 100.0 % 0.97 [ 0.78, 1.19 ]
Total events: 484 (Higher PUFA), 515 (Lower PUFA)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.59, df = 3 (P = 0.09); I2 =54%
Test for overall effect: Z = 0.32 (P = 0.75)
2 PUFA replaced monounsaturated fats
AlphaOmega - ALA 121/2409 133/2428 33.6 % 0.92 [ 0.72, 1.17 ]
EPOCH 2011 (1) 1/195 0/196 0.5 % 3.02 [ 0.12, 73.57 ]
HARP- Sacks 1995 7/41 7/39 5.5 % 0.95 [ 0.37, 2.46 ]
Nye 1990 (2) 5/36 11/37 5.5 % 0.47 [ 0.18, 1.21 ]
Proudman 2015 (3) 1/87 0/53 0.5 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (4) 1/100 3/100 1.1 % 0.33 [ 0.04, 3.15 ]
Rose 1965 12/28 9/26 9.8 % 1.24 [ 0.63, 2.44 ]
Sydney Diet-Heart 1978 35/221 23/237 15.9 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 27.4 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 3541 3538 100.0 % 0.95 [ 0.75, 1.20 ]
Total events: 243 (Higher PUFA), 264 (Lower PUFA)
Heterogeneity: Tau2 = 0.03; Chi2 = 10.73, df = 8 (P = 0.22); I2 =25%
Test for overall effect: Z = 0.42 (P = 0.67)
3 PUFA replaced carbohydrate
Houtsmuller 1979 8/51 30/51 50.0 % 0.27 [ 0.14, 0.52 ]
Rose 1965 12/28 9/26 50.0 % 1.24 [ 0.63, 2.44 ]
Subtotal (95% CI) 79 77 100.0 % 0.57 [ 0.12, 2.65 ]
Total events: 20 (Higher PUFA), 39 (Lower PUFA)
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Heterogeneity: Tau2 = 1.10; Chi2 = 10.18, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 0.71 (P = 0.48)
4 PUFA replaced protein
MRC 1968 50/199 50/194 100.0 % 0.97 [ 0.69, 1.37 ]
Subtotal (95% CI) 199 194 100.0 % 0.97 [ 0.69, 1.37 ]
Total events: 50 (Higher PUFA), 50 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
5 PUFA replaced unclear
Brox 2001 (5) 0/80 1/40 33.4 % 0.17 [ 0.01, 4.05 ]
Doi 2014 (6) 1/119 0/119 33.2 % 3.00 [ 0.12, 72.91 ]
GLAMT 1993 0/54 1/57 33.4 % 0.35 [ 0.01, 8.45 ]
Subtotal (95% CI) 253 216 100.0 % 0.56 [ 0.09, 3.52 ]
Total events: 1 (Higher PUFA), 2 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.70, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Chi2 = 0.78, df = 4 (P = 0.94), I2 =0.0%
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Analysis 1.21. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 21 CHD events - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 21 CHD events - subgroup by sex








1 > 70% men
AlphaOmega - ALA 121/2409 133/2428 17.5 % 0.92 [ 0.72, 1.17 ]
DART fat 1989 339/1018 364/1015 21.8 % 0.93 [ 0.82, 1.05 ]
Doi 2014 (1) 1/119 0/119 0.4 % 3.00 [ 0.12, 72.91 ]
GLAMT 1993 0/54 1/57 0.4 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 3.6 % 0.95 [ 0.37, 2.46 ]
MRC 1968 50/199 50/194 13.9 % 0.97 [ 0.69, 1.37 ]
Nye 1990 (2) 5/36 11/37 3.6 % 0.47 [ 0.18, 1.21 ]
Raitt 2005 (3) 1/100 3/100 0.7 % 0.33 [ 0.04, 3.15 ]
Sydney Diet-Heart 1978 35/221 23/237 9.5 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 15.0 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 4621 4648 86.5 % 0.93 [ 0.82, 1.05 ]
Total events: 619 (Higher PUFA), 670 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 10.29, df = 9 (P = 0.33); I2 =13%
Test for overall effect: Z = 1.23 (P = 0.22)
2 > 70% women
Proudman 2015 (4) 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 87 53 0.4 % 1.84 [ 0.08, 44.38 ]
Total events: 1 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
3 men % women
Brox 2001 (5) 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
Houtsmuller 1979 8/51 30/51 6.2 % 0.27 [ 0.14, 0.52 ]
Subtotal (95% CI) 131 91 6.6 % 0.26 [ 0.13, 0.51 ]
Total events: 8 (Higher PUFA), 31 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.97 (P = 0.000071)
4 sex not reported
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EPOCH 2011 (6) 1/195 0/196 0.4 % 3.02 [ 0.12, 73.57 ]
Rose 1965 12/28 9/26 6.2 % 1.24 [ 0.63, 2.44 ]
Subtotal (95% CI) 223 222 6.5 % 1.29 [ 0.66, 2.50 ]
Total events: 13 (Higher PUFA), 9 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 5062 5014 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 641 (Higher PUFA), 710 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 25.69, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 14.91, df = 3 (P = 0.00), I2 =80%
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Analysis 1.22. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 22 CHD events - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 22 CHD events - subgroup by age








1 Mean age < 50 years
Sydney Diet-Heart 1978 35/221 23/237 9.5 % 1.63 [ 1.00, 2.67 ]
Subtotal (95% CI) 221 237 9.5 % 1.63 [ 1.00, 2.67 ]
Total events: 35 (Higher PUFA), 23 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.052)
2 Mean age 50 to < 65 years
Brox 2001 (1) 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 339/1018 364/1015 21.8 % 0.93 [ 0.82, 1.05 ]
GLAMT 1993 0/54 1/57 0.4 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 3.6 % 0.95 [ 0.37, 2.46 ]
MRC 1968 50/199 50/194 13.9 % 0.97 [ 0.69, 1.37 ]
Nye 1990 (2) 5/36 11/37 3.6 % 0.47 [ 0.18, 1.21 ]
Proudman 2015 (3) 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (4) 1/100 3/100 0.7 % 0.33 [ 0.04, 3.15 ]
Rose 1965 12/28 9/26 6.2 % 1.24 [ 0.63, 2.44 ]
Subtotal (95% CI) 1643 1561 51.0 % 0.93 [ 0.83, 1.03 ]
Total events: 415 (Higher PUFA), 446 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.22, df = 8 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
3 Mean age 65+ years
AlphaOmega - ALA 121/2409 133/2428 17.5 % 0.92 [ 0.72, 1.17 ]
Doi 2014 (5) 1/119 0/119 0.4 % 3.00 [ 0.12, 72.91 ]
Veterans Admin 1969 60/424 78/422 15.0 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 2952 2969 32.9 % 0.86 [ 0.71, 1.04 ]
Total events: 182 (Higher PUFA), 211 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.41, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
4 Mean age unclear
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EPOCH 2011 (6) 1/195 0/196 0.4 % 3.02 [ 0.12, 73.57 ]
Houtsmuller 1979 8/51 30/51 6.2 % 0.27 [ 0.14, 0.52 ]
Subtotal (95% CI) 246 247 6.6 % 0.53 [ 0.06, 4.64 ]
Total events: 9 (Higher PUFA), 30 (Lower PUFA)
Heterogeneity: Tau2 = 1.59; Chi2 = 2.14, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 5062 5014 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 641 (Higher PUFA), 710 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 25.69, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 5.90, df = 3 (P = 0.12), I2 =49%
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Analysis 1.23. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 23 CHD events - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 23 CHD events - subgroup by statin use








1 < 50% on statins
Brox 2001 (1) 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 339/1018 364/1015 21.8 % 0.93 [ 0.82, 1.05 ]
EPOCH 2011 (2) 1/195 0/196 0.4 % 3.02 [ 0.12, 73.57 ]
GLAMT 1993 0/54 1/57 0.4 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 3.6 % 0.95 [ 0.37, 2.46 ]
Houtsmuller 1979 8/51 30/51 6.2 % 0.27 [ 0.14, 0.52 ]
MRC 1968 50/199 50/194 13.9 % 0.97 [ 0.69, 1.37 ]
Nye 1990 (3) 5/36 11/37 3.6 % 0.47 [ 0.18, 1.21 ]
Proudman 2015 (4) 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (5) 1/100 3/100 0.7 % 0.33 [ 0.04, 3.15 ]
Rose 1965 12/28 9/26 6.2 % 1.24 [ 0.63, 2.44 ]
Sydney Diet-Heart 1978 35/221 23/237 9.5 % 1.63 [ 1.00, 2.67 ]
Veterans Admin 1969 60/424 78/422 15.0 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 2534 2467 82.1 % 0.85 [ 0.66, 1.09 ]
Total events: 519 (Higher PUFA), 577 (Lower PUFA)
Heterogeneity: Tau2 = 0.07; Chi2 = 25.16, df = 12 (P = 0.01); I2 =52%
Test for overall effect: Z = 1.30 (P = 0.19)
2 50+% on statins
AlphaOmega - ALA 121/2409 133/2428 17.5 % 0.92 [ 0.72, 1.17 ]
Doi 2014 (6) 1/119 0/119 0.4 % 3.00 [ 0.12, 72.91 ]
Subtotal (95% CI) 2528 2547 17.9 % 0.92 [ 0.73, 1.17 ]
Total events: 122 (Higher PUFA), 133 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 5062 5014 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 641 (Higher PUFA), 710 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 25.69, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.63), I2 =0.0%
0.01 0.1 1 10 100
Favours higher PUFA Favours lower PUFA
270Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)







Analysis 1.24. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 24 CHD events - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 24 CHD events - subgroup by intervention type









DART fat 1989 339/1018 364/1015 21.8 % 0.93 [ 0.82, 1.05 ]
Houtsmuller 1979 8/51 30/51 6.2 % 0.27 [ 0.14, 0.52 ]
Subtotal (95% CI) 1069 1066 28.0 % 0.52 [ 0.15, 1.77 ]
Total events: 347 (Higher PUFA), 394 (Lower PUFA)
Heterogeneity: Tau2 = 0.72; Chi2 = 12.76, df = 1 (P = 0.00035); I2 =92%
Test for overall effect: Z = 1.04 (P = 0.30)
2 Supplemental foods % diet provided
AlphaOmega - ALA 121/2409 133/2428 17.5 % 0.92 [ 0.72, 1.17 ]
Veterans Admin 1969 60/424 78/422 15.0 % 0.77 [ 0.56, 1.04 ]
Subtotal (95% CI) 2833 2850 32.5 % 0.86 [ 0.71, 1.04 ]
Total events: 181 (Higher PUFA), 211 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
3 Supplements (capsules % unusual foods)
Brox 2001 (1) 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
Doi 2014 (2) 1/119 0/119 0.4 % 3.00 [ 0.12, 72.91 ]
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EPOCH 2011 (3) 1/195 0/196 0.4 % 3.02 [ 0.12, 73.57 ]
GLAMT 1993 0/54 1/57 0.4 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 3.6 % 0.95 [ 0.37, 2.46 ]
Nye 1990 (4) 5/36 11/37 3.6 % 0.47 [ 0.18, 1.21 ]
Proudman 2015 (5) 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (6) 1/100 3/100 0.7 % 0.33 [ 0.04, 3.15 ]
Rose 1965 12/28 9/26 6.2 % 1.24 [ 0.63, 2.44 ]
Subtotal (95% CI) 740 667 16.0 % 0.88 [ 0.56, 1.37 ]
Total events: 28 (Higher PUFA), 32 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.17, df = 8 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
4 Any combination
MRC 1968 50/199 50/194 13.9 % 0.97 [ 0.69, 1.37 ]
Sydney Diet-Heart 1978 35/221 23/237 9.5 % 1.63 [ 1.00, 2.67 ]
Subtotal (95% CI) 420 431 23.4 % 1.22 [ 0.74, 2.02 ]
Total events: 85 (Higher PUFA), 73 (Lower PUFA)
Heterogeneity: Tau2 = 0.09; Chi2 = 2.87, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 5062 5014 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 641 (Higher PUFA), 710 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 25.69, df = 14 (P = 0.03); I2 =45%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 2.41, df = 3 (P = 0.49), I2 =0.0%
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Analysis 1.25. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 25 STROKE - fatal & non fatal.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 25 STROKE - fatal % non fatal








AlphaOmega - ALA 10/2409 11/2428 17.5 % 0.92 [ 0.39, 2.15 ]
DART fat 1989 10/1018 3/1015 9.8 % 3.32 [ 0.92, 12.04 ]
Doi 2014 0/119 4/119 2.3 % 0.11 [ 0.01, 2.04 ]
EPOCH 2011 2/195 0/196 2.1 % 5.03 [ 0.24, 104.01 ]
HARP- Sacks 1995 1/41 0/39 2.0 % 2.86 [ 0.12, 68.10 ]
MRC 1968 2/199 0/194 2.1 % 4.88 [ 0.24, 100.89 ]
Nodari 2011 HF 0/67 1/66 2.0 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 2.1 % 4.83 [ 0.23, 99.76 ]
PREDIMED 2013 32/2454 49/2543 32.2 % 0.68 [ 0.43, 1.05 ]
Sydney Diet-Heart 1978 2/221 2/237 4.9 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 23.0 % 0.59 [ 0.30, 1.15 ]
Total (95% CI) 7318 7424 100.0 % 0.91 [ 0.58, 1.44 ]
Total events: 74 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Tau2 = 0.12; Chi2 = 13.10, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 1.26. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 26 Stroke - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 26 Stroke - SA








1 Low risk of bias for allocation concealment
AlphaOmega - ALA 10/2409 11/2428 74.0 % 0.92 [ 0.39, 2.15 ]
EPOCH 2011 2/195 0/196 5.9 % 5.03 [ 0.24, 104.01 ]
ORL 2013 2/171 0/165 5.9 % 4.83 [ 0.23, 99.76 ]
Sydney Diet-Heart 1978 2/221 2/237 14.2 % 1.07 [ 0.15, 7.55 ]
Subtotal (95% CI) 2996 3026 100.0 % 1.14 [ 0.55, 2.38 ]
Total events: 16 (Higher PUFA), 13 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.09, df = 3 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
2 Low risk of bias for attention
AlphaOmega - ALA 10/2409 11/2428 14.8 % 0.92 [ 0.39, 2.15 ]
Doi 2014 0/119 4/119 1.3 % 0.11 [ 0.01, 2.04 ]
EPOCH 2011 2/195 0/196 1.2 % 5.03 [ 0.24, 104.01 ]
HARP- Sacks 1995 1/41 0/39 1.1 % 2.86 [ 0.12, 68.10 ]
Nodari 2011 HF 0/67 1/66 1.1 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 1.2 % 4.83 [ 0.23, 99.76 ]
PREDIMED 2013 32/2454 49/2543 55.4 % 0.68 [ 0.43, 1.05 ]
Veterans Admin 1969 13/424 22/422 24.0 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 5880 5978 100.0 % 0.71 [ 0.51, 0.98 ]
Total events: 60 (Higher PUFA), 87 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.36, df = 7 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.038)
3 Low risk of bias for compliance
DART fat 1989 10/1018 3/1015 29.2 % 3.32 [ 0.92, 12.04 ]
MRC 1968 2/199 0/194 10.4 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 19.3 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 41.1 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 1862 1868 100.0 % 1.36 [ 0.45, 4.11 ]
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Total events: 27 (Higher PUFA), 27 (Lower PUFA)
Heterogeneity: Tau2 = 0.65; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.55 (P = 0.58)
4 Low summary risk of bias
AlphaOmega - ALA 10/2409 11/2428 78.7 % 0.92 [ 0.39, 2.15 ]
EPOCH 2011 2/195 0/196 6.3 % 5.03 [ 0.24, 104.01 ]
Sydney Diet-Heart 1978 2/221 2/237 15.1 % 1.07 [ 0.15, 7.55 ]
Subtotal (95% CI) 2825 2861 100.0 % 1.04 [ 0.49, 2.23 ]
Total events: 14 (Higher PUFA), 13 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
5 Trials registry or pre-2010
AlphaOmega - ALA 10/2409 11/2428 17.5 % 0.92 [ 0.39, 2.15 ]
DART fat 1989 10/1018 3/1015 9.8 % 3.32 [ 0.92, 12.04 ]
Doi 2014 0/119 4/119 2.3 % 0.11 [ 0.01, 2.04 ]
EPOCH 2011 2/195 0/196 2.1 % 5.03 [ 0.24, 104.01 ]
HARP- Sacks 1995 1/41 0/39 2.0 % 2.86 [ 0.12, 68.10 ]
MRC 1968 2/199 0/194 2.1 % 4.88 [ 0.24, 100.89 ]
Nodari 2011 HF 0/67 1/66 2.0 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 2.1 % 4.83 [ 0.23, 99.76 ]
PREDIMED 2013 32/2454 49/2543 32.2 % 0.68 [ 0.43, 1.05 ]
Sydney Diet-Heart 1978 2/221 2/237 4.9 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 23.0 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 7318 7424 100.0 % 0.91 [ 0.58, 1.44 ]
Total events: 74 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Tau2 = 0.12; Chi2 = 13.10, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 0.39 (P = 0.69)
6 No industry funding
MRC 1968 2/199 0/194 29.3 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 70.7 % 1.07 [ 0.15, 7.55 ]
Subtotal (95% CI) 420 431 100.0 % 1.67 [ 0.32, 8.62 ]
Total events: 4 (Higher PUFA), 2 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
7 Randomised 100+ participants
AlphaOmega - ALA 10/2409 11/2428 18.0 % 0.92 [ 0.39, 2.15 ]
DART fat 1989 10/1018 3/1015 10.3 % 3.32 [ 0.92, 12.04 ]
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Doi 2014 0/119 4/119 2.5 % 0.11 [ 0.01, 2.04 ]
EPOCH 2011 2/195 0/196 2.3 % 5.03 [ 0.24, 104.01 ]
MRC 1968 2/199 0/194 2.3 % 4.88 [ 0.24, 100.89 ]
Nodari 2011 HF 0/67 1/66 2.1 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 2.3 % 4.83 [ 0.23, 99.76 ]
PREDIMED 2013 32/2454 49/2543 31.7 % 0.68 [ 0.43, 1.05 ]
Sydney Diet-Heart 1978 2/221 2/237 5.2 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 23.2 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 7277 7385 100.0 % 0.90 [ 0.56, 1.45 ]
Total events: 73 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Tau2 = 0.13; Chi2 = 12.47, df = 9 (P = 0.19); I2 =28%
Test for overall effect: Z = 0.43 (P = 0.67)
8 Randomised 250+ participants
AlphaOmega - ALA 10/2409 11/2428 19.0 % 0.92 [ 0.39, 2.15 ]
DART fat 1989 10/1018 3/1015 10.9 % 3.32 [ 0.92, 12.04 ]
EPOCH 2011 2/195 0/196 2.5 % 5.03 [ 0.24, 104.01 ]
MRC 1968 2/199 0/194 2.5 % 4.88 [ 0.24, 100.89 ]
ORL 2013 2/171 0/165 2.5 % 4.83 [ 0.23, 99.76 ]
PREDIMED 2013 32/2454 49/2543 32.9 % 0.68 [ 0.43, 1.05 ]
Sydney Diet-Heart 1978 2/221 2/237 5.5 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 24.3 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 7091 7200 100.0 % 0.98 [ 0.60, 1.60 ]
Total events: 73 (Higher PUFA), 87 (Lower PUFA)
Heterogeneity: Tau2 = 0.14; Chi2 = 10.46, df = 7 (P = 0.16); I2 =33%
Test for overall effect: Z = 0.09 (P = 0.93)
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Analysis 1.27. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 27 Stroke - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 27 Stroke - SA fixed-effect
Study or subgroup Higher PUFA Lower PUFA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - ALA 10/2409 11/2428 11.6 % 0.92 [ 0.39, 2.15 ]
DART fat 1989 10/1018 3/1015 3.2 % 3.32 [ 0.92, 12.04 ]
Doi 2014 0/119 4/119 4.8 % 0.11 [ 0.01, 2.04 ]
EPOCH 2011 2/195 0/196 0.5 % 5.03 [ 0.24, 104.01 ]
HARP- Sacks 1995 1/41 0/39 0.5 % 2.86 [ 0.12, 68.10 ]
MRC 1968 2/199 0/194 0.5 % 4.88 [ 0.24, 100.89 ]
Nodari 2011 HF 0/67 1/66 1.6 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 0.5 % 4.83 [ 0.23, 99.76 ]
PREDIMED 2013 32/2454 49/2543 51.1 % 0.68 [ 0.43, 1.05 ]
Sydney Diet-Heart 1978 2/221 2/237 2.1 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 23.4 % 0.59 [ 0.30, 1.15 ]
Total (95% CI) 7318 7424 100.0 % 0.82 [ 0.61, 1.11 ]
Total events: 74 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Chi2 = 13.10, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.28. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 28 Stroke - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 28 Stroke - subgroup by PUFA dose








1 total PUFA < 1.0% E
Doi 2014 0/119 4/119 2.3 % 0.11 [ 0.01, 2.04 ]
EPOCH 2011 2/195 0/196 2.1 % 5.03 [ 0.24, 104.01 ]
Nodari 2011 HF 0/67 1/66 2.0 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 2.1 % 4.83 [ 0.23, 99.76 ]
Subtotal (95% CI) 552 546 8.6 % 0.96 [ 0.14, 6.55 ]
Total events: 4 (Higher PUFA), 5 (Lower PUFA)
Heterogeneity: Tau2 = 1.44; Chi2 = 4.80, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 0.04 (P = 0.97)
2 total PUFA 1.0 to < 2.0% E
AlphaOmega - ALA 10/2409 11/2428 17.5 % 0.92 [ 0.39, 2.15 ]
PREDIMED 2013 32/2454 49/2543 32.2 % 0.68 [ 0.43, 1.05 ]
Subtotal (95% CI) 4863 4971 49.7 % 0.72 [ 0.49, 1.07 ]
Total events: 42 (Higher PUFA), 60 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
3 total PUFA 2.0 to < 5.0% E
DART fat 1989 10/1018 3/1015 9.8 % 3.32 [ 0.92, 12.04 ]
HARP- Sacks 1995 1/41 0/39 2.0 % 2.86 [ 0.12, 68.10 ]
Subtotal (95% CI) 1059 1054 11.8 % 3.25 [ 0.99, 10.72 ]
Total events: 11 (Higher PUFA), 3 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.053)
4 total PUFA > 5.0% E
MRC 1968 2/199 0/194 2.1 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 4.9 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 23.0 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 844 853 30.0 % 0.69 [ 0.36, 1.33 ]
Total events: 17 (Higher PUFA), 24 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.03, df = 2 (P = 0.36); I2 =2%
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Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 7318 7424 100.0 % 0.91 [ 0.58, 1.44 ]
Total events: 74 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Tau2 = 0.12; Chi2 = 13.10, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Chi2 = 5.80, df = 3 (P = 0.12), I2 =48%
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Analysis 1.29. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 29 Stroke - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 29 Stroke - subgroup by duration








1 Medium duration 1 to < 2 years
Doi 2014 0/119 4/119 2.3 % 0.11 [ 0.01, 2.04 ]
EPOCH 2011 2/195 0/196 2.1 % 5.03 [ 0.24, 104.01 ]
Nodari 2011 HF 0/67 1/66 2.0 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 2.1 % 4.83 [ 0.23, 99.76 ]
Subtotal (95% CI) 552 546 8.6 % 0.96 [ 0.14, 6.55 ]
Total events: 4 (Higher PUFA), 5 (Lower PUFA)
Heterogeneity: Tau2 = 1.44; Chi2 = 4.80, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 0.04 (P = 0.97)
2 Medium-long duration 2 to < 4 years
AlphaOmega - ALA 10/2409 11/2428 17.5 % 0.92 [ 0.39, 2.15 ]
DART fat 1989 10/1018 3/1015 9.8 % 3.32 [ 0.92, 12.04 ]
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HARP- Sacks 1995 1/41 0/39 2.0 % 2.86 [ 0.12, 68.10 ]
Subtotal (95% CI) 3468 3482 29.3 % 1.60 [ 0.61, 4.16 ]
Total events: 21 (Higher PUFA), 14 (Lower PUFA)
Heterogeneity: Tau2 = 0.24; Chi2 = 2.89, df = 2 (P = 0.24); I2 =31%
Test for overall effect: Z = 0.96 (P = 0.34)
3 Long duration 4+ years
MRC 1968 2/199 0/194 2.1 % 4.88 [ 0.24, 100.89 ]
PREDIMED 2013 32/2454 49/2543 32.2 % 0.68 [ 0.43, 1.05 ]
Sydney Diet-Heart 1978 2/221 2/237 4.9 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 23.0 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 3298 3396 62.1 % 0.68 [ 0.47, 0.97 ]
Total events: 49 (Higher PUFA), 73 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.02, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
Total (95% CI) 7318 7424 100.0 % 0.91 [ 0.58, 1.44 ]
Total events: 74 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Tau2 = 0.12; Chi2 = 13.10, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Chi2 = 2.74, df = 2 (P = 0.25), I2 =27%
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Analysis 1.30. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 30 Stroke - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 30 Stroke - subgroup by primary or secondary prevention








1 Primary prevention of cardiovascular disease (CVD)
EPOCH 2011 2/195 0/196 2.1 % 5.03 [ 0.24, 104.01 ]
ORL 2013 2/171 0/165 2.1 % 4.83 [ 0.23, 99.76 ]
PREDIMED 2013 32/2454 49/2543 32.2 % 0.68 [ 0.43, 1.05 ]
Veterans Admin 1969 13/424 22/422 23.0 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 3244 3326 59.4 % 0.70 [ 0.45, 1.11 ]
Total events: 49 (Higher PUFA), 71 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 3.49, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 1.52 (P = 0.13)
2 Secondary prevention of CVD
AlphaOmega - ALA 10/2409 11/2428 17.5 % 0.92 [ 0.39, 2.15 ]
DART fat 1989 10/1018 3/1015 9.8 % 3.32 [ 0.92, 12.04 ]
Doi 2014 0/119 4/119 2.3 % 0.11 [ 0.01, 2.04 ]
HARP- Sacks 1995 1/41 0/39 2.0 % 2.86 [ 0.12, 68.10 ]
MRC 1968 2/199 0/194 2.1 % 4.88 [ 0.24, 100.89 ]
Nodari 2011 HF 0/67 1/66 2.0 % 0.33 [ 0.01, 7.92 ]
Sydney Diet-Heart 1978 2/221 2/237 4.9 % 1.07 [ 0.15, 7.55 ]
Subtotal (95% CI) 4074 4098 40.6 % 1.24 [ 0.59, 2.62 ]
Total events: 25 (Higher PUFA), 21 (Lower PUFA)
Heterogeneity: Tau2 = 0.16; Chi2 = 7.12, df = 6 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 7318 7424 100.0 % 0.91 [ 0.58, 1.44 ]
Total events: 74 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Tau2 = 0.12; Chi2 = 13.10, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Chi2 = 1.63, df = 1 (P = 0.20), I2 =39%
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Analysis 1.31. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 31 Stroke - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 31 Stroke - subgroup by baseline PUFA dose








1 Baseline total PUFA < 6% E
Veterans Admin 1969 13/424 22/422 23.0 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 424 422 23.0 % 0.59 [ 0.30, 1.15 ]
Total events: 13 (Higher PUFA), 22 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
2 Baseline total PUFA 6 to < 11% E
DART fat 1989 10/1018 3/1015 9.8 % 3.32 [ 0.92, 12.04 ]
PREDIMED 2013 32/2454 49/2543 32.2 % 0.68 [ 0.43, 1.05 ]
Sydney Diet-Heart 1978 2/221 2/237 4.9 % 1.07 [ 0.15, 7.55 ]
Subtotal (95% CI) 3693 3795 46.8 % 1.21 [ 0.41, 3.59 ]
Total events: 44 (Higher PUFA), 54 (Lower PUFA)
Heterogeneity: Tau2 = 0.57; Chi2 = 5.37, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 0.34 (P = 0.73)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
AlphaOmega - ALA 10/2409 11/2428 17.5 % 0.92 [ 0.39, 2.15 ]
Doi 2014 0/119 4/119 2.3 % 0.11 [ 0.01, 2.04 ]
EPOCH 2011 2/195 0/196 2.1 % 5.03 [ 0.24, 104.01 ]
HARP- Sacks 1995 1/41 0/39 2.0 % 2.86 [ 0.12, 68.10 ]
MRC 1968 2/199 0/194 2.1 % 4.88 [ 0.24, 100.89 ]
Nodari 2011 HF 0/67 1/66 2.0 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 2.1 % 4.83 [ 0.23, 99.76 ]
Subtotal (95% CI) 3201 3207 30.2 % 1.10 [ 0.51, 2.41 ]
Total events: 17 (Higher PUFA), 16 (Lower PUFA)
Heterogeneity: Tau2 = 0.07; Chi2 = 6.27, df = 6 (P = 0.39); I2 =4%
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Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 7318 7424 100.0 % 0.91 [ 0.58, 1.44 ]
Total events: 74 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Tau2 = 0.12; Chi2 = 13.10, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Chi2 = 1.97, df = 2 (P = 0.37), I2 =0.0%
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Analysis 1.32. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 32 Stroke - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 32 Stroke - subgroup by replacement








1 PUFA replaced saturated fats
DART fat 1989 10/1018 3/1015 29.2 % 3.32 [ 0.92, 12.04 ]
MRC 1968 2/199 0/194 10.4 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 19.3 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 41.1 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 1862 1868 100.0 % 1.36 [ 0.45, 4.11 ]
Total events: 27 (Higher PUFA), 27 (Lower PUFA)
Heterogeneity: Tau2 = 0.65; Chi2 = 6.79, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.55 (P = 0.58)
2 PUFA replaced monounsaturated fats
AlphaOmega - ALA 10/2409 11/2428 14.8 % 0.92 [ 0.39, 2.15 ]
EPOCH 2011 2/195 0/196 1.2 % 5.03 [ 0.24, 104.01 ]
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HARP- Sacks 1995 1/41 0/39 1.1 % 2.86 [ 0.12, 68.10 ]
Nodari 2011 HF 0/67 1/66 1.1 % 0.33 [ 0.01, 7.92 ]
PREDIMED 2013 32/2454 49/2543 55.2 % 0.68 [ 0.43, 1.05 ]
Sydney Diet-Heart 1978 2/221 2/237 2.8 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 23.9 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 5811 5931 100.0 % 0.72 [ 0.52, 0.99 ]
Total events: 60 (Higher PUFA), 85 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.43, df = 6 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.046)
3 PUFA replaced carbohydrates
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 PUFA replaced protein
MRC 1968 2/199 0/194 100.0 % 4.88 [ 0.24, 100.89 ]
Subtotal (95% CI) 199 194 100.0 % 4.88 [ 0.24, 100.89 ]
Total events: 2 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
5 PUFA replaced unclear
Doi 2014 0/119 4/119 50.6 % 0.11 [ 0.01, 2.04 ]
ORL 2013 2/171 0/165 49.4 % 4.83 [ 0.23, 99.76 ]
Subtotal (95% CI) 290 284 100.0 % 0.71 [ 0.02, 29.08 ]
Total events: 2 (Higher PUFA), 4 (Lower PUFA)
Heterogeneity: Tau2 = 4.85; Chi2 = 3.11, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Chi2 = 2.65, df = 3 (P = 0.45), I2 =0.0%
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Analysis 1.33. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 33 Stroke - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 33 Stroke - subgroup by sex








1 > 70% men
AlphaOmega - ALA 10/2409 11/2428 17.5 % 0.92 [ 0.39, 2.15 ]
DART fat 1989 10/1018 3/1015 9.8 % 3.32 [ 0.92, 12.04 ]
Doi 2014 0/119 4/119 2.3 % 0.11 [ 0.01, 2.04 ]
HARP- Sacks 1995 1/41 0/39 2.0 % 2.86 [ 0.12, 68.10 ]
MRC 1968 2/199 0/194 2.1 % 4.88 [ 0.24, 100.89 ]
Nodari 2011 HF 0/67 1/66 2.0 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 2.1 % 4.83 [ 0.23, 99.76 ]
Sydney Diet-Heart 1978 2/221 2/237 4.9 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 23.0 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 4669 4685 65.7 % 1.04 [ 0.56, 1.93 ]
Total events: 40 (Higher PUFA), 43 (Lower PUFA)
Heterogeneity: Tau2 = 0.21; Chi2 = 10.79, df = 8 (P = 0.21); I2 =26%
Test for overall effect: Z = 0.12 (P = 0.91)
2 > 70% women
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 men % women
PREDIMED 2013 32/2454 49/2543 32.2 % 0.68 [ 0.43, 1.05 ]
Subtotal (95% CI) 2454 2543 32.2 % 0.68 [ 0.43, 1.05 ]
Total events: 32 (Higher PUFA), 49 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.083)
4 sex not reported
EPOCH 2011 2/195 0/196 2.1 % 5.03 [ 0.24, 104.01 ]
Subtotal (95% CI) 195 196 2.1 % 5.03 [ 0.24, 104.01 ]
Total events: 2 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
0.01 0.1 1 10 100
Favours higher PUFA Favours lower PUFA
(Continued . . . )
285Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)








Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 7318 7424 100.0 % 0.91 [ 0.58, 1.44 ]
Total events: 74 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Tau2 = 0.12; Chi2 = 13.10, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Chi2 = 2.63, df = 2 (P = 0.27), I2 =24%
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Analysis 1.34. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 34 Stroke - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 34 Stroke - subgroup by age








1 Mean age < 50 years
Sydney Diet-Heart 1978 2/221 2/237 4.9 % 1.07 [ 0.15, 7.55 ]
Subtotal (95% CI) 221 237 4.9 % 1.07 [ 0.15, 7.55 ]
Total events: 2 (Higher PUFA), 2 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
2 Mean age 50 to < 65 years
DART fat 1989 10/1018 3/1015 9.8 % 3.32 [ 0.92, 12.04 ]
HARP- Sacks 1995 1/41 0/39 2.0 % 2.86 [ 0.12, 68.10 ]
MRC 1968 2/199 0/194 2.1 % 4.88 [ 0.24, 100.89 ]
Nodari 2011 HF 0/67 1/66 2.0 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 2.1 % 4.83 [ 0.23, 99.76 ]
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Subtotal (95% CI) 1496 1479 18.0 % 2.84 [ 1.05, 7.64 ]
Total events: 15 (Higher PUFA), 4 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.06, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.039)
3 Mean age 65+ years
AlphaOmega - ALA 10/2409 11/2428 17.5 % 0.92 [ 0.39, 2.15 ]
Doi 2014 0/119 4/119 2.3 % 0.11 [ 0.01, 2.04 ]
PREDIMED 2013 32/2454 49/2543 32.2 % 0.68 [ 0.43, 1.05 ]
Veterans Admin 1969 13/424 22/422 23.0 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 5406 5512 75.0 % 0.67 [ 0.48, 0.94 ]
Total events: 55 (Higher PUFA), 86 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.14, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.34 (P = 0.019)
4 Mean age unclear
EPOCH 2011 2/195 0/196 2.1 % 5.03 [ 0.24, 104.01 ]
Subtotal (95% CI) 195 196 2.1 % 5.03 [ 0.24, 104.01 ]
Total events: 2 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI) 7318 7424 100.0 % 0.91 [ 0.58, 1.44 ]
Total events: 74 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Tau2 = 0.12; Chi2 = 13.10, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Chi2 = 8.87, df = 3 (P = 0.03), I2 =66%
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Analysis 1.35. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 35 Stroke - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 35 Stroke - subgroup by statin use








1 < 50% on statins
DART fat 1989 10/1018 3/1015 9.8 % 3.32 [ 0.92, 12.04 ]
EPOCH 2011 2/195 0/196 2.1 % 5.03 [ 0.24, 104.01 ]
HARP- Sacks 1995 1/41 0/39 2.0 % 2.86 [ 0.12, 68.10 ]
MRC 1968 2/199 0/194 2.1 % 4.88 [ 0.24, 100.89 ]
Nodari 2011 HF 0/67 1/66 2.0 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 2.1 % 4.83 [ 0.23, 99.76 ]
PREDIMED 2013 32/2454 49/2543 32.2 % 0.68 [ 0.43, 1.05 ]
Sydney Diet-Heart 1978 2/221 2/237 4.9 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 23.0 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 4790 4877 80.1 % 1.02 [ 0.59, 1.78 ]
Total events: 64 (Higher PUFA), 77 (Lower PUFA)
Heterogeneity: Tau2 = 0.17; Chi2 = 11.31, df = 8 (P = 0.18); I2 =29%
Test for overall effect: Z = 0.08 (P = 0.94)
2 50+% on statins
AlphaOmega - ALA 10/2409 11/2428 17.5 % 0.92 [ 0.39, 2.15 ]
Doi 2014 0/119 4/119 2.3 % 0.11 [ 0.01, 2.04 ]
Subtotal (95% CI) 2528 2547 19.9 % 0.50 [ 0.07, 3.40 ]
Total events: 10 (Higher PUFA), 15 (Lower PUFA)
Heterogeneity: Tau2 = 1.14; Chi2 = 1.95, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 7318 7424 100.0 % 0.91 [ 0.58, 1.44 ]
Total events: 74 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Tau2 = 0.12; Chi2 = 13.10, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
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Analysis 1.36. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 36 Stroke - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 36 Stroke - subgroup by intervention type









DART fat 1989 10/1018 3/1015 9.8 % 3.32 [ 0.92, 12.04 ]
Subtotal (95% CI) 1018 1015 9.8 % 3.32 [ 0.92, 12.04 ]
Total events: 10 (Higher PUFA), 3 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
2 Supplemental foods % diet provided
AlphaOmega - ALA 10/2409 11/2428 17.5 % 0.92 [ 0.39, 2.15 ]
PREDIMED 2013 32/2454 49/2543 32.2 % 0.68 [ 0.43, 1.05 ]
Veterans Admin 1969 13/424 22/422 23.0 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 5287 5393 72.7 % 0.68 [ 0.49, 0.96 ]
Total events: 55 (Higher PUFA), 82 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.65, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.029)
3 Supplements (capsules % unusual foods)
Doi 2014 0/119 4/119 2.3 % 0.11 [ 0.01, 2.04 ]
EPOCH 2011 2/195 0/196 2.1 % 5.03 [ 0.24, 104.01 ]
HARP- Sacks 1995 1/41 0/39 2.0 % 2.86 [ 0.12, 68.10 ]
Nodari 2011 HF 0/67 1/66 2.0 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 2.1 % 4.83 [ 0.23, 99.76 ]
Subtotal (95% CI) 593 585 10.5 % 1.18 [ 0.25, 5.62 ]
Total events: 5 (Higher PUFA), 5 (Lower PUFA)
Heterogeneity: Tau2 = 0.74; Chi2 = 5.22, df = 4 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.20 (P = 0.84)
4 Any combination
MRC 1968 2/199 0/194 2.1 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 4.9 % 1.07 [ 0.15, 7.55 ]
Subtotal (95% CI) 420 431 7.0 % 1.67 [ 0.32, 8.62 ]
Total events: 4 (Higher PUFA), 2 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.40); I2 =0.0%
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Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 7318 7424 100.0 % 0.91 [ 0.58, 1.44 ]
Total events: 74 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Tau2 = 0.12; Chi2 = 13.10, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Chi2 = 6.52, df = 3 (P = 0.09), I2 =54%
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Analysis 1.37. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 37 Stroke - subgroup by fatal & non fatal.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 37 Stroke - subgroup by fatal % non fatal









AlphaOmega - ALA 10/2409 11/2428 54.4 % 0.92 [ 0.39, 2.15 ]
MRC 1968 2/199 0/194 5.5 % 4.88 [ 0.24, 100.89 ]
Sydney Diet-Heart 1978 2/221 2/237 12.9 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 3/424 9/422 27.2 % 0.33 [ 0.09, 1.22 ]
Subtotal (95% CI) 3253 3281 100.0 % 0.78 [ 0.38, 1.60 ]
Total events: 17 (Higher PUFA), 22 (Lower PUFA)
Heterogeneity: Tau2 = 0.06; Chi2 = 3.31, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 0.68 (P = 0.50)
2 Non-fatal stroke
Doi 2014 0/119 4/119 23.9 % 0.11 [ 0.01, 2.04 ]
Veterans Admin 1969 10/424 13/422 76.1 % 0.77 [ 0.34, 1.73 ]
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Subtotal (95% CI) 543 541 100.0 % 0.48 [ 0.09, 2.51 ]
Total events: 10 (Higher PUFA), 17 (Lower PUFA)
Heterogeneity: Tau2 = 0.76; Chi2 = 1.64, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 0.87 (P = 0.39)
3 Only combined fatal % non fatal data provided
DART fat 1989 10/1018 3/1015 25.5 % 3.32 [ 0.92, 12.04 ]
EPOCH 2011 2/195 0/196 8.6 % 5.03 [ 0.24, 104.01 ]
HARP- Sacks 1995 1/41 0/39 8.0 % 2.86 [ 0.12, 68.10 ]
Nodari 2011 HF 0/67 1/66 7.9 % 0.33 [ 0.01, 7.92 ]
ORL 2013 2/171 0/165 8.6 % 4.83 [ 0.23, 99.76 ]
PREDIMED 2013 32/2454 49/2543 41.3 % 0.68 [ 0.43, 1.05 ]
Subtotal (95% CI) 3946 4024 100.0 % 1.51 [ 0.56, 4.07 ]
Total events: 47 (Higher PUFA), 53 (Lower PUFA)
Heterogeneity: Tau2 = 0.56; Chi2 = 8.91, df = 5 (P = 0.11); I2 =44%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Chi2 = 1.77, df = 2 (P = 0.41), I2 =0.0%
0.01 0.1 1 10 100
Favours higher PUFA Favours lower PUFA
291Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.38. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 38 Stroke - subgroup by ischaemic & haemorrhagic.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 38 Stroke - subgroup by ischaemic % haemorrhagic









DART fat 1989 7/1018 1/1015 53.8 % 6.98 [ 0.86, 56.62 ]
MRC 1968 1/199 0/194 23.1 % 2.93 [ 0.12, 71.37 ]
ORL 2013 1/171 0/165 23.1 % 2.90 [ 0.12, 70.57 ]
Subtotal (95% CI) 1388 1374 100.0 % 4.66 [ 1.00, 21.63 ]
Total events: 9 (Higher PUFA), 1 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
2 Haemorrhagic stroke
DART fat 1989 3/1018 2/1015 61.5 % 1.50 [ 0.25, 8.93 ]
MRC 1968 1/199 0/194 19.2 % 2.93 [ 0.12, 71.37 ]
ORL 2013 1/171 0/165 19.3 % 2.90 [ 0.12, 70.57 ]
Subtotal (95% CI) 1388 1374 100.0 % 1.93 [ 0.48, 7.85 ]
Total events: 5 (Higher PUFA), 2 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
3 Only combined ischaemic and haemorrhagic data provided
AlphaOmega - ALA 10/2409 11/2428 14.6 % 0.92 [ 0.39, 2.15 ]
Doi 2014 0/119 4/119 1.3 % 0.11 [ 0.01, 2.04 ]
EPOCH 2011 2/195 0/196 1.2 % 5.03 [ 0.24, 104.01 ]
HARP- Sacks 1995 1/41 0/39 1.1 % 2.86 [ 0.12, 68.10 ]
Nodari 2011 HF 0/67 1/66 1.1 % 0.33 [ 0.01, 7.92 ]
PREDIMED 2013 32/2454 49/2543 54.5 % 0.68 [ 0.43, 1.05 ]
Sydney Diet-Heart 1978 2/221 2/237 2.8 % 1.07 [ 0.15, 7.55 ]
Veterans Admin 1969 13/424 22/422 23.6 % 0.59 [ 0.30, 1.15 ]
Subtotal (95% CI) 5930 6050 100.0 % 0.70 [ 0.50, 0.97 ]
Total events: 60 (Higher PUFA), 89 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.98, df = 7 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.031)
Test for subgroup differences: Chi2 = 7.24, df = 2 (P = 0.03), I2 =72%
0.01 0.1 1 10 100
Favours higher PUFA Favours lower PUFA
292Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.39. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 39 MAJOR ADVERSE CARDIAC & CEREBROVASCULAR EVENTS (MACCEs).
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 39 MAJOR ADVERSE CARDIAC % CEREBROVASCULAR EVENTS (MACCEs)








DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 1.40. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 40 MACCEs - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 40 MACCEs - SA








1 Low risk of bias for allocation concealment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Low risk of bias for attention
Veterans Admin 1969 60/424 87/422 100.0 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 100.0 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher PUFA), 87 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
3 Low risk of bias for compliance
DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
4 Low summary risk of bias
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Trials registry or pre-2010
DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
6 No industry funding
Subtotal (95% CI) 0 0 Not estimable
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Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Randomised 100+ participants
DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
8 Randomised 250+ participants
DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
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Analysis 1.41. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 41 MACCEs - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 41 MACCEs - SA fixed-effect
Study or subgroup Higher PUFA Lower PUFA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
DART fat 1989 333/1018 337/1015 79.5 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 20.5 % 0.69 [ 0.51, 0.93 ]
Total (95% CI) 1442 1437 100.0 % 0.92 [ 0.82, 1.04 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.42. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 42 MACCEs - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 42 MACCEs - subgroup by PUFA dose








1 total PUFA < 1.0% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 total PUFA 1.0 to < 2.0% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 total PUFA 2.0 to < 5.0% E
DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Subtotal (95% CI) 1018 1015 57.4 % 0.99 [ 0.87, 1.12 ]
Total events: 333 (Higher PUFA), 337 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
4 total PUFA > 5.0% E
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 42.6 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher PUFA), 87 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.76, df = 1 (P = 0.03), I2 =79%
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Analysis 1.43. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 43 MACCEs - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 43 MACCEs - subgroup by duration








1 Medium duration 1 to < 2 years
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Medium-long duration 2 to < 4 years
DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Subtotal (95% CI) 1018 1015 57.4 % 0.99 [ 0.87, 1.12 ]
Total events: 333 (Higher PUFA), 337 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
3 Long duration 4+ years
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 42.6 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher PUFA), 87 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.76, df = 1 (P = 0.03), I2 =79%
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Analysis 1.44. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 44 MACCEs - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 44 MACCEs - subgroup by primary or secondary prevention








1 Primary prevention of CVD
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 42.6 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher PUFA), 87 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
2 Secondary prevention of CVD
DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Subtotal (95% CI) 1018 1015 57.4 % 0.99 [ 0.87, 1.12 ]
Total events: 333 (Higher PUFA), 337 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.76, df = 1 (P = 0.03), I2 =79%
0.01 0.1 1 10 100
Favours higher PUFA Favours lower PUFA
299Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.45. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 45 MACCEs - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 45 MACCEs - subgroup by baseline PUFA dose








1 Baseline total PUFA < 6% E
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 42.6 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher PUFA), 87 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
2 Baseline total PUFA 6 to < 11% E
DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Subtotal (95% CI) 1018 1015 57.4 % 0.99 [ 0.87, 1.12 ]
Total events: 333 (Higher PUFA), 337 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.76, df = 1 (P = 0.03), I2 =79%
0.01 0.1 1 10 100
Favours higher PUFA Favours lower PUFA
300Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.46. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 46 MACCEs - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 46 MACCEs - subgroup by replacement








1 PUFA replaced saturated fats
DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
2 PUFA replaced monounsaturated fats
Veterans Admin 1969 60/424 87/422 100.0 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 100.0 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher PUFA), 87 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
3 PUFA replaced carbohydrates
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 PUFA replaced protein
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 PUFA replaced unclear
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.77, df = 1 (P = 0.38), I2 =0.0%
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Analysis 1.47. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 47 MACCEs - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 47 MACCEs - subgroup by sex








1 > 70% men
DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
2 > 70% women
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 men % women
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 sex not reported
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 1.48. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 48 MACCEs - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 48 MACCEs - subgroup by age








1 Mean age < 50 years
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Mean age 50 to < 65 years
DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Subtotal (95% CI) 1018 1015 57.4 % 0.99 [ 0.87, 1.12 ]
Total events: 333 (Higher PUFA), 337 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
3 Mean age 65+ years
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 42.6 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher PUFA), 87 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.76, df = 1 (P = 0.03), I2 =79%
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Analysis 1.49. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 49 MACCEs - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 49 MACCEs - subgroup by statin use








1 < 50% on statins
DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
2 50+% on statins
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 1.50. Comparison 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary
outcomes, Outcome 50 MACCEs - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 1 Higher polyunsaturated fatty acids (PUFA) vs lower PUFA intake - primary outcomes
Outcome: 50 MACCEs - subgroup by intervention type









DART fat 1989 333/1018 337/1015 57.4 % 0.99 [ 0.87, 1.12 ]
Subtotal (95% CI) 1018 1015 57.4 % 0.99 [ 0.87, 1.12 ]
Total events: 333 (Higher PUFA), 337 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
2 Supplemental foods % diet provided
Veterans Admin 1969 60/424 87/422 42.6 % 0.69 [ 0.51, 0.93 ]
Subtotal (95% CI) 424 422 42.6 % 0.69 [ 0.51, 0.93 ]
Total events: 60 (Higher PUFA), 87 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
3 Supplements (capsules % unusual foods)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1442 1437 100.0 % 0.84 [ 0.59, 1.20 ]
Total events: 393 (Higher PUFA), 424 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.80, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.76, df = 1 (P = 0.03), I2 =79%
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Analysis 2.1. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome 1
CARDIOVASCULAR MORTALITY.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 1 CARDIOVASCULAR MORTALITY








AlphaOmega - ALA 78/2409 84/2428 17.6 % 0.94 [ 0.69, 1.27 ]
Black 1994 2/67 0/66 0.5 % 4.93 [ 0.24, 100.70 ]
Brox 2001 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 114/1018 91/1015 19.4 % 1.25 [ 0.96, 1.62 ]
Doi 2014 1/119 5/119 1.0 % 0.20 [ 0.02, 1.69 ]
FAAT - Leaf 2005 9/200 9/202 4.6 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
Houtsmuller 1979 0/51 5/51 0.5 % 0.09 [ 0.01, 1.60 ]
Kumar 2013 1/39 1/39 0.6 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.8 % 1.89 [ 0.18, 20.31 ]
MRC 1968 27/199 25/194 10.7 % 1.05 [ 0.63, 1.75 ]
PREDIMED 2013 31/2454 26/2543 10.4 % 1.24 [ 0.74, 2.07 ]
Raitt 2005 2/100 5/100 1.6 % 0.40 [ 0.08, 2.01 ]
Rose 1965 5/28 3/26 2.3 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 37/221 25/237 11.6 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 17.3 % 0.70 [ 0.51, 0.96 ]
Total (95% CI) 7520 7587 100.0 % 1.02 [ 0.82, 1.26 ]
Total events: 366 (Higher PUFA), 363 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 21.84, df = 15 (P = 0.11); I2 =31%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome 2
Cardiovascular mortality - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 2 Cardiovascular mortality - SA








1 Low risk of bias for allocation concealment
AlphaOmega - ALA 78/2409 84/2428 64.1 % 0.94 [ 0.69, 1.27 ]
Brox 2001 0/80 1/40 0.6 % 0.17 [ 0.01, 4.05 ]
FAAT - Leaf 2005 9/200 9/202 7.2 % 1.01 [ 0.41, 2.49 ]
Kumar 2013 1/39 1/39 0.8 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 1.0 % 1.89 [ 0.18, 20.31 ]
Sydney Diet-Heart 1978 37/221 25/237 26.3 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 3019 3012 100.0 % 1.08 [ 0.85, 1.38 ]
Total events: 127 (Higher PUFA), 121 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.95, df = 5 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Low risk of bias for attention
AlphaOmega - ALA 78/2409 84/2428 36.7 % 0.94 [ 0.69, 1.27 ]
Brox 2001 0/80 1/40 0.5 % 0.17 [ 0.01, 4.05 ]
Doi 2014 1/119 5/119 1.1 % 0.20 [ 0.02, 1.69 ]
FAAT - Leaf 2005 9/200 9/202 5.7 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.5 % 0.32 [ 0.01, 7.57 ]
PREDIMED 2013 31/2454 26/2543 15.7 % 1.24 [ 0.74, 2.07 ]
Raitt 2005 2/100 5/100 1.8 % 0.40 [ 0.08, 2.01 ]
Rose 1965 5/28 3/26 2.7 % 1.55 [ 0.41, 5.84 ]
Veterans Admin 1969 57/424 81/422 35.4 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 5855 5919 100.0 % 0.86 [ 0.69, 1.07 ]
Total events: 183 (Higher PUFA), 215 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.77, df = 8 (P = 0.36); I2 =9%
Test for overall effect: Z = 1.36 (P = 0.18)
3 Low risk of bias for compliance
Brox 2001 0/80 1/40 1.1 % 0.17 [ 0.01, 4.05 ]
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DART fat 1989 114/1018 91/1015 26.7 % 1.25 [ 0.96, 1.62 ]
Houtsmuller 1979 0/51 5/51 1.4 % 0.09 [ 0.01, 1.60 ]
Ley 2004 2/70 1/66 1.9 % 1.89 [ 0.18, 20.31 ]
MRC 1968 27/199 25/194 18.6 % 1.05 [ 0.63, 1.75 ]
Rose 1965 5/28 3/26 5.5 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 37/221 25/237 19.7 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 25.1 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 2091 2051 100.0 % 1.06 [ 0.75, 1.49 ]
Total events: 242 (Higher PUFA), 232 (Lower PUFA)
Heterogeneity: Tau2 = 0.10; Chi2 = 15.77, df = 7 (P = 0.03); I2 =56%
Test for overall effect: Z = 0.31 (P = 0.75)
4 Low summary risk of bias
AlphaOmega - ALA 78/2409 84/2428 56.4 % 0.94 [ 0.69, 1.27 ]
Ley 2004 2/70 1/66 3.2 % 1.89 [ 0.18, 20.31 ]
Sydney Diet-Heart 1978 37/221 25/237 40.4 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 2700 2731 100.0 % 1.18 [ 0.77, 1.83 ]
Total events: 117 (Higher PUFA), 110 (Lower PUFA)
Heterogeneity: Tau2 = 0.06; Chi2 = 3.60, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 0.77 (P = 0.44)
5 Trials registry or pre-2010
AlphaOmega - ALA 78/2409 84/2428 17.6 % 0.94 [ 0.69, 1.27 ]
Black 1994 2/67 0/66 0.5 % 4.93 [ 0.24, 100.70 ]
Brox 2001 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 114/1018 91/1015 19.4 % 1.25 [ 0.96, 1.62 ]
Doi 2014 1/119 5/119 1.0 % 0.20 [ 0.02, 1.69 ]
FAAT - Leaf 2005 9/200 9/202 4.6 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
Houtsmuller 1979 0/51 5/51 0.5 % 0.09 [ 0.01, 1.60 ]
Kumar 2013 1/39 1/39 0.6 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.8 % 1.89 [ 0.18, 20.31 ]
MRC 1968 27/199 25/194 10.7 % 1.05 [ 0.63, 1.75 ]
PREDIMED 2013 31/2454 26/2543 10.4 % 1.24 [ 0.74, 2.07 ]
Raitt 2005 2/100 5/100 1.6 % 0.40 [ 0.08, 2.01 ]
Rose 1965 5/28 3/26 2.3 % 1.55 [ 0.41, 5.84 ]
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Sydney Diet-Heart 1978 37/221 25/237 11.6 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 17.3 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 7520 7587 100.0 % 1.02 [ 0.82, 1.26 ]
Total events: 366 (Higher PUFA), 363 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 21.84, df = 15 (P = 0.11); I2 =31%
Test for overall effect: Z = 0.17 (P = 0.87)
6 No industry funding
Black 1994 2/67 0/66 1.8 % 4.93 [ 0.24, 100.70 ]
Brox 2001 0/80 1/40 1.6 % 0.17 [ 0.01, 4.05 ]
FAAT - Leaf 2005 9/200 9/202 16.5 % 1.01 [ 0.41, 2.49 ]
Houtsmuller 1979 0/51 5/51 2.0 % 0.09 [ 0.01, 1.60 ]
Ley 2004 2/70 1/66 2.9 % 1.89 [ 0.18, 20.31 ]
MRC 1968 27/199 25/194 36.2 % 1.05 [ 0.63, 1.75 ]
Sydney Diet-Heart 1978 37/221 25/237 39.0 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 888 856 100.0 % 1.19 [ 0.79, 1.79 ]
Total events: 77 (Higher PUFA), 66 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 7.34, df = 6 (P = 0.29); I2 =18%
Test for overall effect: Z = 0.81 (P = 0.42)
7 Randomised 100+ participants
AlphaOmega - ALA 78/2409 84/2428 17.6 % 0.94 [ 0.69, 1.27 ]
Black 1994 2/67 0/66 0.6 % 4.93 [ 0.24, 100.70 ]
Brox 2001 0/80 1/40 0.5 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 114/1018 91/1015 19.0 % 1.25 [ 0.96, 1.62 ]
Doi 2014 1/119 5/119 1.2 % 0.20 [ 0.02, 1.69 ]
FAAT - Leaf 2005 9/200 9/202 5.3 % 1.01 [ 0.41, 2.49 ]
Houtsmuller 1979 0/51 5/51 0.6 % 0.09 [ 0.01, 1.60 ]
Ley 2004 2/70 1/66 0.9 % 1.89 [ 0.18, 20.31 ]
MRC 1968 27/199 25/194 11.5 % 1.05 [ 0.63, 1.75 ]
PREDIMED 2013 31/2454 26/2543 11.2 % 1.24 [ 0.74, 2.07 ]
Raitt 2005 2/100 5/100 1.9 % 0.40 [ 0.08, 2.01 ]
Sydney Diet-Heart 1978 37/221 25/237 12.3 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 17.3 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 7412 7483 100.0 % 1.01 [ 0.80, 1.28 ]
Total events: 360 (Higher PUFA), 358 (Lower PUFA)
Heterogeneity: Tau2 = 0.06; Chi2 = 20.94, df = 12 (P = 0.05); I2 =43%
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Test for overall effect: Z = 0.09 (P = 0.93)
8 Randomised 250+ participants
AlphaOmega - ALA 78/2409 84/2428 19.3 % 0.94 [ 0.69, 1.27 ]
DART fat 1989 114/1018 91/1015 21.4 % 1.25 [ 0.96, 1.62 ]
FAAT - Leaf 2005 9/200 9/202 4.9 % 1.01 [ 0.41, 2.49 ]
MRC 1968 27/199 25/194 11.6 % 1.05 [ 0.63, 1.75 ]
PREDIMED 2013 31/2454 26/2543 11.3 % 1.24 [ 0.74, 2.07 ]
Sydney Diet-Heart 1978 37/221 25/237 12.6 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 19.0 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 6925 7041 100.0 % 1.06 [ 0.85, 1.32 ]
Total events: 353 (Higher PUFA), 341 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 12.06, df = 6 (P = 0.06); I2 =50%
Test for overall effect: Z = 0.50 (P = 0.62)
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Analysis 2.3. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome 3
Cardiovascular mortality - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 3 Cardiovascular mortality - SA fixed-effect
Study or subgroup Higher PUFA Lower PUFA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - ALA 78/2409 84/2428 22.9 % 0.94 [ 0.69, 1.27 ]
Black 1994 2/67 0/66 0.1 % 4.93 [ 0.24, 100.70 ]
Brox 2001 0/80 1/40 0.5 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 114/1018 91/1015 25.0 % 1.25 [ 0.96, 1.62 ]
Doi 2014 1/119 5/119 1.4 % 0.20 [ 0.02, 1.69 ]
FAAT - Leaf 2005 9/200 9/202 2.5 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
Houtsmuller 1979 0/51 5/51 1.5 % 0.09 [ 0.01, 1.60 ]
Kumar 2013 1/39 1/39 0.3 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.3 % 1.89 [ 0.18, 20.31 ]
MRC 1968 27/199 25/194 6.9 % 1.05 [ 0.63, 1.75 ]
PREDIMED 2013 31/2454 26/2543 7.0 % 1.24 [ 0.74, 2.07 ]
Raitt 2005 2/100 5/100 1.4 % 0.40 [ 0.08, 2.01 ]
Rose 1965 5/28 3/26 0.9 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 37/221 25/237 6.6 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 22.3 % 0.70 [ 0.51, 0.96 ]
Total (95% CI) 7520 7587 100.0 % 1.01 [ 0.88, 1.16 ]
Total events: 366 (Higher PUFA), 363 (Lower PUFA)
Heterogeneity: Chi2 = 21.84, df = 15 (P = 0.11); I2 =31%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome 4
Cardiovascular mortality - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 4 Cardiovascular mortality - subgroup by PUFA dose








1 total PUFA < 1.0% E
Doi 2014 1/119 5/119 1.0 % 0.20 [ 0.02, 1.69 ]
FAAT - Leaf 2005 9/200 9/202 4.6 % 1.01 [ 0.41, 2.49 ]
Kumar 2013 1/39 1/39 0.6 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.8 % 1.89 [ 0.18, 20.31 ]
Raitt 2005 2/100 5/100 1.6 % 0.40 [ 0.08, 2.01 ]
Subtotal (95% CI) 528 526 8.6 % 0.76 [ 0.38, 1.51 ]
Total events: 15 (Higher PUFA), 21 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.13, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
2 total PUFA 1.0 to < 2.0% E
AlphaOmega - ALA 78/2409 84/2428 17.6 % 0.94 [ 0.69, 1.27 ]
Brox 2001 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
PREDIMED 2013 31/2454 26/2543 10.4 % 1.24 [ 0.74, 2.07 ]
Subtotal (95% CI) 4943 5011 28.5 % 0.99 [ 0.76, 1.30 ]
Total events: 109 (Higher PUFA), 111 (Lower PUFA)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.02, df = 2 (P = 0.36); I2 =1%
Test for overall effect: Z = 0.05 (P = 0.96)
3 total PUFA 2.0 to < 5.0% E
Black 1994 2/67 0/66 0.5 % 4.93 [ 0.24, 100.70 ]
DART fat 1989 114/1018 91/1015 19.4 % 1.25 [ 0.96, 1.62 ]
HARP- Sacks 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
Subtotal (95% CI) 1126 1120 20.3 % 1.25 [ 0.96, 1.62 ]
Total events: 116 (Higher PUFA), 92 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.51, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.092)
4 total PUFA > 5.0% E
Houtsmuller 1979 0/51 5/51 0.5 % 0.09 [ 0.01, 1.60 ]
MRC 1968 27/199 25/194 10.7 % 1.05 [ 0.63, 1.75 ]
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Rose 1965 5/28 3/26 2.3 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 37/221 25/237 11.6 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 17.3 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 923 930 42.6 % 1.01 [ 0.62, 1.63 ]
Total events: 126 (Higher PUFA), 139 (Lower PUFA)
Heterogeneity: Tau2 = 0.16; Chi2 = 11.43, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 7520 7587 100.0 % 1.02 [ 0.82, 1.26 ]
Total events: 366 (Higher PUFA), 363 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 21.84, df = 15 (P = 0.11); I2 =31%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 2.68, df = 3 (P = 0.44), I2 =0.0%
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Analysis 2.5. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome 5
Cardiovascular mortality - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 5 Cardiovascular mortality - subgroup by duration








1 Medium duration 1 to <2 years
Brox 2001 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
Doi 2014 1/119 5/119 1.0 % 0.20 [ 0.02, 1.69 ]
FAAT - Leaf 2005 9/200 9/202 4.6 % 1.01 [ 0.41, 2.49 ]
Kumar 2013 1/39 1/39 0.6 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.8 % 1.89 [ 0.18, 20.31 ]
Subtotal (95% CI) 508 466 7.4 % 0.80 [ 0.39, 1.67 ]
Total events: 13 (Higher PUFA), 17 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.37, df = 4 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
2 Medium-long duration 2 to < 4 years
AlphaOmega - ALA 78/2409 84/2428 17.6 % 0.94 [ 0.69, 1.27 ]
Black 1994 2/67 0/66 0.5 % 4.93 [ 0.24, 100.70 ]
DART fat 1989 114/1018 91/1015 19.4 % 1.25 [ 0.96, 1.62 ]
HARP- Sacks 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
Raitt 2005 2/100 5/100 1.6 % 0.40 [ 0.08, 2.01 ]
Rose 1965 5/28 3/26 2.3 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 3663 3674 41.9 % 1.09 [ 0.88, 1.36 ]
Total events: 201 (Higher PUFA), 184 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.30, df = 5 (P = 0.38); I2 =6%
Test for overall effect: Z = 0.79 (P = 0.43)
3 Long duration 4+ years
Houtsmuller 1979 0/51 5/51 0.5 % 0.09 [ 0.01, 1.60 ]
MRC 1968 27/199 25/194 10.7 % 1.05 [ 0.63, 1.75 ]
PREDIMED 2013 31/2454 26/2543 10.4 % 1.24 [ 0.74, 2.07 ]
Sydney Diet-Heart 1978 37/221 25/237 11.6 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 17.3 % 0.70 [ 0.51, 0.96 ]
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Subtotal (95% CI) 3349 3447 50.7 % 1.02 [ 0.67, 1.55 ]
Total events: 152 (Higher PUFA), 162 (Lower PUFA)
Heterogeneity: Tau2 = 0.13; Chi2 = 11.92, df = 4 (P = 0.02); I2 =66%
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 7520 7587 100.0 % 1.02 [ 0.82, 1.26 ]
Total events: 366 (Higher PUFA), 363 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 21.84, df = 15 (P = 0.11); I2 =31%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.65, df = 2 (P = 0.72), I2 =0.0%
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Analysis 2.6. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome 6
Cardiovascular mortality - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 6 Cardiovascular mortality - subgroup by primary or secondary prevention








1 Primary prevention of cardiovascular disease (CVD)
Black 1994 2/67 0/66 0.5 % 4.93 [ 0.24, 100.70 ]
Brox 2001 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
Houtsmuller 1979 0/51 5/51 0.5 % 0.09 [ 0.01, 1.60 ]
Kumar 2013 1/39 1/39 0.6 % 1.00 [ 0.06, 15.43 ]
Ley 2004 2/70 1/66 0.8 % 1.89 [ 0.18, 20.31 ]
PREDIMED 2013 31/2454 26/2543 10.4 % 1.24 [ 0.74, 2.07 ]
Veterans Admin 1969 57/424 81/422 17.3 % 0.70 [ 0.51, 0.96 ]
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Subtotal (95% CI) 3185 3227 30.6 % 0.87 [ 0.54, 1.41 ]
Total events: 93 (Higher PUFA), 115 (Lower PUFA)
Heterogeneity: Tau2 = 0.10; Chi2 = 8.44, df = 6 (P = 0.21); I2 =29%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Secondary prevention of CVD
AlphaOmega - ALA 78/2409 84/2428 17.6 % 0.94 [ 0.69, 1.27 ]
DART fat 1989 114/1018 91/1015 19.4 % 1.25 [ 0.96, 1.62 ]
Doi 2014 1/119 5/119 1.0 % 0.20 [ 0.02, 1.69 ]
FAAT - Leaf 2005 9/200 9/202 4.6 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
MRC 1968 27/199 25/194 10.7 % 1.05 [ 0.63, 1.75 ]
Raitt 2005 2/100 5/100 1.6 % 0.40 [ 0.08, 2.01 ]
Rose 1965 5/28 3/26 2.3 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 37/221 25/237 11.6 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 4335 4360 69.4 % 1.12 [ 0.92, 1.36 ]
Total events: 273 (Higher PUFA), 248 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.14, df = 8 (P = 0.33); I2 =12%
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 7520 7587 100.0 % 1.02 [ 0.82, 1.26 ]
Total events: 366 (Higher PUFA), 363 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 21.84, df = 15 (P = 0.11); I2 =31%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.88, df = 1 (P = 0.35), I2 =0.0%
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Analysis 2.7. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome 7
Cardiovascular mortality - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 7 Cardiovascular mortality - subgroup by baseline PUFA dose








1 Baseline total PUFA < 6% E
Ley 2004 2/70 1/66 0.8 % 1.89 [ 0.18, 20.31 ]
Veterans Admin 1969 57/424 81/422 17.3 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 494 488 18.1 % 0.71 [ 0.52, 0.97 ]
Total events: 59 (Higher PUFA), 82 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.031)
2 Baseline total PUFA 6 to < 11% E
Black 1994 2/67 0/66 0.5 % 4.93 [ 0.24, 100.70 ]
DART fat 1989 114/1018 91/1015 19.4 % 1.25 [ 0.96, 1.62 ]
PREDIMED 2013 31/2454 26/2543 10.4 % 1.24 [ 0.74, 2.07 ]
Sydney Diet-Heart 1978 37/221 25/237 11.6 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 3760 3861 42.0 % 1.32 [ 1.07, 1.62 ]
Total events: 184 (Higher PUFA), 142 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.55, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
AlphaOmega - ALA 78/2409 84/2428 17.6 % 0.94 [ 0.69, 1.27 ]
Brox 2001 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
Doi 2014 1/119 5/119 1.0 % 0.20 [ 0.02, 1.69 ]
FAAT - Leaf 2005 9/200 9/202 4.6 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
Houtsmuller 1979 0/51 5/51 0.5 % 0.09 [ 0.01, 1.60 ]
Kumar 2013 1/39 1/39 0.6 % 1.00 [ 0.06, 15.43 ]
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MRC 1968 27/199 25/194 10.7 % 1.05 [ 0.63, 1.75 ]
Raitt 2005 2/100 5/100 1.6 % 0.40 [ 0.08, 2.01 ]
Rose 1965 5/28 3/26 2.3 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 3266 3238 39.9 % 0.92 [ 0.72, 1.16 ]
Total events: 123 (Higher PUFA), 139 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.04, df = 9 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 7520 7587 100.0 % 1.02 [ 0.82, 1.26 ]
Total events: 366 (Higher PUFA), 363 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 21.84, df = 15 (P = 0.11); I2 =31%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 11.68, df = 2 (P = 0.00), I2 =83%
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Analysis 2.8. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome 8
Cardiovascular mortality - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 8 Cardiovascular mortality - subgroup by replacement








1 PUFA replaced saturated fats
DART fat 1989 114/1018 91/1015 29.7 % 1.25 [ 0.96, 1.62 ]
MRC 1968 27/199 25/194 20.6 % 1.05 [ 0.63, 1.75 ]
Sydney Diet-Heart 1978 37/221 25/237 21.8 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 27.9 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 1862 1868 100.0 % 1.08 [ 0.76, 1.54 ]
Total events: 235 (Higher PUFA), 222 (Lower PUFA)
Heterogeneity: Tau2 = 0.09; Chi2 = 11.14, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.43 (P = 0.67)
2 PUFA replaced monounsaturated fats
AlphaOmega - ALA 78/2409 84/2428 26.2 % 0.94 [ 0.69, 1.27 ]
FAAT - Leaf 2005 9/200 9/202 7.2 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.7 % 0.32 [ 0.01, 7.57 ]
PREDIMED 2013 31/2454 26/2543 16.0 % 1.24 [ 0.74, 2.07 ]
Raitt 2005 2/100 5/100 2.6 % 0.40 [ 0.08, 2.01 ]
Rose 1965 5/28 3/26 3.7 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 37/221 25/237 17.7 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 25.8 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 5877 5997 100.0 % 0.99 [ 0.76, 1.30 ]
Total events: 219 (Higher PUFA), 234 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 11.30, df = 7 (P = 0.13); I2 =38%
Test for overall effect: Z = 0.06 (P = 0.95)
3 PUFA replaced carbohydrates
Black 1994 2/67 0/66 16.2 % 4.93 [ 0.24, 100.70 ]
Houtsmuller 1979 0/51 5/51 17.5 % 0.09 [ 0.01, 1.60 ]
Ley 2004 2/70 1/66 23.0 % 1.89 [ 0.18, 20.31 ]
Rose 1965 5/28 3/26 43.4 % 1.55 [ 0.41, 5.84 ]
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Subtotal (95% CI) 216 209 100.0 % 1.19 [ 0.30, 4.71 ]
Total events: 9 (Higher PUFA), 9 (Lower PUFA)
Heterogeneity: Tau2 = 0.68; Chi2 = 4.53, df = 3 (P = 0.21); I2 =34%
Test for overall effect: Z = 0.25 (P = 0.80)
4 PUFA replaced protein
Ley 2004 2/70 1/66 4.3 % 1.89 [ 0.18, 20.31 ]
MRC 1968 27/199 25/194 95.7 % 1.05 [ 0.63, 1.75 ]
Subtotal (95% CI) 269 260 100.0 % 1.08 [ 0.66, 1.77 ]
Total events: 29 (Higher PUFA), 26 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
5 PUFA replaced unclear
Brox 2001 0/80 1/40 21.9 % 0.17 [ 0.01, 4.05 ]
Doi 2014 1/119 5/119 48.6 % 0.20 [ 0.02, 1.69 ]
Kumar 2013 1/39 1/39 29.5 % 1.00 [ 0.06, 15.43 ]
Subtotal (95% CI) 238 198 100.0 % 0.31 [ 0.07, 1.37 ]
Total events: 2 (Higher PUFA), 7 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.01, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
Test for subgroup differences: Chi2 = 2.71, df = 4 (P = 0.61), I2 =0.0%
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Analysis 2.9. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome 9
Cardiovascular mortality - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 9 Cardiovascular mortality - subgroup by sex








1 > 70% men
AlphaOmega - ALA 78/2409 84/2428 17.6 % 0.94 [ 0.69, 1.27 ]
DART fat 1989 114/1018 91/1015 19.4 % 1.25 [ 0.96, 1.62 ]
Doi 2014 1/119 5/119 1.0 % 0.20 [ 0.02, 1.69 ]
FAAT - Leaf 2005 9/200 9/202 4.6 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
Ley 2004 2/70 1/66 0.8 % 1.89 [ 0.18, 20.31 ]
MRC 1968 27/199 25/194 10.7 % 1.05 [ 0.63, 1.75 ]
Raitt 2005 2/100 5/100 1.6 % 0.40 [ 0.08, 2.01 ]
Sydney Diet-Heart 1978 37/221 25/237 11.6 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 17.3 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 4801 4822 85.2 % 1.00 [ 0.78, 1.27 ]
Total events: 327 (Higher PUFA), 327 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 15.89, df = 9 (P = 0.07); I2 =43%
Test for overall effect: Z = 0.02 (P = 0.98)
2 > 70% women
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 men % women
Black 1994 2/67 0/66 0.5 % 4.93 [ 0.24, 100.70 ]
Brox 2001 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
Houtsmuller 1979 0/51 5/51 0.5 % 0.09 [ 0.01, 1.60 ]
Kumar 2013 1/39 1/39 0.6 % 1.00 [ 0.06, 15.43 ]
PREDIMED 2013 31/2454 26/2543 10.4 % 1.24 [ 0.74, 2.07 ]
Subtotal (95% CI) 2691 2739 12.5 % 0.86 [ 0.30, 2.47 ]
Total events: 34 (Higher PUFA), 33 (Lower PUFA)
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Heterogeneity: Tau2 = 0.45; Chi2 = 5.48, df = 4 (P = 0.24); I2 =27%
Test for overall effect: Z = 0.29 (P = 0.78)
4 sex not reported
Rose 1965 5/28 3/26 2.3 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 28 26 2.3 % 1.55 [ 0.41, 5.84 ]
Total events: 5 (Higher PUFA), 3 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 7520 7587 100.0 % 1.02 [ 0.82, 1.26 ]
Total events: 366 (Higher PUFA), 363 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 21.84, df = 15 (P = 0.11); I2 =31%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.50, df = 2 (P = 0.78), I2 =0.0%
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Analysis 2.10. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
10 Cardiovascular mortality - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 10 Cardiovascular mortality - subgroup by age








1 Mean age < 50 years
Sydney Diet-Heart 1978 37/221 25/237 11.6 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 221 237 11.6 % 1.59 [ 0.99, 2.55 ]
Total events: 37 (Higher PUFA), 25 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.91 (P = 0.056)
2 Mean age 50 to < 65 years
Black 1994 2/67 0/66 0.5 % 4.93 [ 0.24, 100.70 ]
Brox 2001 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 114/1018 91/1015 19.4 % 1.25 [ 0.96, 1.62 ]
HARP- Sacks 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
Ley 2004 2/70 1/66 0.8 % 1.89 [ 0.18, 20.31 ]
MRC 1968 27/199 25/194 10.7 % 1.05 [ 0.63, 1.75 ]
Raitt 2005 2/100 5/100 1.6 % 0.40 [ 0.08, 2.01 ]
Rose 1965 5/28 3/26 2.3 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 1603 1546 36.3 % 1.18 [ 0.95, 1.48 ]
Total events: 152 (Higher PUFA), 127 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.37, df = 7 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
3 Mean age 65+ years
AlphaOmega - ALA 78/2409 84/2428 17.6 % 0.94 [ 0.69, 1.27 ]
Doi 2014 1/119 5/119 1.0 % 0.20 [ 0.02, 1.69 ]
FAAT - Leaf 2005 9/200 9/202 4.6 % 1.01 [ 0.41, 2.49 ]
Kumar 2013 1/39 1/39 0.6 % 1.00 [ 0.06, 15.43 ]
PREDIMED 2013 31/2454 26/2543 10.4 % 1.24 [ 0.74, 2.07 ]
Veterans Admin 1969 57/424 81/422 17.3 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 5645 5753 51.6 % 0.87 [ 0.69, 1.09 ]
Total events: 177 (Higher PUFA), 206 (Lower PUFA)
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Heterogeneity: Tau2 = 0.01; Chi2 = 5.79, df = 5 (P = 0.33); I2 =14%
Test for overall effect: Z = 1.19 (P = 0.23)
4 Mean age unclear
Houtsmuller 1979 0/51 5/51 0.5 % 0.09 [ 0.01, 1.60 ]
Subtotal (95% CI) 51 51 0.5 % 0.09 [ 0.01, 1.60 ]
Total events: 0 (Higher PUFA), 5 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI) 7520 7587 100.0 % 1.02 [ 0.82, 1.26 ]
Total events: 366 (Higher PUFA), 363 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 21.84, df = 15 (P = 0.11); I2 =31%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 9.40, df = 3 (P = 0.02), I2 =68%
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Analysis 2.11. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
11 Cardiovascular mortality - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 11 Cardiovascular mortality - subgroup by statin use








1 < 50% on statins
Black 1994 2/67 0/66 0.5 % 4.93 [ 0.24, 100.70 ]
Brox 2001 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 114/1018 91/1015 19.4 % 1.25 [ 0.96, 1.62 ]
HARP- Sacks 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
Houtsmuller 1979 0/51 5/51 0.5 % 0.09 [ 0.01, 1.60 ]
MRC 1968 27/199 25/194 10.7 % 1.05 [ 0.63, 1.75 ]
PREDIMED 2013 31/2454 26/2543 10.4 % 1.24 [ 0.74, 2.07 ]
Raitt 2005 2/100 5/100 1.6 % 0.40 [ 0.08, 2.01 ]
Rose 1965 5/28 3/26 2.3 % 1.55 [ 0.41, 5.84 ]
Sydney Diet-Heart 1978 37/221 25/237 11.6 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 57/424 81/422 17.3 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 4683 4733 75.4 % 1.05 [ 0.78, 1.40 ]
Total events: 275 (Higher PUFA), 263 (Lower PUFA)
Heterogeneity: Tau2 = 0.08; Chi2 = 18.84, df = 10 (P = 0.04); I2 =47%
Test for overall effect: Z = 0.31 (P = 0.76)
2 50+% on statins
AlphaOmega - ALA 78/2409 84/2428 17.6 % 0.94 [ 0.69, 1.27 ]
Doi 2014 1/119 5/119 1.0 % 0.20 [ 0.02, 1.69 ]
Kumar 2013 1/39 1/39 0.6 % 1.00 [ 0.06, 15.43 ]
Subtotal (95% CI) 2567 2586 19.2 % 0.91 [ 0.67, 1.22 ]
Total events: 80 (Higher PUFA), 90 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.99, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
3 Percentage on statins unclear
FAAT - Leaf 2005 9/200 9/202 4.6 % 1.01 [ 0.41, 2.49 ]
Ley 2004 2/70 1/66 0.8 % 1.89 [ 0.18, 20.31 ]
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Subtotal (95% CI) 270 268 5.4 % 1.09 [ 0.47, 2.54 ]
Total events: 11 (Higher PUFA), 10 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.84)
Total (95% CI) 7520 7587 100.0 % 1.02 [ 0.82, 1.26 ]
Total events: 366 (Higher PUFA), 363 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 21.84, df = 15 (P = 0.11); I2 =31%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.51, df = 2 (P = 0.78), I2 =0.0%
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Analysis 2.12. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
12 Cardiovascular mortality - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 12 Cardiovascular mortality - subgroup by intervention type









Black 1994 2/67 0/66 0.5 % 4.93 [ 0.24, 100.70 ]
DART fat 1989 114/1018 91/1015 19.4 % 1.25 [ 0.96, 1.62 ]
Houtsmuller 1979 0/51 5/51 0.5 % 0.09 [ 0.01, 1.60 ]
Ley 2004 2/70 1/66 0.8 % 1.89 [ 0.18, 20.31 ]
Subtotal (95% CI) 1206 1198 21.2 % 1.15 [ 0.42, 3.12 ]
Total events: 118 (Higher PUFA), 97 (Lower PUFA)
Heterogeneity: Tau2 = 0.37; Chi2 = 4.15, df = 3 (P = 0.25); I2 =28%
Test for overall effect: Z = 0.28 (P = 0.78)
2 Supplemental foods % diet provided
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AlphaOmega - ALA 78/2409 84/2428 17.6 % 0.94 [ 0.69, 1.27 ]
PREDIMED 2013 31/2454 26/2543 10.4 % 1.24 [ 0.74, 2.07 ]
Veterans Admin 1969 57/424 81/422 17.3 % 0.70 [ 0.51, 0.96 ]
Subtotal (95% CI) 5287 5393 45.4 % 0.89 [ 0.66, 1.19 ]
Total events: 166 (Higher PUFA), 191 (Lower PUFA)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.86, df = 2 (P = 0.14); I2 =48%
Test for overall effect: Z = 0.80 (P = 0.42)
3 Supplements (capsules % unusual foods)
Brox 2001 0/80 1/40 0.4 % 0.17 [ 0.01, 4.05 ]
Doi 2014 1/119 5/119 1.0 % 0.20 [ 0.02, 1.69 ]
FAAT - Leaf 2005 9/200 9/202 4.6 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.4 % 0.32 [ 0.01, 7.57 ]
Kumar 2013 1/39 1/39 0.6 % 1.00 [ 0.06, 15.43 ]
Raitt 2005 2/100 5/100 1.6 % 0.40 [ 0.08, 2.01 ]
Rose 1965 5/28 3/26 2.3 % 1.55 [ 0.41, 5.84 ]
Subtotal (95% CI) 607 565 11.0 % 0.76 [ 0.42, 1.40 ]
Total events: 18 (Higher PUFA), 25 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.86, df = 6 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
4 Any combination
MRC 1968 27/199 25/194 10.7 % 1.05 [ 0.63, 1.75 ]
Sydney Diet-Heart 1978 37/221 25/237 11.6 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 420 431 22.4 % 1.31 [ 0.87, 1.95 ]
Total events: 64 (Higher PUFA), 50 (Lower PUFA)
Heterogeneity: Tau2 = 0.02; Chi2 = 1.35, df = 1 (P = 0.25); I2 =26%
Test for overall effect: Z = 1.30 (P = 0.19)
Total (95% CI) 7520 7587 100.0 % 1.02 [ 0.82, 1.26 ]
Total events: 366 (Higher PUFA), 363 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 21.84, df = 15 (P = 0.11); I2 =31%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 3.15, df = 3 (P = 0.37), I2 =5%
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Analysis 2.13. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
13 CARDIOVASCULAR EVENTS.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 13 CARDIOVASCULAR EVENTS








AlphaOmega - ALA 319/2409 352/2428 18.8 % 0.91 [ 0.79, 1.05 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 476/1018 478/1015 22.1 % 0.99 [ 0.91, 1.09 ]
Doi 2014 11/119 24/119 2.8 % 0.46 [ 0.24, 0.89 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 8/195 5/196 1.1 % 1.61 [ 0.54, 4.83 ]
FAAT - Leaf 2005 31/200 39/202 5.8 % 0.80 [ 0.52, 1.23 ]
GLAMT 1993 0/54 1/57 0.1 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 1.5 % 0.95 [ 0.37, 2.46 ]
Kumar 2013 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
MRC 1968 62/199 74/194 10.8 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.3 % 2.35 [ 0.28, 20.02 ]
Nodari 2011 HF 10/67 26/66 3.0 % 0.38 [ 0.20, 0.72 ]
PREDIMED 2013 83/2454 96/2543 10.1 % 0.90 [ 0.67, 1.20 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.1 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 2/100 5/100 0.5 % 0.40 [ 0.08, 2.01 ]
Rose 1965 15/28 11/26 3.7 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 5.0 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 13.0 % 0.79 [ 0.63, 1.00 ]
WAHA - Ros 2016 3/362 4/364 0.6 % 0.75 [ 0.17, 3.35 ]
Total (95% CI) 9071 8728 100.0 % 0.89 [ 0.79, 1.01 ]
Total events: 1170 (Higher PUFA), 1272 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 28.71, df = 20 (P = 0.09); I2 =30%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
14 CVD events - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 14 CVD events - SA








1 Low risk of bias for allocation concealment
AlphaOmega - ALA 319/2409 352/2428 80.9 % 0.91 [ 0.79, 1.05 ]
Brox 2001 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
EPIC-1 2008 1/188 0/186 0.2 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 8/195 5/196 1.3 % 1.61 [ 0.54, 4.83 ]
FAAT - Leaf 2005 31/200 39/202 8.7 % 0.80 [ 0.52, 1.23 ]
Kumar 2013 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
NDHS Open 1st 1968 5/726 1/341 0.3 % 2.35 [ 0.28, 20.02 ]
Proudman 2015 1/87 0/53 0.2 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.2 % 3.05 [ 0.13, 73.40 ]
Sydney Diet-Heart 1978 37/221 25/237 7.1 % 1.59 [ 0.99, 2.55 ]
WAHA - Ros 2016 3/362 4/364 0.7 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 4567 4147 100.0 % 0.95 [ 0.84, 1.08 ]
Total events: 407 (Higher PUFA), 428 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.38, df = 10 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
2 Low risk of bias for attention
AlphaOmega - ALA 319/2409 352/2428 30.8 % 0.91 [ 0.79, 1.05 ]
Brox 2001 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Doi 2014 11/119 24/119 4.5 % 0.46 [ 0.24, 0.89 ]
EPIC-1 2008 1/188 0/186 0.2 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 8/195 5/196 1.8 % 1.61 [ 0.54, 4.83 ]
FAAT - Leaf 2005 31/200 39/202 9.5 % 0.80 [ 0.52, 1.23 ]
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 2.4 % 0.95 [ 0.37, 2.46 ]
0.01 0.1 1 10 100
Favours higher PUFA Favours lower PUFA
(Continued . . . )
329Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)








NDHS Open 1st 1968 5/726 1/341 0.5 % 2.35 [ 0.28, 20.02 ]
Nodari 2011 HF 10/67 26/66 4.8 % 0.38 [ 0.20, 0.72 ]
PREDIMED 2013 83/2454 96/2543 16.5 % 0.90 [ 0.67, 1.20 ]
Proudman 2015 1/87 0/53 0.2 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.2 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 2/100 5/100 0.8 % 0.40 [ 0.08, 2.01 ]
Rose 1965 15/28 11/26 6.0 % 1.27 [ 0.72, 2.23 ]
Veterans Admin 1969 97/424 122/422 21.2 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 7232 6879 100.0 % 0.83 [ 0.72, 0.97 ]
Total events: 591 (Higher PUFA), 690 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 18.51, df = 15 (P = 0.24); I2 =19%
Test for overall effect: Z = 2.36 (P = 0.018)
3 Low risk of bias for compliance
Brox 2001 0/80 1/40 0.3 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 476/1018 478/1015 36.9 % 0.99 [ 0.91, 1.09 ]
MRC 1968 62/199 74/194 20.0 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.6 % 2.35 [ 0.28, 20.02 ]
Rose 1965 15/28 11/26 7.4 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 9.9 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 23.6 % 0.79 [ 0.63, 1.00 ]
WAHA - Ros 2016 3/362 4/364 1.3 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 3058 2639 100.0 % 0.96 [ 0.81, 1.14 ]
Total events: 695 (Higher PUFA), 716 (Lower PUFA)
Heterogeneity: Tau2 = 0.02; Chi2 = 11.71, df = 7 (P = 0.11); I2 =40%
Test for overall effect: Z = 0.44 (P = 0.66)
4 Low summary risk of bias
AlphaOmega - ALA 319/2409 352/2428 57.4 % 0.91 [ 0.79, 1.05 ]
EPOCH 2011 8/195 5/196 8.6 % 1.61 [ 0.54, 4.83 ]
NDHS Open 1st 1968 5/726 1/341 2.5 % 2.35 [ 0.28, 20.02 ]
Proudman 2015 1/87 0/53 1.2 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 1.2 % 3.05 [ 0.13, 73.40 ]
Sydney Diet-Heart 1978 37/221 25/237 29.1 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 3698 3316 100.0 % 1.18 [ 0.83, 1.67 ]
Total events: 371 (Higher PUFA), 383 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 6.99, df = 5 (P = 0.22); I2 =28%
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Test for overall effect: Z = 0.93 (P = 0.35)
5 Trials registry or pre-2010
AlphaOmega - ALA 319/2409 352/2428 18.8 % 0.91 [ 0.79, 1.05 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 476/1018 478/1015 22.1 % 0.99 [ 0.91, 1.09 ]
Doi 2014 11/119 24/119 2.8 % 0.46 [ 0.24, 0.89 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 8/195 5/196 1.1 % 1.61 [ 0.54, 4.83 ]
FAAT - Leaf 2005 31/200 39/202 5.8 % 0.80 [ 0.52, 1.23 ]
GLAMT 1993 0/54 1/57 0.1 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 1.5 % 0.95 [ 0.37, 2.46 ]
Kumar 2013 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
MRC 1968 62/199 74/194 10.8 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.3 % 2.35 [ 0.28, 20.02 ]
Nodari 2011 HF 10/67 26/66 3.0 % 0.38 [ 0.20, 0.72 ]
PREDIMED 2013 83/2454 96/2543 10.1 % 0.90 [ 0.67, 1.20 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.1 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 2/100 5/100 0.5 % 0.40 [ 0.08, 2.01 ]
Rose 1965 15/28 11/26 3.7 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 5.0 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 13.0 % 0.79 [ 0.63, 1.00 ]
WAHA - Ros 2016 3/362 4/364 0.6 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 9071 8728 100.0 % 0.89 [ 0.79, 1.01 ]
Total events: 1170 (Higher PUFA), 1272 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 28.71, df = 20 (P = 0.09); I2 =30%
Test for overall effect: Z = 1.87 (P = 0.061)
6 No industry funding
Brox 2001 0/80 1/40 1.4 % 0.17 [ 0.01, 4.05 ]
FAAT - Leaf 2005 31/200 39/202 29.7 % 0.80 [ 0.52, 1.23 ]
MRC 1968 62/199 74/194 38.5 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 2.9 % 2.35 [ 0.28, 20.02 ]
Sydney Diet-Heart 1978 37/221 25/237 27.5 % 1.59 [ 0.99, 2.55 ]
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Subtotal (95% CI) 1426 1014 100.0 % 0.98 [ 0.67, 1.44 ]
Total events: 135 (Higher PUFA), 140 (Lower PUFA)
Heterogeneity: Tau2 = 0.08; Chi2 = 8.10, df = 4 (P = 0.09); I2 =51%
Test for overall effect: Z = 0.08 (P = 0.93)
7 Randomised 100+ participants
AlphaOmega - ALA 319/2409 352/2428 19.0 % 0.91 [ 0.79, 1.05 ]
Brox 2001 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 476/1018 478/1015 21.7 % 0.99 [ 0.91, 1.09 ]
Doi 2014 11/119 24/119 3.3 % 0.46 [ 0.24, 0.89 ]
EPIC-1 2008 1/188 0/186 0.2 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 8/195 5/196 1.3 % 1.61 [ 0.54, 4.83 ]
FAAT - Leaf 2005 31/200 39/202 6.6 % 0.80 [ 0.52, 1.23 ]
GLAMT 1993 0/54 1/57 0.2 % 0.35 [ 0.01, 8.45 ]
MRC 1968 62/199 74/194 11.7 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.4 % 2.35 [ 0.28, 20.02 ]
Nodari 2011 HF 10/67 26/66 3.4 % 0.38 [ 0.20, 0.72 ]
PREDIMED 2013 83/2454 96/2543 11.0 % 0.90 [ 0.67, 1.20 ]
Proudman 2015 1/87 0/53 0.2 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.2 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 2/100 5/100 0.6 % 0.40 [ 0.08, 2.01 ]
Sydney Diet-Heart 1978 37/221 25/237 5.7 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 13.8 % 0.79 [ 0.63, 1.00 ]
WAHA - Ros 2016 3/362 4/364 0.7 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 8963 8624 100.0 % 0.88 [ 0.77, 1.00 ]
Total events: 1147 (Higher PUFA), 1253 (Lower PUFA)
Heterogeneity: Tau2 = 0.02; Chi2 = 27.55, df = 17 (P = 0.05); I2 =38%
Test for overall effect: Z = 2.00 (P = 0.045)
8 Randomised 250+ participants
AlphaOmega - ALA 319/2409 352/2428 24.4 % 0.91 [ 0.79, 1.05 ]
DART fat 1989 476/1018 478/1015 36.0 % 0.99 [ 0.91, 1.09 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 8/195 5/196 0.7 % 1.61 [ 0.54, 4.83 ]
FAAT - Leaf 2005 31/200 39/202 4.2 % 0.80 [ 0.52, 1.23 ]
MRC 1968 62/199 74/194 9.4 % 0.82 [ 0.62, 1.07 ]
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NDHS Open 1st 1968 5/726 1/341 0.2 % 2.35 [ 0.28, 20.02 ]
PREDIMED 2013 83/2454 96/2543 8.6 % 0.90 [ 0.67, 1.20 ]
Sydney Diet-Heart 1978 37/221 25/237 3.5 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 12.5 % 0.79 [ 0.63, 1.00 ]
WAHA - Ros 2016 3/362 4/364 0.4 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 8396 8128 100.0 % 0.93 [ 0.85, 1.02 ]
Total events: 1122 (Higher PUFA), 1196 (Lower PUFA)
Heterogeneity: Tau2 = 0.00; Chi2 = 12.20, df = 10 (P = 0.27); I2 =18%
Test for overall effect: Z = 1.51 (P = 0.13)
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Analysis 2.15. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
15 CVD events - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 15 CVD events - SA fixed-effect
Study or subgroup Higher PUFA Lower PUFA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - ALA 319/2409 352/2428 27.5 % 0.91 [ 0.79, 1.05 ]
Brox 2001 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 476/1018 478/1015 37.6 % 0.99 [ 0.91, 1.09 ]
Doi 2014 11/119 24/119 1.9 % 0.46 [ 0.24, 0.89 ]
EPIC-1 2008 1/188 0/186 0.0 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 8/195 5/196 0.4 % 1.61 [ 0.54, 4.83 ]
FAAT - Leaf 2005 31/200 39/202 3.0 % 0.80 [ 0.52, 1.23 ]
0.01 0.1 1 10 100
Favours higher PUFA Favours lower PUFA
(Continued . . . )
333Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Higher PUFA Lower PUFA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
GLAMT 1993 0/54 1/57 0.1 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 0.6 % 0.95 [ 0.37, 2.46 ]
Kumar 2013 1/39 1/39 0.1 % 1.00 [ 0.06, 15.43 ]
MRC 1968 62/199 74/194 5.9 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.1 % 2.35 [ 0.28, 20.02 ]
Nodari 2011 HF 10/67 26/66 2.1 % 0.38 [ 0.20, 0.72 ]
PREDIMED 2013 83/2454 96/2543 7.4 % 0.90 [ 0.67, 1.20 ]
Proudman 2015 1/87 0/53 0.0 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.0 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 2/100 5/100 0.4 % 0.40 [ 0.08, 2.01 ]
Rose 1965 15/28 11/26 0.9 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 1.9 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 9.6 % 0.79 [ 0.63, 1.00 ]
WAHA - Ros 2016 3/362 4/364 0.3 % 0.75 [ 0.17, 3.35 ]
Total (95% CI) 9071 8728 100.0 % 0.92 [ 0.86, 0.98 ]
Total events: 1170 (Higher PUFA), 1272 (Lower PUFA)
Heterogeneity: Chi2 = 28.71, df = 20 (P = 0.09); I2 =30%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
16 CVD events - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 16 CVD events - subgroup by PUFA dose








1 total PUFA < 1.0% E
Doi 2014 11/119 24/119 2.8 % 0.46 [ 0.24, 0.89 ]
EPOCH 2011 8/195 5/196 1.1 % 1.61 [ 0.54, 4.83 ]
FAAT - Leaf 2005 31/200 39/202 5.8 % 0.80 [ 0.52, 1.23 ]
Kumar 2013 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
Nodari 2011 HF 10/67 26/66 3.0 % 0.38 [ 0.20, 0.72 ]
Puri 2005 1/60 0/61 0.1 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 2/100 5/100 0.5 % 0.40 [ 0.08, 2.01 ]
Subtotal (95% CI) 780 783 13.5 % 0.63 [ 0.42, 0.96 ]
Total events: 64 (Higher PUFA), 100 (Lower PUFA)
Heterogeneity: Tau2 = 0.09; Chi2 = 8.62, df = 6 (P = 0.20); I2 =30%
Test for overall effect: Z = 2.14 (P = 0.032)
2 total PUFA 1.0 to < 2.0% E
AlphaOmega - ALA 319/2409 352/2428 18.8 % 0.91 [ 0.79, 1.05 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
PREDIMED 2013 83/2454 96/2543 10.1 % 0.90 [ 0.67, 1.20 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 5218 5250 29.3 % 0.91 [ 0.80, 1.03 ]
Total events: 404 (Higher PUFA), 449 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.81, df = 4 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
3 total PUFA 2.0 to < 5.0% E
DART fat 1989 476/1018 478/1015 22.1 % 0.99 [ 0.91, 1.09 ]
GLAMT 1993 0/54 1/57 0.1 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 1.5 % 0.95 [ 0.37, 2.46 ]
Subtotal (95% CI) 1113 1111 23.7 % 0.99 [ 0.90, 1.09 ]
Total events: 483 (Higher PUFA), 486 (Lower PUFA)
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Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
4 total PUFA > 5.0% E
MRC 1968 62/199 74/194 10.8 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.3 % 2.35 [ 0.28, 20.02 ]
Rose 1965 15/28 11/26 3.7 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 5.0 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 13.0 % 0.79 [ 0.63, 1.00 ]
WAHA - Ros 2016 3/362 4/364 0.6 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 1960 1584 33.4 % 0.99 [ 0.76, 1.29 ]
Total events: 219 (Higher PUFA), 237 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 9.45, df = 5 (P = 0.09); I2 =47%
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 9071 8728 100.0 % 0.89 [ 0.79, 1.01 ]
Total events: 1170 (Higher PUFA), 1272 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 28.71, df = 20 (P = 0.09); I2 =30%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Chi2 = 4.97, df = 3 (P = 0.17), I2 =40%
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Analysis 2.17. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
17 CVD events - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 17 CVD events - subgroup by duration








1 Medium duration 1 to < 2 years
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
Doi 2014 11/119 24/119 2.8 % 0.46 [ 0.24, 0.89 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 8/195 5/196 1.1 % 1.61 [ 0.54, 4.83 ]
FAAT - Leaf 2005 31/200 39/202 5.8 % 0.80 [ 0.52, 1.23 ]
GLAMT 1993 0/54 1/57 0.1 % 0.35 [ 0.01, 8.45 ]
Kumar 2013 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
NDHS Open 1st 1968 5/726 1/341 0.3 % 2.35 [ 0.28, 20.02 ]
Nodari 2011 HF 10/67 26/66 3.0 % 0.38 [ 0.20, 0.72 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.1 % 3.05 [ 0.13, 73.40 ]
Subtotal (95% CI) 1815 1360 13.9 % 0.68 [ 0.47, 0.99 ]
Total events: 69 (Higher PUFA), 98 (Lower PUFA)
Heterogeneity: Tau2 = 0.06; Chi2 = 11.75, df = 10 (P = 0.30); I2 =15%
Test for overall effect: Z = 2.03 (P = 0.042)
2 Medium-long duration 2 to < 4 years
AlphaOmega - ALA 319/2409 352/2428 18.8 % 0.91 [ 0.79, 1.05 ]
DART fat 1989 476/1018 478/1015 22.1 % 0.99 [ 0.91, 1.09 ]
HARP- Sacks 1995 7/41 7/39 1.5 % 0.95 [ 0.37, 2.46 ]
Raitt 2005 2/100 5/100 0.5 % 0.40 [ 0.08, 2.01 ]
Rose 1965 15/28 11/26 3.7 % 1.27 [ 0.72, 2.23 ]
WAHA - Ros 2016 3/362 4/364 0.6 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 3958 3972 47.2 % 0.97 [ 0.90, 1.05 ]
Total events: 822 (Higher PUFA), 857 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.15, df = 5 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
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3 Long duration 4+ years
MRC 1968 62/199 74/194 10.8 % 0.82 [ 0.62, 1.07 ]
PREDIMED 2013 83/2454 96/2543 10.1 % 0.90 [ 0.67, 1.20 ]
Sydney Diet-Heart 1978 37/221 25/237 5.0 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 13.0 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 3298 3396 38.9 % 0.92 [ 0.73, 1.16 ]
Total events: 279 (Higher PUFA), 317 (Lower PUFA)
Heterogeneity: Tau2 = 0.03; Chi2 = 7.12, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 9071 8728 100.0 % 0.89 [ 0.79, 1.01 ]
Total events: 1170 (Higher PUFA), 1272 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 28.71, df = 20 (P = 0.09); I2 =30%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Chi2 = 3.48, df = 2 (P = 0.18), I2 =43%
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Analysis 2.18. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
18 CVD events - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 18 CVD events - subgroup by primary or secondary prevention








1 Primary prevention of CVD
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 8/195 5/196 1.1 % 1.61 [ 0.54, 4.83 ]
GLAMT 1993 0/54 1/57 0.1 % 0.35 [ 0.01, 8.45 ]
NDHS Open 1st 1968 5/726 1/341 0.3 % 2.35 [ 0.28, 20.02 ]
PREDIMED 2013 83/2454 96/2543 10.1 % 0.90 [ 0.67, 1.20 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.1 % 3.05 [ 0.13, 73.40 ]
Veterans Admin 1969 97/424 122/422 13.0 % 0.79 [ 0.63, 1.00 ]
WAHA - Ros 2016 3/362 4/364 0.6 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 4630 4263 25.8 % 0.85 [ 0.72, 1.01 ]
Total events: 199 (Higher PUFA), 230 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.43, df = 9 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.070)
2 Secondary prevention of CVD
AlphaOmega - ALA 319/2409 352/2428 18.8 % 0.91 [ 0.79, 1.05 ]
DART fat 1989 476/1018 478/1015 22.1 % 0.99 [ 0.91, 1.09 ]
Doi 2014 11/119 24/119 2.8 % 0.46 [ 0.24, 0.89 ]
FAAT - Leaf 2005 31/200 39/202 5.8 % 0.80 [ 0.52, 1.23 ]
HARP- Sacks 1995 7/41 7/39 1.5 % 0.95 [ 0.37, 2.46 ]
Kumar 2013 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
MRC 1968 62/199 74/194 10.8 % 0.82 [ 0.62, 1.07 ]
Nodari 2011 HF 10/67 26/66 3.0 % 0.38 [ 0.20, 0.72 ]
Raitt 2005 2/100 5/100 0.5 % 0.40 [ 0.08, 2.01 ]
Rose 1965 15/28 11/26 3.7 % 1.27 [ 0.72, 2.23 ]
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Sydney Diet-Heart 1978 37/221 25/237 5.0 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 4441 4465 74.2 % 0.89 [ 0.75, 1.05 ]
Total events: 971 (Higher PUFA), 1042 (Lower PUFA)
Heterogeneity: Tau2 = 0.03; Chi2 = 22.10, df = 10 (P = 0.01); I2 =55%
Test for overall effect: Z = 1.43 (P = 0.15)
Total (95% CI) 9071 8728 100.0 % 0.89 [ 0.79, 1.01 ]
Total events: 1170 (Higher PUFA), 1272 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 28.71, df = 20 (P = 0.09); I2 =30%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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Analysis 2.19. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
19 CVD events - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 19 CVD events - subgroup by baseline PUFA dose








1 Baseline total PUFA < 6% E
NDHS Open 1st 1968 5/726 1/341 0.3 % 2.35 [ 0.28, 20.02 ]
Veterans Admin 1969 97/424 122/422 13.0 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 1150 763 13.3 % 0.80 [ 0.64, 1.01 ]
Total events: 102 (Higher PUFA), 123 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.058)
2 Baseline total PUFA 6 to < 11% E
DART fat 1989 476/1018 478/1015 22.1 % 0.99 [ 0.91, 1.09 ]
PREDIMED 2013 83/2454 96/2543 10.1 % 0.90 [ 0.67, 1.20 ]
Sydney Diet-Heart 1978 37/221 25/237 5.0 % 1.59 [ 0.99, 2.55 ]
WAHA - Ros 2016 3/362 4/364 0.6 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 4055 4159 37.9 % 1.02 [ 0.85, 1.22 ]
Total events: 599 (Higher PUFA), 603 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.38, df = 3 (P = 0.22); I2 =31%
Test for overall effect: Z = 0.21 (P = 0.83)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
AlphaOmega - ALA 319/2409 352/2428 18.8 % 0.91 [ 0.79, 1.05 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
Doi 2014 11/119 24/119 2.8 % 0.46 [ 0.24, 0.89 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 8/195 5/196 1.1 % 1.61 [ 0.54, 4.83 ]
FAAT - Leaf 2005 31/200 39/202 5.8 % 0.80 [ 0.52, 1.23 ]
GLAMT 1993 0/54 1/57 0.1 % 0.35 [ 0.01, 8.45 ]
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HARP- Sacks 1995 7/41 7/39 1.5 % 0.95 [ 0.37, 2.46 ]
Kumar 2013 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
MRC 1968 62/199 74/194 10.8 % 0.82 [ 0.62, 1.07 ]
Nodari 2011 HF 10/67 26/66 3.0 % 0.38 [ 0.20, 0.72 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.1 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 2/100 5/100 0.5 % 0.40 [ 0.08, 2.01 ]
Rose 1965 15/28 11/26 3.7 % 1.27 [ 0.72, 2.23 ]
Subtotal (95% CI) 3866 3806 48.8 % 0.82 [ 0.69, 0.98 ]
Total events: 469 (Higher PUFA), 546 (Lower PUFA)
Heterogeneity: Tau2 = 0.02; Chi2 = 17.24, df = 14 (P = 0.24); I2 =19%
Test for overall effect: Z = 2.17 (P = 0.030)
Total (95% CI) 9071 8728 100.0 % 0.89 [ 0.79, 1.01 ]
Total events: 1170 (Higher PUFA), 1272 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 28.71, df = 20 (P = 0.09); I2 =30%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Chi2 = 3.78, df = 2 (P = 0.15), I2 =47%
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Analysis 2.20. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
20 CVD events - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 20 CVD events - subgroup by replacement








1 PUFA replaced saturated fats
DART fat 1989 476/1018 478/1015 39.3 % 0.99 [ 0.91, 1.09 ]
MRC 1968 62/199 74/194 21.9 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.7 % 2.35 [ 0.28, 20.02 ]
Sydney Diet-Heart 1978 37/221 25/237 11.0 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 25.7 % 0.79 [ 0.63, 1.00 ]
WAHA - Ros 2016 3/362 4/364 1.4 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 2950 2573 100.0 % 0.95 [ 0.79, 1.14 ]
Total events: 680 (Higher PUFA), 704 (Lower PUFA)
Heterogeneity: Tau2 = 0.02; Chi2 = 9.66, df = 5 (P = 0.09); I2 =48%
Test for overall effect: Z = 0.59 (P = 0.56)
2 PUFA replaced monounsaturated fats
AlphaOmega - ALA 319/2409 352/2428 24.2 % 0.91 [ 0.79, 1.05 ]
EPOCH 2011 8/195 5/196 2.3 % 1.61 [ 0.54, 4.83 ]
FAAT - Leaf 2005 31/200 39/202 10.6 % 0.80 [ 0.52, 1.23 ]
HARP- Sacks 1995 7/41 7/39 3.0 % 0.95 [ 0.37, 2.46 ]
NDHS Open 1st 1968 5/726 1/341 0.7 % 2.35 [ 0.28, 20.02 ]
Nodari 2011 HF 10/67 26/66 5.9 % 0.38 [ 0.20, 0.72 ]
PREDIMED 2013 83/2454 96/2543 16.2 % 0.90 [ 0.67, 1.20 ]
Proudman 2015 1/87 0/53 0.3 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 2/100 5/100 1.1 % 0.40 [ 0.08, 2.01 ]
Rose 1965 15/28 11/26 7.2 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 9.3 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 19.2 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 6952 6653 100.0 % 0.91 [ 0.76, 1.08 ]
Total events: 615 (Higher PUFA), 689 (Lower PUFA)
Heterogeneity: Tau2 = 0.03; Chi2 = 18.35, df = 11 (P = 0.07); I2 =40%
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Test for overall effect: Z = 1.10 (P = 0.27)
3 PUFA replaced carbohydrates
Rose 1965 15/28 11/26 87.4 % 1.27 [ 0.72, 2.23 ]
WAHA - Ros 2016 3/362 4/364 12.6 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 390 390 100.0 % 1.19 [ 0.70, 2.01 ]
Total events: 18 (Higher PUFA), 15 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
4 PUFA replaced protein
MRC 1968 62/199 74/194 96.7 % 0.82 [ 0.62, 1.07 ]
WAHA - Ros 2016 3/362 4/364 3.3 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 561 558 100.0 % 0.81 [ 0.62, 1.07 ]
Total events: 65 (Higher PUFA), 78 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
5 PUFA replaced unclear
Brox 2001 0/80 1/40 3.6 % 0.17 [ 0.01, 4.05 ]
Doi 2014 11/119 24/119 81.0 % 0.46 [ 0.24, 0.89 ]
EPIC-1 2008 1/188 0/186 3.5 % 2.97 [ 0.12, 72.40 ]
GLAMT 1993 0/54 1/57 3.6 % 0.35 [ 0.01, 8.45 ]
Kumar 2013 1/39 1/39 4.8 % 1.00 [ 0.06, 15.43 ]
Puri 2005 1/60 0/61 3.6 % 3.05 [ 0.13, 73.40 ]
Subtotal (95% CI) 540 502 100.0 % 0.52 [ 0.29, 0.95 ]
Total events: 14 (Higher PUFA), 27 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.24, df = 5 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.033)
Test for subgroup differences: Chi2 = 5.10, df = 4 (P = 0.28), I2 =21%
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Analysis 2.21. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
21 CVD events - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 21 CVD events - subgroup by sex








1 > 70% men
AlphaOmega - ALA 319/2409 352/2428 18.8 % 0.91 [ 0.79, 1.05 ]
DART fat 1989 476/1018 478/1015 22.1 % 0.99 [ 0.91, 1.09 ]
Doi 2014 11/119 24/119 2.8 % 0.46 [ 0.24, 0.89 ]
FAAT - Leaf 2005 31/200 39/202 5.8 % 0.80 [ 0.52, 1.23 ]
GLAMT 1993 0/54 1/57 0.1 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 1.5 % 0.95 [ 0.37, 2.46 ]
MRC 1968 62/199 74/194 10.8 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.3 % 2.35 [ 0.28, 20.02 ]
Nodari 2011 HF 10/67 26/66 3.0 % 0.38 [ 0.20, 0.72 ]
Raitt 2005 2/100 5/100 0.5 % 0.40 [ 0.08, 2.01 ]
Sydney Diet-Heart 1978 37/221 25/237 5.0 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 13.0 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 5578 5220 83.7 % 0.86 [ 0.74, 1.00 ]
Total events: 1057 (Higher PUFA), 1154 (Lower PUFA)
Heterogeneity: Tau2 = 0.02; Chi2 = 24.16, df = 11 (P = 0.01); I2 =54%
Test for overall effect: Z = 1.97 (P = 0.048)
2 > 70% women
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 87 53 0.1 % 1.84 [ 0.08, 44.38 ]
Total events: 1 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
3 men % women
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
Kumar 2013 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
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PREDIMED 2013 83/2454 96/2543 10.1 % 0.90 [ 0.67, 1.20 ]
Puri 2005 1/60 0/61 0.1 % 3.05 [ 0.13, 73.40 ]
WAHA - Ros 2016 3/362 4/364 0.6 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 3183 3233 11.3 % 0.90 [ 0.68, 1.18 ]
Total events: 89 (Higher PUFA), 102 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.23, df = 5 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
4 sex not reported
EPOCH 2011 8/195 5/196 1.1 % 1.61 [ 0.54, 4.83 ]
Rose 1965 15/28 11/26 3.7 % 1.27 [ 0.72, 2.23 ]
Subtotal (95% CI) 223 222 4.8 % 1.33 [ 0.80, 2.20 ]
Total events: 23 (Higher PUFA), 16 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 9071 8728 100.0 % 0.89 [ 0.79, 1.01 ]
Total events: 1170 (Higher PUFA), 1272 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 28.71, df = 20 (P = 0.09); I2 =30%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Chi2 = 2.88, df = 3 (P = 0.41), I2 =0.0%
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Analysis 2.22. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
22 CVD events - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 22 CVD events - subgroup by age








1 Mean age < 50 years
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
NDHS Open 1st 1968 5/726 1/341 0.3 % 2.35 [ 0.28, 20.02 ]
Puri 2005 1/60 0/61 0.1 % 3.05 [ 0.13, 73.40 ]
Sydney Diet-Heart 1978 37/221 25/237 5.0 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 1195 825 5.6 % 1.66 [ 1.05, 2.61 ]
Total events: 44 (Higher PUFA), 26 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 3 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.029)
2 Mean age 50 to < 65 years
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 476/1018 478/1015 22.1 % 0.99 [ 0.91, 1.09 ]
GLAMT 1993 0/54 1/57 0.1 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 1.5 % 0.95 [ 0.37, 2.46 ]
MRC 1968 62/199 74/194 10.8 % 0.82 [ 0.62, 1.07 ]
Nodari 2011 HF 10/67 26/66 3.0 % 0.38 [ 0.20, 0.72 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 2/100 5/100 0.5 % 0.40 [ 0.08, 2.01 ]
Rose 1965 15/28 11/26 3.7 % 1.27 [ 0.72, 2.23 ]
Subtotal (95% CI) 1674 1590 42.0 % 0.84 [ 0.66, 1.08 ]
Total events: 573 (Higher PUFA), 603 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 13.75, df = 8 (P = 0.09); I2 =42%
Test for overall effect: Z = 1.34 (P = 0.18)
3 Mean age 65+ years
AlphaOmega - ALA 319/2409 352/2428 18.8 % 0.91 [ 0.79, 1.05 ]
Doi 2014 11/119 24/119 2.8 % 0.46 [ 0.24, 0.89 ]
FAAT - Leaf 2005 31/200 39/202 5.8 % 0.80 [ 0.52, 1.23 ]
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Kumar 2013 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
PREDIMED 2013 83/2454 96/2543 10.1 % 0.90 [ 0.67, 1.20 ]
Veterans Admin 1969 97/424 122/422 13.0 % 0.79 [ 0.63, 1.00 ]
WAHA - Ros 2016 3/362 4/364 0.6 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 6007 6117 51.3 % 0.86 [ 0.78, 0.96 ]
Total events: 545 (Higher PUFA), 638 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.85, df = 6 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.77 (P = 0.0056)
4 Mean age unclear
EPOCH 2011 8/195 5/196 1.1 % 1.61 [ 0.54, 4.83 ]
Subtotal (95% CI) 195 196 1.1 % 1.61 [ 0.54, 4.83 ]
Total events: 8 (Higher PUFA), 5 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Total (95% CI) 9071 8728 100.0 % 0.89 [ 0.79, 1.01 ]
Total events: 1170 (Higher PUFA), 1272 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 28.71, df = 20 (P = 0.09); I2 =30%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Chi2 = 8.91, df = 3 (P = 0.03), I2 =66%
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Analysis 2.23. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
23 CVD events - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 23 CVD events - subgroup by statin use








1 < 50% on statins
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 476/1018 478/1015 22.1 % 0.99 [ 0.91, 1.09 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 8/195 5/196 1.1 % 1.61 [ 0.54, 4.83 ]
GLAMT 1993 0/54 1/57 0.1 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 1.5 % 0.95 [ 0.37, 2.46 ]
MRC 1968 62/199 74/194 10.8 % 0.82 [ 0.62, 1.07 ]
NDHS Open 1st 1968 5/726 1/341 0.3 % 2.35 [ 0.28, 20.02 ]
Nodari 2011 HF 10/67 26/66 3.0 % 0.38 [ 0.20, 0.72 ]
PREDIMED 2013 83/2454 96/2543 10.1 % 0.90 [ 0.67, 1.20 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Puri 2005 1/60 0/61 0.1 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 2/100 5/100 0.5 % 0.40 [ 0.08, 2.01 ]
Rose 1965 15/28 11/26 3.7 % 1.27 [ 0.72, 2.23 ]
Sydney Diet-Heart 1978 37/221 25/237 5.0 % 1.59 [ 0.99, 2.55 ]
Veterans Admin 1969 97/424 122/422 13.0 % 0.79 [ 0.63, 1.00 ]
Subtotal (95% CI) 5942 5576 71.8 % 0.92 [ 0.78, 1.08 ]
Total events: 805 (Higher PUFA), 852 (Lower PUFA)
Heterogeneity: Tau2 = 0.02; Chi2 = 23.36, df = 15 (P = 0.08); I2 =36%
Test for overall effect: Z = 1.02 (P = 0.31)
2 50+% on statins
AlphaOmega - ALA 319/2409 352/2428 18.8 % 0.91 [ 0.79, 1.05 ]
Doi 2014 11/119 24/119 2.8 % 0.46 [ 0.24, 0.89 ]
Kumar 2013 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
Subtotal (95% CI) 2567 2586 21.8 % 0.73 [ 0.43, 1.25 ]
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Total events: 331 (Higher PUFA), 377 (Lower PUFA)
Heterogeneity: Tau2 = 0.11; Chi2 = 3.94, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 1.15 (P = 0.25)
3 Percentage on statins unclear
FAAT - Leaf 2005 31/200 39/202 5.8 % 0.80 [ 0.52, 1.23 ]
WAHA - Ros 2016 3/362 4/364 0.6 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 562 566 6.5 % 0.80 [ 0.53, 1.21 ]
Total events: 34 (Higher PUFA), 43 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.29)
Total (95% CI) 9071 8728 100.0 % 0.89 [ 0.79, 1.01 ]
Total events: 1170 (Higher PUFA), 1272 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 28.71, df = 20 (P = 0.09); I2 =30%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Chi2 = 0.95, df = 2 (P = 0.62), I2 =0.0%
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Analysis 2.24. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
24 CVD events - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 24 CVD events - subgroup by intervention type









DART fat 1989 476/1018 478/1015 22.1 % 0.99 [ 0.91, 1.09 ]
Subtotal (95% CI) 1018 1015 22.1 % 0.99 [ 0.91, 1.09 ]
Total events: 476 (Higher PUFA), 478 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 Supplemental foods % diet provided
AlphaOmega - ALA 319/2409 352/2428 18.8 % 0.91 [ 0.79, 1.05 ]
NDHS Open 1st 1968 5/726 1/341 0.3 % 2.35 [ 0.28, 20.02 ]
PREDIMED 2013 83/2454 96/2543 10.1 % 0.90 [ 0.67, 1.20 ]
Veterans Admin 1969 97/424 122/422 13.0 % 0.79 [ 0.63, 1.00 ]
WAHA - Ros 2016 3/362 4/364 0.6 % 0.75 [ 0.17, 3.35 ]
Subtotal (95% CI) 6375 6098 42.8 % 0.88 [ 0.79, 0.99 ]
Total events: 507 (Higher PUFA), 575 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.95, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.026)
3 Supplements (capsules % unusual foods)
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
Doi 2014 11/119 24/119 2.8 % 0.46 [ 0.24, 0.89 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 8/195 5/196 1.1 % 1.61 [ 0.54, 4.83 ]
FAAT - Leaf 2005 31/200 39/202 5.8 % 0.80 [ 0.52, 1.23 ]
GLAMT 1993 0/54 1/57 0.1 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 7/41 7/39 1.5 % 0.95 [ 0.37, 2.46 ]
Kumar 2013 1/39 1/39 0.2 % 1.00 [ 0.06, 15.43 ]
Nodari 2011 HF 10/67 26/66 3.0 % 0.38 [ 0.20, 0.72 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
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Puri 2005 1/60 0/61 0.1 % 3.05 [ 0.13, 73.40 ]
Raitt 2005 2/100 5/100 0.5 % 0.40 [ 0.08, 2.01 ]
Rose 1965 15/28 11/26 3.7 % 1.27 [ 0.72, 2.23 ]
Subtotal (95% CI) 1258 1184 19.3 % 0.75 [ 0.54, 1.04 ]
Total events: 88 (Higher PUFA), 120 (Lower PUFA)
Heterogeneity: Tau2 = 0.07; Chi2 = 15.43, df = 12 (P = 0.22); I2 =22%
Test for overall effect: Z = 1.70 (P = 0.089)
4 Any combination
MRC 1968 62/199 74/194 10.8 % 0.82 [ 0.62, 1.07 ]
Sydney Diet-Heart 1978 37/221 25/237 5.0 % 1.59 [ 0.99, 2.55 ]
Subtotal (95% CI) 420 431 15.8 % 1.11 [ 0.57, 2.13 ]
Total events: 99 (Higher PUFA), 99 (Lower PUFA)
Heterogeneity: Tau2 = 0.19; Chi2 = 5.79, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 0.30 (P = 0.76)
Total (95% CI) 9071 8728 100.0 % 0.89 [ 0.79, 1.01 ]
Total events: 1170 (Higher PUFA), 1272 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 28.71, df = 20 (P = 0.09); I2 =30%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Chi2 = 4.61, df = 3 (P = 0.20), I2 =35%
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Analysis 2.25. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
25 CORONARY HEART DISEASE (CHD) MORTALITY.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 25 CORONARY HEART DISEASE (CHD) MORTALITY








AlphaOmega - ALA 66/2409 72/2428 22.5 % 0.92 [ 0.66, 1.28 ]
Brox 2001 (1) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 162/1018 178/1015 64.6 % 0.91 [ 0.75, 1.10 ]
Doi 2014 (2) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT - Leaf 2005 (3) 9/200 9/202 3.0 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Rose 1965 2/28 1/26 0.4 % 1.86 [ 0.18, 19.29 ]
Veterans Admin 1969 23/424 23/422 7.7 % 1.00 [ 0.57, 1.75 ]
Total (95% CI) 4419 4391 100.0 % 0.91 [ 0.78, 1.06 ]
Total events: 264 (Higher PUFA), 292 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.98, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 2.26. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
26 CHD mortality - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 26 CHD mortality - SA








1 Low risk of bias for allocation concealment
AlphaOmega - ALA 66/2409 72/2428 87.4 % 0.92 [ 0.66, 1.28 ]
Brox 2001 (1) 0/80 1/40 0.9 % 0.17 [ 0.01, 4.05 ]
FAAT - Leaf 2005 (2) 9/200 9/202 11.6 % 1.01 [ 0.41, 2.49 ]
Subtotal (95% CI) 2689 2670 100.0 % 0.92 [ 0.68, 1.25 ]
Total events: 75 (Higher PUFA), 82 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
2 Low risk of bias for attention
AlphaOmega - ALA 66/2409 72/2428 63.7 % 0.92 [ 0.66, 1.28 ]
Brox 2001 (3) 0/80 1/40 0.7 % 0.17 [ 0.01, 4.05 ]
Doi 2014 (4) 0/119 2/119 0.8 % 0.20 [ 0.01, 4.12 ]
FAAT - Leaf 2005 (5) 9/200 9/202 8.5 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.7 % 0.32 [ 0.01, 7.57 ]
Raitt 2005 2/100 5/100 2.6 % 0.40 [ 0.08, 2.01 ]
Rose 1965 2/28 1/26 1.3 % 1.86 [ 0.18, 19.29 ]
Veterans Admin 1969 23/424 23/422 21.8 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 3401 3376 100.0 % 0.91 [ 0.70, 1.18 ]
Total events: 102 (Higher PUFA), 114 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.98, df = 7 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
3 Low risk of bias for compliance
Brox 2001 (6) 0/80 1/40 0.3 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 162/1018 178/1015 88.5 % 0.91 [ 0.75, 1.10 ]
Rose 1965 2/28 1/26 0.6 % 1.86 [ 0.18, 19.29 ]
Veterans Admin 1969 23/424 23/422 10.6 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 1550 1503 100.0 % 0.92 [ 0.76, 1.10 ]
Total events: 187 (Higher PUFA), 203 (Lower PUFA)
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Heterogeneity: Tau2 = 0.0; Chi2 = 1.53, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
4 Low summary risk of bias
AlphaOmega - ALA 66/2409 72/2428 100.0 % 0.92 [ 0.66, 1.28 ]
Subtotal (95% CI) 2409 2428 100.0 % 0.92 [ 0.66, 1.28 ]
Total events: 66 (Higher PUFA), 72 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
5 Trials registry or pre-2010
AlphaOmega - ALA 66/2409 72/2428 22.5 % 0.92 [ 0.66, 1.28 ]
Brox 2001 (7) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 162/1018 178/1015 64.6 % 0.91 [ 0.75, 1.10 ]
Doi 2014 (8) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT - Leaf 2005 (9) 9/200 9/202 3.0 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Rose 1965 2/28 1/26 0.4 % 1.86 [ 0.18, 19.29 ]
Veterans Admin 1969 23/424 23/422 7.7 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 4419 4391 100.0 % 0.91 [ 0.78, 1.06 ]
Total events: 264 (Higher PUFA), 292 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.98, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
6 No industry funding
Brox 2001 (10) 0/80 1/40 12.4 % 0.17 [ 0.01, 4.05 ]
FAAT - Leaf 2005 (11) 9/200 9/202 87.6 % 1.01 [ 0.41, 2.49 ]
Subtotal (95% CI) 280 242 100.0 % 0.81 [ 0.25, 2.58 ]
Total events: 9 (Higher PUFA), 10 (Lower PUFA)
Heterogeneity: Tau2 = 0.19; Chi2 = 1.13, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 0.36 (P = 0.72)
7 Randomised 100+ participants
AlphaOmega - ALA 66/2409 72/2428 22.7 % 0.92 [ 0.66, 1.28 ]
Brox 2001 (12) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 162/1018 178/1015 65.1 % 0.91 [ 0.75, 1.10 ]
Doi 2014 (13) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT - Leaf 2005 (14) 9/200 9/202 3.0 % 1.01 [ 0.41, 2.49 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
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Veterans Admin 1969 23/424 23/422 7.8 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 4350 4326 100.0 % 0.91 [ 0.77, 1.06 ]
Total events: 262 (Higher PUFA), 290 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.20, df = 6 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
8 Randomised 250+ participants
AlphaOmega - ALA 66/2409 72/2428 23.0 % 0.92 [ 0.66, 1.28 ]
DART fat 1989 162/1018 178/1015 66.1 % 0.91 [ 0.75, 1.10 ]
FAAT - Leaf 2005 (15) 9/200 9/202 3.1 % 1.01 [ 0.41, 2.49 ]
Veterans Admin 1969 23/424 23/422 7.9 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 4051 4067 100.0 % 0.92 [ 0.79, 1.08 ]
Total events: 260 (Higher PUFA), 282 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
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Analysis 2.27. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
27 CHD mortality - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 27 CHD mortality - SA fixed-effect
Study or subgroup Higher PUFA Lower PUFA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AlphaOmega - ALA 66/2409 72/2428 24.4 % 0.92 [ 0.66, 1.28 ]
Brox 2001 (1) 0/80 1/40 0.7 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 162/1018 178/1015 60.6 % 0.91 [ 0.75, 1.10 ]
Doi 2014 (2) 0/119 2/119 0.9 % 0.20 [ 0.01, 4.12 ]
FAAT - Leaf 2005 (3) 9/200 9/202 3.0 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.5 % 0.32 [ 0.01, 7.57 ]
Raitt 2005 2/100 5/100 1.7 % 0.40 [ 0.08, 2.01 ]
Rose 1965 2/28 1/26 0.4 % 1.86 [ 0.18, 19.29 ]
Veterans Admin 1969 23/424 23/422 7.8 % 1.00 [ 0.57, 1.75 ]
Total (95% CI) 4419 4391 100.0 % 0.90 [ 0.77, 1.05 ]
Total events: 264 (Higher PUFA), 292 (Lower PUFA)
Heterogeneity: Chi2 = 3.98, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 2.28. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
28 CHD mortality - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 28 CHD mortality - subgroup by PUFA dose








1 total PUFA < 1.0% E
Doi 2014 (1) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT - Leaf 2005 (2) 9/200 9/202 3.0 % 1.01 [ 0.41, 2.49 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Subtotal (95% CI) 419 421 4.2 % 0.74 [ 0.35, 1.59 ]
Total events: 11 (Higher PUFA), 16 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.75, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
2 total PUFA 1.0 to < 2.0% E
AlphaOmega - ALA 66/2409 72/2428 22.5 % 0.92 [ 0.66, 1.28 ]
Brox 2001 (3) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Subtotal (95% CI) 2489 2468 22.8 % 0.85 [ 0.41, 1.76 ]
Total events: 66 (Higher PUFA), 73 (Lower PUFA)
Heterogeneity: Tau2 = 0.12; Chi2 = 1.09, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 0.44 (P = 0.66)
3 total PUFA 2.0 to < 5.0% E
DART fat 1989 162/1018 178/1015 64.6 % 0.91 [ 0.75, 1.10 ]
HARP- Sacks 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Subtotal (95% CI) 1059 1054 64.9 % 0.90 [ 0.74, 1.10 ]
Total events: 162 (Higher PUFA), 179 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
4 total PUFA > 5.0% E
Rose 1965 2/28 1/26 0.4 % 1.86 [ 0.18, 19.29 ]
Veterans Admin 1969 23/424 23/422 7.7 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 452 448 8.2 % 1.03 [ 0.60, 1.78 ]
Total events: 25 (Higher PUFA), 24 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.92)
Total (95% CI) 4419 4391 100.0 % 0.91 [ 0.78, 1.06 ]
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Total events: 264 (Higher PUFA), 292 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.98, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 0.51, df = 3 (P = 0.92), I2 =0.0%
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Analysis 2.29. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
29 CHD mortality - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 29 CHD mortality - subgroup by duration








1 Medium duration 1 to < 2 years
Brox 2001 (1) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Doi 2014 (2) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT - Leaf 2005 (3) 9/200 9/202 3.0 % 1.01 [ 0.41, 2.49 ]
Subtotal (95% CI) 399 361 3.5 % 0.78 [ 0.34, 1.83 ]
Total events: 9 (Higher PUFA), 12 (Lower PUFA)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.01, df = 2 (P = 0.37); I2 =1%
Test for overall effect: Z = 0.56 (P = 0.57)
2 Medium-long duration 2 to < 4 years
AlphaOmega - ALA 66/2409 72/2428 22.5 % 0.92 [ 0.66, 1.28 ]
DART fat 1989 162/1018 178/1015 64.6 % 0.91 [ 0.75, 1.10 ]
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HARP- Sacks 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Rose 1965 2/28 1/26 0.4 % 1.86 [ 0.18, 19.29 ]
Subtotal (95% CI) 3596 3608 88.8 % 0.90 [ 0.77, 1.07 ]
Total events: 232 (Higher PUFA), 257 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.78, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
3 Long duration 4+ years
Veterans Admin 1969 23/424 23/422 7.7 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 424 422 7.7 % 1.00 [ 0.57, 1.75 ]
Total events: 23 (Higher PUFA), 23 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
Total (95% CI) 4419 4391 100.0 % 0.91 [ 0.78, 1.06 ]
Total events: 264 (Higher PUFA), 292 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.98, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 0.22, df = 2 (P = 0.90), I2 =0.0%
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Analysis 2.30. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
30 CHD mortality - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 30 CHD mortality - subgroup by primary or secondary prevention








1 Primary prevention of CVD
Brox 2001 (1) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Veterans Admin 1969 23/424 23/422 7.7 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 504 462 8.0 % 0.84 [ 0.30, 2.34 ]
Total events: 23 (Higher PUFA), 24 (Lower PUFA)
Heterogeneity: Tau2 = 0.22; Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.34 (P = 0.74)
2 Secondary prevention of CVD
AlphaOmega - ALA 66/2409 72/2428 22.5 % 0.92 [ 0.66, 1.28 ]
DART fat 1989 162/1018 178/1015 64.6 % 0.91 [ 0.75, 1.10 ]
Doi 2014 (2) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT - Leaf 2005 (3) 9/200 9/202 3.0 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Rose 1965 2/28 1/26 0.4 % 1.86 [ 0.18, 19.29 ]
Subtotal (95% CI) 3915 3929 92.0 % 0.90 [ 0.77, 1.06 ]
Total events: 241 (Higher PUFA), 268 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.79, df = 6 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 4419 4391 100.0 % 0.91 [ 0.78, 1.06 ]
Total events: 264 (Higher PUFA), 292 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.98, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 2.31. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
31 CHD mortality - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 31 CHD mortality - subgroup by baseline PUFA dose








1 Baseline total PUFA < 6% E
Veterans Admin 1969 23/424 23/422 7.7 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 424 422 7.7 % 1.00 [ 0.57, 1.75 ]
Total events: 23 (Higher PUFA), 23 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
2 Baseline total PUFA 6 to < 11% E
DART fat 1989 162/1018 178/1015 64.6 % 0.91 [ 0.75, 1.10 ]
Subtotal (95% CI) 1018 1015 64.6 % 0.91 [ 0.75, 1.10 ]
Total events: 162 (Higher PUFA), 178 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
AlphaOmega - ALA 66/2409 72/2428 22.5 % 0.92 [ 0.66, 1.28 ]
Brox 2001 (1) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Doi 2014 (2) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT - Leaf 2005 (3) 9/200 9/202 3.0 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Rose 1965 2/28 1/26 0.4 % 1.86 [ 0.18, 19.29 ]
Subtotal (95% CI) 2977 2954 27.6 % 0.88 [ 0.66, 1.19 ]
Total events: 79 (Higher PUFA), 91 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.84, df = 6 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Total (95% CI) 4419 4391 100.0 % 0.91 [ 0.78, 1.06 ]
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Total events: 264 (Higher PUFA), 292 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.98, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 0.14, df = 2 (P = 0.93), I2 =0.0%
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(1) Fatal MI
(2) Fatal MI/ sudden death
(3) Cardiac deaths
Analysis 2.32. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
32 CHD mortality - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 32 CHD mortality - subgroup by replacement








1 PUFA replaced saturated fats
DART fat 1989 162/1018 178/1015 89.3 % 0.91 [ 0.75, 1.10 ]
Veterans Admin 1969 23/424 23/422 10.7 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 1442 1437 100.0 % 0.92 [ 0.76, 1.10 ]
Total events: 185 (Higher PUFA), 201 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
2 PUFA replaced monounsaturated fats
AlphaOmega - ALA 66/2409 72/2428 64.6 % 0.92 [ 0.66, 1.28 ]
FAAT - Leaf 2005 (1) 9/200 9/202 8.6 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.7 % 0.32 [ 0.01, 7.57 ]
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Raitt 2005 2/100 5/100 2.7 % 0.40 [ 0.08, 2.01 ]
Rose 1965 2/28 1/26 1.3 % 1.86 [ 0.18, 19.29 ]
Veterans Admin 1969 23/424 23/422 22.2 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 3202 3217 100.0 % 0.93 [ 0.71, 1.21 ]
Total events: 102 (Higher PUFA), 111 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.91, df = 5 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
3 PUFA replaced carbohydrates
Rose 1965 2/28 1/26 100.0 % 1.86 [ 0.18, 19.29 ]
Subtotal (95% CI) 28 26 100.0 % 1.86 [ 0.18, 19.29 ]
Total events: 2 (Higher PUFA), 1 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
4 PUFA replaced protein
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 PUFA replaced unclear
Brox 2001 (2) 0/80 1/40 47.5 % 0.17 [ 0.01, 4.05 ]
Doi 2014 (3) 0/119 2/119 52.5 % 0.20 [ 0.01, 4.12 ]
Subtotal (95% CI) 199 159 100.0 % 0.18 [ 0.02, 1.65 ]
Total events: 0 (Higher PUFA), 3 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 2.41, df = 3 (P = 0.49), I2 =0.0%
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Analysis 2.33. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
33 CHD mortality - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 33 CHD mortality - subgroup by sex








1 > 70% men
AlphaOmega - ALA 66/2409 72/2428 22.5 % 0.92 [ 0.66, 1.28 ]
DART fat 1989 162/1018 178/1015 64.6 % 0.91 [ 0.75, 1.10 ]
Doi 2014 (1) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT - Leaf 2005 (2) 9/200 9/202 3.0 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Veterans Admin 1969 23/424 23/422 7.7 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 4311 4325 99.3 % 0.91 [ 0.78, 1.06 ]
Total events: 262 (Higher PUFA), 290 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.54, df = 6 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
2 > 70% women
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 men % women
Brox 2001 (3) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Subtotal (95% CI) 80 40 0.2 % 0.17 [ 0.01, 4.05 ]
Total events: 0 (Higher PUFA), 1 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
4 sex not reported
Rose 1965 2/28 1/26 0.4 % 1.86 [ 0.18, 19.29 ]
Subtotal (95% CI) 28 26 0.4 % 1.86 [ 0.18, 19.29 ]
Total events: 2 (Higher PUFA), 1 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Total (95% CI) 4419 4391 100.0 % 0.91 [ 0.78, 1.06 ]
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Total events: 264 (Higher PUFA), 292 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.98, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 1.44, df = 2 (P = 0.49), I2 =0.0%
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Favours higher PUFA Favours lower PUFA
(1) Fatal MI/ sudden death
(2) Cardiac deaths
(3) Fatal MI
Analysis 2.34. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
34 CHD mortality - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 34 CHD mortality - subgroup by age








1 Mean age < 50 years
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Mean age 50 to < 65 years
Brox 2001 (1) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 162/1018 178/1015 64.6 % 0.91 [ 0.75, 1.10 ]
HARP- Sacks 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Rose 1965 2/28 1/26 0.4 % 1.86 [ 0.18, 19.29 ]
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Subtotal (95% CI) 1267 1220 66.5 % 0.89 [ 0.74, 1.08 ]
Total events: 166 (Higher PUFA), 186 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.82, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.24)
3 Mean age 65+ years
AlphaOmega - ALA 66/2409 72/2428 22.5 % 0.92 [ 0.66, 1.28 ]
Doi 2014 (2) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT - Leaf 2005 (3) 9/200 9/202 3.0 % 1.01 [ 0.41, 2.49 ]
Veterans Admin 1969 23/424 23/422 7.7 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 3152 3171 33.5 % 0.94 [ 0.71, 1.23 ]
Total events: 98 (Higher PUFA), 106 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.08, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 4419 4391 100.0 % 0.91 [ 0.78, 1.06 ]
Total events: 264 (Higher PUFA), 292 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.98, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 0.08, df = 1 (P = 0.78), I2 =0.0%
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Analysis 2.35. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
35 CHD mortality - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 35 CHD mortality - subgroup by statin use








1 < 50% on statins
Brox 2001 (1) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 162/1018 178/1015 64.6 % 0.91 [ 0.75, 1.10 ]
HARP- Sacks 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Rose 1965 2/28 1/26 0.4 % 1.86 [ 0.18, 19.29 ]
Veterans Admin 1969 23/424 23/422 7.7 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 1691 1642 74.2 % 0.90 [ 0.75, 1.08 ]
Total events: 189 (Higher PUFA), 209 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.95, df = 5 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
2 50+% on statins
AlphaOmega - ALA 66/2409 72/2428 22.5 % 0.92 [ 0.66, 1.28 ]
Doi 2014 (2) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
Subtotal (95% CI) 2528 2547 22.8 % 0.91 [ 0.65, 1.26 ]
Total events: 66 (Higher PUFA), 74 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
3 Percentage on statins unclear
FAAT - Leaf 2005 (3) 9/200 9/202 3.0 % 1.01 [ 0.41, 2.49 ]
Subtotal (95% CI) 200 202 3.0 % 1.01 [ 0.41, 2.49 ]
Total events: 9 (Higher PUFA), 9 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 4419 4391 100.0 % 0.91 [ 0.78, 1.06 ]
Total events: 264 (Higher PUFA), 292 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.98, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 0.06, df = 2 (P = 0.97), I2 =0.0%
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Analysis 2.36. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
36 CHD mortality - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 36 CHD mortality - subgroup by intervention type









DART fat 1989 162/1018 178/1015 64.6 % 0.91 [ 0.75, 1.10 ]
Subtotal (95% CI) 1018 1015 64.6 % 0.91 [ 0.75, 1.10 ]
Total events: 162 (Higher PUFA), 178 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
2 Supplemental foods % diet provided
AlphaOmega - ALA 66/2409 72/2428 22.5 % 0.92 [ 0.66, 1.28 ]
Veterans Admin 1969 23/424 23/422 7.7 % 1.00 [ 0.57, 1.75 ]
Subtotal (95% CI) 2833 2850 30.2 % 0.94 [ 0.71, 1.25 ]
Total events: 89 (Higher PUFA), 95 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
3 Supplements (capsules % unusual foods)
Brox 2001 (1) 0/80 1/40 0.2 % 0.17 [ 0.01, 4.05 ]
Doi 2014 (2) 0/119 2/119 0.3 % 0.20 [ 0.01, 4.12 ]
FAAT - Leaf 2005 (3) 9/200 9/202 3.0 % 1.01 [ 0.41, 2.49 ]
HARP- Sacks 1995 0/41 1/39 0.2 % 0.32 [ 0.01, 7.57 ]
Raitt 2005 2/100 5/100 0.9 % 0.40 [ 0.08, 2.01 ]
Rose 1965 2/28 1/26 0.4 % 1.86 [ 0.18, 19.29 ]
Subtotal (95% CI) 568 526 5.1 % 0.72 [ 0.36, 1.43 ]
Total events: 13 (Higher PUFA), 19 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.45, df = 5 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
4 Any combination
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
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Test for overall effect: not applicable
Total (95% CI) 4419 4391 100.0 % 0.91 [ 0.78, 1.06 ]
Total events: 264 (Higher PUFA), 292 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.98, df = 8 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 0.50, df = 2 (P = 0.78), I2 =0.0%
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Analysis 2.37. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
37 MYOCARDIAL INFARCTION (MI) - fatal and non fatal.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 37 MYOCARDIAL INFARCTION (MI) - fatal and non fatal








AlphaOmega - ALA 90/2409 101/2428 19.4 % 0.90 [ 0.68, 1.19 ]
Brox 2001 0/80 1/40 0.1 % 0.17 [ 0.01, 4.05 ]
DART fat 1989 197/1018 225/1015 51.7 % 0.87 [ 0.74, 1.04 ]
Doi 2014 1/119 0/119 0.1 % 3.00 [ 0.12, 72.91 ]
EPOCH 2011 1/195 0/196 0.1 % 3.02 [ 0.12, 73.57 ]
GLAMT 1993 0/54 1/57 0.1 % 0.35 [ 0.01, 8.45 ]
HARP- Sacks 1995 1/41 3/39 0.3 % 0.32 [ 0.03, 2.92 ]
Houtsmuller 1979 0/51 6/51 0.2 % 0.08 [ 0.00, 1.33 ]
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MRC 1968 39/199 40/194 9.7 % 0.95 [ 0.64, 1.41 ]
NDHS Open 1st 1968 4/726 1/341 0.3 % 1.88 [ 0.21, 16.75 ]
PREDIMED 2013 31/2454 37/2543 6.7 % 0.87 [ 0.54, 1.39 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 1/100 3/100 0.3 % 0.33 [ 0.04, 3.15 ]
Rose 1965 9/28 7/26 2.2 % 1.19 [ 0.52, 2.74 ]
Veterans Admin 1969 36/424 44/422 8.5 % 0.81 [ 0.54, 1.24 ]
Total (95% CI) 7985 7624 100.0 % 0.88 [ 0.78, 0.99 ]
Total events: 411 (Higher PUFA), 469 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.36, df = 14 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.040)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours higher PUFA Favours lower PUFA
371Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.38. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
38 SUDDEN CARDIAC DEATH (SCD).
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 38 SUDDEN CARDIAC DEATH (SCD)








Doi 2014 0/119 2/119 2.4 % 0.20 [ 0.01, 4.12 ]
MRC 1968 8/199 7/194 22.3 % 1.11 [ 0.41, 3.01 ]
Raitt 2005 2/100 0/100 2.4 % 5.00 [ 0.24, 102.85 ]
Rose 1965 3/28 2/26 7.6 % 1.39 [ 0.25, 7.68 ]
Veterans Admin 1969 18/424 27/422 65.3 % 0.66 [ 0.37, 1.19 ]
Total (95% CI) 870 861 100.0 % 0.80 [ 0.50, 1.29 ]
Total events: 31 (Higher PUFA), 38 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.45, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 2.39. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
39 ATRIAL FIBRILLATION (AF) & ARRHYTHMIAS (including AF, ventricular tachycardia (VT), ventricular
fibrillation(VF).
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 39 ATRIAL FIBRILLATION (AF) % ARRHYTHMIAS (including AF, ventricular tachycardia (VT), ventricular fibrillation(VF)









FAAT - Leaf 2005 60/200 79/202 15.9 % 0.77 [ 0.58, 1.01 ]
Kumar 2012 61/91 78/87 20.0 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 14.7 % 0.65 [ 0.48, 0.89 ]
Raitt 2005 (1) 65/100 59/100 18.0 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 491 488 68.6 % 0.81 [ 0.65, 1.01 ]
Total events: 223 (Higher PUFA), 272 (Lower PUFA)
Heterogeneity: Tau2 = 0.03; Chi2 = 10.62, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 1.89 (P = 0.059)
2 New arrhythmia
AlphaOmega - ALA 62/2409 79/2428 14.0 % 0.79 [ 0.57, 1.10 ]
EPIC-1 2008 1/188 0/186 0.4 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 2/195 1/196 0.6 % 2.01 [ 0.18, 21.99 ]
Nodari 2011 HF 1/67 4/66 0.8 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.4 % 0.32 [ 0.01, 7.84 ]
PREDIMED 2013 92/2210 72/2292 14.9 % 1.33 [ 0.98, 1.79 ]
Proudman 2015 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 5327 5386 31.4 % 1.01 [ 0.70, 1.46 ]
Total events: 159 (Higher PUFA), 157 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 8.19, df = 6 (P = 0.22); I2 =27%
Test for overall effect: Z = 0.06 (P = 0.95)
Total (95% CI) 5818 5874 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 382 (Higher PUFA), 429 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.28, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 1.04, df = 1 (P = 0.31), I2 =4%
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Analysis 2.40. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
40 AF - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 40 AF - SA








1 Low risk of bias for allocation concealment
AlphaOmega - ALA 62/2409 79/2428 27.6 % 0.79 [ 0.57, 1.10 ]
EPIC-1 2008 1/188 0/186 0.3 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 2/195 1/196 0.5 % 2.01 [ 0.18, 21.99 ]
FAAT - Leaf 2005 60/200 79/202 39.8 % 0.77 [ 0.58, 1.01 ]
Nodari 2011 AF 37/100 56/99 31.2 % 0.65 [ 0.48, 0.89 ]
ORL 2013 0/171 1/165 0.3 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.3 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 3350 3329 100.0 % 0.74 [ 0.63, 0.88 ]
Total events: 163 (Higher PUFA), 216 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.86, df = 6 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00071)
2 Low risk of bias for attention
AlphaOmega - ALA 62/2409 79/2428 17.6 % 0.79 [ 0.57, 1.10 ]
EPIC-1 2008 1/188 0/186 0.5 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 2/195 1/196 0.9 % 2.01 [ 0.18, 21.99 ]
FAAT - Leaf 2005 60/200 79/202 19.9 % 0.77 [ 0.58, 1.01 ]
Nodari 2011 AF 37/100 56/99 18.4 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 1.0 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.5 % 0.32 [ 0.01, 7.84 ]
PREDIMED 2013 92/2210 72/2292 18.6 % 1.33 [ 0.98, 1.79 ]
Proudman 2015 1/87 0/53 0.5 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (1) 65/100 59/100 22.2 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 5727 5787 100.0 % 0.90 [ 0.72, 1.13 ]
Total events: 321 (Higher PUFA), 351 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 18.37, df = 9 (P = 0.03); I2 =51%
Test for overall effect: Z = 0.90 (P = 0.37)
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3 Low risk of bias for compliance
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Low summary risk of bias
AlphaOmega - ALA 62/2409 79/2428 97.1 % 0.79 [ 0.57, 1.10 ]
EPOCH 2011 2/195 1/196 1.8 % 2.01 [ 0.18, 21.99 ]
Proudman 2015 1/87 0/53 1.0 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 2691 2677 100.0 % 0.81 [ 0.59, 1.12 ]
Total events: 65 (Higher PUFA), 80 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.21)
5 Trials registry or pre-2010
AlphaOmega - ALA 62/2409 79/2428 14.0 % 0.79 [ 0.57, 1.10 ]
EPIC-1 2008 1/188 0/186 0.4 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 2/195 1/196 0.6 % 2.01 [ 0.18, 21.99 ]
FAAT - Leaf 2005 60/200 79/202 15.9 % 0.77 [ 0.58, 1.01 ]
Kumar 2012 61/91 78/87 20.0 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 14.7 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.8 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.4 % 0.32 [ 0.01, 7.84 ]
PREDIMED 2013 92/2210 72/2292 14.9 % 1.33 [ 0.98, 1.79 ]
Proudman 2015 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (2) 65/100 59/100 18.0 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 5818 5874 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 382 (Higher PUFA), 429 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.28, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.42 (P = 0.16)
6 No industry funding
FAAT - Leaf 2005 60/200 79/202 56.1 % 0.77 [ 0.58, 1.01 ]
Nodari 2011 AF 37/100 56/99 43.9 % 0.65 [ 0.48, 0.89 ]
Subtotal (95% CI) 300 301 100.0 % 0.72 [ 0.58, 0.88 ]
Total events: 97 (Higher PUFA), 135 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.21 (P = 0.0013)
7 Randomised 100+ participants
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AlphaOmega - ALA 62/2409 79/2428 14.0 % 0.79 [ 0.57, 1.10 ]
EPIC-1 2008 1/188 0/186 0.4 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 2/195 1/196 0.6 % 2.01 [ 0.18, 21.99 ]
FAAT - Leaf 2005 60/200 79/202 15.9 % 0.77 [ 0.58, 1.01 ]
Kumar 2012 61/91 78/87 20.0 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 14.7 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.8 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.4 % 0.32 [ 0.01, 7.84 ]
PREDIMED 2013 92/2210 72/2292 14.9 % 1.33 [ 0.98, 1.79 ]
Proudman 2015 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (3) 65/100 59/100 18.0 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 5818 5874 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 382 (Higher PUFA), 429 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.28, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.42 (P = 0.16)
8 Randomised 250+ participants
AlphaOmega - ALA 62/2409 79/2428 30.4 % 0.79 [ 0.57, 1.10 ]
EPIC-1 2008 1/188 0/186 0.9 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 2/195 1/196 1.6 % 2.01 [ 0.18, 21.99 ]
FAAT - Leaf 2005 60/200 79/202 34.1 % 0.77 [ 0.58, 1.01 ]
ORL 2013 0/171 1/165 0.9 % 0.32 [ 0.01, 7.84 ]
PREDIMED 2013 92/2210 72/2292 32.1 % 1.33 [ 0.98, 1.79 ]
Subtotal (95% CI) 5373 5469 100.0 % 0.94 [ 0.69, 1.28 ]
Total events: 217 (Higher PUFA), 232 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 9.53, df = 5 (P = 0.09); I2 =48%
Test for overall effect: Z = 0.39 (P = 0.70)
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Analysis 2.41. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
41 AF - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 41 AF - SA fixed-effect
Study or subgroup Higher PUFA Lower PUFA Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Recurrent arrhythmia
FAAT - Leaf 2005 60/200 79/202 18.3 % 0.77 [ 0.58, 1.01 ]
Kumar 2012 61/91 78/87 18.5 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 13.1 % 0.65 [ 0.48, 0.89 ]
Raitt 2005 (1) 65/100 59/100 13.7 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 491 488 63.5 % 0.81 [ 0.72, 0.91 ]
Total events: 223 (Higher PUFA), 272 (Lower PUFA)
Heterogeneity: Chi2 = 10.62, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 3.47 (P = 0.00051)
2 New arrhythmia
AlphaOmega - ALA 62/2409 79/2428 18.3 % 0.79 [ 0.57, 1.10 ]
EPIC-1 2008 1/188 0/186 0.1 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 2/195 1/196 0.2 % 2.01 [ 0.18, 21.99 ]
Nodari 2011 HF 1/67 4/66 0.9 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.4 % 0.32 [ 0.01, 7.84 ]
PREDIMED 2013 92/2210 72/2292 16.4 % 1.33 [ 0.98, 1.79 ]
Proudman 2015 1/87 0/53 0.1 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 5327 5386 36.5 % 1.03 [ 0.83, 1.28 ]
Total events: 159 (Higher PUFA), 157 (Lower PUFA)
Heterogeneity: Chi2 = 8.19, df = 6 (P = 0.22); I2 =27%
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 5818 5874 100.0 % 0.89 [ 0.80, 1.00 ]
Total events: 382 (Higher PUFA), 429 (Lower PUFA)
Heterogeneity: Chi2 = 23.28, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 2.03 (P = 0.042)
Test for subgroup differences: Chi2 = 3.69, df = 1 (P = 0.05), I2 =73%
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Analysis 2.42. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
42 AF - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 42 AF - subgroup by PUFA dose








1 total PUFA < 1.0% E
EPOCH 2011 2/195 1/196 0.6 % 2.01 [ 0.18, 21.99 ]
FAAT - Leaf 2005 60/200 79/202 15.9 % 0.77 [ 0.58, 1.01 ]
Kumar 2012 61/91 78/87 20.0 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 14.7 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.8 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.4 % 0.32 [ 0.01, 7.84 ]
Raitt 2005 (1) 65/100 59/100 18.0 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 924 915 70.4 % 0.80 [ 0.65, 0.99 ]
Total events: 226 (Higher PUFA), 278 (Lower PUFA)
Heterogeneity: Tau2 = 0.03; Chi2 = 12.69, df = 6 (P = 0.05); I2 =53%
Test for overall effect: Z = 2.07 (P = 0.038)
2 total PUFA 1.0 to < 2.0% E
AlphaOmega - ALA 62/2409 79/2428 14.0 % 0.79 [ 0.57, 1.10 ]
EPIC-1 2008 1/188 0/186 0.4 % 2.97 [ 0.12, 72.40 ]
PREDIMED 2013 92/2210 72/2292 14.9 % 1.33 [ 0.98, 1.79 ]
Proudman 2015 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 4894 4959 29.6 % 1.06 [ 0.70, 1.60 ]
Total events: 156 (Higher PUFA), 151 (Lower PUFA)
Heterogeneity: Tau2 = 0.07; Chi2 = 5.66, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 0.27 (P = 0.79)
3 total PUFA 2.0 to < 5.0% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 total PUFA 5.0+% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
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Test for overall effect: not applicable
Total (95% CI) 5818 5874 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 382 (Higher PUFA), 429 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.28, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 1.34, df = 1 (P = 0.25), I2 =25%
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Analysis 2.43. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
43 AF - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 43 AF - subgroup by duration








1 Medium duration 1 to < 2 years
EPIC-1 2008 1/188 0/186 0.4 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 2/195 1/196 0.6 % 2.01 [ 0.18, 21.99 ]
FAAT - Leaf 2005 60/200 79/202 15.9 % 0.77 [ 0.58, 1.01 ]
Kumar 2012 61/91 78/87 20.0 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 14.7 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.8 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.4 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 1099 1054 53.2 % 0.74 [ 0.65, 0.83 ]
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Total events: 163 (Higher PUFA), 219 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.66, df = 7 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 4.78 (P < 0.00001)
2 Medium-long duration 2 to < 4 years
AlphaOmega - ALA 62/2409 79/2428 14.0 % 0.79 [ 0.57, 1.10 ]
Raitt 2005 (1) 65/100 59/100 18.0 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 2509 2528 32.0 % 0.95 [ 0.66, 1.36 ]
Total events: 127 (Higher PUFA), 138 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 3.37, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 0.27 (P = 0.79)
3 Long duration 4+ years
PREDIMED 2013 92/2210 72/2292 14.9 % 1.33 [ 0.98, 1.79 ]
Subtotal (95% CI) 2210 2292 14.9 % 1.33 [ 0.98, 1.79 ]
Total events: 92 (Higher PUFA), 72 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.068)
Total (95% CI) 5818 5874 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 382 (Higher PUFA), 429 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.28, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 13.13, df = 2 (P = 0.00), I2 =85%
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Analysis 2.44. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
44 AF - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 44 AF - subgroup by primary or secondary prevention








1 Primary prevention of CVD
EPIC-1 2008 1/188 0/186 0.4 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 2/195 1/196 0.6 % 2.01 [ 0.18, 21.99 ]
ORL 2013 0/171 1/165 0.4 % 0.32 [ 0.01, 7.84 ]
PREDIMED 2013 92/2210 72/2292 14.9 % 1.33 [ 0.98, 1.79 ]
Proudman 2015 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 2851 2892 16.6 % 1.33 [ 0.99, 1.79 ]
Total events: 96 (Higher PUFA), 74 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 4 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
2 Secondary prevention of CVD
AlphaOmega - ALA 62/2409 79/2428 14.0 % 0.79 [ 0.57, 1.10 ]
FAAT - Leaf 2005 60/200 79/202 15.9 % 0.77 [ 0.58, 1.01 ]
Kumar 2012 61/91 78/87 20.0 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 14.7 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.8 % 0.25 [ 0.03, 2.15 ]
Raitt 2005 (1) 65/100 59/100 18.0 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 2967 2982 83.4 % 0.80 [ 0.67, 0.96 ]
Total events: 286 (Higher PUFA), 355 (Lower PUFA)
Heterogeneity: Tau2 = 0.03; Chi2 = 11.85, df = 5 (P = 0.04); I2 =58%
Test for overall effect: Z = 2.40 (P = 0.017)
Total (95% CI) 5818 5874 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 382 (Higher PUFA), 429 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.28, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 8.18, df = 1 (P = 0.00), I2 =88%
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Analysis 2.45. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
45 Atrial fibrillation - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 45 Atrial fibrillation - subgroup by baseline PUFA dose








1 Baseline total PUFA < 6% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Baseline total PUFA 6 to < 11% E
PREDIMED 2013 92/2210 72/2292 14.9 % 1.33 [ 0.98, 1.79 ]
Subtotal (95% CI) 2210 2292 14.9 % 1.33 [ 0.98, 1.79 ]
Total events: 92 (Higher PUFA), 72 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.068)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
AlphaOmega - ALA 62/2409 79/2428 14.0 % 0.79 [ 0.57, 1.10 ]
EPIC-1 2008 1/188 0/186 0.4 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 2/195 1/196 0.6 % 2.01 [ 0.18, 21.99 ]
FAAT - Leaf 2005 60/200 79/202 15.9 % 0.77 [ 0.58, 1.01 ]
Kumar 2012 61/91 78/87 20.0 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 14.7 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.8 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.4 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (1) 65/100 59/100 18.0 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 3608 3582 85.1 % 0.81 [ 0.69, 0.95 ]
Total events: 290 (Higher PUFA), 357 (Lower PUFA)
Heterogeneity: Tau2 = 0.02; Chi2 = 13.59, df = 9 (P = 0.14); I2 =34%
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Test for overall effect: Z = 2.59 (P = 0.0097)
Total (95% CI) 5818 5874 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 382 (Higher PUFA), 429 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.28, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 7.94, df = 1 (P = 0.00), I2 =87%
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Analysis 2.46. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
46 AF - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 46 AF - subgroup by replacement








1 PUFA replaced saturated fats
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 PUFA replaced monounsaturated fats
AlphaOmega - ALA 62/2409 79/2428 17.9 % 0.79 [ 0.57, 1.10 ]
EPOCH 2011 2/195 1/196 0.9 % 2.01 [ 0.18, 21.99 ]
FAAT - Leaf 2005 60/200 79/202 20.0 % 0.77 [ 0.58, 1.01 ]
Nodari 2011 AF 37/100 56/99 18.6 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 1.1 % 0.25 [ 0.03, 2.15 ]
PREDIMED 2013 92/2210 72/2292 18.8 % 1.33 [ 0.98, 1.79 ]
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Proudman 2015 1/87 0/53 0.5 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (1) 65/100 59/100 22.1 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 5368 5436 100.0 % 0.90 [ 0.71, 1.14 ]
Total events: 320 (Higher PUFA), 350 (Lower PUFA)
Heterogeneity: Tau2 = 0.05; Chi2 = 17.44, df = 7 (P = 0.01); I2 =60%
Test for overall effect: Z = 0.88 (P = 0.38)
3 PUFA replaced carbohydrates
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 PUFA replaced protein
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 PUFA replaced unclear
EPIC-1 2008 1/188 0/186 0.3 % 2.97 [ 0.12, 72.40 ]
Kumar 2012 61/91 78/87 99.5 % 0.75 [ 0.64, 0.88 ]
ORL 2013 0/171 1/165 0.3 % 0.32 [ 0.01, 7.84 ]
Subtotal (95% CI) 450 438 100.0 % 0.75 [ 0.64, 0.88 ]
Total events: 62 (Higher PUFA), 79 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.54 (P = 0.00040)
Test for subgroup differences: Chi2 = 1.60, df = 1 (P = 0.21), I2 =38%
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Analysis 2.47. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
47 Atrial fibrillation - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 47 Atrial fibrillation - subgroup by sex








1 > 70% men
AlphaOmega - ALA 62/2409 79/2428 14.0 % 0.79 [ 0.57, 1.10 ]
FAAT - Leaf 2005 60/200 79/202 15.9 % 0.77 [ 0.58, 1.01 ]
Kumar 2012 61/91 78/87 20.0 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 HF 1/67 4/66 0.8 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.4 % 0.32 [ 0.01, 7.84 ]
Raitt 2005 (1) 65/100 59/100 18.0 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 3038 3048 69.1 % 0.83 [ 0.69, 1.01 ]
Total events: 249 (Higher PUFA), 300 (Lower PUFA)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.09, df = 5 (P = 0.07); I2 =50%
Test for overall effect: Z = 1.87 (P = 0.061)
2 > 70% women
Proudman 2015 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Subtotal (95% CI) 87 53 0.4 % 1.84 [ 0.08, 44.38 ]
Total events: 1 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
3 men % women
EPIC-1 2008 1/188 0/186 0.4 % 2.97 [ 0.12, 72.40 ]
Nodari 2011 AF 37/100 56/99 14.7 % 0.65 [ 0.48, 0.89 ]
PREDIMED 2013 92/2210 72/2292 14.9 % 1.33 [ 0.98, 1.79 ]
Subtotal (95% CI) 2498 2577 29.9 % 0.98 [ 0.50, 1.93 ]
Total events: 130 (Higher PUFA), 128 (Lower PUFA)
Heterogeneity: Tau2 = 0.23; Chi2 = 11.48, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 0.06 (P = 0.95)
4 sex not reported
EPOCH 2011 2/195 1/196 0.6 % 2.01 [ 0.18, 21.99 ]
Subtotal (95% CI) 195 196 0.6 % 2.01 [ 0.18, 21.99 ]
Total events: 2 (Higher PUFA), 1 (Lower PUFA)
Heterogeneity: not applicable
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Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 5818 5874 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 382 (Higher PUFA), 429 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.28, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 0.93, df = 3 (P = 0.82), I2 =0.0%
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(1) ICD therapy for VT/VF
Analysis 2.48. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
48 AF - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 48 AF - subgroup by age








1 Mean age < 50 years
EPIC-1 2008 1/188 0/186 0.4 % 2.97 [ 0.12, 72.40 ]
Subtotal (95% CI) 188 186 0.4 % 2.97 [ 0.12, 72.40 ]
Total events: 1 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Mean age 50 to < 65 years
Kumar 2012 61/91 78/87 20.0 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 HF 1/67 4/66 0.8 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.4 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (1) 65/100 59/100 18.0 % 1.10 [ 0.89, 1.37 ]
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Subtotal (95% CI) 516 471 39.5 % 0.87 [ 0.62, 1.23 ]
Total events: 128 (Higher PUFA), 142 (Lower PUFA)
Heterogeneity: Tau2 = 0.06; Chi2 = 9.92, df = 4 (P = 0.04); I2 =60%
Test for overall effect: Z = 0.80 (P = 0.42)
3 Mean age 65+ years
AlphaOmega - ALA 62/2409 79/2428 14.0 % 0.79 [ 0.57, 1.10 ]
FAAT - Leaf 2005 60/200 79/202 15.9 % 0.77 [ 0.58, 1.01 ]
Nodari 2011 AF 37/100 56/99 14.7 % 0.65 [ 0.48, 0.89 ]
PREDIMED 2013 92/2210 72/2292 14.9 % 1.33 [ 0.98, 1.79 ]
Subtotal (95% CI) 4919 5021 59.5 % 0.85 [ 0.63, 1.15 ]
Total events: 251 (Higher PUFA), 286 (Lower PUFA)
Heterogeneity: Tau2 = 0.07; Chi2 = 12.11, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 1.04 (P = 0.30)
4 Mean age unclear
EPOCH 2011 2/195 1/196 0.6 % 2.01 [ 0.18, 21.99 ]
Subtotal (95% CI) 195 196 0.6 % 2.01 [ 0.18, 21.99 ]
Total events: 2 (Higher PUFA), 1 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 5818 5874 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 382 (Higher PUFA), 429 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.28, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 1.06, df = 3 (P = 0.79), I2 =0.0%
0.2 0.5 1 2 5
Favours higher PUFA Favours lower PUFA
(1) ICD therapy for VT/VF
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Analysis 2.49. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
49 AF - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 49 AF - subgroup by statin use








1 < 50% on statins
EPIC-1 2008 1/188 0/186 0.4 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 2/195 1/196 0.6 % 2.01 [ 0.18, 21.99 ]
Kumar 2012 61/91 78/87 20.0 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 14.7 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.8 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.4 % 0.32 [ 0.01, 7.84 ]
PREDIMED 2013 92/2210 72/2292 14.9 % 1.33 [ 0.98, 1.79 ]
Proudman 2015 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (1) 65/100 59/100 18.0 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 3209 3244 70.1 % 0.91 [ 0.68, 1.21 ]
Total events: 260 (Higher PUFA), 271 (Lower PUFA)
Heterogeneity: Tau2 = 0.07; Chi2 = 23.83, df = 8 (P = 0.002); I2 =66%
Test for overall effect: Z = 0.63 (P = 0.53)
2 50+% on statins
AlphaOmega - ALA 62/2409 79/2428 14.0 % 0.79 [ 0.57, 1.10 ]
Subtotal (95% CI) 2409 2428 14.0 % 0.79 [ 0.57, 1.10 ]
Total events: 62 (Higher PUFA), 79 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
3 Percentage on statins unclear
FAAT - Leaf 2005 60/200 79/202 15.9 % 0.77 [ 0.58, 1.01 ]
Subtotal (95% CI) 200 202 15.9 % 0.77 [ 0.58, 1.01 ]
Total events: 60 (Higher PUFA), 79 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
Total (95% CI) 5818 5874 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 382 (Higher PUFA), 429 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.28, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 0.80, df = 2 (P = 0.67), I2 =0.0%
0.2 0.5 1 2 5
Favours higher PUFA Favours lower PUFA
(1) ICD therapy for VT/VF
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Analysis 2.50. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
50 AF - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 50 AF - subgroup by intervention type









Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Supplemental foods % diet provided
AlphaOmega - ALA 62/2409 79/2428 14.0 % 0.79 [ 0.57, 1.10 ]
PREDIMED 2013 92/2210 72/2292 14.9 % 1.33 [ 0.98, 1.79 ]
Subtotal (95% CI) 4619 4720 28.9 % 1.03 [ 0.62, 1.70 ]
Total events: 154 (Higher PUFA), 151 (Lower PUFA)
Heterogeneity: Tau2 = 0.11; Chi2 = 5.14, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.11 (P = 0.92)
3 Supplements (capsules % unusual foods)
EPIC-1 2008 1/188 0/186 0.4 % 2.97 [ 0.12, 72.40 ]
EPOCH 2011 2/195 1/196 0.6 % 2.01 [ 0.18, 21.99 ]
FAAT - Leaf 2005 60/200 79/202 15.9 % 0.77 [ 0.58, 1.01 ]
Kumar 2012 61/91 78/87 20.0 % 0.75 [ 0.64, 0.88 ]
Nodari 2011 AF 37/100 56/99 14.7 % 0.65 [ 0.48, 0.89 ]
Nodari 2011 HF 1/67 4/66 0.8 % 0.25 [ 0.03, 2.15 ]
ORL 2013 0/171 1/165 0.4 % 0.32 [ 0.01, 7.84 ]
Proudman 2015 1/87 0/53 0.4 % 1.84 [ 0.08, 44.38 ]
Raitt 2005 (1) 65/100 59/100 18.0 % 1.10 [ 0.89, 1.37 ]
Subtotal (95% CI) 1199 1154 71.1 % 0.81 [ 0.67, 0.98 ]
Total events: 228 (Higher PUFA), 278 (Lower PUFA)
Heterogeneity: Tau2 = 0.02; Chi2 = 13.55, df = 8 (P = 0.09); I2 =41%
Test for overall effect: Z = 2.12 (P = 0.034)
4 Any combination
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Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Higher PUFA), 0 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 5818 5874 100.0 % 0.87 [ 0.72, 1.06 ]
Total events: 382 (Higher PUFA), 429 (Lower PUFA)
Heterogeneity: Tau2 = 0.04; Chi2 = 23.28, df = 10 (P = 0.01); I2 =57%
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Chi2 = 0.73, df = 1 (P = 0.39), I2 =0.0%
0.2 0.5 1 2 5
Favours higher PUFA Favours lower PUFA
(1) ICD therapy for VT/VF
Analysis 2.51. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
51 ANGINA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 51 ANGINA








FAAT - Leaf 2005 (1) 0/200 4/202 3.7 % 0.11 [ 0.01, 2.07 ]
Houtsmuller 1979 8/51 24/51 23.4 % 0.33 [ 0.17, 0.67 ]
MRC 1968 1/199 4/194 6.1 % 0.24 [ 0.03, 2.16 ]
Nye 1990 5/36 11/37 18.4 % 0.47 [ 0.18, 1.21 ]
Raitt 2005 10/100 7/100 18.9 % 1.43 [ 0.57, 3.60 ]
Rose 1965 3/28 2/26 9.0 % 1.39 [ 0.25, 7.68 ]
Veterans Admin 1969 11/424 10/422 20.4 % 1.09 [ 0.47, 2.55 ]
Total (95% CI) 1038 1032 100.0 % 0.64 [ 0.35, 1.16 ]
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Total events: 38 (Higher PUFA), 62 (Lower PUFA)
Heterogeneity: Tau2 = 0.27; Chi2 = 11.12, df = 6 (P = 0.08); I2 =46%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours higher PUFA Favours lower PUFA
(1) Worsening angina
Analysis 2.52. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
52 HEART FAILURE.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 52 HEART FAILURE








DART fat 1989 3/1018 6/1015 12.0 % 0.50 [ 0.13, 1.99 ]
FAAT - Leaf 2005 6/200 8/202 16.5 % 0.76 [ 0.27, 2.14 ]
HARP- Sacks 1995 0/41 1/39 3.3 % 0.32 [ 0.01, 7.57 ]
MRC 1968 1/199 0/194 3.3 % 2.93 [ 0.12, 71.37 ]
Nodari 2011 HF 4/67 20/66 16.8 % 0.20 [ 0.07, 0.55 ]
PREDIMED 2013 (1) 33/10279 29/11737 26.2 % 1.30 [ 0.79, 2.14 ]
Raitt 2005 14/100 12/100 22.0 % 1.17 [ 0.57, 2.40 ]
Total (95% CI) 11904 13353 100.0 % 0.74 [ 0.40, 1.36 ]
Total events: 61 (Higher PUFA), 76 (Lower PUFA)
Heterogeneity: Tau2 = 0.30; Chi2 = 13.00, df = 6 (P = 0.04); I2 =54%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Favours higher PUFA Favours lower PUFA
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(1) data from Papadaki 2017
Analysis 2.53. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
53 PERIPHERAL ARTERIAL DISEASE (PAD).
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 53 PERIPHERAL ARTERIAL DISEASE (PAD)








DART fat 1989 0/1018 1/1015 1.5 % 0.33 [ 0.01, 8.15 ]
NDHS Open 1st 1968 1/726 0/341 1.5 % 1.41 [ 0.06, 34.55 ]
PREDIMED 2013 26/2452 18/2539 42.8 % 1.50 [ 0.82, 2.72 ]
Veterans Admin 1969 26/424 25/422 54.2 % 1.04 [ 0.61, 1.76 ]
Total (95% CI) 4620 4317 100.0 % 1.20 [ 0.81, 1.77 ]
Total events: 53 (Higher PUFA), 44 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.45, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 2.54. Comparison 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes, Outcome
54 REVASCULARISATION - angioplasty and/or coronary artery bypass grafting.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 2 Higher PUFA vs lower PUFA - dichotomous secondary outcomes
Outcome: 54 REVASCULARISATION - angioplasty and/or coronary artery bypass grafting








Doi 2014 9/119 15/119 52.9 % 0.60 [ 0.27, 1.32 ]
EPOCH 2011 2/195 2/196 8.6 % 1.01 [ 0.14, 7.06 ]
HARP- Sacks 1995 3/41 3/39 13.8 % 0.95 [ 0.20, 4.43 ]
Nye 1990 1/36 1/37 4.4 % 1.03 [ 0.07, 15.82 ]
Raitt 2005 2/100 4/100 11.7 % 0.50 [ 0.09, 2.67 ]
Vijayakumar 2014 2/100 2/100 8.7 % 1.00 [ 0.14, 6.96 ]
Total (95% CI) 591 591 100.0 % 0.70 [ 0.40, 1.24 ]
Total events: 19 (Higher PUFA), 27 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 5 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 1
ADIPOSITY - BODY WEIGHT, kg.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 1 ADIPOSITY - BODY WEIGHT, kg





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 8.3 % 0.0 [ -1.14, 1.14 ]
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 6.7 % 0.18 [ -1.17, 1.53 ]
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Dullaart 1992 16 77 (10) 20 76 (11.2) 0.4 % 1.00 [ -5.94, 7.94 ]
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.3 % 2.00 [ -5.43, 9.43 ]
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 0.2 % -0.30 [ -10.57, 9.97 ]
Ley 2004 (1) 70 0.59 (13.4702) 66 -3.32 (5.5243) 1.4 % 3.91 [ 0.48, 7.34 ]
MARINA - Sanders 2011 (2) 80 0.2 (1.8) 71 -0.3 (2.53) 13.2 % 0.50 [ -0.21, 1.21 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
PREDIMED 2013 (3) 1062 -0.5 (7.5) 1236 -1 (6.3) 15.2 % 0.50 [ -0.07, 1.07 ]
PREDIMED 2013 (4) 662 0.02 (5.3) 663 -0.2 (5.9) 14.7 % 0.22 [ -0.38, 0.82 ]
PREDIMED 2013 (5) 54 -0.1 (0.37) 54 -1.3 (0.37) 20.5 % 1.20 [ 1.06, 1.34 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 11.3 % 0.76 [ -0.09, 1.61 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.5 % 3.70 [ -2.22, 9.62 ]
WINS 2006 (6) 1328 72.8 (14.8609) 840 70.6 (14.7661) 7.2 % 2.20 [ 0.92, 3.48 ]
Total (95% CI) 3710 3390 100.0 % 0.76 [ 0.34, 1.19 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 29.28, df = 12 (P = 0.004); I2 =59%
Test for overall effect: Z = 3.52 (P = 0.00044)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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(1) Change data, variance presented as SDs, but assumed to be SEs and converted
(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(3) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(4) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(5) Barcelona hospital cohort at 5 years, Casa 2016
(6) One year data
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Analysis 3.2. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 2
Body weight, kg - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 2 Body weight, kg - SA





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias for allocation concealment
Dullaart 1992 16 77 (10) 20 76 (11.2) 3.9 % 1.00 [ -5.94, 7.94 ]
Ley 2004 (1) 70 0.59 (13.4702) 66 -3.32 (5.5243) 12.8 % 3.91 [ 0.48, 7.34 ]
MARINA - Sanders 2011 (2) 80 0.2 (1.8) 71 -0.3 (2.53) 43.2 % 0.50 [ -0.21, 1.21 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 5.2 % 3.70 [ -2.22, 9.62 ]
WINS 2006 (3) 1328 72.8 (14.8609) 840 70.6 (14.7661) 34.9 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 1541 1045 100.0 % 1.72 [ 0.29, 3.15 ]
Heterogeneity: Tau2 = 1.10; Chi2 = 8.86, df = 4 (P = 0.06); I2 =55%
Test for overall effect: Z = 2.35 (P = 0.019)
2 Low risk of bias for attention
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 10.6 % 0.0 [ -1.14, 1.14 ]
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 8.6 % 0.18 [ -1.17, 1.53 ]
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.4 % 2.00 [ -5.43, 9.43 ]
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 0.2 % -0.30 [ -10.57, 9.97 ]
MARINA - Sanders 2011 (4) 80 0.2 (1.8) 71 -0.3 (2.53) 16.7 % 0.50 [ -0.21, 1.21 ]
PREDIMED 2013 (5) 1062 -0.5 (7.5) 1236 -1 (6.3) 19.0 % 0.50 [ -0.07, 1.07 ]
PREDIMED 2013 (6) 54 -0.1 (0.37) 54 -1.3 (0.37) 25.3 % 1.20 [ 1.06, 1.34 ]
PREDIMED 2013 (7) 662 0.02 (5.3) 663 -0.2 (5.9) 18.5 % 0.22 [ -0.38, 0.82 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.7 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 1994 2162 100.0 % 0.57 [ 0.08, 1.06 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 23.17, df = 8 (P = 0.003); I2 =65%
Test for overall effect: Z = 2.30 (P = 0.022)
3 Low risk of bias for compliance
Dullaart 1992 16 77 (10) 20 76 (11.2) 5.6 % 1.00 [ -5.94, 7.94 ]
Ley 2004 (8) 70 0.59 (13.4702) 66 -3.32 (5.5243) 18.8 % 3.91 [ 0.48, 7.34 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 68.2 % 0.76 [ -0.09, 1.61 ]
-4 -2 0 2 4
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 7.4 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 377 379 100.0 % 1.59 [ -0.11, 3.28 ]
Heterogeneity: Tau2 = 0.90; Chi2 = 3.87, df = 3 (P = 0.28); I2 =23%
Test for overall effect: Z = 1.84 (P = 0.066)
4 Low summary risk of bias
Ley 2004 (9) 70 0.59 (13.4702) 66 -3.32 (5.5243) 14.6 % 3.91 [ 0.48, 7.34 ]
MARINA - Sanders 2011 (10) 80 0.2 (1.8) 71 -0.3 (2.53) 43.2 % 0.50 [ -0.21, 1.21 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 6.2 % 3.70 [ -2.22, 9.62 ]
WINS 2006 (11) 1328 72.8 (14.8609) 840 70.6 (14.7661) 36.1 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 1525 1025 100.0 % 1.81 [ 0.23, 3.38 ]
Heterogeneity: Tau2 = 1.37; Chi2 = 8.86, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 2.25 (P = 0.024)
5 Trials registry or pre-2010
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 8.3 % 0.0 [ -1.14, 1.14 ]
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 6.7 % 0.18 [ -1.17, 1.53 ]
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Dullaart 1992 16 77 (10) 20 76 (11.2) 0.4 % 1.00 [ -5.94, 7.94 ]
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.3 % 2.00 [ -5.43, 9.43 ]
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 0.2 % -0.30 [ -10.57, 9.97 ]
Ley 2004 (12) 70 0.59 (13.4702) 66 -3.32 (5.5243) 1.4 % 3.91 [ 0.48, 7.34 ]
MARINA - Sanders 2011 (13) 80 0.2 (1.8) 71 -0.3 (2.53) 13.2 % 0.50 [ -0.21, 1.21 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
PREDIMED 2013 (14) 1062 -0.5 (7.5) 1236 -1 (6.3) 15.2 % 0.50 [ -0.07, 1.07 ]
PREDIMED 2013 (15) 54 -0.1 (0.37) 54 -1.3 (0.37) 20.5 % 1.20 [ 1.06, 1.34 ]
PREDIMED 2013 (16) 662 0.02 (5.3) 663 -0.2 (5.9) 14.7 % 0.22 [ -0.38, 0.82 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 11.3 % 0.76 [ -0.09, 1.61 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.5 % 3.70 [ -2.22, 9.62 ]
WINS 2006 (17) 1328 72.8 (14.8609) 840 70.6 (14.7661) 7.2 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 3710 3390 100.0 % 0.76 [ 0.34, 1.19 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 29.28, df = 12 (P = 0.004); I2 =59%
Test for overall effect: Z = 3.52 (P = 0.00044)
6 No industry funding
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Dullaart 1992 16 77 (10) 20 76 (11.2) 4.3 % 1.00 [ -5.94, 7.94 ]
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
(Continued . . . )
396Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ley 2004 (18) 70 0.59 (13.4702) 66 -3.32 (5.5243) 14.0 % 3.91 [ 0.48, 7.34 ]
MARINA - Sanders 2011 (19) 80 0.2 (1.8) 71 -0.3 (2.53) 44.9 % 0.50 [ -0.21, 1.21 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
WINS 2006 (20) 1328 72.8 (14.8609) 840 70.6 (14.7661) 36.7 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 1640 1143 100.0 % 1.62 [ 0.11, 3.14 ]
Heterogeneity: Tau2 = 1.19; Chi2 = 8.07, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 2.10 (P = 0.035)
7 Randomised 100+ participants
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Ley 2004 (21) 70 0.59 (13.4702) 66 -3.32 (5.5243) 1.8 % 3.91 [ 0.48, 7.34 ]
MARINA - Sanders 2011 (22) 80 0.2 (1.8) 71 -0.3 (2.53) 15.8 % 0.50 [ -0.21, 1.21 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
PREDIMED 2013 (23) 54 -0.1 (0.37) 54 -1.3 (0.37) 23.7 % 1.20 [ 1.06, 1.34 ]
PREDIMED 2013 (24) 662 0.02 (5.3) 663 -0.2 (5.9) 17.5 % 0.22 [ -0.38, 0.82 ]
PREDIMED 2013 (25) 1062 -0.5 (7.5) 1236 -1 (6.3) 18.0 % 0.50 [ -0.07, 1.07 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 13.7 % 0.76 [ -0.09, 1.61 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.6 % 3.70 [ -2.22, 9.62 ]
WINS 2006 (26) 1328 72.8 (14.8609) 840 70.6 (14.7661) 8.9 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 3605 3280 100.0 % 0.89 [ 0.41, 1.36 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 23.89, df = 7 (P = 0.001); I2 =71%
Test for overall effect: Z = 3.62 (P = 0.00029)
8 Randomised 250+ participants
MARINA - Sanders 2011 (27) 80 0.2 (1.8) 71 -0.3 (2.53) 16.1 % 0.50 [ -0.21, 1.21 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
PREDIMED 2013 (28) 1062 -0.5 (7.5) 1236 -1 (6.3) 18.5 % 0.50 [ -0.07, 1.07 ]
PREDIMED 2013 (29) 662 0.02 (5.3) 663 -0.2 (5.9) 17.9 % 0.22 [ -0.38, 0.82 ]
PREDIMED 2013 (30) 54 -0.1 (0.37) 54 -1.3 (0.37) 24.8 % 1.20 [ 1.06, 1.34 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 13.9 % 0.76 [ -0.09, 1.61 ]
WINS 2006 (31) 1328 72.8 (14.8609) 840 70.6 (14.7661) 8.9 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 3430 3109 100.0 % 0.81 [ 0.34, 1.28 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 20.57, df = 5 (P = 0.00098); I2 =76%
Test for overall effect: Z = 3.36 (P = 0.00079)
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(1) Change data, variance presented as SDs, but assumed to be SEs and converted
(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(3) One year data
(4) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(5) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(6) Barcelona hospital cohort at 5 years, Casa 2016
(7) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(8) Change data, variance presented as SDs, but assumed to be SEs and converted
(9) Change data, variance presented as SDs, but assumed to be SEs and converted
(10) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(11) One year data
(12) Change data, variance presented as SDs, but assumed to be SEs and converted
(13) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(14) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(15) Barcelona hospital cohort at 5 years, Casa 2016
(16) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(17) One year data
(18) Change data, variance presented as SDs, but assumed to be SEs and converted
(19) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(20) One year data
(21) Change data, variance presented as SDs, but assumed to be SEs and converted
(22) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(23) Barcelona hospital cohort at 5 years, Casa 2016
(24) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(25) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(26) One year data
(27) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(28) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(29) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(30) Barcelona hospital cohort at 5 years, Casa 2016
(31) One year data
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Analysis 3.3. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 3
Body weight, kg - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 3 Body weight, kg - SA fixed-effect





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 1.2 % 0.0 [ -1.14, 1.14 ]
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 0.9 % 0.18 [ -1.17, 1.53 ]
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Dullaart 1992 16 77 (10) 20 76 (11.2) 0.0 % 1.00 [ -5.94, 7.94 ]
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.0 % 2.00 [ -5.43, 9.43 ]
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 0.0 % -0.30 [ -10.57, 9.97 ]
Ley 2004 (1) 70 0.59 (13.4702) 66 -3.32 (5.5243) 0.1 % 3.91 [ 0.48, 7.34 ]
MARINA - Sanders 2011 (2) 80 0.2 (1.8) 71 -0.3 (2.53) 3.2 % 0.50 [ -0.21, 1.21 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
PREDIMED 2013 (3) 1062 -0.5 (7.5) 1236 -1 (6.3) 4.9 % 0.50 [ -0.07, 1.07 ]
PREDIMED 2013 (4) 662 0.02 (5.3) 663 -0.2 (5.9) 4.4 % 0.22 [ -0.38, 0.82 ]
PREDIMED 2013 (5) 54 -0.1 (0.37) 54 -1.3 (0.37) 82.0 % 1.20 [ 1.06, 1.34 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 2.2 % 0.76 [ -0.09, 1.61 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.0 % 3.70 [ -2.22, 9.62 ]
WINS 2006 (6) 1328 72.8 (14.8609) 840 70.6 (14.7661) 1.0 % 2.20 [ 0.92, 3.48 ]
Total (95% CI) 3710 3390 100.0 % 1.08 [ 0.96, 1.21 ]
Heterogeneity: Chi2 = 29.28, df = 12 (P = 0.004); I2 =59%
Test for overall effect: Z = 16.78 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) Change data, variance presented as SDs, but assumed to be SEs and converted
(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(3) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(4) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(5) Barcelona hospital cohort at 5 years, Casa 2016
(6) One year data
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Analysis 3.4. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 4
Body weight, kg - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 4 Body weight, kg - subgroup by PUFA dose





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 total PUFA < 1.0% E
Ley 2004 (1) 70 0.59 (13.4702) 66 -3.32 (5.5243) 1.4 % 3.91 [ 0.48, 7.34 ]
MARINA - Sanders 2011 (2) 80 0.2 (1.8) 71 -0.3 (2.53) 13.2 % 0.50 [ -0.21, 1.21 ]
Subtotal (95% CI) 150 137 14.7 % 1.78 [ -1.46, 5.01 ]
Heterogeneity: Tau2 = 4.22; Chi2 = 3.65, df = 1 (P = 0.06); I2 =73%
Test for overall effect: Z = 1.08 (P = 0.28)
2 total PUFA 1.0 to < 2.0% E
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 8.3 % 0.0 [ -1.14, 1.14 ]
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 6.7 % 0.18 [ -1.17, 1.53 ]
PREDIMED 2013 (3) 662 0.02 (5.3) 663 -0.2 (5.9) 14.7 % 0.22 [ -0.38, 0.82 ]
PREDIMED 2013 (4) 54 -0.1 (0.37) 54 -1.3 (0.37) 20.5 % 1.20 [ 1.06, 1.34 ]
PREDIMED 2013 (5) 1062 -0.5 (7.5) 1236 -1 (6.3) 15.2 % 0.50 [ -0.07, 1.07 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.5 % 3.70 [ -2.22, 9.62 ]
WINS 2006 (6) 1328 72.8 (14.8609) 840 70.6 (14.7661) 7.2 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 3193 2886 73.1 % 0.74 [ 0.18, 1.30 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 23.28, df = 6 (P = 0.00071); I2 =74%
Test for overall effect: Z = 2.59 (P = 0.0095)
3 total PUFA 2.0 to < 5.0% E
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Dullaart 1992 16 77 (10) 20 76 (11.2) 0.4 % 1.00 [ -5.94, 7.94 ]
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.3 % 2.00 [ -5.43, 9.43 ]
Subtotal (95% CI) 105 105 0.7 % 1.47 [ -3.60, 6.53 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
4 total PUFA 5.0+% E
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 0.2 % -0.30 [ -10.57, 9.97 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 11.3 % 0.76 [ -0.09, 1.61 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 262 262 11.5 % 0.75 [ -0.10, 1.60 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
Total (95% CI) 3710 3390 100.0 % 0.76 [ 0.34, 1.19 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 29.28, df = 12 (P = 0.004); I2 =59%
Test for overall effect: Z = 3.52 (P = 0.00044)
Test for subgroup differences: Chi2 = 0.46, df = 3 (P = 0.93), I2 =0.0%
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
(1) Change data, variance presented as SDs, but assumed to be SEs and converted
(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(3) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(4) Barcelona hospital cohort at 5 years, Casa 2016
(5) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(6) One year data
401Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.5. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 5
Body weight, kg - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 5 Body weight, kg - subgroup by duration





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 8.3 % 0.0 [ -1.14, 1.14 ]
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 6.7 % 0.18 [ -1.17, 1.53 ]
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 0.2 % -0.30 [ -10.57, 9.97 ]
Ley 2004 (1) 70 0.59 (13.4702) 66 -3.32 (5.5243) 1.4 % 3.91 [ 0.48, 7.34 ]
MARINA - Sanders 2011 (2) 80 0.2 (1.8) 71 -0.3 (2.53) 13.2 % 0.50 [ -0.21, 1.21 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.5 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 255 247 30.4 % 0.47 [ -0.20, 1.14 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 5.86, df = 5 (P = 0.32); I2 =15%
Test for overall effect: Z = 1.37 (P = 0.17)
2 Medium-long duration 2 to < 4 years
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Dullaart 1992 16 77 (10) 20 76 (11.2) 0.4 % 1.00 [ -5.94, 7.94 ]
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.3 % 2.00 [ -5.43, 9.43 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 11.3 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 261 261 12.0 % 0.78 [ -0.06, 1.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.070)
3 Long duration 4+ years
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
PREDIMED 2013 (3) 54 -0.1 (0.37) 54 -1.3 (0.37) 20.5 % 1.20 [ 1.06, 1.34 ]
PREDIMED 2013 (4) 1062 -0.5 (7.5) 1236 -1 (6.3) 15.2 % 0.50 [ -0.07, 1.07 ]
PREDIMED 2013 (5) 662 0.02 (5.3) 663 -0.2 (5.9) 14.7 % 0.22 [ -0.38, 0.82 ]
WINS 2006 (6) 1328 72.8 (14.8609) 840 70.6 (14.7661) 7.2 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 3194 2882 57.6 % 0.90 [ 0.27, 1.54 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 17.04, df = 3 (P = 0.00069); I2 =82%
Test for overall effect: Z = 2.79 (P = 0.0053)
Total (95% CI) 3710 3390 100.0 % 0.76 [ 0.34, 1.19 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.22; Chi2 = 29.28, df = 12 (P = 0.004); I2 =59%
Test for overall effect: Z = 3.52 (P = 0.00044)
Test for subgroup differences: Chi2 = 0.87, df = 2 (P = 0.65), I2 =0.0%
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
(1) Change data, variance presented as SDs, but assumed to be SEs and converted
(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(5) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(6) One year data
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Analysis 3.6. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 6
Body weight, kg - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 6 Body weight, kg - subgroup by primary or secondary prevention





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention of CVD
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 8.3 % 0.0 [ -1.14, 1.14 ]
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 6.7 % 0.18 [ -1.17, 1.53 ]
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Dullaart 1992 16 77 (10) 20 76 (11.2) 0.4 % 1.00 [ -5.94, 7.94 ]
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 0.2 % -0.30 [ -10.57, 9.97 ]
Ley 2004 (1) 70 0.59 (13.4702) 66 -3.32 (5.5243) 1.4 % 3.91 [ 0.48, 7.34 ]
MARINA - Sanders 2011 (2) 80 0.2 (1.8) 71 -0.3 (2.53) 13.2 % 0.50 [ -0.21, 1.21 ]
PREDIMED 2013 (3) 1062 -0.5 (7.5) 1236 -1 (6.3) 15.2 % 0.50 [ -0.07, 1.07 ]
PREDIMED 2013 (4) 54 -0.1 (0.37) 54 -1.3 (0.37) 20.5 % 1.20 [ 1.06, 1.34 ]
PREDIMED 2013 (5) 662 0.02 (5.3) 663 -0.2 (5.9) 14.7 % 0.22 [ -0.38, 0.82 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 11.3 % 0.76 [ -0.09, 1.61 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.5 % 3.70 [ -2.22, 9.62 ]
WINS 2006 (6) 1328 72.8 (14.8609) 840 70.6 (14.7661) 7.2 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 3591 3273 99.7 % 0.76 [ 0.33, 1.19 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 29.22, df = 11 (P = 0.002); I2 =62%
Test for overall effect: Z = 3.44 (P = 0.00059)
2 Secondary prevention of CVD
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.3 % 2.00 [ -5.43, 9.43 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
Subtotal (95% CI) 119 117 0.3 % 2.00 [ -5.43, 9.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Total (95% CI) 3710 3390 100.0 % 0.76 [ 0.34, 1.19 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 29.28, df = 12 (P = 0.004); I2 =59%
Test for overall effect: Z = 3.52 (P = 0.00044)
Test for subgroup differences: Chi2 = 0.11, df = 1 (P = 0.74), I2 =0.0%
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(1) Change data, variance presented as SDs, but assumed to be SEs and converted
(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(3) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(4) Barcelona hospital cohort at 5 years, Casa 2016
(5) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(6) One year data
Analysis 3.7. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 7
Body weight, kg - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 7 Body weight, kg - subgroup by baseline PUFA dose





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Baseline total PUFA < 6% E
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 0.2 % -0.30 [ -10.57, 9.97 ]
Ley 2004 (1) 70 0.59 (13.4702) 66 -3.32 (5.5243) 1.4 % 3.91 [ 0.48, 7.34 ]
WINS 2006 (2) 1328 72.8 (14.8609) 840 70.6 (14.7661) 7.2 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 1416 923 8.8 % 2.37 [ 1.18, 3.56 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.10, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.91 (P = 0.000093)
2 Baseline total PUFA 6 to < 11% E
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Dullaart 1992 16 77 (10) 20 76 (11.2) 0.4 % 1.00 [ -5.94, 7.94 ]
MARINA - Sanders 2011 (3) 80 0.2 (1.8) 71 -0.3 (2.53) 13.2 % 0.50 [ -0.21, 1.21 ]
PREDIMED 2013 (4) 54 -0.1 (0.37) 54 -1.3 (0.37) 20.5 % 1.20 [ 1.06, 1.34 ]
PREDIMED 2013 (5) 662 0.02 (5.3) 663 -0.2 (5.9) 14.7 % 0.22 [ -0.38, 0.82 ]
PREDIMED 2013 (6) 1062 -0.5 (7.5) 1236 -1 (6.3) 15.2 % 0.50 [ -0.07, 1.07 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 11.3 % 0.76 [ -0.09, 1.61 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 2088 2257 75.3 % 0.68 [ 0.21, 1.15 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 17.69, df = 5 (P = 0.003); I2 =72%
Test for overall effect: Z = 2.85 (P = 0.0043)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 8.3 % 0.0 [ -1.14, 1.14 ]
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 6.7 % 0.18 [ -1.17, 1.53 ]
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.3 % 2.00 [ -5.43, 9.43 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.5 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 206 210 15.9 % 0.18 [ -0.68, 1.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.68, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 3710 3390 100.0 % 0.76 [ 0.34, 1.19 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 29.28, df = 12 (P = 0.004); I2 =59%
Test for overall effect: Z = 3.52 (P = 0.00044)
Test for subgroup differences: Chi2 = 8.94, df = 2 (P = 0.01), I2 =78%
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Favours higher PUFA Favours lower PUFA
(1) Change data, variance presented as SDs, but assumed to be SEs and converted
(2) One year data
(3) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(4) Barcelona hospital cohort at 5 years, Casa 2016
(5) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(6) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
406Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.8. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 8
Body weight, kg - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 8 Body weight, kg - subgroup by replacement





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PUFA replaced saturated fats
Dullaart 1992 16 77 (10) 20 76 (11.2) 68.7 % 1.00 [ -5.94, 7.94 ]
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 31.3 % -0.30 [ -10.57, 9.97 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
Subtotal (95% CI) 122 126 100.0 % 0.59 [ -5.15, 6.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
2 PUFA replaced monounsaturated fats
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.5 % 2.00 [ -5.43, 9.43 ]
MARINA - Sanders 2011 (1) 80 0.2 (1.8) 71 -0.3 (2.53) 20.7 % 0.50 [ -0.21, 1.21 ]
PREDIMED 2013 (2) 662 0.02 (5.3) 663 -0.2 (5.9) 22.9 % 0.22 [ -0.38, 0.82 ]
PREDIMED 2013 (3) 1062 -0.5 (7.5) 1236 -1 (6.3) 23.6 % 0.50 [ -0.07, 1.07 ]
PREDIMED 2013 (4) 54 -0.1 (0.37) 54 -1.3 (0.37) 31.5 % 1.20 [ 1.06, 1.34 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.8 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 1936 2100 100.0 % 0.69 [ 0.15, 1.23 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 17.91, df = 5 (P = 0.003); I2 =72%
Test for overall effect: Z = 2.51 (P = 0.012)
3 PUFA replaced carbohydrates
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Ley 2004 (5) 70 0.59 (13.4702) 66 -3.32 (5.5243) 6.7 % 3.91 [ 0.48, 7.34 ]
MARINA - Sanders 2011 (6) 80 0.2 (1.8) 71 -0.3 (2.53) 35.7 % 0.50 [ -0.21, 1.21 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 32.8 % 0.76 [ -0.09, 1.61 ]
WINS 2006 (7) 1328 72.8 (14.8609) 840 70.6 (14.7661) 24.8 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 1692 1190 100.0 % 1.23 [ 0.27, 2.20 ]
Heterogeneity: Tau2 = 0.54; Chi2 = 8.26, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 2.52 (P = 0.012)
4 PUFA replaced protein
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 4.3 % -0.30 [ -10.57, 9.97 ]
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ley 2004 (8) 70 0.59 (13.4702) 66 -3.32 (5.5243) 26.8 % 3.91 [ 0.48, 7.34 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 68.9 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 332 328 100.0 % 1.56 [ -0.64, 3.75 ]
Heterogeneity: Tau2 = 1.63; Chi2 = 3.11, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 1.39 (P = 0.16)
5 unclear
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 58.3 % 0.0 [ -1.14, 1.14 ]
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 41.7 % 0.18 [ -1.17, 1.53 ]
Subtotal (95% CI) 40 45 100.0 % 0.08 [ -0.80, 0.95 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 3.74, df = 4 (P = 0.44), I2 =0.0%
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
(1) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(2) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(3) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(4) Barcelona hospital cohort at 5 years, Casa 2016
(5) Change data, variance presented as SDs, but assumed to be SEs and converted
(6) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(7) One year data
(8) Change data, variance presented as SDs, but assumed to be SEs and converted
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Analysis 3.9. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 9
Body weight, kg - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 9 Body weight, kg - subgroup by sex





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 > 70% men
Dullaart 1992 16 77 (10) 20 76 (11.2) 0.4 % 1.00 [ -5.94, 7.94 ]
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.3 % 2.00 [ -5.43, 9.43 ]
Ley 2004 (1) 70 0.59 (13.4702) 66 -3.32 (5.5243) 1.4 % 3.91 [ 0.48, 7.34 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
Subtotal (95% CI) 205 203 2.1 % 3.14 [ 0.31, 5.98 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.65, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.17 (P = 0.030)
2 > 70% women
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 8.3 % 0.0 [ -1.14, 1.14 ]
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 6.7 % 0.18 [ -1.17, 1.53 ]
WINS 2006 (2) 1328 72.8 (14.8609) 840 70.6 (14.7661) 7.2 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 1368 885 22.3 % 0.78 [ -0.60, 2.17 ]
Heterogeneity: Tau2 = 1.08; Chi2 = 7.28, df = 2 (P = 0.03); I2 =73%
Test for overall effect: Z = 1.11 (P = 0.27)
3 men % women
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
MARINA - Sanders 2011 (3) 80 0.2 (1.8) 71 -0.3 (2.53) 13.2 % 0.50 [ -0.21, 1.21 ]
PREDIMED 2013 (4) 54 -0.1 (0.37) 54 -1.3 (0.37) 20.5 % 1.20 [ 1.06, 1.34 ]
PREDIMED 2013 (5) 1062 -0.5 (7.5) 1236 -1 (6.3) 15.2 % 0.50 [ -0.07, 1.07 ]
PREDIMED 2013 (6) 662 0.02 (5.3) 663 -0.2 (5.9) 14.7 % 0.22 [ -0.38, 0.82 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 11.3 % 0.76 [ -0.09, 1.61 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.5 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 2119 2285 75.5 % 0.70 [ 0.22, 1.18 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 18.43, df = 5 (P = 0.002); I2 =73%
Test for overall effect: Z = 2.86 (P = 0.0042)
4 sex not reported
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 0.2 % -0.30 [ -10.57, 9.97 ]
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 18 17 0.2 % -0.30 [ -10.57, 9.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Total (95% CI) 3710 3390 100.0 % 0.76 [ 0.34, 1.19 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 29.28, df = 12 (P = 0.004); I2 =59%
Test for overall effect: Z = 3.52 (P = 0.00044)
Test for subgroup differences: Chi2 = 2.82, df = 3 (P = 0.42), I2 =0.0%
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
(1) Change data, variance presented as SDs, but assumed to be SEs and converted
(2) One year data
(3) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(4) Barcelona hospital cohort at 5 years, Casa 2016
(5) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(6) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
410Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.10. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 10
Body weight, kg - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 10 Body weight, kg - subgroup by age





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean age < 50 years
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 6.7 % 0.18 [ -1.17, 1.53 ]
Dullaart 1992 16 77 (10) 20 76 (11.2) 0.4 % 1.00 [ -5.94, 7.94 ]
Subtotal (95% CI) 35 44 7.1 % 0.21 [ -1.12, 1.54 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
2 Mean age 50 to < 65 years
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 8.3 % 0.0 [ -1.14, 1.14 ]
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.3 % 2.00 [ -5.43, 9.43 ]
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 0.2 % -0.30 [ -10.57, 9.97 ]
Ley 2004 (1) 70 0.59 (13.4702) 66 -3.32 (5.5243) 1.4 % 3.91 [ 0.48, 7.34 ]
MARINA - Sanders 2011 (2) 80 0.2 (1.8) 71 -0.3 (2.53) 13.2 % 0.50 [ -0.21, 1.21 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.5 % 3.70 [ -2.22, 9.62 ]
WINS 2006 (3) 1328 72.8 (14.8609) 840 70.6 (14.7661) 7.2 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 1741 1237 31.2 % 1.15 [ 0.12, 2.18 ]
Heterogeneity: Tau2 = 0.67; Chi2 = 11.41, df = 6 (P = 0.08); I2 =47%
Test for overall effect: Z = 2.20 (P = 0.028)
3 Mean age 65+ years
PREDIMED 2013 (4) 662 0.02 (5.3) 663 -0.2 (5.9) 14.7 % 0.22 [ -0.38, 0.82 ]
PREDIMED 2013 (5) 1062 -0.5 (7.5) 1236 -1 (6.3) 15.2 % 0.50 [ -0.07, 1.07 ]
PREDIMED 2013 (6) 54 -0.1 (0.37) 54 -1.3 (0.37) 20.5 % 1.20 [ 1.06, 1.34 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 11.3 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 1934 2109 61.7 % 0.71 [ 0.16, 1.26 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 14.96, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 2.52 (P = 0.012)
Total (95% CI) 3710 3390 100.0 % 0.76 [ 0.34, 1.19 ]
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.22; Chi2 = 29.28, df = 12 (P = 0.004); I2 =59%
Test for overall effect: Z = 3.52 (P = 0.00044)
Test for subgroup differences: Chi2 = 1.25, df = 2 (P = 0.54), I2 =0.0%
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
(1) Change data, variance presented as SDs, but assumed to be SEs and converted
(2) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(3) One year data
(4) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(5) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(6) Barcelona hospital cohort at 5 years, Casa 2016
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Analysis 3.11. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 11
Body weight, kg - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 11 Body weight, kg - subgroup by statin use





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 50% on statins
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 8.3 % 0.0 [ -1.14, 1.14 ]
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 6.7 % 0.18 [ -1.17, 1.53 ]
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Dullaart 1992 16 77 (10) 20 76 (11.2) 0.4 % 1.00 [ -5.94, 7.94 ]
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.3 % 2.00 [ -5.43, 9.43 ]
MARINA - Sanders 2011 (1) 80 0.2 (1.8) 71 -0.3 (2.53) 13.2 % 0.50 [ -0.21, 1.21 ]
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
PREDIMED 2013 (2) 662 0.02 (5.3) 663 -0.2 (5.9) 14.7 % 0.22 [ -0.38, 0.82 ]
PREDIMED 2013 (3) 1062 -0.5 (7.5) 1236 -1 (6.3) 15.2 % 0.50 [ -0.07, 1.07 ]
PREDIMED 2013 (4) 54 -0.1 (0.37) 54 -1.3 (0.37) 20.5 % 1.20 [ 1.06, 1.34 ]
WINS 2006 (5) 1328 72.8 (14.8609) 840 70.6 (14.7661) 7.2 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 3419 3103 86.6 % 0.69 [ 0.21, 1.17 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 25.30, df = 8 (P = 0.001); I2 =68%
Test for overall effect: Z = 2.84 (P = 0.0045)
2 50+% on statins
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 0.2 % -0.30 [ -10.57, 9.97 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.5 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 65 65 0.7 % 2.70 [ -2.43, 7.83 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
3 Percentage on statins unclear
Ley 2004 (6) 70 0.59 (13.4702) 66 -3.32 (5.5243) 1.4 % 3.91 [ 0.48, 7.34 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 11.3 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 226 222 12.8 % 1.88 [ -1.08, 4.84 ]
Heterogeneity: Tau2 = 3.34; Chi2 = 3.06, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 1.25 (P = 0.21)
Total (95% CI) 3710 3390 100.0 % 0.76 [ 0.34, 1.19 ]
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.22; Chi2 = 29.28, df = 12 (P = 0.004); I2 =59%
Test for overall effect: Z = 3.52 (P = 0.00044)
Test for subgroup differences: Chi2 = 1.17, df = 2 (P = 0.56), I2 =0.0%
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
(1) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
(2) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(3) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(4) Barcelona hospital cohort at 5 years, Casa 2016
(5) One year data
(6) Change data, variance presented as SDs, but assumed to be SEs and converted
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Analysis 3.12. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 12
Body weight, kg - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 12 Body weight, kg - subgroup by intervention type





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
Black 1994 58 80 (0) 57 76.5 (0) Not estimable
Dullaart 1992 16 77 (10) 20 76 (11.2) 0.4 % 1.00 [ -5.94, 7.94 ]
Ley 2004 (1) 70 0.59 (13.4702) 66 -3.32 (5.5243) 1.4 % 3.91 [ 0.48, 7.34 ]
WINS 2006 (2) 1328 72.8 (14.8609) 840 70.6 (14.7661) 7.2 % 2.20 [ 0.92, 3.48 ]
Subtotal (95% CI) 1472 983 9.0 % 2.37 [ 1.19, 3.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.93 (P = 0.000084)
2 Supplemental foods % diet provided
HERO-Tapsell 2009 18 92 (17.1) 17 92.3 (13.8) 0.2 % -0.30 [ -10.57, 9.97 ]
PREDIMED 2013 (3) 54 -0.1 (0.37) 54 -1.3 (0.37) 20.5 % 1.20 [ 1.06, 1.34 ]
PREDIMED 2013 (4) 1062 -0.5 (7.5) 1236 -1 (6.3) 15.2 % 0.50 [ -0.07, 1.07 ]
PREDIMED 2013 (5) 662 0.02 (5.3) 663 -0.2 (5.9) 14.7 % 0.22 [ -0.38, 0.82 ]
WAHA - Ros 2016 156 -0.29 (3.85) 156 -1.05 (3.85) 11.3 % 0.76 [ -0.09, 1.61 ]
Subtotal (95% CI) 1952 2126 61.9 % 0.71 [ 0.18, 1.25 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 15.03, df = 4 (P = 0.005); I2 =73%
Test for overall effect: Z = 2.61 (P = 0.0090)
3 Supplements (capsules % unusual foods)
Bassey 2000-Post 21 0.74 (2.2913) 21 0.74 (1.3748) 8.3 % 0.0 [ -1.14, 1.14 ]
Bassey 2000-Pre 19 0.37 (2.6589) 24 0.19 (1.5677) 6.7 % 0.18 [ -1.17, 1.53 ]
HARP- Sacks 1995 31 82 (14) 28 80 (15) 0.3 % 2.00 [ -5.43, 9.43 ]
MARINA - Sanders 2011 (6) 80 0.2 (1.8) 71 -0.3 (2.53) 13.2 % 0.50 [ -0.21, 1.21 ]
WELCOME 2015 47 94.1 (13) 48 90.4 (16.3) 0.5 % 3.70 [ -2.22, 9.62 ]
Subtotal (95% CI) 198 192 29.1 % 0.37 [ -0.18, 0.91 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.01, df = 4 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
4 Any combination
MRC 1968 88 0 (0) 89 -1.4 (0) Not estimable
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 88 89 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 3710 3390 100.0 % 0.76 [ 0.34, 1.19 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 29.28, df = 12 (P = 0.004); I2 =59%
Test for overall effect: Z = 3.52 (P = 0.00044)
Test for subgroup differences: Chi2 = 9.08, df = 2 (P = 0.01), I2 =78%
-4 -2 0 2 4
Favours higher PUFA Favours lower PUFA
(1) Change data, variance presented as SDs, but assumed to be SEs and converted
(2) One year data
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Babio CMAJ 2014 - Participants with metabolic syndrome at baseline, 5 year data
(5) Babio CMAJ 2014 participants without metabolic syndrome at baseline, 5 year data
(6) 0.9g/d n3 vs placebo (as these arms were well balanced for weight at baseline)
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Analysis 3.13. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 13
ADIPOSITY - Body Mass Index (BMI), kg/m2.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 13 ADIPOSITY - Body Mass Index (BMI), kg/m2





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA (1) 630 0.07 (1.5) 630 -0.08 (1.8) 15.6 % 0.15 [ -0.03, 0.33 ]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 2.8 % -1.50 [ -2.86, -0.14 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 1.2 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 15.7 % 0.0 [ -0.17, 0.17 ]
PREDIMED 2013 (2) 51 28.7 (3.01) 42 28.6 (2.9) 3.4 % 0.10 [ -1.10, 1.30 ]
PREDIMED 2013 (3) 54 -0.02 (0.18) 54 -0.5 (0.37) 16.5 % 0.48 [ 0.37, 0.59 ]
PREDIMED 2013 (4) 102 -0.5 (2.04) 112 -0.5 (1.6) 10.1 % 0.0 [ -0.49, 0.49 ]
PREDIMED 2013 (5) 58 -0.1 (1.36) 59 -0.1 (1.18) 10.7 % 0.0 [ -0.46, 0.46 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 12.5 % -0.20 [ -0.56, 0.16 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.5 % 2.60 [ 0.71, 4.49 ]
WINS 2006 (6) 1328 27.6 (5.5728) 840 26.8 (5.9064) 10.0 % 0.80 [ 0.30, 1.30 ]
Total (95% CI) 2631 2167 100.0 % 0.17 [ -0.08, 0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 51.21, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours higher PUFA Favours lower PUFA
(1) Numer of participants equally divided between groups
(2) Reus subcohort, 2 year data
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(5) Damasceno 2013, Barcelona North subcohort, 1 year data
(6) One year data
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Analysis 3.14. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 14
BMI, kg/m2 - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 14 BMI, kg/m2 - SA





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias for allocation concealment
AlphaOmega - ALA (1) 630 0.07 (1.5) 630 -0.08 (1.8) 35.2 % 0.15 [ -0.03, 0.33 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 31.3 % -0.20 [ -0.56, 0.16 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 6.2 % 2.60 [ 0.71, 4.49 ]
WINS 2006 (2) 1328 27.6 (5.5728) 840 26.8 (5.9064) 27.4 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 2184 1710 100.0 % 0.37 [ -0.15, 0.88 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 16.58, df = 3 (P = 0.00086); I2 =82%
Test for overall effect: Z = 1.41 (P = 0.16)
2 Low risk of bias for attention
AlphaOmega - ALA (3) 630 0.07 (1.5) 630 -0.08 (1.8) 20.4 % 0.15 [ -0.03, 0.33 ]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 3.3 % -1.50 [ -2.86, -0.14 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 1.4 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 20.6 % 0.0 [ -0.17, 0.17 ]
PREDIMED 2013 (4) 51 28.7 (3.01) 42 28.6 (2.9) 4.1 % 0.10 [ -1.10, 1.30 ]
PREDIMED 2013 (5) 58 -0.1 (1.36) 59 -0.1 (1.18) 13.6 % 0.0 [ -0.46, 0.46 ]
PREDIMED 2013 (6) 54 -0.02 (0.18) 54 -0.5 (0.37) 21.7 % 0.48 [ 0.37, 0.59 ]
PREDIMED 2013 (7) 102 -0.5 (2.04) 112 -0.5 (1.6) 12.8 % 0.0 [ -0.49, 0.49 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.9 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 1124 1135 100.0 % 0.15 [ -0.12, 0.42 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 40.16, df = 8 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.10 (P = 0.27)
3 Low risk of bias for compliance
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 27.0 % 1.00 [ -1.18, 3.18 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 43.2 % -0.20 [ -0.56, 0.16 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 29.8 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 256 270 100.0 % 0.96 [ -0.86, 2.78 ]
Heterogeneity: Tau2 = 1.97; Chi2 = 9.07, df = 2 (P = 0.01); I2 =78%
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 1.03 (P = 0.30)
4 Low summary risk of bias
AlphaOmega - ALA (8) 630 0.07 (1.5) 630 -0.08 (1.8) 35.2 % 0.15 [ -0.03, 0.33 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 31.3 % -0.20 [ -0.56, 0.16 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 6.2 % 2.60 [ 0.71, 4.49 ]
WINS 2006 (9) 1328 27.6 (5.5728) 840 26.8 (5.9064) 27.4 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 2184 1710 100.0 % 0.37 [ -0.15, 0.88 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 16.58, df = 3 (P = 0.00086); I2 =82%
Test for overall effect: Z = 1.41 (P = 0.16)
5 Trials registry or pre-2010
AlphaOmega - ALA (10) 630 0.07 (1.5) 630 -0.08 (1.8) 15.6 % 0.15 [ -0.03, 0.33 ]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 2.8 % -1.50 [ -2.86, -0.14 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 1.2 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 15.7 % 0.0 [ -0.17, 0.17 ]
PREDIMED 2013 (11) 51 28.7 (3.01) 42 28.6 (2.9) 3.4 % 0.10 [ -1.10, 1.30 ]
PREDIMED 2013 (12) 58 -0.1 (1.36) 59 -0.1 (1.18) 10.7 % 0.0 [ -0.46, 0.46 ]
PREDIMED 2013 (13) 54 -0.02 (0.18) 54 -0.5 (0.37) 16.5 % 0.48 [ 0.37, 0.59 ]
PREDIMED 2013 (14) 102 -0.5 (2.04) 112 -0.5 (1.6) 10.1 % 0.0 [ -0.49, 0.49 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 12.5 % -0.20 [ -0.56, 0.16 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.5 % 2.60 [ 0.71, 4.49 ]
WINS 2006 (15) 1328 27.6 (5.5728) 840 26.8 (5.9064) 10.0 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 2631 2167 100.0 % 0.17 [ -0.08, 0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 51.21, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.36 (P = 0.17)
6 No industry funding
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 51.6 % -0.20 [ -0.56, 0.16 ]
WINS 2006 (16) 1328 27.6 (5.5728) 840 26.8 (5.9064) 48.4 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 1507 1032 100.0 % 0.28 [ -0.70, 1.26 ]
Heterogeneity: Tau2 = 0.45; Chi2 = 10.17, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 0.57 (P = 0.57)
7 Randomised 100+ participants
AlphaOmega - ALA (17) 630 0.07 (1.5) 630 -0.08 (1.8) 15.7 % 0.15 [ -0.03, 0.33 ]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 2.8 % -1.50 [ -2.86, -0.14 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 15.9 % 0.0 [ -0.17, 0.17 ]
PREDIMED 2013 (18) 58 -0.1 (1.36) 59 -0.1 (1.18) 10.8 % 0.0 [ -0.46, 0.46 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (19) 102 -0.5 (2.04) 112 -0.5 (1.6) 10.3 % 0.0 [ -0.49, 0.49 ]
PREDIMED 2013 (20) 54 -0.02 (0.18) 54 -0.5 (0.37) 16.6 % 0.48 [ 0.37, 0.59 ]
PREDIMED 2013 (21) 51 28.7 (3.01) 42 28.6 (2.9) 3.4 % 0.10 [ -1.10, 1.30 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 12.7 % -0.20 [ -0.56, 0.16 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.6 % 2.60 [ 0.71, 4.49 ]
WINS 2006 (22) 1328 27.6 (5.5728) 840 26.8 (5.9064) 10.2 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 2601 2137 100.0 % 0.16 [ -0.09, 0.41 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 50.78, df = 9 (P<0.00001); I2 =82%
Test for overall effect: Z = 1.27 (P = 0.20)
8 Randomised 250+ participants
AlphaOmega - ALA (23) 630 0.07 (1.5) 630 -0.08 (1.8) 20.7 % 0.15 [ -0.03, 0.33 ]
PREDIMED 2013 (24) 51 28.7 (3.01) 42 28.6 (2.9) 3.7 % 0.10 [ -1.10, 1.30 ]
PREDIMED 2013 (25) 58 -0.1 (1.36) 59 -0.1 (1.18) 13.1 % 0.0 [ -0.46, 0.46 ]
PREDIMED 2013 (26) 54 -0.02 (0.18) 54 -0.5 (0.37) 22.3 % 0.48 [ 0.37, 0.59 ]
PREDIMED 2013 (27) 102 -0.5 (2.04) 112 -0.5 (1.6) 12.3 % 0.0 [ -0.49, 0.49 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 15.8 % -0.20 [ -0.56, 0.16 ]
WINS 2006 (28) 1328 27.6 (5.5728) 840 26.8 (5.9064) 12.1 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 2402 1929 100.0 % 0.21 [ -0.04, 0.46 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 26.43, df = 6 (P = 0.00019); I2 =77%
Test for overall effect: Z = 1.62 (P = 0.11)
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(1) Numer of participants equally divided between groups
(2) One year data
(3) Numer of participants equally divided between groups
(4) Reus subcohort, 2 year data
(5) Damasceno 2013, Barcelona North subcohort, 1 year data
(6) Barcelona hospital cohort at 5 years, Casa 2016
(7) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(8) Numer of participants equally divided between groups
(9) One year data
(10) Numer of participants equally divided between groups
(11) Reus subcohort, 2 year data
(12) Damasceno 2013, Barcelona North subcohort, 1 year data
(13) Barcelona hospital cohort at 5 years, Casa 2016
(14) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(15) One year data
(16) One year data
(17) Numer of participants equally divided between groups
(18) Damasceno 2013, Barcelona North subcohort, 1 year data
(19) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(20) Barcelona hospital cohort at 5 years, Casa 2016
(21) Reus subcohort, 2 year data
(22) One year data
(23) Numer of participants equally divided between groups
(24) Reus subcohort, 2 year data
(25) Damasceno 2013, Barcelona North subcohort, 1 year data
(26) Barcelona hospital cohort at 5 years, Casa 2016
(27) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(28) One year data
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Analysis 3.15. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 15
BMI, kg/m2 - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 15 BMI, kg/m2 - SA fixed-effect





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
AlphaOmega - ALA (1) 630 0.07 (1.5) 630 -0.08 (1.8) 17.7 % 0.15 [ -0.03, 0.33 ]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 0.3 % -1.50 [ -2.86, -0.14 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 0.1 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 19.7 % 0.0 [ -0.17, 0.17 ]
PREDIMED 2013 (2) 102 -0.5 (2.04) 112 -0.5 (1.6) 2.4 % 0.0 [ -0.49, 0.49 ]
PREDIMED 2013 (3) 54 -0.02 (0.18) 54 -0.5 (0.37) 49.3 % 0.48 [ 0.37, 0.59 ]
PREDIMED 2013 (4) 58 -0.1 (1.36) 59 -0.1 (1.18) 2.8 % 0.0 [ -0.46, 0.46 ]
PREDIMED 2013 (5) 51 28.7 (3.01) 42 28.6 (2.9) 0.4 % 0.10 [ -1.10, 1.30 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 4.6 % -0.20 [ -0.56, 0.16 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 0.2 % 2.60 [ 0.71, 4.49 ]
WINS 2006 (6) 1328 27.6 (5.5728) 840 26.8 (5.9064) 2.4 % 0.80 [ 0.30, 1.30 ]
Total (95% CI) 2631 2167 100.0 % 0.27 [ 0.20, 0.35 ]
Heterogeneity: Chi2 = 51.21, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 6.98 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) Numer of participants equally divided between groups
(2) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
(5) Reus subcohort, 2 year data
(6) One year data
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Analysis 3.16. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 16
BMI, kg/m2 - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 16 BMI, kg/m2 - subgroup by PUFA dose





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 total PUFA < 1.0% E
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 1.2 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 15.7 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 97 96 16.9 % 0.01 [ -0.17, 0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
2 total PUFA 1.0 to < 2.0% E
AlphaOmega - ALA (1) 630 0.07 (1.5) 630 -0.08 (1.8) 15.6 % 0.15 [ -0.03, 0.33 ]
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 2.8 % -1.50 [ -2.86, -0.14 ]
PREDIMED 2013 (2) 102 -0.5 (2.04) 112 -0.5 (1.6) 10.1 % 0.0 [ -0.49, 0.49 ]
PREDIMED 2013 (3) 54 -0.02 (0.18) 54 -0.5 (0.37) 16.5 % 0.48 [ 0.37, 0.59 ]
PREDIMED 2013 (4) 58 -0.1 (1.36) 59 -0.1 (1.18) 10.7 % 0.0 [ -0.46, 0.46 ]
PREDIMED 2013 (5) 51 28.7 (3.01) 42 28.6 (2.9) 3.4 % 0.10 [ -1.10, 1.30 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.5 % 2.60 [ 0.71, 4.49 ]
WINS 2006 (6) 1328 27.6 (5.5728) 840 26.8 (5.9064) 10.0 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 2355 1879 70.6 % 0.26 [ -0.03, 0.55 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 29.63, df = 7 (P = 0.00011); I2 =76%
Test for overall effect: Z = 1.78 (P = 0.076)
3 total PUFA 2.0 to < 5.0% E
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 total PUFA 5.0+% E
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 12.5 % -0.20 [ -0.56, 0.16 ]
Subtotal (95% CI) 179 192 12.5 % -0.20 [ -0.56, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Total (95% CI) 2631 2167 100.0 % 0.17 [ -0.08, 0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 51.21, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Chi2 = 4.13, df = 2 (P = 0.13), I2 =52%
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(1) Numer of participants equally divided between groups
(2) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
(5) Reus subcohort, 2 year data
(6) One year data
Analysis 3.17. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 17
BMI, kg/m2 - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 17 BMI, kg/m2 - subgroup by duration





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 2.8 % -1.50 [ -2.86, -0.14 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 15.7 % 0.0 [ -0.17, 0.17 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.5 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 199 208 20.0 % 0.21 [ -1.40, 1.81 ]
Heterogeneity: Tau2 = 1.61; Chi2 = 11.90, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 0.25 (P = 0.80)
2 Medium-long duration 2 to < 4 years
AlphaOmega - ALA (1) 630 0.07 (1.5) 630 -0.08 (1.8) 15.6 % 0.15 [ -0.03, 0.33 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 1.2 % 1.00 [ -1.18, 3.18 ]
Subtotal (95% CI) 660 660 16.8 % 0.16 [ -0.03, 0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.094)
3 Long duration 4+ years
PREDIMED 2013 (2) 51 28.7 (3.01) 42 28.6 (2.9) 3.4 % 0.10 [ -1.10, 1.30 ]
PREDIMED 2013 (3) 102 -0.5 (2.04) 112 -0.5 (1.6) 10.1 % 0.0 [ -0.49, 0.49 ]
PREDIMED 2013 (4) 54 -0.02 (0.18) 54 -0.5 (0.37) 16.5 % 0.48 [ 0.37, 0.59 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (5) 58 -0.1 (1.36) 59 -0.1 (1.18) 10.7 % 0.0 [ -0.46, 0.46 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 12.5 % -0.20 [ -0.56, 0.16 ]
WINS 2006 (6) 1328 27.6 (5.5728) 840 26.8 (5.9064) 10.0 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 1772 1299 63.2 % 0.22 [ -0.12, 0.55 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 20.92, df = 5 (P = 0.00084); I2 =76%
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 2631 2167 100.0 % 0.17 [ -0.08, 0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 51.21, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Chi2 = 0.10, df = 2 (P = 0.95), I2 =0.0%
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(2) Reus subcohort, 2 year data
(3) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(4) Barcelona hospital cohort at 5 years, Casa 2016
(5) Damasceno 2013, Barcelona North subcohort, 1 year data
(6) One year data
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Analysis 3.18. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 18
BMI, kg/m2 - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 18 BMI, kg/m2 - subgroup by primary or secondary prevention





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention of CVD
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 2.8 % -1.50 [ -2.86, -0.14 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 1.2 % 1.00 [ -1.18, 3.18 ]
PREDIMED 2013 (1) 58 -0.1 (1.36) 59 -0.1 (1.18) 10.7 % 0.0 [ -0.46, 0.46 ]
PREDIMED 2013 (2) 51 28.7 (3.01) 42 28.6 (2.9) 3.4 % 0.10 [ -1.10, 1.30 ]
PREDIMED 2013 (3) 102 -0.5 (2.04) 112 -0.5 (1.6) 10.1 % 0.0 [ -0.49, 0.49 ]
PREDIMED 2013 (4) 54 -0.02 (0.18) 54 -0.5 (0.37) 16.5 % 0.48 [ 0.37, 0.59 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.5 % 2.60 [ 0.71, 4.49 ]
WINS 2006 (5) 1328 27.6 (5.5728) 840 26.8 (5.9064) 10.0 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 1755 1279 56.2 % 0.30 [ -0.09, 0.69 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 22.38, df = 7 (P = 0.002); I2 =69%
Test for overall effect: Z = 1.53 (P = 0.13)
2 Secondary prevention of CVD
AlphaOmega - ALA (6) 630 0.07 (1.5) 630 -0.08 (1.8) 15.6 % 0.15 [ -0.03, 0.33 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 15.7 % 0.0 [ -0.17, 0.17 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 12.5 % -0.20 [ -0.56, 0.16 ]
Subtotal (95% CI) 876 888 43.8 % 0.03 [ -0.13, 0.19 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.32, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.34 (P = 0.74)
Total (95% CI) 2631 2167 100.0 % 0.17 [ -0.08, 0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 51.21, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Chi2 = 1.63, df = 1 (P = 0.20), I2 =39%
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(4) Barcelona hospital cohort at 5 years, Casa 2016
(5) One year data
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Analysis 3.19. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 19
BMI, kg/m2 - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 19 BMI, kg/m2 - subgroup by baseline PUFA dose





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Baseline total PUFA < 6% E
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 2.8 % -1.50 [ -2.86, -0.14 ]
WINS 2006 (1) 1328 27.6 (5.5728) 840 26.8 (5.9064) 10.0 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 1413 934 12.8 % -0.26 [ -2.51, 1.99 ]
Heterogeneity: Tau2 = 2.37; Chi2 = 9.65, df = 1 (P = 0.002); I2 =90%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Baseline total PUFA 6 to < 11% E
PREDIMED 2013 (2) 102 -0.5 (2.04) 112 -0.5 (1.6) 10.1 % 0.0 [ -0.49, 0.49 ]
PREDIMED 2013 (3) 58 -0.1 (1.36) 59 -0.1 (1.18) 10.7 % 0.0 [ -0.46, 0.46 ]
PREDIMED 2013 (4) 54 -0.02 (0.18) 54 -0.5 (0.37) 16.5 % 0.48 [ 0.37, 0.59 ]
PREDIMED 2013 (5) 51 28.7 (3.01) 42 28.6 (2.9) 3.4 % 0.10 [ -1.10, 1.30 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 12.5 % -0.20 [ -0.56, 0.16 ]
Subtotal (95% CI) 444 459 53.2 % 0.10 [ -0.27, 0.47 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 18.34, df = 4 (P = 0.001); I2 =78%
Test for overall effect: Z = 0.52 (P = 0.60)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
AlphaOmega - ALA (6) 630 0.07 (1.5) 630 -0.08 (1.8) 15.6 % 0.15 [ -0.03, 0.33 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 1.2 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 15.7 % 0.0 [ -0.17, 0.17 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.5 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 774 774 34.0 % 0.16 [ -0.16, 0.48 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 8.86, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 0.99 (P = 0.32)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 2631 2167 100.0 % 0.17 [ -0.08, 0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 51.21, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Chi2 = 0.18, df = 2 (P = 0.91), I2 =0.0%
-2 -1 0 1 2
Favours higher PUFA Favours lower PUFA
(1) One year data
(2) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(3) Damasceno 2013, Barcelona North subcohort, 1 year data
(4) Barcelona hospital cohort at 5 years, Casa 2016
(5) Reus subcohort, 2 year data
(6) Numer of participants equally divided between groups
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Analysis 3.20. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 20
BMI, kg/m2 - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 20 BMI, kg/m2 - subgroup by replacement





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PUFA replaced saturated fats
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 100.0 % -0.20 [ -0.56, 0.16 ]
Subtotal (95% CI) 179 192 100.0 % -0.20 [ -0.56, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
2 PUFA replaced monounsaturated fats
AlphaOmega - ALA (1) 630 0.07 (1.5) 630 -0.08 (1.8) 18.5 % 0.15 [ -0.03, 0.33 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 18.7 % 0.0 [ -0.17, 0.17 ]
PREDIMED 2013 (2) 54 -0.02 (0.18) 54 -0.5 (0.37) 19.8 % 0.48 [ 0.37, 0.59 ]
PREDIMED 2013 (3) 58 -0.1 (1.36) 59 -0.1 (1.18) 12.1 % 0.0 [ -0.46, 0.46 ]
PREDIMED 2013 (4) 102 -0.5 (2.04) 112 -0.5 (1.6) 11.4 % 0.0 [ -0.49, 0.49 ]
PREDIMED 2013 (5) 51 28.7 (3.01) 42 28.6 (2.9) 3.6 % 0.10 [ -1.10, 1.30 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 14.4 % -0.20 [ -0.56, 0.16 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.6 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 1188 1203 100.0 % 0.14 [ -0.11, 0.39 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 39.97, df = 7 (P<0.00001); I2 =82%
Test for overall effect: Z = 1.09 (P = 0.28)
3 PUFA replaced carbohydrates
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 46.0 % -1.50 [ -2.86, -0.14 ]
WINS 2006 (6) 1328 27.6 (5.5728) 840 26.8 (5.9064) 54.0 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 1413 934 100.0 % -0.26 [ -2.51, 1.99 ]
Heterogeneity: Tau2 = 2.37; Chi2 = 9.65, df = 1 (P = 0.002); I2 =90%
Test for overall effect: Z = 0.23 (P = 0.82)
4 PUFA replaced protein
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 PUFA replaced unclear
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 100.0 % 1.00 [ -1.18, 3.18 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 30 30 100.0 % 1.00 [ -1.18, 3.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 3.14, df = 3 (P = 0.37), I2 =4%
-2 -1 0 1 2
Favours higher PUFA Favours lower PUFA
(1) Numer of participants equally divided between groups
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Damasceno 2013, Barcelona North subcohort, 1 year data
(4) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(5) Reus subcohort, 2 year data
(6) One year data
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Analysis 3.21. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 21
BMI, kg/m2 - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 21 BMI, kg/m2 - subgroup by sex





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 > 70% men
AlphaOmega - ALA (1) 630 0.07 (1.5) 630 -0.08 (1.8) 15.6 % 0.15 [ -0.03, 0.33 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 15.7 % 0.0 [ -0.17, 0.17 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 12.5 % -0.20 [ -0.56, 0.16 ]
Subtotal (95% CI) 876 888 43.8 % 0.03 [ -0.13, 0.19 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.32, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.34 (P = 0.74)
2 > 70% women
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 2.8 % -1.50 [ -2.86, -0.14 ]
WINS 2006 (2) 1328 27.6 (5.5728) 840 26.8 (5.9064) 10.0 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 1413 934 12.8 % -0.26 [ -2.51, 1.99 ]
Heterogeneity: Tau2 = 2.37; Chi2 = 9.65, df = 1 (P = 0.002); I2 =90%
Test for overall effect: Z = 0.23 (P = 0.82)
3 men % women
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 1.2 % 1.00 [ -1.18, 3.18 ]
PREDIMED 2013 (3) 54 -0.02 (0.18) 54 -0.5 (0.37) 16.5 % 0.48 [ 0.37, 0.59 ]
PREDIMED 2013 (4) 51 28.7 (3.01) 42 28.6 (2.9) 3.4 % 0.10 [ -1.10, 1.30 ]
PREDIMED 2013 (5) 58 -0.1 (1.36) 59 -0.1 (1.18) 10.7 % 0.0 [ -0.46, 0.46 ]
PREDIMED 2013 (6) 102 -0.5 (2.04) 112 -0.5 (1.6) 10.1 % 0.0 [ -0.49, 0.49 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.5 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 342 345 43.4 % 0.31 [ -0.08, 0.71 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 12.60, df = 5 (P = 0.03); I2 =60%
Test for overall effect: Z = 1.56 (P = 0.12)
Total (95% CI) 2631 2167 100.0 % 0.17 [ -0.08, 0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 51.21, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Chi2 = 1.82, df = 2 (P = 0.40), I2 =0.0%
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(1) Numer of participants equally divided between groups
(2) One year data
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Reus subcohort, 2 year data
(5) Damasceno 2013, Barcelona North subcohort, 1 year data
(6) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
Analysis 3.22. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 22
BMI, kg/m2 - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 22 BMI, kg/m2 - subgroup by age





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean age < 50 years
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 12.5 % -0.20 [ -0.56, 0.16 ]
Subtotal (95% CI) 179 192 12.5 % -0.20 [ -0.56, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
2 Mean age 50 to < 65 years
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 2.8 % -1.50 [ -2.86, -0.14 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 1.2 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 15.7 % 0.0 [ -0.17, 0.17 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.5 % 2.60 [ 0.71, 4.49 ]
WINS 2006 (1) 1328 27.6 (5.5728) 840 26.8 (5.9064) 10.0 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 1557 1078 31.2 % 0.38 [ -0.42, 1.18 ]
Heterogeneity: Tau2 = 0.51; Chi2 = 21.45, df = 4 (P = 0.00026); I2 =81%
Test for overall effect: Z = 0.93 (P = 0.35)
3 Mean age 65+ years
AlphaOmega - ALA (2) 630 0.07 (1.5) 630 -0.08 (1.8) 15.6 % 0.15 [ -0.03, 0.33 ]
PREDIMED 2013 (3) 102 -0.5 (2.04) 112 -0.5 (1.6) 10.1 % 0.0 [ -0.49, 0.49 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (4) 51 28.7 (3.01) 42 28.6 (2.9) 3.4 % 0.10 [ -1.10, 1.30 ]
PREDIMED 2013 (5) 58 -0.1 (1.36) 59 -0.1 (1.18) 10.7 % 0.0 [ -0.46, 0.46 ]
PREDIMED 2013 (6) 54 -0.02 (0.18) 54 -0.5 (0.37) 16.5 % 0.48 [ 0.37, 0.59 ]
Subtotal (95% CI) 895 897 56.2 % 0.21 [ -0.04, 0.47 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 14.20, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 1.66 (P = 0.098)
Total (95% CI) 2631 2167 100.0 % 0.17 [ -0.08, 0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 51.21, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Chi2 = 3.93, df = 2 (P = 0.14), I2 =49%
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(1) One year data
(2) Numer of participants equally divided between groups
(3) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(4) Reus subcohort, 2 year data
(5) Damasceno 2013, Barcelona North subcohort, 1 year data
(6) Barcelona hospital cohort at 5 years, Casa 2016
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Analysis 3.23. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 23
BMI, kg/m2 - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 23 BMI, kg/m2 - subgroup by statin use





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 50% on statins
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 2.8 % -1.50 [ -2.86, -0.14 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 1.2 % 1.00 [ -1.18, 3.18 ]
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 15.7 % 0.0 [ -0.17, 0.17 ]
PREDIMED 2013 (1) 51 28.7 (3.01) 42 28.6 (2.9) 3.4 % 0.10 [ -1.10, 1.30 ]
PREDIMED 2013 (2) 102 -0.5 (2.04) 112 -0.5 (1.6) 10.1 % 0.0 [ -0.49, 0.49 ]
PREDIMED 2013 (3) 54 -0.02 (0.18) 54 -0.5 (0.37) 16.5 % 0.48 [ 0.37, 0.59 ]
PREDIMED 2013 (4) 58 -0.1 (1.36) 59 -0.1 (1.18) 10.7 % 0.0 [ -0.46, 0.46 ]
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 12.5 % -0.20 [ -0.56, 0.16 ]
WINS 2006 (5) 1328 27.6 (5.5728) 840 26.8 (5.9064) 10.0 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 1954 1489 82.9 % 0.12 [ -0.17, 0.42 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 43.38, df = 8 (P<0.00001); I2 =82%
Test for overall effect: Z = 0.83 (P = 0.40)
2 50+% on statins
AlphaOmega - ALA (6) 630 0.07 (1.5) 630 -0.08 (1.8) 15.6 % 0.15 [ -0.03, 0.33 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.5 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 677 678 17.1 % 1.19 [ -1.19, 3.56 ]
Heterogeneity: Tau2 = 2.53; Chi2 = 6.38, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.98 (P = 0.33)
3 Percentage on statins unclear
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 2631 2167 100.0 % 0.17 [ -0.08, 0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 51.21, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Chi2 = 0.76, df = 1 (P = 0.38), I2 =0.0%
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(1) Reus subcohort, 2 year data
(2) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
(5) One year data
(6) Numer of participants equally divided between groups
Analysis 3.24. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 24
BMI, kg/m2 - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 24 BMI, kg/m2 - subgroup by intervention type





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
WINS 2006 (1) 1328 27.6 (5.5728) 840 26.8 (5.9064) 10.0 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 1328 840 10.0 % 0.80 [ 0.30, 1.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.14 (P = 0.0017)
2 Supplemental foods % diet provided
AlphaOmega - ALA (2) 630 0.07 (1.5) 630 -0.08 (1.8) 15.6 % 0.15 [ -0.03, 0.33 ]
PREDIMED 2013 (3) 51 28.7 (3.01) 42 28.6 (2.9) 3.4 % 0.10 [ -1.10, 1.30 ]
PREDIMED 2013 (4) 54 -0.02 (0.18) 54 -0.5 (0.37) 16.5 % 0.48 [ 0.37, 0.59 ]
PREDIMED 2013 (5) 102 -0.5 (2.04) 112 -0.5 (1.6) 10.1 % 0.0 [ -0.49, 0.49 ]
PREDIMED 2013 (6) 58 -0.1 (1.36) 59 -0.1 (1.18) 10.7 % 0.0 [ -0.46, 0.46 ]
Subtotal (95% CI) 895 897 56.2 % 0.21 [ -0.04, 0.47 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 14.20, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 1.66 (P = 0.098)
3 Supplements (capsules % unusual foods)
Dodin 2005 85 25.9 (4.5) 94 27.4 (4.8) 2.8 % -1.50 [ -2.86, -0.14 ]
Mita 2007 30 25.1 (5.3) 30 24.1 (3) 1.2 % 1.00 [ -1.18, 3.18 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nodari 2011 HF 67 26 (0.4) 66 26 (0.6) 15.7 % 0.0 [ -0.17, 0.17 ]
WELCOME 2015 47 33.4 (4.9) 48 30.8 (4.5) 1.5 % 2.60 [ 0.71, 4.49 ]
Subtotal (95% CI) 229 238 21.2 % 0.33 [ -0.99, 1.64 ]
Heterogeneity: Tau2 = 1.26; Chi2 = 12.71, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 0.49 (P = 0.63)
4 Any combination
Sydney Diet-Heart 1978 179 24.3 (1.5) 192 24.5 (2) 12.5 % -0.20 [ -0.56, 0.16 ]
Subtotal (95% CI) 179 192 12.5 % -0.20 [ -0.56, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Total (95% CI) 2631 2167 100.0 % 0.17 [ -0.08, 0.42 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 51.21, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Chi2 = 10.36, df = 3 (P = 0.02), I2 =71%
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(1) One year data
(2) Numer of participants equally divided between groups
(3) Reus subcohort, 2 year data
(4) Barcelona hospital cohort at 5 years, Casa 2016
(5) Canaries subcohort, change from baseline to 1 year, Alvarez-Perez 2016
(6) Damasceno 2013, Barcelona North subcohort, 1 year data
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Analysis 3.25. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 25
Adiposity - waist circumference, cm.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 25 Adiposity - waist circumference, cm





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ORL 2013 168 0.1 (2.9) 165 -0.6 (4.1) 51.4 % 0.70 [ -0.06, 1.46 ]
PREDIMED 2013 (1) 63 -0.23 (3.6) 65 -0.63 (4.76) 15.1 % 0.40 [ -1.06, 1.86 ]
PREDIMED 2013 (2) 102 -2.3 (5.6) 112 -1.1 (6.41) 12.5 % -1.20 [ -2.81, 0.41 ]
PREDIMED 2013 (3) 54 -1.6 (4.76) 54 -1.2 (4.76) 10.1 % -0.40 [ -2.20, 1.40 ]
PREDIMED 2013 55 -2.8 (5.5) 55 -3.2 (5.5) 7.7 % 0.40 [ -1.66, 2.46 ]
PREDIMED 2013 (4) 51 102.7 (7.8) 42 103 (7.8) 3.2 % -0.30 [ -3.49, 2.89 ]
WAHA - Ros 2016 156 2.25 (0) 156 1.94 (0) Not estimable
Total (95% CI) 649 649 100.0 % 0.25 [ -0.32, 0.83 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 5.13, df = 5 (P = 0.40); I2 =2%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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(1) AP-UNAV centre, 3 year data
(2) Canaries cohort, change to 1 year, Alvarez-Perez 2016
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Reus subcohort, 2 year data
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Analysis 3.26. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 26
Adiposity - % body fat.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 26 Adiposity - % body fat





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (1) 102 0.6 (4.58) 112 -0.2 (4.27) 70.3 % 0.80 [ -0.39, 1.99 ]
WELCOME 2015 47 33.5 (9.6) 48 29 (13.8) 29.7 % 4.50 [ -0.27, 9.27 ]
Total (95% CI) 149 160 100.0 % 1.90 [ -1.41, 5.21 ]
Heterogeneity: Tau2 = 3.70; Chi2 = 2.17, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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(1) Canaries cohort, change to 1 year, Alvarez-Perez 2016
Analysis 3.27. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 27
Adiposity - body fat, kg.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 27 Adiposity - body fat, kg





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (1) 102 -0.1 (4.0729) 112 -0.1 (4.2726) 100.0 % 0.0 [ -1.12, 1.12 ]
Total (95% CI) 102 112 100.0 % 0.0 [ -1.12, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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(1) Canaries cohort, change to 1 year, Alvarez-Perez 2016
Analysis 3.28. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 28
Serum TOTAL CHOLESTEROL (TC, mmoL/L).
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 28 Serum TOTAL CHOLESTEROL (TC, mmoL/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 3.6 % -0.15 [ -0.47, 0.17 ]
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 5.4 % -0.02 [ -0.13, 0.09 ]
Brox 2001 (1) 67 7.8896 (0.8168) 37 7.9 (0.8) 3.6 % -0.01 [ -0.33, 0.31 ]
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 5.5 % -0.26 [ -0.37, -0.15 ]
DIPP-Tokudome 2015 (2) 91 5.52 (0.9) 75 5.4 (0.79) 4.2 % 0.12 [ -0.14, 0.38 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 4.6 % -0.30 [ -0.51, -0.09 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 3.0 % 0.03 [ -0.38, 0.44 ]
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 1.9 % 0.30 [ -0.30, 0.90 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 3.9 % -0.47 [ -0.76, -0.18 ]
Ley 2004 (3) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 3.2 % 0.10 [ -0.28, 0.48 ]
MARINA - Sanders 2011 (4) 80 0.2 (0.8987) 71 0.1 (0.63) 4.3 % 0.10 [ -0.15, 0.35 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 3.5 % 0.16 [ -0.18, 0.50 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 2.6 % -0.12 [ -0.58, 0.34 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 (5) 141 -0.9901 (0.6366) 51 -0.18 (0.5713) 4.8 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 (6) 653 -0.6663 (0.693) 309 -0.25 (0.5274) 5.6 % -0.42 [ -0.50, -0.34 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 4.6 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 1.0 % 0.63 [ -0.30, 1.56 ]
PREDIMED 2013 (7) 58 -0.35 (0.9) 59 -0.3 (0.89) 3.6 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (8) 54 -1.01 (0.92) 54 -0.8 (0.99) 3.3 % -0.21 [ -0.57, 0.15 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (9) 51 5.17 (1) 42 5.02 (0.94) 3.0 % 0.15 [ -0.25, 0.55 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 1.1 % -0.49 [ -1.34, 0.36 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 1.2 % 0.31 [ -0.52, 1.14 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 2.6 % 0.34 [ -0.12, 0.80 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 4.6 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 3.0 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 4.0 % 0.06 [ -0.22, 0.34 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 5.4 % -0.18 [ -0.29, -0.07 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 2.9 % -0.10 [ -0.52, 0.32 ]
Total (95% CI) 4278 3794 100.0 % -0.12 [ -0.23, -0.02 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 127.08, df = 27 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours higher PUFA Favours lower PUFA
(1) 14 month data, cod liver oil % seal oil combined
(2) 2 year data
(3) Change data
(4) G2 arm data used
(5) Arms A, B % E combined vs D (control), 52 week data, change data
(6) Arms A, B % X combined vs D (control), 52 week data, change data
(7) Damasceno 2013, Barcelona North subcohort, 1 year data
(8) Barcelona hospital cohort at 5 years, Casas 2016
(9) Fernandez-Real 2012, Reus subcohort, 2 year data
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Analysis 3.29. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 29
TC, mmoL/L - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 29 TC, mmoL/L - SA





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias for allocation concealment
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 9.2 % -0.15 [ -0.47, 0.17 ]
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 11.7 % -0.02 [ -0.13, 0.09 ]
Brox 2001 (1) 67 7.8896 (0.8168) 37 7.9 (0.8) 9.1 % -0.01 [ -0.33, 0.31 ]
DIPP-Tokudome 2015 (2) 91 5.52 (0.9) 75 5.4 (0.79) 10.1 % 0.12 [ -0.14, 0.38 ]
Ley 2004 (3) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 8.4 % 0.10 [ -0.28, 0.48 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 10.2 % 0.10 [ -0.15, 0.35 ]
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 11.0 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 12.0 % -0.42 [ -0.50, -0.34 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 10.7 % -0.30 [ -0.51, -0.09 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 7.7 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 2013 1535 100.0 % -0.16 [ -0.36, 0.03 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 89.20, df = 9 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.66 (P = 0.097)
2 Low risk of bias for attention
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 6.8 % -0.02 [ -0.13, 0.09 ]
Brox 2001 67 7.8896 (0.8168) 37 7.9 (0.8) 5.1 % -0.01 [ -0.33, 0.31 ]
DIPP-Tokudome 2015 (4) 91 5.52 (0.9) 75 5.4 (0.79) 5.7 % 0.12 [ -0.14, 0.38 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 6.1 % -0.30 [ -0.51, -0.09 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 4.4 % 0.03 [ -0.38, 0.44 ]
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 3.0 % 0.30 [ -0.30, 0.90 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 5.8 % 0.10 [ -0.15, 0.35 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 5.0 % 0.16 [ -0.18, 0.50 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 4.0 % -0.12 [ -0.58, 0.34 ]
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 6.3 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 7.0 % -0.42 [ -0.50, -0.34 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 6.1 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 1.7 % 0.63 [ -0.30, 1.56 ]
PREDIMED 2013 (5) 51 5.17 (1) 42 5.02 (0.94) 4.5 % 0.15 [ -0.25, 0.55 ]
PREDIMED 2013 (6) 58 -0.35 (0.9) 59 -0.3 (0.89) 5.1 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (7) 54 -1.01 (0.92) 54 -0.8 (0.99) 4.8 % -0.21 [ -0.57, 0.15 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 1.9 % -0.49 [ -1.34, 0.36 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 2.0 % 0.31 [ -0.52, 1.14 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 4.5 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 5.6 % 0.06 [ -0.22, 0.34 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 4.3 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 2660 2170 100.0 % -0.10 [ -0.23, 0.04 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 114.02, df = 20 (P<0.00001); I2 =82%
Test for overall effect: Z = 1.36 (P = 0.17)
3 Low risk of bias for compliance
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 6.5 % -0.15 [ -0.47, 0.17 ]
Brox 2001 67 7.8896 (0.8168) 37 7.9 (0.8) 6.5 % -0.01 [ -0.33, 0.31 ]
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 10.8 % -0.26 [ -0.37, -0.15 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 7.0 % -0.47 [ -0.76, -0.18 ]
Ley 2004 (8) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 5.6 % 0.10 [ -0.28, 0.48 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 4.4 % -0.12 [ -0.58, 0.34 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 9.2 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 11.2 % -0.42 [ -0.50, -0.34 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 1.8 % -0.49 [ -1.34, 0.36 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 8.7 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 5.3 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 7.4 % 0.06 [ -0.22, 0.34 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 10.7 % -0.18 [ -0.29, -0.07 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 4.9 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 3048 2594 100.0 % -0.27 [ -0.39, -0.14 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 58.52, df = 13 (P<0.00001); I2 =78%
Test for overall effect: Z = 4.26 (P = 0.000020)
4 Low summary risk of bias
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 16.3 % -0.02 [ -0.13, 0.09 ]
Ley 2004 (9) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 11.8 % 0.10 [ -0.28, 0.48 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 14.3 % 0.10 [ -0.15, 0.35 ]
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 15.2 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 16.6 % -0.42 [ -0.50, -0.34 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 14.9 % -0.30 [ -0.51, -0.09 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 10.9 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 1817 1387 100.0 % -0.23 [ -0.46, 0.01 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 76.39, df = 6 (P<0.00001); I2 =92%
Test for overall effect: Z = 1.88 (P = 0.060)
5 Trials registry or pre-2010
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 5.8 % -0.02 [ -0.13, 0.09 ]
Brox 2001 67 7.8896 (0.8168) 37 7.9 (0.8) 3.9 % -0.01 [ -0.33, 0.31 ]
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 5.9 % -0.26 [ -0.37, -0.15 ]
DIPP-Tokudome 2015 (10) 91 5.52 (0.9) 75 5.4 (0.79) 4.5 % 0.12 [ -0.14, 0.38 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 5.0 % -0.30 [ -0.51, -0.09 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 3.2 % 0.03 [ -0.38, 0.44 ]
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 2.0 % 0.30 [ -0.30, 0.90 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 4.2 % -0.47 [ -0.76, -0.18 ]
Ley 2004 (11) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 3.5 % 0.10 [ -0.28, 0.48 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 4.7 % 0.10 [ -0.15, 0.35 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 3.8 % 0.16 [ -0.18, 0.50 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 2.8 % -0.12 [ -0.58, 0.34 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 5.2 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 6.0 % -0.42 [ -0.50, -0.34 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 5.0 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 1.1 % 0.63 [ -0.30, 1.56 ]
PREDIMED 2013 (12) 51 5.17 (1) 42 5.02 (0.94) 3.3 % 0.15 [ -0.25, 0.55 ]
PREDIMED 2013 (13) 54 -1.01 (0.92) 54 -0.8 (0.99) 3.6 % -0.21 [ -0.57, 0.15 ]
PREDIMED 2013 (14) 58 -0.35 (0.9) 59 -0.3 (0.89) 3.9 % -0.05 [ -0.37, 0.27 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 1.2 % -0.49 [ -1.34, 0.36 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 1.3 % 0.31 [ -0.52, 1.14 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 2.9 % 0.34 [ -0.12, 0.80 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 5.0 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 3.3 % -0.37 [ -0.77, 0.03 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 5.8 % -0.18 [ -0.29, -0.07 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 3.1 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 4146 3662 100.0 % -0.13 [ -0.24, -0.03 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 122.74, df = 25 (P<0.00001); I2 =80%
Test for overall effect: Z = 2.45 (P = 0.014)
6 No industry funding
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 9.3 % -0.15 [ -0.47, 0.17 ]
Brox 2001 67 7.8896 (0.8168) 37 7.9 (0.8) 9.3 % -0.01 [ -0.33, 0.31 ]
DIPP-Tokudome 2015 (15) 91 5.52 (0.9) 75 5.4 (0.79) 10.2 % 0.12 [ -0.14, 0.38 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 9.7 % -0.47 [ -0.76, -0.18 ]
Ley 2004 (16) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 8.5 % 0.10 [ -0.28, 0.48 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 10.3 % 0.10 [ -0.15, 0.35 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 9.0 % 0.16 [ -0.18, 0.50 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 11.0 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 12.0 % -0.42 [ -0.50, -0.34 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 10.8 % -0.30 [ -0.51, -0.09 ]
Subtotal (95% CI) 1523 1047 100.0 % -0.19 [ -0.39, 0.01 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 71.77, df = 9 (P<0.00001); I2 =87%
Test for overall effect: Z = 1.83 (P = 0.068)
7 Randomised 100+ participants
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 6.6 % -0.02 [ -0.13, 0.09 ]
Brox 2001 67 7.8896 (0.8168) 37 7.9 (0.8) 4.4 % -0.01 [ -0.33, 0.31 ]
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 6.6 % -0.26 [ -0.37, -0.15 ]
DIPP-Tokudome 2015 (17) 91 5.52 (0.9) 75 5.4 (0.79) 5.1 % 0.12 [ -0.14, 0.38 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 5.6 % -0.30 [ -0.51, -0.09 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 4.7 % -0.47 [ -0.76, -0.18 ]
Ley 2004 (18) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 3.9 % 0.10 [ -0.28, 0.48 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 5.2 % 0.10 [ -0.15, 0.35 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 5.9 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 6.8 % -0.42 [ -0.50, -0.34 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 5.6 % -0.10 [ -0.31, 0.11 ]
PREDIMED 2013 (19) 58 -0.35 (0.9) 59 -0.3 (0.89) 4.4 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (20) 54 -1.01 (0.92) 54 -0.8 (0.99) 4.0 % -0.21 [ -0.57, 0.15 ]
PREDIMED 2013 (21) 51 5.17 (1) 42 5.02 (0.94) 3.7 % 0.15 [ -0.25, 0.55 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 3.2 % 0.34 [ -0.12, 0.80 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 5.6 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 3.7 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 4.9 % 0.06 [ -0.22, 0.34 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 6.6 % -0.18 [ -0.29, -0.07 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 3.5 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 4096 3615 100.0 % -0.16 [ -0.27, -0.05 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 111.80, df = 19 (P<0.00001); I2 =83%
Test for overall effect: Z = 2.87 (P = 0.0041)
8 Randomised 250+ participants
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 13.3 % -0.02 [ -0.13, 0.09 ]
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 13.5 % -0.26 [ -0.37, -0.15 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 9.4 % 0.10 [ -0.15, 0.35 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 14.1 % -0.42 [ -0.50, -0.34 ]
PREDIMED 2013 (22) 58 -0.35 (0.9) 59 -0.3 (0.89) 7.4 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (23) 54 -1.01 (0.92) 54 -0.8 (0.99) 6.6 % -0.21 [ -0.57, 0.15 ]
PREDIMED 2013 (24) 51 5.17 (1) 42 5.02 (0.94) 6.0 % 0.15 [ -0.25, 0.55 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 10.4 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 5.9 % -0.37 [ -0.77, 0.03 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 13.3 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 3348 3000 100.0 % -0.17 [ -0.30, -0.05 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 48.69, df = 9 (P<0.00001); I2 =82%
Test for overall effect: Z = 2.72 (P = 0.0066)
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(5) Fernandez-Real 2012, Reus subcohort, 2 year data
(6) Damasceno 2013, Barcelona North subcohort, 1 year data





(12) Fernandez-Real 2012, Reus subcohort, 2 year data
(13) Barcelona hospital cohort at 5 years, Casas 2016





(19) Damasceno 2013, Barcelona North subcohort, 1 year data
(20) Barcelona hospital cohort at 5 years, Casas 2016
(21) Fernandez-Real 2012, Reus subcohort, 2 year data
(22) Damasceno 2013, Barcelona North subcohort, 1 year data
(23) Barcelona hospital cohort at 5 years, Casas 2016
(24) Fernandez-Real 2012, Reus subcohort, 2 year data
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Analysis 3.30. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 30
TC, mmoL/L - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 30 TC, mmoL/L - SA fixed-effect





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 1.5 % -0.15 [ -0.47, 0.17 ]
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 12.5 % -0.02 [ -0.13, 0.09 ]
Brox 2001 67 7.8896 (0.8168) 37 7.9 (0.8) 1.5 % -0.01 [ -0.33, 0.31 ]
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 13.7 % -0.26 [ -0.37, -0.15 ]
DIPP-Tokudome 2015 (1) 91 5.52 (0.9) 75 5.4 (0.79) 2.3 % 0.12 [ -0.14, 0.38 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 3.4 % -0.30 [ -0.51, -0.09 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 0.9 % 0.03 [ -0.38, 0.44 ]
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 0.4 % 0.30 [ -0.30, 0.90 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 1.8 % -0.47 [ -0.76, -0.18 ]
Ley 2004 (2) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 1.1 % 0.10 [ -0.28, 0.48 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 2.5 % 0.10 [ -0.15, 0.35 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 1.3 % 0.16 [ -0.18, 0.50 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 0.7 % -0.12 [ -0.58, 0.34 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 4.3 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 24.4 % -0.42 [ -0.50, -0.34 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 3.4 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 0.2 % 0.63 [ -0.30, 1.56 ]
PREDIMED 2013 (3) 54 -1.01 (0.92) 54 -0.8 (0.99) 1.2 % -0.21 [ -0.57, 0.15 ]
PREDIMED 2013 (4) 58 -0.35 (0.9) 59 -0.3 (0.89) 1.4 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (5) 51 5.17 (1) 42 5.02 (0.94) 1.0 % 0.15 [ -0.25, 0.55 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 0.2 % -0.49 [ -1.34, 0.36 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 0.2 % 0.31 [ -0.52, 1.14 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 0.7 % 0.34 [ -0.12, 0.80 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 3.4 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 1.0 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 2.0 % 0.06 [ -0.22, 0.34 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 12.2 % -0.18 [ -0.29, -0.07 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 0.9 % -0.10 [ -0.52, 0.32 ]
Total (95% CI) 4278 3794 100.0 % -0.22 [ -0.26, -0.18 ]
Heterogeneity: Chi2 = 127.12, df = 27 (P<0.00001); I2 =79%
Test for overall effect: Z = 11.21 (P < 0.00001)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) 2 year data
(2) Change data
(3) Barcelona hospital cohort at 5 years, Casas 2016
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
(5) Fernandez-Real 2012, Reus subcohort, 2 year data
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Analysis 3.31. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 31
TC, mmoL/L - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 31 TC, mmoL/L - subgroup by PUFA dose





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 total PUFA < 1.0% E
Ley 2004 (1) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 3.2 % 0.10 [ -0.28, 0.48 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 4.3 % 0.10 [ -0.15, 0.35 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 2.6 % -0.12 [ -0.58, 0.34 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 4.6 % -0.10 [ -0.31, 0.11 ]
Subtotal (95% CI) 247 233 14.7 % -0.01 [ -0.15, 0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.02, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
2 total PUFA 1.0 to < 2.0% E
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 3.6 % -0.15 [ -0.47, 0.17 ]
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 5.4 % -0.02 [ -0.13, 0.09 ]
Brox 2001 (2) 67 7.8896 (0.8168) 37 7.9 (0.8) 3.6 % -0.01 [ -0.33, 0.31 ]
DIPP-Tokudome 2015 (3) 91 5.52 (0.9) 75 5.4 (0.79) 4.2 % 0.12 [ -0.14, 0.38 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 4.6 % -0.30 [ -0.51, -0.09 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 1.0 % 0.63 [ -0.30, 1.56 ]
PREDIMED 2013 (4) 58 -0.35 (0.9) 59 -0.3 (0.89) 3.6 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (5) 51 5.17 (1) 42 5.02 (0.94) 3.0 % 0.15 [ -0.25, 0.55 ]
PREDIMED 2013 (6) 54 -1.01 (0.92) 54 -0.8 (0.99) 3.3 % -0.21 [ -0.57, 0.15 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 2.9 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 1108 1062 35.3 % -0.06 [ -0.16, 0.04 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 11.60, df = 9 (P = 0.24); I2 =22%
Test for overall effect: Z = 1.14 (P = 0.25)
3 total PUFA 2.0 to < 5.0% E
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 5.5 % -0.26 [ -0.37, -0.15 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 3.0 % 0.03 [ -0.38, 0.44 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 3.5 % 0.16 [ -0.18, 0.50 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 1.2 % 0.31 [ -0.52, 1.14 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 926 931 13.0 % -0.03 [ -0.31, 0.25 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 8.22, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 0.20 (P = 0.84)
4 total PUFA 5.0+% E
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 1.9 % 0.30 [ -0.30, 0.90 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 3.9 % -0.47 [ -0.76, -0.18 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 4.8 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 5.6 % -0.42 [ -0.50, -0.34 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 1.1 % -0.49 [ -1.34, 0.36 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 2.6 % 0.34 [ -0.12, 0.80 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 4.6 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 3.0 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 4.0 % 0.06 [ -0.22, 0.34 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 5.4 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 1997 1568 37.0 % -0.28 [ -0.45, -0.10 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 57.08, df = 9 (P<0.00001); I2 =84%
Test for overall effect: Z = 3.05 (P = 0.0023)
Total (95% CI) 4278 3794 100.0 % -0.12 [ -0.23, -0.02 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 127.12, df = 27 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 5.96, df = 3 (P = 0.11), I2 =50%
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(1) Change data
(2) 14 month data
(3) 2-year data
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
(5) Fernandez-Real 2012, Reus subcohort, 2 year data
(6) Barcelona hospital cohort at 5 years, Casas 2016
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Analysis 3.32. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 32
TC, mmoL/L - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 32 TC, mmoL/L - subgroup by duration





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 3.6 % -0.15 [ -0.47, 0.17 ]
Brox 2001 (1) 67 7.8896 (0.8168) 37 7.9 (0.8) 3.6 % -0.01 [ -0.33, 0.31 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 4.6 % -0.30 [ -0.51, -0.09 ]
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 1.9 % 0.30 [ -0.30, 0.90 ]
Ley 2004 (2) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 3.2 % 0.10 [ -0.28, 0.48 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 4.3 % 0.10 [ -0.15, 0.35 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 3.5 % 0.16 [ -0.18, 0.50 ]
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 4.8 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 5.6 % -0.42 [ -0.50, -0.34 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 4.6 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 1.0 % 0.63 [ -0.30, 1.56 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 1.2 % 0.31 [ -0.52, 1.14 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 2.9 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 1318 850 44.7 % -0.11 [ -0.30, 0.08 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 75.37, df = 12 (P<0.00001); I2 =84%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Medium-long duration 2 to < 4 years
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 5.4 % -0.02 [ -0.13, 0.09 ]
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 5.5 % -0.26 [ -0.37, -0.15 ]
DIPP-Tokudome 2015 (3) 91 5.52 (0.9) 75 5.4 (0.79) 4.2 % 0.12 [ -0.14, 0.38 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 3.0 % 0.03 [ -0.38, 0.44 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 2.6 % -0.12 [ -0.58, 0.34 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 1.1 % -0.49 [ -1.34, 0.36 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 2.6 % 0.34 [ -0.12, 0.80 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 4.0 % 0.06 [ -0.22, 0.34 ]
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(Continued . . . )
451Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 5.4 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 2017 1995 33.8 % -0.07 [ -0.19, 0.05 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 21.11, df = 8 (P = 0.01); I2 =62%
Test for overall effect: Z = 1.12 (P = 0.26)
3 Long duration 4+ years
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 3.9 % -0.47 [ -0.76, -0.18 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
PREDIMED 2013 (4) 58 -0.35 (0.9) 59 -0.3 (0.89) 3.6 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (5) 51 5.17 (1) 42 5.02 (0.94) 3.0 % 0.15 [ -0.25, 0.55 ]
PREDIMED 2013 (6) 54 -1.01 (0.92) 54 -0.8 (0.99) 3.3 % -0.21 [ -0.57, 0.15 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 4.6 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 3.0 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 943 949 21.5 % -0.23 [ -0.40, -0.06 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 8.16, df = 5 (P = 0.15); I2 =39%
Test for overall effect: Z = 2.71 (P = 0.0067)
Total (95% CI) 4278 3794 100.0 % -0.12 [ -0.23, -0.02 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 127.12, df = 27 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 2.44, df = 2 (P = 0.30), I2 =18%
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(1) 14 month data
(2) Change data
(3) 2 year data
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
(5) Fernandez-Real 2012, Reus subcohort, 2 year data
(6) Barcelona hospital cohort at 5 years, Casas 2016
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Analysis 3.33. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 33
TC, mmoL/L - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 33 TC, mmoL/L - subgroup by primary or secondary prevention





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention of CVD
Brox 2001 (1) 67 7.8896 (0.8168) 37 7.9 (0.8) 3.6 % -0.01 [ -0.33, 0.31 ]
DIPP-Tokudome 2015 (2) 91 5.52 (0.9) 75 5.4 (0.79) 4.2 % 0.12 [ -0.14, 0.38 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 4.6 % -0.30 [ -0.51, -0.09 ]
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 1.9 % 0.30 [ -0.30, 0.90 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 3.9 % -0.47 [ -0.76, -0.18 ]
Ley 2004 (3) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 3.2 % 0.10 [ -0.28, 0.48 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 4.3 % 0.10 [ -0.15, 0.35 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 3.5 % 0.16 [ -0.18, 0.50 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 2.6 % -0.12 [ -0.58, 0.34 ]
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 4.8 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 5.6 % -0.42 [ -0.50, -0.34 ]
PREDIMED 2013 (4) 58 -0.35 (0.9) 59 -0.3 (0.89) 3.6 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (5) 51 5.17 (1) 42 5.02 (0.94) 3.0 % 0.15 [ -0.25, 0.55 ]
PREDIMED 2013 (6) 54 -1.01 (0.92) 54 -0.8 (0.99) 3.3 % -0.21 [ -0.57, 0.15 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 1.2 % 0.31 [ -0.52, 1.14 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 2.6 % 0.34 [ -0.12, 0.80 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 3.0 % -0.37 [ -0.77, 0.03 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 5.4 % -0.18 [ -0.29, -0.07 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 2.9 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 2254 1752 67.2 % -0.12 [ -0.26, 0.02 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 98.37, df = 18 (P<0.00001); I2 =82%
Test for overall effect: Z = 1.74 (P = 0.082)
2 Secondary prevention of CVD
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 3.6 % -0.15 [ -0.47, 0.17 ]
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 5.4 % -0.02 [ -0.13, 0.09 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 5.5 % -0.26 [ -0.37, -0.15 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 3.0 % 0.03 [ -0.38, 0.44 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 4.6 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 1.0 % 0.63 [ -0.30, 1.56 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 1.1 % -0.49 [ -1.34, 0.36 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 4.6 % -0.30 [ -0.51, -0.09 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 4.0 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 2024 2042 32.8 % -0.12 [ -0.24, 0.00 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 17.80, df = 8 (P = 0.02); I2 =55%
Test for overall effect: Z = 2.01 (P = 0.044)
Total (95% CI) 4278 3794 100.0 % -0.12 [ -0.23, -0.02 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 127.12, df = 27 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
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(1) 14 month data
(2) 2 year data
(3) Change data
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
(5) Fernandez-Real 2012, Reus subcohort, 2 year data
(6) Barcelona hospital cohort at 5 years, Casas 2016
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Analysis 3.34. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 34
TC, mmoL/L - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 34 TC, mmoL/L - subgroup by baseline PUFA dose





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Baseline total PUFA < 6% E
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 4.6 % -0.30 [ -0.51, -0.09 ]
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 1.9 % 0.30 [ -0.30, 0.90 ]
Ley 2004 (1) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 3.2 % 0.10 [ -0.28, 0.48 ]
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 4.8 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 5.6 % -0.42 [ -0.50, -0.34 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 3.0 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 1390 957 23.1 % -0.33 [ -0.56, -0.09 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 30.47, df = 5 (P = 0.00001); I2 =84%
Test for overall effect: Z = 2.72 (P = 0.0065)
2 Baseline total PUFA 6 to < 11% E
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 5.5 % -0.26 [ -0.37, -0.15 ]
DIPP-Tokudome 2015 (2) 91 5.52 (0.9) 75 5.4 (0.79) 4.2 % 0.12 [ -0.14, 0.38 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 4.3 % 0.10 [ -0.15, 0.35 ]
PREDIMED 2013 (3) 54 -1.01 (0.92) 54 -0.8 (0.99) 3.3 % -0.21 [ -0.57, 0.15 ]
PREDIMED 2013 (4) 58 -0.35 (0.9) 59 -0.3 (0.89) 3.6 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (5) 51 5.17 (1) 42 5.02 (0.94) 3.0 % 0.15 [ -0.25, 0.55 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 2.6 % 0.34 [ -0.12, 0.80 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 4.6 % -0.30 [ -0.51, -0.09 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 5.4 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 1708 1686 36.6 % -0.09 [ -0.21, 0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 21.57, df = 8 (P = 0.01); I2 =63%
Test for overall effect: Z = 1.38 (P = 0.17)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 3.6 % -0.15 [ -0.47, 0.17 ]
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 5.4 % -0.02 [ -0.13, 0.09 ]
Brox 2001 (6) 67 7.8896 (0.8168) 37 7.9 (0.8) 3.6 % -0.01 [ -0.33, 0.31 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 3.0 % 0.03 [ -0.38, 0.44 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 3.9 % -0.47 [ -0.76, -0.18 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 3.5 % 0.16 [ -0.18, 0.50 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 2.6 % -0.12 [ -0.58, 0.34 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 4.6 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 1.0 % 0.63 [ -0.30, 1.56 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 1.1 % -0.49 [ -1.34, 0.36 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 1.2 % 0.31 [ -0.52, 1.14 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 4.0 % 0.06 [ -0.22, 0.34 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 2.9 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 1180 1151 40.3 % -0.06 [ -0.16, 0.04 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 14.94, df = 12 (P = 0.24); I2 =20%
Test for overall effect: Z = 1.20 (P = 0.23)
Total (95% CI) 4278 3794 100.0 % -0.12 [ -0.23, -0.02 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 127.12, df = 27 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 4.24, df = 2 (P = 0.12), I2 =53%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) 2 year data
(3) Barcelona hospital cohort at 5 years, Casas 2016
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
(5) Fernandez-Real 2012, Reus subcohort, 2 year data
(6) 14 month data
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Analysis 3.35. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 35
TC, mmoL/L - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 35 TC, mmoL/L - subgroup by replacement





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PUFA replaced saturated fats
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 18.7 % -0.26 [ -0.37, -0.15 ]
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 6.2 % 0.30 [ -0.30, 0.90 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 16.4 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 19.2 % -0.42 [ -0.50, -0.34 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 15.7 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 10.2 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 13.6 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 2493 2079 100.0 % -0.32 [ -0.50, -0.14 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 40.88, df = 6 (P<0.00001); I2 =85%
Test for overall effect: Z = 3.46 (P = 0.00053)
2 PUFA replaced monounsaturated fats
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 9.6 % -0.02 [ -0.13, 0.09 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 6.2 % 0.03 [ -0.38, 0.44 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 8.2 % 0.10 [ -0.15, 0.35 ]
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 8.8 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 9.8 % -0.42 [ -0.50, -0.34 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 8.6 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 2.4 % 0.63 [ -0.30, 1.56 ]
PREDIMED 2013 (1) 51 5.17 (1) 42 5.02 (0.94) 6.3 % 0.15 [ -0.25, 0.55 ]
PREDIMED 2013 (2) 58 -0.35 (0.9) 59 -0.3 (0.89) 7.2 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (3) 54 -1.01 (0.92) 54 -0.8 (0.99) 6.7 % -0.21 [ -0.57, 0.15 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 2.7 % -0.49 [ -1.34, 0.36 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 2.8 % 0.31 [ -0.52, 1.14 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 8.6 % -0.30 [ -0.51, -0.09 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 6.3 % -0.37 [ -0.77, 0.03 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 6.0 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 2470 2030 100.0 % -0.17 [ -0.33, 0.00 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 90.40, df = 14 (P<0.00001); I2 =85%
Test for overall effect: Z = 1.98 (P = 0.047)
3 PUFA replaced carbohydrates
DIPP-Tokudome 2015 (4) 91 5.52 (0.9) 75 5.4 (0.79) 12.9 % 0.12 [ -0.14, 0.38 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 14.4 % -0.30 [ -0.51, -0.09 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 11.7 % -0.47 [ -0.76, -0.18 ]
Ley 2004 (5) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 9.3 % 0.10 [ -0.28, 0.48 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 13.3 % 0.10 [ -0.15, 0.35 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 10.3 % 0.16 [ -0.18, 0.50 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 3.0 % -0.49 [ -1.34, 0.36 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 7.5 % 0.34 [ -0.12, 0.80 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 17.6 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 711 683 100.0 % -0.06 [ -0.23, 0.10 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 24.30, df = 8 (P = 0.002); I2 =67%
Test for overall effect: Z = 0.79 (P = 0.43)
4 PUFA replaced protein
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 15.3 % 0.30 [ -0.30, 0.90 ]
Ley 2004 (6) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 28.2 % 0.10 [ -0.28, 0.48 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 56.5 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 436 426 100.0 % -0.03 [ -0.30, 0.24 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 4.10, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.20 (P = 0.84)
5 PUFA replaced unclear
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 40.5 % -0.15 [ -0.47, 0.17 ]
Brox 2001 (7) 67 7.8896 (0.8168) 37 7.9 (0.8) 39.9 % -0.01 [ -0.33, 0.31 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 19.6 % -0.12 [ -0.58, 0.34 ]
Subtotal (95% CI) 135 103 100.0 % -0.09 [ -0.29, 0.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Chi2 = 5.62, df = 4 (P = 0.23), I2 =29%
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(1) Fernandez-Real 2012, Reus subcohort, 2 year data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Barcelona hospital cohort at 5 years, Casas 2016
(4) 2 year data
(5) Change data
(6) Change data
(7) 14 month data
Analysis 3.36. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 36
TC, mmoL/L - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 36 TC, mmoL/L - subgroup by sex





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 > 70% men
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 3.6 % -0.15 [ -0.47, 0.17 ]
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 5.4 % -0.02 [ -0.13, 0.09 ]
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 5.5 % -0.26 [ -0.37, -0.15 ]
DIPP-Tokudome 2015 (1) 91 5.52 (0.9) 75 5.4 (0.79) 4.2 % 0.12 [ -0.14, 0.38 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 3.0 % 0.03 [ -0.38, 0.44 ]
Ley 2004 (2) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 3.2 % 0.10 [ -0.28, 0.48 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 3.5 % 0.16 [ -0.18, 0.50 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 4.8 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 5.6 % -0.42 [ -0.50, -0.34 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 4.6 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 1.0 % 0.63 [ -0.30, 1.56 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 4.6 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 3.0 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 4.0 % 0.06 [ -0.22, 0.34 ]
Subtotal (95% CI) 3415 2978 56.0 % -0.15 [ -0.30, -0.01 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 97.18, df = 13 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.05 (P = 0.040)
2 > 70% women
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 4.6 % -0.30 [ -0.51, -0.09 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 2.6 % 0.34 [ -0.12, 0.80 ]
Subtotal (95% CI) 123 128 7.2 % -0.01 [ -0.64, 0.61 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 6.18, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.04 (P = 0.97)
3 men % women
Brox 2001 (3) 67 7.8896 (0.8168) 37 7.9 (0.8) 3.6 % -0.01 [ -0.33, 0.31 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 3.9 % -0.47 [ -0.76, -0.18 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 4.3 % 0.10 [ -0.15, 0.35 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 2.6 % -0.12 [ -0.58, 0.34 ]
PREDIMED 2013 (4) 58 -0.35 (0.9) 59 -0.3 (0.89) 3.6 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (5) 54 -1.01 (0.92) 54 -0.8 (0.99) 3.3 % -0.21 [ -0.57, 0.15 ]
PREDIMED 2013 (6) 51 5.17 (1) 42 5.02 (0.94) 3.0 % 0.15 [ -0.25, 0.55 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 1.2 % 0.31 [ -0.52, 1.14 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 5.4 % -0.18 [ -0.29, -0.07 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 2.9 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 709 658 33.8 % -0.11 [ -0.22, 0.01 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 13.27, df = 9 (P = 0.15); I2 =32%
Test for overall effect: Z = 1.75 (P = 0.081)
4 sex not reported
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 1.9 % 0.30 [ -0.30, 0.90 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 1.1 % -0.49 [ -1.34, 0.36 ]
Subtotal (95% CI) 31 30 3.0 % -0.04 [ -0.80, 0.73 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 2.21, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 4278 3794 100.0 % -0.12 [ -0.23, -0.02 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 127.12, df = 27 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 0.42, df = 3 (P = 0.94), I2 =0.0%
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(1) 2 year data
(2) Change data
(3) 14 month data
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
(5) Barcelona hospital cohort at 5 years, Casas 2016
(6) Fernandez-Real 2012, Reus subcohort, 2 year data
Analysis 3.37. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 37
TC, mmoL/L - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 37 TC, mmoL/L - subgroup by age





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean age < 50 years
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 4.8 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 5.6 % -0.42 [ -0.50, -0.34 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 1.2 % 0.31 [ -0.52, 1.14 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 2.6 % 0.34 [ -0.12, 0.80 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 4.6 % -0.30 [ -0.51, -0.09 ]
Subtotal (95% CI) 1067 646 18.8 % -0.30 [ -0.59, -0.02 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 31.04, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.10 (P = 0.036)
2 Mean age 50 to < 65 years
Brox 2001 (1) 67 7.8896 (0.8168) 37 7.9 (0.8) 3.6 % -0.01 [ -0.33, 0.31 ]
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 5.5 % -0.26 [ -0.37, -0.15 ]
DIPP-Tokudome 2015 (2) 91 5.52 (0.9) 75 5.4 (0.79) 4.2 % 0.12 [ -0.14, 0.38 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 4.6 % -0.30 [ -0.51, -0.09 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 3.0 % 0.03 [ -0.38, 0.44 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 1.9 % 0.30 [ -0.30, 0.90 ]
Ley 2004 (3) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 3.2 % 0.10 [ -0.28, 0.48 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 4.3 % 0.10 [ -0.15, 0.35 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 2.6 % -0.12 [ -0.58, 0.34 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 4.6 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 1.0 % 0.63 [ -0.30, 1.56 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 1.1 % -0.49 [ -1.34, 0.36 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 4.0 % 0.06 [ -0.22, 0.34 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 2.9 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 1648 1602 46.4 % -0.05 [ -0.17, 0.06 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 24.97, df = 13 (P = 0.02); I2 =48%
Test for overall effect: Z = 0.93 (P = 0.35)
3 Mean age 65+ years
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 5.4 % -0.02 [ -0.13, 0.09 ]
PREDIMED 2013 (4) 51 5.17 (1) 42 5.02 (0.94) 3.0 % 0.15 [ -0.25, 0.55 ]
PREDIMED 2013 (5) 58 -0.35 (0.9) 59 -0.3 (0.89) 3.6 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (6) 54 -1.01 (0.92) 54 -0.8 (0.99) 3.3 % -0.21 [ -0.57, 0.15 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 3.0 % -0.37 [ -0.77, 0.03 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 5.4 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 1451 1434 23.8 % -0.10 [ -0.21, 0.00 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 7.75, df = 5 (P = 0.17); I2 =36%
Test for overall effect: Z = 1.88 (P = 0.061)
4 Mean age unclear
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 3.6 % -0.15 [ -0.47, 0.17 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 3.9 % -0.47 [ -0.76, -0.18 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 3.5 % 0.16 [ -0.18, 0.50 ]
Subtotal (95% CI) 112 112 11.0 % -0.16 [ -0.52, 0.20 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 7.62, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 0.88 (P = 0.38)
Total (95% CI) 4278 3794 100.0 % -0.12 [ -0.23, -0.02 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 127.12, df = 27 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 2.75, df = 3 (P = 0.43), I2 =0.0%
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(1) 14 month data
(2) 2 year data
(3) Change data
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
(5) Damasceno 2013, Barcelona North subcohort, 1 year data
(6) Barcelona hospital cohort at 5 years, Casas 2016
Analysis 3.38. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 38
TC, mmoL/L - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 38 TC, mmoL/L - subgroup by statin use





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 50% on statins
Brox 2001 (1) 67 7.8896 (0.8168) 37 7.9 (0.8) 3.6 % -0.01 [ -0.33, 0.31 ]
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 5.5 % -0.26 [ -0.37, -0.15 ]
DIPP-Tokudome 2015 (2) 91 5.52 (0.9) 75 5.4 (0.79) 4.2 % 0.12 [ -0.14, 0.38 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 4.6 % -0.30 [ -0.51, -0.09 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 3.0 % 0.03 [ -0.38, 0.44 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 3.9 % -0.47 [ -0.76, -0.18 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 4.3 % 0.10 [ -0.15, 0.35 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 3.5 % 0.16 [ -0.18, 0.50 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 2.6 % -0.12 [ -0.58, 0.34 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 4.8 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 5.6 % -0.42 [ -0.50, -0.34 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 4.6 % -0.10 [ -0.31, 0.11 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 1.0 % 0.63 [ -0.30, 1.56 ]
PREDIMED 2013 (3) 51 5.17 (1) 42 5.02 (0.94) 3.0 % 0.15 [ -0.25, 0.55 ]
PREDIMED 2013 (4) 54 -1.01 (0.92) 54 -0.8 (0.99) 3.3 % -0.21 [ -0.57, 0.15 ]
PREDIMED 2013 (5) 58 -0.35 (0.9) 59 -0.3 (0.89) 3.6 % -0.05 [ -0.37, 0.27 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 1.1 % -0.49 [ -1.34, 0.36 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 1.2 % 0.31 [ -0.52, 1.14 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 2.6 % 0.34 [ -0.12, 0.80 ]
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 4.6 % -0.30 [ -0.51, -0.09 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 3.0 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 3146 2672 73.6 % -0.15 [ -0.28, -0.03 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 96.16, df = 20 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.45 (P = 0.014)
2 50+% on statins
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 3.6 % -0.15 [ -0.47, 0.17 ]
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 5.4 % -0.02 [ -0.13, 0.09 ]
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 1.9 % 0.30 [ -0.30, 0.90 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 4.0 % 0.06 [ -0.22, 0.34 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 2.9 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 802 802 17.8 % -0.02 [ -0.11, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.17, df = 4 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
3 Percentage on statins unclear
Ley 2004 (6) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 3.2 % 0.10 [ -0.28, 0.48 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 5.4 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 330 320 8.6 % -0.10 [ -0.35, 0.15 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 1.95, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI) 4278 3794 100.0 % -0.12 [ -0.23, -0.02 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 127.12, df = 27 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 3.03, df = 2 (P = 0.22), I2 =34%
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(1) 14 month data
(2) 2 year data
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Barcelona hospital cohort at 5 years, Casas 2016
(5) Damasceno 2013, Barcelona North subcohort, 1 year data
(6) Change data
Analysis 3.39. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 39
TC, mmoL/L - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 39 TC, mmoL/L - subgroup by intervention type





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
DART fat 1989 855 6.29 (1.13) 860 6.55 (1.1) 5.5 % -0.26 [ -0.37, -0.15 ]
Houtsmuller 1979 48 6.43 (0.65) 48 6.9 (0.81) 3.9 % -0.47 [ -0.76, -0.18 ]
Ley 2004 (1) 70 -0.05 (1.4223) 66 -0.15 (0.7312) 3.2 % 0.10 [ -0.28, 0.48 ]
Simon 1997 38 5.21 (1.11) 34 4.87 (0.87) 2.6 % 0.34 [ -0.12, 0.80 ]
Subtotal (95% CI) 1011 1008 15.1 % -0.13 [ -0.41, 0.15 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 11.75, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 0.88 (P = 0.38)
2 Supplemental foods % diet provided
AlphaOmega - ALA 605 -0.3 (0.98) 605 -0.28 (0.98) 5.4 % -0.02 [ -0.13, 0.09 ]
HERO-Tapsell 2009 18 4.9 (0.8) 17 4.6 (1) 1.9 % 0.30 [ -0.30, 0.90 ]
NDHS Faribault 1968 141 -0.99 (0.637) 51 -0.18 (0.571) 4.8 % -0.81 [ -1.00, -0.62 ]
NDHS Open 1st 1968 653 -0.666 (0.69) 309 -0.25 (0.527) 5.6 % -0.42 [ -0.50, -0.34 ]
PREDIMED 2013 (2) 58 -0.35 (0.9) 59 -0.3 (0.89) 3.6 % -0.05 [ -0.37, 0.27 ]
PREDIMED 2013 (3) 51 5.17 (1) 42 5.02 (0.94) 3.0 % 0.15 [ -0.25, 0.55 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (4) 54 -1.01 (0.92) 54 -0.8 (0.99) 3.3 % -0.21 [ -0.57, 0.15 ]
Veterans Admin 1969 423 4.93 (3.72) 420 5.3 (1.87) 3.0 % -0.37 [ -0.77, 0.03 ]
Vijayakumar 2014 94 3.92 (1.15) 96 3.86 (0.74) 4.0 % 0.06 [ -0.22, 0.34 ]
WAHA - Ros 2016 260 -0.19 (0.65) 254 -0.01 (0.64) 5.4 % -0.18 [ -0.29, -0.07 ]
Subtotal (95% CI) 2357 1907 40.2 % -0.19 [ -0.37, -0.01 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 82.14, df = 9 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.08 (P = 0.038)
3 Supplements (capsules % unusual foods)
Ahn 2016 38 3.6 (0.74) 36 3.75 (0.67) 3.6 % -0.15 [ -0.47, 0.17 ]
Brox 2001 (5) 67 7.8896 (0.8168) 37 7.9 (0.8) 3.6 % -0.01 [ -0.33, 0.31 ]
Dodin 2005 85 5.66 (0.72) 94 5.96 (0.72) 4.6 % -0.30 [ -0.51, -0.09 ]
HARP- Sacks 1995 31 5.02 (0.96) 28 4.99 (0.62) 3.0 % 0.03 [ -0.38, 0.44 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.1 (0.63) 4.3 % 0.10 [ -0.15, 0.35 ]
Mita 2007 30 5.15 (0.83) 30 5.27 (0.99) 2.6 % -0.12 [ -0.58, 0.34 ]
Nodari 2011 HF 67 4.8 (0.62) 66 4.9 (0.62) 4.6 % -0.10 [ -0.31, 0.11 ]
Nye 1990 12 6.83 (1) 12 6.2 (1.31) 1.0 % 0.63 [ -0.30, 1.56 ]
Rose 1965 13 -0.51 (1.25) 13 -0.02 (0.94) 1.1 % -0.49 [ -1.34, 0.36 ]
Rossing 1996 14 5.51 (1.12) 15 5.2 (1.16) 1.2 % 0.31 [ -0.52, 1.14 ]
WELCOME 2015 47 4.7 (1.1) 48 4.8 (1) 2.9 % -0.10 [ -0.52, 0.32 ]
Subtotal (95% CI) 484 450 32.4 % -0.09 [ -0.19, 0.02 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 10.85, df = 10 (P = 0.37); I2 =8%
Test for overall effect: Z = 1.62 (P = 0.11)
4 Any combination
DIPP-Tokudome 2015 (6) 91 5.52 (0.9) 75 5.4 (0.79) 4.2 % 0.12 [ -0.14, 0.38 ]
Mendis 2001 26 -0.42 (0.5447) 28 -0.58 (0.7221) 3.5 % 0.16 [ -0.18, 0.50 ]
MRC 1968 88 -1.11 (0) 89 -0.47 (0) Not estimable
Sydney Diet-Heart 1978 221 6.5 (1.2) 237 6.8 (1.1) 4.6 % -0.30 [ -0.51, -0.09 ]
Subtotal (95% CI) 426 429 12.3 % -0.02 [ -0.34, 0.29 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 8.40, df = 2 (P = 0.01); I2 =76%
Test for overall effect: Z = 0.14 (P = 0.89)
Total (95% CI) 4278 3794 100.0 % -0.12 [ -0.23, -0.02 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 127.12, df = 27 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 1.26, df = 3 (P = 0.74), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
466Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(1) Change data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Barcelona hospital cohort at 5 years, Casas 2016
(5) 14 month data
(6) 2 year data
Analysis 3.40. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 40
Serum fasting TRIGLYCERIDE (TG, mmoL/L).
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 40 Serum fasting TRIGLYCERIDE (TG, mmoL/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 9.0 % -0.06 [ -0.17, 0.05 ]
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 2.9 % -0.13 [ -0.54, 0.27 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.5 % 0.01 [ -0.28, 0.30 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 6.9 % -0.02 [ -0.20, 0.16 ]
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.5 % -0.50 [ -1.64, 0.64 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.6 % -0.47 [ -0.81, -0.13 ]
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.2 % 0.30 [ -0.39, 0.99 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 5.5 % -0.26 [ -0.50, -0.02 ]
Ley 2004 (1) 70 0.07 (1.757) 66 0.03 (0.8936) 2.3 % 0.04 [ -0.42, 0.50 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 7.1 % -0.30 [ -0.48, -0.12 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 2.8 % 0.58 [ 0.17, 0.99 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 2.1 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.9 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.4 % -0.40 [ -0.85, 0.05 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 6.7 % -0.38 [ -0.57, -0.19 ]
PREDIMED 2013 (2) 58 -0.18 (0.58) 59 -0.04 (0.58) 6.2 % -0.14 [ -0.35, 0.07 ]
PREDIMED 2013 (3) 54 -0.28 (0.77) 54 -0.25 (0.84) 4.2 % -0.03 [ -0.33, 0.27 ]
PREDIMED 2013 (4) 51 1.27 (0.58) 42 1.4 (0.7) 4.9 % -0.13 [ -0.39, 0.13 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 2.9 % -0.10 [ -0.50, 0.30 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 7.4 % -0.10 [ -0.26, 0.06 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 7.9 % 0.04 [ -0.11, 0.19 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.1 % -0.30 [ -0.68, 0.08 ]
Total (95% CI) 1977 1928 100.0 % -0.12 [ -0.20, -0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 42.24, df = 21 (P = 0.004); I2 =50%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Not applicable
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(1) Change data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Barcelona hospital cohort at 5 years, Casas 2016
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
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Analysis 3.41. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 41
TG, mmoL/L - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 41 TG, mmoL/L - SA





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias for allocation concealment
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 23.0 % -0.06 [ -0.17, 0.05 ]
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 5.7 % -0.13 [ -0.54, 0.27 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 9.6 % 0.01 [ -0.28, 0.30 ]
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.9 % -0.50 [ -1.64, 0.64 ]
Ley 2004 (1) 70 0.07 (1.757) 66 0.03 (0.8936) 4.6 % 0.04 [ -0.42, 0.50 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 16.7 % -0.30 [ -0.48, -0.12 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 15.6 % -0.38 [ -0.57, -0.19 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 17.7 % -0.10 [ -0.26, 0.06 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 6.3 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 1366 1320 100.0 % -0.17 [ -0.28, -0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 14.12, df = 8 (P = 0.08); I2 =43%
Test for overall effect: Z = 3.08 (P = 0.0021)
2 Low risk of bias for attention
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 10.1 % -0.06 [ -0.17, 0.05 ]
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 3.8 % -0.13 [ -0.54, 0.27 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 5.7 % 0.01 [ -0.28, 0.30 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 8.2 % -0.02 [ -0.20, 0.16 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 4.7 % -0.47 [ -0.81, -0.13 ]
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.7 % 0.30 [ -0.39, 0.99 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 8.4 % -0.30 [ -0.48, -0.12 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 3.7 % 0.58 [ 0.17, 0.99 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 2.8 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 7.2 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 3.3 % -0.40 [ -0.85, 0.05 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 8.0 % -0.38 [ -0.57, -0.19 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (2) 51 1.27 (0.58) 42 1.4 (0.7) 6.2 % -0.13 [ -0.39, 0.13 ]
PREDIMED 2013 (3) 54 -0.28 (0.77) 54 -0.25 (0.84) 5.4 % -0.03 [ -0.33, 0.27 ]
PREDIMED 2013 (4) 58 -0.18 (0.58) 59 -0.04 (0.58) 7.5 % -0.14 [ -0.35, 0.07 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 9.1 % 0.04 [ -0.11, 0.19 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 4.1 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 1585 1523 100.0 % -0.11 [ -0.20, -0.01 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 39.86, df = 16 (P = 0.00081); I2 =60%
Test for overall effect: Z = 2.19 (P = 0.029)
3 Low risk of bias for compliance
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 6.7 % -0.13 [ -0.54, 0.27 ]
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.9 % -0.50 [ -1.64, 0.64 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 16.3 % -0.26 [ -0.50, -0.02 ]
Ley 2004 (5) 70 0.07 (1.757) 66 0.03 (0.8936) 5.3 % 0.04 [ -0.42, 0.50 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 4.6 % 0.26 [ -0.24, 0.76 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 27.5 % -0.10 [ -0.26, 0.06 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 31.2 % 0.04 [ -0.11, 0.19 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 7.5 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 593 582 100.0 % -0.08 [ -0.19, 0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.57, df = 7 (P = 0.28); I2 =18%
Test for overall effect: Z = 1.41 (P = 0.16)
4 Low summary risk of bias
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 36.8 % -0.06 [ -0.17, 0.05 ]
Ley 2004 (6) 70 0.07 (1.757) 66 0.03 (0.8936) 5.5 % 0.04 [ -0.42, 0.50 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 24.0 % -0.30 [ -0.48, -0.12 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 25.9 % -0.10 [ -0.26, 0.06 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 7.7 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 1023 1027 100.0 % -0.14 [ -0.26, -0.03 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.48, df = 4 (P = 0.17); I2 =38%
Test for overall effect: Z = 2.41 (P = 0.016)
5 Trials registry or pre-2010
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 10.0 % -0.06 [ -0.17, 0.05 ]
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 3.1 % -0.13 [ -0.54, 0.27 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.9 % 0.01 [ -0.28, 0.30 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 7.5 % -0.02 [ -0.20, 0.16 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.5 % -0.50 [ -1.64, 0.64 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.9 % -0.47 [ -0.81, -0.13 ]
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.3 % 0.30 [ -0.39, 0.99 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 6.0 % -0.26 [ -0.50, -0.02 ]
Ley 2004 (7) 70 0.07 (1.757) 66 0.03 (0.8936) 2.5 % 0.04 [ -0.42, 0.50 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 7.8 % -0.30 [ -0.48, -0.12 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 3.0 % 0.58 [ 0.17, 0.99 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 2.2 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 6.4 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.6 % -0.40 [ -0.85, 0.05 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 7.4 % -0.38 [ -0.57, -0.19 ]
PREDIMED 2013 (8) 51 1.27 (0.58) 42 1.4 (0.7) 5.4 % -0.13 [ -0.39, 0.13 ]
PREDIMED 2013 (9) 54 -0.28 (0.77) 54 -0.25 (0.84) 4.6 % -0.03 [ -0.33, 0.27 ]
PREDIMED 2013 (10) 58 -0.18 (0.58) 59 -0.04 (0.58) 6.8 % -0.14 [ -0.35, 0.07 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 3.1 % -0.10 [ -0.50, 0.30 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 8.1 % -0.10 [ -0.26, 0.06 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.3 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 1883 1832 100.0 % -0.13 [ -0.21, -0.05 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 37.70, df = 20 (P = 0.01); I2 =47%
Test for overall effect: Z = 3.08 (P = 0.0020)
6 No industry funding
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 10.2 % -0.13 [ -0.54, 0.27 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 14.3 % 0.01 [ -0.28, 0.30 ]
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 2.0 % -0.50 [ -1.64, 0.64 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 16.3 % -0.26 [ -0.50, -0.02 ]
Ley 2004 (11) 70 0.07 (1.757) 66 0.03 (0.8936) 8.6 % 0.04 [ -0.42, 0.50 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 19.1 % -0.30 [ -0.48, -0.12 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 9.9 % 0.58 [ 0.17, 0.99 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 19.6 % -0.10 [ -0.26, 0.06 ]
Subtotal (95% CI) 618 578 100.0 % -0.08 [ -0.25, 0.09 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 17.92, df = 7 (P = 0.01); I2 =61%
Test for overall effect: Z = 0.93 (P = 0.35)
7 Randomised 100+ participants
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 13.7 % -0.06 [ -0.17, 0.05 ]
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 2.4 % -0.13 [ -0.54, 0.27 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.3 % 0.01 [ -0.28, 0.30 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 8.2 % -0.02 [ -0.20, 0.16 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 5.7 % -0.26 [ -0.50, -0.02 ]
Ley 2004 (12) 70 0.07 (1.757) 66 0.03 (0.8936) 1.9 % 0.04 [ -0.42, 0.50 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 8.7 % -0.30 [ -0.48, -0.12 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 6.3 % -0.14 [ -0.36, 0.08 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 7.9 % -0.38 [ -0.57, -0.19 ]
PREDIMED 2013 (13) 58 -0.18 (0.58) 59 -0.04 (0.58) 6.9 % -0.14 [ -0.35, 0.07 ]
PREDIMED 2013 (14) 54 -0.28 (0.77) 54 -0.25 (0.84) 4.0 % -0.03 [ -0.33, 0.27 ]
PREDIMED 2013 (15) 51 1.27 (0.58) 42 1.4 (0.7) 4.9 % -0.13 [ -0.39, 0.13 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 2.4 % -0.10 [ -0.50, 0.30 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 9.4 % -0.10 [ -0.26, 0.06 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 10.6 % 0.04 [ -0.11, 0.19 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 2.7 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 1844 1793 100.0 % -0.12 [ -0.19, -0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 21.83, df = 15 (P = 0.11); I2 =31%
Test for overall effect: Z = 3.66 (P = 0.00026)
8 Randomised 250+ participants
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 22.2 % -0.06 [ -0.17, 0.05 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 15.7 % -0.30 [ -0.48, -0.12 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 14.6 % -0.38 [ -0.57, -0.19 ]
PREDIMED 2013 (16) 54 -0.28 (0.77) 54 -0.25 (0.84) 8.0 % -0.03 [ -0.33, 0.27 ]
PREDIMED 2013 (17) 51 1.27 (0.58) 42 1.4 (0.7) 9.8 % -0.13 [ -0.39, 0.13 ]
PREDIMED 2013 (18) 58 -0.18 (0.58) 59 -0.04 (0.58) 13.0 % -0.14 [ -0.35, 0.07 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 16.7 % -0.10 [ -0.26, 0.06 ]
Subtotal (95% CI) 1239 1233 100.0 % -0.17 [ -0.27, -0.07 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 11.96, df = 6 (P = 0.06); I2 =50%
Test for overall effect: Z = 3.23 (P = 0.0012)
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(1) Change data
(2) Fernandez-Real 2012, Reus subcohort, 2 year data
(3) Barcelona hospital cohort at 5 years, Casas 2016




(8) Fernandez-Real 2012, Reus subcohort, 2 year data
(9) Barcelona hospital cohort at 5 years, Casas 2016
(10) Damasceno 2013, Barcelona North subcohort, 1 year data
(11) Change data
(12) Change data
(13) Damasceno 2013, Barcelona North subcohort, 1 year data
(14) Barcelona hospital cohort at 5 years, Casas 2016
(15) Fernandez-Real 2012, Reus subcohort, 2 year data
(16) Barcelona hospital cohort at 5 years, Casas 2016
(17) Fernandez-Real 2012, Reus subcohort, 2 year data
(18) Damasceno 2013, Barcelona North subcohort, 1 year data
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Analysis 3.42. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 42
TG, mmoL/L - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 42 TG, mmoL/L - SA fixed-effect





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 20.5 % -0.06 [ -0.17, 0.05 ]
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 1.5 % -0.13 [ -0.54, 0.27 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 3.0 % 0.01 [ -0.28, 0.30 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 7.4 % -0.02 [ -0.20, 0.16 ]
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.2 % -0.50 [ -1.64, 0.64 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 2.1 % -0.47 [ -0.81, -0.13 ]
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 0.5 % 0.30 [ -0.39, 0.99 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 4.3 % -0.26 [ -0.50, -0.02 ]
Ley 2004 (1) 70 0.07 (1.757) 66 0.03 (0.8936) 1.2 % 0.04 [ -0.42, 0.50 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 8.0 % -0.30 [ -0.48, -0.12 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 1.5 % 0.58 [ 0.17, 0.99 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 1.0 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.0 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 1.2 % -0.40 [ -0.85, 0.05 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 6.9 % -0.38 [ -0.57, -0.19 ]
PREDIMED 2013 (2) 58 -0.18 (0.58) 59 -0.04 (0.58) 5.6 % -0.14 [ -0.35, 0.07 ]
PREDIMED 2013 (3) 51 1.27 (0.58) 42 1.4 (0.7) 3.6 % -0.13 [ -0.39, 0.13 ]
PREDIMED 2013 (4) 54 -0.28 (0.77) 54 -0.25 (0.84) 2.7 % -0.03 [ -0.33, 0.27 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 1.5 % -0.10 [ -0.50, 0.30 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 9.2 % -0.10 [ -0.26, 0.06 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 11.4 % 0.04 [ -0.11, 0.19 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 1.7 % -0.30 [ -0.68, 0.08 ]
Total (95% CI) 1977 1928 100.0 % -0.11 [ -0.16, -0.06 ]
Heterogeneity: Chi2 = 42.24, df = 21 (P = 0.004); I2 =50%
Test for overall effect: Z = 4.37 (P = 0.000012)
Test for subgroup differences: Not applicable
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(1) Change data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Barcelona hospital cohort at 5 years, Casas 2016
Analysis 3.43. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 43
TG, mmoL/L - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 43 TG, mmoL/L - subgroup by PUFA dose





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 total PUFA < 1.0% E
Ley 2004 (1) 70 0.07 (1.757) 66 0.03 (0.8936) 2.3 % 0.04 [ -0.42, 0.50 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 7.1 % -0.30 [ -0.48, -0.12 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 2.1 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.9 % -0.14 [ -0.36, 0.08 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 6.7 % -0.38 [ -0.57, -0.19 ]
Subtotal (95% CI) 417 398 24.1 % -0.20 [ -0.37, -0.02 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 8.52, df = 4 (P = 0.07); I2 =53%
Test for overall effect: Z = 2.24 (P = 0.025)
2 total PUFA 1.0 to < 2.0% E
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 9.0 % -0.06 [ -0.17, 0.05 ]
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 2.9 % -0.13 [ -0.54, 0.27 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.5 % 0.01 [ -0.28, 0.30 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 6.9 % -0.02 [ -0.20, 0.16 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.4 % -0.40 [ -0.85, 0.05 ]
PREDIMED 2013 (2) 54 -0.28 (0.77) 54 -0.25 (0.84) 4.2 % -0.03 [ -0.33, 0.27 ]
PREDIMED 2013 (3) 51 1.27 (0.58) 42 1.4 (0.7) 4.9 % -0.13 [ -0.39, 0.13 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (4) 58 -0.18 (0.58) 59 -0.04 (0.58) 6.2 % -0.14 [ -0.35, 0.07 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.1 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 1069 1022 44.2 % -0.08 [ -0.15, -0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.72, df = 8 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.027)
3 total PUFA 2.0 to < 5.0% E
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.5 % -0.50 [ -1.64, 0.64 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.6 % -0.47 [ -0.81, -0.13 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 2.8 % 0.58 [ 0.17, 0.99 ]
Subtotal (95% CI) 73 76 6.8 % -0.08 [ -0.91, 0.75 ]
Heterogeneity: Tau2 = 0.43; Chi2 = 15.20, df = 2 (P = 0.00050); I2 =87%
Test for overall effect: Z = 0.19 (P = 0.85)
4 total PUFA 5.0+% E
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.2 % 0.30 [ -0.39, 0.99 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 5.5 % -0.26 [ -0.50, -0.02 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 2.9 % -0.10 [ -0.50, 0.30 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 7.4 % -0.10 [ -0.26, 0.06 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 7.9 % 0.04 [ -0.11, 0.19 ]
Subtotal (95% CI) 418 432 24.9 % -0.07 [ -0.20, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.74, df = 4 (P = 0.22); I2 =30%
Test for overall effect: Z = 1.05 (P = 0.29)
Total (95% CI) 1977 1928 100.0 % -0.12 [ -0.20, -0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 42.24, df = 21 (P = 0.004); I2 =50%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Chi2 = 1.62, df = 3 (P = 0.65), I2 =0.0%
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(2) Barcelona hospital cohort at 5 years, Casas 2016
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
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Analysis 3.44. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 44
TG, mmoL/L - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 44 TG, mmoL/L - subgroup by duration





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 2.9 % -0.13 [ -0.54, 0.27 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 6.9 % -0.02 [ -0.20, 0.16 ]
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.2 % 0.30 [ -0.39, 0.99 ]
Ley 2004 (1) 70 0.07 (1.757) 66 0.03 (0.8936) 2.3 % 0.04 [ -0.42, 0.50 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 7.1 % -0.30 [ -0.48, -0.12 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 2.8 % 0.58 [ 0.17, 0.99 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.9 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.4 % -0.40 [ -0.85, 0.05 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 6.7 % -0.38 [ -0.57, -0.19 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.1 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 642 604 41.3 % -0.12 [ -0.28, 0.04 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 26.05, df = 9 (P = 0.002); I2 =65%
Test for overall effect: Z = 1.50 (P = 0.13)
2 Medium-long duration 2 to < 4 years
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 9.0 % -0.06 [ -0.17, 0.05 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.5 % 0.01 [ -0.28, 0.30 ]
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.5 % -0.50 [ -1.64, 0.64 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.6 % -0.47 [ -0.81, -0.13 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 2.1 % 0.26 [ -0.24, 0.76 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 2.9 % -0.10 [ -0.50, 0.30 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 7.9 % 0.04 [ -0.11, 0.19 ]
Subtotal (95% CI) 903 884 30.5 % -0.06 [ -0.18, 0.07 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 9.46, df = 6 (P = 0.15); I2 =37%
Test for overall effect: Z = 0.87 (P = 0.38)
3 Long duration 4+ years
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 5.5 % -0.26 [ -0.50, -0.02 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (2) 58 -0.18 (0.58) 59 -0.04 (0.58) 6.2 % -0.14 [ -0.35, 0.07 ]
PREDIMED 2013 (3) 54 -0.28 (0.77) 54 -0.25 (0.84) 4.2 % -0.03 [ -0.33, 0.27 ]
PREDIMED 2013 (4) 51 1.27 (0.58) 42 1.4 (0.7) 4.9 % -0.13 [ -0.39, 0.13 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 7.4 % -0.10 [ -0.26, 0.06 ]
Subtotal (95% CI) 432 440 28.3 % -0.13 [ -0.23, -0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.67, df = 4 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0086)
Total (95% CI) 1977 1928 100.0 % -0.12 [ -0.20, -0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 42.24, df = 21 (P = 0.004); I2 =50%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Chi2 = 0.96, df = 2 (P = 0.62), I2 =0.0%
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(1) Change data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Barcelona hospital cohort at 5 years, Casas 2016
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
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Analysis 3.45. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 45
TG, mmoL/L - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 45 TG, mmoL/L - subgroup by primary or secondary prevention





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention of CVD
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 2.9 % -0.13 [ -0.54, 0.27 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.5 % 0.01 [ -0.28, 0.30 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 6.9 % -0.02 [ -0.20, 0.16 ]
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.5 % -0.50 [ -1.64, 0.64 ]
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.2 % 0.30 [ -0.39, 0.99 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 5.5 % -0.26 [ -0.50, -0.02 ]
Ley 2004 (1) 70 0.07 (1.757) 66 0.03 (0.8936) 2.3 % 0.04 [ -0.42, 0.50 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 7.1 % -0.30 [ -0.48, -0.12 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 2.8 % 0.58 [ 0.17, 0.99 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 2.1 % 0.26 [ -0.24, 0.76 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 6.7 % -0.38 [ -0.57, -0.19 ]
PREDIMED 2013 (2) 54 -0.28 (0.77) 54 -0.25 (0.84) 4.2 % -0.03 [ -0.33, 0.27 ]
PREDIMED 2013 (3) 58 -0.18 (0.58) 59 -0.04 (0.58) 6.2 % -0.14 [ -0.35, 0.07 ]
PREDIMED 2013 (4) 51 1.27 (0.58) 42 1.4 (0.7) 4.9 % -0.13 [ -0.39, 0.13 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 2.9 % -0.10 [ -0.50, 0.30 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.1 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 947 884 63.8 % -0.10 [ -0.21, 0.01 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 30.75, df = 15 (P = 0.01); I2 =51%
Test for overall effect: Z = 1.84 (P = 0.065)
2 Secondary prevention of CVD
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 9.0 % -0.06 [ -0.17, 0.05 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.6 % -0.47 [ -0.81, -0.13 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.9 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.4 % -0.40 [ -0.85, 0.05 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 7.4 % -0.10 [ -0.26, 0.06 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 7.9 % 0.04 [ -0.11, 0.19 ]
Subtotal (95% CI) 1030 1044 36.2 % -0.11 [ -0.22, 0.00 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 9.86, df = 5 (P = 0.08); I2 =49%
Test for overall effect: Z = 1.91 (P = 0.056)
Total (95% CI) 1977 1928 100.0 % -0.12 [ -0.20, -0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 42.24, df = 21 (P = 0.004); I2 =50%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Barcelona hospital cohort at 5 years, Casas 2016
(3) Damasceno 2013, Barcelona North subcohort, 1 year data
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
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Analysis 3.46. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 46
TG, mmoL/L - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 46 TG, mmoL/L - subgroup by baseline PUFA dose





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Baseline total PUFA < 6% E
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 6.9 % -0.02 [ -0.20, 0.16 ]
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.2 % 0.30 [ -0.39, 0.99 ]
Ley 2004 (1) 70 0.07 (1.757) 66 0.03 (0.8936) 2.3 % 0.04 [ -0.42, 0.50 ]
Subtotal (95% CI) 173 177 10.4 % 0.01 [ -0.16, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
2 Baseline total PUFA 6 to < 11% E
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.5 % 0.01 [ -0.28, 0.30 ]
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.5 % -0.50 [ -1.64, 0.64 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 7.1 % -0.30 [ -0.48, -0.12 ]
PREDIMED 2013 (2) 51 1.27 (0.58) 42 1.4 (0.7) 4.9 % -0.13 [ -0.39, 0.13 ]
PREDIMED 2013 (3) 58 -0.18 (0.58) 59 -0.04 (0.58) 6.2 % -0.14 [ -0.35, 0.07 ]
PREDIMED 2013 (4) 54 -0.28 (0.77) 54 -0.25 (0.84) 4.2 % -0.03 [ -0.33, 0.27 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 2.9 % -0.10 [ -0.50, 0.30 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 7.4 % -0.10 [ -0.26, 0.06 ]
Subtotal (95% CI) 607 588 37.8 % -0.14 [ -0.23, -0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.34, df = 7 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 9.0 % -0.06 [ -0.17, 0.05 ]
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 2.9 % -0.13 [ -0.54, 0.27 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.6 % -0.47 [ -0.81, -0.13 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 5.5 % -0.26 [ -0.50, -0.02 ]
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(Continued . . . )
481Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 2.8 % 0.58 [ 0.17, 0.99 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 2.1 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.9 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.4 % -0.40 [ -0.85, 0.05 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 6.7 % -0.38 [ -0.57, -0.19 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 7.9 % 0.04 [ -0.11, 0.19 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.1 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 1197 1163 51.8 % -0.13 [ -0.27, 0.01 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 33.61, df = 10 (P = 0.00021); I2 =70%
Test for overall effect: Z = 1.83 (P = 0.067)
Total (95% CI) 1977 1928 100.0 % -0.12 [ -0.20, -0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 42.24, df = 21 (P = 0.004); I2 =50%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Chi2 = 2.54, df = 2 (P = 0.28), I2 =21%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Fernandez-Real 2012, Reus subcohort, 2 year data
(3) Damasceno 2013, Barcelona North subcohort, 1 year data
(4) Barcelona hospital cohort at 5 years, Casas 2016
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Analysis 3.47. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 47
TG, mmoL/L - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 47 TG, mmoL/L - subgroup by replacement





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PUFA replaced saturated fats
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.9 % -0.50 [ -1.64, 0.64 ]
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 2.6 % 0.30 [ -0.39, 0.99 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 43.2 % -0.10 [ -0.26, 0.06 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 53.3 % 0.04 [ -0.11, 0.19 ]
Subtotal (95% CI) 349 370 100.0 % -0.02 [ -0.13, 0.09 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 0.33 (P = 0.74)
2 PUFA replaced monounsaturated fats
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 25.1 % -0.06 [ -0.17, 0.05 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 4.7 % -0.47 [ -0.81, -0.13 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 14.1 % -0.30 [ -0.48, -0.12 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 9.8 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.8 % -0.40 [ -0.85, 0.05 ]
PREDIMED 2013 (1) 51 1.27 (0.58) 42 1.4 (0.7) 7.4 % -0.13 [ -0.39, 0.13 ]
PREDIMED 2013 (2) 58 -0.18 (0.58) 59 -0.04 (0.58) 10.9 % -0.14 [ -0.35, 0.07 ]
PREDIMED 2013 (3) 54 -0.28 (0.77) 54 -0.25 (0.84) 5.8 % -0.03 [ -0.33, 0.27 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 15.5 % -0.10 [ -0.26, 0.06 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.9 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 1226 1222 100.0 % -0.16 [ -0.24, -0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 11.37, df = 9 (P = 0.25); I2 =21%
Test for overall effect: Z = 3.96 (P = 0.000074)
3 PUFA replaced carbohydrates
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 14.8 % 0.01 [ -0.28, 0.30 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 18.7 % -0.02 [ -0.20, 0.16 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 16.6 % -0.26 [ -0.50, -0.02 ]
Ley 2004 (4) 70 0.07 (1.757) 66 0.03 (0.8936) 9.4 % 0.04 [ -0.42, 0.50 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 19.0 % -0.30 [ -0.48, -0.12 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 10.7 % 0.58 [ 0.17, 0.99 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 10.9 % -0.10 [ -0.50, 0.30 ]
Subtotal (95% CI) 436 412 100.0 % -0.05 [ -0.23, 0.14 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 18.59, df = 6 (P = 0.005); I2 =68%
Test for overall effect: Z = 0.51 (P = 0.61)
4 PUFA replaced protein
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 31.4 % 0.30 [ -0.39, 0.99 ]
Ley 2004 (5) 70 0.07 (1.757) 66 0.03 (0.8936) 68.6 % 0.04 [ -0.42, 0.50 ]
Subtotal (95% CI) 88 83 100.0 % 0.12 [ -0.26, 0.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
5 PUFA replaced unclear
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 30.5 % -0.13 [ -0.54, 0.27 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 25.3 % 0.26 [ -0.24, 0.76 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 44.2 % -0.38 [ -0.57, -0.19 ]
Subtotal (95% CI) 267 232 100.0 % -0.14 [ -0.50, 0.21 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 6.03, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 5.84, df = 4 (P = 0.21), I2 =31%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Fernandez-Real 2012, Reus subcohort, 2 year data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Barcelona hospital cohort at 5 years, Casas 2016
(4) Change data
(5) Change data
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Analysis 3.48. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 48
TG, mmoL/L - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 48 TG, mmoL/L - subgroup by sex





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 > 70% men
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 9.0 % -0.06 [ -0.17, 0.05 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.5 % 0.01 [ -0.28, 0.30 ]
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.5 % -0.50 [ -1.64, 0.64 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.6 % -0.47 [ -0.81, -0.13 ]
Ley 2004 (1) 70 0.07 (1.757) 66 0.03 (0.8936) 2.3 % 0.04 [ -0.42, 0.50 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 2.8 % 0.58 [ 0.17, 0.99 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.9 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.4 % -0.40 [ -0.85, 0.05 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 6.7 % -0.38 [ -0.57, -0.19 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 7.4 % -0.10 [ -0.26, 0.06 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 7.9 % 0.04 [ -0.11, 0.19 ]
Subtotal (95% CI) 1402 1394 53.1 % -0.10 [ -0.23, 0.03 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 30.25, df = 10 (P = 0.00078); I2 =67%
Test for overall effect: Z = 1.58 (P = 0.12)
2 > 70% women
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 6.9 % -0.02 [ -0.20, 0.16 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 2.9 % -0.10 [ -0.50, 0.30 ]
Subtotal (95% CI) 122 128 9.8 % -0.03 [ -0.20, 0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.69)
3 men % women
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 2.9 % -0.13 [ -0.54, 0.27 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 5.5 % -0.26 [ -0.50, -0.02 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 7.1 % -0.30 [ -0.48, -0.12 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 2.1 % 0.26 [ -0.24, 0.76 ]
PREDIMED 2013 (2) 54 -0.28 (0.77) 54 -0.25 (0.84) 4.2 % -0.03 [ -0.33, 0.27 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (3) 58 -0.18 (0.58) 59 -0.04 (0.58) 6.2 % -0.14 [ -0.35, 0.07 ]
PREDIMED 2013 (4) 51 1.27 (0.58) 42 1.4 (0.7) 4.9 % -0.13 [ -0.39, 0.13 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.1 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 435 389 36.0 % -0.19 [ -0.28, -0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.79, df = 7 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.91 (P = 0.000092)
4 sex not reported
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.2 % 0.30 [ -0.39, 0.99 ]
Subtotal (95% CI) 18 17 1.2 % 0.30 [ -0.39, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 1977 1928 100.0 % -0.12 [ -0.20, -0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 42.24, df = 21 (P = 0.004); I2 =50%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Chi2 = 4.34, df = 3 (P = 0.23), I2 =31%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Barcelona hospital cohort at 5 years, Casas 2016
(3) Damasceno 2013, Barcelona North subcohort, 1 year data
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
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Analysis 3.49. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 49
TG, mmoL/L - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 49 TG, mmoL/L - subgroup by age





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean age < 50 years
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.5 % -0.50 [ -1.64, 0.64 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 2.9 % -0.10 [ -0.50, 0.30 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 7.4 % -0.10 [ -0.26, 0.06 ]
Subtotal (95% CI) 274 291 10.8 % -0.11 [ -0.26, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.46, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.17)
2 Mean age 50 to < 65 years
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 2.9 % -0.13 [ -0.54, 0.27 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.5 % 0.01 [ -0.28, 0.30 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 6.9 % -0.02 [ -0.20, 0.16 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.6 % -0.47 [ -0.81, -0.13 ]
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.2 % 0.30 [ -0.39, 0.99 ]
Ley 2004 (1) 70 0.07 (1.757) 66 0.03 (0.8936) 2.3 % 0.04 [ -0.42, 0.50 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 7.1 % -0.30 [ -0.48, -0.12 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 2.1 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.9 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.4 % -0.40 [ -0.85, 0.05 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 6.7 % -0.38 [ -0.57, -0.19 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 7.9 % 0.04 [ -0.11, 0.19 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.1 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 861 801 56.6 % -0.15 [ -0.26, -0.03 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 27.78, df = 12 (P = 0.01); I2 =57%
Test for overall effect: Z = 2.39 (P = 0.017)
3 Mean age 65+ years
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 9.0 % -0.06 [ -0.17, 0.05 ]
PREDIMED 2013 (2) 54 -0.28 (0.77) 54 -0.25 (0.84) 4.2 % -0.03 [ -0.33, 0.27 ]
-0.5 -0.25 0 0.25 0.5
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (3) 51 1.27 (0.58) 42 1.4 (0.7) 4.9 % -0.13 [ -0.39, 0.13 ]
PREDIMED 2013 (4) 58 -0.18 (0.58) 59 -0.04 (0.58) 6.2 % -0.14 [ -0.35, 0.07 ]
Subtotal (95% CI) 768 760 24.4 % -0.08 [ -0.17, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 3 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.077)
4 Mean age unclear
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 5.5 % -0.26 [ -0.50, -0.02 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 2.8 % 0.58 [ 0.17, 0.99 ]
Subtotal (95% CI) 74 76 8.2 % 0.14 [ -0.68, 0.96 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 11.82, df = 1 (P = 0.00059); I2 =92%
Test for overall effect: Z = 0.34 (P = 0.73)
Total (95% CI) 1977 1928 100.0 % -0.12 [ -0.20, -0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 42.24, df = 21 (P = 0.004); I2 =50%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Chi2 = 1.11, df = 3 (P = 0.78), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Barcelona hospital cohort at 5 years, Casas 2016
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
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Analysis 3.50. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 50
TG, mmoL/L - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 50 TG, mmoL/L - subgroup by statin use





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 50% on statins
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 2.9 % -0.13 [ -0.54, 0.27 ]
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.5 % 0.01 [ -0.28, 0.30 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 6.9 % -0.02 [ -0.20, 0.16 ]
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.5 % -0.50 [ -1.64, 0.64 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.6 % -0.47 [ -0.81, -0.13 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 5.5 % -0.26 [ -0.50, -0.02 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 7.1 % -0.30 [ -0.48, -0.12 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 2.8 % 0.58 [ 0.17, 0.99 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 2.1 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.9 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.4 % -0.40 [ -0.85, 0.05 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 6.7 % -0.38 [ -0.57, -0.19 ]
PREDIMED 2013 (1) 51 1.27 (0.58) 42 1.4 (0.7) 4.9 % -0.13 [ -0.39, 0.13 ]
PREDIMED 2013 (2) 58 -0.18 (0.58) 59 -0.04 (0.58) 6.2 % -0.14 [ -0.35, 0.07 ]
PREDIMED 2013 (3) 54 -0.28 (0.77) 54 -0.25 (0.84) 4.2 % -0.03 [ -0.33, 0.27 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 2.9 % -0.10 [ -0.50, 0.30 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 7.4 % -0.10 [ -0.26, 0.06 ]
Subtotal (95% CI) 1143 1096 76.4 % -0.14 [ -0.24, -0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 32.73, df = 16 (P = 0.01); I2 =51%
Test for overall effect: Z = 2.87 (P = 0.0042)
2 50+% on statins
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 9.0 % -0.06 [ -0.17, 0.05 ]
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.2 % 0.30 [ -0.39, 0.99 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 7.9 % 0.04 [ -0.11, 0.19 ]
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.1 % -0.30 [ -0.68, 0.08 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 764 766 21.2 % -0.03 [ -0.15, 0.08 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.94, df = 3 (P = 0.27); I2 =24%
Test for overall effect: Z = 0.56 (P = 0.58)
3 Percentage on statins unclear
Ley 2004 (4) 70 0.07 (1.757) 66 0.03 (0.8936) 2.3 % 0.04 [ -0.42, 0.50 ]
Subtotal (95% CI) 70 66 2.3 % 0.04 [ -0.42, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Total (95% CI) 1977 1928 100.0 % -0.12 [ -0.20, -0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 42.24, df = 21 (P = 0.004); I2 =50%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Chi2 = 2.32, df = 2 (P = 0.31), I2 =14%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Fernandez-Real 2012, Reus subcohort, 2 year data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Barcelona hospital cohort at 5 years, Casas 2016
(4) Change data
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Analysis 3.51. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 51
TG, mmoL/L - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 51 TG, mmoL/L - subgroup by intervention type





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
Dullaart 1992 16 1.3 (1.2) 20 1.8 (2.24) 0.5 % -0.50 [ -1.64, 0.64 ]
Houtsmuller 1979 48 0.79 (0.6) 48 1.05 (0.6) 5.5 % -0.26 [ -0.50, -0.02 ]
Ley 2004 (1) 70 0.07 (1.757) 66 0.03 (0.8936) 2.3 % 0.04 [ -0.42, 0.50 ]
Simon 1997 37 1.25 (0.61) 34 1.35 (1.05) 2.9 % -0.10 [ -0.50, 0.30 ]
Subtotal (95% CI) 171 168 11.1 % -0.18 [ -0.37, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.74, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.052)
2 Supplemental foods % diet provided
AlphaOmega - ALA 605 -0.11 (0.98) 605 -0.05 (0.98) 9.0 % -0.06 [ -0.17, 0.05 ]
HERO-Tapsell 2009 18 2.1 (1.3) 17 1.8 (0.7) 1.2 % 0.30 [ -0.39, 0.99 ]
PREDIMED 2013 (2) 51 1.27 (0.58) 42 1.4 (0.7) 4.9 % -0.13 [ -0.39, 0.13 ]
PREDIMED 2013 (3) 54 -0.28 (0.77) 54 -0.25 (0.84) 4.2 % -0.03 [ -0.33, 0.27 ]
PREDIMED 2013 (4) 58 -0.18 (0.58) 59 -0.04 (0.58) 6.2 % -0.14 [ -0.35, 0.07 ]
Vijayakumar 2014 94 1.27 (0.51) 96 1.23 (0.53) 7.9 % 0.04 [ -0.11, 0.19 ]
Subtotal (95% CI) 880 873 33.5 % -0.04 [ -0.12, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.50, df = 5 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
3 Supplements (capsules % unusual foods)
Brox 2001 67 2.0657 (1.1999) 37 2.2 (0.89) 2.9 % -0.13 [ -0.54, 0.27 ]
Dodin 2005 85 1.15 (0.53) 94 1.17 (0.72) 6.9 % -0.02 [ -0.20, 0.16 ]
HARP- Sacks 1995 31 1.14 (0.56) 28 1.61 (0.76) 3.6 % -0.47 [ -0.81, -0.13 ]
MARINA - Sanders 2011 80 -0.2 (0.45) 71 0.1 (0.63) 7.1 % -0.30 [ -0.48, -0.12 ]
Mita 2007 30 1.77 (1.07) 30 1.51 (0.9) 2.1 % 0.26 [ -0.24, 0.76 ]
Nodari 2011 HF 67 1.61 (0.51) 66 1.75 (0.78) 5.9 % -0.14 [ -0.36, 0.08 ]
Nye 1990 12 1.4 (0.58) 12 1.8 (0.55) 2.4 % -0.40 [ -0.85, 0.05 ]
ORL 2013 170 -0.78 (0.9) 165 -0.4 (0.87) 6.7 % -0.38 [ -0.57, -0.19 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
WELCOME 2015 47 1.5 (1.2) 48 1.8 (0.6) 3.1 % -0.30 [ -0.68, 0.08 ]
Subtotal (95% CI) 589 551 40.6 % -0.22 [ -0.35, -0.10 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 15.05, df = 8 (P = 0.06); I2 =47%
Test for overall effect: Z = 3.47 (P = 0.00052)
4 Any combination
DIPP-Tokudome 2015 90 1.45 (1.05) 71 1.44 (0.81) 4.5 % 0.01 [ -0.28, 0.30 ]
Mendis 2001 26 0.35 (0.5199) 28 -0.23 (0.98) 2.8 % 0.58 [ 0.17, 0.99 ]
Sydney Diet-Heart 1978 221 1.6 (0.9) 237 1.7 (0.9) 7.4 % -0.10 [ -0.26, 0.06 ]
Subtotal (95% CI) 337 336 14.7 % 0.12 [ -0.22, 0.46 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 8.94, df = 2 (P = 0.01); I2 =78%
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 1977 1928 100.0 % -0.12 [ -0.20, -0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 42.24, df = 21 (P = 0.004); I2 =50%
Test for overall effect: Z = 2.84 (P = 0.0046)
Test for subgroup differences: Chi2 = 8.16, df = 3 (P = 0.04), I2 =63%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Fernandez-Real 2012, Reus subcohort, 2 year data
(3) Barcelona hospital cohort at 5 years, Casas 2016
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
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Analysis 3.52. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 52
Serum HIGH DENSITY LIPOPROTEIN (HDL, mmoL/L).
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 52 Serum HIGH DENSITY LIPOPROTEIN (HDL, mmoL/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.2 % 0.05 [ -0.10, 0.20 ]
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 33.2 % -0.02 [ -0.05, 0.01 ]
Brox 2001 67 1.3448 (0.3596) 37 1.3 (0.3) 1.6 % 0.04 [ -0.08, 0.17 ]
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 36.2 % -0.01 [ -0.04, 0.02 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.3 % -0.03 [ -0.14, 0.08 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 2.3 % -0.09 [ -0.20, 0.02 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 0.4 % -0.01 [ -0.25, 0.23 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.0 % 0.0 [ -0.16, 0.16 ]
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.4 % 0.10 [ -0.17, 0.37 ]
Ley 2004 (1) 70 0.01 (0.4183) 66 -0.02 (0.1625) 2.4 % 0.03 [ -0.08, 0.14 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.2 % 0.0 [ -0.11, 0.11 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 2.3 % -0.01 [ -0.12, 0.10 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.4 % 0.07 [ -0.18, 0.32 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.2 % -0.07 [ -0.39, 0.25 ]
PREDIMED 2013 (2) 54 0.19 (0.37) 54 0.11 (0.38) 1.3 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (3) 51 1.33 (0.29) 42 1.33 (0.38) 1.3 % 0.0 [ -0.14, 0.14 ]
PREDIMED 2013 (4) 58 0.05 (0.2) 59 0.02 (0.17) 5.8 % 0.03 [ -0.04, 0.10 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 0.4 % 0.12 [ -0.14, 0.38 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 2.5 % 0.03 [ -0.07, 0.13 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.5 % 0.0 [ -0.10, 0.10 ]
Total (95% CI) 2364 2310 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.25, df = 19 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
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(1) Change data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
Analysis 3.53. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 53
HDL, mmoL/L - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 53 HDL, mmoL/L - SA





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias for allocation concealment
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 2.7 % 0.05 [ -0.10, 0.20 ]
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 72.5 % -0.02 [ -0.05, 0.01 ]
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 3.4 % 0.04 [ -0.08, 0.17 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 5.1 % -0.03 [ -0.14, 0.08 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 1.0 % -0.01 [ -0.25, 0.23 ]
Ley 2004 (1) 70 0.01 (0.4183) 66 -0.02 (0.1625) 5.2 % 0.03 [ -0.08, 0.14 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 4.7 % 0.0 [ -0.11, 0.11 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 5.4 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 1012 956 100.0 % -0.01 [ -0.04, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.56, df = 7 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
2 Low risk of bias for attention
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 55.8 % -0.02 [ -0.05, 0.01 ]
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 2.6 % 0.04 [ -0.08, 0.17 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 3.9 % -0.03 [ -0.14, 0.08 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 3.9 % -0.09 [ -0.20, 0.02 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.7 % 0.0 [ -0.16, 0.16 ]
-0.2 -0.1 0 0.1 0.2
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.6 % 0.10 [ -0.17, 0.37 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 3.7 % 0.0 [ -0.11, 0.11 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 3.8 % -0.01 [ -0.12, 0.10 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.7 % 0.07 [ -0.18, 0.32 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.4 % -0.07 [ -0.39, 0.25 ]
PREDIMED 2013 (2) 58 0.05 (0.2) 59 0.02 (0.17) 9.8 % 0.03 [ -0.04, 0.10 ]
PREDIMED 2013 (3) 51 1.33 (0.29) 42 1.33 (0.38) 2.3 % 0.0 [ -0.14, 0.14 ]
PREDIMED 2013 (4) 54 0.19 (0.37) 54 0.11 (0.38) 2.2 % 0.08 [ -0.06, 0.22 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 4.3 % 0.03 [ -0.07, 0.13 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 4.2 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 1347 1294 100.0 % -0.01 [ -0.03, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 8.23, df = 14 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
3 Low risk of bias for compliance
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 2.6 % 0.05 [ -0.10, 0.20 ]
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 3.3 % 0.04 [ -0.08, 0.17 ]
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 76.6 % -0.01 [ -0.04, 0.02 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 0.9 % -0.01 [ -0.25, 0.23 ]
Ley 2004 (5) 70 0.01 (0.4183) 66 -0.02 (0.1625) 5.0 % 0.03 [ -0.08, 0.14 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.9 % 0.07 [ -0.18, 0.32 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 5.4 % 0.03 [ -0.07, 0.13 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 5.3 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 1217 1193 100.0 % 0.00 [ -0.02, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.39, df = 7 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
4 Low summary risk of bias
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 82.5 % -0.02 [ -0.05, 0.01 ]
Ley 2004 (6) 70 0.01 (0.4183) 66 -0.02 (0.1625) 5.9 % 0.03 [ -0.08, 0.14 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 5.4 % 0.0 [ -0.11, 0.11 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 6.2 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 802 790 100.0 % -0.01 [ -0.04, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
5 Trials registry or pre-2010
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 34.5 % -0.02 [ -0.05, 0.01 ]
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 1.6 % 0.04 [ -0.08, 0.17 ]
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 37.6 % -0.01 [ -0.04, 0.02 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.4 % -0.03 [ -0.14, 0.08 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 2.4 % -0.09 [ -0.20, 0.02 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 0.5 % -0.01 [ -0.25, 0.23 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.1 % 0.0 [ -0.16, 0.16 ]
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.4 % 0.10 [ -0.17, 0.37 ]
Ley 2004 (7) 70 0.01 (0.4183) 66 -0.02 (0.1625) 2.5 % 0.03 [ -0.08, 0.14 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.3 % 0.0 [ -0.11, 0.11 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 2.4 % -0.01 [ -0.12, 0.10 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.4 % 0.07 [ -0.18, 0.32 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.3 % -0.07 [ -0.39, 0.25 ]
PREDIMED 2013 (8) 54 0.19 (0.37) 54 0.11 (0.38) 1.4 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (9) 51 1.33 (0.29) 42 1.33 (0.38) 1.4 % 0.0 [ -0.14, 0.14 ]
PREDIMED 2013 (10) 58 0.05 (0.2) 59 0.02 (0.17) 6.0 % 0.03 [ -0.04, 0.10 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 0.4 % 0.12 [ -0.14, 0.38 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.6 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 2232 2178 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 9.13, df = 17 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
6 No industry funding
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 10.0 % 0.05 [ -0.10, 0.20 ]
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 12.7 % 0.04 [ -0.08, 0.17 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 18.8 % -0.03 [ -0.14, 0.08 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 3.6 % -0.01 [ -0.25, 0.23 ]
Ley 2004 (11) 70 0.01 (0.4183) 66 -0.02 (0.1625) 19.1 % 0.03 [ -0.08, 0.14 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 17.6 % 0.0 [ -0.11, 0.11 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 18.3 % -0.01 [ -0.12, 0.10 ]
Subtotal (95% CI) 386 331 100.0 % 0.01 [ -0.04, 0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.44, df = 6 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
7 Randomised 100+ participants
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 35.3 % -0.02 [ -0.05, 0.01 ]
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 1.7 % 0.04 [ -0.08, 0.17 ]
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 38.5 % -0.01 [ -0.04, 0.02 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.5 % -0.03 [ -0.14, 0.08 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 2.4 % -0.09 [ -0.20, 0.02 ]
Ley 2004 (12) 70 0.01 (0.4183) 66 -0.02 (0.1625) 2.5 % 0.03 [ -0.08, 0.14 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.3 % 0.0 [ -0.11, 0.11 ]
PREDIMED 2013 (13) 54 0.19 (0.37) 54 0.11 (0.38) 1.4 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (14) 51 1.33 (0.29) 42 1.33 (0.38) 1.4 % 0.0 [ -0.14, 0.14 ]
PREDIMED 2013 (15) 58 0.05 (0.2) 59 0.02 (0.17) 6.2 % 0.03 [ -0.04, 0.10 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 0.4 % 0.12 [ -0.14, 0.38 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 2.7 % 0.03 [ -0.07, 0.13 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.7 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 2193 2139 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 8.50, df = 12 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
8 Randomised 250+ participants
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 41.5 % -0.02 [ -0.05, 0.01 ]
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 45.2 % -0.01 [ -0.04, 0.02 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.7 % 0.0 [ -0.11, 0.11 ]
PREDIMED 2013 (16) 58 0.05 (0.2) 59 0.02 (0.17) 7.3 % 0.03 [ -0.04, 0.10 ]
PREDIMED 2013 (17) 54 0.19 (0.37) 54 0.11 (0.38) 1.6 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (18) 51 1.33 (0.29) 42 1.33 (0.38) 1.7 % 0.0 [ -0.14, 0.14 ]
Subtotal (95% CI) 1703 1691 100.0 % -0.01 [ -0.03, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.44, df = 5 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
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(1) Change data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Fernandez-Real 2012, Reus subcohort, 2 year data




(8) Barcelona hospital cohort at 5 years, Casa 2016
(9) Fernandez-Real 2012, Reus subcohort, 2 year data
(10) Damasceno 2013, Barcelona North subcohort, 1 year data
(11) Change data
(12) Change data
(13) Barcelona hospital cohort at 5 years, Casa 2016
(14) Fernandez-Real 2012, Reus subcohort, 2 year data
(15) Damasceno 2013, Barcelona North subcohort, 1 year data
(16) Damasceno 2013, Barcelona North subcohort, 1 year data
(17) Barcelona hospital cohort at 5 years, Casa 2016
(18) Fernandez-Real 2012, Reus subcohort, 2 year data
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Analysis 3.54. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 54
HDL, mmoL/L - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 54 HDL, mmoL/L - SA fixed-effect





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.2 % 0.05 [ -0.10, 0.20 ]
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 33.2 % -0.02 [ -0.05, 0.01 ]
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 1.6 % 0.04 [ -0.08, 0.17 ]
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 36.2 % -0.01 [ -0.04, 0.02 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.3 % -0.03 [ -0.14, 0.08 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 2.3 % -0.09 [ -0.20, 0.02 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 0.4 % -0.01 [ -0.25, 0.23 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.0 % 0.0 [ -0.16, 0.16 ]
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.4 % 0.10 [ -0.17, 0.37 ]
Ley 2004 (1) 70 0.01 (0.4183) 66 -0.02 (0.1625) 2.4 % 0.03 [ -0.08, 0.14 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.2 % 0.0 [ -0.11, 0.11 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 2.3 % -0.01 [ -0.12, 0.10 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.4 % 0.07 [ -0.18, 0.32 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.2 % -0.07 [ -0.39, 0.25 ]
PREDIMED 2013 (2) 54 0.19 (0.37) 54 0.11 (0.38) 1.3 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (3) 51 1.33 (0.29) 42 1.33 (0.38) 1.3 % 0.0 [ -0.14, 0.14 ]
PREDIMED 2013 (4) 58 0.05 (0.2) 59 0.02 (0.17) 5.8 % 0.03 [ -0.04, 0.10 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 0.4 % 0.12 [ -0.14, 0.38 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 2.5 % 0.03 [ -0.07, 0.13 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.5 % 0.0 [ -0.10, 0.10 ]
Total (95% CI) 2364 2310 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Chi2 = 10.25, df = 19 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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(1) Change data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
Analysis 3.55. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 55
HDL, mmoL/L - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 55 HDL, mmoL/L - subgroup by PUFA dose





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 total PUFA < 1.0% E
Ley 2004 (1) 70 0.01 (0.4183) 66 -0.02 (0.1625) 2.4 % 0.03 [ -0.08, 0.14 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.2 % 0.0 [ -0.11, 0.11 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.4 % 0.07 [ -0.18, 0.32 ]
Subtotal (95% CI) 180 167 5.0 % 0.02 [ -0.05, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.59)
2 total PUFA 1.0 to < 2.0% E
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.2 % 0.05 [ -0.10, 0.20 ]
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 33.2 % -0.02 [ -0.05, 0.01 ]
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 1.6 % 0.04 [ -0.08, 0.17 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.3 % -0.03 [ -0.14, 0.08 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 2.3 % -0.09 [ -0.20, 0.02 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.2 % -0.07 [ -0.39, 0.25 ]
PREDIMED 2013 (2) 54 0.19 (0.37) 54 0.11 (0.38) 1.3 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (3) 51 1.33 (0.29) 42 1.33 (0.38) 1.3 % 0.0 [ -0.14, 0.14 ]
PREDIMED 2013 (4) 58 0.05 (0.2) 59 0.02 (0.17) 5.8 % 0.03 [ -0.04, 0.10 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.5 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 1106 1060 51.8 % -0.01 [ -0.03, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.21, df = 9 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
3 total PUFA 2.0 to < 5.0% E
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 36.2 % -0.01 [ -0.04, 0.02 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 0.4 % -0.01 [ -0.25, 0.23 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.0 % 0.0 [ -0.16, 0.16 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 2.3 % -0.01 [ -0.12, 0.10 ]
Subtotal (95% CI) 928 936 39.9 % -0.01 [ -0.04, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
4 total PUFA 5.0+% E
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.4 % 0.10 [ -0.17, 0.37 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 0.4 % 0.12 [ -0.14, 0.38 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 2.5 % 0.03 [ -0.07, 0.13 ]
Subtotal (95% CI) 150 147 3.3 % 0.05 [ -0.04, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 2364 2310 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.25, df = 19 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 2.15, df = 3 (P = 0.54), I2 =0.0%
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(1) Change data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
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Analysis 3.56. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 56
HDL, mmoL/L - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 56 HDL, mmoL/L - subgroup by duration





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.2 % 0.05 [ -0.10, 0.20 ]
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 1.6 % 0.04 [ -0.08, 0.17 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 2.3 % -0.09 [ -0.20, 0.02 ]
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.4 % 0.10 [ -0.17, 0.37 ]
Ley 2004 (1) 70 0.01 (0.4183) 66 -0.02 (0.1625) 2.4 % 0.03 [ -0.08, 0.14 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.2 % 0.0 [ -0.11, 0.11 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 2.3 % -0.01 [ -0.12, 0.10 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.2 % -0.07 [ -0.39, 0.25 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.5 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 443 409 15.0 % 0.00 [ -0.04, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.70, df = 8 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
2 Medium-long duration 2 to < 4 years
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 33.2 % -0.02 [ -0.05, 0.01 ]
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 36.2 % -0.01 [ -0.04, 0.02 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.3 % -0.03 [ -0.14, 0.08 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 0.4 % -0.01 [ -0.25, 0.23 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.0 % 0.0 [ -0.16, 0.16 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.4 % 0.07 [ -0.18, 0.32 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 0.4 % 0.12 [ -0.14, 0.38 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 2.5 % 0.03 [ -0.07, 0.13 ]
Subtotal (95% CI) 1758 1746 76.5 % -0.01 [ -0.03, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.51, df = 7 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
3 Long duration 4+ years
PREDIMED 2013 (2) 51 1.33 (0.29) 42 1.33 (0.38) 1.3 % 0.0 [ -0.14, 0.14 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (3) 54 0.19 (0.37) 54 0.11 (0.38) 1.3 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (4) 58 0.05 (0.2) 59 0.02 (0.17) 5.8 % 0.03 [ -0.04, 0.10 ]
Subtotal (95% CI) 163 155 8.5 % 0.03 [ -0.02, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.65, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
Total (95% CI) 2364 2310 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.25, df = 19 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 2.39, df = 2 (P = 0.30), I2 =16%
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(1) Change data
(2) Fernandez-Real 2012, Reus subcohort, 2 year data
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
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Analysis 3.57. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 57
HDL, mmoL/L - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 57 HDL, mmoL/L - subgroup by primary or secondary prevention





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention of CVD
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 1.6 % 0.04 [ -0.08, 0.17 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.3 % -0.03 [ -0.14, 0.08 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 2.3 % -0.09 [ -0.20, 0.02 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 0.4 % -0.01 [ -0.25, 0.23 ]
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.4 % 0.10 [ -0.17, 0.37 ]
Ley 2004 (1) 70 0.01 (0.4183) 66 -0.02 (0.1625) 2.4 % 0.03 [ -0.08, 0.14 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.2 % 0.0 [ -0.11, 0.11 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 2.3 % -0.01 [ -0.12, 0.10 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.4 % 0.07 [ -0.18, 0.32 ]
PREDIMED 2013 (2) 54 0.19 (0.37) 54 0.11 (0.38) 1.3 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (3) 58 0.05 (0.2) 59 0.02 (0.17) 5.8 % 0.03 [ -0.04, 0.10 ]
PREDIMED 2013 (4) 51 1.33 (0.29) 42 1.33 (0.38) 1.3 % 0.0 [ -0.14, 0.14 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 0.4 % 0.12 [ -0.14, 0.38 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.5 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 729 673 25.6 % 0.01 [ -0.02, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.18, df = 13 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
2 Secondary prevention of CVD
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.2 % 0.05 [ -0.10, 0.20 ]
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 33.2 % -0.02 [ -0.05, 0.01 ]
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 36.2 % -0.01 [ -0.04, 0.02 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.0 % 0.0 [ -0.16, 0.16 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.2 % -0.07 [ -0.39, 0.25 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 2.5 % 0.03 [ -0.07, 0.13 ]
Subtotal (95% CI) 1635 1637 74.4 % -0.01 [ -0.03, 0.01 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.0; Chi2 = 1.82, df = 5 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.21)
Total (95% CI) 2364 2310 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.25, df = 19 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 1.24, df = 1 (P = 0.26), I2 =20%
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Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Damasceno 2013, Barcelona North subcohort, 1 year data
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
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Analysis 3.58. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 58
HDL, mmoL/L - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 58 HDL, mmoL/L - subgroup by baseline PUFA dose





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Baseline total PUFA < 6% E
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 2.3 % -0.09 [ -0.20, 0.02 ]
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.4 % 0.10 [ -0.17, 0.37 ]
Ley 2004 (1) 70 0.01 (0.4183) 66 -0.02 (0.1625) 2.4 % 0.03 [ -0.08, 0.14 ]
Subtotal (95% CI) 173 177 5.0 % -0.01 [ -0.11, 0.09 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.29, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 0.26 (P = 0.79)
2 Baseline total PUFA 6 to < 11% E
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 36.2 % -0.01 [ -0.04, 0.02 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.3 % -0.03 [ -0.14, 0.08 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 0.4 % -0.01 [ -0.25, 0.23 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.2 % 0.0 [ -0.11, 0.11 ]
PREDIMED 2013 (2) 51 1.33 (0.29) 42 1.33 (0.38) 1.3 % 0.0 [ -0.14, 0.14 ]
PREDIMED 2013 (3) 58 0.05 (0.2) 59 0.02 (0.17) 5.8 % 0.03 [ -0.04, 0.10 ]
PREDIMED 2013 (4) 54 0.19 (0.37) 54 0.11 (0.38) 1.3 % 0.08 [ -0.06, 0.22 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 0.4 % 0.12 [ -0.14, 0.38 ]
Subtotal (95% CI) 1241 1213 50.0 % 0.00 [ -0.03, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.60, df = 7 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.2 % 0.05 [ -0.10, 0.20 ]
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 33.2 % -0.02 [ -0.05, 0.01 ]
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 1.6 % 0.04 [ -0.08, 0.17 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.0 % 0.0 [ -0.16, 0.16 ]
-0.2 -0.1 0 0.1 0.2
Favours higher PUFA Favours lower PUFA
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 2.3 % -0.01 [ -0.12, 0.10 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.4 % 0.07 [ -0.18, 0.32 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.2 % -0.07 [ -0.39, 0.25 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 2.5 % 0.03 [ -0.07, 0.13 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.5 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 950 920 45.0 % -0.01 [ -0.03, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.00, df = 8 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI) 2364 2310 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.25, df = 19 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.25, df = 2 (P = 0.88), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Fernandez-Real 2012, Reus subcohort, 2 year data
(3) Damasceno 2013, Barcelona North subcohort, 1 year data
(4) Barcelona hospital cohort at 5 years, Casa 2016
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HDL, mmoL/L - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 59 HDL, mmoL/L - subgroup by replacement





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PUFA replaced saturated fats
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 91.5 % -0.01 [ -0.04, 0.02 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 1.1 % -0.01 [ -0.25, 0.23 ]
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.9 % 0.10 [ -0.17, 0.37 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 6.4 % 0.03 [ -0.07, 0.13 ]
Subtotal (95% CI) 983 993 100.0 % -0.01 [ -0.03, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.18, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
2 PUFA replaced monounsaturated fats
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 69.7 % -0.02 [ -0.05, 0.01 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 2.2 % 0.0 [ -0.16, 0.16 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 4.6 % 0.0 [ -0.11, 0.11 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.5 % -0.07 [ -0.39, 0.25 ]
PREDIMED 2013 (1) 58 0.05 (0.2) 59 0.02 (0.17) 12.2 % 0.03 [ -0.04, 0.10 ]
PREDIMED 2013 (2) 54 0.19 (0.37) 54 0.11 (0.38) 2.8 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (3) 51 1.33 (0.29) 42 1.33 (0.38) 2.8 % 0.0 [ -0.14, 0.14 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 5.2 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 938 919 100.0 % -0.01 [ -0.03, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.61, df = 7 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
3 PUFA replaced carbohydrates
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 19.7 % -0.03 [ -0.14, 0.08 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 19.5 % -0.09 [ -0.20, 0.02 ]
Ley 2004 (4) 70 0.01 (0.4183) 66 -0.02 (0.1625) 20.0 % 0.03 [ -0.08, 0.14 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 18.4 % 0.0 [ -0.11, 0.11 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 19.2 % -0.01 [ -0.12, 0.10 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 3.3 % 0.12 [ -0.14, 0.38 ]
-0.2 -0.1 0 0.1 0.2
Favours higher PUFA Favours lower PUFA
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 388 366 100.0 % -0.02 [ -0.06, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.76, df = 5 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
4 PUFA replaced protein
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 13.7 % 0.10 [ -0.17, 0.37 ]
Ley 2004 (5) 70 0.01 (0.4183) 66 -0.02 (0.1625) 86.3 % 0.03 [ -0.08, 0.14 ]
Subtotal (95% CI) 88 83 100.0 % 0.04 [ -0.06, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
5 PUFA replaced unclear
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 38.2 % 0.05 [ -0.10, 0.20 ]
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 48.6 % 0.04 [ -0.08, 0.17 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 13.1 % 0.07 [ -0.18, 0.32 ]
Subtotal (95% CI) 135 103 100.0 % 0.05 [ -0.04, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Chi2 = 2.51, df = 4 (P = 0.64), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours higher PUFA Favours lower PUFA
(1) Damasceno 2013, Barcelona North subcohort, 1 year data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Change data
(5) Change data
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Analysis 3.60. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 60
HDL, mmoL/L - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 60 HDL, mmoL/L - subgroup by sex





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 > 70% men
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.2 % 0.05 [ -0.10, 0.20 ]
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 33.2 % -0.02 [ -0.05, 0.01 ]
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 36.2 % -0.01 [ -0.04, 0.02 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.3 % -0.03 [ -0.14, 0.08 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 0.4 % -0.01 [ -0.25, 0.23 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.0 % 0.0 [ -0.16, 0.16 ]
Ley 2004 (1) 70 0.01 (0.4183) 66 -0.02 (0.1625) 2.4 % 0.03 [ -0.08, 0.14 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 2.3 % -0.01 [ -0.12, 0.10 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.2 % -0.07 [ -0.39, 0.25 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 2.5 % 0.03 [ -0.07, 0.13 ]
Subtotal (95% CI) 1836 1824 81.8 % -0.01 [ -0.03, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.54, df = 9 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
2 > 70% women
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 2.3 % -0.09 [ -0.20, 0.02 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 0.4 % 0.12 [ -0.14, 0.38 ]
Subtotal (95% CI) 123 128 2.7 % -0.02 [ -0.21, 0.17 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.12, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 0.21 (P = 0.84)
3 men % women
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 1.6 % 0.04 [ -0.08, 0.17 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.2 % 0.0 [ -0.11, 0.11 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.4 % 0.07 [ -0.18, 0.32 ]
PREDIMED 2013 (2) 58 0.05 (0.2) 59 0.02 (0.17) 5.8 % 0.03 [ -0.04, 0.10 ]
PREDIMED 2013 (3) 54 0.19 (0.37) 54 0.11 (0.38) 1.3 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (4) 51 1.33 (0.29) 42 1.33 (0.38) 1.3 % 0.0 [ -0.14, 0.14 ]
-0.2 -0.1 0 0.1 0.2
Favours higher PUFA Favours lower PUFA
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.5 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 387 341 15.1 % 0.03 [ -0.02, 0.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.37, df = 6 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
4 sex not reported
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.4 % 0.10 [ -0.17, 0.37 ]
Subtotal (95% CI) 18 17 0.4 % 0.10 [ -0.17, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 2364 2310 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.25, df = 19 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 3.11, df = 3 (P = 0.37), I2 =4%
-0.2 -0.1 0 0.1 0.2
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
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HDL, mmoL/L - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 61 HDL, mmoL/L - subgroup by age





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean age < 50 years
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 0.4 % -0.01 [ -0.25, 0.23 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 0.4 % 0.12 [ -0.14, 0.38 ]
Subtotal (95% CI) 54 54 0.8 % 0.05 [ -0.13, 0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
2 Mean age 50 to < 65 years
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 1.6 % 0.04 [ -0.08, 0.17 ]
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 36.2 % -0.01 [ -0.04, 0.02 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.3 % -0.03 [ -0.14, 0.08 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 2.3 % -0.09 [ -0.20, 0.02 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.0 % 0.0 [ -0.16, 0.16 ]
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.4 % 0.10 [ -0.17, 0.37 ]
Ley 2004 (1) 70 0.01 (0.4183) 66 -0.02 (0.1625) 2.4 % 0.03 [ -0.08, 0.14 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.2 % 0.0 [ -0.11, 0.11 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.4 % 0.07 [ -0.18, 0.32 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.2 % -0.07 [ -0.39, 0.25 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 2.5 % 0.03 [ -0.07, 0.13 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.5 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 1478 1432 54.0 % -0.01 [ -0.03, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.32, df = 11 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
3 Mean age 65+ years
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 33.2 % -0.02 [ -0.05, 0.01 ]
PREDIMED 2013 (2) 51 1.33 (0.29) 42 1.33 (0.38) 1.3 % 0.0 [ -0.14, 0.14 ]
PREDIMED 2013 (3) 54 0.19 (0.37) 54 0.11 (0.38) 1.3 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (4) 58 0.05 (0.2) 59 0.02 (0.17) 5.8 % 0.03 [ -0.04, 0.10 ]
-0.2 -0.1 0 0.1 0.2
Favours higher PUFA Favours lower PUFA
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 768 760 41.7 % 0.00 [ -0.04, 0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.41, df = 3 (P = 0.33); I2 =12%
Test for overall effect: Z = 0.22 (P = 0.83)
4 Mean age unclear
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.2 % 0.05 [ -0.10, 0.20 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 2.3 % -0.01 [ -0.12, 0.10 ]
Subtotal (95% CI) 64 64 3.5 % 0.01 [ -0.08, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI) 2364 2310 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.25, df = 19 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.53, df = 3 (P = 0.91), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Fernandez-Real 2012, Reus subcohort, 2 year data
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
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HDL, mmoL/L - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 62 HDL, mmoL/L - subgroup by statin use





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 50% on statins
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 1.6 % 0.04 [ -0.08, 0.17 ]
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 36.2 % -0.01 [ -0.04, 0.02 ]
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.3 % -0.03 [ -0.14, 0.08 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 2.3 % -0.09 [ -0.20, 0.02 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 0.4 % -0.01 [ -0.25, 0.23 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.0 % 0.0 [ -0.16, 0.16 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.2 % 0.0 [ -0.11, 0.11 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 2.3 % -0.01 [ -0.12, 0.10 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.4 % 0.07 [ -0.18, 0.32 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.2 % -0.07 [ -0.39, 0.25 ]
PREDIMED 2013 (1) 51 1.33 (0.29) 42 1.33 (0.38) 1.3 % 0.0 [ -0.14, 0.14 ]
PREDIMED 2013 (2) 54 0.19 (0.37) 54 0.11 (0.38) 1.3 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (3) 58 0.05 (0.2) 59 0.02 (0.17) 5.8 % 0.03 [ -0.04, 0.10 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 0.4 % 0.12 [ -0.14, 0.38 ]
Subtotal (95% CI) 1492 1442 57.8 % 0.00 [ -0.03, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.17, df = 13 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
2 50+% on statins
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.2 % 0.05 [ -0.10, 0.20 ]
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 33.2 % -0.02 [ -0.05, 0.01 ]
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.4 % 0.10 [ -0.17, 0.37 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 2.5 % 0.03 [ -0.07, 0.13 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.5 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 802 802 39.8 % -0.01 [ -0.04, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.39, df = 4 (P = 0.66); I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours higher PUFA Favours lower PUFA
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.93 (P = 0.35)
3 Percentage on statins unclear
Ley 2004 (4) 70 0.01 (0.4183) 66 -0.02 (0.1625) 2.4 % 0.03 [ -0.08, 0.14 ]
Subtotal (95% CI) 70 66 2.4 % 0.03 [ -0.08, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
Total (95% CI) 2364 2310 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.25, df = 19 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.69, df = 2 (P = 0.71), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours higher PUFA Favours lower PUFA
(1) Fernandez-Real 2012, Reus subcohort, 2 year data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Damasceno 2013, Barcelona North subcohort, 1 year data
(4) Change data
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Analysis 3.63. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 63
HDL, mmoL/L - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 63 HDL, mmoL/L - subgroup by intervention type





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
DART fat 1989 855 1.04 (0.29) 860 1.05 (0.28) 36.2 % -0.01 [ -0.04, 0.02 ]
Dullaart 1992 16 1.28 (0.37) 20 1.29 (0.37) 0.4 % -0.01 [ -0.25, 0.23 ]
Ley 2004 (1) 70 0.01 (0.4183) 66 -0.02 (0.1625) 2.4 % 0.03 [ -0.08, 0.14 ]
Simon 1997 38 1.56 (0.55) 34 1.44 (0.58) 0.4 % 0.12 [ -0.14, 0.38 ]
Subtotal (95% CI) 979 980 39.4 % -0.01 [ -0.03, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.42, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
2 Supplemental foods % diet provided
AlphaOmega - ALA 605 0.13 (0.25) 605 0.15 (0.25) 33.2 % -0.02 [ -0.05, 0.01 ]
HERO-Tapsell 2009 18 1.5 (0.4) 17 1.4 (0.4) 0.4 % 0.10 [ -0.17, 0.37 ]
PREDIMED 2013 (2) 58 0.05 (0.2) 59 0.02 (0.17) 5.8 % 0.03 [ -0.04, 0.10 ]
PREDIMED 2013 (3) 54 0.19 (0.37) 54 0.11 (0.38) 1.3 % 0.08 [ -0.06, 0.22 ]
PREDIMED 2013 (4) 51 1.33 (0.29) 42 1.33 (0.38) 1.3 % 0.0 [ -0.14, 0.14 ]
Vijayakumar 2014 94 1.15 (0.42) 96 1.12 (0.28) 2.5 % 0.03 [ -0.07, 0.13 ]
Subtotal (95% CI) 880 873 44.6 % -0.01 [ -0.03, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.57, df = 5 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
3 Supplements (capsules % unusual foods)
Ahn 2016 38 1.19 (0.31) 36 1.14 (0.33) 1.2 % 0.05 [ -0.10, 0.20 ]
Brox 2001 67 1.345 (0.36) 37 1.3 (0.3) 1.6 % 0.04 [ -0.08, 0.17 ]
Dodin 2005 85 1.68 (0.35) 94 1.77 (0.38) 2.3 % -0.09 [ -0.20, 0.02 ]
HARP- Sacks 1995 31 1.09 (0.28) 28 1.09 (0.34) 1.0 % 0.0 [ -0.16, 0.16 ]
MARINA - Sanders 2011 80 0 (0.45) 71 0 (0.21) 2.2 % 0.0 [ -0.11, 0.11 ]
Mita 2007 30 1.51 (0.59) 30 1.44 (0.37) 0.4 % 0.07 [ -0.18, 0.32 ]
Nye 1990 12 1.38 (0.43) 12 1.45 (0.38) 0.2 % -0.07 [ -0.39, 0.25 ]
WELCOME 2015 47 1.1 (0.3) 48 1.1 (0.2) 2.5 % 0.0 [ -0.10, 0.10 ]
-0.2 -0.1 0 0.1 0.2
Favours higher PUFA Favours lower PUFA
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 390 356 11.5 % -0.01 [ -0.05, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.07, df = 7 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
4 Any combination
DIPP-Tokudome 2015 89 1.43 (0.36) 73 1.46 (0.33) 2.3 % -0.03 [ -0.14, 0.08 ]
Mendis 2001 26 0.26 (0.1981) 28 0.27 (0.2063) 2.3 % -0.01 [ -0.12, 0.10 ]
Subtotal (95% CI) 115 101 4.6 % -0.02 [ -0.10, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Total (95% CI) 2364 2310 100.0 % -0.01 [ -0.02, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.25, df = 19 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.13, df = 3 (P = 0.99), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
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Analysis 3.64. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 64
Serum LOW DENSITY LIPOPROTEIN (LDL, mmoL/L).
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 64 Serum LOW DENSITY LIPOPROTEIN (LDL, mmoL/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 2.8 % 0.16 [ -0.26, 0.58 ]
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 14.5 % 0.01 [ -0.07, 0.09 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 8.2 % -0.19 [ -0.39, 0.01 ]
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 3.7 % 0.25 [ -0.11, 0.61 ]
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.2 % -0.10 [ -0.59, 0.39 ]
Ley 2004 (1) 70 -0.02 (1.255) 66 -0.18 (0.7312) 3.9 % 0.16 [ -0.18, 0.50 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 7.2 % 0.0 [ -0.22, 0.22 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 2.6 % -0.07 [ -0.51, 0.37 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 11.3 % 0.09 [ -0.04, 0.23 ]
PREDIMED 2013 (2) 54 -1.14 (0.95) 54 -0.62 (0.92) 3.7 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (3) 58 -0.32 (0.76) 59 -0.3 (0.76) 5.4 % -0.02 [ -0.30, 0.26 ]
PREDIMED 2013 (4) 51 3.26 (0.86) 42 3.07 (0.7) 4.4 % 0.19 [ -0.13, 0.51 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.2 % 0.12 [ -0.56, 0.80 ]
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 2.8 % 0.30 [ -0.12, 0.72 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 8.5 % -0.03 [ -0.22, 0.16 ]
WAHA - Ros 2016 (5) 260 -0.18 (0.48) 254 -0.03 (0.64) 13.6 % -0.15 [ -0.25, -0.05 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 3.9 % 0.0 [ -0.34, 0.34 ]
Total (95% CI) 1694 1668 100.0 % -0.01 [ -0.09, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 28.67, df = 16 (P = 0.03); I2 =44%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Damasceno 2013, Barcelona North subcohort, 1 year data
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
(5) change from baseline
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Analysis 3.65. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 65
LDL, mmoL/L - SA.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 65 LDL, mmoL/L - SA





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias for allocation concealment
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 2.3 % 0.16 [ -0.26, 0.58 ]
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 60.1 % 0.01 [ -0.07, 0.09 ]
Ley 2004 (1) 70 -0.02 (1.255) 66 -0.18 (0.7312) 3.5 % 0.16 [ -0.18, 0.50 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 8.6 % 0.0 [ -0.22, 0.22 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 22.0 % 0.09 [ -0.04, 0.23 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 3.5 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 967 948 100.0 % 0.04 [ -0.03, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.04, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
2 Low risk of bias for attention
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 22.1 % 0.01 [ -0.07, 0.09 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 10.5 % -0.19 [ -0.39, 0.01 ]
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 4.2 % 0.25 [ -0.11, 0.61 ]
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.4 % -0.10 [ -0.59, 0.39 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 9.1 % 0.0 [ -0.22, 0.22 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 2.9 % -0.07 [ -0.51, 0.37 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 15.6 % 0.09 [ -0.04, 0.23 ]
PREDIMED 2013 (2) 51 3.26 (0.86) 42 3.07 (0.7) 5.2 % 0.19 [ -0.13, 0.51 ]
PREDIMED 2013 (3) 54 -1.14 (0.95) 54 -0.62 (0.92) 4.4 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (4) 58 -0.32 (0.76) 59 -0.3 (0.76) 6.5 % -0.02 [ -0.30, 0.26 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.3 % 0.12 [ -0.56, 0.80 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 11.1 % -0.03 [ -0.22, 0.16 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 4.6 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 1288 1278 100.0 % -0.01 [ -0.09, 0.07 ]
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.01; Chi2 = 17.54, df = 12 (P = 0.13); I2 =32%
Test for overall effect: Z = 0.31 (P = 0.75)
3 Low risk of bias for compliance
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 6.8 % 0.16 [ -0.26, 0.58 ]
Ley 2004 (5) 70 -0.02 (1.255) 66 -0.18 (0.7312) 10.0 % 0.16 [ -0.18, 0.50 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 25.1 % -0.03 [ -0.22, 0.16 ]
WAHA - Ros 2016 (6) 260 -0.18 (0.48) 254 -0.03 (0.64) 48.1 % -0.15 [ -0.25, -0.05 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 10.0 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 509 500 100.0 % -0.05 [ -0.17, 0.06 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.46, df = 4 (P = 0.24); I2 =27%
Test for overall effect: Z = 0.89 (P = 0.37)
4 Low summary risk of bias
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 79.4 % 0.01 [ -0.07, 0.09 ]
Ley 2004 (7) 70 -0.02 (1.255) 66 -0.18 (0.7312) 4.7 % 0.16 [ -0.18, 0.50 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 11.3 % 0.0 [ -0.22, 0.22 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 4.7 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 759 747 100.0 % 0.02 [ -0.06, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
5 Trials registry or pre-2010
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 15.3 % 0.01 [ -0.07, 0.09 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 9.3 % -0.19 [ -0.39, 0.01 ]
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 4.4 % 0.25 [ -0.11, 0.61 ]
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.6 % -0.10 [ -0.59, 0.39 ]
Ley 2004 (8) 70 -0.02 (1.255) 66 -0.18 (0.7312) 4.7 % 0.16 [ -0.18, 0.50 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 8.2 % 0.0 [ -0.22, 0.22 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 3.1 % -0.07 [ -0.51, 0.37 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 12.3 % 0.09 [ -0.04, 0.23 ]
PREDIMED 2013 (9) 54 -1.14 (0.95) 54 -0.62 (0.92) 4.5 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (10) 51 3.26 (0.86) 42 3.07 (0.7) 5.2 % 0.19 [ -0.13, 0.51 ]
PREDIMED 2013 (11) 58 -0.32 (0.76) 59 -0.3 (0.76) 6.3 % -0.02 [ -0.30, 0.26 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.5 % 0.12 [ -0.56, 0.80 ]
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 3.4 % 0.30 [ -0.12, 0.72 ]
WAHA - Ros 2016 (12) 260 -0.18 (0.48) 254 -0.03 (0.64) 14.5 % -0.15 [ -0.25, -0.05 ]
-0.5 -0.25 0 0.25 0.5
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 4.7 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 1562 1536 100.0 % -0.02 [ -0.10, 0.07 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 27.92, df = 14 (P = 0.01); I2 =50%
Test for overall effect: Z = 0.35 (P = 0.73)
6 No industry funding
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 13.9 % 0.16 [ -0.26, 0.58 ]
Ley 2004 (13) 70 -0.02 (1.255) 66 -0.18 (0.7312) 21.4 % 0.16 [ -0.18, 0.50 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 51.8 % 0.0 [ -0.22, 0.22 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 12.9 % -0.07 [ -0.51, 0.37 ]
Subtotal (95% CI) 214 201 100.0 % 0.05 [ -0.11, 0.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.13, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
7 Randomised 100+ participants
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 15.7 % 0.01 [ -0.07, 0.09 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 9.4 % -0.19 [ -0.39, 0.01 ]
Ley 2004 (14) 70 -0.02 (1.255) 66 -0.18 (0.7312) 4.8 % 0.16 [ -0.18, 0.50 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 8.4 % 0.0 [ -0.22, 0.22 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 12.5 % 0.09 [ -0.04, 0.23 ]
PREDIMED 2013 (15) 51 3.26 (0.86) 42 3.07 (0.7) 5.3 % 0.19 [ -0.13, 0.51 ]
PREDIMED 2013 (16) 54 -1.14 (0.95) 54 -0.62 (0.92) 4.6 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (17) 58 -0.32 (0.76) 59 -0.3 (0.76) 6.4 % -0.02 [ -0.30, 0.26 ]
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 3.5 % 0.30 [ -0.12, 0.72 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 9.8 % -0.03 [ -0.22, 0.16 ]
WAHA - Ros 2016 (18) 260 -0.18 (0.48) 254 -0.03 (0.64) 14.8 % -0.15 [ -0.25, -0.05 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 4.8 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 1569 1545 100.0 % -0.03 [ -0.11, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 25.26, df = 11 (P = 0.01); I2 =56%
Test for overall effect: Z = 0.60 (P = 0.55)
8 Randomised 250+ participants
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 22.0 % 0.01 [ -0.07, 0.09 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 12.9 % 0.0 [ -0.22, 0.22 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 18.3 % 0.09 [ -0.04, 0.23 ]
PREDIMED 2013 (19) 54 -1.14 (0.95) 54 -0.62 (0.92) 7.3 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (20) 51 3.26 (0.86) 42 3.07 (0.7) 8.5 % 0.19 [ -0.13, 0.51 ]
-0.5 -0.25 0 0.25 0.5
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDIMED 2013 (21) 58 -0.32 (0.76) 59 -0.3 (0.76) 10.1 % -0.02 [ -0.30, 0.26 ]
WAHA - Ros 2016 (22) 260 -0.18 (0.48) 254 -0.03 (0.64) 21.0 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 1235 1207 100.0 % -0.04 [ -0.15, 0.08 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 19.12, df = 6 (P = 0.004); I2 =69%
Test for overall effect: Z = 0.62 (P = 0.53)
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Fernandez-Real 2012, Reus subcohort, 2 year data
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
(5) Change data
(6) change from baseline
(7) Change data
(8) Change data
(9) Barcelona hospital cohort at 5 years, Casa 2016
(10) Fernandez-Real 2012, Reus subcohort, 2 year data
(11) Damasceno 2013, Barcelona North subcohort, 1 year data
(12) change from baseline
(13) Change data
(14) Change data
(15) Fernandez-Real 2012, Reus subcohort, 2 year data
(16) Barcelona hospital cohort at 5 years, Casa 2016
(17) Damasceno 2013, Barcelona North subcohort, 1 year data
(18) change from baseline
(19) Barcelona hospital cohort at 5 years, Casa 2016
(20) Fernandez-Real 2012, Reus subcohort, 2 year data
(21) Damasceno 2013, Barcelona North subcohort, 1 year data
(22) change from baseline
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Analysis 3.66. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 66
LDL, mmoL/L - SA fixed-effect.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 66 LDL, mmoL/L - SA fixed-effect





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 1.2 % 0.16 [ -0.26, 0.58 ]
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 31.8 % 0.01 [ -0.07, 0.09 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 5.7 % -0.19 [ -0.39, 0.01 ]
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 1.7 % 0.25 [ -0.11, 0.61 ]
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 0.9 % -0.10 [ -0.59, 0.39 ]
Ley 2004 (1) 70 -0.02 (1.255) 66 -0.18 (0.7312) 1.9 % 0.16 [ -0.18, 0.50 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 4.5 % 0.0 [ -0.22, 0.22 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 1.1 % -0.07 [ -0.51, 0.37 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 11.7 % 0.09 [ -0.04, 0.23 ]
PREDIMED 2013 (2) 54 -1.14 (0.95) 54 -0.62 (0.92) 1.8 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (3) 51 3.26 (0.86) 42 3.07 (0.7) 2.2 % 0.19 [ -0.13, 0.51 ]
PREDIMED 2013 (4) 58 -0.32 (0.76) 59 -0.3 (0.76) 2.9 % -0.02 [ -0.30, 0.26 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 0.5 % 0.12 [ -0.56, 0.80 ]
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 1.3 % 0.30 [ -0.12, 0.72 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 6.2 % -0.03 [ -0.22, 0.16 ]
WAHA - Ros 2016 (5) 260 -0.18 (0.48) 254 -0.03 (0.64) 22.9 % -0.15 [ -0.25, -0.05 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 1.9 % 0.0 [ -0.34, 0.34 ]
Total (95% CI) 1694 1668 100.0 % -0.03 [ -0.07, 0.02 ]
Heterogeneity: Chi2 = 28.67, df = 16 (P = 0.03); I2 =44%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
(5) change from baseline
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Analysis 3.67. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 67
LDL, mmoL/L - subgroup by PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 67 LDL, mmoL/L - subgroup by PUFA dose





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 total PUFA < 1.0% E
Ley 2004 (1) 70 -0.02 (1.255) 66 -0.18 (0.7312) 3.9 % 0.16 [ -0.18, 0.50 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 7.2 % 0.0 [ -0.22, 0.22 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 11.3 % 0.09 [ -0.04, 0.23 ]
Subtotal (95% CI) 320 302 22.4 % 0.08 [ -0.03, 0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
2 total PUFA 1.0 to < 2.0% E
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 2.8 % 0.16 [ -0.26, 0.58 ]
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 14.5 % 0.01 [ -0.07, 0.09 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 8.2 % -0.19 [ -0.39, 0.01 ]
PREDIMED 2013 (2) 58 -0.32 (0.76) 59 -0.3 (0.76) 5.4 % -0.02 [ -0.30, 0.26 ]
PREDIMED 2013 (3) 54 -1.14 (0.95) 54 -0.62 (0.92) 3.7 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (4) 51 3.26 (0.86) 42 3.07 (0.7) 4.4 % 0.19 [ -0.13, 0.51 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 3.9 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 895 895 43.0 % -0.05 [ -0.19, 0.09 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 13.47, df = 6 (P = 0.04); I2 =55%
Test for overall effect: Z = 0.76 (P = 0.45)
3 total PUFA 2.0 to < 5.0% E
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 3.7 % 0.25 [ -0.11, 0.61 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 2.6 % -0.07 [ -0.51, 0.37 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.2 % 0.12 [ -0.56, 0.80 ]
Subtotal (95% CI) 71 71 7.5 % 0.12 [ -0.13, 0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.22, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
4 total PUFA 5.0+% E
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.2 % -0.10 [ -0.59, 0.39 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 2.8 % 0.30 [ -0.12, 0.72 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 8.5 % -0.03 [ -0.22, 0.16 ]
WAHA - Ros 2016 (5) 260 -0.18 (0.48) 254 -0.03 (0.64) 13.6 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 408 400 27.2 % -0.06 [ -0.21, 0.09 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.02, df = 3 (P = 0.17); I2 =40%
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 1694 1668 100.0 % -0.01 [ -0.09, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 28.67, df = 16 (P = 0.03); I2 =44%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 3.86, df = 3 (P = 0.28), I2 =22%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
(5) change from baseline
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Analysis 3.68. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 68
LDL, mmoL/L - subgroup by duration.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 68 LDL, mmoL/L - subgroup by duration





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Medium duration 1 to < 2 years
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 2.8 % 0.16 [ -0.26, 0.58 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 8.2 % -0.19 [ -0.39, 0.01 ]
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.2 % -0.10 [ -0.59, 0.39 ]
Ley 2004 (1) 70 -0.02 (1.255) 66 -0.18 (0.7312) 3.9 % 0.16 [ -0.18, 0.50 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 7.2 % 0.0 [ -0.22, 0.22 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 2.6 % -0.07 [ -0.51, 0.37 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 11.3 % 0.09 [ -0.04, 0.23 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.2 % 0.12 [ -0.56, 0.80 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 3.9 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 546 539 43.2 % 0.01 [ -0.07, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.06, df = 8 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
2 Medium-long duration 2 to < 4 years
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 14.5 % 0.01 [ -0.07, 0.09 ]
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 3.7 % 0.25 [ -0.11, 0.61 ]
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 2.8 % 0.30 [ -0.12, 0.72 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 8.5 % -0.03 [ -0.22, 0.16 ]
WAHA - Ros 2016 (2) 260 -0.18 (0.48) 254 -0.03 (0.64) 13.6 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 985 974 43.2 % 0.00 [ -0.13, 0.12 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 11.30, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 0.07 (P = 0.95)
3 Long duration 4+ years
PREDIMED 2013 (3) 54 -1.14 (0.95) 54 -0.62 (0.92) 3.7 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (4) 51 3.26 (0.86) 42 3.07 (0.7) 4.4 % 0.19 [ -0.13, 0.51 ]
PREDIMED 2013 (5) 58 -0.32 (0.76) 59 -0.3 (0.76) 5.4 % -0.02 [ -0.30, 0.26 ]
Subtotal (95% CI) 163 155 13.6 % -0.11 [ -0.49, 0.28 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.09; Chi2 = 8.95, df = 2 (P = 0.01); I2 =78%
Test for overall effect: Z = 0.55 (P = 0.58)
Total (95% CI) 1694 1668 100.0 % -0.01 [ -0.09, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 28.67, df = 16 (P = 0.03); I2 =44%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 0.39, df = 2 (P = 0.82), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) change from baseline
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
(5) Damasceno 2013, Barcelona North subcohort, 1 year data
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Analysis 3.69. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 69
LDL, mmoL/L - subgroup by primary or secondary prevention.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 69 LDL, mmoL/L - subgroup by primary or secondary prevention





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Primary prevention of CVD
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 8.2 % -0.19 [ -0.39, 0.01 ]
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.2 % -0.10 [ -0.59, 0.39 ]
Ley 2004 (1) 70 -0.02 (1.255) 66 -0.18 (0.7312) 3.9 % 0.16 [ -0.18, 0.50 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 7.2 % 0.0 [ -0.22, 0.22 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 2.6 % -0.07 [ -0.51, 0.37 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 11.3 % 0.09 [ -0.04, 0.23 ]
PREDIMED 2013 (2) 54 -1.14 (0.95) 54 -0.62 (0.92) 3.7 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (3) 51 3.26 (0.86) 42 3.07 (0.7) 4.4 % 0.19 [ -0.13, 0.51 ]
PREDIMED 2013 (4) 58 -0.32 (0.76) 59 -0.3 (0.76) 5.4 % -0.02 [ -0.30, 0.26 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.2 % 0.12 [ -0.56, 0.80 ]
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 2.8 % 0.30 [ -0.12, 0.72 ]
WAHA - Ros 2016 (5) 260 -0.18 (0.48) 254 -0.03 (0.64) 13.6 % -0.15 [ -0.25, -0.05 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 3.9 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 969 946 70.5 % -0.03 [ -0.14, 0.07 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 23.88, df = 12 (P = 0.02); I2 =50%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Secondary prevention of CVD
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 2.8 % 0.16 [ -0.26, 0.58 ]
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 14.5 % 0.01 [ -0.07, 0.09 ]
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 3.7 % 0.25 [ -0.11, 0.61 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 8.5 % -0.03 [ -0.22, 0.16 ]
Subtotal (95% CI) 725 722 29.5 % 0.02 [ -0.05, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.33, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Total (95% CI) 1694 1668 100.0 % -0.01 [ -0.09, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 28.67, df = 16 (P = 0.03); I2 =44%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 0.62, df = 1 (P = 0.43), I2 =0.0%
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(1) Change data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Damasceno 2013, Barcelona North subcohort, 1 year data
(5) change from baseline
Analysis 3.70. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 70
LDL, mmoL/L - subgroup by baseline PUFA dose.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 70 LDL, mmoL/L - subgroup by baseline PUFA dose





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Baseline total PUFA < 6% E
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 8.2 % -0.19 [ -0.39, 0.01 ]
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.2 % -0.10 [ -0.59, 0.39 ]
Ley 2004 (1) 70 -0.02 (1.255) 66 -0.18 (0.7312) 3.9 % 0.16 [ -0.18, 0.50 ]
Subtotal (95% CI) 171 176 14.3 % -0.07 [ -0.30, 0.15 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.01, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 0.64 (P = 0.52)
2 Baseline total PUFA 6 to < 11%E
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 7.2 % 0.0 [ -0.22, 0.22 ]
PREDIMED 2013 (2) 54 -1.14 (0.95) 54 -0.62 (0.92) 3.7 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (3) 58 -0.32 (0.76) 59 -0.3 (0.76) 5.4 % -0.02 [ -0.30, 0.26 ]
PREDIMED 2013 (4) 51 3.26 (0.86) 42 3.07 (0.7) 4.4 % 0.19 [ -0.13, 0.51 ]
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 2.8 % 0.30 [ -0.12, 0.72 ]
WAHA - Ros 2016 (5) 260 -0.18 (0.48) 254 -0.03 (0.64) 13.6 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 541 514 37.3 % -0.05 [ -0.22, 0.12 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 14.29, df = 5 (P = 0.01); I2 =65%
Test for overall effect: Z = 0.58 (P = 0.56)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
3 Baseline total PUFA 11+% E
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Baseline total PUFA unclear
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 2.8 % 0.16 [ -0.26, 0.58 ]
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 14.5 % 0.01 [ -0.07, 0.09 ]
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 3.7 % 0.25 [ -0.11, 0.61 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 2.6 % -0.07 [ -0.51, 0.37 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 11.3 % 0.09 [ -0.04, 0.23 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.2 % 0.12 [ -0.56, 0.80 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 8.5 % -0.03 [ -0.22, 0.16 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 3.9 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 982 978 48.5 % 0.03 [ -0.03, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.55, df = 7 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 1694 1668 100.0 % -0.01 [ -0.09, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 28.67, df = 16 (P = 0.03); I2 =44%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 1.46, df = 2 (P = 0.48), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Damasceno 2013, Barcelona North subcohort, 1 year data
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
(5) change from baseline
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Analysis 3.71. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 71
LDL, mmoL/L - subgroup by replacement.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 71 LDL, mmoL/L - subgroup by replacement





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PUFA replaced saturated fats
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 12.9 % -0.10 [ -0.59, 0.39 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 87.1 % -0.03 [ -0.22, 0.16 ]
Subtotal (95% CI) 110 112 100.0 % -0.04 [ -0.21, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.66)
2 PUFA replaced monounsaturated fats
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 30.4 % 0.01 [ -0.07, 0.09 ]
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 8.8 % 0.25 [ -0.11, 0.61 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 16.5 % 0.0 [ -0.22, 0.22 ]
PREDIMED 2013 (1) 58 -0.32 (0.76) 59 -0.3 (0.76) 12.6 % -0.02 [ -0.30, 0.26 ]
PREDIMED 2013 (2) 54 -1.14 (0.95) 54 -0.62 (0.92) 9.0 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (3) 51 3.26 (0.86) 42 3.07 (0.7) 10.5 % 0.19 [ -0.13, 0.51 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 3.0 % 0.12 [ -0.56, 0.80 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 9.3 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 897 879 100.0 % 0.00 [ -0.12, 0.12 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 11.78, df = 7 (P = 0.11); I2 =41%
Test for overall effect: Z = 0.01 (P = 0.99)
3 PUFA replaced carbohydrates
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 21.3 % -0.19 [ -0.39, 0.01 ]
Ley 2004 (4) 70 -0.02 (1.255) 66 -0.18 (0.7312) 10.2 % 0.16 [ -0.18, 0.50 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 18.8 % 0.0 [ -0.22, 0.22 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 6.7 % -0.07 [ -0.51, 0.37 ]
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 7.4 % 0.30 [ -0.12, 0.72 ]
WAHA - Ros 2016 (5) 260 -0.18 (0.48) 254 -0.03 (0.64) 35.6 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 559 547 100.0 % -0.06 [ -0.18, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.32, df = 5 (P = 0.14); I2 =40%
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.95 (P = 0.34)
4 PUFA replaced protein
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 11.8 % -0.10 [ -0.59, 0.39 ]
Ley 2004 (6) 70 -0.02 (1.255) 66 -0.18 (0.7312) 21.0 % 0.16 [ -0.18, 0.50 ]
WAHA - Ros 2016 (7) 260 -0.18 (0.48) 254 -0.03 (0.64) 67.2 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 346 336 100.0 % -0.08 [ -0.26, 0.10 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.91, df = 2 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.85 (P = 0.39)
5 PUFA replaced unclear
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 9.4 % 0.16 [ -0.26, 0.58 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 90.6 % 0.09 [ -0.04, 0.23 ]
Subtotal (95% CI) 208 201 100.0 % 0.10 [ -0.03, 0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi2 = 4.04, df = 4 (P = 0.40), I2 =1%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Damasceno 2013, Barcelona North subcohort, 1 year data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Change data
(5) change from baseline
(6) Change data
(7) change from baseline
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Analysis 3.72. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 72
LDL, mmoL/L - subgroup by sex.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 72 LDL, mmoL/L - subgroup by sex





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 > 70% men
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 2.8 % 0.16 [ -0.26, 0.58 ]
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 14.5 % 0.01 [ -0.07, 0.09 ]
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 3.7 % 0.25 [ -0.11, 0.61 ]
Ley 2004 (1) 70 -0.02 (1.255) 66 -0.18 (0.7312) 3.9 % 0.16 [ -0.18, 0.50 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 2.6 % -0.07 [ -0.51, 0.37 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 11.3 % 0.09 [ -0.04, 0.23 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 8.5 % -0.03 [ -0.22, 0.16 ]
Subtotal (95% CI) 991 981 47.3 % 0.04 [ -0.03, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.96, df = 6 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
2 > 70% women
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 8.2 % -0.19 [ -0.39, 0.01 ]
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 2.8 % 0.30 [ -0.12, 0.72 ]
Subtotal (95% CI) 123 128 11.0 % 0.02 [ -0.46, 0.49 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 4.32, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.08 (P = 0.94)
3 men % women
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 7.2 % 0.0 [ -0.22, 0.22 ]
PREDIMED 2013 (2) 54 -1.14 (0.95) 54 -0.62 (0.92) 3.7 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (3) 58 -0.32 (0.76) 59 -0.3 (0.76) 5.4 % -0.02 [ -0.30, 0.26 ]
PREDIMED 2013 (4) 51 3.26 (0.86) 42 3.07 (0.7) 4.4 % 0.19 [ -0.13, 0.51 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.2 % 0.12 [ -0.56, 0.80 ]
WAHA - Ros 2016 (5) 260 -0.18 (0.48) 254 -0.03 (0.64) 13.6 % -0.15 [ -0.25, -0.05 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 3.9 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 564 543 39.5 % -0.07 [ -0.21, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 11.47, df = 6 (P = 0.07); I2 =48%
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 1.05 (P = 0.29)
4 sex not reported
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.2 % -0.10 [ -0.59, 0.39 ]
Subtotal (95% CI) 16 16 2.2 % -0.10 [ -0.59, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 1694 1668 100.0 % -0.01 [ -0.09, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 28.67, df = 16 (P = 0.03); I2 =44%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 2.28, df = 3 (P = 0.52), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Damasceno 2013, Barcelona North subcohort, 1 year data
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
(5) change from baseline
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Analysis 3.73. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 73
LDL, mmoL/L - subgroup by age.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 73 LDL, mmoL/L - subgroup by age





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean age < 50 years
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.2 % 0.12 [ -0.56, 0.80 ]
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 2.8 % 0.30 [ -0.12, 0.72 ]
Subtotal (95% CI) 52 49 4.0 % 0.25 [ -0.11, 0.61 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
2 Mean age 50 to < 65 years
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 8.2 % -0.19 [ -0.39, 0.01 ]
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 3.7 % 0.25 [ -0.11, 0.61 ]
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.2 % -0.10 [ -0.59, 0.39 ]
Ley 2004 (1) 70 -0.02 (1.255) 66 -0.18 (0.7312) 3.9 % 0.16 [ -0.18, 0.50 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 7.2 % 0.0 [ -0.22, 0.22 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 11.3 % 0.09 [ -0.04, 0.23 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 8.5 % -0.03 [ -0.22, 0.16 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 3.9 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 593 584 48.8 % 0.01 [ -0.08, 0.10 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.25, df = 7 (P = 0.31); I2 =15%
Test for overall effect: Z = 0.24 (P = 0.81)
3 Mean age 65+ years
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 14.5 % 0.01 [ -0.07, 0.09 ]
PREDIMED 2013 (2) 58 -0.32 (0.76) 59 -0.3 (0.76) 5.4 % -0.02 [ -0.30, 0.26 ]
PREDIMED 2013 (3) 51 3.26 (0.86) 42 3.07 (0.7) 4.4 % 0.19 [ -0.13, 0.51 ]
PREDIMED 2013 (4) 54 -1.14 (0.95) 54 -0.62 (0.92) 3.7 % -0.52 [ -0.87, -0.17 ]
WAHA - Ros 2016 (5) 260 -0.18 (0.48) 254 -0.03 (0.64) 13.6 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 985 971 41.8 % -0.08 [ -0.23, 0.07 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 14.98, df = 4 (P = 0.005); I2 =73%
Test for overall effect: Z = 1.04 (P = 0.30)
4 Mean age unclear
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 2.8 % 0.16 [ -0.26, 0.58 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 2.6 % -0.07 [ -0.51, 0.37 ]
Subtotal (95% CI) 64 64 5.4 % 0.05 [ -0.26, 0.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Total (95% CI) 1694 1668 100.0 % -0.01 [ -0.09, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 28.67, df = 16 (P = 0.03); I2 =44%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 3.14, df = 3 (P = 0.37), I2 =4%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Fernandez-Real 2012, Reus subcohort, 2 year data
(4) Barcelona hospital cohort at 5 years, Casa 2016
(5) change from baseline
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Analysis 3.74. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 74
LDL, mmoL/L - subgroup by statin use.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 74 LDL, mmoL/L - subgroup by statin use





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 50% on statins
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 8.2 % -0.19 [ -0.39, 0.01 ]
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 3.7 % 0.25 [ -0.11, 0.61 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 7.2 % 0.0 [ -0.22, 0.22 ]
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 2.6 % -0.07 [ -0.51, 0.37 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 11.3 % 0.09 [ -0.04, 0.23 ]
PREDIMED 2013 (1) 51 3.26 (0.86) 42 3.07 (0.7) 4.4 % 0.19 [ -0.13, 0.51 ]
PREDIMED 2013 (2) 54 -1.14 (0.95) 54 -0.62 (0.92) 3.7 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (3) 58 -0.32 (0.76) 59 -0.3 (0.76) 5.4 % -0.02 [ -0.30, 0.26 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.2 % 0.12 [ -0.56, 0.80 ]
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 2.8 % 0.30 [ -0.12, 0.72 ]
Subtotal (95% CI) 607 590 50.5 % 0.00 [ -0.13, 0.13 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 19.18, df = 9 (P = 0.02); I2 =53%
Test for overall effect: Z = 0.02 (P = 0.98)
2 50+% on statins
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 2.8 % 0.16 [ -0.26, 0.58 ]
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 14.5 % 0.01 [ -0.07, 0.09 ]
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.2 % -0.10 [ -0.59, 0.39 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 8.5 % -0.03 [ -0.22, 0.16 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 3.9 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 757 758 31.9 % 0.01 [ -0.07, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 4 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
3 Percentage on statins unclear
Ley 2004 (4) 70 -0.02 (1.255) 66 -0.18 (0.7312) 3.9 % 0.16 [ -0.18, 0.50 ]
WAHA - Ros 2016 (5) 260 -0.18 (0.48) 254 -0.03 (0.64) 13.6 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 330 320 17.6 % -0.04 [ -0.33, 0.25 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.03; Chi2 = 2.90, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 0.27 (P = 0.79)
Total (95% CI) 1694 1668 100.0 % -0.01 [ -0.09, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 28.67, df = 16 (P = 0.03); I2 =44%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 0.09, df = 2 (P = 0.96), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Fernandez-Real 2012, Reus subcohort, 2 year data
(2) Barcelona hospital cohort at 5 years, Casa 2016
(3) Damasceno 2013, Barcelona North subcohort, 1 year data
(4) Change data
(5) change from baseline
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Analysis 3.75. Comparison 3 Higher PUFA vs lower PUFA - continuous secondary outcomes, Outcome 75
LDL, mmoL/L - subgroup by intervention type.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 3 Higher PUFA vs lower PUFA - continuous secondary outcomes
Outcome: 75 LDL, mmoL/L - subgroup by intervention type





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Dietary advice
Ley 2004 (1) 70 -0.02 (1.255) 66 -0.18 (0.7312) 3.9 % 0.16 [ -0.18, 0.50 ]
Simon 1997 38 3.09 (0.99) 34 2.79 (0.82) 2.8 % 0.30 [ -0.12, 0.72 ]
Subtotal (95% CI) 108 100 6.8 % 0.22 [ -0.05, 0.48 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
2 Supplemental foods % diet provided
AlphaOmega - ALA 562 -0.38 (0.71) 562 -0.39 (0.71) 14.5 % 0.01 [ -0.07, 0.09 ]
HERO-Tapsell 2009 16 2.4 (0.6) 16 2.5 (0.8) 2.2 % -0.10 [ -0.59, 0.39 ]
PREDIMED 2013 (2) 58 -0.32 (0.76) 59 -0.3 (0.76) 5.4 % -0.02 [ -0.30, 0.26 ]
PREDIMED 2013 (3) 54 -1.14 (0.95) 54 -0.62 (0.92) 3.7 % -0.52 [ -0.87, -0.17 ]
PREDIMED 2013 (4) 51 3.26 (0.86) 42 3.07 (0.7) 4.4 % 0.19 [ -0.13, 0.51 ]
Vijayakumar 2014 94 2.32 (0.75) 96 2.35 (0.56) 8.5 % -0.03 [ -0.22, 0.16 ]
WAHA - Ros 2016 (5) 260 -0.18 (0.48) 254 -0.03 (0.64) 13.6 % -0.15 [ -0.25, -0.05 ]
Subtotal (95% CI) 1095 1083 52.5 % -0.07 [ -0.18, 0.05 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 15.09, df = 6 (P = 0.02); I2 =60%
Test for overall effect: Z = 1.19 (P = 0.23)
3 Supplements (capsules % unusual foods)
Ahn 2016 38 2.23 (1.33) 36 2.07 (0.13) 2.8 % 0.16 [ -0.26, 0.58 ]
Dodin 2005 85 3.45 (0.67) 94 3.64 (0.67) 8.2 % -0.19 [ -0.39, 0.01 ]
HARP- Sacks 1995 31 3.41 (0.78) 28 3.16 (0.62) 3.7 % 0.25 [ -0.11, 0.61 ]
MARINA - Sanders 2011 80 0.2 (0.8987) 71 0.2 (0.4225) 7.2 % 0.0 [ -0.22, 0.22 ]
ORL 2013 170 0.08 (0.68) 165 -0.01 (0.6) 11.3 % 0.09 [ -0.04, 0.23 ]
Rossing 1996 14 3.52 (0.9) 15 3.4 (0.97) 1.2 % 0.12 [ -0.56, 0.80 ]
WELCOME 2015 47 2.8 (0.9) 48 2.8 (0.8) 3.9 % 0.0 [ -0.34, 0.34 ]
Subtotal (95% CI) 465 457 38.2 % 0.02 [ -0.09, 0.13 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 7.62, df = 6 (P = 0.27); I2 =21%
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.43 (P = 0.67)
4 Any combination
Mendis 2001 26 -0.65 (0.718) 28 -0.58 (0.9284) 2.6 % -0.07 [ -0.51, 0.37 ]
Subtotal (95% CI) 26 28 2.6 % -0.07 [ -0.51, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 1694 1668 100.0 % -0.01 [ -0.09, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 28.67, df = 16 (P = 0.03); I2 =44%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 4.24, df = 3 (P = 0.24), I2 =29%
-0.5 -0.25 0 0.25 0.5
Favours higher PUFA Favours lower PUFA
(1) Change data
(2) Damasceno 2013, Barcelona North subcohort, 1 year data
(3) Barcelona hospital cohort at 5 years, Casa 2016
(4) Fernandez-Real 2012, Reus subcohort, 2 year data
(5) change from baseline
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Analysis 4.1. Comparison 4 Higher PUFA vs lower PUFA intake - tertiary outcomes, Outcome 1
SYSTOLIC BLOOD PRESSURE (sBP, mmHg).
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Higher PUFA vs lower PUFA intake - tertiary outcomes
Outcome: 1 SYSTOLIC BLOOD PRESSURE (sBP, mmHg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA 632 -0.24 (20) 632 -2.29 (21.3) 19.8 % 2.05 [ -0.23, 4.33 ]
Dodin 2005 85 120.6 (14.4) 94 120.8 (17.1) 9.6 % -0.20 [ -4.82, 4.42 ]
HARP- Sacks 1995 31 129 (16) 28 137 (29) 1.9 % -8.00 [ -20.13, 4.13 ]
Ley 2004 (1) 70 3.37 (26.8568) 66 -4.1 (16.1668) 4.6 % 7.47 [ 0.07, 14.87 ]
MARINA - Sanders 2011 80 118.3 (12.1) 71 122.1 (12.7) 11.7 % -3.80 [ -7.77, 0.17 ]
MRC 1968 88 2 (0) 89 0 (0) Not estimable
PREDIMED 2013 (2) 2367 -0.9 (21.6) 2441 0.42 (22.2) 26.1 % -1.32 [ -2.56, -0.08 ]
Rossing 1996 14 142 (18.7) 15 144 (15.5) 1.8 % -2.00 [ -14.55, 10.55 ]
Sydney Diet-Heart 1978 221 136.8 (16.1) 237 137.9 (16.1) 16.1 % -1.10 [ -4.05, 1.85 ]
WELCOME 2015 47 133.3 (13.7) 48 133.9 (11.3) 8.4 % -0.60 [ -5.66, 4.46 ]
Total (95% CI) 3635 3721 100.0 % -0.47 [ -2.20, 1.26 ]
Heterogeneity: Tau2 = 2.59; Chi2 = 15.13, df = 8 (P = 0.06); I2 =47%
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Not applicable
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(1) change data
(2) Toledo BMC Med 2013
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Analysis 4.2. Comparison 4 Higher PUFA vs lower PUFA intake - tertiary outcomes, Outcome 2
DIASTOLIC BLOOD PRESSURE (dBP, mmHg).
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Higher PUFA vs lower PUFA intake - tertiary outcomes
Outcome: 2 DIASTOLIC BLOOD PRESSURE (dBP, mmHg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
AlphaOmega - ALA 632 -1.79 (10.3) 632 -2.75 (10.3) 23.5 % 0.96 [ -0.18, 2.10 ]
Dodin 2005 85 75.5 (10.9) 94 76.1 (11.9) 5.0 % -0.60 [ -3.94, 2.74 ]
HARP- Sacks 1995 31 77 (7) 28 77 (7) 4.4 % 0.0 [ -3.58, 3.58 ]
Ley 2004 (1) 70 2.11 (17.4862) 66 -1.73 (12.2673) 2.3 % 3.84 [ -1.21, 8.89 ]
MARINA - Sanders 2011 80 71.2 (6.1652) 71 72.9 (6.3372) 11.6 % -1.70 [ -3.70, 0.30 ]
MRC 1968 88 -1 (0) 89 3 (0) Not estimable
PREDIMED 2013 (2) 2367 -0.61 (12.8) 2441 -1.41 (12.7) 33.1 % 0.80 [ 0.08, 1.52 ]
Sydney Diet-Heart 1978 221 88.4 (9.4) 237 88.7 (9.6) 14.1 % -0.30 [ -2.04, 1.44 ]
WELCOME 2015 47 81.7 (8.2) 48 82.9 (6.5) 6.1 % -1.20 [ -4.18, 1.78 ]
Total (95% CI) 3621 3706 100.0 % 0.24 [ -0.55, 1.02 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 10.17, df = 7 (P = 0.18); I2 =31%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Not applicable
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(1) Change data
(2) Toledo BMC MED 2013
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Analysis 4.3. Comparison 4 Higher PUFA vs lower PUFA intake - tertiary outcomes, Outcome 3 SERIOUS
ADVERSE EVENTS (SAEs).
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Higher PUFA vs lower PUFA intake - tertiary outcomes
Outcome: 3 SERIOUS ADVERSE EVENTS (SAEs)









DART fat 1989 4/1018 2/1015 77.6 % 1.99 [ 0.37, 10.86 ]
Rose 1965 1/28 0/26 22.4 % 2.79 [ 0.12, 65.66 ]
Subtotal (95% CI) 1046 1041 100.0 % 2.15 [ 0.48, 9.57 ]
Total events: 5 (Higher PUFA), 2 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
2 Multiple Sclerosis worsened or had acute attack - GLA supplement
Bates 1977 24/76 21/76 9.8 % 1.14 [ 0.70, 1.87 ]
Bates 1978 51/58 46/58 90.2 % 1.11 [ 0.94, 1.30 ]
Subtotal (95% CI) 134 134 100.0 % 1.11 [ 0.95, 1.30 ]
Total events: 75 (Higher PUFA), 67 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
3 Bleeding
EPIC-1 2008 0/187 2/184 7.7 % 0.20 [ 0.01, 4.07 ]
EPIC-2 2008 9/189 10/188 92.3 % 0.90 [ 0.37, 2.15 ]
Subtotal (95% CI) 376 372 100.0 % 0.80 [ 0.34, 1.85 ]
Total events: 9 (Higher PUFA), 12 (Lower PUFA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.90, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
4 GI hospitalisation
Raitt 2005 7/100 4/100 100.0 % 1.75 [ 0.53, 5.79 ]
Subtotal (95% CI) 100 100 100.0 % 1.75 [ 0.53, 5.79 ]
Total events: 7 (Higher PUFA), 4 (Lower PUFA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
5 Retinopathy
PREDIMED 2013 20/1142 22/1282 100.0 % 1.02 [ 0.56, 1.86 ]
Subtotal (95% CI) 1142 1282 100.0 % 1.02 [ 0.56, 1.86 ]
Total events: 20 (Higher PUFA), 22 (Lower PUFA)
0.2 0.5 1 2 5
Favours higher PUFA Favours lower PUFA
(Continued . . . )
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Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Chi2 = 1.98, df = 4 (P = 0.74), I2 =0.0%
0.2 0.5 1 2 5
Favours higher PUFA Favours lower PUFA
Analysis 4.4. Comparison 4 Higher PUFA vs lower PUFA intake - tertiary outcomes, Outcome 4
DROPOUTS.
Review: Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Comparison: 4 Higher PUFA vs lower PUFA intake - tertiary outcomes
Outcome: 4 DROPOUTS








AlphaOmega - ALA 189/1197 191/1236 10.0 % 1.02 [ 0.85, 1.23 ]
Bates 1978 (1) 3/29 6/29 0.9 % 0.50 [ 0.14, 1.81 ]
Bates 1978 (2) 0/29 1/29 0.2 % 0.33 [ 0.01, 7.86 ]
Bates 1989 10/155 10/157 2.0 % 1.01 [ 0.43, 2.37 ]
Black 1994 28/66 28/66 5.8 % 1.00 [ 0.67, 1.49 ]
Brox 2001 13/80 3/40 1.1 % 2.17 [ 0.65, 7.17 ]
DIPP-Tokudome 2015 3/104 5/101 0.8 % 0.58 [ 0.14, 2.37 ]
Dodin 2005 26/101 17/98 3.9 % 1.48 [ 0.86, 2.56 ]
Dullaart 1992 2/20 4/20 0.6 % 0.50 [ 0.10, 2.43 ]
EPIC-1 2008 80/188 91/186 9.2 % 0.87 [ 0.70, 1.09 ]
EPIC-2 2008 114/189 112/190 10.5 % 1.02 [ 0.87, 1.21 ]
FAAT - Leaf 2005 73/200 69/202 8.3 % 1.07 [ 0.82, 1.39 ]
GLAMT 1993 10/54 17/57 2.8 % 0.62 [ 0.31, 1.23 ]
0.5 0.7 1 1.5 2
Favours higher PUFA Favours lower PUFA
(Continued . . . )
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HARP- Sacks 1995 10/41 11/39 2.5 % 0.86 [ 0.41, 1.80 ]
HERO-Tapsell 2009 7/26 5/24 1.5 % 1.29 [ 0.47, 3.53 ]
Ley 2004 20/90 19/85 3.8 % 0.99 [ 0.57, 1.73 ]
MARINA - Sanders 2011 38/279 17/88 4.2 % 0.71 [ 0.42, 1.19 ]
Mendis 2001 4/30 2/30 0.6 % 2.00 [ 0.40, 10.11 ]
Mita 2007 10/40 11/41 2.5 % 0.93 [ 0.45, 1.95 ]
Nodari 2011 AF 6/100 5/99 1.1 % 1.19 [ 0.37, 3.77 ]
ORL 2013 22/336 21/167 3.7 % 0.52 [ 0.29, 0.92 ]
Raitt 2005 17/100 26/100 3.9 % 0.65 [ 0.38, 1.13 ]
Rose 1965 3/28 5/26 0.9 % 0.56 [ 0.15, 2.10 ]
Rossing 1996 4/18 3/18 0.9 % 1.33 [ 0.35, 5.13 ]
Simon 1997 21/96 26/98 4.4 % 0.82 [ 0.50, 1.36 ]
Veterans Admin 1969 117/424 58/422 7.8 % 2.01 [ 1.51, 2.67 ]
Vijayakumar 2014 6/99 4/99 1.0 % 1.50 [ 0.44, 5.15 ]
WAHA - Ros 2016 38/362 34/346 5.2 % 1.07 [ 0.69, 1.66 ]
Total (95% CI) 4481 4093 100.0 % 0.99 [ 0.87, 1.13 ]
Total events: 874 (Higher PUFA), 801 (Lower PUFA)
Heterogeneity: Tau2 = 0.03; Chi2 = 45.54, df = 27 (P = 0.01); I2 =41%
Test for overall effect: Z = 0.13 (P = 0.89)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours higher PUFA Favours lower PUFA
(1) Arms C vs D, both given spread
(2) Arms A vs B, both given capsules
A D D I T I O N A L T A B L E S
Table 1. Risk of bias assessment - detailed assessment methods
Risk of bias element Criteria for low risk of bias Criteria for unclear Criteria for high risk of bias
Selection bias: random se-
quence generation
The trial authors needed to
have described themethod used
to generate the allocation se-
quence in sufficient detail to al-
The trial authors have not de-
scribed their method in suffi-
cient detail for the assessment
of whether it would produce
The randomisationmethodwas
assessed as not truly random,
and may not produce compara-
ble groups
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Table 1. Risk of bias assessment - detailed assessment methods (Continued)
low an assessment of whether
it should produce comparable
groups. For example “the ran-
domisation sequence was com-
puter-generated”. We allowed
that a goodmethodof randomi-
sation was strongly implied
if the trial authors discussed
stratification and/or blocking.
Therefore, if they were not ex-
plicit about their randomisa-
tion method but did describe
stratification or blocking we as-
sessed this as low risk
comparable groups. For exam-
ple, the trial authors state “the
trial was randomised” and pro-
vide no further information
Selection bias: allocation con-
cealment
The trial authors needed tohave
described the method used to
conceal allocation sequence in
sufficient detail to determine
whether the allocations could
have been foreseen in advance
of, or during, enrolment. Good
methods included putting allo-
cation codes in opaque, sealed
envelopes (ideally prepared by
someone outside the treatment
or assessment teams and se-
quentially numbered), using a
telephone allocation system af-
ter the participants had con-
sented to participate or provid-
ing a random number that links
to a specific set of capsules pre-
pared and distributed centrally
or by an arms-length pharma-
cist
The authors gave insufficient
detail as to method.
The allocation was known in
advance of participants con-
senting to take part in the trial
Performance bias: blinding of
participants and personnel
The trial authors needed tohave
described all measures used, if
any, to blind trial participants
and personnel from knowledge
of which intervention a par-
ticipant received. Ideally, they
should also have provided in-
formation relating to whether
the intended blinding was ef-
fective. For example, the au-
thors could say “both the in-
tervention and placebo capsules
looked and tasted the same.
Insufficient methodological de-
tails were provided e.g. “the trial
was blinded.”
The trial was unblinded or
where blinding was broken, e.
g. “the capsules were visually
identical but the participants re-
ported a strong fishy flavour in
the intervention group only.”
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Table 1. Risk of bias assessment - detailed assessment methods (Continued)
” However if the trial authors
did not provide information on
whether the blinding was ef-
fective, but sufficient detail was
given on a good method of
blinding, then it was assumed
that the blinding was effective
and the risk of bias was low
Detection bias: blinding of
outcome assessment
Trial authors needed to have
described measures used, if
any, to blind outcome asses-
sors from knowledge of which
intervention a participant re-
ceived. Ideally, they should also
have provided information re-
lating to whether the intended
blinding was effective. For ex-
ample, the authors could say
“the outcome assessors had no
knowledge of the group alloca-
tion, and both the intervention
and placebo capsules looked
and tasted the same so the
self-assessment scales were also
blinded.” However if the trial
authors did not provide infor-
mation onwhether the blinding
was effective, but sufficient de-
tail was given on a goodmethod
of blinding of the assessors, then
it was assumed that the blind-
ing was effective and the risk of
bias is low. All biochemical as-
sessment (lipids, glucose, CRP,
insulin, PSA etc.) were consid-
ered at low risk of detection bias
if outcome assessor blinding or
double blinding was stated
Insufficient methodological de-
tails were provided e.g. “the trial
was blinded.”
The trial was unblinded or
blinding was broken, e.g. for
a self-assessment measure “the
capsules were visually identical
but the participants reported a
strong fishy flavour in the inter-
vention group only.”
(Because the level of blinding
could vary by outcome assess-
ment of risk of bias was based
on blinding of the review’s pri-
mary outcome(s). Where pri-
mary outcomes had different
assessments we opted for the
higher risk of bias but noted




The trial authors needed to de-
scribe the completeness of out-
come data for each main out-
come, including attrition and
exclusions from the analysis.
They needed to report the num-
ber of attrition/exclusions, the
numbers in each group at each
time point, reasons for attri-
The trial authors didn’t state
reasons for attrition/exclusion,
or were unclear about the num-
bers lost to attrition/exclusion
in each trial arm
The trial authors demonstrated
a substantial difference in the
rates of attrition/ exclusions be-
tween the trial arms and/or >
20% of the baseline sample was
lost over a year (> 10% over 6
months)
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Table 1. Risk of bias assessment - detailed assessment methods (Continued)
tion/exclusion and any re-inclu-
sions in analyses. Ideally, they
would report how they imputed
any missing data e.g. last obser-
vation carried forward. There
needed to be a reasonable bal-
ance of attrition/exclusions be-
tween trial arms and ≤ 20% of
the sample should be lost over a
year
Reporting bias: selective out-
come reporting
The trial authors needed tohave
published their trial protocol or
trials registry entry before the
end of the trial’s recruitment
period i.e. prospectively. They
needed to have reported on all
of the primary and secondary
outcomes listed in the protocol/
registry entry. Reporting addi-
tional secondary outcomes in
the results paper(s), although
not ideal, was deemed to still be
low risk
No trial protocol or trials reg-
istry entry was found, it was
registered retrospectively, or the
dates of registration and partic-
ipant recruitment were unclear
The trial authors did not re-
port at least one primary or sec-
ondary outcome listed in the
protocol/registry entry OR the
results paper(s) reported a pri-
mary outcome that was not
listed at all in the protocol or
not listed as a primary outcome
in the protocol
Other sources of bias: Atten-
tion bias
The trial authors needed tohave
reported that participants in all
trial arms received the same
amount of attention and time
from researchers and clinical
teams. For example, “All partic-
ipants attended the clinic for a
baseline assessment which took
2 hours. They were then fol-
lowed with monthly telephone
calls, and finally attended for a 6
month assessment at the clinic
which took 1 hour.” If the trial
only differed by the content of
the capsules, and the assessment
schedule was not stated to dif-
fer between the two arms, it was
assumed to be at low risk
The trial authors did not state
the attention each arm received
Participants in different arms
received different amounts of
attention. For example, “The
intervention group only at-
tended for additional assess-
ments at months 2, 4, and
6” or “the rates of relapse dif-
fered substantially between the
groups which led to differing
amounts of treatment time and
attention,” or “the intervention
group received a 40 minute di-
etary education session.”
Other sources of bias: limited
compliance
The higher PUFA arm had
to demonstrate an increase in
PUFA fats over control in a
body biomarker (total PUFA
had to be assessed by at least LA
plus one or more further com-
Biomarker data not reported or
not in a way that could be inter-
preted. Where lipid biomarker
andTC contradicted each other
we chose unclear
Measures of compliance were
reported but did not suggest
higher total PUFA in the appro-
priate arm
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Table 1. Risk of bias assessment - detailed assessment methods (Continued)
ponents of PUFA), or greater
reduction in TC in the higher
PUFA arm
Other sources of bias: other In the absence of any additional
issues this item was coded “low
risk of bias”
If fraud concerns had been
raised and the paper had been
withdrawn, or the trial author
had been found guilty of fraud
by a legal or medical entity the
paper was excluded from the re-
view.However if fraud concerns
were raised, but the journal had
not withdrawn the paper, and
the trial author had not been
formally sanctioned; then the
trial was included in the review,
but concerns were raised here,
and the risk of bias for this item
was high
LA: linoleic acid; PUFA: polyunsaturated fatty acids; TC: total cholesterol
A P P E N D I C E S
Appendix 1. Searches run for this review, to 27 April 2017
These searches have each been run from database inception, then de-duplicated with each other. The RCT filter for MEDLINE is
the Cochrane sensitivity and precision-maximising RCT filter, and for Embase, terms as recommended in the Cochrane Handbook for
Systematic Reviews of Interventions have been applied (Lefebvre 2011).
CENTRAL
#1 MeSH descriptor: [Fatty Acids, Essential] explode all trees
#2 MeSH descriptor: [Fatty Acids, Unsaturated] this term only
#3 ((polyunsaturat* or poly-unsaturat*) near/3 fat*)
#4 (poly* adj4 unsat* near/4 fatty acid*)
#5 PUFA
#6 MeSH descriptor: [Fatty Acids, Omega-6] explode all trees
#7 omega-6
#8 (n-6 near/4 acid*) or (“n 6” near/4 acid*)
#9 linoleic acid*
#10 MeSH descriptor: [Corn Oil] this term only
#11 MeSH descriptor: [Cottonseed Oil] this term only
#12 MeSH descriptor: [Olive Oil] this term only
#13 MeSH descriptor: [Safflower Oil] this term only
#14 MeSH descriptor: [Sesame Oil] this term only
#15 MeSH descriptor: [Soybean Oil] this term only
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#16 ((corn or maize or mazola) near/4 oil*)
#17 (cottonseed* or (cotton next seed*))
#18 (olive near/4 oil*)
#19 (safflower near/4 oil*)
#20 (sesame near/4 oil*)
#21 ((soy bean or soybean) near/4 (oil* or fat*))
#22 (so?a near/4 oil*)
#23 so?aoil*
#24 (soy near/4 oil*)
#25 (sunflower near/4 oil*)
#26 helianth*
#27 (grapeseed near/4 oil*)
#28 (canola near/4 oil*)
#29 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
MEDLINE Ovid
1. exp fatty acids, essential/
2. fatty acids, unsaturated/
3. ((polyunsaturat* or poly-unsaturat*) adj3 fat*).ti,ab.
4. (poly* adj4 unsat* adj4 fatty acid*).ti,ab.
5. PUFA.ti,ab.
6. exp fatty acids, omega-6/
7. omega-6.ti,ab.
8. (n-6 adj4 acid*).ti,ab.
9. linoleic acid*.ti,ab.
10. corn oil/ or cottonseed oil/ or olive oil/ or safflower oil/ or sesame oil/ or soybean oil/
11. ((corn or maize or mazola) adj4 oil*).ti,ab.
12. (cottonseed* or (cotton adj seed*)).ti,ab.
13. (olive adj4 oil*).ti,ab.
14. (safflower adj4 oil*).ti,ab.
15. (sesame adj4 oil*).ti,ab.
16. ((soy bean or soybean) adj4 (oil* or fat*)).ti,ab.
17. (so?a adj4 oil*).ti,ab.
18. so?aoil*.ti,ab.
19. (soy adj4 oil*).ti,ab.
20. (sunflower adj4 oil*).ti,ab.
21. helianth*.ti,ab.
22. (grapeseed adj4 oil*).ti,ab.
23. (canola adj4 oil*).ti,ab.
24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. randomized.ab.
28. placebo.ab.
29. clinical trials as topic.sh.
30. randomly.ab.
31. trial.ti.
32. 25 or 26 or 27 or 28 or 29 or 30 or 31
33. exp animals/ not humans.sh.
34. 32 not 33
35. 24 and 34
Embase Ovid
1. exp essential fatty acid/
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2. unsaturated fatty acid/ or docosapentaenoic acid/ or omega 6 fatty acid/ or polyunsaturated fatty acid/
3. ((polyunsaturat* or poly-unsaturat*) adj3 fat*).ti,ab.
4. (poly* adj4 unsat* adj4 fatty acid*).ti,ab.
5. PUFA.ti,ab.
6. omega-6.ti,ab.
7. (n-6 adj4 acid*).ti,ab.
8. linoleic acid*.ti,ab.
9. edible oil/ or canola oil/ or corn oil/ or cotton seed oil/ or olive oil/ or safflower oil/ or safflower oil plus soybean oil/ or sesame seed
oil/ or soybean oil/ or sunflower oil/
10. ((corn or maize or mazola) adj4 oil*).ti,ab.
11. (cottonseed* or (cotton adj seed*)).ti,ab.
12. (olive adj4 oil*).ti,ab.
13. (safflower adj4 oil*).ti,ab.
14. (sesame adj4 oil*).ti,ab.
15. ((soy bean or soybean) adj4 (oil* or fat*)).ti,ab.
16. (so?a adj4 oil*).ti,ab.
17. so?aoil*.ti,ab.
18. (soy adj4 oil*).ti,ab.
19. (sunflower adj4 oil*).ti,ab.
20. helianth*.ti,ab.
21. (grapeseed adj4 oil*).ti,ab.
22. (canola adj4 oil*).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. double blind procedure/
25. single blind procedure/
26. randomized controlled trial/
27. ((double* or single*) adj blind*).ti,ab.
28. (random* or placebo*).ti,ab.
29. 24 or 25 or 26 or 27 or 28
30. (animal/ or nonhuman/) not human/
31. 29 not 30
32. 23 and 31
Appendix 2. Searches run for the allied review, to 27 April 2017
The searches for the omega-3 review (Abdelhamid 2018) were last run in 20 February 2002. We have updated the search strategies and
have now re-run the searches to identify any records added to the databases since the last search. We applied date limits to the terms
from the original strategies so that only new records would be found, but have not applied date limits to the newly added terms. The
RCT filter for MEDLINE is the Cochrane sensitivity and precision-maximising RCT filter, and for Embase, we have applied terms as
recommended in the Cochrane Handbook for Systematic Reviews of Interventions (Lefebvre 2011).
CENTRAL
#1 MeSH descriptor: [Fish Oils] explode all trees
#2 MeSH descriptor: [Linseed Oil] this term only
#3 MeSH descriptor: [Linolenic Acids] this term only
#4 MeSH descriptor: [Fatty Acids, Omega-3] explode all trees
#5 (fish near/3 oil*)
#6 (oil* near/3 (cod* or marin*))
#7 (omega-3 or omega3 or (omega* near/5 fat*))
#8 eicosapentaen*
#9 docosahexaen*
#10 (oil* near/3 (flax* or rapeseed* or canola*))
#11 (Linolen* or alpha-linolen* or alphalinolen*)
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#12 (perilla* or linseed* or maxepa*)
#13 (oil* near/3 (rape or colza))
#14 (marin* near/3 lipid*)
#15 (naudicelle* or herring* or sild)
#16 (clupe* near/3 hareng*)
#17 (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*)
#18 (salmo* near/3 trut*)
#19 (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish)
#20 (thunnus* or swordfish* or xiphias* or dogfish or scyliorrhinus*)
#21 (crab or crabs or (cancer pagarus))
#22 (DHA or EPA)
#23 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 Publication Year from 2002 to 2016
#24 MeSH descriptor: [Salmoniformes] explode all trees
#25 MeSH descriptor: [Tuna] this term only
#26 MeSH descriptor: [alpha-Linolenic Acid] this term only
#27 MeSH descriptor: [Flax] this term only
#28 (fish near/3 (diet* or capsul* or nutrit* or supplement*))
#29 (icosapentaen* or docosapentaen*)
#30 (oil* near/3 (purslane or mustard* or candlenut* or stillingia or walnut*))
#31 (laks or lax)
#32 (ALA or DPA)
#33 (algal near oil*)
#34 #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33
#35 #23 or #34
MEDLINE Ovid
1. exp Fish Oils/
2. Linseed Oil/
3. linolenic acids/ or alpha-linolenic acid/
4. Flax/
5. exp Fatty Acids, Omega-3/
6. (fish adj3 (diet* or nutrit* or oil* or supplement*)).ti,ab.
7. (oil* adj3 (cod* or marin*)).ti,ab.
8. (omega-3 or omega3 or (omega* adj5 fat*)).ti,ab.
9. eicosapentaen*.ti,ab.
10. docosahexaen*.ti,ab.
11. (oil* adj3 (flax* or rapeseed* or canola*)).ti,ab.
12. (Linolen* or alpha-linolen* or alphalinolen*).ti,ab.
13. (perilla* or linseed* or maxepa*).ti,ab.
14. (oil* adj3 (rape or colza)).ti,ab.
15. (marin* adj3 lipid*).ti,ab.
16. (naudicelle* or herring* or sild).ti,ab.
17. (clupe* adj3 hareng*).ti,ab.
18. (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*).ti,ab.
19. (salmo* adj3 trut*).ti,ab.
20. (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish).ti,ab.
21. (thunnus* or swordfish* or xiphias* or dogfish or scyliorrhinus* or laks or lax).ti,ab.
22. (crab or crabs or cancer pagarus).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. randomized controlled trial.pt.
25. controlled clinical trial.pt.
26. randomized.ab.
27. placebo.ab.
552Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
28. clinical trials as topic.sh.
29. randomly.ab.
30. trial.ti.
31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. exp animals/ not humans.sh.
33. 31 not 32
34. 23 and 33
35. limit 34 to ed=20020201-20160721
36. exp salmoniformes/ or tuna/
37. (fish adj3 capsul*).ti,ab.
38. icosapentaen*.ti,ab.
39. docosapentaen*.ti,ab.
40. (oil* adj3 (purslane or mustard* or candlenut* or stillingia or walnut*)).ti,ab.
41. 36 or 37 or 38 or 39 or 40
42. 33 and 41
43. 35 or 42
Embase Ovid





6. omega 3 fatty acid/
7. (fish adj3 (diet* or nutrit* or oil* or supplement*)).ti,ab.
8. (oil* adj3 (cod* or marin*)).ti,ab.
9. (omega-3 or omega3 or (omega* adj5 fat*)).ti,ab.
10. (eicosapentaen* or icosapentaen*).ti,ab.
11. docosahexaen*.ti,ab.
12. (oil* adj3 (flax* or rapeseed* or canola*)).ti,ab.
13. (Linolen* or alpha-linolen* or alphalinolen*).ti,ab.
14. (perilla* or linseed* or maxepa*).ti,ab.
15. (marin* adj3 lipid*).ti,ab.
16. (naudicelle* or herring* or sild).ti,ab.
17. (clupe* adj3 hareng*).ti,ab.
18. (whitebait or sardine* or sardina* or pilchard* or sprat* or brisling*).ti,ab.
19. (salmo* adj3 trut*).ti,ab.
20. (trout or bloater or kipper* or salmon or mackerel* or scomb* or conger* or tuna or tunny or tunafish or tuna-fish).ti,ab.
21. (thunnus* or swordfish* or xiphias* or dogfish or scyliorrhinus* or laks or lax).ti,ab.
22. (crab or crabs or (cancer adj3 pagarus)).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. random$.tw.
25. placebo$.tw.
26. (doubl$ adj blind$).tw.
27. (singl$ adj blind$).tw.
28. double blind procedure/
29. randomized controlled trial/
30. single blind procedure/
31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. (animal/ or nonhuman/) not human/
33. 31 not 32
34. 23 and 33
35. (2002* or 2003* or 2004* or 2005* or 2006* or 2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or
2015* or 2016*).dd,em.
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36. 34 and 35
37. exp salmonine/
38. (fish adj3 capsul*).ti,ab.
39. docosapentaen*.ti,ab.
40. (ALA or DHA or DPA or EPA).ti,ab.
41. (algal adj oil*).ti,ab.
42. 37 or 38 or 39 or 40 or 41
43. 33 and 42
44. 36 or 43
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WHO NUGAG Subgroup on Diet and Health requested and funded this systematic review
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol we planned to omit small trials (that randomised fewer than 100 participants) due to concerns over small study bias
and the consequent potential for random error to result in false positive conclusions (Roberts 2015).
To ensure that the largest body of RCT evidence was considered in the formulation of recommendations, theWHONUGAGSubgroup
on Diet and Health requested that trials of all sizes be included as long as they fit the other inclusion criteria.
To do this we re-assessed all titles and abstracts in duplicate to ensure that we collected all smaller as well as larger trials, and carried out
a sensitivity analysis omitting trials that had randomised fewer than 100 participants, as well as omitting trials that randomised fewer
than 250 participants (this sensitivity analysis was already agreed).
We were also requested by WHO NUGAG Subgroup on Diet and Health to add the following sensitivity analyses:
1. only including trials with a low risk of bias from compliance, and
2. only including trials at low summary risk of bias.
We intended to assess causality (another aspect of performance bias, where a trial intervention included changes other than the change
in PUFA intake, when there would be high risk of bias) but as we limited inclusion to trials where the dietary changes were limited
to dietary fats this was not needed and so omitted. We also planned to assess whether a trial was pre-registered on a trials register
(registration date is before outcome data collection begins; Roberts 2015) but we incorporated the issue of pre-registration into selective
outcome reporting and did not use a separate form of assessment. We recorded funding data in the Characteristics of included studies
and did not use them as a separate issue for assessing risk of bias, as recommended (Higgins 2011a).
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